0000950170-24-09633610-Q SUTRO BIOPHARMA, INC. 20240813202408131631341631341631340 0000950170-24-096336 10-Q 69 20240630 20240813 20240813 SUTRO BIOPHARMA, INC. 0001382101 2836 452441988 1231 10-Q 34 001-38662 241202202 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 SUTRO BIOPHARMA INC 20061127 10-Q 1 stro-20240630.htm 10-Q 10-Q --12-31Q20001382101false0001382101stro:BristolMyersSquibbCompanyBMSMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-04-012023-06-300001382101us-gaap:CommercialPaperMember2023-12-310001382101stro:AstellasPharmaIncAstellasMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-01-012023-06-300001382101stro:TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember2023-12-310001382101stro:MaterialsSupplyMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-01-012023-06-300001382101stro:VaxcyteIncMember2024-05-012024-05-310001382101us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001382101us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2023-01-010001382101012023-01-012023-03-310001382101012023-03-310001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2018-09-242018-09-260001382101012024-07-012024-06-300001382101us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101us-gaap:CommonStockMember2023-06-300001382101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:FinancingComponentOnUnearnedRevenueMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-01-012024-06-300001382101us-gaap:CommercialPaperMember2024-06-300001382101us-gaap:MoneyMarketFundsMember2024-06-300001382101stro:MarketableSecuritiesMember2024-06-300001382101stro:IpsenAgreementMember2024-04-300001382101stro:TwoThousandEighteenMerckAgreementMemberstro:MerckSharpAndDohmeCorporationMember2021-01-012021-12-310001382101stro:ResearchAndDevelopmentServicesMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-04-012023-06-300001382101stro:MerckSharpAndDohmeCorporationMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-01-012024-06-300001382101us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMembersrt:MaximumMember2018-09-242018-09-260001382101us-gaap:RestrictedStockUnitsRSUMemberstro:TwoThousandEighteenEquityIncentivePlanMember2024-06-3000013821012023-06-300001382101us-gaap:CashEquivalentsMember2023-12-310001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001382101stro:OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMemberstro:AstellasLicenseAndCollaborationAgreementMember2023-04-012023-06-300001382101us-gaap:CommonStockMember2024-04-012024-06-300001382101us-gaap:EmployeeStockOptionMemberstro:TwoThousandEighteenEquityIncentivePlanMember2023-01-012023-06-300001382101us-gaap:WarrantMember2024-06-300001382101us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101us-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:MaterialsSupplyMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2024-04-012024-06-300001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2024-01-012024-06-300001382101us-gaap:CommonStockMember2023-12-310001382101stro:CommonStockAwardsIssuedAndOutstandingMember2024-06-300001382101us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001382101stro:TwoThousandTwentyOneEquityInducementPlanMember2021-08-040001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001382101stro:TwoThousandEighteenEquityIncentivePlanMembersrt:MaximumMember2018-09-242018-09-250001382101us-gaap:AdditionalPaidInCapitalMember2024-03-310001382101us-gaap:RestrictedStockUnitsRSUMember2023-12-310001382101stro:AmendedAndRestatedTwoThousandTwentyOneEquityInducementPlanMember2024-06-300001382101stro:TaslyBiopharmaceuticalsCoLtdMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-01-012024-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMemberstro:FinancingComponentOnUnearnedRevenueMember2023-04-012023-06-300001382101stro:VaxcyteIncMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-01-012023-06-300001382101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-06-300001382101stro:TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember2024-06-300001382101stro:TwoThousandEighteenMerckAgreementMemberstro:MerckSharpAndDohmeCorporationMember2018-07-012018-07-310001382101us-gaap:MoneyMarketFundsMember2023-12-310001382101us-gaap:CommonStockMember2023-04-012023-06-300001382101stro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-12-310001382101us-gaap:CashEquivalentsMember2024-06-300001382101stro:IpsenAgreementMember2024-04-012024-06-300001382101stro:TaslyLicenseAgreementMember2023-01-012023-06-300001382101stro:TwoThousandTwentyMerckMasterServicesAgreementMember2024-06-300001382101us-gaap:AdditionalPaidInCapitalMember2022-12-310001382101stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-01-012024-06-300001382101us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001382101stro:EmployeeStockPurchasePlanMemberstro:TwoThousandEighteenEquityIncentivePlanMember2023-06-300001382101stro:MaterialsSupplyMemberstro:TaslyLicenseAgreementMember2024-01-012024-06-300001382101stro:IpsenAgreementMember2024-03-012024-03-310001382101us-gaap:RetainedEarningsMember2023-03-310001382101us-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001382101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:TwoThousandEighteenEquityIncentivePlanMember2024-01-010001382101stro:CmoMember2023-12-310001382101us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310001382101srt:MaximumMember2024-01-012024-06-300001382101stro:TwoThousandEighteenMerckAgreementMember2023-12-310001382101stro:TaslyLicenseAgreementMember2024-04-012024-06-300001382101stro:SharesToBeIssuedUnderEmployeeStockPurchasePlanMember2023-01-012023-06-300001382101us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001382101stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-04-012024-06-300001382101stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-01-012023-06-300001382101stro:VaxcyteAgreementsMember2024-04-012024-06-300001382101stro:BlackstoneLifeSciencesMemberstro:TwoThousandFifteenLicenseAgreementMember2023-06-012023-06-300001382101stro:MerckSharpAndDohmeCorporationMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-01-012023-06-300001382101stro:EmployeeStockPurchasePlanMemberstro:TwoThousandEighteenEquityIncentivePlanMember2024-06-300001382101stro:TwoThousandTwentyMerckMasterServicesAgreementMember2024-04-012024-06-300001382101us-gaap:RetainedEarningsMember2024-03-3100013821012023-12-310001382101stro:TwoThousandEighteenEquityIncentivePlanMember2018-09-242018-09-250001382101012024-01-012024-06-300001382101us-gaap:EmployeeStockOptionMemberstro:TwoThousandEighteenEquityIncentivePlanMember2024-06-300001382101us-gaap:OverAllotmentOptionMember2024-04-012024-06-300001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001382101us-gaap:AdditionalPaidInCapitalMember2023-12-310001382101us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001382101stro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-04-012023-06-300001382101stro:AmendedAndRestatedTwoThousandTwentyOneEquityInducementPlanMember2022-08-310001382101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:VaxcyteIncMember2023-11-300001382101stpr:CAstro:SanCarlosLeaseMember2024-01-012024-06-300001382101stro:BlackstoneLifeSciencesMember2023-06-012023-06-300001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2024-06-300001382101stro:VaxcyteIncMemberstro:SupplyAgreementMember2024-06-300001382101stro:VaxcyteIncMemberstro:VaxcyteCommonStockMember2024-04-012024-06-300001382101stro:VaxcyteIncMemberstro:VaxcyteCommonStockMember2023-01-012023-06-300001382101us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001382101stro:AstellasLicenseAndCollaborationAgreementMember2023-01-012023-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2023-04-012023-06-310001382101stro:MerckSharpAndDohmeCorporationMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-04-012023-06-300001382101us-gaap:RetainedEarningsMember2023-06-300001382101stro:TwoThousandEighteenMerckAgreementMemberstro:MerckSharpAndDohmeCorporationMember2024-01-012024-06-300001382101us-gaap:RestrictedStockUnitsRSUMemberstro:TwoThousandEighteenEquityIncentivePlanMember2023-06-300001382101us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-06-300001382101stro:BristolMyersSquibbCompanyBMSMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-01-012023-06-3000013821012024-01-012024-03-310001382101stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-06-300001382101stro:TaslyLicenseAgreementMember2024-01-012024-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2022-06-012022-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2023-04-012023-06-300001382101stro:TwoThousandFourPlanTwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember2024-06-300001382101stro:FutureServicesOnCollaborationJointSteeringCommitteeMemberstro:AstellasLicenseAndCollaborationAgreementMember2022-06-300001382101srt:MaximumMember2023-01-012023-12-310001382101stro:BlackstoneLifeSciencesMembersrt:MaximumMember2023-06-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2024-01-012024-06-300001382101stro:VaxcyteIncMemberstro:VaxcyteCommonStockMember2023-04-012023-06-300001382101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-04-012024-06-300001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001382101stro:TaslyBiopharmaceuticalsCoLtdMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-04-012024-06-300001382101stro:WarrantsToPurchaseCommonStockMember2024-01-012024-06-300001382101stro:VaxcyteIncMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-04-012024-06-300001382101us-gaap:CommonStockMember2024-01-012024-03-310001382101stro:TwoThousandEighteenEquityIncentivePlanMember2018-09-250001382101us-gaap:RetainedEarningsMember2023-01-012023-03-310001382101stro:IpsenPharmaSASMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-04-012024-06-300001382101stro:VaxcyteIncMemberstro:VaxcyteCommonStockMember2023-12-310001382101us-gaap:AdditionalPaidInCapitalMember2023-06-300001382101us-gaap:AdditionalPaidInCapitalMember2024-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2022-06-300001382101us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-06-300001382101stro:MaterialsSupplyMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-01-012024-06-300001382101us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:RestrictedStockUnitsIssuedAndOutstandingMember2023-01-012023-06-300001382101stro:OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMemberstro:AstellasLicenseAndCollaborationAgreementMember2023-01-012023-06-300001382101us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:AstellasPharmaIncAstellasMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-04-012023-06-300001382101stro:VaxcyteIncMemberstro:SupplyAgreementMember2023-12-310001382101stro:CommonStockOptionIssuedAndOutstandingMember2024-01-012024-06-300001382101stro:AttheMarketIssuanceSalesAgreementMember2023-01-012023-03-310001382101us-gaap:AssetBackedSecuritiesMember2023-12-3100013821012023-01-012023-06-300001382101stro:MaterialsSupplyMemberstro:IpsenAgreementMember2024-04-012024-06-300001382101us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001382101stro:MaterialsSupplyMemberstro:VaxcyteAgreementsMember2024-04-012024-06-300001382101stro:VaxcyteIncMemberstro:VaxcyteCommonStockMember2024-06-300001382101us-gaap:WarrantMember2023-12-310001382101us-gaap:RetainedEarningsMember2023-04-012023-06-300001382101stro:VaxcyteIncMemberstro:VaxcyteCommonStockMember2024-01-012024-06-300001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2018-09-260001382101stro:ResearchAndDevelopmentServicesMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-01-012023-06-300001382101stro:OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-01-012024-06-300001382101stro:VaxcyteIncMember2024-01-012024-06-300001382101us-gaap:RestrictedStockUnitsRSUMemberstro:TwoThousandEighteenEquityIncentivePlanMember2024-01-012024-06-300001382101stro:AstellasPharmaIncAstellasMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-04-012024-06-300001382101us-gaap:EmployeeStockOptionMemberstro:TwoThousandEighteenEquityIncentivePlanMember2024-01-012024-06-300001382101us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:MaterialsSupplyMemberstro:IpsenAgreementMember2024-01-012024-06-300001382101stpr:CAstro:SanCarlosLeaseMember2024-06-300001382101us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001382101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310001382101us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001382101stro:ClinicalTrialsMember2024-06-300001382101stro:VaxcyteIncMemberstro:SupplyAgreementMember2023-01-012023-06-300001382101stro:VaxcyteIncMemberstro:SupplyAgreementMember2024-04-012024-06-300001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2024-06-300001382101stro:IpsenAgreementMember2024-04-012024-04-300001382101stro:TwoThousandEighteenMerckAgreementMember2024-06-300001382101stro:FinancingComponentOnUnearnedRevenueMemberstro:AstellasLicenseAndCollaborationAgreementMember2023-01-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-04-012024-06-300001382101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:TaslyLicenseAgreementMember2022-04-300001382101stro:SharesToBeIssuedUnderEmployeeStockPurchasePlanMember2024-01-012024-06-300001382101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001382101stro:MaterialsSupplyMemberstro:VaxcyteAgreementsMember2023-01-012023-06-300001382101stro:TaslyLicenseAgreementMember2023-04-012023-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2023-12-

310001382101stro:ClinicalTrialsMember2023-12-310001382101stro:IpsenAgreementMember2024-06-300001382101us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:IpsenAgreementMember2024-01-012024-06-300001382101stro:VaxcyteIncMember2023-12-310001382101us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101stro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-01-012023-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2024-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2024-04-012024-06-300001382101stro:MaterialsSupplyMemberstro:VaxcyteAgreementsMember2024-01-012024-06-300001382101stro:VaxcyteIncMemberstro:SupplyAgreementMember2023-04-012023-06-300001382101us-gaap:CorporateDebtSecuritiesMember2023-12-310001382101stro:AttheMarketIssuanceSalesAgreementMember2023-04-012023-06-300001382101stro:MaterialsSupplyMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-04-012024-06-300001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001382101us-gaap:RetainedEarningsMember2024-04-012024-06-300001382101us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-06-300001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001382101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:MaterialsSupplyMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2024-01-012024-06-300001382101us-gaap:AdditionalPaidInCapitalMember2023-03-310001382101us-gaap:CorporateDebtSecuritiesMember2024-06-300001382101us-gaap:RestrictedStockUnitsRSUMember2024-06-300001382101stro:BlackstoneLifeSciencesMemberstro:TwoThousandFifteenLicenseAgreementMemberus-gaap:RoyaltyMember2023-06-012023-06-300001382101stro:TaslyLicenseAgreementMember2023-01-012023-12-310001382101stro:MaterialsSupplyMemberstro:VaxcyteAgreementsMember2023-04-012023-06-300001382101stro:IpsenAgreementMember2024-03-310001382101stro:VaxcyteAgreementsMember2024-06-300001382101us-gaap:CommonStockMember2024-03-310001382101us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001382101us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember2024-06-300001382101stro:VaxcyteIncMember2024-06-300001382101stro:VaxcyteAgreementsMember2023-01-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:AstellasLicenseAndCollaborationAgreementMember2023-04-012023-06-300001382101stro:TwoThousandFourPlanTwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember2024-01-012024-06-300001382101stro:CmoMember2024-06-300001382101srt:MinimumMember2024-01-012024-06-300001382101stro:CommonStockOptionIssuedAndOutstandingMember2023-01-012023-06-300001382101stro:WarrantsToPurchaseCommonStockMember2023-01-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:TaslyLicenseAgreementMember2024-04-012024-06-300001382101stro:RestrictedStockUnitsIssuedAndOutstandingMember2024-01-012024-06-300001382101us-gaap:RetainedEarningsMember2024-06-300001382012024-04-012024-06-300001382101stro:CommonStockAwardsIssuedAndOutstandingMember2023-12-310001382101stro:AmendedAndRestatedTwoThousandTwentyOneEquityInducementPlanMember2023-02-280001382101stro:VaxcyteIncMember2023-11-012023-11-300001382101stro:ResearchAndDevelopmentServicesMemberstro:TaslyLicenseAgreementMember2024-01-012024-06-300001382101stro:MarketableSecuritiesMember2023-12-310001382101stro:TaslyLicenseAgreementMember2022-04-012022-04-300001382101stro:MaterialsSupplyMemberstro:TwoThousandTwentyMerckMasterServicesAgreementMember2023-04-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:IpsenAgreementMember2024-01-012024-06-300001382101stro:IpsenPharmaSASMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-01-012024-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:VaxcyteAgreementsMember2024-01-012024-06-300001382101us-gaap:CommonStockMember2024-06-300001382101stro:AstellasPharmaIncAstellasMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-01-012024-06-300001382101us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:VaxcyteIncMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-01-012024-06-300001382101us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001382101us-gaap:AssetBackedSecuritiesMember2024-06-300001382101us-gaap:RetainedEarningsMember2024-01-012024-03-310001382101us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001382101us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101stro:AstellasLicenseAndCollaborationAgreementMemberstro:FinancingComponentOnUnearnedRevenueMember2024-04-012024-06-300001382101us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:VaxcyteAgreementsMember2023-01-012023-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2024-01-012024-06-300001382101us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001382101us-gaap:CommonStockMember2023-01-012023-03-310001382101stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-04-012023-06-300001382101stro:VaxcyteAgreementsMember2024-01-012024-06-300001382101stro:OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-06-012024-06-300001382101us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001382101us-gaap:RetainedEarningsMember2023-12-310001382101us-gaap:EmployeeStockOptionMemberstro:TwoThousandEighteenEquityIncentivePlanMember2023-06-300001382101stro:BlackstoneLifeSciencesMemberstro:TwoThousandFifteenLicenseAgreementMemberus-gaap:RoyaltyMember2024-01-012024-06-300001382101stro:MerckSharpAndDohmeCorporationMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2024-04-012024-06-300001382101stro:AmendmentNumberThreeTwoThousandFifteenLicenseAgreementMemberus-gaap:RoyaltyMemberstro:VaxcyteMember2024-01-012024-06-300001382101us-gaap:CommonStockMember2023-03-310001382101us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001382101us-gaap:CommonStockMember2022-12-310001382101stro:ResearchAndDevelopmentServicesMemberstro:IpsenAgreementMember2024-04-012024-06-300001382101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-06-300001382101stro:VaxcyteIncMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-04-012023-06-300001382101us-gaap:RetainedEarningsMember2022-12-310001382101stro:TwoThousandEighteenEmployeeStockPurchasePlanMember2023-12-310001382101stro:TwoThousandTwentyMerckMasterServicesAgreementMember2024-01-012024-06-300001382101stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-12-310001382101us-gaap:RestrictedStockUnitsRSUMemberstro:TwoThousandEighteenEquityIncentivePlanMember2023-01-012023-06-300001382101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:AstellasLicenseAndCollaborationAgreementMember2024-01-012024-06-300001382101stro:TwoThousandFourPlanTwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember2023-12-310001382101stro:MerckKGaADarmstadtGermanyMemberstro:CollaborationAndLicenseAgreementsAndSupplyAgreementsMember2023-01-012023-06-300001382101stro:VaxcyteIncMemberstro:SupplyAgreementMember2024-01-012024-06-300001382101stro:AstellasLicenseAndCollaborationAgreementMember2022-12-310001382101stro:ResearchAndDevelopmentServicesMemberstro:VaxcyteAgreementsMember2024-04-012024-06-300001382101stro:VaxcyteAgreementsMember2023-04-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:AstellasLicenseAndCollaborationAgreementMember2023-01-012023-06-300001382101stro:ResearchAndDevelopmentServicesMemberstro:VaxcyteAgreementsMember2023-04-012023-06-30stro:Programstro:PerformanceObligationxbrli:purexbrli:sharesiso4217:USDxbrli:sharesiso4217:USDstro:Segmentstro:GoodsAndServicesstro:Installment Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38662 Â SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Â Delaware 47-0926186 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) Â Â 111 Oyster Point Blvd, South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (650) 881-6500 Not Applicable: (Former name, former address and former fiscal year, if changed since last report) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol Â Name of each exchange on which registered Common stock, $0.001 par value Â STRO Â The Nasdaq Stock Market LLC(Nasdaq Global Market) Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer Â â˜’ Smaller reporting company â˜’ Â Â Â Â Emerging growth company Â â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of August 8, 2024, the registrant had 81,963,659 shares of common stock, $0.001 par value per share, outstanding. Â Â Table of Contents Â Â Page PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) 2 Condensed Balance Sheets 2 Condensed Statements of Operations 3 Â Condensed Statements of Comprehensive Loss 4 Â Condensed Statements of Stockholdersâ€™ Equity 5 Â Condensed Statements of Cash Flows 6 Â Notes to Unaudited Interim Condensed Financial Statements 7 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Quantitative and Qualitative Disclosures About Market Risk 37 Item 4. Controls and Procedures 38 PART II. OTHER INFORMATION Â Item 1. Legal Proceedings 39 Item 1A. Risk Factors 39 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 91 Item 3. Defaults Upon Senior Securities 91 Item 4. Mine Safety Disclosures 91 Item 5. Other Information 92 Item 6. Exhibits 93 Signatures Â 94 Â Â Â Â Â Â 1 Â PART Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements. Sutro Biopharma, Inc. Condensed Balance Sheets (Unaudited) (In thousands, except share and per share data) Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Assets Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 90,788 Â Â $ 69,268 Â Marketable securities Â Â 284,780 Â Â Â 264,413 Â Investment in equity securities Â Â 50,424 Â Â Â 41,937 Â Accounts receivable Â Â 6,950 Â Â Â 36,078 Â Prepaid expenses and other current assets Â Â 10,533 Â Â Â 9,846 Â Total current assets Â Â 443,475 Â Â Â 421,542 Â Property and equipment, net Â Â 19,414 Â Â Â 21,940 Â Operating lease right-of-use assets Â Â 20,333 Â Â Â 22,815 Â Other non-current assets Â Â 4,964 Â Â Â 3,567 Â Restricted cash Â Â 857 Â Â Â 872 Â Total assets Â $ 489,043 Â Â $ 470,736 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 6,086 Â Â $ 9,440 Â Accrued compensation Â Â 9,940 Â Â Â 14,686 Â Deferred revenue - current Â Â 73,964 Â Â Â 20,666 Â Operating lease liability - current Â Â 6,933 Â Â Â 6,420 Â Debt - current Â Â - Â Â Â 4,061 Â Accrued expenses and other current liabilities Â Â 33,062 Â Â Â 38,473 Â Total current liabilities Â Â 129,985 Â Â Â 93,746 Â Deferred revenue - non-current Â Â 21,690 Â Â Â 53,379 Â Operating lease liability - non-current Â Â 19,593 Â Â Â 23,154 Â Deferred royalty obligation related to the sale of future royalties Â Â 163,905 Â Â Â 149,114 Â Other non-current liabilities Â Â 1,694 Â Â Â 1,694 Â Total liabilities Â Â 336,867 Â Â Â 321,087 Â Commitments and contingencies (Note 6) Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, $0.001Â par value â€” 10,000,000Â shares authorizedÂ Â Â as of June 30, 2024 and December 31, 2023; noÂ shares issued andÂ Â Â outstanding as of June 30, 2024 and December 31, 2023 Â Â - Â Â Â - Â Common stock, $0.001Â par value â€” 300,000,000Â shares authorizedÂ Â Â as of June 30, 2024 and December 31, 2023; 81,861,584Â andÂ Â Â 61,009,829Â shares issued and outstanding as of June 30, 2024 Â Â Â and December 31, 2023, respectively Â Â 82 Â Â Â 61 Â Additional paid-in-capital Â Â 817,896 Â Â Â 708,975 Â Accumulated other comprehensive (loss) income Â Â (163) Â Â 21 Â Accumulated deficit Â Â (665,639) Â Â (559,408) Total stockholdersâ€™ equity Â Â 152,176 Â Â Â 149,649 Â Total Liabilities and Stockholdersâ€™ Equity Â $ 489,043 Â Â $ 470,736 Â Â See accompanying notes to unaudited interim condensed financial statements. 2 Â Sutro Biopharma, Inc. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share amounts) Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â 2024 Â Â 2023 Â Revenue Â $ 25,706 Â Â $ 10,412 Â Â $ 38,714 Â Â $ 23,086 Â Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development Â Â 62,020 Â Â Â 41,592 Â Â Â 118,898 Â Â Â 80,991 Â General and administrative Â Â 12,371 Â Â Â 14,999 Â Â Â 25,092 Â Â Â 30,511 Â Total operating expenses Â Â 74,391 Â Â Â 56,591 Â Â Â 143,990 Â Â Â 111,502 Â Loss from operations Â Â (48,685) Â Â (46,179) Â Â (105,276) Â Â (88,416) Interest income Â Â 4,911 Â Â Â 2,842 Â Â Â 9,007 Â Â Â 5,402 Â Unrealized gain on equity securities Â Â 4,808 Â Â Â 8,321 Â Â Â 8,487 Â Â Â 1,329 Â Non-cash interest expense related to the Â Â Â Â sale of future royalties Â Â (7,286) Â Â (442) Â Â (14,470) Â Â (442) Interest and other income (expense), net Â Â (1,758) Â Â (2,915) Â Â (3,971) Â Â (5,901) Loss before provision for income taxes Â Â (48,010) Â Â (38,373) Â Â (106,223) Â Â (88,028) Provision for income taxes Â Â 8 Â Â Â 151 Â Â Â 8 Â Â Â 546 Â Net loss Â $ (48,018) Â $ (38,524) Â $ (106,231) Â $ (88,574) Net loss per share, basic and diluted Â $ (0.59) Â $ (0.64) Â $ (1.49) Â $ (1.49) Weighted-average shares used in computingÂ Â Â basic and diluted net loss per share Â Â 81,224,628 Â Â Â 60,339,475 Â Â Â 71,341,211 Â Â Â 59,535,918 Â Â See accompanying notes to unaudited interim condensed financial statements. 3 Â Sutro Biopharma, Inc. Condensed Statements of Comprehensive Loss (Unaudited) (In thousands) Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Net loss Â $ (48,018) Â $ (38,524) Â $ (106,231) Â $ (88,574) Other comprehensive (loss) income: Â Â Â Â Â Â Â Â Â Â Net unrealized (loss) income on available-for-sale Â Â Â securities Â Â (50) Â Â 123 Â Â Â (184) Â Â 634 Â Comprehensive loss Â $ (48,068) Â $ (38,401) Â $ (106,415) Â $ (87,940) Â See accompanying notes to unaudited interim condensed financial statements. 4 Â Sutro Biopharma, Inc. Condensed Statements of Stockholdersâ€™ Equity (Unaudited) (In thousands, except share amounts) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Â Additional Â Other Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In- Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss) Â Â Deficit Â Â Equity Â Balances at December 31, 2023 Â Â 61,009,829 Â Â $ 61 Â Â $ 708,975 Â Â $ 21 Â Â $ (559,408) Â $ 149,649 Â Exercise of common stock options Â Â 23,748 Â Â Â Â Â Â 117 Â Â Â Â Â Â 117 Â Â Â Â Â 117 Â Issuance of common stock underÂ Â Employee Stock Purchase Plan Â Â 284,362 Â Â Â Â Â Â 911 Â Â Â Â Â Â 911 Â Vesting of restricted stock units Â Â 1,215,729 Â Â Â 1 Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Â â€” Â Â Â â€” Â Â Â 71,527 Â Issuance of common stock to Ipsen Biopharmaceuticals, Inc. Â Â Â (USA) under the Ipsen Investment Agreement Â Â 4,827,373 Â Â Â 5 Â Â Â 24,566 Â Â Â Â Â Â Â Â Â Â 24,571 Â Net unrealized loss on available-for-sale securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (50) Â Â â€” Â Â Â (50) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (48,018) Â Â (48,018) Balances at June 30, 2024 Â Â 81,861,584 Â Â $ 82 Â Â $ 817,896 Â Â $ (163) Â $ (665,639) Â $ 152,176 Â Â Â Â Â Â Â Â Â Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Â Â Additional Â Â Other Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In- Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss) Â Â Deficit Â Â Equity Â Balances at December 31, 2022 Â Â 57,499,541 Â Â $ 58 Â Â $ 670,223 Â Â $ (618) Â $ (452,615) Â $ 217,048 Â Exercise of common stock options Â Â 53,060 Â Â Â â€” Â Â Â 314 Â Â Â â€” Â Â Â â€” Â Â Â 314 Â Issuance of common stock underÂ Â Â Employee Stock Purchase Plan Â Â 239,060 Â Â Â â€” Â Â Â 1,097 Â Â Â â€” Â Â Â â€” Â Â Â 1,097 Â Vesting of restricted stock units Â Â 801,769 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock transaction associated with taxesÂ Â Â withheld on restricted stock units Â Â (73,003) Â Â â€” Â Â Â (451) Â Â â€” Â Â Â â€” Â Â Â (451) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 6,021 Â Â Â â€” Â Â Â â€” Â Â Â 6,021 Â Issuance of common stock in connection withÂ Â Â At-The-Market sale, net of issuance costs of $308 Â Â 1,641,374 Â Â Â 2 Â Â Â 10,921 Â Â Â â€” Â Â Â â€” Â Â Â 10,923 Â Net unrealized income on available-for-sale securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 511 Â Â Â â€” Â Â Â 511 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (50,050) Â Â (50,050) Balances at March 31, 2023 Â Â 60,161,801 Â Â $ 60 Â Â $ 688,125 Â Â $ (107) Â $ (502,665) Â $ 185,413 Â Vesting of restricted stock units Â Â 94,500 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock transaction associated with taxesÂ Â Â withheld on restricted stock units Â Â (1,296) Â Â â€” Â Â Â (6) Â Â â€” Â Â Â â€” Â Â Â (6) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 6,661 Â Â Â â€” Â Â Â â€” Â Â Â 6,661 Â Issuance of common stock in connection withÂ Â Â At-The-Market sale, net of issuance costs of $151 Â Â 216,036 Â Â Â â€” Â Â Â 1,048 Â Â Â â€” Â Â Â â€” Â Â Â 1,048 Â Net unrealized income on available-for-sale securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 123 Â Â Â â€” Â Â Â 123 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (38,524) Â Â (38,524) Balances at June 30, 2023 Â Â 60,471,041 Â Â $ 60 Â Â $ 695,828 Â Â $ 16 Â Â $ (541,189) Â $ 154,715 Â Â See accompanying notes to unaudited interim condensed financial statements. 5 Â Sutro Biopharma, Inc. Condensed Statements of Cash Flows (Unaudited) (In thousands) Â Â Â Six Months Ended Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Operating activities Â Â Â Â Â Â Net loss Â $ (106,231) Â $ (88,574) Adjustments to reconcile net loss to net cash used inÂ Â Â operating activities: Â Â Â Â Â Â Depreciation and amortization Â Â 3,551 Â Â Â 3,346 Â Accretion of discount on marketable securities Â Â (5,483) Â Â (3,628) Stock-based compensation Â Â 12,227 Â Â Â 12,682 Â Non-cash lease expenses Â Â 2,482 Â Â Â 1,305 Â Unrealized gain on equity securities Â Â (8,487) Â Â (1,329) Non-cash interest expense on deferred royalty obligation Â Â 14,470 Â Â Â 442 Â Other Â Â 430 Â Â Â 106 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â 29,128 Â Â Â (2,877) Prepaid expenses and other assets Â Â (2,084) Â Â (90) Accounts payable Â Â (3,292) Â Â (659) Accrued compensation Â Â (4,746) Â Â (3,633) Accrued expenses and other liabilities Â Â (5,383) Â Â 1,150 Â Deferred revenue Â Â 21,180 Â Â Â (8,728) Change in operating lease liability Â Â (3,048) Â Â (1,699) Net cash used in operating activities Â Â (55,286) Â Â (92,186) Investing activities Â Â Â Â Â Â Purchases of marketable securities Â Â (292,332) Â Â (141,361) Maturities of marketable securities Â Â 265,313 Â Â Â 268,460 Â Sales of marketable securities Â Â 11,951 Â Â Â 9,055 Â Purchases of equipment and leasehold improvements Â Â (1,202) Â Â (2,546) Net cash (used in) provided by investing activities Â Â (16,270) Â Â 133,608 Â Financing activities Â Â Â Â Â Â Proceeds from sales of common stock, net of issuance costs Â Â 71,527 Â Â Â 11,971 Â Proceeds from sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA) Â Â 25,000 Â Â Â - Â Payment of debt Â Â (4,083) Â Â (6,250) Proceeds from the sale of future royalties, net of issuance costs Â Â - Â Â Â 139,744 Â Proceeds from exercise of common stock options Â Â 117 Â Â Â 314 Â Taxes paid related to net shares settlement of restricted stock units Â Â (411) Â Â (457) Proceeds from employee stock purchase plan Â Â 911 Â Â Â 1,097 Â Net cash provided by financing activities Â Â 93,061 Â Â Â 146,419 Â Net increase in cash, cash equivalents and restricted cash Â Â 21,505 Â Â Â 187,841 Â Cash, cash equivalents and restricted cash at beginning of period Â Â 70,140 Â Â Â 48,126 Â Cash, cash equivalents and restricted cash at end of period Â $ 91,645 Â Â $ 235,967 Â Supplemental disclosure of cash flow information: Â Â Â Â Â Â Cash paid for interest Â $ 63 Â Â $ 722 Â Income tax paid Â $ 15,164 Â Â $ - Â Supplemental disclosure of non-cash investing and financing information: Â Â Â Â Â Â Purchases of equipment included in accounts payable and accrued expense Â $ 123 Â Â $ 141 Â Financing component associated with program fees Â $ 3,918 Â Â $ 5,075 Â Issuance costs related to deferred royalty obligation in accrued expenses Â $ - Â Â $ 3,536 Â Premium on common stock issued to Ipsen Biopharma, Inc. (USA) Â $ 429 Â Â $ - Â Â See accompanying notes to unaudited interim condensed financial statements. 6 Â Sutro Biopharma, Inc. Notes to Unaudited Interim Condensed Financial Statements 1. Organization and Principal ActivitiesDescription of Business Sutro Biopharma, Inc. (the â€œCompanyâ€), is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs. The Company was incorporated on April 21, 2003, and is headquartered in South San Francisco, California. The Company operates in one business segment, the development of biopharmaceutical products. Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Chief Executive Officer, the Companyâ€™s chief operating decision maker, in deciding how to allocate resources and assessing performance. The Company operates and manages its business as one operating segment. The Companyâ€™s Chief Executive Officer reviews financial information on an aggregate basis for the purposes of allocating and evaluating financial performance.All of the Companyâ€™s long-lived assets are maintained in the United States.LiquidityThe Company has incurred significant losses and has negative cash flows from operations. As of June 30, 2024, there was an accumulated deficit of $665.6 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Companyâ€™s research and development and other operational activities. As of June 30, 2024, the Company had unrestricted cash, cash equivalents, and marketable securities of $375.6 million and equity securities of $50.4 million, consisting solely of common stock of Vaxcyte, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.The Company believes that its unrestricted cash, cash equivalents, marketable securities and investments in equity securities as of June 30, 2024, will enable the Company to maintain its operations for a period of at least 12 months following the filing date of its condensed financial statements. 2. Summary of Significant Accounting PoliciesBasis of Presentation and Use of EstimatesThe accompanying interim condensed financial statements of the Company are unaudited. These interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) and the applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The December 31, 2023 condensed balance sheet was derived from the audited financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Companyâ€™s condensed Balance Sheets and the amounts of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining research and development periods under collaboration arrangements, stock-based compensation expense, valuation of marketable securities, impairment of long-lived assets, income taxes, deferred royalty obligation related to the sale of future royalties and related non-cash interest expense, and certain accrued liabilities. Actual results could differ from such estimates or assumptions. 7 Â The accompanying unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to state fairly the Companyâ€™s financial position, results of operations, comprehensive loss, and cash flows for the interim periods. The interim results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, or for any other future annual or interim period.The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Companyâ€™s audited financial statements included in the Annual Report on Form 10-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, for the year ended December 31, 2023.Recent Accounting Pronouncements Not Yet Adopted There were no new accounting pronouncements issued since the Company's filing of the Annual Report on Form 10-K for the year ended December 31, 2023, which could have a significant effect on the Company's condensed financial statements.Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed Balance Sheets that sum to the total of the same amounts shown in the Company's condensed Statements of Cash Flows. Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â (in thousands) Â Cash and cash equivalents Â $ 90,788 Â Â $ 235,095 Â Restricted cash Â Â 857 Â Â Â 872 Â Total cash, cash equivalents, and restricted cash shown in theÂ Â Â condensed Statements of Cash Flows Â $ 91,645 Â Â $ 235,967 Â Investments in Equity SecuritiesVaxcyte common stock held by the Company is measured at fair value at each reporting period based on the closing price of Vaxcyteâ€™s common stock on the last trading day of each reporting period, with any realized or unrealized gains and losses recorded in the Companyâ€™s condensed Statements of Operations.Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date and establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs that may be used to measure fair value, as follows: Level 1â€”Quoted prices in active markets for identical assets and liabilities; Level 2â€”Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3â€”Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of accounts receivable, prepaid expenses, accounts payable, accrued liabilities and accrued compensation and benefits approximate fair value due to the short-term nature of these items. 8 Â The carrying value of the deferred royalty obligation related to the sale of future royalties under the 2015 License Agreement with Vaxcyte approximates its fair value as of June 30, 2024, and is based on our current estimates of future royalties expected to be earned over the estimated life of the royalty term arrangement. See Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties for a description of the Level 3 inputs used to estimate the fair value of the liability.Revenue Recognition When the Company enters into collaboration agreements, it assesses whether the arrangements fall within the scope of ASC 808, Collaborative Arrangements ("ASC 808") based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If it concludes that payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of Accounting Standards Update (ASU) No. 2014-09 (Topic 606), Revenue from Contracts with Customers (â€œASC 606â€).Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The total revenue to date has been generated principally from collaboration and license agreements and to a lesser extent, from manufacturing, supply and services, and materials the Company provides to its collaboration partners.Collaboration Revenue: The Company derives revenue from collaboration arrangements, under which the Company may grant licenses to its collaboration partners to further develop and commercialize its proprietary product candidates. The Company may also perform research and development activities under the collaboration agreements. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial milestones and other contingent payments, and royalties based on net sales of approved products. Additionally, the collaborations may provide options for the customer to acquire from the Company materials and reagents, clinical product supply or additional research and development services under separate agreements.The Company assesses which activities in the collaboration agreements are considered distinct performance obligations that should be accounted for separately. The Company develops assumptions that require judgement to determine whether the license to the Companyâ€™s intellectual property is distinct from the research and development services or participation in activities under the collaboration agreements.At the inception of each agreement, the Company determines the arrangement transaction price, which includes variable consideration, based on the assessment of the probability of achievement of future milestones and contingent payments and other potential consideration. The Company recognizes revenue over time by measuring its progress towards the complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer.For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price ("SSP"), of each distinct performance obligation. In instances where SSP is not directly observable, the Company develops assumptions that require judgment to determine the SSP for each performance obligation identified in the contract. These key assumptions may include full-time equivalent ("FTE"), personnel effort, estimated costs, discount rates and probabilities of clinical development and regulatory success. 9 Â Upfront Payments: For collaboration arrangements that include a nonrefundable upfront payment, if the license fee and research and development services cannot be accounted for as separate performance obligations, the transaction price is deferred and recognized as revenue over the expected period of performance using a cost-based input methodology. The Company uses judgement to assess the pattern of delivery of the performance obligation. In addition, amounts paid in advance of services being rendered may result in an associated financing component to the upfront payment. Accordingly, the interest on such borrowing cost component will be recorded as interest expense and revenue, based on an appropriate borrowing rate applied to the value of services to be performed by the Company over the estimated service performance period.License Grants: For collaboration arrangements that include a grant of a license to the Companyâ€™s intellectual property, the Company considers whether the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.Milestone and Contingent Payments: At the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments, the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result in recognizing revenue for previously satisfied performance obligations in such period. The Companyâ€™s collaborators generally pay milestones and contingent payments subsequent to achievement of the triggering event.Research and Development Services: For amounts allocated to the Companyâ€™s research and development obligations in a collaboration arrangement, the Company recognizes revenue over time using a cost-based input methodology, representing the transfer of goods or services as activities are performed over

the term of the agreement.Materials Supply: The Company provides materials and reagents, clinical materials, and services to certain of its collaborators under separate agreements. The consideration for such services is generally based on FTE personnel effort used to manufacture those materials, reimbursed at an agreed upon rate in addition to agreed-upon pricing for the provided materials. The amounts billed are recognized as revenue as the performance obligations are met by the Company. Revenue subject to governmental withholding taxes is recognized on a gross basis with the withholding taxes recorded as a component of income tax expense. 3. Fair Value Measurements The following table sets forth the fair value of the Companyâ€™s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy: Â Â Â June 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 43,592 Â Â $ 43,592 Â Â $ - Â Â $ - Â Commercial paper Â Â 37,830 Â Â - Â Â Â 37,830 Â Â Â - Â Corporate debt securities Â Â 86,275 Â Â - Â Â Â 86,275 Â Â Â - Â Equity securities Â Â 50,424 Â Â Â 50,424 Â Â Â - Â Â Â - Â Asset-backed securities Â Â 65,597 Â Â - Â Â Â 65,597 Â Â Â - Â U.S. government securities Â Â 128,306 Â Â Â 128,306 Â Â Â - Â Â Â - Â Total Â $ 412,024 Â Â $ 222,322 Â Â $ 189,702 Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10 Â Â Â Â December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 56,397 Â Â $ 56,397 Â Â $ - Â Â $ - Â Commercial paper Â Â 82,152 Â Â Â - Â Â Â 82,152 Â Â Â - Â Corporate debt securities Â Â 61,894 Â Â Â - Â Â Â 61,894 Â Â Â - Â Equity securities Â Â 41,937 Â Â Â 41,937 Â Â Â - Â Â Â - Â Asset-backed securities Â Â 10,505 Â Â Â - Â Â Â 10,505 Â Â Â - Â U.S. government securities Â Â 113,652 Â Â Â 113,652 Â Â Â - Â Â Â - Â U.S. agency securities Â Â 4,961 Â Â Â - Â Â Â 4,961 Â Â Â - Â Total Â $ 371,498 Â Â $ 211,986 Â Â $ 159,512 Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Where applicable, the Company uses quoted market prices in active markets for identical assets to determine fair value. This pricing methodology applies to Level 1 investments, which are comprised of money market funds, U.S. government securities and the shares of Vaxcyte common stock held by the Company. If quoted prices in active markets for identical assets are not available, then the Company uses quoted prices for similar assets or inputs other than quoted prices that are observable, either directly or indirectly. These investments are included in Level 2 and consist of commercial paper, corporate debt securities, asset-backed securities, and U.S. agency securities. These assets are valued using market prices when available, adjusting for accretion of the purchase price to face value at maturity. A financial instrumentâ€™s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. As of June 30, 2024 and December 31, 2023, the deferred royalty obligation related to the sale of future Vaxcyte royalties was classified as Level 3 within the valuation hierarchy. Refer to Note 8 below for information relating to the Purchase Agreement between the Company and Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in potential future net sales of Vaxcyteâ€™s pneumococcal conjugate vaccine, or PCV, products, including VAX-24 and VAX-31.Investments in Equity SecuritiesAs of June 30, 2024 and December 31, 2023, the Company held 667,780 shares of Vaxcyte common stock with an estimated fair value of $50.4 million and $41.9 million, respectively. The Company recognized an unrealized gain of $4.8 million and $8.3 million for the three months ended June 30, 2024, and 2023, respectively, and an unrealized gain of $8.5 million and $1.3 million for the six months ended June 30, 2024, and 2023, respectively. 4. Cash Equivalents and Marketable SecuritiesCash equivalents and marketable securities consisted of the following: Â Â Â June 30, 2024 Â Â Â AmortizedCost Basis Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Â Â (in thousands) Â Money market funds Â $ 43,592 Â Â $ - Â Â $ - Â Â $ 43,592 Â Commercial paper Â Â 37,857 Â Â Â - Â Â Â Â (27) Â Â 37,830 Â Corporate debt securities Â Â 86,300 Â Â Â 4 Â Â Â (29) Â Â 86,275 Â Asset-based securities Â Â 65,650 Â Â Â - Â Â Â (53) Â Â 65,597 Â U.S. government securities Â Â 128,364 Â Â Â 2 Â Â Â (60) Â Â 128,306 Â Total Â Â 361,763 Â Â Â 6 Â Â Â (169) Â Â 361,600 Â Less amounts classified as cash equivalents Â Â (76,827) Â Â - Â Â Â 7 Â Â Â (76,820) Total marketable securities Â $ 284,936 Â Â $ 6 Â Â $ (162) Â $ 284,780 Â Â 11 Â Â Â Â December 31, 2023 Â Â Â AmortizedCost Basis Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Â Â (in thousands) Â Money market funds Â $ 56,397 Â Â $ - Â Â $ - Â Â $ 56,397 Â Commercial paper Â Â 82,179 Â Â Â 1 Â Â Â (28) Â Â 82,152 Â Corporate debt securities Â Â 61,887 Â Â Â 12 Â Â Â (5) Â Â 61,894 Â Asset-based securities Â Â 10,505 Â Â Â - Â Â Â â€” Â Â Â 10,505 Â U.S. government securities Â Â 113,612 Â Â Â 40 Â Â Â â€” Â Â Â 113,652 Â U.S. agency securities Â Â 4,960 Â Â Â 1 Â Â Â â€” Â Â Â 4,961 Â Total Â Â 329,540 Â Â Â 54 Â Â Â (33) Â Â 329,561 Â Less amounts classified as cash equivalents Â Â (65,144) Â Â (4) Â Â - Â Â Â (65,148) Total marketable securities Â $ 264,396 Â Â $ 50 Â Â $ (33) Â $ 264,413 Â No marketable securities had maturities of more than one year as of June 30, 2024 and December 31, 2023.There were $287.6 million and $110.9 million of investments in an unrealized loss position of $0.2 million and $33,000 as of June 30, 2024 and December 31, 2023, respectively. During the three and six months ended June 30, 2024, and 2023, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Companyâ€™s procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio after June 30, 2024, and 2023, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of June 30, 2024. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Companyâ€™s cost basis. The Company recognized no material gains or losses on its cash equivalents and current and non-current marketable securities as of June 30, 2024 and December 31, 2023 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income (loss) for the period then ended. 5. Collaboration and License Agreements and Supply Agreements The Company has entered into collaboration and license agreements and supply agreements with various pharmaceutical and biotechnology companies. See â€œNote 5. Collaboration and License Agreements and Supply Agreementsâ€ to the Companyâ€™s financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2023, or as further described below, for additional information on each of its collaboration agreements. The Companyâ€™s accounts receivable balances may contain billed and unbilled amounts from upfront payments, milestones and other contingent payments, as well as reimbursable costs from collaboration and license agreements and supply agreements. The Company performs a regular review of its customersâ€™ credit risk and payment histories, including payments made after the period end. Historically, the Company has not experienced credit loss from its accounts receivable and, therefore, has not recorded a reserve for estimated credit losses as of June 30, 2024 and December 31, 2023.In accordance with the collaboration, license and supply agreements, the Company recognized revenue as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Merck Sharp & Dohme Corporation (â€œMerckâ€) Â $ 8 Â Â $ 140 Â Â $ 14 Â Â $ 2,693 Â Astellas Pharma Inc. (â€œAstellasâ€) Â Â 24,752 Â Â Â 7,333 Â Â Â 36,137 Â Â Â 13,605 Â Tasly Biopharmaceuticals Co., Ltd. (â€œTaslyâ€) Â Â 5 Â Â Â - Â Â Â 975 Â Â Â - Â Vaxcyte, Inc. ("Vaxcyte") Â Â 846 Â Â Â 703 Â Â Â 1,493 Â Â Â 1,378 Â Ipsen Pharma SAS (â€œIpsenâ€) Â Â 95 Â Â Â - Â Â Â 95 Â Â Â - Â Bristol Myers Squibb Company (â€œBMSâ€) Â Â - Â Â Â 2,236 Â Â Â - Â Â Â 5,402 Â Merck KGaA, Darmstadt, Germany (operating in the UnitedÂ States and Canada under the name â€œEMD Seronoâ€) Â Â - Â Â Â - Â Â Â - Â Â Â 8 Â Total revenue Â $ 25,706 Â Â $ 10,412 Â Â $ 38,714 Â Â $ 23,086 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 12 Â The following table presents the changes in the Companyâ€™s deferred revenue balance from the agreements during the six months ended June 30, 2024: Â Â Six Months Ended Â Â Â June 30, 2024 Â Â Â (in thousands) Â Deferred revenueâ€”December 31, 2023 Â $ 74,045 Â Additions to deferred revenue Â Â 50,429 Â Recognition of revenue in current period Â Â (28,820) Deferred revenueâ€”June 30, 2024 Â $ 95,654 Â The Companyâ€™s balance of deferred revenue contains upfront and contingent payments for obligations from our agreements which remain partially unsatisfied. The Company expects to recognize approximately $74.0 million of the deferred revenue over the next twelve months.Collaboration with Merck2018 Merck AgreementIn July 2018, the Company entered into an agreement (the â€œ2018 Merck Agreementâ€) with Merck for access to the Companyâ€™s technology and the identification and preclinical research and development of two target programs, with an option for Merck to engage the Company to continue these activities for a third program, upon the payment of an additional amount, focusing on cytokine derivatives for cancer and autoimmune disorders. In April 2021, Merck initiated the first IND-enabling toxicology study under the first cytokine-derivative program in the collaboration. In December 2021, Merck did not extend the research term for the second research program of the collaboration, which research program reverted to the Company. The first research program of the collaboration is focused on MK-1484, a distinct cytokine derivative molecule for the treatment of cancer. The Company is eligible to receive aggregate contingent payments of up to approximately $500 million for the target program selected by Merck, assuming the development and sale of the therapeutic candidate and all possible indications identified under the collaboration. If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low-teen digit percentages on the worldwide sales of any commercial products that may result from the collaboration.In July 2022, the first patient was dosed with MK-1484 in a Phase 1 study.As of both June 30, 2024 and December 31, 2023, there was no deferred revenue under the 2018 Merck Agreement and 2021 Amendment.2020 Merck Master Services AgreementIn August 2020, the Company entered into a Pre-Clinical and Clinical Supply Agreement (the â€œ2020 Merck Master Services Agreementâ€) with Merck, wherein Merck requested the Company to provide development, manufacturing and supply chain management services, including clinical product supply, upon completion of the research programs under the 2018 Merck Agreement. As of both June 30, 2024 and December 31, 2023, there was no deferred revenue under the 2020 Merck Master Services Agreement.Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ - Â Â $ 79 Â Â $ 6 Â Â $ 204 Â Materials supply Â Â 8 Â Â Â 61 Â Â Â 8 Â Â Â 2,489 Â Total revenue Â $ 8 Â Â $ 140 Â Â $ 14 Â Â $ 2,693 Â Â 13 Â Astellas License and Collaboration AgreementIn June 2022, the Company entered into a License and Collaboration Agreement (the â€œAstellas Agreementâ€) with Astellas for the development of immunostimulatory antibody-drug conjugates for up to three biological targets, to be identified by Astellas. The Company will conduct research and pre-clinical development of any compound (as designated by Astellas) in each of the three programs in accordance with the terms of a research plan between the Company and Astellas. Astellas will have an exclusive worldwide license to develop and commercialize any such designated compound, subject to the Companyâ€™s rights to participate in cost and profit sharing in the United States, as described below. Pursuant to the Astellas Agreement, the Company received from Astellas a one-time, nonrefundable, non-creditable, upfront payment of $90.0 million during the year ended December 31, 2022. Under ASC 808 and ASC 606, the Company determined that both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the development program, and identified four performance obligations under the Astellas Agreement as: (1) performance of services related to the first target program; (2) performance of services related to the second target program; (3) performance of services related to the third target program; and (4) the Companyâ€™s estimated future services on the collaboration JSC. The transaction price of $90.0 million was allocated among the performance obligations using the Companyâ€™s best estimate of the standalone selling price, or SSP, for each of the associated performance obligations. Revenue allocated to the three target programs, which totaled $89.1 million, is being recognized on a proportional performance basis, using FTE cost as the basis of measurement, with such performance expected to occur over an estimated service period of four years for each target program. For the JSC performance obligation, revenue allocated to such performance obligation was $0.9 million, and is being recognized on a proportional performance basis using FTE cost as the basis of measurement, and such effort is expected to be incurred on a relatively consistent basis throughout the term of the Astellas Agreement. Additionally, under ASC 606, the Company determined a financing component associated with the $90.0 million upfront payment and has calculated $24.8 million as of June 30, 2024, on the unearned revenue portion beyond one year from the effective date of the agreement, which amount is being recognized as interest expense and revenue over the estimated service period for the target programs.The Company is also eligible to receive up to $422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teen percentages on worldwide sales of any commercial products that may result from the collaboration, subject to customary deductions under certain circumstances. The Company can also elect to convert any product candidate into a cost and profit-sharing arrangement, for the United States only. In the event the Company makes such election, it will share commercialization costs and profits relating to such product candidate equally with Astellas in the United States, and no royalties will be due from Astellas for net sales of such product candidates in the United States.In June 2024, Astellas notified the Company that it would not be nominating a third target program. This decision was based on Astellas' strategic portfolio considerations. Pursuant to ASC 606, Astellas' decision to not elect a third target program is a change in the scope of the original contract and thus represents a contract modification. At the date of the modification, the Company determined that the remaining research and development activities related to the first target program and the second target program to be undertaken by the Company after the notice of termination were not distinct from the related activities performed on each target prior to the modification. Accordingly, after re-allocation of the updated transaction price, the Company updated the cost-based input measure of progress for the remaining performance obligations and recorded a cumulative catch-up adjustment to revenue of $17.8 million on the modification date relating to the ongoing unsatisfied performance obligations. For the JSC performance obligation, as the remaining services were determined to be distinct from those already provided, the Company determined that the contract modification should be treated as a termination of the existing contract and the creation of a new contract, to be accounted for prospectively.Revenues under the Astellas Agreement were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Ongoing performance related to Â Â Â unsatisfied performance obligations Â $ 21,590 Â Â $ 3,239 Â Â $ 28,820 Â Â $ 5,811 Â Research and development services Â Â 1,381 Â Â Â 1,562 Â Â Â 3,004 Â Â Â 2,719 Â Financing component on unearned revenue Â Â 1,758 Â Â Â 2,532 Â Â Â 3,918 Â Â Â 5,075 Â Materials supply Â Â 23 Â Â Â - Â Â Â 395 Â Â Â - Â Total revenue Â $ 24,752 Â Â $ 7,333 Â Â $ 36,137 Â Â $ 13,605 Â 14 Â As of June 30, 2024 and December 31, 2023, there was $40.2 million and $69.0 million of deferred revenue, respectively, related to the upfront payment received by the Company under the Astellas Agreement.Collaboration with TaslyTasly License Agreement In December 2021, the Company entered into a license agreement with Tasly to grant Tasly an exclusive license to develop and commercialize STRO-002, or luveltamab tazevibulin, or luvelta, in Greater China (the â€œTasly License Agreementâ€). Tasly will pursue the clinical development, regulatory approval, and commercialization of luvelta in multiple indications, including ovarian cancer, non-small cell lung cancer, triple-negative breast cancer, and other indications in Greater China. The Company will retain development and commercial rights of luvelta globally outside of Greater China, including the United States.The Company determined that the Tasly License Agreement falls within the scope of ASC 808, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of indications for luvelta in Greater China. The Company concluded that the Tasly License Agreement contained the following units of account: i) licensed know-how and Sutro patents, license to trademark rights, and initial regulatory data and information necessary to prepare an IND; and ii) collaboration governance and information sharing activities, such as JSC participation and ongoing regulatory and pharmacovigilance support.The promises related to the licensed know-how and Sutro patents, license to trademark rights, and initial regulatory data and information necessary to prepare an IND are considered to be interdependent and not distinct from each other, representing a combined output. The Company determined that these promises are capable of being distinct from the collaboration governance and information sharing activities discussed below and further determined that this unit of account is a vendor-customer relationship and accounted for it in accordance with ASC 606. All potential future milestones and other payments were considered constrained at the inception of the Tasly License Agreement since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur. Since there is only one performance obligation accounted for under ASC 606, no allocation of the transaction price was necessary. The Company determined that the unit of account consisting of collaboration governance and information sharing activities, such as JSC participation and ongoing regulatory and pharmacovigilance support, do not represent a customer-vendor relationship between the Company and Tasly. These promises are considered to be interdependent and not distinct from each other, representing a combined output. However, the Company determined that these promises are capable of being distinct from the intellectual property and data license promises discussed above. As such, based on the nature of the agreement and collaborative activities, the Company determined that the costs associated with these governance and information sharing activities performed under the agreement will be included in research and development expenses in the Statements of Operations, with any reimbursement of costs by Tasly reflected as a reduction of such expenses. During the three and six months ended June 30, 2024, and 2023, the Company did not recognize any material reduction of research and development expenses under the Tasly License Agreement.In April 2022, the Company entered into amendment No. 1 (the â€œTasly Amendmentâ€) to the Tasly License Agreement with Tasly. Pursuant to the Tasly Amendment, the

initial nonrefundable upfront payment due by Tasly was amended to $25.0 million, and a $15.0 million payment will become payable to the Company upon the achievement of certain regulatory milestones. The Tasly Amendment also added an additional regulatory milestone payment to the Tasly License Agreement, providing additional potential payments totaling up to $350.0 million related to development, regulatory and commercialization milestones, beyond the payments described above, and made certain other ministerial edits.During 2023, the Company recognized a $5.0 million contingent payment as revenue, net of withholding tax, after Tasly received its first IND clearance by National Medical Products Administration, or NMPA, in Greater China. The withholding tax of $0.5 million was recorded as an income tax charge related to the contingent payment.During 2023, the Company also recorded a $5.0 million contingent payment, received by the Company from Tasly related to the first patient dosed in the Companyâ€™s REFRaME-O1 trial for luvelta, as deferred revenue, net of withholding tax of $0.5 million. The REFRaME-O1 study consists of two parts, Part I being the dose-finding portion and Part II being the portion of the study that will focus on the selected dose from Part I, and is intended to generate data to enable the potential registration of luvelta. Although it currently intends to conduct the REFRaME-O1 study to completion, the Company has the sole discretion to terminate the REFRaME-O1 study at any time. Given the above, the contingent payment received by the Company was considered constrained for accounting purposes during the three and six months ended June 30, 2024, since the Company could not conclude it was probable that a significant reversal in the amount of 15 Â revenue recognized would not occur. The withholding tax was recorded by the Company as a tax charge related to the received contingent payment.2023 Tasly Supply AgreementIn June 2023, the Company entered into a Master Development and Clinical Supply Agreement (the â€œ2023 Tasly Supply Agreementâ€) with Tasly, wherein Tasly requested the Company to provide development, manufacturing and supply chain management services, including clinical product supply.Revenues under the Tasly agreements were as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 5 Â Â $ â€“ Â Â $ 38 Â Â $ â€“ Â Materials supply Â Â - Â Â Â â€“ Â Â Â 937 Â Â Â â€“ Â Total revenue Â $ 5 Â Â $ â€“ Â Â $ 975 Â Â $ â€“ Â Agreements with VaxcyteVaxcyte Supply Agreement In May 2018, the Company entered into a Supply Agreement (the â€œSupply Agreementâ€) with Vaxcyte, wherein Vaxcyte engaged the Company to provide research and development services and to supply extracts and custom reagents, as requested by Vaxcyte. The pricing is based on an agreed upon cost-plus arrangement. During 2020, upon Vaxcyteâ€™s request and their agreement to reimburse the related costs, the Company entered into agreements with third-party contract manufacturing organizations, or CMOs, to conduct process transfers to allow for such CMOs to manufacture and supply extract and custom reagents for Vaxcyte. As part of the agreement with Vaxcyte, should the Company decide to purchase extract from the extract CMO, the Company would be required to reimburse Vaxcyte for a portion of all incurred process transfer costs. As of June 30, 2024 and December 31, 2023, there was $8.3 million and $6.9 million, respectively, in such accruals related to the Vaxcyte Supply Agreement.For the three and six months ended June 30, 2024, the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $2.6 million and $4.2 million, respectively, and were accounted for by the Company as a reduction to research and development expense based on the Companyâ€™s conclusion that Vaxcyte was not a customer for such activities and associated payments.For the three and six months ended June 30, 2023, the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $0.9 million and $2.8 million, respectively.Â Vaxcyte Agreement In December 2022, the Company entered into a letter agreement (the â€œVaxcyte Agreementâ€) with Vaxcyte under which the Company granted to Vaxcyte (i) authorization to enter into an agreement with an independent alternate CMO to source cell-free extract solely for the products it licensed from the Company, allowing Vaxcyte to have direct oversight over financial and operational aspects of the relationship with the CMO (â€œCMO Relationship Rightsâ€), and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract for use in connection with the exploitation of certain vaccine compositions (the â€œOptionâ€). In November 2023 (the "Exercise Date"), Vaxcyte exercised the Option by submitting written notice thereof to the Company and concurrently paid the Company $50.0 million in cash as the first of two installment payments for the Option exercise price. In May 2024, Vaxcyte paid the Company an additional $25.0 million in cash as the second of two installment payments for the Option exercise price under the Vaxcyte Agreement.Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay the Company certain additional payments totaling up to $60.0 million in cash. In the event that Vaxcyte undergoes a change of control, certain rights and payments may be accelerated. These contingent payments were considered constrained variable consideration or otherwise not eligible for revenue recognition at inception and as of June 30, 2024. 16 Â Revenues under the Vaxcyte agreements were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 650 Â Â $ 567 Â Â $ 1,297 Â Â $ 1,071 Â Materials supply Â Â 196 Â Â Â 136 Â Â Â 196 Â Â Â 307 Â Total revenue Â $ 846 Â Â $ 703 Â Â $ 1,493 Â Â $ 1,378 Â Refer to Note 8 below for information relating to the Purchase Agreement between the Company and Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in potential future net sales of Vaxcyte products, including VAX-24 and VAX-31.Â Ipsen Agreements In March 2024, the Company and Ipsen Pharma SAS (â€œIpsenâ€) entered into an Exclusive License Agreement (the â€œIpsen License Agreementâ€) pursuant to which the Company licensed to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. In consideration for the rights and licenses granted by the Company to Ipsen in the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $50.0 million in April 2024 and (ii) Ipsen Biopharmaceuticals, Inc. (USA) (â€œIpsen USAâ€), a fully-owned Affiliate of Ipsen, purchased 4,827,373 shares of the Companyâ€™s common stock for $25.0 million, at a price of approximately $5.18 per share, in accordance with the terms set forth in a certain investment agreement by and between the Company and Ipsen USA dated March 29, 2024 (the â€œIpsen Investment Agreementâ€, and, together with the Ipsen License Agreement, the â€œIpsen Agreementsâ€). The fair market value of the common stock issued to Ipsen USA in April 2024 was $24.6 million, based on the stock price on the date of issuance, resulting in a $0.4 million premium on the Ipsen Investment Agreement.Further, pursuant to the Ipsen License Agreement, upon the occurrence of a specified developmental milestone according to a specified timetable, the Company will receive a payment of up to $7.0 million and Ipsen is obligated to purchase up to an additional $10.0 million in shares of the Companyâ€™s common stock at a price per share representing a 17% premium to the VWAP of the Companyâ€™s common stock for the twenty trading day period prior to such milestone achievement, in accordance with the terms set forth in the Ipsen Investment Agreement. The Company is also eligible to receive up to an additional $447.0 million in developmental and regulatory milestones, assuming multiple indications, and up to $360.0 million in sales milestones, as well as tiered royalty payments ranging from low double-digit to mid-teen digit percentages of annual net sales of STRO-003, subject to certain adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of STRO-003 in the applicable country. Ipsen may terminate the Ipsen License Agreement for convenience with sixty calendar days prior written notice or for certain other specified reasons. The Company may terminate the Ipsen License Agreement if Ipsen or any of its Affiliates challenge the validity of any patents controlled by the Company that are licensed under the agreement. Both Ipsen and the Company may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other partyâ€™s bankruptcy event.The Company concluded that the Ipsen License Agreement contains three promised goods and services consisting of the STRO-003 license, technology transfer, and IND-enabling activities. The Company concluded that these promised goods and services are not distinct from each other, and all play an integral role in allowing Ipsen to file an IND and begin its development of STRO-003. As such, the STRO-003 license, technology transfer, and IND-enabling activities are accounted for as one single performance obligation. The Ipsen License Agreement and the Ipsen Investment Agreement are being accounted for as one arrangement because they were entered into at or near the same time and negotiated in contemplation of one another. The Company determined that the total transaction price of the Ipsen License Agreement was $50.4 million, comprised of the one-time, nonrefundable, non-creditable upfront payment of $50.0 million paid by Ipsen under the Ipsen License Agreement, and a $0.4 million premium from the Ipsen Investment Agreement.Revenue for the performance obligation will be recognized at a point in time when the Company has completed all its deliverables, i.e., STRO-003 license, technology transfer, and IND-enabling activities, at which time Ipsen would have what it needs from the Company to file an IND for STRO-003. 17 Â Revenues under the Ipsen License Agreement were as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 18 Â Â $ â€“ Â Â $ 18 Â Â $ â€“ Â Materials supply Â Â 77 Â Â Â â€“ Â Â Â 77 Â Â Â â€“ Â Total revenue Â $ 95 Â Â $ â€“ Â Â $ 95 Â Â $ â€“ Â As of June 30, 2024, there was $50.4 million of deferred revenue related to the Ipsen Agreements. 6. Commitments and ContingenciesLeasesThe Company leases certain office, laboratory and manufacturing facilities in South San Francisco, California and San Carlos, California. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional 5 years. These renewal options have not been considered in the determination of the right-of-use assets and lease liabilities associated with these leases as the Company has determined it is not reasonably certain it will exercise such options.The Company recognizes rent expense for these operating leases on a straight-line basis over the lease period. The components of lease costs, which the Company includes in operating expenses in the Company's condensed Statements of Operations, were as follows (in thousands): Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 1,984 Â Â $ 1,538 Â Â $ 3,968 Â Â $ 3,076 Â Short-term lease cost Â Â 38 Â Â Â 19 Â Â Â 91 Â Â Â 43 Â Variable lease cost Â Â 853 Â Â Â 441 Â Â Â 1,447 Â Â Â 851 Â Total lease costs Â $ 2,875 Â Â $ 1,998 Â Â $ 5,506 Â Â $ 3,970 Â During the three and six months ended June 30, 2024 and 2023, the Company recorded operating lease expense of $2.0 million and $4.0 million, respectively. As of June 30, 2024, the Company paid $4.5 million of operating lease payments related to the lease liabilities, which the Company includes in net cash used in operating activities in the Company's condensed Statements of Cash Flows.During the three and six months ended June 30, 2023, the Company recorded operating lease expense of $1.5 million and $3.1 million, respectively. As of June 30, 2023, the Company paid $3.5 million of operating lease payments related to the lease liabilities, which the Company includes in net cash used in operating activities in the Company's condensed Statements of Cash Flows.As of June 30, 2024 and December 31, 2023, the weighted-average remaining lease term was 3.3 years and 3.8 years, respectively, and the weighted-average discount rate used to determine the operating lease liability was 10.8% for both periods.As of June 30, 2024, the maturities of the Companyâ€™s operating lease liabilities were as follows (in thousands):18 Â Â Year Ending December 31, Â Amount Â Â Â (in thousands) Â Remaining in 2024 Â $ 4,684 Â 2025 Â Â 9,533 Â 2026 Â Â 8,994 Â 2027 Â Â 8,289 Â Total lease payments Â Â 31,500 Â Less: imputed interest Â Â (4,974) Operating lease liabilities Â Â 26,526 Â Less: current portion Â Â (6,933) Total lease liabilities, non-current Â $ 19,593 Â Indemnification & OtherIn the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Companyâ€™s condensed Balance Sheets, condensed Statements of Operations, or condensed Statements of Cash Flows. The Company currently has directorsâ€™ and officersâ€™ liability insurance. In addition, the Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. 7. Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Vaxcyte-related accrual under Vaxcyte Supply Agreement Â $ 8,342 Â Â $ 6,933 Â CMO-related accrual Â Â 12,260 Â Â Â 8,195 Â Clinical trials-related accrual Â Â 8,868 Â Â Â 4,283 Â Tax and related expenses Â Â 11 Â Â Â 15,165 Â Other Â Â 3,581 Â Â Â 3,897 Â Total accrued expenses and other current liabilities Â $ 33,062 Â Â $ 38,473 Â Â 8. Deferred Royalty Obligation related to the Sale of Future RoyaltiesIn June 2023, the Company entered into the Purchase Agreement with Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte products, including the Purchased Interest under the 2015 License Agreement. As described in Note 5. Collaboration and License Agreements and Supply Agreements, Vaxcyte Agreement, following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of the amendment No. 3 to the 2015 License Agreement, the revenue interest in the 4% royalty on potential future net sales of Vaxcyte products other than Vaxcyteâ€™s PCV products reverted to the Company. The Company retains the right to discover and develop vaccines for the treatment or prophylaxis of any disease that is not caused by an infectious pathogen, including cancer.In June 2023, Blackstone made an upfront payment of $140.0 million to the Company and will also pay up to an additional $250.0 million upon the achievement of various return thresholds as set forth in the Purchase Agreement.19 Â Under the Purchase Agreement, and in connection with its sale of the Purchased Interest, the Company has agreed to certain covenants with respect to the exercise of its rights under the 2015 License Agreement, including with respect to the Companyâ€™s right to amend, assign and terminate the 2015 License Agreement. The Purchase Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The Company recorded the $140.0 million upfront payment from Blackstone as a deferred royalty obligation related to the sale of future royalties on the Company's condensed Balance Sheets. Due to the Company's then ongoing manufacturing obligations under the 2015 License Agreement, the Company accounted for the proceeds as imputed debt and, therefore, will recognize future non-cash royalty revenues. Non-cash interest expense will be recognized over the estimated life of the royalty term arrangement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of potential future royalty payments to be received from Vaxcyte. As part of the sale, the Company incurred approximately $3.8 million in transaction costs, which are being amortized over the estimated life of the royalty term arrangement using the effective interest method. As future royalties are earned from Vaxcyte by Blackstone, the balance of the deferred royalty obligation will be amortized over the estimated life of the royalty term arrangement.There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the vaccine products, and other events or circumstances that could result in reduced royalty payments from Vaxcyte to Blackstone, which are not within the Company's control, and all of which would result in a reduction or increase of non-cash royalty revenues and the non-cash interest expense over the estimated life of the royalty term arrangement. The Company periodically assesses the estimated royalty payments to be earned by Blackstone from Vaxcyte and, to the extent that the amount or timing of such payments is materially different than our original estimates, the Company prospectively adjusts the imputed interest rate and the related amortization of the deferred royalty obligation. As of June 30, 2024, the effective interest rate used by the Company to amortize the liability is 18.4%.During the three and six months ended June 30, 2024, the Company recognized approximately $7.3 million and $14.5 million, respectively, of non-cash interest expense on the deferred royalty obligation, which amount will increase such balance. During the three and six months ended June 30, 2023, the Company recognized approximately $0.4 million of non-cash interest expense on the deferred royalty obligation. As of June 30, 2024, Blackstone has not received any royalty payment from Vaxcyte and, therefore, the deferred royalty obligation has not begun to be amortized.The following table shows the activity of the deferred royalty obligation for the six months ended June 30, 2024:Â Â Â June 30, 2024 Â Â Â (in thousands) Â Liability related to sale of future Vaxcyte royalties - beginning balance Â $ 149,114 Â Non-cash interest expense associated with the sale of future Vaxcyte royalties Â Â 14,470 Â Amortization of issuance costs Â Â 321 Â Liability related to the sale of future Vaxcyte royalties - ending balance Â $ 163,905 Â Â 20 Â 9. Stockholdersâ€™ Equity Common StockHolders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. The Company has reserved common stock, on an if-converted basis, for issuance as follows: Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Common stock options issued and outstanding Â Â 8,779,966 Â Â Â 7,905,032 Â Â Common stock awards issued and outstanding Â Â 6,050,784 Â Â Â 5,244,873 Â Â Remaining shares reserved for issuance under 2018 Equity Â Â Â Incentive Plan and 2021 Equity Inducement Plan Â Â 1,844,438 Â Â Â 1,777,919 Â Â Shares reserved for issuance under 2018 Employee Â Â Â Stock Purchase Plan Â Â 1,495,303 Â Â Â 914,911 Â Â Warrants to purchase common stock Â Â 127,616 Â Â Â 127,616 Â

Total Â Â 18,298,107 Â Â Â 15,970,351 Â Preferred Stock As of June 30, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock authorized with a par value of $0.001 per share. No shares of preferred stock were outstanding as of June 30, 2024 and December 31, 2023. 10. Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based CompensationÂ 2004 Equity Incentive Plan, 2018 Equity Incentive Plan, 2021 Equity Inducement Plan, and Amended and Restated 2021 Equity Inducement PlanIn September 2018, the Company adopted the 2018 Equity Incentive Plan (â€œ2018 Planâ€), which became effective on September 25, 2018. As a result, the Company will not grant any additional awards under the 2004 Equity Incentive Plan (â€œ2004 Planâ€). The terms of the 2004 Plan and applicable award agreements will continue to govern any outstanding awards thereunder. In addition to the shares of common stock reserved for future issuance under the 2004 Plan that were added to the 2018 Plan upon its effective date, the Company initially reserved 2,300,000 shares of common stock for issuance under the 2018 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2019, in an amount equal to 5% of the total number of shares of the Companyâ€™s capital stock outstanding on the last day of the preceding year (rounded to the nearest whole share), or a lesser number of shares determined by the Companyâ€™s board of directors. As a result, common stock reserved for issuance under the 2018 Plan was increased by 3,050,491 shares on January 1, 2024.In August 2021, the Company adopted the 2021 Equity Inducement Plan (â€œ2021 Planâ€), which became effective on August 4, 2021. Upon its effective date, the Company initially reserved 750,000 shares of common stock for issuance pursuant to non-qualified stock options and restricted stock units (â€œRSUsâ€) under the 2021 Plan. In accordance with Rule 5635(c)(4) of the Nasdaq listing rules, equity awards under the 2021 Plan may only be made to an employee if he or she is granted such equity awards in connection with his or her commencement of employment with the Company and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. In addition, awards under the 2021 Plan may only be made to employees who have not previously been an employee or member of the Board (or any parent or subsidiary of the Company) or following a bona fide period of non-employment of the employee by the Company (or a parent or subsidiary of the Company). At all times, the Company will reserve and keep available a sufficient number of shares as will be required to satisfy the requirements of all outstanding awards granted under the 2021 Plan.In August 2022, the Company amended and restated the 2021 Plan (the â€œAmended and Restated 2021 Planâ€) and reserved an additional 750,000 shares of common stock available for issuance under the Amended and Restated 2021 Plan to be granted by the Company to certain employees as a material inducement to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).21 Â Additionally, in February 2023, the Company amended and restated the Amended and Restated 2021 Plan and reserved an additional 500,000 shares of common stock available for issuance under the Amended and Restated 2021 Plan to be granted by the Company to certain employees as a material inducement to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The total number of shares reserved for issuance pursuant to the Amended and Restated 2021 Plan is 2,000,000 shares.As of June 30, 2024, the Company had a total of 1,844,438 shares available for grant under the 2018 Plan and the 2021 Plan.The following table summarizes option activity under the Companyâ€™s 2004 Plan, 2018 Plan and 2021 Plan: Â Â Â Shares Â Â Weighted-AverageExercise Price Â Stock options outstanding at December 31, 2023 Â Â 7,905,032 Â Â $ 11.24 Â Granted Â Â 1,284,250 Â Â Â 4.36 Â Exercised Â Â (23,748) Â Â 4.91 Â Canceled and forfeited Â Â (385,568) Â Â 10.45 Â Stock options outstanding at June 30, 2024 Â Â 8,779,966 Â Â Â 10.28 Â Stock options exercisable at June 30, 2024 Â Â 6,078,851 Â Â $ 12.09 Â Restricted Stock UnitsThe RSUs vest annually, and generally, will become fully vested over four years. A summary of the status and activity of non-vested RSUs during the six months ended June 30, 2024 is as follows:Â Â Â Number ofshares Â Â WeightedAverage Grant-DateFair Value Â Non-vested December 31, 2023 Â Â 5,244,873 Â Â $ 8.31 Â Granted Â Â 2,437,530 Â Â Â 4.49 Â Vested and released Â Â (1,323,104) Â Â 9.76 Â Canceled and forfeited Â Â (308,515) Â Â 8.53 Â Non-vested June 30, 2024 Â Â 6,050,784 Â Â $ 6.44 Â Â Â 2018 Employee Stock Purchase PlanIn September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (â€œESPPâ€), which became effective on September 26, 2018, in order to enable eligible employees to purchase shares of the Companyâ€™s common stock. The Company initially reserved 230,000 shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2019, in an amount equal to 1% of the total number of shares of the Companyâ€™s capital stock outstanding on the last day of the preceding year (rounded to the nearest whole share), or a lesser number of shares determined by the Companyâ€™s board of directors. As a result, common stock reserved for issuance under the ESPP was increased by 114,754 shares on January 1, 2023. The aggregate number of shares issued over the term of the Companyâ€™s ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed 2,300,000 shares of the Companyâ€™s common stock.At the Companyâ€™s annual stockholder meeting in June 2024, the Company amended the ESPP (the â€œAmended ESPPâ€) to increase the overall limit on the number of shares that may be issued under the Amended ESPP throughout its ten-year term from 2,300,000 shares to 3,050,0000 shares of the Companyâ€™s common stock.As of June 30, 2024, 1,554,697 shares had been purchased and 1,495,303 shares were available for future issuance under the ESPP.22 Â Stock-Based Compensation Expense Total stock-based compensation expense recognized was as follows: Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development expense: Â $ 3,072 Â Â $ 3,127 Â Â $ 6,246 Â Â $ 5,948 Â General and administrative expense: Â Â 3,087 Â Â Â 3,534 Â Â Â 5,981 Â Â Â 6,734 Â Total Â $ 6,159 Â Â $ 6,661 Â Â $ 12,227 Â Â $ 12,682 Â As of June 30, 2024, unrecognized stock-based compensation expense related to the unvested stock options and RSUs granted was $10.9 million and $31.9 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options and RSUs is expected to be recognized over a weighted-average period of 2.1 years and 2.5 years, respectively. As of June 30, 2024, there was $0.3 million of unrecognized stock-based compensation expense related to the ESPP.As of June 30, 2023, unrecognized stock-based compensation expense related to the unvested stock options and RSUs granted was $15.3 million and $38.1 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options and RSUs is expected to be recognized over a weighted-average period of 2.2 years and 2.6 years, respectively. As of June 30, 2023, there was $0.2 million of unrecognized stock-based compensation expense related to the ESPP. 11. Net Loss Per Share The following table sets forth the computation of the Companyâ€™s basic and diluted net loss per share. Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share amounts) Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (48,018) Â $ (38,524) Â $ (106,231) Â $ (88,574) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Â Shares used in computing net loss per share Â Â 81,224,628 Â Â Â 60,339,475 Â Â Â 71,341,211 Â Â Â 59,535,918 Â Net loss per share, basic and diluted Â $ (0.59) Â $ (0.64) Â $ (1.49) Â $ (1.49) The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended June 30, 2024, and 2023, because including them would have been antidilutive:Â Â Â As of June 30, Â Â Â 2024 Â Â 2023 Â Common stock options issued and outstanding Â Â 8,779,966 Â Â Â 8,351,659 Â Restricted stock units issued and outstanding Â Â 6,050,784 Â Â Â 5,212,174 Â Warrants to purchase common stock Â Â 127,616 Â Â Â 127,616 Â Shares to be issued under employee stock purchase plan Â Â 300,818 Â Â Â 203,206 Â Total Â Â 15,259,184 Â Â Â 13,894,655 Â Â 23 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion of our financial condition and results of operations in conjunction with our condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2023. In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as statements of our plans, objectives, expectations, intentions and belief. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled â€œRisk Factorsâ€ under Part II, Item 1A below. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements related to our expectations regarding our future results of operations and financial position, business strategy, market size for our product candidates, potential future milestone and royalty payments, the value of the our holdings of Vaxcyte common stock, potential growth opportunities, nonclinical and clinical development activities, efficacy and safety profile of our product candidates, our ability to maintain and recognize the benefits of certain designations received by product candidates, our ability to successfully leverage Fast Track Designation, the timing and results of nonclinical studies and clinical trials, collaboration with third parties, the expected impact of pandemics or contagious diseases, such as the COVID-19 pandemic, on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, are forward-looking statements. The words â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œpotentially,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œpredict,â€ â€œtarget,â€ â€œintend,â€ â€œcould,â€ â€œwould,â€ â€œshould,â€ â€œproject,â€ â€œplan,â€ â€œexpect,â€ and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete; and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Overview We are a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCFÂ®, and our site-specific conjugation platform, XpressCF+Â®. We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, dual conjugate ADCs, or ADC2s, and cytokine derivatives. Our molecules are directed primarily against clinically validated targets where the current standard of care is suboptimal. We believe that our platform allows us to accelerate the discovery and development of potential first-in-class and/or best-in-class molecules by enabling the rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. Our mission is to transform the lives of patients by creating medicines with improved therapeutic profiles for areas of unmet need. Once identified, production of protein drug candidates can be rapidly and predictably scaled in our current Good Manufacturing Practices, or cGMP, compliant manufacturing facility. We have the ability to manufacture our proprietary cell-free extract that supports our production of proteins on a large scale using a semi-continuous fermentation process. Our most advanced product candidate is STRO-002, or luveltamab tazevibulin, or luvelta, an ADC directed against folate receptor-alpha, or FolRÎ±, for patients with FolRÎ±-expressing cancers, including ovarian cancer. Luvelta was designed and optimized for an improved therapeutic index by placing a precise number of linker-warheads at four specific locations within the antibody using our proprietary XpressCF+Â® platform. Our first Phase 1 trial for luvelta is an open-label study evaluating luvelta as a monotherapy for patients with ovarian and endometrial cancers. This trial is being conducted in two-parts, dose escalation and dose expansion. The primary objectives of the clinical trial are to determine the safety and tolerability profile, to define the recommended Phase 2 dose level and interval and to evaluate preliminary anti-tumor activity. Our secondary objectives are to characterize the human pharmacokinetics and additional safety, tolerability, and efficacy measures. In 2019, we began enrolling patients in a Phase 1 trial of luvelta that focused on ovarian and endometrial cancers. The Phase 1 trial assessing safety, tolerability and preliminary efficacy of luvelta to treat platinum resistant ovarian cancer has been completed and near-final results from this Phase 1 trial reported in January 2024 showed that luvelta exhibited a manageable safety profile together with promising preliminary efficacy data in the tested patient population. We began enrolling patients in a Phase 2/3 trial of luvelta for the treatment of platinum-resistant ovarian cancer, the REFRÎ±ME-O1 study, in June 2023. In April 2024 we announced we had completed enrollment of Part 1 of this study and had initiated enrollment of Part 2 of the study. 24 Â In January 2024, we presented an aggregated data set from our Phase I trials of luvelta. This data set included data from all ovarian cancer patients treated with luvelta as a monotherapy in Phase 1 studies, regardless of FolRÎ± expression levels, dose level of luvelta, or platinum sensitivity or resistance, corresponding to a total of 99 patients, of which 92 were RECIST-evaluable, with 21% platinum sensitive patients and 78% platinum refractory patients. Patients received a median of three prior lines of therapy. There were 72% of the patients that had experienced prior bevacizumab therapy and 70% had been treated with a PARP inhibitor. These patients were not selected for FolRÎ± expression levels and were treated at starting dose levels â‰¤2.9 mg/kg, 4.3 mg/kg, 5.2 mg/kg or â‰¥5.6 mg/kg. The safety profile of luvelta from these aggregated data was shown to be manageable, with a low rate of discontinuation of treatment resulting from neutropenia. The predominant TEAE was neutropenia, encompassing neutropenia, febrile neutropenia, and decreased neutrophil count, with 69.7% patients reporting any grade neutropenia and 64.6% patients reporting Grade 3 or higher neutropenia. Neuropathy and arthralgia were the other most commonly reported significant TEAEs, with 57.6% and 16% of patients reporting any grade and Grade 3 or higher arthralgia, respectively, and 44% and 7% patients reporting any grade and Grade 3 or higher neuropathy, respectively. The observed neutropenia was primarily uncomplicated, with less than 5% incidence of febrile neutropenia. Neutropenia and arthralgia each led to discontinuation of treatment in 1.5% of patients. Neuropathy led to discontinuation of treatment in 2.9% of patients. There were six patients that experienced grade 5 safety events on study, with one such event assessed as probably luvelta related and the remainder assessed as unrelated to luvelta. We also presented a subset of the aggregated data from our Phase 1 trials of luvelta for which 43 patients with platinum resistant ovarian cancer selected for FolRÎ± TPS â‰¥25%, or tumors with â‰¥25% of the tumor cells expressing FolRÎ± at any level of staining intensity, were treated with 4.3 mg/kg or 5.2 mg/kg doses of luvelta, corresponding to all patients treated in phase 1 studies that would be eligible for enrollment in the REFRÎ±ME-O1 registrational study. The ORR observed for this subset population was 28%, with a DOR of 5.7 months and PFS of 5.8 months. Based on the data from our Phase 1 program, we selected FolRÎ± expression TPS â‰¥25% as the target eligibility cutoff or threshold for further study in clinical development of luvelta. We estimate that approximately 80% of the platinum resistant ovarian cancer patients would be eligible for luvelta treatment based on this TPS â‰¥25% threshold for FolRÎ± expression. We also opened for enrollment a Phase 1 trial to assess the combination of luvelta and bevacizumab for treatment of ovarian cancer in December 2021 and presented initial preliminary results of this study in January 2024. Safety signals from this study were generally consistent with those previously reported and the combination treatment with luvelta and bevacizumab demonstrated clinical activity in treated patients regardless of their FolRÎ± expression status. We expect to present updated results from the initial cohort of the bevacizumab combination study at 2024 ESMO Congress in September 2024. In addition, we are enrolling patients in the expansion phase of the bevacizumab combination Phase 1b study and expect to present initial data from this trial in in the first half of 2025. We also began enrolling patients in an expansion cohort for FolRÎ±-selected endometrial cancer in the fourth quarter of 2021 and presented initial preliminary results from the study at the 2023 ESMO Congress in October 2023. In this trial, luvelta showed encouraging preliminary anti-tumor activity in FolRÎ±-selected patients, defined by a TPS of >25% FolRÎ± expression, and the safety profile was consistent with prior data in patients with platinum-resistant ovarian cancer. Finally, our IND for the treatment of NSCLC with luvelta was cleared by the FDA in the first half of 2024 and we expect to initiate the Phase 2 study in the second half of 2024. Initial data is expected in the first half of 2025. In addition to the Phase 1 studies discussed above, we initiated a Phase 2/3 study, the REFRÎ±ME-O1 study, of luvelta for the treatment of platinum-resistant ovarian cancer in June 2023. This study comprises two parts; in Part 1, we anticipate enrolling 50 patients randomized 1:1 to two different doses of luvelta, either 4.3 mg/kg or 5.2 mg/kg plus prophylactic pegfilgrastim for two cycles, followed by reduction to 4.3 mg/kg. After proceeding to Part 2 of the study, the non-optimized dose of luvelta will be dropped and approximately 516 patients will be randomized 1:1 to the selected luvelta dose or investigators choice of chemotherapy. The protocol will include an optional interim analysis for ORR and DOR to support a potential application for accelerated approval and the endpoints that will be assessed for a potential full approval are PFS and OS. The REFRÎ±ME-O1 study patient population includes those with platinum-resistant ovarian cancer, 1-3 lines of prior treatment and tumors that express FolRÎ± at TPSâ‰¥25% and excludes primary platinum refractory patients and those with ECOG PS of 0-1. In 2022 we initiated an exploratory cohort, or cohort C, of 15 patients to assess the safety of treatment with luvelta at 5.2 mg/kg in combination with prophylactic pegfilgrastim and presented preliminary data from ten patients from this cohort in January 2023. In January 2024 we announced updated data from this cohort based on 16 patients. In particular: 25 Â â€¢Grade 3+ neutropenia was reduced from 66.7% to 6.3%, resulting in a 90.6% decrease in Grade 3+ neutropenia rates at the first cycle of luvelta (p=0.0002); Grade 3 neutropenia was reduced from 71.4% to 18.8%, resulting in a 73.7% decrease in Grade 3+ neutropenia rates at the first and second cycle (p=0.0015) â€¢Overall Grade 3+ neutropenia was reduced from 76.2% to 37.5% In addition, we have been offering compassionate use of luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2, or CBF/GLIS, acute myeloid leukemia, or AML, commonly known as RAM phenotype AML. Updated compassionate use data continued to show anti-leukemic activity of luvelta in pediatric patients with relapsed/refractory CBF/GLIS AML and was presented at ASH 2023 in December 2023. The data showed that luvelta was well tolerated as a monotherapy agent and in combination with standard cancer therapies. Luvelta was granted Orphan Drug Designation by the FDA in December 2022 in this pediatric patient population. We expect to begin enrollment of a registration-directed trial of luvelta for treatment of pediatric RAM phenotype AML in the second half of 2024. Our most advanced asset

in preclinical development is STRO-004. We believe STRO-004 has the potential to be a best-in-class ADC targeting TF. Preclinical data suggest that STRO-004 has potent antitumor activity and the potential for a differentiated safety profile. We anticipate being ready to file an IND for STRO-004 in 2025. Enabled through our proprietary XpressCFÂ® and XpressCF+Â® platforms, we have entered into multi-target, product-focused collaborations with leading pharmaceutical and biotechnology companies in the field of oncology, with our ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003; an immunostimulatory antibody-drug conjugates collaboration with Astellas; a cytokine derivatives collaboration with Merck; and a licensing agreement for luvelta in Greater China with Tasly. In August 2023, Tasly received its first IND clearance by NMPA in Greater China for luvelta. Our XpressCFÂ® and XpressCF+Â® platforms have also supported Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease. The lead programs for Vaxcyte are VAX-31 and VAX-24, its 31-valent and 24-valent, respectively, pneumococcal conjugate vaccine candidates. Vaxcyte is responsible for performing all research and development activities, and we provide technical support and supply XtractCFÂ® and other materials to Vaxcyte. In June 2023, we entered into a purchase and sale agreement (the â€œPurchase Agreementâ€) with Blackstone, in which Blackstone acquired the right to receive our 4% revenue interest in Vaxcyteâ€™s future products, including Vaxcyteâ€™s pneumococcal conjugate vaccine, or PCV, products such as VAX-24 and VAX-31. As described further below, following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of an amendment to the licensing agreement, the revenue interest in the 4% royalty on potential future sales of Vaxcyte products other than Vaxcyteâ€™s PCV products reverted to us. In November 2023, Vaxcyte exercised its option to access expanded rights to develop and manufacture cell-free extract for use in development and manufacture of its vaccine products, among certain other rights. Since the commencement of our operations, we have devoted substantially all of our resources to performing research and development and manufacturing activities in support of our own product development efforts and those of our collaborators, raising capital to support and expand such activities and providing general and administrative support for these operations. We have funded our operations to date primarily from upfront, milestone and other payments under our collaboration agreements with Merck, Astellas, Vaxcyte, Ipsen, BMS, EMD Serono, BioNova, and Tasly, the issuance and sale of redeemable convertible preferred stock, our initial public offering, or IPO, follow-on public and other offerings of common stock, sales of our common stock through our At-the-Market Facility (â€œATM Facilityâ€) pursuant to our Open Market Sales AgreementSM dated April 2, 2021 (the â€œSales Agreementâ€) with Jefferies LLC (â€œJefferiesâ€), debt financing, and the royalty monetization agreement with Blackstone. We do not have any products approved for commercial sale and have not generated any revenue from commercial product sales. We had a loss from operations of $105.3 million and a net loss of $106.2 million for the six months ended June 30, 2024, which net loss included the non-operating, unrealized gain of $8.5 million related to our holdings of Vaxcyte common stock. We had a loss from operations of $88.4 million and a net loss of $88.6 million for the six months ended June 30, 2023, which net loss included the non-operating, unrealized gain of $1.3 million related to our holdings of Vaxcyte common stock. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We cannot assure you that we will have net income or that we will generate positive cash flow from operating activities in the future. As of June 30, 2024, we had an accumulated deficit of $665.6 million. We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, access, marketing, manufacturing and distribution. Our operating expenses would significantly increase due to continued activities to develop, and seek regulatory approvals for, our product candidates, engage in other research and development activities, expand our pipeline of product candidates, continue to develop our manufacturing facility and capabilities, 26 Â maintain and expand our intellectual property portfolio, seek regulatory and marketing approval for any product candidates that we may develop, acquire or in-license other assets or technologies, ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval, and operate as a public company. Current capital market conditions provide a challenging financing environment. In this context, we are continuing our process of evaluating our programs and spending. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials, our expenditures on other research and development activities and the timing of achievement and receipt of upfront, milestones and other collaboration agreement payments. Financial Operations Overview Revenue We do not have any products approved for commercial sale and have not generated any revenue from commercial product sales. Our total revenue to date has been generated principally from our collaboration and license agreements with BMS, Merck, Astellas, Vaxcyte, Tasly, and Ipsen, and to a lesser extent, from manufacturing, supply and services and materials we provide to the above collaborators. We derive revenue from collaboration arrangements, under which we may grant licenses to our collaboration partners to further develop and commercialize our proprietary product candidates. We may also perform research and development activities under the collaboration agreements. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial milestones and other contingent payments, and royalties based on net sales of approved products. Additionally, the collaborations may provide options for the customer to acquire from us materials and reagents, clinical product supply, or additional research and development services under separate agreements. We assess which activities in the collaboration agreements are considered distinct performance obligations that should be accounted for separately. We develop assumptions that require judgement to determine whether the license to our intellectual property is distinct from the research and development services or participation in activities under the collaboration agreements. At the inception of each agreement, we determine the arrangement transaction price, which includes variable consideration, based on the assessment of the probability of achievement of future milestones and contingent payments and other potential consideration. We recognize revenue over time by measuring our progress towards the complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. For arrangements that include multiple performance obligations, we allocate the transaction price to the identified performance obligations based on the standalone selling price, or SSP, of each distinct performance obligation. In instances where SSP is not directly observable, we develop assumptions that require judgment to determine the SSP for each performance obligation identified in the contract. These key assumptions may include full-time equivalent, or FTE, personnel effort, estimated costs, discount rates and probabilities of clinical development and regulatory success. Operating Expenses Research and Development Research and development expenses represent costs incurred in performing research, development and manufacturing activities in support of our own product development efforts and those of our collaborators, and include salaries, employee benefits, stock-based compensation, laboratory supplies, outsourced research and development expenses, professional services, and allocated facilities and IT-related costs. We expense both internal and external research and development costs as they are incurred. Nonrefundable advance payments for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as expenses as the related services are performed. Our research and development expenses would increase in the future due to continued activities to advance our product candidates into and through preclinical studies and clinical trials, pursue regulatory approval of our product candidates, expand our pipeline of product candidates, and continue to develop our manufacturing facility and capabilities. The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research 27 Â and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates. The following table summarizes our research and development expenses incurred during the indicated periods. The internal costs include personnel, facility costs and research and scientific related activities associated with our pipeline. The external program costs reflect external costs attributable to our clinical development candidates and preclinical candidates selected for further development. Such expenses include third-party costs for preclinical and clinical studies and research, development and manufacturing services, and other consulting costs. Â Â

Three Months Ended Â Â	Six Months Ended Â Â Â
June 30, Â Â	June 30, Â Â Â
2024 Â Â	2023 Â Â	2024 Â Â	2023 Â Â Â
(in thousands) Â Â	(in thousands) Â
Internal costs: Â Â Â

Merck Sharp & Dohme Corporation (â€œMerckâ€) Â $ 14 Â Â $ 2,693 Â Â $ (2,679) Â Â (99)% Astellas Pharma Inc. (â€œAstellasâ€) Â Â 36,137 Â Â Â 13,605 Â Â Â 22,532 Â Â Â 166 % Tasly Biopharmaceuticals Co., Ltd. (â€œTaslyâ€) Â Â 975 Â Â Â â€“ Â Â 975 Â Â * Â Vaxcyte, Inc. ("Vaxcyte") Â Â 1,493 Â Â Â 1,378 Â Â Â 115 Â Â Â 8 % Ipsen Pharma SAS (â€œIpsenâ€) Â Â 95 Â Â Â â€“ Â Â 95 Â Â * Â Bristol Myers Squibb Company (â€œBMSâ€) Â Â â€“ Â Â Â 5,402 Â Â Â (5,402) Â Â (100)% Merck KGaA, Darmstadt, Germany (operating in the UnitedÂ States and Canada under the name â€œEMD Seronoâ€) Â Â â€“ Â Â Â 8 Â Â Â (8) Â Â (100)% Total revenue Â $ 38,714 Â Â $ 23,086 Â Â $ 15,628 Â Â Â 68 % *Percentage not meaningful Total revenue increased by $15.6 million during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This was primarily due to a $22.5 million increase from Astellas, of which $23.0 million was from the ongoing performance related to partially unsatisfied performance obligations, and included a cumulative catch-up adjustment of $17.8 million on the contract modification date from Astellas' decision not to nominate a third target program under the Astellas Agreement, $0.4 million from materials supply, and $0.3 million from research and development services, which were partially offset by a decrease of $1.2 million from the financing component related to the Astellas Agreement. Additionally, there was a $1.0 million increase in Tasly revenue, primarily due to an increase in clinical product supply under the 2023 Tasly Supply Agreement, a $0.1 million increase in Vaxcyte revenue, primarily due to an increase in research and development services and materials supply, and a $0.1 million in Ipsen revenue from research and development services and materials supply, which commenced in the second quarter of 2024. These increases were partially offset by a $5.4 million combined decrease in BMS and EMD Serono revenue due to their decisions to end clinical development of CC-99712 and M1231, respectively, in 2023, and a $2.7 million decrease in Merck revenue, primarily due to a $2.5 million decrease in manufacturing activities supporting clinical trial supply and a $0.2 million decrease in research and development services and materials supply. 31 Â Research and Development Expense Research and development expense increased by $37.9 million, or 47%, during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. The overall increase was due primarily to increases of $23.4 million in outside services mainly due to increased CMO-related activities, $6.2 million in preclinical research and clinical development expenses, $5.8 million in facilities expenses and IT-related expenses, $3.0 million in personnel related expenses due to higher headcount, and $1.7 million in equipment and office-related expenses, partially offset by a decrease of $2.2 million in laboratory supplies. General and Administrative Expense General and administrative expense decreased by $5.4 million, or 18%, during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. The overall decrease was due primarily to decreases of $5.1 million in IT-related expenses and $1.9 million in personnel related expenses, partially offset by increases of $0.8 million in outside services, $0.4 million in equipment and office-related expenses, and $0.4 million in allocated facilities-related expenses. Interest Income Interest income increased by $3.6 million during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, due primarily to higher average investment balances and higher average rates of return in 2024. Unrealized Gain on Equity Securities Unrealized gain on equity securities was $8.5 million during the six months ended June 30, 2024, as compared to an unrealized gain of $1.3 million for the six months ended June 30, 2023. The unrealized gain on equity securities in each period was entirely due to the remeasurement of the fair value of our investment in Vaxcyte common stock. Non-cash interest expense related to the sale of future royalties Non-cash interest expense increased by $14.0 million during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. Non-cash interest expense was recognized on our deferred royalty obligation related to the June 2023 sale of future Vaxcyte royalties pursuant to the Purchase Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement. Interest and Other Income (Expense), Net Interest and other income (expense), net, decreased by $1.9 million during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, due primarily to the decreases of $1.2 million from the financing component related to the Astellas Agreement and $0.7 million in interest incurred on our loan which was fully paid in March 2024. Liquidity and Capital Resources Sources of Liquidity To date, we have incurred significant net losses, and negative cash flows from operations. Our operations have been funded primarily by payments received from our collaborators, and net proceeds from equity sales, debt, and a royalty monetization. As of June 30, 2024, we had cash, cash equivalents and marketable securities of $375.6 million, equity securities of $50.4 million, and an accumulated deficit of $665.6 million. Ipsen Agreements In March 2024, we and Ipsen Pharma SAS (â€œIpsenâ€) entered into an Exclusive License Agreement (the â€œIpsen License Agreementâ€) pursuant to which we licensed to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. In consideration for the rights and licenses granted by us to Ipsen in the Ipsen License Agreement, Ipsen (i) paid us an upfront license fee in the amount of $50.0 million in April 2024 and (ii) Ipsen Biopharmaceuticals, Inc. (USA) (â€œIpsen USAâ€) purchased 4,827,373 shares of our common stock for $25.0 million, at a price of approximately $5.18 per share, in 32 Â accordance with the terms set forth in a certain investment agreement by and between us and the Ipsen USA dated March 29, 2024 (the â€œIpsen Investment Agreementâ€, and, together with the Ipsen License Agreement, the â€œIpsen Agreementsâ€). Further, pursuant to the Ipsen License Agreement, upon the occurrence of a specified developmental milestone according to a specified timetable, we will receive a payment of up to $7.0 million and Ipsen is obligated to purchase up to an additional $10.0 million in shares of our common stock at a price per share representing a 17% premium to the VWAP of our common stock for the twenty trading day period prior to such milestone achievement, in accordance with the terms set forth in the Ipsen Investment Agreement. We are also eligible to receive up to an additional $447.0 million in developmental and regulatory milestones, assuming multiple indications, and up to $360.0 million in sales milestones, as well as tiered royalty payments ranging from low double-digit to mid-teen digit percentages of annual net sales of STRO-003, subject to certain adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of STRO-003 in the applicable country. Ipsen may terminate the Ipsen License Agreement for convenience with sixty calendar days prior written notice or for certain other specified reasons. We may terminate the Ipsen License Agreement if Ipsen or any of its Affiliates challenge the validity of any patents controlled by us that are licensed under the agreement. Both Ipsen and we may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other partyâ€™s bankruptcy event. Underwritten Offering In April 2024, we closed an underwritten offering with BofA Securities, Inc., pursuant to which we issued and sold 14,478,764 shares of our common stock at an offering price of $5.18 per share. The gross proceeds from these sales were approximately $75.0 million, before deducting fees and offering expenses. Vaxcyte Agreement In May 2024, Vaxcyte paid us $25.0 million in cash as the second of two installment payments for the Option exercise price under the Vaxcyte Agreement. Leases In June 2021, we entered into a third amendment, or Third Amendment, to our manufacturing facility lease, dated May 18, 2011, as amended, by and between Alemany Plaza LLC, located at San Carlos, California, or San Carlos Lease, as an extension to the term of the San Carlos Lease for a period of five years, or the Lease Extension Period. Pursuant to the Third Amendment, the San Carlos Lease will expire on July 31, 2026, and it includes an option to renew the San Carlos Lease for an additional five years. The aggregate estimated base rent payments due over the Lease Extension Period is approximately $4.2 million, subject to certain terms contained in the San Carlos Lease. In June 2021, we entered into a first amendment, or First Amendment, to our manufacturing facility lease, dated March 4, 2015, as amended, by and between 870 Industrial Road LLC, located at San Carlos, California, or the Industrial Lease, as an extension to the term of the Industrial Lease for a period of five years, or the Industrial Lease Extension Period. Pursuant to the first Amendment, the Industrial Lease will expire on June 30, 2026, and it includes an option to renew the Industrial Lease for an additional five years. The aggregate estimated base rent payments due over the Industrial Lease Extension Period is approximately $4.3 million, subject to certain terms contained in the Industrial Lease. In September 2020, we entered into a sublease agreement, or the Sublease with Five Prime Therapeutics, Inc., or the Sublessor, for approximately 115,466 square feet, in a building located in South San Francisco, California, or the Premises. We use the Premises as our corporate headquarters and to conduct (or expand) research and development activities. We commenced making monthly payments for the first 85,755 square feet of the Premises, or Initial Premises, in July 2021, with occupancy of such space commencing in August 2021. We were provided early access to the Initial Premises in the fourth quarter of 2020 to conduct certain planning and tenant improvement work. The Sublease is subordinate to the lease agreement, effective December 12, 2016, between the Sublessor and HCP Oyster Point III LLC, or the Landlord. We commenced using the remaining 29,711 square feet of the Premises, or the Expansion Premises, on July 1, 2023 under the sublease agreement. The Sublease for both the Initial Premises and Expansion Premises will expire on December 31, 2027. With a commencement date on the Initial Premises of July 1, 2021, and Expansion Premises of July 1, 2023, the aggregate estimated base rent payments due over the term of the Sublease are approximately $39.1 million, including the approximately $5.2 million in potential financial benefit to us of base rent abatement to be provided by the Sublessor, subject to certain terms contained in the Sublease. The Sublease contains customary provisions requiring us to pay our pro rata share of utilities and a portion of the operating expenses and certain taxes, assessments and fees of the Premises and provisions allowing the Sublessor to terminate the Sublease upon the 33 Â termination of the lease with the Landlord or if we fail to remedy a breach of certain of our obligations within specified time periods. Additionally, we posted a security deposit of $0.9 million, which is reflected as restricted cash in non-current assets on our Balance Sheets as of June 30, 2024 and December 31, 2023. Funding Requirements Based upon our current operating plan, we believe that our existing capital resources will enable us to fund our operating expenses and capital expenditure requirements through at least the next twelve months after the date of this filing. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates into and through clinical development, to develop, acquire or in-license other potential product candidates, pay our obligations and to fund operations for the foreseeable future. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, marketing and distribution arrangements, royalty monetizations, or other sources of financing. Adequate additional funding may not be available to us on acceptable terms, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, and may cause us to delay, reduce the scope of or suspend one or more of our pre-clinical and clinical studies, research and development programs or commercialization efforts, and may necessitate us to delay, reduce or terminate planned activities in order to reduce costs. Due to the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies. To the extent we raise additional capital through new collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholdersâ€™ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Cash Flows The following table summarizes our cash flows during the periods indicated: Â Â Â Six Months Ended Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net cash used in operating activities Â $ (55,286) Â $ (92,186) Net cash (used in) provided by investing activities Â Â (16,270) Â Â 133,608 Â Net cash provided by financing activities Â Â 93,061 Â Â Â 146,419 Â Net increase in cash, cash equivalents and restricted cash Â $ 21,505 Â Â $ 187,841 Â Cash Flows from Operating Activities Cash used in operating activities for the six months ended June 30, 2024 was $55.3 million. Our net loss of $106.2 million included non-cash charges of $14.5 million for non-cash interest expense on our deferred royalty obligation, $12.2 million for stock-based compensation, $8.5 million for the unrealized gain on equity securities as a result of the remeasurement of the estimated fair value of our investment in Vaxcyte common stock, $5.5 million for the accretion of discount on marketable securities, $3.5 million for depreciation and amortization, and $2.5 million for non-cash lease expense. Cash used in operating activities also reflected a net change in operating assets and liabilities of $31.7 million, due to a decrease of $29.1 million in accounts receivable primarily from receiving $25.0 million from Vaxcyte as the second of two installment payments for the Option exercise price under the Vaxcyte Agreement, and an increase of $21.2 million in deferred revenue primarily due to the upfront payment from Ipsen, partially offset by revenue recognized under the Astellas Agreement, which were partially offset by a decrease of $8.7 million in accounts payable, accrued expenses and other liabilities due to timing of payments, a decrease of $4.7 million in accrued compensation expense primarily due to bonuses paid in 2024 in connection with certain company 2023 goal achievements, a decrease of $3.0 million in our operating lease liability, and an increase of $2.1 million in prepaid expenses and other assets. 34 Â Cash used in operating activities for the six months ended June 30, 2023 was $92.2 million. Our net loss of $88.6 million included non-cash charges of $12.7 million for stock-based compensation, $3.6 million for the accretion of discount on marketable securities, $3.3 million for depreciation and amortization, $1.3 million for the unrealized gain on equity securities as a result of the remeasurement of the estimated fair value of our investment in Vaxcyte common stock, $1.3 million for non-cash lease expense, and $0.4 million for non-cash interest expense on our deferred royalty obligation. Cash used in operating activities also reflected a net change in operating assets and liabilities of $16.7 million, due to a decrease of $8.7 million in deferred revenue from revenue recognized under our collaboration agreements, a decrease of $3.6 million in accrued compensation expense primarily due to bonuses paid in 2023 in connection with certain company 2022 goal achievements, an increase of $2.9 million in accounts receivable from our collaborators, a decrease of $1.7 million in our operating lease liability, and an increase of $0.1 million in prepaid expenses and other assets, which were partially offset by an increase of $0.5 million in accounts payable, accrued expenses and other liabilities due to timing of payments. Cash Flows from Investing Activities Cash used in investing activities of $16.3 million for the six months ended June 30, 2024 was primarily related to purchases of marketable securities of $292.3 million, and purchases of property and equipment of $1.2 million, principally for laboratory equipment, partially offset by maturities and sales of marketable securities of $277.2 million, . Cash provided by investing activities of $133.6 million for the six months ended June 30, 2023 was primarily related to maturities and sales of marketable securities of $277.5 million, partially offset by purchases of marketable securities of $141.4 million, and purchases of property and equipment of $2.5 million, principally for laboratory equipment. Cash Flows from Financing Activities Cash provided by financing activities of $93.1 million for the six months ended June 30, 2024 was primarily related to $71.5 million of net proceeds from the underwritten offering, $25.0 million of proceeds from Ipsen USA upon the purchase of our common stock under the Ipsen Investment Agreement, $0.9 million of net proceeds received from participants in our employee equity plans, and $0.1 million of proceeds received from the exercise of common stock options, partially offset by debt repayment of $4.1 million and a $0.4 million tax payment related to the net shares settlement of vested restricted stock units. Cash provided by financing activities of $146.4 million for the six months ended June 30, 2023 was primarily related to $139.7 million of net proceeds from the sale of future royalties, $12.0 million of net proceeds from our ATM Facility sales of common stock, $1.1 million of net proceeds received from participants in our employee equity plans, and $0.3 million of proceeds received from the exercise of common stock options, partially offset by a debt repayment of $6.3 million and a $0.5 million tax payment related to the net shares settlement of vested restricted stock units. Contractual Obligations and Other Commitments In addition to the contractual obligations and commitments as noted above and elsewhere in this Quarterly Report on Form 10-Q with regards to the leases and term loans, we enter into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. Critical Accounting Policies and Estimates Our managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the year ended December 31, 2023. 35 Â Recent Accounting Pronouncements See Note 2 to our financial statements included elsewhere in this report for more information. 36 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve our capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we

maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. We had cash, cash equivalents and marketable securities of $375.6 million and $333.7 million as of June 30, 2024 and December 31, 2023, respectively, which consisted primarily of money market funds, commercial paper, corporate debt securities, asset-based securities, U.S. government securities, and U.S. agency securities. Such interest earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant. Additionally, we had equity securities of $50.4 million as of June 30, 2024, consisting solely of common stock of Vaxcyte. Equity risk is the risk we will incur economic losses due to adverse changes in equity prices. Our potential exposure to changes in equity prices results from our Vaxcyte common stock holdings. Therefore, we are subject to market risk if such holdings materially decrease in value. A hypothetical 10 percent decrease in the market price for our equity investments as of June 30, 2024, would decrease the fair value of such investments by $5.0 million. We intend to manage equity risk going forward by continuously evaluating market conditions. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in market interest rates would not have a material impact on our financial statements. We do not believe that our cash, cash equivalents or marketable securities have a significant risk of default or illiquidity. Â 37 Â Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures As of June 30, 2024, management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2024, our disclosure controls and procedures were effective at a reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. 38 Â Â PART IIâ€”OTHER INFORMATION Â Â Item 1. Legal Proceedings. Â Â From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. Item 1A. Risk Factors RISK FACTORS Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q, including our interim condensed financial statements and the related notes and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. Summary of Risk Factors Our business is subject to a number of risks and uncertainties, including those highlighted in the section titled â€œRisk Factorsâ€ immediately following this summary. Some of these risks include: â€¢We have a history of significant losses and may never achieve or maintain profitability. â€¢We will need substantial additional funds to advance development of our product candidates and failure to obtain sufficient funding may force us to delay, limit or terminate our product development programs, commercialization efforts or other operations. We may have difficulties accessing the required additional capital on reasonable, or even any, terms to continue our product and platform development or other operations, and may have to make difficult prioritization decisions regarding development and potential partnering of our clinical and preclinical product candidates. â€¢Our product candidates are in development and may fail, be impacted by competitive products or suffer delays that materially and adversely affect their commercial viability. â€¢Our business is dependent on the success of our product candidates, including Iuvelta, which is generated from our proprietary XpressCFÂ® and XpressCF+Â® platforms. â€¢If we do not achieve our development goals in the timeframes we anticipate and project, the commercialization of our products may be delayed and, as a result, our stock price may decline. â€¢Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products. â€¢We depend on our information technology systems, and any failure of these systems, or those of our CROs, third-party vendors, or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or other personal information or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, reputation, results of operations, financial condition and prospects. â€¢Our information technology systems could face serious disruptions that could adversely affect our business. 39 Â â€¢Our failure to comply with privacy and data protection laws or to adequately secure the personal information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, member base and revenue. â€¢If our collaborations with third parties to develop and commercialize certain product candidates are not successful, we may not be able to capitalize on the market potential of our XpressCFÂ® and XpressCF+Â® platforms and the product candidates. â€¢Our inability to manufacture sufficient quantities of our product candidates or such materials, or the loss of our third-party suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business. â€¢We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected. â€¢If we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected. â€¢Our collaborators may fail to abide by the terms of the agreements with us, which would require us to seek to enforce our agreements in accordance with the dispute resolution procedures set forth therein. These procedures may require us to engage in litigation or arbitration to enforce our rights, which can be expensive, time-consuming, and distracting to our management and Board of Directors and that may ultimately end up being unsuccessful. â€¢If we are unable to develop, obtain regulatory approval for or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. Changes in regulatory policy may render our strategies for obtaining regulatory approval less effective or completely ineffective, preventing us from obtaining regulatory approval for our product candidates on time or at all. Â Risks Related to Our Business We are a clinical stage biopharmaceutical company with no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. We are a clinical stage biopharmaceutical company. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have no products approved for commercial sale, have not generated any revenue from commercial product sales and, as of June 30, 2024, had an accumulated deficit of $665.6 million. For the six months ended June 30, 2024 and the year ended December 31, 2023, our net loss was $106.2 million and $106.8 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. In addition, our expenses could increase beyond expectations if we are required by the FDA, or foreign regulatory agencies, to perform studies or clinical trials in addition to those studies and clinical trials that we currently anticipate conducting for our product candidates, or if there are any delays in our or our partners completing clinical trials or the development of any of our product candidates. Our technologies and product candidates are in varying stages of development, and we are subject to the risks of failure inherent in the development of product candidates based on novel technologies. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry. Furthermore, we do not expect to generate any revenue from commercial product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for our product candidates and manufacturing clinical and early commercial supply of our product candidates. We expect our net losses to increase substantially as we progress further into clinical development of our lead programs and create additional infrastructure to support operations as a public company. However, the amount of our future losses is uncertain. We may never generate revenues from the commercial sale of our or our collaboratorsâ€™ products. Our ability to achieve profitability, if ever, will depend on, among other things, 40 Â our, or our existing or future collaboratorsâ€™, successful development of product candidates, evaluating the related commercial opportunities, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third-party alternatives for any approved product, and raising sufficient funds to finance business activities. If we, or our existing or future collaborators, are unable to develop our technologies and commercialize one or more of our product candidates or if sales revenue from any product candidate that receives approval is insufficient, we will not achieve profitability, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. We will need substantial additional funds to advance development of our product candidates and failure to obtain sufficient funding may force us to delay, limit or terminate our product development programs, commercialization efforts or other operations. We may have difficulty accessing additional capital on reasonable, or even any, terms to continue our product and platform development or other operations and may have to make difficult prioritization decisions regarding development and potential partnering of our clinical and preclinical product candidates. The development of biopharmaceutical product candidates is capital-intensive. As our product candidates advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant funds to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates, to manufacture extract and products, if any, which may be approved for commercial sale, to establish marketing and sales capabilities to commercialize our product candidates, and to provide support to our collaborators in the development of their products. In addition, we expect to continue to incur additional costs associated with operating as a public company. Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our clinical-stage product candidates and the development of our technology platform, including our in-house manufacturing capabilities. Clinical trials for our product candidates have required substantial funds to date and will continue to require substantial funds to complete. As of June 30, 2024, we had $375.6 million in cash, cash equivalents and marketable securities. We expect to incur substantial expenditures in the foreseeable future as we seek to advance multiple product candidates through clinical development, manufacturing, the regulatory approval process and, if approved, commercial launch activities, as well as in connection with the continued development of our technology platform and manufacturing capabilities. Based on our current operating plan, we believe that our available cash, cash equivalents and marketable securities will be sufficient to fund our operations through at least the next 12 months. However, our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect, and we may need to seek additional funds sooner than planned. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities for approved products. For example, the timing and amount of our operating expenditures will depend largely on: â€¢the timing, progress and results of preclinical and worldwide clinical development activities; â€¢the costs associated with the development of our internal manufacturing and research and development facilities and processes; â€¢the number and scope of preclinical and clinical programs we decide to pursue; â€¢the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and research and development agreements; â€¢the timing and amount of milestone and other payments we may receive under our collaboration and/or research and development agreements; â€¢our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all; 41 Â â€¢our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved product candidates; â€¢the costs involved in prosecuting, defending and enforcing patent and other intellectual property claims; â€¢the costs of manufacturing our product candidates and those of our collaborators using our proprietary XpressCFÂ® and XpressCF+Â® platforms; â€¢the cost and timing of regulatory approvals; â€¢the cost of commercialization activities if our product candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs; â€¢our efforts to enhance operational systems and hire and retain key personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company; and â€¢general economic, industry and market conditions, including market volatility, high levels of inflation, changes in interest rates, uncertainty with respect to the federal debt ceiling and budget and potential government shutdowns related thereto. If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We cannot provide assurance that anticipated collaborator payments will, in fact, be received. We do not expect to realize revenue from sales of commercial products or royalties from licensed products in the foreseeable future, if at all, and, in no event, before our product candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through payments received under our collaboration and other associated agreements, the sale of equity securities, debt financing and a royalty monetization agreement. We will be required to seek additional funding in the future and currently intend to do so through additional collaborations and/or licensing agreements, public or private equity offerings or debt financings, credit or loan facilities, royalty monetization or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Any future debt financings, if available, are likely to involve, restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities receive any distribution of our corporate assets. Failure to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. Our product candidates are in varying development stages and may fail in development or be impacted by competitive products or suffer delays that materially and adversely affect their commercial viability. If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. We have no products on the market and all of our product candidates for cancer therapy are in clinical development. Our most advanced product candidate, luvelta, is being evaluated in REFRÎ±ME-O1, a Phase 2/3 pivotal trial for treatment of women with platinum resistant ovarian cancer, as well as non-small cell lung cancer and children with pediatric AML. Additionally, we have programs that are being evaluated by partners in clinical trials and by us in earlier stages of discovery and preclinical

development and may never advance to clinical-stage development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to 42 Â obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: â€¢negative or inconclusive results from our, or our licenseesâ€™ clinical trials, or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; â€¢product-related side effects experienced by patients in our clinical trials or by individuals using drugs or therapeutic biologics similar to our product candidates; â€ ¢difficulty achieving successful continued development, or transfer to third-parties, of our internal manufacturing processes, including process development and scale-up activities to supply products for preclinical studies, clinical trials and commercial sale; â€¢delays in submitting INDs or comparable foreign applications or delays or failures in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; â€¢conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; â€¢delays in enrolling patients or high drop-out rates in our clinical trials; â€¢inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; â€¢inability to obtain alternative sources of supply for which we have a single source for product candidate components or materials; â€¢occurrence of epidemics, pandemics or contagious diseases and potential effects on our business, clinical trial sites, highly complex supply chain and manufacturing facilities; â€¢greater than anticipated costs of our clinical programs; â€¢harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials, which can be unpredictable even in light of earlier non-clinical and clinical data; â€¢failure to demonstrate in our clinical trials a sufficient response rate or duration of response; â€ ¢failure to demonstrate a benefit-risk profile acceptable to the FDA or other regulatory agencies; â€¢unfavorable FDA or other regulatory agency inspection and review of one or more of our clinical trial sites or manufacturing facilities; â€¢failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; â€¢delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; and â€¢varying interpretations of our data by the FDA and similar foreign regulatory agencies. 43 Â We or our collaboratorsâ€™ inability to complete development of or commercialize our product candidates or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects. Our business is dependent on the success of our product candidates, including luvelta, which is generated from our proprietary XpressCFÂ® and XpressCF+Â® platforms. Existing and future preclinical studies and clinical trials of our product candidates may not be successful. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. We have invested a significant portion of our efforts and financial resources in the development of our proprietary XpressCFÂ® and XpressCF+Â® platforms and our proprietary product candidates, luvelta and STRO-004. Our ability to generate commercial product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. We have not previously submitted a new drug application, or NDA, or a biologics license application, or BLA, to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. In addition, while the REFRÎ±ME-O1 Phase 2/3 pivotal trial of luvelta is designed to support a regulatory approval for the treatment of women with platinum resistant ovarian cancer by the FDA or equivalent regulatory agencies, we cannot assure you that the FDA will agree with our conclusions or require data prior to approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved. We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approvals generally is similar in other countries, in order to obtain separate regulatory approvals in other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions. The success of luvelta, STRO-004 and our other future proprietary product candidates will depend on many factors, including the following: â€¢successful enrollment of patients in, and the completion of, our clinical trials; â€¢receiving required regulatory approvals for the development, manufacturing, and commercialization of our product candidates; â€¢establishing our commercial manufacturing capabilities or making arrangements with third-party manufacturers; â€¢establishing successful technology transfers and collaborations to develop our product candidates with licensees, including our licensees with rights to luvelta in Greater China; â€¢obtaining and maintaining patent, trademark and trade secret protection and non-patent exclusivity for our product candidates and their components; â€¢enforcing and defending our intellectual property rights and claims and avoiding or defending against intellectual property rights and claims from third parties; â€¢achieving desirable therapeutic properties for our product candidatesâ€™ intended indications; â€¢launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties; 44 Â â€¢acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; â€¢effectively competing with other therapies, including those that have not yet entered the market; â€¢maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval; and â€¢achieving commercially relevant success in the market post approval. Many of these factors are out of our control and if we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business, financial condition, results of operations and prospects. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and cliniciansâ€™ and patientsâ€™ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance. We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Additionally, we have in the past and may in the future create benchmark molecules for comparative purposes. For example, we have created a benchmark FolRÎ± targeting antibody-drug conjugate, or ADC, using conventional technology that results in a heterogeneous ADC mixture. We have compared luvelta to this benchmark molecule in multiple preclinical models. We believe the results of these tests help us understand how the therapeutic index of luvelta compares to competitorsâ€™ product candidates. However, we cannot be certain that any benchmark molecule that we create is the same as the molecule we are attempting to recreate, and the results of the tests comparing any such benchmark molecule to any other potential or current product candidate may be different than the actual results of a head-to-head test of any such other potential or current product candidate against a competitor molecule. Additional preclinical and clinical testing will be needed to evaluate the therapeutic index of our potential or current product candidates, and to understand their therapeutic potential relative to other product candidates in development. While we believe our ADCs may be superior to other investigative agents in development, without head-to-head comparative data, we will not be able to make claims of superiority to other products in our promotional materials, if our product candidates are approved. If we do not achieve our projected development goals in the time frames we anticipate and project, the commercialization of our products may be delayed and our stock price may decline. From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory, commercial and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control, such as health epidemics and pandemics, global instability and geopolitical conflicts within regions where our clinical trials are conducted. For example, we have opened a clinical trial site in Israel, which may face enrollment, operational or other difficulties due to conflicts within the region, including, for example, difficulties importing clinical study drug through Israeli customs, difficulties with patient enrollment, or difficulties with patients or medical personnel accessing appropriate medical facilities. In addition, we rely on third party vendors, contractors and consultants to provide services in connection with our clinical trials. If these third parties do not perform their services in a timely or workmanlike manner, our clinical studies may be delayed. If we do not meet these milestones as publicly announced, or at all, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline. 45 Â Our approach to the discovery and development of our therapeutic treatments is based on novel technologies, including unprecedented Immunostimulatory Antibody Drug Conjugate, or iADC, and dual Antibody Drug Conjugates, or ADC2 technology, that are unproven and may not result in marketable products. We are developing a pipeline of product candidates using our proprietary XpressCFÂ® and XpressCF+Â® platforms. We believe that product candidates identified with our product discovery platform may offer an improved therapeutic approach by taking advantage of precision design and rapid empirical optimization, thereby reducing the dose-limiting toxic effects associated with existing products. However, the scientific research that forms the basis of our efforts to develop product candidates based on our XpressCFÂ® and XpressCF+Â® platforms is ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our XpressCFÂ® and XpressCF+Â® platforms is both preliminary and limited. To date, our clinical stage product candidates have been tested in a relatively limited number of clinical trial patients. We may ultimately discover that our XpressCFÂ® and XpressCF+Â® platforms and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness. XpressCFÂ® product candidates may also be unable to remain stable in the human body for the period of time required for the drug to reach the target tissue or they may trigger immune responses that inhibit the ability of the product candidate to reach the target tissue or that cause adverse side effects in humans. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary properties into these product candidates derived from our XpressCFÂ® and XpressCF+Â® platforms. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, product candidates based on our XpressCFÂ® and XpressCF+Â® platforms may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Although our XpressCFÂ® and XpressCF+Â® platforms and certain product candidates have produced successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. Further, in our oncology clinical trials to date, we have used achievement of stable disease as evidence for disease control (stable disease, partial response or complete response) by our product candidates; however, the FDA does not view stable disease as an objective response for the purposes of FDA approval. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects could result in the delay, suspension or termination of clinical trials by us or regulatory authorities for a number of reasons. In our clinical trials to date, our product candidates have been generally well tolerated, and the most common treatment-emergent adverse events, or TEAEs, that resulted in a treatment delay or dose reduction was reversible neutropenia and myalgia/arthralgia, which has also been observed as a TEAE. It is possible that, as we test our product candidates in larger, longer and more extensive clinical trials or as the use of our product candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly. If product candidates based on our XpressCFÂ® and XpressCF+Â® platforms are unable to demonstrate sufficient safety and efficacy data to obtain marketing approval, we may never succeed in developing a marketable product, we may not become profitable and the value of our common stock will decline. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied product candidates. We are not aware of any company currently developing a therapeutic using our approach to ADC, iADC or ADC2 development and no regulatory authority has granted approval for such a therapeutic. We believe the FDA has limited experience with therapeutics in oncology or other disease areas developed in cell-free-based synthesis systems, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. For example, our XpressCFÂ® ADC product candidates contain cleavable or non-cleavable linker-warhead combinations or novel warheads that may result in unforeseen events when administered in a human. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or an existing or future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If the products resulting from our XpressCFÂ® platform prove to be ineffective, unsafe or commercially unviable, our entire platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. 46 Â Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and preliminary results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. While certain relevant members of our company have significant clinical experience, we in general have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, current or future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial patients. In addition, results from compassionate use of our product candidates, such as luvelta to treat pediatric CFB/GLIS AML, may not be confirmed in Company-sponsored trials and/or may negatively impact the prospects for marketing approval for our product candidates. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted. Interim, top-line, or preliminary data from our clinical trials that we announce may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we have publicly disclosed, and in the future will disclose, interim, top-line, or preliminary data from our preclinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review and/or maturation of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate

all data. Therefore, final results from the studies may differ from the top-line results initially reported, and the final results may indicate different conclusions once additional data have been evaluated. As such, top-line data should be viewed with caution until the final data are available. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive data, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the final results differ from the interim, top-line, or preliminary data, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and to commercialize, our product candidates may be harmed, which may negatively affect our business, financial condition, results of operations, and prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses, or may interpret or weigh the importance of data differently, which could negatively affect the approvability or commercialization of the particular product candidate. The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates. Even if regulatory approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost, competition in the therapeutic area(s) we have received or may receive approval for, and whether it will otherwise be accepted in the market. Historically, there have been concerns regarding the safety and efficacy of ADCs, and an ADC drug was voluntarily withdrawn from the market for an extended period of time. These historical concerns may negatively impact the perception market participants have on ADCs, including our product candidates. Additionally, the product candidates that we are developing are based on our proprietary XpressCFÂ® and XpressCF+Â® platforms, which are new technologies. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party 47 Â payors, may not adopt an ADC product, or a product or treatment based on our novel cell-free production technologies, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on the following, among other factors: â€¢the timing of our receipt of any marketing and commercialization approvals; â€¢the terms of any approvals and the countries in which approvals are obtained; â€¢the safety and efficacy of our product candidates; â€¢the prevalence and severity of any adverse side effects associated with our product candidates; â€¢limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; â€¢relative convenience and ease of administration of our product candidates; â€¢the willingness of patients to accept any new methods of administration; â€¢the success of our physician education programs; â€¢the availability of coverage and adequate reimbursement from government and third-party payors; â€¢the availability of commercially approved companion diagnostic or assay or biomarker to appropriately identify patients that will benefit from treatment; â€¢the pricing of our products, particularly as compared to alternative treatments; and â€¢the availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. Because our product candidates are based on new technology, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects. iADC and ADC2 are novel technologies, which makes it difficult to predict the time, risks and cost of development and of subsequently obtaining regulatory approval of these potential product candidates. Certain of our preclinical product candidates are based on our proprietary iADC and ADC2 technology. Some of our future success depends on the successful development of this technology and products based on it. To our knowledge, no regulatory authority has granted approval to any person or entity, including us, to market and commercialize therapeutics using our novel and unprecedented iADC or ADC2 technology. We may never receive approval to market and commercialize any potential iADC or ADC2 product candidate. If we uncover any previously unknown risks related to our iADC and ADC2 technology, or if we experience unanticipated or unsolvable problems or delays in developing our iADC or ADC2 product candidates, we may be unable to complete our preclinical studies and clinical trials, meet the obligations of our collaboration and license agreements or commercialize our product candidates on a timely or profitable basis. If serious adverse events or unacceptable side effects are observed in preclinical studies or clinical trials of a product candidate based on our iADC or ADC2 technology, or if iADCs or ADC2s were shown to have limited efficacy, our ability to develop other product candidates based on our iADC or ADC2 technology would be adversely affected. We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates using our XpressCFÂ® and XpressCF+Â® platforms. 48 Â If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our XpressCFÂ® and XpressCF+Â® platforms and resulting product candidates. Since 2014, we have entered into several collaborations to develop and commercialize certain cancer and other therapeutics. Our XpressCFÂ® and XpressCF+Â® platforms have also supported a spin-out company, now known as Vaxcyte Inc., focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease. In addition, we may in the future seek third-party collaborators for research, development and commercialization of other therapeutic technologies or product candidates. Biopharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. With respect to our existing collaboration agreements, and what we expect will be the case with any future collaboration agreements, we have and would expect to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaboratorsâ€™ abilities to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates currently pose, and will continue to pose, the following risks to us: â€¢collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; â€¢collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaboratorsâ€™ strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; â€¢collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; â€¢collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; â€¢collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; â€¢collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability; â€¢collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; â€¢disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and â€¢collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. Moreover, if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects. 49 Â Our existing collaborations with Astellas, Ipsen, Merck, Vaxcyte and Tasly are important to our business. If our collaborators cease development efforts under our existing or future collaboration agreements, fail to fulfill their contract obligations, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements. We have entered into collaborations with other biotechnology companies to develop or commercialize several of our product candidates, and such collaborations currently represent a significant portion of our product pipeline and discovery and preclinical programs. A substantial portion of our revenue to date has been derived from our collaborations, and a significant portion of our future revenue and cash resources is expected to be derived from some of these agreements, our royalty monetization agreement, or the Purchase Agreement, with an affiliate of Blackstone Life Sciences, or Blackstone, or other similar agreements into which we may enter in the future. Revenue from research and development collaborations depends upon continuation of the collaborations, payments for research and development and other services and product supply, and the achievement of milestones, contingent payments and royalties, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates, achieve milestones or earn contingent payments under our collaboration agreements or royalty monetization agreement, future revenue and cash resources will be substantially less than expected. We are unable to predict the success of our collaborations and we may not realize the anticipated benefits of our strategic collaborations. Our collaborators have discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, they apply to the development and, if approval is obtained, commercialization and marketing of the product candidates covered by such collaborations. As a result, our collaborators may elect to de-prioritize our programs, change their strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. For example, each of EMD Serono and BMS elected not to continue the development of their licensed candidates and Astellas decided not to nominate a third program under our collaboration, each such decision was noted as based on strategic portfolio considerations. Our collaborators may have other marketed products and product candidates under collaboration with other companies, including some of our competitors, and their corporate objectives may not be consistent with our best interests. Our collaborators may also be unsuccessful in developing or commercializing our products. If our collaborations are unsuccessful, our business, financial condition, results of operations and prospects could be adversely affected. Our collaborators may fail to live up to the terms of their agreements with us, which would require us to seek to enforce our agreements in accordance with the dispute resolution procedures set forth therein. These procedures may require us to engage in litigation or arbitration to enforce our rights, which can be expensive, time-consuming and distracting to our management and Board of Directors. Further, the type and timing of resolution of such disputes are difficult to predict; and there is the potential that we could fail to enforce our rights either in part or in whole. Lastly, even if we successfully enforce our rights under our agreements with our collaborators, there is the possibility that we could fail to recover our expectancy following the litigation or arbitration, particularly for collaborators that are not subject to the jurisdiction of U.S. courts. In addition, from time to time we may have disputes with our collaborators. Any dispute or litigation proceedings we may have with our collaborators could delay development programs, reduce or eliminate potential milestone or other payments, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense. Moreover, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management. From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases or sales and out- or in-licensing of product candidates or technologies that we believe will complement or augment our existing business. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations, or the 50 Â collaborator terminates the collaboration. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future strategic partners. Additionally, antitrust or other competition laws, including increased enforcement within the United States in the healthcare space, may also limit our ability to enter into collaborations with certain businesses or to fully realize the benefits of strategic transactions. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the strategic partnerâ€™s resources and expertise, the terms and conditions of the proposed collaboration and the proposed strategic partnerâ€™s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership, without regard to the merits of the challenge, and industry and market conditions generally. Moreover, if we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets due to an inability to successfully integrate them with our existing technologies and may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that following any such collaboration, or other strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our managementâ€™s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. To date, no product developed on a cell-free manufacturing platform has received approval from the FDA, so the requirements for the manufacturing of products using our XpressCFÂ® and XpressCF+Â® platforms are uncertain. We have invested in our own current Good Manufacturing Practices, or cGMP, compliant manufacturing facility in San Carlos, California. In this facility, we are developing and implementing novel, proprietary cell-free production technologies to supply our planned preclinical and clinical trials. However, before we may initiate a clinical trial or commercialize any of our product candidates, we must demonstrate to the FDA that the chemistry, manufacturing and controls for our product candidates meet applicable requirements, and in the European Union, or EU, a manufacturing authorization must be obtained from the appropriate EU regulatory authorities. The FDA has allowed clinical trial use of our product candidate luvelta, and our partner Merckâ€™s MK-1484 product candidate, portions of which are manufactured in our San Carlos manufacturing facility; however, because no product manufactured on a cell-free manufacturing platform has yet been approved in the United States, there is no manufacturing facility that has demonstrated the ability to comply with FDA requirements for later stage clinical development or commercialization, and, therefore, the time frame for demonstrating compliance to the FDAâ€™s satisfaction is uncertain. Delays in establishing that our manufacturing process and facility comply with cGMPs or disruptions in our manufacturing processes, implementation of novel in-house technologies or scale-up activities, may delay or disrupt our development efforts. We have ongoing technology transfers to enable large scale manufacture of extract and the reagents necessary to manufacture our products using our XpressCFÂ®

and XpressCF+Â® platforms. These large scale technology transfers may fail or be delayed, resulting in impacts to our development timelines and the costs associated with manufacturing our development products. 51 Â We expect to rely on third parties to conduct certain of our preclinical studies or clinical trials. If those third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospects. We do not have the ability to independently conduct all aspects of our preclinical testing or clinical trials ourselves. We have accordingly relied in some cases and intend to rely in the future on third-party clinical investigators, clinical research organizations, or CROs, clinical data management organizations and consultants to assist or provide the design, conduct, supervision and monitoring of preclinical studies and clinical trials of our product candidates. Because we intend to rely on these third parties and will not have the ability to conduct all preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations and prospects. Our inability to manufacture sufficient quantities of our product candidates, or the loss of our third-party suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business. Manufacturing is a vital component of our business strategy. To ensure timely and consistent product supply, we currently use a hybrid product supply approach wherein certain elements of our product candidates are manufactured internally at our manufacturing facilities in San Carlos, California, and other elements, including raw and intermediate materials, are manufactured at qualified third-party CMOs. Since our own manufacturing facilities may be limited or unable to manufacture certain of our preclinical and clinical trial product materials and supplies, we rely on third-party contract manufacturers to manufacture such clinical trial product materials and supplies for our or our collaboratorâ€™s needs. For example, we have entered into a manufacturing agreement with EMD Millipore Corporation to perform conjugation of the applicable linker-warhead with the antibody component of our luvelta product candidate. We have also entered into agreements with Capua Bioservices, S.p.A. and with AGC Biologics GmbH for the manufacture of certain reagents used in the manufacture of our products with our XpressCFÂ® and XpressCF+Â® platforms. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. Further, while efforts are made to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. In particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements. In addition, replacement of a manufacturer may require a technology transfer to the new manufacturer, which involves technical risk that the transfer may not succeed or may be delayed, and which can incur significant costs. The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. If we or our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on our or their manufacturing facilities for the manufacture of elements of our product candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with 52 Â current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty applying such skills or technology ourselves, or in transferring such to another third party. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third partyâ€™s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: â€¢an inability to initiate or continue clinical trials of product candidates under development; â€¢delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; â€¢loss of an existing or future collaborator; â€¢losses resulting from an inability to utilize reserved manufacturing capacity because of delays or difficulties encountered in the supply chain; â€¢subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; â€¢requirements to cease distribution or to recall batches of our product candidates; and â€¢in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. Additionally, we and our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes, unstable political environments, or epidemics, pandemics, or contagious diseases or failures or delays in our manufacturing supply chain. For example, restrictions on travel imposed by governments, including China, or restrictions on person-in-plant permissions imposed by our contract manufacturers may limit the ability of our subject matter experts to visit our manufacturers and assist with technology transfers. Further, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providersâ€™ ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation. If we or our contract manufacturers were to encounter interruptions from any of these events or other unforeseen events, our ability to provide our product candidates to patients in clinical trials, or to provide product for treatment of patients once approved, would be jeopardized. We, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates or materials used to manufacture components of our product candidates in sufficient quality and 53 Â quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. We, or any manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates, or materials used in manufacturing components of our product candidates, in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. Scaling up a biologic manufacturing process is a difficult and uncertain task, and we may not be successful in transferring our production system or our third-party manufacturers may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or scale-up the manufacturing process at our own manufacturing facilities or those of our current manufacturers, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates at our manufacturing facility or with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us. The manufacture of biologics is complex and we or our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped. Our product candidates are considered to be biologics and the process of manufacturing biologics and materials used to manufacture components of our products can be complex, time-consuming, highly regulated and subject to multiple risks. We and our contract manufacturers must comply with cGMPs, regulations and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. To date, we and our contract manufacturers have limited experience in the manufacturing of cGMP batches of our product candidates and materials used to manufacture components of our product candidates. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at our manufacturing facilities or those of our third-party manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our manufacturing facilities or those of our third-party manufacturers are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance. In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency, timely availability of raw materials and other technical challenges. Even if we or our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects. We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. If we or our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any 54 Â adverse developments affecting clinical or commercial manufacturing of our product candidates or products, such as epidemics, pandemics or contagious diseases, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, financial condition, results of operations and prospects. As part of our process development efforts, we also may make changes to our manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. We may not be successful in our efforts to use our XpressCFÂ® and XpressCF+Â® platforms to expand our pipeline of product candidates and develop marketable products. The success of our business depends in large part upon our ability to identify, develop and commercialize products based on our XpressCFÂ® and XpressCF+Â® platforms. Luvelta is our most advanced clinical stage program, and our preclinical and research programs may fail to identify other potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success. Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. For example, in June 2023, we announced our Purchase Agreement with Blackstone. Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our product candidates could harm our drug development strategy and operational results. If companion diagnostics are developed in conjunction with clinical programs, the FDA may require regulatory approval of a companion diagnostic as a condition to approval of the product candidate. For example, as we are developing luvelta for treatment of patients having ovarian cancer with elevated FolRÎ± expression levels, we are likely to be required to obtain FDA approval or clearance of a companion diagnostic, concurrent with approval of luvelta, to test for elevated FolRÎ± expression. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We have entered into an agreement to develop diagnostic assays suitable for use as a companion diagnostic for luvelta. Companion diagnostics are subject to regulation by the FDA and foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization. We may also be required to demonstrate to the FDA the predictive utility of the companion 55 Â diagnosticâ€”namely, that the diagnostic selects for patients in whom the biologic therapy will be effective or more effective compared to patients not selected for

by the diagnostic. If we or our collaborators, or any third party, are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so: â€¢the development of our product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our planned clinical trials; â€¢our product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and â€¢we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our product candidates. In addition, although we believe genetic testing is becoming more prevalent in the diagnosis and treatment of various diseases and conditions, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates. If any of these events were to occur, our business would be harmed, possibly materially. We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected. The development and commercialization of drugs and therapeutic biologics is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources, including financial, technical, manufacturing, marketing, sales, supply, human resources, or general experience than we do and we may not be able to successfully compete. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as with technologies and product candidates being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments, including those based on novel technology platforms, that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are trying, or may try, to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody and immunoregulatory therapeutics fields. While we believe that our XpressCFÂ® and XpressCF+Â® platforms, associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources exists or may arise in the future. Our competitors include larger and well-funded biopharmaceutical, biotechnological and therapeutics companies, including large and specialty companies focused on cancer immunotherapies and ADCs, as well as numerous small and mid-cap companies. Moreover, we also compete with current and future therapeutics developed at research-stage biotechnology companies, universities and other research institutions. We are aware of several companies that are developing ADCs, cytokine derivatives, bispecific antibodies and cancer immunotherapies, including companies developing ADCs directed to the same target as luvelta. For example, Immunogen recently received approval for a folate receptor Î± targeted ADC, mirvetuximab soravtansine (ElahereÂ®) and was subsequently acquired by Abbvie Inc. In addition, large pharmaceutical companies and smaller biotechnology companies are developing other ADCs; and we anticipate more FolRÎ±-targeting ADCs and other potential FolRÎ±-targeting modalities to be evaluated in the clinic in the coming years. Further, other companies may develop ADCs targeting receptors other than folate receptor Î± for the treatment of the same indications for which we are developing luvelta. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future collaborators. In addition, these companies compete with us in recruiting scientific and managerial talent. 56 Â Our success will depend partially on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop. If our most advanced product candidates are approved, they will compete with a range of therapeutic treatments that are either in development or currently marketed. Currently marketed oncology therapeutics include a range of biologic modalities with the top selling products by class spanning tumor targeting monoclonal antibodies, to ADCs, to immune checkpoint inhibitors, to T cell-engager immunotherapies, and to CAR-T cell therapies. In addition, numerous compounds are in clinical development for cancer treatment. The clinical development pipeline for cancer includes small molecules, antibodies, vaccines, cell therapies and immunotherapies from a variety of companies and institutions. Further, if we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement, coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. We are highly dependent on the research and development, clinical development, manufacturing, and business development expertise of our management team, advisors and other specialized personnel. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and XpressCFÂ® and XpressCF+Â® platform technologies and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Should our competitors recruit our key employees, our level of expertise and ability to execute our business plan would be negatively impacted. Further, if we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates will be limited, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations. As of June 30, 2024, we had 304 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development and began our first clinical trial in 2018. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects. If any of our product candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to 57 Â perform these functions on acceptable terms, we will be unable to commercialize successfully any such future products. We currently have limited sales, marketing and distribution capabilities or experience. If any of our product candidates are approved, we will need to develop additional sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time consuming, or enter into collaborations with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and support distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote products with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance or adoption of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets, for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market and may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and do not receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business, financial condition, results of operations and prospects could be materially and adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. Price controls imposed in either the U.S. or foreign markets may adversely affect our future profitability. Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in recent Executive Orders, several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Current and future presidential budget proposals and future legislation may contain further drug price control measures that could be enacted. Congress and current and future U.S. presidential administrations may continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. If such pricing controls are enacted and are set at unsatisfactory levels, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, in some countries, particularly member states of the EU, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, 58 Â we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations and prospects could be materially and adversely affected. Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. As we are conducting clinical trials of our product candidates, we may be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of managementâ€™s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. While we currently have product liability insurance that we believe is appropriate for our stage of development, we may need to obtain higher levels prior to later stages of clinical development or marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. As with all companies, we are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, inappropriately share confidential and proprietary information externally, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm. Moreover, our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition, results of operations and prospects. Our employees could also inappropriately utilize artificial intelligence, or AI, in connection with their social media communications, introducing another potential source of reputational damage or other potential legal or financial exposure. 59 Â We depend on our information technology systems, and any failure of these systems, or those of our

CROs, third-party vendors, or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or other personal information or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, reputation, results of operations, financial condition and prospects. We collect, use and store information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, use, store and transmit large amounts of confidential information, including intellectual property, proprietary business information health information, and personal information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data security incident (which may include, for example: data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or information technology incidents caused by threat actors, technological vulnerabilities or human error), and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result, a number of third-party vendors may or could have access to our confidential information subject to contractual protections. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, CROs, third-party vendors, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a formal security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. For example, targeted deep fakes supported by sophisticated AI tools and other forms of impersonation of our executives are becoming increasingly prevalent. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us or our CROs or other contractors or consultants we may utilize to mitigate a data security incident and security vulnerabilities could be significant, and while we have implemented security measures designed to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. We have incurred successful phishing attempts in the past, although we believe that these attempts were detected and neutralized without any compromise to our data and prior to any significant impact to our business. We have also implemented measures to prevent such attacks, but we may still be subject to similar attacks in the future. We are also aware of publicly disclosed security breaches at certain third parties on which we rely. If such an event were to occur, whether to us or a third party on which we rely, and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Further, if we are unable to generate or maintain access to essential patient samples or data for our research, development, and manufacturing activities for our programs, our business could be materially adversely affected. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. Such a breach may require formal notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, such as the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing rules and regulations, regulations promulgated by the Federal Trade Commission and state breach notification laws. We also may be subject to global privacy laws, such as Europeâ€™s General Data Protection Regulation, or GDPR. We would also be exposed to a risk of loss or litigation and potential liability under laws, regulations and contracts that protect the privacy and security of personal information that may result in regulatory scrutiny, fines, private right of action settlements, and other consequences. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules and possible government oversight. Our failure to comply with such laws or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, member base and revenue. 60 Â Our information technology systems could face serious disruptions that could adversely affect our business. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines, and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development and manufacturing work. In addition, some of our employees work remotely from time to time, which presents certain risks to our business. For example, remote work presents significant demands on our information technology resources and systems and can be at risk for phishing and other malicious activity, which can result in an increase to the number of points of potential exposure, such as laptops and mobile devices, that need to be secured. Any failure to effectively manage these risks, including to timely identify and appropriately respond to any security incidents, may adversely affect our business. In our ongoing efforts to innovate and optimize operational efficiency, we have integrated artificial intelligence, or AI, into various aspects of our workplace. For example, we are implementing AI machine learning for email behavioral monitoring. While AI presents opportunities for enhanced productivity and innovation, it also introduces inherent risks, including legal and regulatory, that could adversely impact our business and reputation. Proper use of AI can lead to improved decision-making, cost reduction, and competitive advantage. However, improper use, including algorithmic biases, ethical considerations, data privacy issues, unknown or zero-day software vulnerabilities, and potential regulatory non-compliance, could result in reputational damage, legal liabilities, and financial losses. The rapidly evolving regulatory landscape surrounding AI also poses a risk, as new laws and regulations could impose additional compliance burdens, resulting in increased operational costs. We are committed to implementing robust governance and control mechanisms to mitigate these risks, but there can be no assurance that such measures will adequately prevent or mitigate the adverse effects that the integration and use of AI may have on our business, financial condition, and results of operations. If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be affected adversely. Our research, development and manufacturing involve the use of hazardous chemicals and materials, including radioactive materials. We maintain quantities of various flammable and toxic chemicals in our facilities in South San Francisco and San Carlos, California that are required for our research, development and manufacturing activities. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We and our third-party contractors are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous chemicals and materials. We believe our and our third-party contractorsâ€™ procedures for storing, handling and disposing these materials in our South San Francisco and San Carlos facilities comply with the relevant guidelines of the two municipalities, the county of San Mateo, the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, including employee and contractor training and procedures regarding safe handling and disposal, the risk of accidental or mistaken contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial and exceed any available insurance. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workersâ€™ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials or from other hazards potentially present in our workplaces, such as high voltage electricity, process steam or other hot material, liquid nitrogen or other cold material, materials stored under pressure, laboratory instruments that incorporate powerful lasers or magnets, sonic resonance, heavy machinery, and the like, this insurance may not provide adequate coverage against potential liabilities. While we maintain pollution legal liability insurance for our manufacturing facility in San Carlos, California, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials in our other locations. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future and existing laws and regulations could become more stringent. Further, we may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations. 61 Â U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit, among other things, companies and their employees, agents, CROs, CMOs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or making or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing authorizations. We can be held liable for corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. Our current operations are in two cities in the San Francisco Bay Area, and we, or the third parties upon whom we depend, may be adversely affected by earthquakes, other natural disasters, pandemics or other catastrophic events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. Our current operations are located in our facilities in South San Francisco and San Carlos, California. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather condition, epidemic, pandemic or contagious disease, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes, epidemics, pandemics or contagious diseases, or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage, epidemics, pandemics or contagious disease, or other events occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research or manufacturing facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear, and may heighten or intensify existing risk of natural disasters. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Further, many of our employees conduct business outside of our leased or owned facilities and these locations may be subject to additional security risks outside of our control. Any business interruption could have a material and adverse effect on our business, financial condition, results of operations and prospects. Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations. New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the 2017 Tax Act, enacted many significant changes to the U.S. tax laws. Beginning in 2022, the 2017 Tax Act eliminates the option to currently deduct research and development expenditures and requires taxpayers to capitalize and amortize U.S. based and non-U.S. based research and development expenditures over five and fifteen years, respectively, pursuant to IRC Section 174. Although there have been legislative 62 Â proposals to repeal or defer the capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. We also cannot predict whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholdersâ€™ tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. Our ability to use net operating loss carryforwards to offset taxable income could be limited. Under current law, our net operating loss carryforwards generated in tax years ending on or prior to December 31, 2017, are permitted to be carried forward for 20 years and our federal net operating losses generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses, is limited to 80% of taxable income (without regard to certain deductions). In addition, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if we experience an â€œownership changeâ€ which is generally defined as a greater than 50% change, by value, in our equity ownership over a three-year period, our ability to use our pre-change net operating loss carryforwards to offset our post-change income may be limited. Based on Section 382 studies performed for certain prior periods, we experienced an ownership change on November 20, 2019 and December 31, 2022, which imposed limitations on the use of our net operating losses arising before that date. In addition, we may have experienced other ownership changes in the past and may also experience ownership changes in the future as a result of equity offerings or other shifts in our stock ownership, some of which are outside our control. As a result, our use of federal NOL carryforwards could be limited. State net operating loss carryforwards may be similarly limited. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Any such limitations may result in greater tax liabilities than we would incur in the absence of such limitations and any increased liabilities could adversely affect our business, results of operations, financial position and cash flows. Our investment in Vaxcyte is subject to risk As of June 30, 2024, we held Vaxcyte common stock with a fair value of $50.4 million. Vaxcyte common stock is publicly traded and therefore subject to the various risk factors associated with any publicly traded company, including risks associated with Vaxcyteâ€™s business, its business outlook, cash flow requirements and financial performance, the state of the market and the general economic climate, including the impact of health pandemics, regional geopolitical conflicts, changes in interest rates, inflation, potential uncertainty with respect to the debt ceiling and potential government shutdowns related thereto. Vaxcyte common stock has been subject to substantial volatility, and the change in fair value of our interests in Vaxcyte will materially impact our reported net income or net loss in our financial statements. Our cash and investments could be adversely affected if the financial institutions in which we hold our cash and investments fail. We regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit and similar regulatory insurance limits outside the United States and governments may not guarantee all depositors if such financial institutions were to fail, as the U.S. government did in 2023 with Silicon Valley Bank depositors, in the event of further bank closures and continued instability in the global banking system. Any future adverse developments in the global banking system could directly or indirectly negatively impact our business, financial condition, results of operations and prospects. Further, if we enter into a credit, loan or other similar facility with a financial institution, certain covenants included in such facility may require as security that we keep a significant portion of our cash with the institution providing such facility. If a depository institution where we maintain deposits fails or is subject to adverse conditions in the financial or credit markets, we may not be able to recover all, if any, of our deposits, which

could adversely impact our operating liquidity and financial performance. Our financial results may be adversely affected by changes in accounting principles generally accepted in the United States. Generally accepted accounting principles in the United States, or U.S. GAAP, are subject to interpretation by the Financial Accounting Standards Board, or the FASB, the American Institute of Certified Public Accountants, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. For example, in May 2014, the 63 Â FASB issued accounting standards update No. 2014-09 (Topic 606), Revenue from Contracts with Customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. We adopted this new accounting standard as of January 1, 2019. Any difficulties in implementing this guidance could cause us to fail to meet our financial reporting obligations, which could result in regulatory discipline and harm investorsâ€™ confidence in us. Additionally, the implementation of this guidance or a change in other principles or interpretations could have a significant effect on our financial results, and could affect the reporting of transactions completed before the announcement of a change. Risks Related to Intellectual Property If we are not able to obtain, maintain and enforce sufficient patent and other intellectual property protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected. Our success depends in part on our, our licensorsâ€™s and our collaboratorsâ€™ ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. We, our licensors and collaborators may not be able to apply for patents on certain aspects of our product candidates in a timely fashion or at all. Further, we, our licensors and collaborators may not be able to prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we, our licensors and collaborators will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. It is also possible that we, our licensors, and our collaborators will fail to file patent applications covering inventions made in the course of development and commercialization activities before a competitor or another third party files a patent application covering, or publishes information disclosing, a similar, independently-developed invention. Such competitorâ€™s patent application may pose obstacles to our ability to obtain or limit the scope of patent protection we may obtain. We may not have the right to control the preparation, filing and prosecution of all patent applications that we license from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our licensors or collaborators fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Also, although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we, our licensors or collaborators were the first to make the inventions claimed in our patents or pending patent applications, or were the first to file for patent protection of such inventions, or if such patents rights may otherwise become invalid. Composition of matter patents for biological and pharmaceutical therapeutic candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications directed to composition of matter of our therapeutic candidates will be considered patentable by the United States Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our therapeutics for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, clinicians may prescribe these products â€œoff-label.â€ Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our product candidates or to provide meaningful protection from our competitors. Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary 64 Â technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market. The USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary products and technology. While we will endeavor to try to protect our product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time consuming, expensive and sometimes unpredictable. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: â€¢others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license; â€¢we or our licensors, or our existing or future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license; â€¢we or our licensors, or our existing or future collaborators are the first to file patent applications covering certain aspects of our inventions; â€¢others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; â€¢a third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed; â€¢any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties; â€¢we may develop additional proprietary technologies that are patentable; â€¢the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects; and â€¢our competitors may conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. In addition, our in-licensed patents may be subject to a reservation of rights by the licensor, its affiliates and one or more third parties. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties or allow third parties to use our licensed technology. The government can also exercise its march-in rights if it 65 Â determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. In addition to seeking patent protection for certain aspects of our product candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time- consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed which could have a material and adverse effect on our business, financial condition, results of operations and prospects. Other companies or organizations may challenge our or our licensorsâ€™ patent rights or may assert patent rights that prevent us from developing and commercializing our products. Therapeutics in oncology or other disease areas developed in cell-free-based synthesis systems are a relatively new scientific field. We have obtained grants and issuances of, and have obtained a license from a third party on an exclusive basis to, patents related to our proprietary XpressCFÂ® and XpressCF+Â® platforms. The issued patents and pending patent applications in the United States and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of antibody-based and other therapeutics. As the field of antibody-based therapeutics continues to mature, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business, financial condition, results of operations and prospects or our ability to successfully compete. We may not be able to protect our intellectual property rights throughout the world. Obtaining a valid and enforceable issued or granted patent covering our technology in the United States and worldwide can be extremely costly, and our or our licensorsâ€™ or collaboratorsâ€™ intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In jurisdictions where we or our licensors or collaborators have not obtained patent protection, competitors may seek to use our or their technology to develop their own products and further, may export otherwise infringing products to territories where we or they have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our or our licensorsâ€™ or collaboratorsâ€™ issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly relating to biopharmaceuticals. This could make it difficult for us or our licensors or collaborators to prevent the infringement of our or their patents or marketing of competing products in violation of our or their proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our and our licensorsâ€™ or collaboratorsâ€™ efforts and 66 Â attention from other aspects of our business, could put our and our licensorsâ€™ or collaboratorsâ€™ patents at risk of being invalidated or interpreted narrowly and our and our licensorsâ€™ or collaboratorsâ€™ patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaborators. We or our licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the Patent Cooperation Treaty, PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, EU, Japan, Australia and Canada and, depending on the individual case, also in any or all of, inter alia, Brazil, China, Hong Kong, India, Israel, Mexico, New Zealand, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same product candidate or technology. Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russiaâ€™s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors or collaborators encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors or collaborators are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business, financial condition, results of operations and prospects may be adversely affected. European patent applications now have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or UPC. This will be a significant change in European patent practice. As the UPC is a new court system, there is very limited precedent for the court, increasing the uncertainty of any litigation. Limited information is available to make judgments about advantages and disadvantages of either opting into or remaining out of UPC jurisdiction; either choice may ultimately prove to have significant implications as to cost, enforceability and scope of protection, among other factors, for applicable European patents. We, our licensors or collaborators, or any future strategic partners may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights at risk.

Competitors may infringe our patents or other intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several 67 Â statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that an individual connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Such a loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our therapeutics. As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe existing or future third-party patents. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our therapeutic candidates in any jurisdiction. Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our therapeutics. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the U.S. can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our therapeutics or the use of our therapeutics. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our therapeutics. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patentâ€™s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our therapeutics are not covered by a third-party patent or may incorrectly predict whether a third-partyâ€™s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our research programs, product candidates, their respective methods of use, manufacture and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to 68 Â our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. Intellectual property rights of third parties could adversely affect our ability to commercialize our product candidates, and we, our licensors or collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights. We might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms. We, our licensors or collaborators, or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes review proceedings before the USPTO, and corresponding foreign patent offices. For example, one of our European patents related to technology auxiliary to our XpressCFÂ® platform is involved in an opposition proceeding at the European Patent Office, or EPO, and was revoked by the EPO in 2021. In April 2022, an appeal was filed; the process for this appeal is ongoing. This may prevent us from asserting this patent against our competitors practicing otherwise infringing methods in relevant European countries where this patent has been granted. There are many issued and pending patents that might claim aspects of our product candidates and modifications that we may need to apply to our product candidates. There are also many issued patents that claim antibodies, portions of antibodies, cytokines, half-life extending polymers, linkers, cytotoxins, or other warheads that may be relevant for the products we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may be delayed or may not be able to market products or perform research and development or other activities covered by these patents which could have a material and adverse effect on our business, financial condition, results of operations and prospects. We are obligated under certain of our license and collaboration agreements to indemnify and hold harmless our licensors or collaborators for damages arising from intellectual property infringement by use. For example, we are obligated under the Stanford Agreement to indemnify and hold harmless Stanford for damages arising from intellectual property infringement by us resulting from exercise of the license from Stanford. If we, our licensors or collaborators, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have infringed willfully. In addition, we, our licensors or collaborators, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or our existing or future collaborators may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation could divert our managementâ€™s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. Because the antibody-based therapeutics landscape is still evolving, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering antibodies generally, covering antibodies directed against the same targets as, or targets similar to, those we are pursuing, or covering linkers and cytotoxic warheads similar to those that we are using in our product candidates. For example, we are aware of an issued patent, expected to expire in 2031, that relates to strained alkyne reagents that can be used as synthetic precursors for certain of our linker-warheads. We are further aware of an issued patent, expected to expire in 2034, relating to certain conjugates comprising a genus of hemiasterlin derivatives that may be potentially relevant to products incorporating our hemiasterlin-derived linker-warhead. If any of these patents are valid and not yet expired when, and if, we receive marketing approval for luvelta, as applicable, we may need to seek a license to one or more of these patents, each of which may not be available on commercially reasonable terms or at all. Failure to receive a license to any of these patents, or other potentially relevant patents currently unknown to us, could delay commercialization of any or all of luvelta, STRO-004 or any other product candidate. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we 69 Â may not be in a position to develop or commercialize products or product candidates until such patents expire or unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our XpressCFÂ® and XpressCF+Â® platforms and related technologies and product candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our XpressCFÂ® and XpressCF+Â® platforms and related technologies and product candidates. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, including potentially treble damages and attorneysâ€™ fees for willful infringement, and we may be forced to abandon our product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all. It is also possible that we have failed to identify relevant third-party patents or applications. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could have a material and adverse effect on our business, financial condition, results of operations and prospects. Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. 70 Â If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell any future products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensorâ€™s rights. In addition, while we cannot determine currently the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: â€¢the scope of rights granted under the license agreement and other interpretation-related issues; â€¢the extent to which our product candidates, technologies and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; â€¢the sublicensing of patent and other rights under our collaborative development relationships; â€¢our diligence obligations under the license agreement and what activities satisfy those diligence obligations; â€¢the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and â€¢the priority of invention of patented technology. In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employeesâ€™ or consultantsâ€™ former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary

damages and may lose valuable intellectual property rights or personnel. Many of our employees were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. 71 Â Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations and prospects could be materially harmed. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and/or rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. Changes in U.S. patent and ex-U.S. patent laws could diminish the value of patents in general, thereby impairing our ability to protect our products. Changes in either the patent laws or interpretation of the patent laws in the United States or in other ex-U.S. jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the United States, numerous recent changes to the patent laws and proposed changes to the rules of the USPTO that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the America Invents Act, enacted within the last several years involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. For example, the decision by the U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc. precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this 72 Â decision on our patents or patent applications because we are developing product candidates that contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, and similar legislative and regulatory bodies in other countries in which we may pursue patent protection, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. Risks Related to Government Regulation We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates. Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is 73 Â possible that none of the product candidates we may develop, either alone or with our collaborators, will obtain the regulatory approvals necessary for us or our existing or future collaborators to begin selling them. Although some of our employees have experience in conducting and managing clinical trials from prior employment at other companies, we, as a company, have no prior experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of the initial clinical trials, depending upon the type, complexity and novelty of the product candidate and the availability of applicable government resources. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty their application. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We or our collaborators may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or the impact of such changes, if any. For example, the Oncology Center of Excellence within the FDA has advanced Project Optimus, which is an initiative to reform the dose optimization and dose selection paradigm in oncology drug development to emphasize selection of an optimal dose, which is a dose or doses that maximizes not only the efficacy of a drug but the safety and tolerability as well. This shift from the prior approach, which generally determined the maximum tolerated dose, may require sponsors to spend additional time and resources to further explore a product candidateâ€™s dose-response relationship to facilitate optimum dose selection in a target population. Other Oncology Center of Excellence initiatives have included Project FrontRunner, an initiative with a goal of developing a framework for identifying candidate drugs for initial clinical development in the earlier advanced setting rather than for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. We are considering these policy changes as they relate to our programs. We may also be affected by ex-US regulatory requirements, given that our trials may be conducted globally; current and unforeseen new EU-specific clinical trial conduct regulations, such as IVDR and GDPR, may delay, or increase the difficulty and expense of conducting, our clinical studies. Given that the product candidates we are developing, either alone or with our collaborators, represent a new approach to the manufacturing and type of therapeutic biologics, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these product candidates. Moreover, the FDA may respond to any BLA that we may submit by defining requirements that we do not anticipate. Such responses could delay clinical development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been increased public and political pressure on the FDA with respect to the approval process for new drugs and therapeutic biologics, and FDA standards, especially regarding product safety, appear to have become more stringent. Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or on the labeling or other restrictions. In addition, the FDA has the authority to require a risk evaluation and mitigation strategy, or REMS, as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors. We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval process described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. FDA approval does not ensure approval by regulatory authorities outside the United States and vice versa. Any delay or failure to obtain U.S. or foreign regulatory approval for a product candidate could have a material and adverse effect on our business, financial condition, results of operations and prospects. 74 Â Delays in obtaining regulatory approval of our manufacturing process may delay or disrupt our commercialization efforts. To date, no product using a cell-free manufacturing process in the United States has received approval from the FDA. Before we can begin to commercially manufacture our product candidates in third-party or our own facilities, we must obtain regulatory approval from the FDA for a BLA that describes in detail the chemistry, manufacturing, and controls for the product. A manufacturing authorization must also be obtained from the appropriate EU regulatory authorities. The timeframe required to obtain such approval or authorization is uncertain. In addition, we must pass a pre-approval inspection of our manufacturing facility by the FDA before any of our product candidates can obtain marketing approval, if ever. In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any products that we may develop. Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal. We may also be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. Any regulatory approvals that we or our existing or future collaborators obtain for our product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion

and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA or similar foreign regulatory bodies to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution. Subsequent discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: â€¢restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; â€¢fines, warning or untitled letters or holds on clinical trials; 75 Â â€¢refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners; â€¢suspension or revocation of product license approvals; â€¢product seizure or detention or refusal to permit the import or export of products; and â€¢injunctions or the imposition of civil or criminal penalties. The FDA policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. Moreover, the ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDAâ€™s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDAâ€™s ability to perform routine functions. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions could significantly impact the ability of the FDA and other agencies to fulfill their functions, and could greatly impact healthcare and the pharmaceutical industry. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Further, three decisions from the U.S. Supreme Court in July 2024 may lead to an increase in litigation against regulatory agencies that could create uncertainty and thus negatively impact our business. The first decision overturned established precedent that required courts to defer to regulatory agenciesâ€™ interpretations of ambiguous statutory language. The second decision overturned regulatory agenciesâ€™ ability to impose civil penalties in administrative proceedings. The third decision extended the statute of limitations within which entities may challenge agency actions. These cases may result in increased litigation by industry against regulatory agencies and impact how such agencies choose to pursue enforcement and compliance actions. However, the specific, lasting effects of these decisions, which may vary within different judicial districts and circuits, is unknown. We also cannot predict the extent to which FDA and SEC regulations, policies, and decisions may become subject to increasing legal challenges, delays, and changes. Further, if a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. We may face difficulties from healthcare legislative reform measures. Existing regulatory policies may change and additional government regulations may be enacted that could affect pricing and third-party payments for our product candidates, which could negatively affect our business, financial condition and prospects. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Healthcare and 76 Â Education Reconciliation Act, or together, the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. While there have been legislative and judicial efforts to modify, repeal or otherwise invalidate all or certain aspects of the ACA or its implementing regulations, the ACA remains in effect in its current form. It is unclear how any such efforts in the future will impact the ACA or our business. In addition, other legislative changes have been proposed and adopted in the United States federal and state levels to reduce healthcare expenditures, including the Budget Control Act, which, subject to certain temporary suspension periods, imposed 2% reductions in Medicare payments to providers per fiscal year starting April 1, 2013 and, due to subsequent legislative amendments to the statute, that will remain in effect through 2031, unless additional Congressional action is taken, and the Infrastructure Investment and Jobs Act, which added a requirement for manufacturers of certain single-source drugs (including biologics and biosimilars) separately paid for under Medicare Part B for at least 18 months and marketed in single-dose containers or packages (known as refundable single-dose containers or single-use package drugs) to provide annual refunds for any portions of the dispensed drug that are unused and discarded if those unused or discarded portions exceed an applicable percentage defined by statute or regulation. Further, in November 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of this final rule was delayed by the Inflation Reduction Act, or IRA, until January 1, 2032. In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs is eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of products. Moreover, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. Moreover, payment methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and regulatory initiatives. CMS has begun bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting and, beginning in 2018, CMS will pay for clinical laboratory services based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care plans pay for laboratory services. Further, on March 16, 2018, CMS finalized its National Coverage Determination, or NCD, for certain diagnostic laboratory tests using next generation sequencing that are approved by the FDA as a companion in vitro diagnostic and used in a cancer with an FDA-approved companion diagnostic indication. Under the NCD, diagnostic tests that gain FDA approval or clearance as an in vitro companion diagnostic will automatically receive full coverage and be available for patients with recurrent, metastatic relapsed, refractory or stages III and IV cancer. Additionally, the NCD extended coverage to repeat testing when the patient has a new primary diagnosis of cancer. There has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The FDA released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada, and the FDA authorized the first such plan in January 2024. Recently, several healthcare reform initiatives culminated in the enactment of the IRA in August 2022, which allows, among other things, HHS to negotiate the selling price of a statutorily specified number of drugs and biologics each year 77 Â that CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for single-source small molecule therapeutics) can qualify for negotiations, with the negotiated price taking effect two years after the selection year. Negotiations for Medicare Part D products begin in 2024 with the negotiated price taking effect in 2026, and negotiations for Medicare Part B products begin in 2026 with the negotiated price taking effect in 2028. HHS will announce the negotiated maximum fair price by September 1, 2024, and this price cap, which cannot exceed a statutory ceiling price, will come into effect on January 1, 2026. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the IRAâ€™s price negotiations requirements, but loses that exclusion if it has designations for more than one rare disease or condition, or if it is approved for an indication that is not within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. In August 2023, HHS announced the ten Medicare Part D drugs and biologics that it selected for negotiations, and by October 1, 2023, each manufacturer of the selected drugs signed a manufacturer agreement to participate in the negotiations. The IRA also penalizes drug manufacturers that increase prices of Medicare Part D and Part B drugs at a rate greater than the rate of inflation. In addition, the law eliminates the â€œdonut holeâ€ under Medicare Part D beginning in 2025 by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrolleesâ€™ prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, some significant, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These provisions are taking effect progressively starting in 2023, although they may be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and our product candidates. At the state level, legislatures are increasingly enacting laws and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law. We may choose to seek an expanded access program for our product candidates, or to utilize comparable rules in other countries that allow the use of a drug, on a named patient basis or under a compassionate use program. We expect that the ACA, the IRA and other state or federal healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Our operations and relationships with healthcare providers, healthcare organizations, customers and third-party payors will be subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. Our current and future arrangements with healthcare providers, healthcare organizations, third-party payors and customers expose us to broadly applicable anti-bribery, fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our product candidates. In addition, we may be subject to patient data privacy and security regulation by the U.S. federal government and the states and the foreign governments in which we conduct our business. Restrictions under applicable federal and state anti-bribery and healthcare laws and regulations, include the following: â€¢the federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or 78 Â reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal and state healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; â€¢the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be imposed through civil whistleblower or qui tam actions against individuals or entities, prohibits, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; â€¢HIPAA, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; â€¢HIPAA, as amended by HITECH, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; â€¢the federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Childrenâ€™s Health Insurance Program, with certain exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website; â€¢the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; â€¢analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and â€¢certain state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information, state and local

laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. If we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell 79 Â our products successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others: â€¢exclusion from participation in government-funded healthcare programs; â€¢exclusion of company products from coverage under federal health care programs; and â€¢exclusion from eligibility for the award of government contracts for our products. Efforts to ensure that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm, any of which could adversely affect our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our managementâ€™s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. Our failure to comply with privacy and data security laws, regulations and standards may cause our business to be materially adversely affected. We maintain a quantity of sensitive information, including confidential business and patient health information in connection with our clinical trials that are subject to US and international laws and regulations governing the privacy and data protection of such information. Each of these laws is subject to varying interpretations and subject to evolving regulations. For example, the EU and United Kingdom (â€œUKâ€) GDPR, which applies extraterritorially, imposes several strict requirements for controllers and processors of personal information, which include higher standards for obtaining consent from individuals to process their personal information, increased requirements pertaining to the processing of special categories of personal information (such as health information) and pseudonymized (i.e., key-coded) data, and heightened transfer requirements of personal information from the European Economic Area/UK/Switzerland to countries not deemed to have adequate data protections laws. Notably, the U.S. is one such country as of January 1, 2024, although effective July 10, 2023, the new EU-U.S. Data Privacy Framework (â€œDPFâ€) has been recognized as adequate under EU law to allow transfers of personal data from the EU (as well as the U.K. and Switzerland) to certified companies in the U.S. However, the DPF is likely to face legal challenge at the Court of Justice of the European Union which could cause the legal requirements for personal data transfers from the Europe to the U.S. to become uncertain once again. We will monitor these legal developments and continue to use best practices to follow established European legal standards to conduct cross-border transfer of personal data. The GDPR also provides that countries in the European Economic Area may establish their own laws and regulations further restricting the processing of certain personal information, including genetic data, biometric data, and health data. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to â‚¬20 million (approximately $22.6 million) or 4 percent of the annual global revenues of the noncompliant company, whichever is greater. In the United States, in addition to HIPAA, various federal (for example, the Federal Trade Commission) and state regulators have adopted, or are considering adopting, laws and regulations concerning personal information and data security that may conflict or be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than existing federal, international, or other state laws. For example, California, which continues to be a critical state with respect to evolving consumer privacy laws after enacting the California Consumer Privacy Act (the â€œCCPAâ€), as amended by the California Privacy Rights Act, took effect in January 2023 and may be subject to additional regulations promulgated through a newly created enforcement agency called the California Privacy Protection Agency (â€œCPPAâ€). Failure to comply with the CCPA may result in significant civil penalties, injunctive relief, or statutory or actual damages as determined by the CPPA and California Attorney General, the latter still retaining some CCPA enforcement authority. Following Californiaâ€™s lead, several other states have enacted privacy laws in recent years. In addition, a comprehensive federal privacy bill, which includes a private right of action for violations, has been proposed in Congress. 80 Â We cannot provide assurance that (i) current or future legislation will not prevent us from generating or maintaining personal information, or (ii) that patients will consent to the use of their personal information (as necessary). Either of these circumstances may prevent us from undertaking or publishing essential research and development, manufacturing, and commercialization, which could have a material adverse effect on our business, results of operations, financial condition, and prospects. Further, on July 26, 2023, the SEC adopted cybersecurity disclosure rules for public companies that require disclosure regarding cybersecurity risk management (including our boardâ€™s role in overseeing cybersecurity risks, managementâ€™s role and expertise in assessing and managing cybersecurity risks and processes for assessing, identifying and managing cybersecurity risks) in annual reports on Form 10-K. These cybersecurity disclosure rules also require the disclosure of material cybersecurity incidents by Form 8-K. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards. It is possible that if our practices are not consistent or viewed as not consistent with legal and regulatory requirements and interpretations, we may become subject to audits, inquiries, whistleblower complaints, adverse media coverage, investigations, loss of export privileges, or severe criminal or civil sanctions, all of which may have a material adverse effect on our business, operating results, reputation, and financial condition. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us to comply with any applicable federal, state, or similar foreign laws and regulations relating to data privacy and security could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, injunctions, penalties, or judgments. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition, and prospects. If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue. We currently have a limited team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. To commercialize any product candidates after approval, we must build, on a territory-by-territory basis, marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish a sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time consuming and will require significant attention of our executive officers to manage. For example, some state and local jurisdictions have licensing and continuing education requirements for pharmaceutical sales representatives, which requires time and financial resources. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, an abbreviated pathway for the licensure of biosimilar biological products (both highly similar and interchangeable biological products) was 81 Â created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. The BPCIA provides a period of exclusivity for products granted â€œreference product exclusivity,â€ under which an application for a biosimilar product referencing such products cannot be licensed by the FDA until 12 years after the first licensure date of the reference product licensed under a BLA. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA licenses a full BLA for the competing product containing the sponsorâ€™s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our product candidates. There is a risk that any product candidates we may develop that are licensed as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Most states have enacted substitution laws that permit substitution of interchangeable biosimilars. The extent to which a highly similar biosimilar, once licensed, will be substituted for any one of our reference products that may be approved in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidates, our ability to market and derive revenue from the product candidates could be compromised. Undesirable side effects caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in more restrictive labeling or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Given the nature of ADCs, it is likely that there may be side effects associated with their use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trials or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. In the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by one of our products, any of the following adverse events could occur: â€¢regulatory authorities may withdraw their approval of the product or seize the product; â€¢we may be required to recall the product or change the way the product is administered to patients; â€¢additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; â€¢we may be subject to fines, injunctions or the imposition of civil or criminal penalties; â€¢regulatory authorities may require the addition of labeling statements, such as a black box warning or a contraindication; â€¢we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; 82 Â â€¢we could be sued and held liable for harm caused to patients; â€¢the product may become less competitive; and â€¢our reputation may suffer. Any of these occurrences could have a material and adverse effect on our business, financial condition, results of operations and prospects. While we have been granted a Fast Track Designation by the FDA for luvelta, it may not lead to a faster development or regulatory review or approval process. We have been granted a Fast Track Designation for luvelta for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior lines of systemic therapy. As part of our business strategy, we may also seek Fast Track Designation for other of our product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, as we have for luvelta, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program, which may happen in connection with luvelta or other of our product candidates if granted Fast Track Designation. While we have been granted Orphan Drug Designation by the FDA for luvelta for the treatment of Pediatric (CBF/GLIS) AML, if we decide to seek Orphan Drug Designation for some of our other product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity. We have been granted Orphan Drug Designation by the FDA for luvelta for the treatment of Pediatric CBF/GLIS AML. As part of our business strategy, we may seek Orphan Drug Designation for our other product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and therapeutic biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or therapeutic biologic as an orphan drug if it is a drug or therapeutic biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or therapeutic biologic will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. Even if we obtain Orphan Drug Designation for our product candidates in specific conditions, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated condition due to the uncertainties associated with developing pharmaceutical products; in such case, no orphan drug exclusivity would be available unless we could demonstrate â€œclinical superiority.â€ In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated condition or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs or therapeutic biologics with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug or therapeutic biologic with the same principal molecular structural features for the same condition if the FDA concludes that the later drug or therapeutic biologic is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug or therapeutic biologic nor gives the drug or therapeutic biologic any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our product candidates, we may never receive such designations. 83 Â The tax reform legislation signed into law on December 22, 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This may further limit the advantage and may impact our future business strategy of seeking the Orphan Drug Designation. If we decide to pursue accelerated approval for any of our product candidates, it may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. In the future, we may decide to pursue

accelerated approval for one or more of our product candidates. Under the FDAâ€™s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening disease or condition that provides a meaningful advantage over available therapies based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence, and the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. If we were to pursue accelerated approval for a product candidate for a disease or condition, we would do so on the basis that there is no available therapy for that disease or condition or that our product candidate provides a benefit over available therapy. If standard of care were to evolve or if any of our competitors were to receive full approval on the basis of a confirmatory trial for a drug or biologic for a disease or condition for which we are seeking accelerated approval before we receive accelerated approval, the disease or condition would no longer qualify as one for which there is no available therapy, and accelerated approval of our product candidate would not occur without a showing of benefit over available therapy. Many cancer therapies rely on accelerated approval, and the treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials. Whether any trial is sufficient to receive FDA approval under the accelerated approval pathway will depend on the design and safety and efficacy results of such trial and will only be determined by the FDA upon review of the trial design and a submitted BLA. Moreover, the FDA may withdraw approval of any product candidate approved under the accelerated approval pathway if, for example: â€¢the trial or trials required to verify the predicted clinical benefit of our product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product; â€¢other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use; â€¢we fail to conduct any required post-approval trial of our product candidate with due diligence; or â€¢we disseminate false or misleading promotional materials relating to the relevant product candidate. In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. Recently, the accelerated approval pathway has come under scrutiny within the FDA and by Congress. The FDA has put increased focus on ensuring that confirmatory studies are conducted with diligence and, ultimately, that such studies confirm the benefit. For example, the FDA has convened its Oncologic Drugs Advisory Committee to review what the FDA has called â€œdanglingâ€ or delinquent accelerated approvals, where confirmatory studies have not been completed or where results did not confirm benefit, but for which marketing approval continues in effect, and some companies have subsequently voluntarily requested withdrawal of approval of their products. In addition, the Oncology Center of Excellence has announced Project Confirm, which is an initiative to promote the transparency of outcomes related to accelerated approvals for oncology indications and provide a framework to foster discussion, research and innovation in approval and post-marketing processes, with the goal to enhance the balance of access and verification of benefit for therapies available to patients with cancer and hematologic malignancies. 84 Â Further, the enactment of The Food and Drug Omnibus Reform Act, or FDORA, included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA. FDORA enables the FDA to initiate enforcement action for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports. Risks Related to Our Common Stock Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. We expect our operating results to be subject to quarterly and annual fluctuations. Our net income or loss and other operating results will be affected by numerous factors, including: â€¢variations in the level of expense related to the ongoing development of our XpressCFÂ® and XpressCF+Â® platforms, our product candidates or future development programs; â€¢the fair value of our holding of common stock of Vaxcyte; â€¢results of preclinical and clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or future collaborators or licensing partners; â€¢our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; â€¢any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; â€¢additions and departures of key personnel; â€¢strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; â€¢if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates; â€¢regulatory developments affecting our product candidates or those of our competitors; â€¢the impact of accounting principles and tax laws, including as a result of recent tax law changes; â€¢epidemics, pandemics or contagious diseases; â€¢changes in general market and economic conditions; and â€¢cybersecurity incidents If our quarterly and annual operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly and annual fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly and annual comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. 85 Â Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. Our restated certificate of incorporation and our restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions: â€¢establish a classified board of directors so that not all members of our board are elected at one time; â€¢permit only the board of directors to establish the number of directors and fill vacancies on the board; â€¢provide that directors may only be removed â€œfor causeâ€ and only with the approval of two-thirds of our stockholders; â€¢require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws; â€¢authorize the issuance of â€œblank checkâ€ preferred stock that our board could use to implement a stockholder rights plan; â€¢eliminate the ability of our stockholders to call special meetings of stockholders; â€¢prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; â€¢prohibit cumulative voting; and â€¢establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. In addition, our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Furthermore, our amended and restated bylaws also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision. While the Supreme Court of the State of Delaware has held that such provisions are facially valid under Delaware law, there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case; application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act of 1933, as amended, or the Securities Act, must be brought in federal court and cannot be brought in state court. These choice of forum provisions may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the specified courts could face additional litigation costs in pursuing any such claim. The specified courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our governance documents inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition, results of operations and prospects. 86 Â In addition, Section 203 of the DGCL may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock. The exclusive forum provision in our organizational documents may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers or other employees, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits with respect to such claims. Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision. This choice of forum provision may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, or the underwriters of any offering giving rise to such claims, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition. Section 22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our amended and restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision, including for all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While federal or state courts may not follow the holding of the Delaware Supreme Court or may determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court, and our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. The market price of our stock may be volatile, and you could lose all or part of your investment. The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, investors may not be able to sell their common stock at or above the purchase price. The market price for our common stock may be influenced by many factors, including the other risks described in this section and the following: â€¢results of preclinical studies and clinical trials of our product candidates, or those of our competitors or our existing or future collaborators; â€¢regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our product candidates; 87 Â â€¢the success of competitive products or technologies; â€¢introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; â€¢actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms; â€¢actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; â€¢the success of our efforts to acquire or in-license additional technologies, products or product candidates; â€¢developments concerning current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; â€¢market conditions in the pharmaceutical and biotechnology sectors; â€¢general economic uncertainty and capital markets disruptions, including changes in interest rates, rising inflation, potential instability with respect to the federal debt ceiling and budget and potential government shutdowns related thereto, which have been substantially impacted by regional geopolitical instability due to the impact of geopolitical tensions and the ongoing military conflicts around the world; â€¢any adverse impact of health pandemics, including on our clinical trials and clinical trial operations; â€¢announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments; â€¢developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates and products; â€¢our ability or inability to raise additional capital and the terms on which we raise it; â€¢the recruitment or departure of key personnel; â€¢changes in the structure of healthcare payment systems; â€¢actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; â€¢our failure or the failure of our competitors to meet analystsâ€™ projections or guidance that we or our competitors may give to the market; â€¢fluctuations in the valuation of companies perceived by investors to be comparable to us; â€¢announcement and expectation of additional financing efforts; â€¢speculation in the press or investment community; â€¢trading volume of our common stock; â€¢sales of our common stock by us or our stockholders; â€¢changes in accounting principles or tax laws; â€¢terrorist acts, acts of war or periods of widespread civil unrest, including the ongoing armed conflicts around the world; 88 Â â€¢natural disasters, epidemics, pandemics or contagious diseases, and other calamities; â€¢political instability; and â€¢general economic, industry and market conditions. In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this â€œRisk Factorsâ€ section, could have a dramatic and adverse impact on the market price of our common stock. The future sale and issuance of equity or of debt securities that are convertible into equity will dilute our share capital. We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock. A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline. Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options or warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock. For example, we are party to a Sales Agreement with Jefferies, pursuant to which, from time to time, we may offer and sell through Jefferies common stock pursuant to one or more â€œat the marketâ€ offerings. Sales of our common stock under the Sales Agreement could be subject to business, economic or competitive uncertainties and contingencies, many of which may be beyond our control, and which could cause actual results from the sale of our common stock to differ materially from

expectations. Any future sales of common stock through our â€œat the marketâ€ offering program will result in dilution and may have a negative impact on the price of our common stock. We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. General Risk Factors Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. Our business, financial condition or results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets, and the global economy has continued to be impacted by changes in interest rates, rising inflation, potential uncertainty with respect to the federal debt ceiling and budget and potential government shutdowns related thereto. Further, the capital and credit markets may be adversely affected by rising regional geopolitical tensions, and global sanctions imposed in response thereto. Our business and operations may be impacted by the current 89 Â political instability and military hostilities in multiple geographies including Ukraine, the Middle East and the tensions between China and Taiwan. Moreover, a severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the analysts or the content and opinions included in their reports. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, financial condition and results of operations, our intellectual property or our stock performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume. The requirements of being a public company may strain our resources, divert managementâ€™s attention and affect our ability to attract and retain additional executive management and qualified board members. The additional requirements we must comply with may strain our resources and divert managementâ€™s attention from other business concerns. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the listing requirements of The Nasdaq Global Select Market, and other applicable securities rules and regulations. Compliance with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming, or costly, and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Additionally, we may be subject to stockholder activism, which can be costly and time-consuming, disrupting our operations and diverting the attention of management and may lead to additional compliance costs and impact the manner in which we operate our business. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, managementâ€™s attention may be diverted from other business concerns, which could adversely affect our business and operating results. In order to comply with these requirements, we may need to hire more employees in the future or engage outside consultants, or may have difficulty attracting and retaining sufficient employees, which would increase our costs and expenses. As a result of no longer being an emerging growth company, we have incurred, and will continue to incur, significant additional expenses that we did not previously incur in complying with the Sarbanes-Oxley Act and rules implemented by the SEC. The cost of compliance with Section 404 of the Sarbanes-Oxley Act has required us to incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. We became a â€œsmaller reporting companyâ€ as of December 31, 2022. We will continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and are eligible to take advantage of certain of the reduced disclosure obligations regarding compensation disclosures in 2023. As a smaller reporting company and a â€œnon-accelerated filerâ€, we still need to comply with Section 404(a) of the Sarbanes-Oxley Act, which will continue to require substantial management time and expense. Based on our annual revenue for the 2023 fiscal year, and the market value of our non-affiliated common stock, we expect to be an â€œaccelerated filerâ€ and a smaller reporting company as of December 31, 2024. As such, we will be required to comply with Section 404(b) of the Sarbanes-Oxley Act for our annual report on Form 10-K for the period ended December 31, 2024. 90 Â In addition, changing laws, regulations, and standards relating to corporate governance, stockholder litigation, and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, making some activities more time consuming, and increasing the likelihood and expense of litigation. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve or otherwise change over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters, higher costs necessitated by ongoing revisions to disclosure and governance practices, and increased expenses and management attention due to actual or threatened litigation. We intend to invest resources to comply with evolving laws, regulations and standards (or changing interpretations of them), and this investment may result in increased general and administrative expenses and a diversion of managementâ€™s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with these laws, regulations, and standards differ from the activities intended by regulatory or governing bodies, regulatory authorities may initiate legal proceedings against us, and our business may be adversely affected. Being a public company and complying with the associated rules and regulations, and being subject to heightened likelihood of litigation, makes it more expensive for us to obtain director and officer liability insurance, the costs of which can fluctuate significantly from year-to-year due to general market conditions in obtaining such insurance, but in recent years have risen significantly, consistent with the increase in market rates. As a result, we may be required to accept reduced coverage, incur substantially higher costs to obtain coverage or may be unable to obtain coverage on economically reasonable terms, or at all. These factors could also make it more difficult for us to attract and retain qualified executives and qualified members of our board of directors, particularly to serve on our audit committee, our compensation committee, and our nominating and corporate governance committee. As a result of disclosure of information in filings required of a public company, our business and financial condition have become more visible, which may result in threatened or actual litigation, including by competitors. If such claims are successful, our business and operating results could be adversely affected, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our business and operating results. In addition, as a result of our disclosure obligations as a public company, we could face pressure to focus on short-term results, which may adversely affect our ability to achieve long-term profitability. We may be subject to securities litigation, which is expensive and could divert management attention. The market price of our common stock has been volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our managementâ€™s attention from other business concerns, which could seriously harm our business. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. Unregistered Sales of Equity Securities On April 4, 2024, the Company issued 4,827,373 shares of the Companyâ€™s common stock to Ipsen Biopharmaceuticals, Inc. (USA) (â€œIpsen USAâ€), a fully owned Affiliate of Ipsen Pharma SAS (â€œIpsenâ€), pursuant to that certain Investment Agreement between the Company and Ipsen USA (the â€œIpsen Investment Agreementâ€), for $25.0 million, at a price of approximately $5.18 per share, in accordance with the terms set forth in a certain investment agreement by and between the Company and Ipsen USA dated March 29, 2024. The issuance of shares pursuant to the Ipsen Investment Agreement was made pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. 91 Â Item 5. Other Information. None. 92 Â Item 6. Exhibits. The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, below. Â ExhibitNumber Â Description Â Form Â File No. Â ExhibitFilingDate Â ExhibitNo. Â Filed/FurnishedHerewith 10.1# Â Amended 2018 Employee Stock Purchase Plan Â Â Â Â Â Â Â Â Â Â X 31.1 Â Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â X 31.2 Â Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â X 32.1* Â Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â X 32.2* Â Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â X 101.INS Â Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Â Â Â Â Â Â Â Â Â Â X 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Â Â Â X 104 Â The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline XBRL and contained in Exhibit 101. Â Â Â Â Â Â Â Â Â Â X * This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.# Indicates a management contract or any compensatory plan, contract or arrangement. Â 93 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â SUTRO BIOPHARMA, INC. Date: August 13, 2024 By: /s/ William J. Newell William J. Newell Chief Executive Officer Â Date: August 13, 2024 By: /s/ Edward C. Albini Edward C. Albini Chief Financial Officer Â 94 EX-10.1 2 stro-ex10_1.htm EX-10.1 EX-10.1 Â Exhibit 10.1 SUTRO BIOPHARMA, INC. SUTRO BIOPHARMA, INC. AMENDED 2018 EMPLOYEE STOCK PURCHASE PLAN Â 1.Purpose. Sutro Biopharma, Inc. adopted the Plan effective as of the date of the IPO. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such employeesâ€™ sense of participation in the affairs of the Company and to provide an incentive for continued employment. Capitalized terms not defined elsewhere in the text are defined in Section 28. 2.Establishment of Plan. The Company proposes to grant rights to purchase Shares to eligible employees of the Company and its Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an â€œemployee stock purchase planâ€ under Section 423 of the Code (including any amendments to or replacements of such Section), and this Plan shall be so construed. Any term not expressly defined in this Plan but defined for purposes of Section 423 of the Code shall have the same definition herein. In addition, with regard to offers of options to purchase Shares under the Plan to employees working for a Subsidiary or an Affiliate outside the United States, this Plan authorizes the grant of options that are not intended to meet Section 423 requirements, provided, if necessary under Section 423 of the Code, the other terms and conditions of the Plan are met. Subject to Section 14, a total of Two Hundred Thirty Thousand (230,000) Shares is reserved for issuance under this Plan. In addition, on each January 1 for the first ten (10) calendar years after the Effective Date, the aggregate number of Shares reserved for issuance under the Plan shall be increased automatically by the number of Shares equal to one percent (1%) of the total number of outstanding Shares outstanding on the immediately preceding December 31 (rounded down to the nearest whole share); provided, that the Board or the Committee may in its sole discretion reduce the amount of the increase in any particular year. Subject to Section 14, no more than Three Million Fifty Thousand (3,050,000) Shares may be issued over the term of this Plan. The number of Shares initially reserved for issuance under this Plan and the maximum number of Shares that may be issued under this Plan shall be subject to adjustments effected in accordance with Section 14. 3.ADMINISTRATION. The Plan will be administered by the Committee. Subject to the provisions of this Plan and the limitations of Section 423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all Participants. The Committee will have full and exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to determine eligibility, to designate the Participating Corporations, to determine when to grant options which are not intended to meet the Code Section 423 requirements and to decide upon any and all claims filed under the Plan. Every finding, decision and determination made by the Committee will, to the full extent permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this Plan, the Committee may adopt rules, sub-plans, and/or procedures relating to the operation and administration of the Plan designed to comply with local laws, regulations or customs or to achieve tax, securities law or other objectives for eligible employees outside of the United States. The Committee will have the authority to determine the Fair Market Value of the Shares (which determination shall be final, binding and conclusive for all purposes) in accordance with Section 8 below and to interpret Section 8 of the Plan in connection with circumstances that impact the Fair Market Value. Members of the Committee shall receive no compensation for their services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for services rendered by Board members serving on Board committees. All expenses incurred in connection with the administration of this Plan shall be paid by the Company. For purposes of this Plan, the Committee may designate separate offerings under the Plan Â (the terms of which need not be identical) in which eligible employees of one or more Participating Corporations will participate, even if the dates of the applicable Offering Periods of each such offering are identical. 4.ELIGIBILITY. (a)Any employee of the Company or the Participating Corporations is eligible to participate in an Offering Period under this Plan, except that one or more of the following categories of employees may be excluded from coverage under the Plan by the Committee (other than where prohibited by applicable law): (i)employees who are customarily employed for twenty (20) hours or less per week; (ii)employees who are customarily employed for five (5) months or less in a calendar year; (iii)individuals who provide services to the Company or any of its Participating Corporations as independent contractors who are reclassified as common law employees for any reason except for federal income and employment tax purposes; and (iv)employees who do not meet any other eligibility requirements that the Committee may choose to impose (within the limits permitted by the Code). The foregoing notwithstanding, an individual shall not be eligible if his or her participation in the Plan is prohibited by the law of any country that has jurisdiction over him or her, if complying with the laws of the applicable country would cause the Plan to violate Section 423 of the Code, or if he or she is subject to a collective bargaining agreement that does not provide for participation in the Plan. (b)No employee who, together with any other person whose stock would be attributed to such employee pursuant to Section 424(d) of the Code, owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary or who, as a result of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary shall be granted an option to purchase Shares under the Plan. 5.OFFERING DATES. (a)Each Offering Period of this Plan may be of up to twenty-seven (27) months duration and shall commence and end at the times designated by the Committee. Each Offering Period may consist of one or more Purchase Periods during which payroll deductions of Participants are accumulated under this Plan. (b)The Offering Periods under this Plan shall commence on each March 16th and September 16th of each year, with each such Offering Period consisting of one six-month Purchase Period ending on September 15th and March 15th, respectively, except as otherwise provided by an applicable subplan, or on such other date determined by the Committee. The Committee may at any time establish a different duration for any subsequent Offering Period or Purchase Period. - 2 -Â Â 6.PARTICIPATION IN THIS PLAN. (a)Enrollment. Any eligible employee determined in accordance with Section 4 may elect to become a Participant by submitting a subscription agreement in a form determined by the Administrator, or electronic representation thereof, to the Company and/or via the standard process of a third party administrator authorized by the Company, confirming or changing his or her contribution rate prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement relates in accordance with such rules as the Committee may determine. (b)Continued Enrollment in Offering Periods. Once an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in each subsequent Offering Period commencing immediately following the last day of the prior Offering Period at the same

contribution level unless the Participant withdraws or is deemed to withdraw from this Plan or terminates further participation in an Offering Period as set forth in Section 11 below or otherwise notifies the Company of a change in the Participantâ€™s contribution level by filing an additional subscription agreement or electronic representation thereof with the Company and/or the Companyâ€™s third party administrator, prior to the next Offering Period. A Participant who is continuing participation pursuant to the preceding sentence (i) is not required to file any additional subscription agreement in order to continue participation in this Plan, and (ii) will be deemed to have accepted the terms and conditions of the Plan, any sub-plan, and subscription agreement in effect at the time each subsequent Offering Period begins, subject to Participantâ€™s right to withdraw from the Plan in accordance with the withdrawal procedures in effect at that time. 7.GRANT OF OPTION ON ENROLLMENT. Becoming a Participant with respect to an Offering Period will constitute the grant (as of the Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of Shares determined by a fraction, the numerator of which is the amount accumulated in such Participantâ€™s payroll deduction account during such Purchase Period and the denominator of which is the lower of (i) eighty-five percent (85%) of the Fair Market Value of a Share on the Offering Date (but in no event less than the par value of such Share), or (ii) eighty-five percent (85%) of the Fair Market Value of a Share on the Purchase Date, and provided, that the number of Shares subject to any option granted pursuant to this Plan shall not exceed the lesser of (x) the maximum number of Shares set by the Committee pursuant to Section 10(b) below with respect to the applicable Purchase Date, or (y) the maximum number of Shares which may be purchased pursuant to Section 10(a) below with respect to the applicable Purchase Date. 8.PURCHASE PRICE. The Purchase Price at which a Share will be sold in any Offering Period shall be eighty-five percent (85%) of the lesser of: (a)The Fair Market Value on the Offering Date; or (b)The Fair Market Value on the Purchase Date. 9.PAYMENT OF PURCHASE PRICE; PAYROLL DEDUCTION CHANGES; SHARE ISSUANCES. (a)The Purchase Price shall be accumulated by regular payroll deductions made during each Offering Period, unless the Company determines that contributions may be made in another form due to local legal or other requirements. The deductions are made as a percentage of the Participantâ€™s Compensation in one percent (1%) increments not less than one percent (1%), nor greater than fifteen percent (15%) or such lower limit set by the Committee. â€œCompensationâ€ shall mean base salary (or in foreign jurisdictions, equivalent cash compensation); however, the Committee may at any time prior to the - 3 -Â Â beginning of an Offering Period determine that for that and future Offering Periods, Compensation shall mean all W-2 cash compensation, including without limitation base salary or regular hourly wages, bonuses, incentive compensation, commissions, overtime, shift premiums, plus draws against commissions (or in foreign jurisdictions, equivalent cash compensation). For purposes of determining a Participantâ€™s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 401(k) of the Code (or in foreign jurisdictions, equivalent salary deductions) shall be treated as if the Participant did not make such election. Payroll deductions shall commence for each Offering Period on the first payday following the last Purchase Date and shall continue to the end of the applicable Offering Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the foregoing, the terms of any sub-plan may permit matching Shares without the payment of any purchase price. (b)A Participant may decrease the rate of payroll deductions during an Offering Period by filing with the Company a new authorization for payroll deductions, with the new rate to become effective as soon as administratively practicable after the Companyâ€™s receipt of the authorization and continuing for the remainder of the Offering Period unless changed as described below. A decrease in the rate of payroll deductions may be made once during any Offering Period, or more or less frequently under rules determined by the Committee. An increase in the rate of payroll deductions may not be made with respect to an on-going Offering Period unless otherwise determined by the Committee. A Participant may increase or decrease the rate of payroll deductions for any subsequent Offering Period by filing with the Company a new authorization for payroll deductions prior to the beginning of such Offering Period, or such other time period as specified by the Committee. (c)A Participant may reduce his or her payroll deduction percentage to zero during an Offering Period by filing with the Company a request for cessation of payroll deductions. Such reduction shall be effective as soon as administratively practicable after the Companyâ€™s receipt of the request and no further payroll deductions will be made for the duration of the Offering Period. Payroll deductions credited to the Participantâ€™s account prior to the effective date of the request shall be used to purchase Shares in accordance with Subsection (e) below. A reduction of the payroll deduction percentage to zero shall be treated as such Participantâ€™s withdrawal from the Plan, effective as of the day after the next Purchase Date following the filing date of such request with the Company. (d)All payroll deductions made for a Participant are credited to his or her account under this Plan and are deposited with the general funds of the Company, except to the extent local legal restrictions outside the United States require segregation of such payroll deductions. No interest accrues on the payroll deductions, except to the extent required due to local legal requirements. All payroll deductions received or held by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions, except to the extent necessary to comply with local legal requirements outside the United States. (e)On each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not submitted a signed and completed withdrawal form before that date which notifies the Company that the Participant wishes to withdraw from that Offering Period under this Plan and have all payroll deductions accumulated in the account maintained on behalf of the Participant as of that date returned to the Participant, the Company shall apply the funds then in the Participantâ€™s account to the purchase of whole Shares reserved under the option granted to such Participant with respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The Purchase Price per share shall be as specified in Section 8 of this Plan. Any fractional share, as calculated under this Subsection (e), shall be rounded down to the next lower whole share, unless the Committee determines with respect to all Participants that any fractional share shall be credited as a fractional share. Any amount remaining in a Participantâ€™s account on a Purchase Date which is less than the amount necessary to purchase a full Share shall be carried forward, without interest (except to the extent necessary to comply with local legal - 4 -Â Â requirements outside the United States), into the next Purchase Period or Offering Period, as the case may be. In the event that this Plan has been oversubscribed, all funds not used to purchase Shares on the Purchase Date shall be returned to the Participant, without interest (except to the extent required due to local legal requirements outside the United States). No Shares shall be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has terminated prior to such Purchase Date, except to the extent required due to local legal requirements outside the United States. (f)As promptly as practicable after the Purchase Date, the Company shall issue Shares for the Participantâ€™s benefit representing the Shares purchased upon exercise of his or her option. (g)During a Participantâ€™s lifetime, his or her option to purchase Shares hereunder is exercisable only by him or her. The Participant will have no interest or voting right in Shares covered by his or her option until such option has been exercised. (h)To the extent required by applicable federal, state, local or foreign law, a Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company or any Subsidiary or Affiliate, as applicable, may withhold, by any method permissible under the applicable law, the amount necessary for the Company or Subsidiary or Affiliate, as applicable, to meet applicable withholding obligations, including any withholding required to make available to the Company or Subsidiary or Affiliate, as applicable, any tax deductions or benefits attributable to the sale or early disposition of Shares by a Participant. The Company shall not be required to issue any Shares under the Plan until such obligations are satisfied. 10.LIMITATIONS ON SHARES TO BE PURCHASED. (a)Any other provision of the Plan notwithstanding, no Participant shall purchase Shares with a Fair Market Value in excess of the following limit: (i) In the case of Shares purchased during an Offering Period that commenced in the current calendar year, the limit shall be equal to (A) $25,000 minus (B) the Fair Market Value of the Shares that the Participant previously purchased in the current calendar year (under this Plan and all other employee stock purchase plans of the Company or any parent or Subsidiary of the Company). (ii) In the case of Shares purchased during an Offering Period that commenced in the immediately preceding calendar year, the limit shall be equal to (A) $50,000 minus (B) the Fair Market Value of the Shares that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or any parent or Subsidiary of the Company) in the current calendar year and in the immediately preceding calendar year. For purposes of this Subsection (a), the Fair Market Value of Shares shall be determined in each case as of the beginning of the Offering Period in which such Shares are purchased. Employee stock purchase plans not described in Section 423 of the Code shall be disregarded. If a Participant is precluded by this Subsection (a) from purchasing additional Shares under the Plan, then his or her employee contributions shall automatically be discontinued and shall automatically resume at the beginning of the earliest Purchase Period that will end in the next calendar year (if he or she then is an eligible employee), provided that when the Company automatically resumes such payroll deductions, the Company must apply the rate in effect immediately prior to such suspension. (b)The Committee may, in its sole discretion, set a lower maximum number of Shares that may be purchased by any Participant during any Offering Period than that determined under Section - 5 -Â Â 10(a); provided, however, in no event shall a Participant be permitted to purchase more than 2,500 Shares on any one Purchase Date or such greater or lesser number as the Committee shall determine. If a greater or lower limit is set under this Subsection (b), then all Participants will be notified of such limit prior to the commencement of the next Offering Period for which it is to be effective. (c)If the number of Shares to be purchased on a Purchase Date by all Participants exceeds the number of Shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining Shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company will give notice of such reduction of the number of Shares to be purchased under a Participantâ€™s option to each Participant affected. (d)Any payroll deductions accumulated in a Participantâ€™s account that are not used to purchase Shares due to the limitations in this Section 10, and not covered by Section 9(e), shall be returned to the Participant as soon as practicable after the end of the applicable Purchase Period, without interest (except to the extent required due to local legal requirements outside the United States). Â 11.WITHDRAWAL. (a)Each Participant may withdraw from an Offering Period under this Plan pursuant to a method specified for such purpose by the Company. Such withdrawal may be elected at any time prior to the end of an Offering Period, or such other time period as specified by the Committee. (b)Upon withdrawal from this Plan, the accumulated payroll deductions shall be returned to the withdrawn Participant, without interest (except to the extent required due to local legal requirements outside the United States), and his or her interest in this Plan shall terminate. In the event a Participant voluntarily elects to withdraw from this Plan, he or she may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan which commences on a date subsequent to such withdrawal by filing a new authorization for payroll deductions in the same manner as set forth in Section 6 above for initial participation in this Plan (c)To the extent applicable, if the Fair Market Value on the first day of the current Offering Period in which a participant is enrolled is higher than the Fair Market Value on the first day of any subsequent Offering Period, the Company will automatically enroll such participant in the subsequent Offering Period. Any funds accumulated in a Participantâ€™s account prior to the first day of such subsequent Offering Period will be applied to the purchase of Shares on the Purchase Date immediately prior to the first day of such subsequent Offering Period, if any. 12.TERMINATION OF EMPLOYMENT. Termination of a Participantâ€™s employment for any reason, including retirement, death, disability, or the failure of a Participant to remain an eligible employee of the Company or of a Participating Corporation, immediately terminates his or her participation in this Plan. In such event, accumulated payroll deductions credited to the Participantâ€™s account will be returned to him or her or, in the case of his or her death, to his or her legal representative, without interest (except to the extent required due to local legal requirements outside the United States). For purposes of this Section 12, an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating Corporation in the case of sick leave, military leave, or any other leave of absence approved by the Company; provided that such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute. The Company will have sole discretion to determine whether a Participant has terminated employment and the effective date on which the Participant terminated employment, regardless of any notice period or garden leave required under local law. - 6 -Â Â 13.RETURN OF PAYROLL DEDUCTIONS. In the event a Participantâ€™s interest in this Plan is terminated by withdrawal, termination of employment or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated payroll deductions credited to such Participantâ€™s account. No interest shall accrue on the payroll deductions of a Participant in this Plan (except to the extent required due to local legal requirements outside the United States). 14.CAPITAL CHANGES. If the number of outstanding shares is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then the Committee shall adjust the number and class of Shares that may be delivered under the Plan, the Purchase Price per share and the number of Shares covered by each option under the Plan which has not yet been exercised, and the numerical limits of Sections 2 and 10 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with the applicable securities laws; provided that fractions of a share will not be issued. 15.NONASSIGNABILITY. Neither payroll deductions credited to a Participantâ€™s account nor any rights with regard to the exercise of an option or to receive Shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 22 below) by the Participant. Any such attempt at assignment, transfer, pledge or other disposition shall be void and without effect. 16.USE OF PARTICIPANT FUNDS AND REPORTS. The Company may use all payroll deductions received or held by it under the Plan for any corporate purpose, and the Company will not be required to segregate Participant payroll deductions (except to the extent required due to local legal requirements outside the United States). Until Shares are issued, Participants will only have the rights of an unsecured creditor unless otherwise required under local law. Each Participant shall receive promptly after the end of each Purchase Period a report of his or her account setting forth the total payroll deductions accumulated, the number of Shares purchased, the per share price thereof and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering Period, as the case may be. 17.NOTICE OF DISPOSITION. Each U.S. taxpayer Participant shall notify the Company in writing if the Participant disposes of any of the Shares purchased in any Offering Period pursuant to this Plan if such disposition occurs within two (2) years from the Offering Date or within one (1) year from the Purchase Date on which such Shares were purchased (the â€œNotice Periodâ€). The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing Shares acquired pursuant to this Plan requesting the Companyâ€™s transfer agent to notify the Company of any transfer of the Shares. The obligation of the Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates. 18.NO RIGHTS TO CONTINUED EMPLOYMENT. Neither this Plan nor the grant of any option hereunder shall confer any right on any employee to remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employeeâ€™s employment. 19.EQUAL RIGHTS AND PRIVILEGES. All eligible employees granted an option under this Plan that is intended to meet the Code Section 423 requirements shall have equal rights and privileges with respect to this Plan or within any separate offering under the Plan so that this Plan qualifies as an â€œemployee stock purchase planâ€ within the meaning of Section 423 or any successor provision of the Code and the related regulations. Any provision of this Plan which is inconsistent with Section 423 or any successor provision of the Code, without further act or amendment by the Company, the Committee or the - 7 -Â Â Board, shall be reformed to comply with the requirements of Section 423. This Section 19 shall take precedence over all other provisions in this Plan. 20.NOTICES. All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. 21.TERM; STOCKHOLDER APPROVAL. This Plan will become effective on the Effective Date. This Plan shall be approved by the stockholders of the Company, in any manner permitted by applicable corporate law, within twelve (12) months before or after the date this Plan is adopted by the Board. No purchase of Shares that are subject to such stockholder approval before becoming available under this Plan shall occur prior to stockholder approval of such Shares and the Board or Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval (provided that if a Purchase Date would occur more than twenty-four (24) months after commencement of the Offering Period to which it relates, then such Purchase Date shall not occur and instead such Offering Period shall terminate without the purchase of such Shares and Participants in such Offering Period shall be refunded their contributions without interest). This Plan shall continue until the earlier to occur of (a) termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section 25 below), (b) issuance of all of the Shares reserved for issuance under this Plan, or (c) the tenth anniversary of the Effective Date under the Plan. 22.DESIGNATION OF BENEFICIARY. (a)Unless otherwise determined by the Committee, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participantâ€™s account under this Plan in the event of such Participantâ€™s death prior to a Purchase Date. Such form shall be valid only if it was filed with the Company at the prescribed location before the Participantâ€™s death. (b)Such designation of beneficiary may be changed by the Participant at any time by written notice filed with the Company at the prescribed location before the Participantâ€™s death. In the event of the death of a Participant and in the absence of a beneficiary validly designated under this Plan who is living at the time of such Participantâ€™s death, the Company shall deliver such cash to the executor or administrator of the estate of the

Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such cash to the spouse or, if no spouse is known to the Company, then to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. 23.CONDITIONS UPON ISSUANCE OF SHARES; LIMITATION ON SALE OF SHARES. Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such Shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the Shares may then be listed, exchange control restrictions and/or securities law restrictions outside the United States, and shall be further subject to the approval of counsel for the Company with respect to such compliance. Shares may be held in trust or subject to further restrictions as permitted by any subplan or as permitted by the Committee from time to time. - 8 -Â Â 24.APPLICABLE LAW. The Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware. 25.AMENDMENT OR TERMINATION. The Committee, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Committee, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of Shares on the next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 14). If an Offering Period is terminated prior to its previously-scheduled expiration, all amounts then credited to Participantsâ€™ accounts for such Offering Period, which have not been used to purchase Shares, shall be returned to those Participants (without interest thereon, except as otherwise required under local laws) as soon as administratively practicable. Further, the Committee will be entitled to change the Purchase Periods and Offering Periods, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld or contributed in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the administration of the Plan, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Shares for each Participant properly correspond with amounts withheld from the Participantâ€™s base salary and other eligible compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion advisable which are consistent with the Plan. Such actions will not require stockholder approval or the consent of any Participants. However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with Section 21 above) within twelve (12) months of the adoption of such amendment (or earlier if required by Section 21) if such amendment would: (a) increase the number of Shares that may be issued under this Plan; or (b) change the designation of the employees (or class of employees) eligible for participation in this Plan. In addition, in the event the Board or Committee determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Board or Committee may, in its discretion and, to the extent necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequences including, but not limited to: (i) amending the definition of Compensation, including with respect to an Offering Period underway at the time; (ii) altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price; (iii) shortening any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committeeâ€™s action; (iv) reducing the maximum percentage of Compensation a participant may elect to set aside as payroll deductions; and (v) reducing the maximum number of Shares a Participant may purchase during any Offering Period. Such modifications or amendments will not require approval of the stockholders of the Company or the consent of any Participants. 26.CORPORATE TRANSACTIONS. In the event of a Corporate Transaction, the Offering Period for each outstanding right to purchase Shares will be shortened by setting a new Purchase Date and will end on the new Purchase Date. The new Purchase Date shall occur on or prior to the consummation of the Corporate Transaction, as determined by the Board or Committee, and the Plan shall terminate on the consummation of the Corporate Transaction. 27.CODE SECTION 409A; TAX QUALIFICATION. (a)Options granted under the Plan generally are exempt from the application of Section 409A of the Code. However, options granted to U.S. taxpayers which are not intended to meet the Code Section 423 requirements are intended to be exempt from the application of Section 409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. Subject to Subsection (b), options granted to U.S. taxpayers outside of the - 9 -Â Â Code Section 423 requirements shall be subject to such terms and conditions that will permit such options to satisfy the requirements of the short-term deferral exception available under Section 409A of the Code, including the requirement that the Shares subject to an option be delivered within the short-term deferral period. Subject to Subsection (b), in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the extent the Committee determines that an option or the exercise, payment, settlement or deferral thereof is subject to Section 409A of the Code, the option shall be granted, exercised, paid, settled or deferred in a manner that will comply with Section 409A of the Code, including Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto. (b)Although the Company may endeavor to (i) qualify an option for favorable tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii) avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company makes no representation to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan, including Subsection (a). The Company shall be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants under the Plan. 28.DEFINITIONS. (a)â€œAffiliateâ€ means (i) any entity that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (ii) any entity in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing. (b)â€œBoardâ€ means the Board of Directors of the Company. (c)â€œCodeâ€ means the Internal Revenue Code of 1986, as amended. (d)â€œCommitteeâ€ means the Compensation Committee of the Board that consists exclusively or one or more members of the Board appointed by the Board. (e)â€œCompanyâ€ means Sutro Biopharma, Inc., a Delaware corporation. (f)â€œCorporate Transactionâ€ means the occurrence of any of the following events: (i) any â€œpersonâ€ (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the â€œbeneficial ownerâ€ (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Companyâ€™s then outstanding voting securities; or (ii) the consummation of the sale or disposition by the Company of all or substantially all of the Companyâ€™s assets; or (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. (g)â€œEffective Dateâ€ means the date on which the Registration Statement covering the initial public offering of Shares is declared effective by the U.S. Securities and Exchange Commission. - 10 -Â Â (h)â€œFair Market Valueâ€ means, as of any date, the value of Shares determined as follows: (1)if such Shares are then quoted on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (collectively, the â€œNasdaq Marketâ€), the closing price on the Nasdaq Market on the date of determination, or if there are no sales for such date, then the last preceding business day on which there were sales, as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or (2)if such Shares are publicly traded and are then listed on a national securities exchange, the closing price of such Shares on the date of determination on the principal national securities exchange on which the Shares are listed or admitted to trading as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or (3)if such Shares are publicly traded but are neither quoted on the Nasdaq Market nor listed or admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; and (4)if none of the foregoing is applicable, by the Board or the Committee in good faith. (i)â€œIPOâ€ means the initial public offering of Companyâ€™s common stock. (j)â€œOffering Dateâ€ means the first business day of each Offering Period. (k)â€œOffering Periodâ€ means a period with respect to which the right to purchase Shares may be granted under the Plan, as determined by the Committee pursuant to Section 5(a). (l)â€œParentâ€ has the same meaning as â€œparent corporationâ€ in Sections 424(e) and 424(f) of the Code. (m)â€œParticipantâ€ means an eligible employee who meets the eligibility requirements set forth in Section 4 and who elects to participate in this Plan pursuant to Section 6(b). (n)â€œParticipating Corporationâ€ means any Parent, Subsidiary or Affiliate that the Committee designates from time to time as eligible to participate in this Plan, provided, however, that employees of Affiliates that are designated for participation may be granted only options that do not intend to comply with the Code Section 423 requirements. (o)â€œPlanâ€ means this Sutro Biopharma, Inc. 2018 Employee Stock Purchase Plan, as amended. (p)â€œPurchase Dateâ€ means the last business day of each Purchase Period. (q)â€œPurchase Periodâ€ means a period during which contributions may be made toward the purchase of Shares under the Plan, as determined by the Committee pursuant to Section 5(b). (r)â€œPurchase Priceâ€ means the price at which Participants may purchase Shares under the Plan, as determined pursuant to Section 8. - 11 -Â Â (s)â€œSharesâ€ means shares of the Companyâ€™s common stock. (t)â€œSubsidiaryâ€ has the same meaning as â€œsubsidiary corporationâ€ in Sections 424(e) and 424(f) of the Code. - 12 -Â EX-31.1 3 stro-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, William J. Newell certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Sutro Biopharma, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: August 13, 2024 Â /s/ William J. Newell William J. Newell Chief Executive Officer (Principal Executive Officer) Â Â EX-31.2 4 stro-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Edward C. Albini, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Sutro Biopharma, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: August 13, 2024 Â /s/ Edward C. Albini Edward C. Albini Chief Financial Officer Â (Principal Accounting Officer and Principal Financial Officer) Â Â EX-32.1 5 stro-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â I, William J. Newell, Chief Executive Officer of Sutro Biopharma, Inc. (the â€œCompanyâ€), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: 1.the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 13, 2024 /s/ William J. Newell William J. Newell Chief Executive Officer (Principal Executive Officer) Â Â EX-32.2 6 stro-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Edward C. Albini, Chief Financial Officer of Sutro Biopharma, Inc. (the â€œCompanyâ€), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: 1.the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 13, 2024 /s/ Edward C. Albini Edward C. Albini Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Â Â EX-101.SCH 7 stro-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 -

Statement - Condensed Statements of Stockholders' Equity (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Organization and Principal Activities link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Collaboration and License Agreements and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Collaboration and License Agreements and Supply Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Organization and Principal Activities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Collaboration and License Agreements and Supply Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Employee Stock Options Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Fair Value of ESPP Shares Using Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Equity Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of the Status of Call Options (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name Plan Name [Domain] Transaction price Transaction Price Transaction price. Deferred Royalty Obligation Related to the sale of Future Royalties and Non Cash Interest Expense Policy. Deferred Royalty Obligation Related to the sale of Future Royalties and Non Cash Interest Expense Policy Stock transaction associated with taxes withheld on restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Deferred royalty obligation related to the sale of future royalties. Deferred Royalty Obligation related to the Sale of Future Royalties [Text Block] Deferred Royalty Obligation related to the Sale of Future Royalties Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Number of operating segments Number of Operating Segments January 1 , 2017 Share-Based Payment Arrangement, Tranche One [Member] Income tax charge related to contingent payment Income Tax Charge Related To Contingent Payment Income tax charge related to contingent payment. Stock options exercisable, Weighted - Average Exercise Price, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Cash Equivalents and Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Common Stock Balance, Shares Common Stock Balance, Shares Shares, Outstanding Other Noncash Income (Expense), Total Other Other Noncash Income (Expense) Level 2 Fair Value Hierarchy and NAV [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Non-cash interest expense related to the sale of future royalties. Non-cash Interest Expense Related To The Sale Of Future Royalties Non-cash interest expense related to the sale of future royalties Non-cash interest expense related to the sale of future royalties 2004 Plan, 2018 Plan and 2021 Plan Two Thousand Four Plan Two Thousand Eighteen Equity Incentive Plan And Two Thousand Twenty One Equity Inducement Plan [Member] Two thousand four plan two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan. Two thousand fifteen license agreement. Two Thousand Fifteen License Agreement [Member] 2015 License Agreement Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Remaining in 2024 Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Product and Service Product and Service [Axis] Depreciation, Depletion and Amortization, Total Depreciation and amortization Depreciation, Depletion and Amortization Issuance costs included in accounts payable. Issuance Costs Included In Accounts Payable Issuance costs included in accounts payable Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Supplemental disclosure of non-cash investing and financing information: Noncash Investing and Financing Items [Abstract] Stockholders' Equity Equity [Text Block] Revenue interest percentage. Revenue Interest Percentage Revenue interest percentage January 1 , 2022 Share Based Compensation Award Tranche Six [Member] Share-based compensation award tranche six. Award Date Award Date [Axis] Sale of Stock Sale of Stock [Domain] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Amortization of issuance costs. Amortization of issuance costs Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Entity Central Index Key Entity Central Index Key Warrants to Purchase Common Stock Warrant [Member] Canceled and forfeited, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period 2018 Merck Agreement Two Thousand Eighteen Merck Agreement [Member] Two thousand eighteen Merck agreement. First installment milestone payment received. First Installment Milestone Payment Received First installment milestone payment received Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] BMS Agreement and the 2018 BMS Master Services Agreement BMS Agreement And Two Thousand Eighteen BMS Master Services Agreement [Member] BMS agreement and two thousand eighteen BMS master services agreement. Royalty obligation. Royalty Obligation [Table Text Block] Schedule of Royalty Obligation transaction Realized gain on sale of equity securities Equity Securities, FV-NI, Realized Gain (Loss) Equity Securities, FV-NI, Realized Gain (Loss), Total Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Common stock, shares issued Common Stock, Shares, Issued Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Risk-free interest rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Award Date Award Date [Domain] Remaining Shares Reserved for Issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan Remaining shares reserved for issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan 2018 Equity Incentive Plan and 2021 Equity Inducement Plan Two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan. Income Statement [Abstract] Sales of marketable securities Proceeds From Sales Of Marketable Securities Proceeds from sales of marketable securities. Investment Income, Nonoperating, Total Interest income Investment Income, Nonoperating Headquartered in state Entity Address, State or Province Entity Address, State or Province Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Issuance of common stock under Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Contingent payment recognized as deferred revenue Contingent Payment Recognized As Deferred Revenue Contingent payment recognized as deferred revenue. Loss Contingencies [Table] Loss Contingencies [Table] Tasly Biopharmaceuticals Co., Ltd. ("Tasly") Tasly Biopharmaceuticals Co. Ltd [Member] Tasly Biopharmaceuticals Co. Ltd. Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Cover [Abstract] Net loss per share, basic Net loss per share, basic Earnings Per Share, Basic, Total Net (loss) income per share, basic Interest and other income (expense), net Interest and Other Income (Expense), Net Interest and other income (expense), net. Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Operating expenses Operating Expenses [Abstract] Deferred revenueâ€“current Contract with Customer, Liability, Current Additional purchase of common stock. Additional purchase of Common Stock Additional purchase of common stock Stock-based compensation expense Total stock-based compensation expense Share-Based Payment Arrangement, Expense Stockholders Equity [Table] Stockholders Equity [Table] Stockholders equity. Common Stock Options Issued and Outstanding Common Stock Option Issued And Outstanding [Member] Common stock option issued and outstanding. Maturities of marketable securities Proceeds From Maturities Of Marketable Securities Proceeds from maturities of marketable securities. Upfront payment received Upfront Payment Received Upfront payment received. Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Plan Name Plan Name [Axis] Astellas pharma inc. ("Astellas"). Astellas Pharma Inc. ("Astellas") [Member] Astellas Pharma Inc. ("Astellas") Options vested and outstanding Stock options outstanding, Beginning Balance, Shares Stock options outstanding, Ending Balance, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Current assets: Assets, Current [Abstract] Reserved common stock Common Stock, Capital Shares Reserved for Future Issuance Annual increase period of common stock reserved for issuance Annual Increment Period Of Common Stock Reserved For Issuance Annual increase period of common stock reserved for issuance. 2020 Merck Master Services Agreement Two Thousand Twenty Merck Master Services Agreement [Member] 2020 Merck master services agreement. Investment Type Investment Type [Axis] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Canceled and forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Product and Service Product and Service [Domain] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Call Option Plan Call Option Plan [Member] Call option plan. Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Investments in Equity Securities Investment, Policy [Policy Text Block] Deferred revenue - non-current Contract with Customer, Liability, Noncurrent Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value Measurements Recurring Fair Value, Recurring [Member] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value of Financial Assets and Liabilities Measured on Recurring Basis Vesting Vesting [Axis] Common stock value per share Common stock, par value Common Stock, Par or Stated Value Per Share Stock Options Employee Stock Options Employee Stock Option [Member] Clinical Trials Clinical Trials [Member] Clinical trials. 2021 Equity Inducement Plan Two Thousand Twenty One Equity Inducement Plan Member Two thousand twenty one equity inducement plan. Contract with Customer, Liability, Total Deferred revenue Deferred revenue Deferred revenue Contract with Customer, Liability Statement of Cash Flows [Abstract] Counterparty Name Counterparty Name [Axis] Astellas License and Collaboration Agreement Astellas License and Collaboration Agreement [Member] Astellas license and collaboration agreement. Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Shares to be Issued Under Employee Stock Purchase Plan Shares to be issued under employee stock purchase plan [Member] Shares to be issued under employee stock purchase plan. Unrestricted cash, cash equivalents and equity securities at carrying value Unrestricted Cash Cash Equivalents And Equity Securities At Carrying Value unrestricted cash cash equivalents and equity securities at carrying value. Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Summary of Computation of Company's Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Granted Restricted common stock granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Subsequent Event Type Subsequent Event Type [Axis] Milestone payment received Milestone Payment Received Milestone payment received. Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Milestone payment receivable. Milestone Payment Receivable Milestone payment

receivable Additional milestone payment received Additional Milestone Payment Received Additional milestone payment received. Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Percentage of volume weighted average price premium. Percentage Of VWAP Premium Percentage of VWAP premium Non-vested, Beginning Balance Non-vested, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amendment Flag Amendment Flag Change in operating lease liability Increase (Decrease) in Operating Lease Liability Operating lease liability - non-current Total lease liabilities, non-current Operating lease liabilities non-current Corporate Debt Securities Corporate Debt Securities [Member] 2019 EMD Serono Supply Agreement Two Thousand Nineteen E M D Serono Supply Agreements [Member] 2019 EMD Serono supply agreements. Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in-capital Additional Paid in Capital, Common Stock Net loss Net loss Net (loss) income, basic and diluted Net Income (Loss) Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table] Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table] Schedule of organization consolidation and presentation of financial statements. Exercised, Shares Options vested and exercised Exercise of common stock options, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of shares issued Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Stock options exercisable, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and Development Expense Research and Development Expense [Member] Initial Premises Initial Premises [Member] Initial premises. Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] General and Administrative Expense, Total General and administrative General and Administrative Expense Vaxcyte Vaxcyte, Inc. Vaxcyte Inc [Member] Vaxcyte, Inc. Ipsen agreement. Ipsen Agreement [Member] Ipsen Agreement Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Preferred Stock, Shares Issued, Total Preferred stock, shares issued Preferred Stock, Shares Issued Impacts of Recently Adopted Accounting Pronouncements on 2021 Interim Reporting Impacts of Recently Adopted Accounting Pronouncements on 2021 Interim Reporting policy [Policy Text Block] Impacts of Recently Adopted Accounting Pronouncements on 2021 Interim Reporting policy. Blackstone life sciences. Blackstone Life Sciences [Member] Blackstone Life Sciences Operating lease payments Operating Lease, Payments U.S. Government Securities US Government Corporations and Agencies Securities [Member] Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Options unvested and outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Initial licensing payment in escrow Initial Licensing Payment in escrow Initial licensing payment in escrow. Payables and Accruals [Abstract] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Issuance costs related to deferred royalty obligation in accrued expenses. Issuance Costs Related To Deferred Royalty Obligation In Accrued Expenses Issuance costs related to deferred royalty obligation in accrued expenses Number of target programs Number Of Target Programs Number of target programs. Issuance of common stock under Employee Stock Purchase Plan, Shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Award Type All Award Types Operating lease expense Operating Lease, Expense Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Risk-free interest rate, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Weighted - Average Exercise Price, Canceled and forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Bristol-Myers Squibb Company ("BMS") Bristol Myers Squibb Company B M S [Member] Bristol-Myers Squibb Company ("BMS"). Restricted cash Restricted Cash, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock, Shares, Outstanding Non cash interest expense on deferred royalty obligation. Non Cash Interest Expense On Deferred Royalty Obligation Non-cash interest expense on deferred royalty obligation Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items] Share based compensation arrangement by share based payment award fair value assumptions and methodology. Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Collaboration and License Agreements and Supply Agreements Collaboration And License Agreements And Supply Agreements [Text Block] Collaboration and license agreements and supply agreements. Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Collaboration Agreements And Supply Agreements [Abstract] Collaboration agreements and supply agreements. Antidilutive Securities Antidilutive Securities [Axis] Summary of Status and Activity of Non-vested RSUs Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'') Merck K Ga A Darmstadt Germany [Member] Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name â€œEMD Seronoâ€). Entity Interactive Data Current Entity Interactive Data Current Purchases of equipment and leasehold improvements Payments To Acquire Equipment And Leasehold Improvements Payments to acquire equipment and leasehold improvements. Document Quarterly Report Document Quarterly Report Vested and released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Related Party Transaction Related Party Transaction [Domain] Total cash, cash equivalents, and restricted cash shown in the condensed Statements of Cash Flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities. Total accrued expenses and other current liabilities Statistical Measurement Statistical Measurement [Axis] Proceeds from sale of future royalties net of issuance costs. Proceeds From Sale of Future Royalties Net of Issuance Costs Proceeds from the sale of future royalties, net of issuance costs Schedule of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities and Other Liabilities Disclosure, Current [Table Text Block] Schedule of accrued liabilities and other liabilities disclosure, current. Operating lease cost Operating Lease, Cost Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders equity. January 1 , 2019 Share-Based Payment Arrangement, Tranche Three [Member] Assets, Fair Value Disclosure, Total Securities held Total Assets, Fair Value Disclosure Underwritten offering Underwritten Offering [Member] Underwritten Offering [Member] Related Party Related and Nonrelated Parties [Domain] Total lease costs Lease, Cost Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Commercial Paper Commercial Paper [Member] Shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2018 Equity Incentive Plan Two Thousand Eighteen Equity Incentive Plan [Member] Two thousand eighteen equity incentive plan. Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Remaining unrecognized compensation cost expected to be recognized over weighted-average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Financing Component On Unearned Revenue [Member] Financing component on unearned revenue. Financing Component on Unearned Revenue Income Statement Location Statement of Income Location, Balance [Axis] Non cash interest expense associated with the sale of future royalties Non Cash Interest Expense Associated With The Sale of Future Royalties Non-cash interest expense associated with the sale of future Vaxcyte royalties Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Number of shares held Investment Owned, Balance, Shares Total assets Assets Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Common Stock Awards Issued and Outstanding Common Stock Awards Issued And Outstanding [Member] Common stock awards issued and outstanding. Amendment Number Three Two Thousand Fifteen License Agreement. Amendment Number Three Two Thousand Fifteen License Agreement [Member] Amendment 3 2015 License Agreement Marketable Securities Marketable Securities [Member] Marketable securities. Marketable Securities Vested and released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Headquartered in Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements line items. Assets: Assets, Fair Value Disclosure [Abstract] Canceled and forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Maximum potential payments related to development regulatory commercialization contingent payments and milestones Maximum Potential Payments Related To Development Regulatory Commercialization Contingent Payments And Milestones Maximum potential payments related to development regulatory commercialization contingent payments and milestones. Deferred royalty obligation. Deferred Royalty Obligation [Table] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Deferred Charges, Policy [Policy Text Block] Deferred Royalty Obligation related to the Sale of Future Royalties and Non-cash Interest Expense Number of installments Number of Installments Number of installments. Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Maximum number of shares issuable Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Recognition of revenue in current period Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Warrants to Purchase Common Stock Warrants To Purchase Common Stock [Member] Warrants to purchase common stock. Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Estimated service period Estimated Service Period Estimated service period. Fair Value Disclosures [Abstract] Basis of Presentation and Use of Estimates Basis Of Presentation And Use Of Estimates Policy Policy [Text Block] Basis of presentation and use of estimates. Unrealized gain on equity securities Unrealized gain on equity securities Unrealized (loss) gain on equity securities Unrealized loss on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss), Total Less amounts classified as cash equivalents, Unrealized Gains Cash Equivalents Unrealized Gains Cash equivalents unrealized gains. Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement Stock Issued During Period, Value, New Issues Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Current liabilities: Liabilities, Current [Abstract] Accrued expenses and other liabilities Increase (Decrease) in Accrued Expenses and Other Liabilities Increase (decrease) in accrued expenses and other liabilities. Lease Contractual Term Lease Contractual Term [Axis] Sublease Agreement Sublease Agreement [Member] Sublease agreement. Vaxcyte. Vaxcyte [Member] Vaxcyte Income Taxes Paid, Net, Total Income Taxes Paid, Net Income tax paid Document Type Document Type U.S. Agency Securities US Government Agencies Debt Securities [Member] Issuance of common stock in connection with the underwritten offering, net of issuance costs Stock Issued During Period Value Through The Underwritten Offerings Stock issued during period value through the underwritten offerings. Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Less amounts classified as cash equivalents, Amortized Cost Basis Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Additional milestone payment Additional Milestone Payment Additional milestone payment. Schedule of Components of Lease Costs Lease, Cost [Table Text Block] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and development Research and Development Expense Taxes paid related to net shares settlement of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Long-term Debt, Excluding Current Maturities, Total Debt, non-current Debtâ€”non-current Long-Term Debt, Excluding Current Maturities California CALIFORNIA Total options granted Share-based compensation arrangement by share-based payment award options, shares granted Granted, Shares Number of goods and services Number Of Goods And Services Number of goods and services. Asset Class Asset Class [Domain] Subsequent Event Type Subsequent Event Type [Domain] Vaxcyte agreements. Vaxcyte Agreements [Member] Vaxcyte Agreements Five Prime Therapeutics, Inc. (the "Sublessor") Five Prime Therapeutics Inc [Member] Five Prime Therapeutics, Inc. Schedule of Employee Stock Options Valuation Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Withholding tax on deferred revenue Withholding Tax On Deferred Revenue Withholding tax on deferred revenue. Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Schedule of common stock reserved for future issuance. Upfront Payment Upfront Payment [Member] Upfront payment. Ipsen Pharma SAS ("Ipsen") Ipsen Pharma S A S [Member] Ipsen Pharma S A S. Financial Instruments Financial Instruments [Domain] Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Sale of Stock Sale of Stock [Axis] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investments Investments [Domain] Earnings Per Share Basic [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Marketable Securities, Current, Total Marketable securities Marketable Securities, Current Total revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue from Contract with Customer, Excluding Assessed Tax Revenue Statement of Comprehensive Income [Abstract] Additional payment related to sales milestone. Additional Payment Related To Sales Milestone Payments related to sales milestone Shares available for grant, increase Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Increase Share based compensation arrangement by share based payment award number of shares available for grant , increase. Percentage of interest rate amortize liability Percentage Of Interest Rate Amortize Liability Percentage of interest rate amortize liability Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Liabilities and Stockholdersâ€™ Equity Liabilities and Equity [Abstract] Document Period End Date Document Period End Date First Cytokine-Derivative Program First Cytokine Derivative Program [Member] First cytokine-derivative program. Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Stockholders' Equity Note [Abstract] Transaction costs incurred. Transaction costs incurred Antidilutive securities excluded from computation of net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Vaxcyte Common Stock Vaxcyte Common Stock [Member] Vaxcyte common stock. Number of performance obligations Number Of Performance Obligations Number of performance obligations. APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accrued Liabilities, Current, Total Accrued compensation Accrued Liabilities, Current Revenue recognition aggregate contingent payments eligible to receive Revenue Recognition Aggregate Contingent Payments Eligible To Receive Revenue recognition aggregate contingent payments eligible to receive. Income tax expense Provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Trading Symbol Trading Symbol Total stockholdersâ€™ equity Balances Balances Equity, Attributable to Parent At-The-Market Sale At-The-Market Offering [Member] At-the-market offering. Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Other Liabilities, Noncurrent, Total Other Liabilities, Noncurrent Other non-current liabilities Restricted Stock Units Restricted Stock Units (RSUs) [Member] Variable lease cost Variable Lease, Cost Substantial doubt about going concern, within one year Substantial Doubt about Going Concern, within One Year [true false] Financing component associated with program fees. Financing Component Associated with Program Fees Financing component associated with program fees Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Total unrecognized compensation cost related to unvested granted Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Collaboration and license agreements and supply agreement accruals Collaboration and License Agreements and Supply Agreement Accruals Current Collaboration and license agreements and supply agreement accruals current. Schedule of Stock-Based Compensation Expense Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Organization and Principal Activities Nature of Operations [Text Block] Geographical Geographical [Axis] Period from issuance date of unaudited interim condensed financial statements Period From Issuance Of Unaudited Interim Condensed Financial Statements Period from issuance of unaudited interim condensed financial statements Unrealized Losses Unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax January 1 , 2020 Share Based Compensation Award Tranche Four [Member] Share-based compensation award tranche four. Shares Reserved for Issuance Under 2018 Employee Stock Purchase Plan 2018 Employee Stock Purchase Plan Two Thousand Eighteen Employee Stock Purchase Plan [Member] Two thousand

eighteen employee stock purchase plan. Summary of Deferred Revenue Balance Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Expected volatility, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected dividend Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Security Exchange Name Security Exchange Name Upfront license fee. Upfront License Fee Upfront license fee Counterparty Name Counterparty Name [Domain] Reimbursements expenses accruals Reimbursements Expenses Accruals Reimbursements expenses accruals. Total operating expenses Operating Expenses Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Reduction of research and development expenses recognized Reduction of Research and Development Expenses Recognized Reduction of research and development expenses recognized. Revenue recognized from contingent payment Revenue Recognized From Contingent Payment , Net Of Withholding Tax Revenue recognized from contingent payment , net of withholding tax. Collaboration and License Agreements and Supply Agreements Collaboration And License Agreements And Supply Agreements [Member] Collaboration and license agreements and supply agreements. Fair Value Measurements Fair Value Disclosures [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Less amounts classified as cash equivalents, Unrealized Losses Cash Equivalents Unrealized Losses Cash equivalents unrealized losses. Subsequent Event Subsequent Event [Member] Maximum Maximum Maximum [Member] January 1 , 2021 Share Based Compensation Award Tranche Five [Member] Share-based compensation award tranche five. Total Liabilities and Stockholdersâ€™ Equity Liabilities and Equity Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Net loss per share, diluted Net loss per share, diluted Earnings Per Share, Diluted, Total Net (loss) income per share, diluted Deferred royalty obligation. Deferred Royalty Obligation [Line Items] Entity Ex Transition Period Entity Ex Transition Period Contingent Payment Contingent Payment [Member] Contingent payment. Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate Maximum Amount Eligible To Receive For Development Regulatory And Commercial Milestones For Each Product Candidate Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate. Total liabilities Liabilities Voting rights per share Common Stock, Voting Rights Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Fair market value of common stock issued Fair Market Value of Common Stock Issued Fair market value of common stock issued. Total current assets Assets, Current Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Nonrefundable, non-creditable upfront payment receivable Nonrefundable Noncreditable Upfront Payment Receivable Nonrefundable non-creditable upfront payment receivable. San Carlos Lease San Carlos Lease [Member] San carlos lease. Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement ,Shares Shares of common stock Stock Issued During Period, Shares, New Issues Shares vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Entity Filer Category Entity Filer Category Deferred royalty obligation. Deferred Royalty Obligation [Abstract] EMD Serono E M D Serono [Member] EMD Serono. Nonrefundable, non-creditable upfront payment Nonrefundable, Non-creditable Upfront Fee Payment Nonrefundable, non-creditable upfront fee payment. Recognition of other-than-temporary impairment Other Than Temporary Impairment Losses Debt Securities Available For Sale Recognized In Earnings Other than temporary impairment losses debt securities available for sale recognized in earnings. Payments to Acquire Marketable Securities, Total Purchases of marketable securities Payments to Acquire Marketable Securities Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Award Type Award Type [Axis] Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Related Party Transaction Related Party Transaction [Axis] Aggregate Intrinsic Value, Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Related Party Related and Nonrelated Parties [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Entity Registrant Name Entity Registrant Name Investments in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss, Total MDA Agreement M D A Agreement [Member] MDA agreement. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss Per Share Earnings Per Share [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Money Market Funds Money Market Funds [Member] Other Other Liabilities, Current, Total Other current liabilities Other Liabilities, Current Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average shares used in computing basic net (loss) income per share Weighted Average Number of Shares Outstanding, Basic Weighted-average shares used in computing basic net loss per share Vesting Vesting [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Schedule Of Earnings Per Share Basic By Common Class [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Expected volatility, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Common stock, shares authorized Common Stock, Shares Authorized Stock transaction associated with taxes withheld on restricted stock units,Shares Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Royalty [Member] Royalty Proceeds from sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA) Proceeds from Issuance of Common Stock Payment receivable from common stock Cash and Cash Equivalents [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Weighted - Average Exercise Price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financial Instrument Financial Instrument [Axis] Deferred royalty obligations related to the sale of future royalties and non cash interest expense policy. Deferred Royalty Obligations Related to the sale of Future Royalties and Non Cash Interest Expense Policy [Policy Text Block] Deferred Royalty Obligation related to the Sale of Future Royalties and Non-cash Interest Expense Weighted - Average Remaining Contract Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term General and Administrative Expense General and Administrative Expense [Member] Unrealized losses Available For Sale Debt Securities Investments In Unrealized Loss Available for sale debt securities investments in unrealized loss. Revenue Recognition Revenue [Policy Text Block] Tasly License Agreement Tasly License Agreement [Member] Tasly license agreement. Share-Based Payment Arrangement [Abstract] Other comprehensive (loss) income : OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract] Materials Supply [Member] Materials supply. Materials Supply Debt, Current, Total Debtâ€”current Debt, Current Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaboration And License Agreements And Supply Agreements [Abstract] Collaboration and license agreements and supply agreements. Estimated fair value of equity securities Investment in equity securities Equity Securities, FV-NI, Current Debt Securities, Available-for-sale, Total Fair Value Debt Securities, Available-for-Sale Accounting Policies [Abstract] Summary of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Cash And Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Marketable Securities, Noncurrent, Total Marketable securities, non-current Long-term marketable securities Marketable Securities, Noncurrent Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Industrial Lease Industrial Lease [Member] Industrial lease. Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Statement [Table] Statement [Table] Preferred stock shares authorized Preferred Stock, Shares Authorized Issuance of common stock in connection with the underwritten offering, net of issuance costs , Shares Stock Issued During Period Shares Through The Underwritten Offering Stock issued during period shares through the underwritten offering. Revenue recognition of up-front payment amount. Revenue Recognition Of Up Front Payment Amount Recognition of up front payment Entity File Number Securities Act File Number Asset-backed Securities Asset-Backed Securities [Member] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Summary of Recognized Revenue Milestone Method Revenue Recognition Table [Text Block] Milestone method revenue recognition. Earnings Per Share [Abstract] Cash Equivalents Cash Equivalents [Member] Lease Contractual Term Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Supply Agreement Supply Agreement [Member] Supply agreement. Date of incorporation Entity Incorporation, Date of Incorporation Loss from operations Operating Income (Loss) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accrued Income Taxes, Current Tax and related expenses Unrestricted cash, cash equivalents and marketable securities Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value Unrestricted cash, cash equivalents and marketable securities at carrying value. Schedule of Fair Value of ESPP Shares Using Option Pricing Model Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Entity Shell Company Entity Shell Company Premium on common stock issued to Ipsen Biopharma, Inc. (USA) Premium On Common Stock Issued Premium on common stock issued, Entity Tax Identification Number Entity Tax Identification Number Issuance of common stock in connection with At-The-Market sale, net of issuance costs Stock Issued During Period Value Through At The Market Sale Stock issued during period value through At The Market sale. Assets Assets [Abstract] Bionova pharmaceuticals, ltd. (bionova). BioNova Pharmaceuticals, Ltd. (BioNova) [Member] BioNova Pharmaceuticals, Ltd. ("BioNova") Entity Current Reporting Status Entity Current Reporting Status Weighted - Average Remaining Contract Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Contingent Payment Earned [Member] Contingent payment earned. Contingent Payment Earned Deferred royalty obligation related to the sale of future royalties, classified as noncurrent. Deferred Royalty Obligation Related To Sale Of Future Royalties, Noncurrent Deferred royalty obligation related to the sale of future royalties Deferred royalty obligation related to the sale of future Vaxcyte royalties, net Deferred revenue Increase (Decrease) in Contract with Customer, Liability Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus January 1 , 2018 Share-Based Payment Arrangement, Tranche Two [Member] Preferred stock, $0.001 par value - 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued Purchases of equipment included in accounts payable and accrued expense Capital Expenditures Incurred but Not yet Paid Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Proceeds from sales of common stock, net of issuance costs Proceeds from Issuance Initial Public Offering Future Services on Collaboration Joint Steering Committee ("JSC") Future Services On Collaboration Joint Steering Committee [Member] Future services on collaboration Joint Steering Committee. City Area Code City Area Code Issuance of common stock in connection with At-The-Market sale, net of issuance costs, Shares Stock Issued During Period Shares Through At The Market Sale Stock issued during period shares through At The Market sale. Total current liabilities Liabilities, Current Ongoing Performance Related To Unsatisfied Performance Obligations [Member] Ongoing performance related to unsatisfied performance obligations. Ongoing Performance Related to Unsatisfied Performance Obligations 2018 BMS Master Services Agreement Two Thousand Eighteen BMS Master Services Agreement [Member] Two thousand eighteen BMS master services agreement. Equity Securities Equity Securities [Member] Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year Increase In Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Last Day Of Preceding Year Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, outstanding Preferred stock shares outstanding Preferred Stock, Shares Outstanding ESPP Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] 2018 Employee Stock Purchase Plan. Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Disclosure Text Block [Abstract] Commitments and Contingencies Disclosure [Abstract] Amortized Cost Basis Debt Securities, Available-for-Sale, Amortized Cost Operating lease liabilities current Less: current portion Operating lease liability - current Operating Lease, Liability, Current At-the-Market (â€œATM") ATM Atthe Market Issuance Sales Agreement [Member] At-the-Market issuance sales agreement. Additions to deferred revenue Contract With Customer Liability Additions Contract with customer liability additions. Accumulated Deficit Retained Earnings [Member] Underwritten Offering Over-Allotment Option [Member] Document Transition Report Document Transition Report Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Option Granted in August 2019 Option Granted In August Two Thousand And Nineteen [Member] Option granted in August 2019. Lease extension period Lessee Operating Lease Option To Extend Period Lessee operating lease option to extend period. Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Additional payment related to development and regulatory milestone. Additional Payment Related To Development And Regulatory Milestone Payment related to development and regulatory milestone Proceeds from employee stock purchase plan Proceeds from Stock Plans Weighted - Average Exercise Price, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Initial licensing payment due Initial Licensing Payment due Initial licensing payment due. Minimum Minimum Minimum [Member] Common Stock Options Issued and Outstanding Common Stock Common Stock [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Deferred offering cost included in accounts payable and accrued expenses. Deferred Offering Cost Included In Accounts Payable And Accrued Expenses Deferred offering cost included in accounts payable and accrued expenses Non-vested, Beginning Balance Non-vested, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Additional Paid-in Capital Additional Paid-in Capital [Member] Expansion Premises Expansion Premises [Member] Expansion premises. Marketable securities maturity period Marketable Securities Maturity Period Marketable securities maturity period. Milestone method revenue recognition description Milestone Method Revenue Recognition Description Milestone method revenue recognition description. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Other Assets, Noncurrent, Total Other non-current assets Other Assets, Noncurrent Research And Development Services [Member] Research and development services. Research and Development Services Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Maximum refund period on termination of study Maximum Refund Period On Termination Of Study Maximum refund period on termination of study. Upfront payment revenue not recognized Upfront Payment Revenue Not Yet Recognized Upfront payment revenue not yet recognized. Supranational Debt Securities Supranational Debt Securities [Member] Supranational Debt Securities. Option Granted in February 2017 Option Granted In February Two Thousand And Seventeen [Member] Option granted in February 2017. Common stock, $0.001 par value - 300,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 81,861,584 and 61,009,829 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Common stock value issued Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Increase (Decrease) in Employee Related Liabilities, Total Accrued compensation Increase (Decrease) in Employee Related Liabilities Less amounts classified as cash equivalents, Fair Value Cash and Cash Equivalents, Fair Value Disclosure Schedule Of Cash And Cash Equivalents [Table] Cash and Cash Equivalent [Table] Proceed from sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Merck Sharp & Dohme Corporation ("Merck") Merck Sharp & Dohme Corp Merck Sharp And Dohme Corporation [Member] Merck Sharp and Dohme Corporation. Common stock premium Common Stock, Premium Value Common stock premium value. Operating lease liabilities Operating Lease, Liability Fair Value Measurements Recurring Measurement Frequency [Axis] Noncash Lease Expenses Noncash lease expenses Non-cash lease expenses Commitments and contingencies (Note 6) Commitments and Contingencies Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Restricted Stock Units Issued and Outstanding Restricted Stock Units Issued And Outstanding [Member] Restricted stock units issued and outstanding. Liability Related Sale Of Future Vaxcyte Royalties Liability Related Sale Of Future Vaxcyte Royalties Liability related to sale of future Vaxcyte royalties - beginning balance Liability related to the sale of future Vaxcyte royalties - ending balance Weighted-average shares used to compute diluted EPS Weighted-average shares used in computing diluted net (loss) income per share Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares used in computing diluted net loss per share Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] CMO CMO

[Member] CMO. Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Lease renewal term Lessee, Operating Lease, Renewal Term Total transaction price Aggregate Transaction Price Aggregate transaction price. Total lease payments Aggregate estimated base rent payments due Lessee, Operating Lease, Liability, to be Paid Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table] Share based compensation arrangement by share based payment award fair value assumptions and methodology. Entity Small Business Entity Small Business Payment of debt Repayments of Debt Revenues, Total Revenues Revenues Summary of the Status of Call Options Summary Of Status Of Call Options Table [Text Block] Summary of status of call options. Additional milestone payment receivable. Additional Milestone Payment Receivable Additional milestone payment receivable Vesting of restricted stock units, Shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures BMS Agreement BMS Agreement [Member] BMS agreement. Amortization of premium on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on marketable securities Amended and restated two thousand twenty one equity inducement plan. Amended And Restated Two Thousand Twenty One Equity Inducement Plan [Member] Amended and Restated 2021 Equity Inducement Plan Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Stock options outstanding, Weighted - Average Exercise Price, Beginning Balance Stock options outstanding, Weighted - Average Exercise Price, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Asset Class Asset Class [Axis] Common stock, issuance costs Common Stock Issuance Costs Common stock issuance costs. Measurement Frequency Measurement Frequency [Domain] Level 3 Fair Value, Inputs, Level 3 [Member] Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Net unrealized (loss) income on available-for-sale securities Net unrealized gain (loss) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Reimbursements expenses Reimbursements Expenses Reimbursements expenses. Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Weighted Average Grant-Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Short-term lease cost Short-Term Lease, Cost Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss, Beginning Balance Accounts receivable, reserve for credit losses Accounts Receivable, Allowance for Credit Loss XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 08, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Trading Symbol STRO Â Entity Registrant Name SUTRO BIOPHARMA, INC. Â Entity Central Index Key 0001382101 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity File Number 001-38662 Â Entity Tax Identification Number 47-0926186 Â Entity Address, Address Line One 111 Oyster Point Blvd Â Entity Address, City or Town South San Francisco Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94080 Â City Area Code 650 Â Local Phone Number 881-6500 Â Entity Common Stock, Shares Outstanding Â 81,963,659 Security Exchange Name NASDAQ Â Title of 12(b) Security Common stock, $0.001 par value Â Document Quarterly Report true Â Document Transition Report false Â Entity Incorporation, State or Country Code DE Â Entity Interactive Data Current Yes Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 90,788 $ 69,268 Marketable securities 284,780 264,413 Investment in equity securities 50,424 41,937 Accounts receivable 6,950 36,078 Prepaid expenses and other current assets 10,533 9,846 Total current assets 443,475 421,542 Property and equipment, net 19,414 21,940 Operating lease right-of-use assets 20,333 22,815 Other non-current assets 4,964 3,567 Restricted cash 857 872 Total assets 489,043 470,736 Current liabilities: Â Â Accounts payable 6,086 9,440 Accrued compensation 9,940 14,686 Deferred revenueâ€”current 73,964 20,666 Operating lease liability - current 6,933 6,420 Debtâ€”current Â 4,061 Accrued expenses and other current liabilities 33,062 38,473 Total current liabilities 129,985 93,746 Deferred revenue - non-current 21,690 53,379 Operating lease liability - non-current 19,593 23,154 Deferred royalty obligation related to the sale of future royalties 163,905 149,114 Other non-current liabilities 1,694 1,694 Total liabilities 336,867 321,087 Commitments and contingencies (Note 6) Stockholdersâ€™ equity: Â Â Preferred stock, $0.001 par value - 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 Common stock, $0.001 par value - 300,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 81,861,584 and 61,009,829 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 82 61 Additional paid-in-capital 817,896 708,975 Accumulated other comprehensive (loss) income (163) 21 Accumulated deficit (665,639) (559,408) Total stockholdersâ€™ equity 152,176 149,649 Total Liabilities and Stockholdersâ€™ Equity $ 489,043 $ 470,736 X - DefinitionAccrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: stro_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDeferred royalty obligation related to the sale of future royalties, classified as noncurrent. + ReferencesNo definition available. + Details Name: stro_DeferredRoyaltyObligationRelatedToSaleOfFutureRoyaltiesNoncurrent Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of debt and lease obligation, classified as current. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are

expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock shares outstanding 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares issued 81,861,584 61,009,829 Common stock, shares outstanding 81,861,584 61,009,829 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Â Â Revenue $ 25,706 $ 10,412 $ 38,714 $ 23,086 Operating expenses Â Â Â Â Research and development 62,020 41,592 118,898 80,991 General and administrative 12,371 14,999 25,092 30,511 Total operating expenses 74,391 56,591 143,990 111,502 Loss from operations (48,685) (46,179) (105,276) (88,416) Interest income 4,911 2,842 9,007 5,402 Unrealized gain on equity securities 4,808 8,321 8,487 1,329 Non-cash interest expense related to the sale of future royalties (7,286) (442) (14,470) (442) Interest and other income (expense), net (1,758) (2,915) (3,971) (5,901) Loss before provision for income taxes (48,010) (38,373) (106,223) (88,028) Provision for income taxes 8 151 8 546 Net loss $ (48,018) $ (38,524) $ (106,231) $ (88,574) Net loss per share, basic $ (0.59) $ (0.64) $ (1.49) $ (1.49) Net loss per share, diluted $ (0.59) $ (0.64) $ (1.49) $ (1.49) Weighted-average shares used in computing basic net loss per share 81,224,628 60,339,475 71,341,211 59,535,918 Weighted-average shares used in computing diluted net loss per share 81,224,628 60,339,475 71,341,211 59,535,918 X - DefinitionInterest and other income (expense), net. + ReferencesNo definition available. + Details Name: stro_InterestAndOtherIncomeExpenseNet Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash interest expense related to the sale of future royalties. + ReferencesNo definition available. + Details Name: stro_NonCashInterestExpenseRelatedToTheSaleOfFutureRoyalties Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 13 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (48,018) $ (38,524) $ (106,231) $ (88,574) Other comprehensive (loss) income : Â Â Â Â Net unrealized (loss) income on available-for-sale securities (50) 123 (184) 634 Comprehensive loss $ (48,068) $ (38,401) $ (106,415) $ (87,940) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Balances at Dec. 31, 2022 $ 217,048 $ 58 $ 670,223 $ (618) $ (452,615) Common Stock Balance, Shares at Dec. 31, 2022 Â 57,499,541 Â Â Â Exercise of common stock options 314 Â 314 Â Â Exercise of common stock options, Shares Â 53,060 Â Â Â Issuance of common stock under Employee Stock Purchase Plan 1,097 Â 1,097 Â Â Issuance of common stock under Employee Stock Purchase Plan, Shares Â 239,060 Â Â Â Vesting of restricted stock units, Shares Â 801,769 Â Â Â Stock transaction associated with taxes withheld on restricted stock units (451) Â (451) Â Â Stock transaction associated with taxes withheld on restricted stock units,Shares Â (73,003) Â Â Â Stock-based compensation expense 6,021 Â 6,021 Â Â Issuance of common stock in connection with At-The-Market sale, net of issuance costs 10,923 $ 2 10,921 Â Â Issuance of common stock in connection with At-The-Market sale, net of issuance costs, Shares Â 1,641,374 Â Â Â Net unrealized gain (loss) on available-for-sale securities 511 Â Â 511 Â Net loss (50,050) Â Â Â (50,050) Balances at Mar. 31, 2023 185,413 $ 60 688,125 (107) (502,665) Common Stock Balance, Shares at Mar. 31, 2023 Â 60,161,801 Â Â Â Balances at Dec. 31, 2022 217,048 $ 58 670,223 (618) (452,615) Common Stock Balance, Shares at Dec. 31, 2022 Â 57,499,541 Â Â Â Net unrealized gain (loss) on available-for-sale securities 634 Â Â Â Â Net loss (88,574) Â Â Â Â Balances at Jun. 30, 2023 154,715 $ 60 695,828 16 (541,189) Common Stock Balance, Shares at Jun. 30, 2023 Â 60,471,041 Â Â Â Balances at Mar. 31, 2023 185,413 $ 60 688,125 (107) (502,665) Common Stock Balance, Shares at Mar. 31, 2023 Â 60,161,801 Â Â Â Vesting of restricted stock units, Shares Â 94,500 Â Â Â Stock transaction associated with taxes withheld on restricted stock units (6) Â (6) Â Â Stock transaction associated with taxes withheld on restricted stock units,Shares Â (1,296) Â Â Â Stock-based compensation expense 6,661 Â 6,661 Â Â Issuance of common stock in connection with At-The-Market sale, net of issuance costs 1,048 Â 1,048 Â Â Issuance of common stock in connection with At-The-Market sale, net of issuance costs, Shares Â 216,036 Â Â Â Net unrealized gain (loss) on available-for-sale securities 123 Â Â 123 Â Net loss (38,524) Â Â Â (38,524) Balances at Jun. 30, 2023 154,715 $ 60 695,828 16 (541,189) Common Stock Balance, Shares at Jun. 30, 2023 Â 60,471,041 Â Â Â Balances at Dec. 31, 2023 149,649 $ 61 708,975 21 (559,408) Common Stock Balance, Shares at Dec. 31, 2023 Â 61,009,829 Â Â Â Exercise of common stock options 117 Â 117 Â Â Exercise of common stock options, Shares Â 23,748 Â Â Â Issuance of common stock under Employee Stock Purchase Plan 911 Â 911 Â Â Issuance of common stock under Employee Stock Purchase Plan, Shares Â 284,362 Â Â Â Vesting of restricted stock units Â $ 1 (1) Â Â Vesting of restricted stock units, Shares Â 1,215,729 Â Â Â Stock transaction associated with taxes withheld on restricted stock units (374) Â (374) Â Â Stock transaction associated with taxes withheld on restricted stock units,Shares Â (77,122) Â Â Â Stock-based compensation expense 6,068 Â 6,068 Â Â Net unrealized gain (loss) on available-for-sale securities (134) Â Â (134) Â Net loss (58,213) Â Â Â (58,213) Balances at Mar. 31, 2024 98,024 $ 62 715,696 (113) (617,621) Common Stock Balance, Shares at Mar. 31, 2024 Â 62,456,546 Â Â Â Balances at Dec. 31, 2023 149,649 $ 61 708,975 21 (559,408) Common Stock Balance, Shares at Dec. 31, 2023 Â 61,009,829 Â Â Â Net unrealized gain (loss) on available-for-sale securities (184) Â Â Â Â Net loss (106,231) Â Â Â Â Balances at Jun. 30, 2024 152,176 $ 82 817,896 (163) (665,639) Common Stock Balance, Shares at Jun. 30, 2024 Â 81,861,584 Â Â Â Balances at Mar. 31, 2024 98,024 $ 62 715,696 (113) (617,621) Common Stock Balance, Shares at Mar. 31, 2024 Â 62,456,546 Â Â Â Vesting of restricted stock units, Shares Â 107,375 Â Â Â Stock transaction associated with taxes withheld on restricted stock units (37) Â (37) Â Â Stock transaction associated with taxes withheld on restricted stock units,Shares Â (8,474) Â Â Â Stock-based compensation expense 6,159 Â 6,159 Â Â Issuance of common stock in connection with the underwritten offering, net of issuance costs 71,527 $ 15 71,512 Â Â Issuance of common stock in connection with the underwritten offering, net of issuance costs , Shares Â 14,478,764 Â Â Â Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement 24,571 $ 5 24,566 Â Â Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement ,Shares Â 4,827,373 Â Â Â Net unrealized gain (loss) on available-for-sale securities (50) Â Â (50) Â Net loss (48,018) Â Â Â (48,018) Balances at Jun. 30, 2024 $ 152,176 $ 82 $ 817,896 $ (163) $ (665,639) Common Stock Balance, Shares at Jun. 30, 2024 Â 81,861,584 Â Â Â Â X - DefinitionStock issued during period shares through At The Market sale. + ReferencesNo definition available. + Details Name: stro_StockIssuedDuringPeriodSharesThroughAtTheMarketSale Namespace Prefix: stro_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares through the underwritten offering. + ReferencesNo definition available. + Details Name: stro_StockIssuedDuringPeriodSharesThroughTheUnderwrittenOffering Namespace Prefix: stro_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value through At The Market sale. + ReferencesNo definition available. + Details Name: stro_StockIssuedDuringPeriodValueThroughAtTheMarketSale Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value through the underwritten offerings. + ReferencesNo definition available. + Details Name: stro_StockIssuedDuringPeriodValueThroughTheUnderwrittenOfferings Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Stockholders' Equity (Parenthetical) (Unaudited) - USD ($) $ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2023 ATM Â Â Â Common stock, issuance costs Â $ 151 $ 308 Underwritten Offering Â Â Â Common stock, issuance costs $ 3,474 Â Â X - DefinitionCommon stock issuance costs. + ReferencesNo definition available. + Details Name: stro_CommonStockIssuanceCosts Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=stro_AttheMarketIssuanceSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Operating activities Â Â Net loss $ (106,231) $ (88,574) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 3,551 3,346 Accretion of discount on marketable securities (5,483) (3,628) Stock-based compensation 12,227 12,682 Non-cash lease expenses 2,482 1,305 Unrealized gain on equity securities (8,487) (1,329) Non-cash interest expense on deferred royalty obligation 14,470 442 Other 430 106 Changes in operating assets and liabilities: Â Â Accounts receivable 29,128 (2,877) Prepaid expenses and other assets (2,084) (90) Accounts payable (3,292) (659) Accrued compensation (4,746) (3,633) Accrued expenses and other liabilities (5,383) 1,150 Deferred revenue 21,180 (8,728) Change in operating lease liability (3,048) (1,699) Net cash used in operating activities (55,286) (92,186) Investing activities Â Â Purchases of marketable securities (292,332) (141,361) Maturities of marketable securities 265,313 268,460 Sales of marketable securities 11,951 9,055 Purchases of equipment and leasehold improvements (1,202) (2,546) Net cash (used in) provided by investing activities (16,270) 133,608 Financing activities Â Â Proceeds from sales of common stock, net of issuance costs 71,527 11,971 Proceeds from sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA) 25,000 Payment of debt (4,083) (6,250) Proceeds from the sale of future royalties, net of issuance costs 139,744 Proceeds from exercise of common stock options 117 314 Taxes paid related to net shares settlement of restricted stock units (411) (457) Proceeds from employee stock purchase plan 911 1,097 Net cash provided by financing activities 93,061 146,419 Net increase in cash, cash equivalents and restricted cash 21,505 187,841 Cash, cash equivalents and restricted cash at beginning of period 70,140 48,126 Cash, cash equivalents and restricted cash at end of period 91,645 235,967 Supplemental disclosure of cash flow information: Â Â Cash paid for interest 63 722 Income tax paid 15,164 Supplemental disclosure of non-cash investing and financing information: Â Â Purchases of equipment included in accounts payable and accrued expense 123 141 Financing component associated with program fees 3,918 5,075 Issuance costs related to deferred royalty obligation in accrued expenses 3,536 Premium on common stock issued to Ipsen Biopharma, Inc. (USA) $ 429 X - DefinitionFinancing component associated with program fees. + ReferencesNo definition available. + Details Name: stro_FinancingComponentAssociatedWithProgramFees Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) in accrued expenses and other liabilities. + ReferencesNo definition available. + Details Name: stro_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance costs related to deferred royalty obligation in accrued expenses. + ReferencesNo definition available. + Details Name: stro_IssuanceCostsRelatedToDeferredRoyaltyObligationInAccruedExpenses Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon cash interest expense on deferred royalty obligation. + ReferencesNo definition available. + Details Name: stro_NonCashInterestExpenseOnDeferredRoyaltyObligation Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash lease expenses + ReferencesNo definition available. + Details Name: stro_NoncashLeaseExpenses Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments to acquire equipment and leasehold improvements. + ReferencesNo definition available. + Details Name: stro_PaymentsToAcquireEquipmentAndLeaseholdImprovements Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPremium on common stock issued, + ReferencesNo definition available. + Details Name: stro_PremiumOnCommonStockIssued Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from maturities of marketable securities. + ReferencesNo definition available. + Details Name: stro_ProceedsFromMaturitiesOfMarketableSecurities Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from sale of future royalties net of issuance costs. + ReferencesNo definition available. + Details Name: stro_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from sales of marketable securities. + ReferencesNo definition available. + Details Name: stro_ProceedsFromSalesOfMarketableSecurities Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-

gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Principal Activities 6 Months Ended Jun. 30, 2024 Disclosure Text Block [Abstract] Â Organization and Principal Activities 1. Organization and Principal ActivitiesDescription of Business Sutro Biopharma, Inc. (the â€œCompanyâ€), is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs. The Company was incorporated on April 21, 2003, and is headquartered in South San Francisco, California. The Company operates in one business segment, the development of biopharmaceutical products. Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Chief Executive Officer, the Companyâ€™s chief operating decision maker, in deciding how to allocate resources and assessing performance. The Company operates and manages its business as one operating segment. The Companyâ€™s Chief Executive Officer reviews financial information on an aggregate basis for the purposes of allocating and evaluating financial performance.All of the Companyâ€™s long-lived assets are maintained in the United States.LiquidityThe Company has incurred significant losses and has negative cash flows from operations. As of June 30, 2024, there was an accumulated deficit of $665.6 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Companyâ€™s research and development and other operational activities. As of June 30, 2024, the Company had unrestricted cash, cash equivalents, and marketable securities of $375.6 million and equity securities of $50.4 million, consisting solely of common stock of Vaxcyte, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.The Company believes that its unrestricted cash, cash equivalents, marketable securities and investments in equity securities as of June 30, 2024, will enable the Company to maintain its operations for a period of at least 12 months following the filing date of its condensed financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesBasis of Presentation and Use of EstimatesThe accompanying interim condensed financial statements of the Company are unaudited. These interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) and the applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The December 31, 2023 condensed balance sheet was derived from the audited financial statements as of

that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Companyâ€™s condensed Balance Sheets and the amounts of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining research and development periods under collaboration arrangements, stock-based compensation expense, valuation of marketable securities, impairment of long-lived assets, income taxes, deferred royalty obligation related to the sale of future royalties and related non-cash interest expense, and certain accrued liabilities. Actual results could differ from such estimates or assumptions. The accompanying unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to state fairly the Companyâ€™s financial position, results of operations, comprehensive loss, and cash flows for the interim periods. The interim results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, or for any other future annual or interim period.The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Companyâ€™s audited financial statements included in the Annual Report on Form 10-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, for the year ended December 31, 2023.Recent Accounting Pronouncements Not Yet Adopted There were no new accounting pronouncements issued since the Company's filing of the Annual Report on Form 10-K for the year ended December 31, 2023, which could have a significant effect on the Company's condensed financial statements.Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed Balance Sheets that sum to the total of the same amounts shown in the Company's condensed Statements of Cash Flows. Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Cash and cash equivalents Â $ 90,788 Â Â $ 235,095 Â Restricted cash Â Â 857 Â Â Â 872 Â Total cash, cash equivalents, and restricted cash shown in theÂ Â Â condensed Statements of Cash Flows Â $ 91,645 Â Â $ 235,967 Â Investments in Equity SecuritiesVaxcyte common stock held by the Company is measured at fair value at each reporting period based on the closing price of Vaxcyteâ€™s common stock on the last trading day of each reporting period, with any realized or unrealized gains and losses recorded in the Companyâ€™s condensed Statements of Operations.Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date and establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs that may be used to measure fair value, as follows: Level 1â€”Quoted prices in active markets for identical assets and liabilities; Level 2â€”Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3â€”Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of accounts receivable, prepaid expenses, accounts payable, accrued liabilities and accrued compensation and benefits approximate fair value due to the short-term nature of these items. The carrying value of the deferred royalty obligation related to the sale of future royalties under the 2015 License Agreement with Vaxcyte approximates its fair value as of June 30, 2024, and is based on our current estimates of future royalties expected to be earned over the estimated life of the royalty term arrangement. See Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties for a description of the Level 3 inputs used to estimate the fair value of the liability.Revenue Recognition When the Company enters into collaboration agreements, it assesses whether the arrangements fall within the scope of ASC 808, Collaborative Arrangements ("ASC 808") based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If it concludes that payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of Accounting Standards Update (ASU) No. 2014-09 (Topic 606), Revenue from Contracts with Customers (â€œASC 606â€).Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The total revenue to date has been generated principally from collaboration and license agreements and to a lesser extent, from manufacturing, supply and services, and materials the Company provides to its collaboration partners.Collaboration Revenue: The Company derives revenue from collaboration arrangements, under which the Company may grant licenses to its collaboration partners to further develop and commercialize its proprietary product candidates. The Company may also perform research and development activities under the collaboration agreements. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial milestones and other contingent payments, and royalties based on net sales of approved products. Additionally, the collaborations may provide options for the customer to acquire from the Company materials and reagents, clinical product supply or additional research and development services under separate agreements.The Company assesses which activities in the collaboration agreements are considered distinct performance obligations that should be accounted for separately. The Company develops assumptions that require judgement to determine whether the license to the Companyâ€™s intellectual property is distinct from the research and development services or participation in activities under the collaboration agreements.At the inception of each agreement, the Company determines the arrangement transaction price, which includes variable consideration, based on the assessment of the probability of achievement of future milestones and contingent payments and other potential consideration. The Company recognizes revenue over time by measuring its progress towards the complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer.For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price ("SSP"), of each distinct performance obligation. In instances where SSP is not directly observable, the Company develops assumptions that require judgment to determine the SSP for each performance obligation identified in the contract. These key assumptions may include full-time equivalent ("FTE"), personnel effort, estimated costs, discount rates and probabilities of clinical development and regulatory success. Upfront Payments: For collaboration arrangements that include a nonrefundable upfront payment, if the license fee and research and development services cannot be accounted for as separate performance obligations, the transaction price is deferred and recognized as revenue over the expected period of performance using a cost-based input methodology. The Company uses judgement to assess the pattern of delivery of the performance obligation. In addition, amounts paid in advance of services being rendered may result in an associated financing component to the upfront payment. Accordingly, the interest on such borrowing cost component will be recorded as interest expense and revenue, based on an appropriate borrowing rate applied to the value of services to be performed by the Company over the estimated service performance period.License Grants: For collaboration arrangements that include a grant of a license to the Companyâ€™s intellectual property, the Company considers whether the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.Milestone and Contingent Payments: At the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments, the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result in recognizing revenue for previously satisfied performance obligations in such period. The Companyâ€™s collaborators generally pay milestones and contingent payments subsequent to achievement of the triggering event.Research and Development Services: For amounts allocated to the Companyâ€™s research and development obligations in a collaboration arrangement, the Company recognizes revenue over time using a cost-based input methodology, representing the transfer of goods or services as activities are performed over the term of the agreement.Materials Supply: The Company provides materials and reagents, clinical materials, and services to certain of its collaborators under separate agreements. The consideration for such services is generally based on FTE personnel effort used to manufacture those materials, reimbursed at an agreed upon rate in addition to agreed-upon pricing for the provided materials. The amounts billed are recognized as revenue as the performance obligations are met by the Company. Revenue subject to governmental withholding taxes is recognized on a gross basis with the withholding taxes recorded as a component of income tax expense. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 3. Fair Value Measurements The following table sets forth the fair value of the Companyâ€™s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy: Â Â Â June 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 43,592 Â Â $ 43,592 Â Â $ - Â Â $ - Â Commercial paper Â Â 37,830 Â Â - Â Â Â 37,830 Â Â Â - Â Corporate debt securities Â Â 86,275 Â Â - Â Â Â 86,275 Â Â Â - Â Equity securities Â Â 50,424 Â Â Â 50,424 Â Â Â - Â Â Â - Â Asset-backed securities Â Â 65,597 Â Â - Â Â Â 65,597 Â Â Â - Â U.S. government securities Â Â 128,306 Â Â Â 128,306 Â Â Â - Â Â Â - Â Total Â $ 412,024 Â Â $ 222,322 Â Â $ 189,702 Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 56,397 Â Â $ 56,397 Â Â $ - Â Â $ - Â Commercial paper Â Â 82,152 Â Â Â - Â Â Â 82,152 Â Â Â - Â Corporate debt securities Â Â 61,894 Â Â Â - Â Â Â 61,894 Â Â Â - Â Equity securities Â Â 41,937 Â Â Â 41,937 Â Â Â - Â Â Â - Â Asset-backed securities Â Â 10,505 Â Â Â - Â Â Â 10,505 Â Â Â - Â U.S. government securities Â Â 113,652 Â Â Â 113,652 Â Â Â - Â Â Â - Â U.S. agency securities Â Â 4,961 Â Â Â - Â Â Â 4,961 Â Â Â - Â Total Â $ 371,498 Â Â $ 211,986 Â Â $ 159,512 Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Where applicable, the Company uses quoted market prices in active markets for identical assets to determine fair value. This pricing methodology applies to Level 1 investments, which are comprised of money market funds, U.S. government securities and the shares of Vaxcyte common stock held by the Company. If quoted prices in active markets for identical assets are not available, then the Company uses quoted prices for similar assets or inputs other than quoted prices that are observable, either directly or indirectly. These investments are included in Level 2 and consist of commercial paper, corporate debt securities, asset-backed securities, and U.S. agency securities. These assets are valued using market prices when available, adjusting for accretion of the purchase price to face value at maturity. A financial instrumentâ€™s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. As of June 30, 2024 and December 31, 2023, the deferred royalty obligation related to the sale of future Vaxcyte royalties was classified as Level 3 within the valuation hierarchy. Refer to Note 8 below for information relating to the Purchase Agreement between the Company and Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in potential future net sales of Vaxcyteâ€™s pneumococcal conjugate vaccine, or PCV, products, including VAX-24 and VAX-31.Investments in Equity SecuritiesAs of June 30, 2024 and December 31, 2023, the Company held 667,780 shares of Vaxcyte common stock with an estimated fair value of $50.4 million and $41.9 million, respectively. The Company recognized an unrealized gain of $4.8 million and $8.3 million for the three months ended June 30, 2024, and 2023, respectively, and an unrealized gain of $8.5 million and $1.3 million for the six months ended June 30, 2024, and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash Equivalents and Marketable Securities 6 Months Ended Jun. 30, 2024 Cash and Cash Equivalents [Abstract] Â Cash Equivalents and Marketable Securities 4. Cash Equivalents and Marketable SecuritiesCash equivalents and marketable securities consisted of the following: Â Â Â June 30, 2024 Â Â Â AmortizedCost Basis Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Â Â (in thousands) Â Money market funds Â $ 43,592 Â Â $ - Â Â $ - Â Â $ 43,592 Â Commercial paper Â Â 37,857 Â Â Â - Â Â Â (27) Â Â 37,830 Â Corporate debt securities Â Â 86,300 Â Â Â 4 Â Â Â (29) Â Â 86,275 Â Asset-based securities Â Â 65,650 Â Â Â - Â Â Â (53) Â Â 65,597 Â U.S. government securities Â Â 128,364 Â Â Â 2 Â Â Â (60) Â Â 128,306 Â Total Â Â 361,763 Â Â Â 6 Â Â Â (169) Â Â 361,600 Â Less amounts classified as cash equivalents Â Â (76,827) Â Â - Â Â Â 7 Â Â Â (76,820) Total marketable securities Â $ 284,936 Â Â $ 6 Â Â $ (162) Â $ 284,780 Â Â Â Â December 31, 2023 Â Â Â AmortizedCost Basis Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Â Â (in thousands) Â Money market funds Â $ 56,397 Â Â $ - Â Â $ - Â Â $ 56,397 Â Commercial paper Â Â 82,179 Â Â Â 1 Â Â Â (28) Â Â 82,152 Â Corporate debt securities Â Â 61,887 Â Â Â 12 Â Â Â (5) Â Â 61,894 Â Asset-based securities Â Â 10,505 Â Â Â - Â Â Â â€“ Â Â Â 10,505 Â U.S. government securities Â Â 113,612 Â Â Â 40 Â Â Â â€“ Â Â Â 113,652 Â U.S. agency securities Â Â 4,960 Â Â Â 1 Â Â Â â€“ Â Â Â 4,961 Â Total Â Â 329,540 Â Â Â 54 Â Â Â (33) Â Â 329,561 Â Less amounts classified as cash equivalents Â Â (65,144) Â Â (4) Â Â - Â Â Â (65,148) Total marketable securities Â $ 264,396 Â Â $ 50 Â Â $ (33) Â $ 264,413 Â No marketable securities had maturities of more than one year as of June 30, 2024 and December 31, 2023.There were $287.6 million and $110.9 million of investments in an unrealized loss position of $0.2 million and $33,000 as of June 30, 2024 and December 31, 2023, respectively. During the three and six months ended June 30, 2024, and 2023, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Companyâ€™s procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio after June 30, 2024, and 2023, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of June 30, 2024. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Companyâ€™s cost basis. The Company recognized no material gains or losses on its cash equivalents and current and non-current marketable securities as of June 30, 2024 and December 31, 2023 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income (loss) for the period then ended. X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and License Agreements and Supply Agreements 6 Months Ended Jun. 30, 2024 Collaboration And License Agreements And Supply Agreements [Abstract] Â Collaboration and License Agreements and Supply Agreements 5. Collaboration and License Agreements and Supply Agreements The Company has entered into collaboration and license agreements and supply agreements with various pharmaceutical and biotechnology companies. See â€œNote 5. Collaboration and License Agreements and Supply Agreementsâ€ to the Companyâ€™s financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2023, or as further described below, for additional information on each of its collaboration agreements. The Companyâ€™s accounts receivable balances may contain billed and unbilled amounts from upfront payments, milestones and other contingent payments, as well as reimbursable costs from collaboration and license agreements and supply agreements. The Company performs a regular review of its customersâ€™ credit risk and payment histories, including payments made after the period end. Historically, the Company has not experienced credit loss from its accounts receivable and, therefore, has not recorded a reserve for estimated credit losses as of June 30, 2024 and December 31, 2023.In accordance with the collaboration, license and supply agreements, the Company recognized revenue as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Merck Sharp & Dohme Corporation (â€œMerckâ€) Â $ 8 Â Â $ 140 Â Â $ 14 Â Â $ 2,693 Â Astellas Pharma Inc. (â€œAstellasâ€) Â Â 24,752 Â Â Â 7,333 Â Â Â 36,137 Â Â Â 13,605 Â Tasly Biopharmaceuticals Co., Ltd. (â€œTaslyâ€) Â Â 5 Â Â Â - Â Â Â 975 Â Â Â - Â Vaxcyte, Inc. ("Vaxcyte") Â Â 846 Â Â Â 703 Â Â Â 1,493 Â Â Â 1,378 Â Ipsen Pharma SAS (â€œIpsenâ€) Â Â 95 Â Â Â - Â Â Â 95 Â Â Â - Â Bristol Myers Squibb Company (â€œBMSâ€) Â Â - Â Â Â 2,236 Â Â Â - Â Â Â 5,402 Â Merck KGaA, Darmstadt, Germany (operating in the UnitedÂ States and Canada under the name â€œEMD Seronoâ€) Â Â - Â Â Â - Â Â Â - Â Â Â 8 Â Total revenue Â $ 25,706 Â Â $ 10,412 Â Â $ 38,714 Â Â $ 23,086 Â Â Â Â Â Â Â Â Â Â Â Â Â The following table presents the changes in the Companyâ€™s deferred revenue balance from the agreements during the six months ended June 30, 2024: Â Â Six Months Ended Â Â Â June 30, 2024 Â Â Â (in thousands) Â Deferred revenueâ€”December 31, 2023 Â $ 74,045 Â Additions to deferred revenue Â Â 50,429 Â Recognition of revenue in current period Â Â (28,820) Deferred revenueâ€”June 30, 2024 Â $ 95,654 Â The Companyâ€™s balance of deferred revenue contains upfront and contingent payments for obligations from our agreements which remain partially unsatisfied. The Company expects to recognize approximately $74.0 million of the deferred revenue over the next twelve months.Collaboration with Merck2018 Merck AgreementIn July 2018, the Company entered into an agreement (the â€œ2018 Merck Agreementâ€) with Merck for access to the Companyâ€™s technology and the identification and preclinical research and development of two target programs, with an option for Merck to engage the Company to continue these activities for a third program, upon the payment of an additional amount, focusing on cytokine derivatives for cancer and autoimmune disorders. In April 2021, Merck initiated the first IND-enabling toxicology study under the first cytokine-derivative program in the collaboration. In December 2021, Merck did not extend the research term for the second research program of the collaboration, which research program reverted to the Company. The first research program of the collaboration is focused on MK-1484, a distinct cytokine derivative molecule for the treatment of cancer. The Company is eligible to receive aggregate contingent payments of up to approximately $500 million for the target program selected by Merck, assuming the development and sale of the therapeutic candidate and all possible indications identified under the collaboration. If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low-teen digit percentages on the worldwide sales of any commercial products that may result from the collaboration.In July 2022, the first patient was dosed with MK-1484 in a Phase 1 study.As of both June 30, 2024 and December 31, 2023, there was no deferred revenue under the 2018 Merck Agreement and 2021 Amendment.2020 Merck Master Services AgreementIn August 2020, the Company entered into a Pre-Clinical and Clinical Supply Agreement (the â€œ2020 Merck Master Services Agreementâ€) with Merck, wherein Merck requested the Company to provide development, manufacturing and supply chain management services, including clinical product supply, upon completion of the research programs under the 2018 Merck Agreement. As of both June 30, 2024 and December 31, 2023, there was no deferred revenue under the 2020 Merck Master Services Agreement.Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ - Â Â $ 79 Â Â $ 6 Â Â $ 204 Â Materials supply Â Â 8 Â Â Â 61 Â Â Â 8 Â Â Â 2,489 Â Total revenue Â $ 8 Â Â $ 140 Â Â $ 14 Â Â $ 2,693 Â Â Astellas License and Collaboration AgreementIn June 2022, the Company entered into a License and Collaboration Agreement (the â€œAstellas Agreementâ€) with Astellas for the development of immunostimulatory antibody-drug conjugates for up to three biological targets, to be identified by Astellas. The Company will conduct research and pre-clinical development of any compound (as designated by Astellas) in each of the three programs in accordance with the terms of a research plan between the Company and Astellas. Astellas will have an exclusive worldwide license to develop and commercialize any such designated compound, subject to the Companyâ€™s rights to participate in cost and profit sharing in the United States, as described below. Pursuant to the Astellas Agreement, the Company received from Astellas a one-time, nonrefundable, non-creditable, upfront payment of $90.0 million during the year ended December 31, 2022. Under ASC 808 and ASC 606, the Company determined that both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the development program, and identified four performance obligations under the Astellas Agreement as: (1) performance of services related to the first target program; (2) performance of services related to the second target program; (3) performance of services related to the third target program; and (4) the Companyâ€™s estimated future services on the collaboration JSC. The transaction price of $90.0 million was allocated among the performance obligations using the Companyâ€™s best estimate of the standalone selling price, or SSP, for each of the associated performance obligations. Revenue allocated to the three target programs, which totaled $89.1 million, is being recognized on a proportional performance basis, using FTE cost as the basis of measurement, with such performance expected to occur over an estimated service period of four years for each target program. For the JSC performance obligation, revenue allocated to such performance obligation was $0.9 million, and is being recognized on a proportional performance basis using FTE cost as the basis of measurement, and such effort is expected to be incurred on a relatively consistent basis throughout the term of the Astellas Agreement. Additionally, under ASC 606, the Company determined a financing component associated with the $90.0 million upfront payment and has calculated $24.8 million as of June 30, 2024, on the unearned revenue portion beyond one year from the effective date of the agreement, which amount is being recognized as interest expense and revenue over the estimated service period for the target programs.The Company is also eligible to receive up to $422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teen percentages on worldwide sales of any commercial products that may result from the collaboration, subject to customary deductions under certain circumstances. The Company can also elect to convert any product candidate into a cost and profit-sharing arrangement, for the United States only. In the event the Company makes such election, it will share commercialization costs and profits relating to such product candidate equally with Astellas in the United States, and no royalties will be due from Astellas for net sales of such product candidates in the United States.In June 2024, Astellas notified the Company that it would not be nominating a third target program. This decision was based on Astellas' strategic portfolio considerations. Pursuant to ASC 606, Astellas' decision to not elect a third target program is a change in the scope of the original contract and thus represents a contract modification. At the date of the modification, the Company determined that the remaining research and development activities related to the first target program and the second target program to be undertaken by the Company after the notice of termination were not distinct from the related activities performed on each target prior to the modification. Accordingly, after re-allocation of the updated transaction price, the Company updated the cost-based input measure of progress for the remaining performance obligations and recorded a cumulative catch-up adjustment to revenue of $17.8 million on the modification date relating to the ongoing unsatisfied performance obligations. For the JSC performance obligation, as the remaining services were determined to be distinct from those already provided, the Company determined that the contract modification should be treated as a termination of the existing contract and the creation of a new contract, to be accounted for prospectively.Revenues under the Astellas Agreement were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Ongoing performance related to Â Â Â unsatisfied performance obligations Â $ 21,590 Â Â $ 3,239 Â Â $ 28,820 Â Â $ 5,811 Â Research and development services Â Â 1,381 Â Â Â 1,562 Â Â Â 3,004 Â Â Â 2,719 Â Financing component on unearned revenue Â Â 1,758 Â Â Â 2,532 Â Â Â 3,918 Â Â Â 5,075 Â Materials supply Â Â 23 Â Â Â - Â Â Â 395 Â Â Â - Â Total revenue Â $ 24,752 Â Â $ 7,333 Â Â $ 36,137 Â Â $ 13,605 Â Â As of June 30, 2024 and December 31, 2023, there was $40.2 million and $69.0 million of deferred revenue, respectively, related to the upfront payment received by the Company under the Astellas Agreement.Collaboration with TaslyTasly License Agreement In December 2021, the Company entered into a license agreement with Tasly to grant Tasly an exclusive license to develop and commercialize STRO-002, or luveltamab tazevibulin, or luvelta, in Greater China (the â€œTasly License Agreementâ€). Tasly will pursue the clinical development, regulatory approval, and commercialization of luvelta in multiple indications, including ovarian cancer, non-small cell lung cancer, triple-negative breast cancer, and other indications in Greater China. The Company will retain development and commercial rights of luvelta globally outside of Greater China, including the United States.The Company determined that the Tasly License Agreement falls within the scope of ASC 808, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of indications for luvelta in Greater China. The Company concluded that the Tasly License Agreement contained the following units of account: i) licensed know-how and Sutro patents, license to trademark rights, and initial regulatory data and information necessary to prepare an IND; and ii) collaboration governance and information sharing activities, such as JSC participation and ongoing regulatory and pharmacovigilance support.The promises related to the licensed know-how and Sutro patents, license to trademark rights, and initial regulatory data and information necessary to prepare an IND are considered to be interdependent and not distinct from each other, representing a combined output. The Company determined that these promises are capable of being distinct from the collaboration governance and information sharing activities discussed below and further determined that this unit of account is a vendor-customer relationship and accounted for it in accordance with ASC 606. All potential future milestones and other payments were considered constrained at the inception of the Tasly License Agreement since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur. Since there is only one performance obligation accounted for under ASC 606, no allocation of the transaction price was necessary. The Company determined that the unit of account consisting of collaboration governance and information sharing activities, such as JSC participation and ongoing regulatory and pharmacovigilance support, do not represent a customer-vendor relationship between the Company and Tasly. These promises are considered to be interdependent and not distinct from each other, representing a combined output. However, the Company determined that these promises are capable of being distinct from the intellectual property and data license promises discussed above. As such, based on the nature of the agreement and collaborative activities, the Company determined that the costs associated with these governance and information sharing activities performed under the agreement will be included in research and development expenses in the Statements of Operations, with any reimbursement of costs by Tasly reflected as a reduction of such expenses. During the three and six months ended June 30, 2024, and 2023, the Company did not recognize any material reduction of research and development expenses under the Tasly License Agreement.In April 2022, the Company entered into amendment No. 1 (the â€œTasly Amendmentâ€) to the Tasly License Agreement with Tasly. Pursuant to the Tasly Amendment, the initial nonrefundable upfront payment due by Tasly was amended to $25.0 million, and a $15.0 million payment will become payable to the Company upon the achievement of certain regulatory milestones. The Tasly Amendment also added an additional regulatory milestone payment to the Tasly License Agreement, providing additional potential payments totaling up to $350.0 million related to development, regulatory and commercialization milestones, beyond the payments described above, and made certain other ministerial edits.During 2023, the Company recognized a $5.0 million contingent payment as revenue, net of withholding tax, after Tasly received its first IND clearance by National Medical Products Administration, or NMPA, in Greater China. The withholding tax of $0.5 million was recorded as an income tax charge related to the contingent payment.During 2023, the Company also recorded a $5.0 million contingent payment, received by the Company from Tasly related to the first patient dosed in the Companyâ€™s REFRaME-O1 trial for luvelta, as deferred revenue, net of withholding tax of $0.5 million. The REFRaME-O1 study consists of two parts, Part I being the dose-finding portion and Part II being the portion of the study that will focus on the selected dose from Part I, and is intended to generate data to enable the potential registration of luvelta. Although it currently intends to conduct the REFRaME-O1 study to completion, the Company has the sole discretion to terminate the REFRaME-O1

study at any time. Given the above, the contingent payment received by the Company was considered constrained for accounting purposes during the three and six months ended June 30, 2024, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur. The withholding tax was recorded by the Company as a tax charge related to the received contingent payment.2023 Tasly Supply AgreementIn June 2023, the Company entered into a Master Development and Clinical Supply Agreement (the â€œ2023 Tasly Supply Agreementâ€) with Tasly, wherein Tasly requested the Company to provide development, manufacturing and supply chain management services, including clinical product supply.Revenues under the Tasly agreements were as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 5 Â Â $ â€“ Â Â $ 38 Â Â $ â€“ Â Materials supply Â Â - Â Â Â â€“ Â Â Â 937 Â Â Â â€“ Â Total revenue Â $ 5 Â Â $ â€“ Â Â $ 975 Â Â $ â€“ Â Agreements with VaxcyteVaxcyte Supply Agreement In May 2018, the Company entered into a Supply Agreement (the â€œSupply Agreementâ€) with Vaxcyte, wherein Vaxcyte engaged the Company to provide research and development services and to supply extracts and custom reagents, as requested by Vaxcyte. The pricing is based on an agreed upon cost-plus arrangement. During 2020, upon Vaxcyteâ€™s request and their agreement to reimburse the related costs, the Company entered into agreements with third-party contract manufacturing organizations, or CMOs, to conduct process transfers to allow for such CMOs to manufacture and supply extract and custom reagents for Vaxcyte. As part of the agreement with Vaxcyte, should the Company decide to purchase extract from the extract CMO, the Company would be required to reimburse Vaxcyte for a portion of all incurred process transfer costs. As of June 30, 2024 and December 31, 2023, there was $8.3 million and $6.9 million, respectively, in such accruals related to the Vaxcyte Supply Agreement.For the three and six months ended June 30, 2024, the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $2.6 million and $4.2 million, respectively, and were accounted for by the Company as a reduction to research and development expense based on the Companyâ€™s conclusion that Vaxcyte was not a customer for such activities and associated payments.For the three and six months ended June 30, 2023, the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $0.9 million and $2.8 million, respectively.Â Vaxcyte Agreement In December 2022, the Company entered into a letter agreement (the â€œVaxcyte Agreementâ€) with Vaxcyte under which the Company granted to Vaxcyte (i) authorization to enter into an agreement with an independent alternate CMO to source cell-free extract solely for the products it licensed from the Company, allowing Vaxcyte to have direct oversight over financial and operational aspects of the relationship with the CMO (â€œCMO Relationship Rightsâ€), and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract for use in connection with the exploitation of certain vaccine compositions (the â€œOptionâ€). In November 2023 (the "Exercise Date"), Vaxcyte exercised the Option by submitting written notice thereof to the Company and concurrently paid the Company $50.0 million in cash as the first of two installment payments for the Option exercise price. In May 2024, Vaxcyte paid the Company an additional $25.0 million in cash as the second of two installment payments for the Option exercise price under the Vaxcyte Agreement.Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay the Company certain additional payments totaling up to $60.0 million in cash. In the event that Vaxcyte undergoes a change of control, certain rights and payments may be accelerated. These contingent payments were considered constrained variable consideration or otherwise not eligible for revenue recognition at inception and as of June 30, 2024. Revenues under the Vaxcyte agreements were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 650 Â Â $ 567 Â Â $ 1,297 Â Â $ 1,071 Â Materials supply Â Â 196 Â Â Â 136 Â Â Â 196 Â Â Â 307 Â Total revenue Â $ 846 Â Â $ 703 Â Â $ 1,493 Â Â $ 1,378 Â Refer to Note 8 below for information relating to the Purchase Agreement between the Company and Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in potential future net sales of Vaxcyte products, including VAX-24 and VAX-31.Â Ipsen Agreements In March 2024, the Company and Ipsen Pharma SAS (â€œIpsenâ€) entered into an Exclusive License Agreement (the â€œIpsen License Agreementâ€) pursuant to which the Company licensed to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. In consideration for the rights and licenses granted by the Company to Ipsen in the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $50.0 million in April 2024 and (ii) Ipsen Biopharmaceuticals, Inc. (USA) (â€œIpsen USAâ€), a fully-owned Affiliate of Ipsen, purchased 4,827,373 shares of the Companyâ€™s common stock for $25.0 million, at a price of approximately $5.18 per share, in accordance with the terms set forth in a certain investment agreement by and between the Company and Ipsen USA dated March 29, 2024 (the â€œIpsen Investment Agreementâ€, and, together with the Ipsen License Agreement, the â€œIpsen Agreementsâ€). The fair market value of the common stock issued to Ipsen USA in April 2024 was $24.6 million, based on the stock price on the date of issuance, resulting in a $0.4 million premium on the Ipsen Investment Agreement.Further, pursuant to the Ipsen License Agreement, upon the occurrence of a specified developmental milestone according to a specified timetable, the Company will receive a payment of up to $7.0 million and Ipsen is obligated to purchase up to an additional $10.0 million in shares of the Companyâ€™s common stock at a price per share representing a 17% premium to the VWAP of the Companyâ€™s common stock for the twenty trading day period prior to such milestone achievement, in accordance with the terms set forth in the Ipsen Investment Agreement. The Company is also eligible to receive up to an additional $447.0 million in developmental and regulatory milestones, assuming multiple indications, and up to $360.0 million in sales milestones, as well as tiered royalty payments ranging from low double-digit to mid-teen digit percentages of annual net sales of STRO-003, subject to certain adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of STRO-003 in the applicable country. Ipsen may terminate the Ipsen License Agreement for convenience with sixty calendar days prior written notice or for certain other specified reasons. The Company may terminate the Ipsen License Agreement if Ipsen or any of its Affiliates challenge the validity of any patents controlled by the Company that are licensed under the agreement. Both Ipsen and the Company may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other partyâ€™s bankruptcy event.The Company concluded that the Ipsen License Agreement contains three promised goods and services consisting of the STRO-003 license, technology transfer, and IND-enabling activities. The Company concluded that these promised goods and services are not distinct from each other, and all play an integral role in allowing Ipsen to file an IND and begin its development of STRO-003. As such, the STRO-003 license, technology transfer, and IND-enabling activities are accounted for as one single performance obligation. The Ipsen License Agreement and the Ipsen Investment Agreement are being accounted for as one arrangement because they were entered into at or near the same time and negotiated in contemplation of one another. The Company determined that the total transaction price of the Ipsen License Agreement was $50.4 million, comprised of the one-time, nonrefundable, non-creditable upfront payment of $50.0 million paid by Ipsen under the Ipsen License Agreement, and a $0.4 million premium from the Ipsen Investment Agreement.Revenue for the performance obligation will be recognized at a point in time when the Company has completed all its deliverables, i.e., STRO-003 license, technology transfer, and IND-enabling activities, at which time Ipsen would have what it needs from the Company to file an IND for STRO-003. Revenues under the Ipsen License Agreement were as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 18 Â Â $ â€“ Â Â $ 18 Â Â $ â€“ Â Materials supply Â Â 77 Â Â Â â€“ Â Â Â 77 Â Â Â â€“ Â Total revenue Â $ 95 Â Â $ â€“ Â Â $ 95 Â Â $ â€“ Â As of June 30, 2024, there was $50.4 million of deferred revenue related to the Ipsen Agreements. X - DefinitionCollaboration and license agreements and supply agreements. + ReferencesNo definition available. + Details Name: stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsAbstract Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCollaboration and license agreements and supply agreements. + ReferencesNo definition available. + Details Name: stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 6. Commitments and ContingenciesLeasesThe Company leases certain office, laboratory and manufacturing facilities in South San Francisco, California and San Carlos, California. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional 5 years. These renewal options have not been considered in the determination of the right-of-use assets and lease liabilities associated with these leases as the Company has determined it is not reasonably certain it will exercise such options.The Company recognizes rent expense for these operating leases on a straight-line basis over the lease period. The components of lease costs, which the Company includes in operating expenses in the Company's condensed Statements of Operations, were as follows (in thousands): Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 1,984 Â Â $ 1,538 Â Â $ 3,968 Â Â $ 3,076 Â Short-term lease cost Â Â 38 Â Â Â 19 Â Â Â 91 Â Â Â 43 Â Variable lease cost Â Â 853 Â Â Â 441 Â Â Â 1,447 Â Â Â 851 Â Total lease costs Â $ 2,875 Â Â $ 1,998 Â Â $ 5,506 Â Â $ 3,970 Â During the three and six months ended June 30, 2024 and 2023, the Company recorded operating lease expense of $2.0 million and $4.0 million, respectively. As of June 30, 2024, the Company paid $4.5 million of operating lease payments related to the lease liabilities, which the Company includes in net cash used in operating activities in the Company's condensed Statements of Cash Flows.During the three and six months ended June 30, 2023, the Company recorded operating lease expense of $1.5 million and $3.1 million, respectively. As of June 30, 2023, the Company paid $3.5 million of operating lease payments related to the lease liabilities, which the Company includes in net cash used in operating activities in the Company's condensed Statements of Cash Flows.As of June 30, 2024 and December 31, 2023, the weighted-average remaining lease term was 3.3 years and 3.8 years, respectively, and the weighted-average discount rate used to determine the operating lease liability was 10.8% for both periods.As of June 30, 2024, the maturities of the Companyâ€™s operating lease liabilities were as follows (in thousands):Â Year Ending December 31, Â Amount Â Â Â (in thousands) Â Remaining in 2024 Â $ 4,684 Â 2025 Â Â 9,533 Â 2026 Â Â 8,994 Â 2027 Â Â 8,289 Â Total lease payments Â Â 31,500 Â Less: imputed interest Â Â (4,974) Operating lease liabilities Â Â 26,526 Â Less: current portion Â Â (6,933) Total lease liabilities, non-current Â $ 19,593 Â Indemnification & OtherIn the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Companyâ€™s condensed Balance Sheets, condensed Statements of Operations, or condensed Statements of Cash Flows. The Company currently has directorsâ€™ and officersâ€™ liability insurance. In addition, the Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses and Other Current Liabilities 7. Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Vaxcyte-related accrual under Vaxcyte Supply Agreement Â $ 8,342 Â Â $ 6,933 Â CMO-related accrual Â Â 12,260 Â Â Â 8,195 Â Clinical trials-related accrual Â Â 8,868 Â Â Â 4,283 Â Tax and related expenses Â Â 11 Â Â Â 15,165 Â Other Â Â 3,581 Â Â Â 3,897 Â Total accrued expenses and other current liabilities Â $ 33,062 Â Â $ 38,473 Â X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Deferred Royalty Obligation related to the Sale of Future Royalties 6 Months Ended Jun. 30, 2024 Deferred Royalty Obligation [Abstract] Â Deferred Royalty Obligation related to the Sale of Future Royalties 8. Deferred Royalty Obligation related to the Sale of Future RoyaltiesIn June 2023, the Company entered into the Purchase Agreement with Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte products, including the Purchased Interest under the 2015 License Agreement. As described in Note 5. Collaboration and License Agreements and Supply Agreements, Vaxcyte Agreement, following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of the amendment No. 3 to the 2015 License Agreement, the revenue interest in the 4% royalty on potential future net sales of Vaxcyte products other than Vaxcyteâ€™s PCV products reverted to the Company. The Company retains the right to discover and develop vaccines for the treatment or prophylaxis of any disease that is not caused by an infectious pathogen, including cancer.In June 2023, Blackstone made an upfront payment of $140.0 million to the Company and will also pay up to an additional $250.0 million upon the achievement of various return thresholds as set forth in the Purchase Agreement.Under the Purchase Agreement, and in connection with its sale of the Purchased Interest, the Company has agreed to certain covenants with respect to the exercise of its rights under the 2015 License Agreement, including with respect to the Companyâ€™s right to amend, assign and terminate the 2015 License Agreement. The Purchase Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The Company recorded the $140.0 million upfront payment from Blackstone as a deferred royalty obligation related to the sale of future royalties on the Company's condensed Balance Sheets. Due to the Company's then ongoing manufacturing obligations under the 2015 License Agreement, the Company accounted for the proceeds as imputed debt and, therefore, will recognize future non-cash royalty revenues. Non-cash interest expense will be recognized over the estimated life of the royalty term arrangement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of potential future royalty payments to be received from Vaxcyte. As part of the sale, the Company incurred approximately $3.8 million in transaction costs, which are being amortized over the estimated life of the royalty term arrangement using the effective interest method. As future royalties are earned from Vaxcyte by Blackstone, the balance of the deferred royalty obligation will be amortized over the estimated life of the royalty term arrangement.There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the vaccine products, and other events or circumstances that could result in reduced royalty payments from Vaxcyte to Blackstone, which are not within the Company's control, and all of which would result in a reduction

or increase of non-cash royalty revenues and the non-cash interest expense over the estimated life of the royalty term arrangement. The Company periodically assesses the estimated royalty payments to be earned by Blackstone from Vaxcyte and, to the extent that the amount or timing of such payments is materially different than our original estimates, the Company prospectively adjusts the imputed interest rate and the related amortization of the deferred royalty obligation. As of June 30, 2024, the effective interest rate used by the Company to amortize the liability is 18.4%.During the three and six months ended June 30, 2024, the Company recognized approximately $7.3 million and $14.5 million, respectively, of non-cash interest expense on the deferred royalty obligation, which amount will increase such balance. During the three and six months ended June 30, 2023, the Company recognized approximately $0.4 million of non-cash interest expense on the deferred royalty obligation. As of June 30, 2024, Blackstone has not received any royalty payment from Vaxcyte and, therefore, the deferred royalty obligation has not begun to be amortized.The following table shows the activity of the deferred royalty obligation for the six months ended June 30, 2024:Â Â Â June 30, 2024 Â Â Â (in thousands) Â Liability related to sale of future Vaxcyte royalties - beginning balance Â $ 149,114 Â Non-cash interest expense associated with the sale of future Vaxcyte royalties Â Â 14,470 Â Amortization of issuance costs Â Â 321 Â Liability related to the sale of future Vaxcyte royalties - ending balance Â $ 163,905 Â Â X - DefinitionDeferred royalty obligation. + ReferencesNo definition available. + Details Name: stro_DeferredRoyaltyObligationAbstract Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDeferred royalty obligation related to the sale of future royalties. + ReferencesNo definition available. + Details Name: stro_DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders' Equity Note [Abstract] Â Stockholders' Equity 9. Stockholdersâ€™ Equity Common StockHolders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. The Company has reserved common stock, on an if-converted basis, for issuance as follows: Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Common stock options issued and outstanding Â Â 8,779,966 Â Â Â 7,905,032 Â Â Common stock awards issued and outstanding Â Â 6,050,784 Â Â Â 5,244,873 Â Â Remaining shares reserved for issuance under 2018 Equity Â Â Â Incentive Plan and 2021 Equity Inducement Plan Â Â 1,844,438 Â Â Â 1,777,919 Â Â Shares reserved for issuance under 2018 Employee Â Â Â Stock Purchase Plan Â Â 1,495,303 Â Â Â 914,911 Â Â Warrants to purchase common stock Â Â 127,616 Â Â Â 127,616 Â Total Â Â 18,298,107 Â Â Â 15,970,351 Â Preferred Stock As of June 30, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock authorized with a par value of $0.001 per share. No shares of preferred stock were outstanding as of June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation 10. Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based CompensationÂ 2004 Equity Incentive Plan, 2018 Equity Incentive Plan, 2021 Equity Inducement Plan, and Amended and Restated 2021 Equity Inducement PlanIn September 2018, the Company adopted the 2018 Equity Incentive Plan (â€œ2018 Planâ€), which became effective on September 25, 2018. As a result, the Company will not grant any additional awards under the 2004 Equity Incentive Plan (â€œ2004 Planâ€). The terms of the 2004 Plan and applicable award agreements will continue to govern any outstanding awards thereunder. In addition to the shares of common stock reserved for future issuance under the 2004 Plan that were added to the 2018 Plan upon its effective date, the Company initially reserved 2,300,000 shares of common stock for issuance under the 2018 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2019, in an amount equal to 5% of the total number of shares of the Companyâ€™s capital stock outstanding on the last day of the preceding year (rounded to the nearest whole share), or a lesser number of shares determined by the Companyâ€™s board of directors. As a result, common stock reserved for issuance under the 2018 Plan was increased by 3,050,491 shares on January 1, 2024.In August 2021, the Company adopted the 2021 Equity Inducement Plan (â€œ2021 Planâ€), which became effective on August 4, 2021. Upon its effective date, the Company initially reserved 750,000 shares of common stock for issuance pursuant to non-qualified stock options and restricted stock units (â€œRSUsâ€) under the 2021 Plan. In accordance with Rule 5635(c)(4) of the Nasdaq listing rules, equity awards under the 2021 Plan may only be made to an employee if he or she is granted such equity awards in connection with his or her commencement of employment with the Company and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. In addition, awards under the 2021 Plan may only be made to employees who have not previously been an employee or member of the Board (or any parent or subsidiary of the Company) or following a bona fide period of non-employment of the employee by the Company (or a parent or subsidiary of the Company). At all times, the Company will reserve and keep available a sufficient number of shares as will be required to satisfy the requirements of all outstanding awards granted under the 2021 Plan.In August 2022, the Company amended and restated the 2021 Plan (the â€œAmended and Restated 2021 Planâ€) and reserved an additional 750,000 shares of common stock available for issuance under the Amended and Restated 2021 Plan to be granted by the Company to certain employees as a material inducement to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).Additionally, in February 2023, the Company amended and restated the Amended and Restated 2021 Plan and reserved an additional 500,000 shares of common stock available for issuance under the Amended and Restated 2021 Plan to be granted by the Company to certain employees as a material inducement to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The total number of shares reserved for issuance pursuant to the Amended and Restated 2021 Plan is 2,000,000 shares.As of June 30, 2024, the Company had a total of 1,844,438 shares available for grant under the 2018 Plan and the 2021 Plan.The following table summarizes option activity under the Companyâ€™s 2004 Plan, 2018 Plan and 2021 Plan: Â Â Â Shares Â Â Weighted-AverageExercise Price Â Stock options outstanding at December 31, 2023 Â Â 7,905,032 Â Â $ 11.24 Â Granted Â Â 1,284,250 Â Â Â 4.36 Â Exercised Â Â (23,748) Â Â 4.91 Â Canceled and forfeited Â Â (385,568) Â Â 10.45 Â Stock options outstanding at June 30, 2024 Â Â 8,779,966 Â Â Â 10.28 Â Stock options exercisable at June 30, 2024 Â Â 6,078,851 Â Â $ 12.09 Â Restricted Stock UnitsThe RSUs vest annually, and generally, will become fully vested over four years. A summary of the status and activity of non-vested RSUs during the six months ended June 30, 2024 is as follows:Â Â Â Number ofshares Â Â WeightedAverage Grant-DateFair Value Â Non-vested December 31, 2023 Â Â 5,244,873 Â Â $ 8.31 Â Granted Â Â 2,437,530 Â Â Â 4.49 Â Vested and released Â Â (1,323,104) Â Â 9.76 Â Canceled and forfeited Â Â (308,515) Â Â 8.53 Â Non-vested June 30, 2024 Â Â 6,050,784 Â Â $ 6.44 Â Â Â 2018 Employee Stock Purchase PlanIn September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (â€œESPPâ€), which became effective on September 26, 2018, in order to enable eligible employees to purchase shares of the Companyâ€™s common stock. The Company initially reserved 230,000 shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2019, in an amount equal to 1% of the total number of shares of the Companyâ€™s capital stock outstanding on the last day of the preceding year (rounded to the nearest whole share), or a lesser number of shares determined by the Companyâ€™s board of directors. As a result, common stock reserved for issuance under the ESPP was increased by 114,754 shares on January 1, 2023. The aggregate number of shares issued over the term of the Companyâ€™s ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed 2,300,000 shares of the Companyâ€™s common stock.At the Companyâ€™s annual stockholder meeting in June 2024, the Company amended the ESPP (the â€œAmended ESPPâ€) to increase the overall limit on the number of shares that may be issued under the Amended ESPP throughout its ten-year term from 2,300,000 shares to 3,050,0000 shares of the Companyâ€™s common stock.As of June 30, 2024, 1,554,697 shares had been purchased and 1,495,303 shares were available for future issuance under the ESPP.Stock-Based Compensation Expense Total stock-based compensation expense recognized was as follows: Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development expense: Â $ 3,072 Â Â $ 3,127 Â Â $ 6,246 Â Â $ 5,948 Â General and administrative expense: Â Â 3,087 Â Â Â 3,534 Â Â Â 5,981 Â Â Â 6,734 Â Total Â $ 6,159 Â Â $ 6,661 Â Â $ 12,227 Â Â $ 12,682 Â As of June 30, 2024, unrecognized stock-based compensation expense related to the unvested stock options and RSUs granted was $10.9 million and $31.9 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options and RSUs is expected to be recognized over a weighted-average period of 2.1 years and 2.5 years, respectively. As of June 30, 2024, there was $0.3 million of unrecognized stock-based compensation expense related to the ESPP.As of June 30, 2023, unrecognized stock-based compensation expense related to the unvested stock options and RSUs granted was $15.3 million and $38.1 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options and RSUs is expected to be recognized over a weighted-average period of 2.2 years and 2.6 years, respectively. As of June 30, 2023, there was $0.2 million of unrecognized stock-based compensation expense related to the ESPP. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Net Loss Per Share 11. Net Loss Per Share The following table sets forth the computation of the Companyâ€™s basic and diluted net loss per share. Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share amounts) Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (48,018) Â $ (38,524) Â $ (106,231) Â $ (88,574) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Shares used in computing net loss per share Â Â 81,224,628 Â Â Â 60,339,475 Â Â Â 71,341,211 Â Â Â 59,535,918 Â Net loss per share, basic and diluted Â $ (0.59) Â $ (0.64) Â $ (1.49) Â $ (1.49) The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended June 30, 2024, and 2023, because including them would have been antidilutive:Â Â Â As of June 30, Â Â Â 2024 Â Â 2023 Â Common stock options issued and outstanding Â Â 8,779,966 Â Â Â 8,351,659 Â Restricted stock units issued and outstanding Â Â 6,050,784 Â Â Â 5,212,174 Â Warrants to purchase common stock Â Â 127,616 Â Â Â 127,616 Â Shares to be issued under employee stock purchase plan Â Â 300,818 Â Â Â 203,206 Â Total Â Â 15,259,184 Â Â Â 13,894,655 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation and Use of Estimates Basis of Presentation and Use of EstimatesThe accompanying interim condensed financial statements of the Company are unaudited. These interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) and the applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The December 31, 2023 condensed balance sheet was derived from the audited financial statements as of that date but does not

include all of the information and footnotes required by U.S. GAAP for complete financial statements. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Companyâ€™s condensed Balance Sheets and the amounts of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining research and development periods under collaboration arrangements, stock-based compensation expense, valuation of marketable securities, impairment of long-lived assets, income taxes, deferred royalty obligation related to the sale of future royalties and related non-cash interest expense, and certain accrued liabilities. Actual results could differ from such estimates or assumptions. The accompanying unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to state fairly the Companyâ€™s financial position, results of operations, comprehensive loss, and cash flows for the interim periods. The interim results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, or for any other future annual or interim period.The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Companyâ€™s audited financial statements included in the Annual Report on Form 10-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, for the year ended December 31, 2023. Recent Accounting Pronouncements Not Yet Adopted Recent Accounting Pronouncements Not Yet Adopted There were no new accounting pronouncements issued since the Company's filing of the Annual Report on Form 10-K for the year ended December 31, 2023, which could have a significant effect on the Company's condensed financial statements. Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed Balance Sheets that sum to the total of the same amounts shown in the Company's condensed Statements of Cash Flows. Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Cash and cash equivalents Â $ 90,788 Â Â $ 235,095 Â Restricted cash Â Â 857 Â Â Â 872 Â Total cash, cash equivalents, and restricted cash shown in theÂ Â Â condensed Statements of Cash Flows Â $ 91,645 Â Â $ 235,967 Â Investments in Equity Securities Investments in Equity SecuritiesVaxcyte common stock held by the Company is measured at fair value at each reporting period based on the closing price of Vaxcyteâ€™s common stock on the last trading day of each reporting period, with any realized or unrealized gains and losses recorded in the Companyâ€™s condensed Statements of Operations. Fair Value Measurements Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date and establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs that may be used to measure fair value, as follows: Level 1â€”Quoted prices in active markets for identical assets and liabilities; Level 2â€”Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3â€”Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of accounts receivable, prepaid expenses, accounts payable, accrued liabilities and accrued compensation and benefits approximate fair value due to the short-term nature of these items. The carrying value of the deferred royalty obligation related to the sale of future royalties under the 2015 License Agreement with Vaxcyte approximates its fair value as of June 30, 2024, and is based on our current estimates of future royalties expected to be earned over the estimated life of the royalty term arrangement. See Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties for a description of the Level 3 inputs used to estimate the fair value of the liability. Revenue Recognition Revenue Recognition When the Company enters into collaboration agreements, it assesses whether the arrangements fall within the scope of ASC 808, Collaborative Arrangements ("ASC 808") based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If it concludes that payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of Accounting Standards Update (ASU) No. 2014-09 (Topic 606), Revenue from Contracts with Customers (â€œASC 606â€).Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The total revenue to date has been generated principally from collaboration and license agreements and to a lesser extent, from manufacturing, supply and services, and materials the Company provides to its collaboration partners.Collaboration Revenue: The Company derives revenue from collaboration arrangements, under which the Company may grant licenses to its collaboration partners to further develop and commercialize its proprietary product candidates. The Company may also perform research and development activities under the collaboration agreements. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial milestones and other contingent payments, and royalties based on net sales of approved products. Additionally, the collaborations may provide options for the customer to acquire from the Company materials and reagents, clinical product supply or additional research and development services under separate agreements.The Company assesses which activities in the collaboration agreements are considered distinct performance obligations that should be accounted for separately. The Company develops assumptions that require judgement to determine whether the license to the Companyâ€™s intellectual property is distinct from the research and development services or participation in activities under the collaboration agreements.At the inception of each agreement, the Company determines the arrangement transaction price, which includes variable consideration, based on the assessment of the probability of achievement of future milestones and contingent payments and other potential consideration. The Company recognizes revenue over time by measuring its progress towards the complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer.For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price ("SSP"), of each distinct performance obligation. In instances where SSP is not directly observable, the Company develops assumptions that require judgment to determine the SSP for each performance obligation identified in the contract. These key assumptions may include full-time equivalent ("FTE"), personnel effort, estimated costs, discount rates and probabilities of clinical development and regulatory success. Upfront Payments: For collaboration arrangements that include a nonrefundable upfront payment, if the license fee and research and development services cannot be accounted for as separate performance obligations, the transaction price is deferred and recognized as revenue over the expected period of performance using a cost-based input methodology. The Company uses judgement to assess the pattern of delivery of the performance obligation. In addition, amounts paid in advance of services being rendered may result in an associated financing component to the upfront payment. Accordingly, the interest on such borrowing cost component will be recorded as interest expense and revenue, based on an appropriate borrowing rate applied to the value of services to be performed by the Company over the estimated service performance period.License Grants: For collaboration arrangements that include a grant of a license to the Companyâ€™s intellectual property, the Company considers whether the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.Milestone and Contingent Payments: At the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments, the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result in recognizing revenue for previously satisfied performance obligations in such period. The Companyâ€™s collaborators generally pay milestones and contingent payments subsequent to achievement of the triggering event.Research and Development Services: For amounts allocated to the Companyâ€™s research and development obligations in a collaboration arrangement, the Company recognizes revenue over time using a cost-based input methodology, representing the transfer of goods or services as activities are performed over the term of the agreement.Materials Supply: The Company provides materials and reagents, clinical materials, and services to certain of its collaborators under separate agreements. The consideration for such services is generally based on FTE personnel effort used to manufacture those materials, reimbursed at an agreed upon rate in addition to agreed-upon pricing for the provided materials. The amounts billed are recognized as revenue as the performance obligations are met by the Company. Revenue subject to governmental withholding taxes is recognized on a gross basis with the withholding taxes recorded as a component of income tax expense. X - DefinitionBasis of presentation and use of estimates. + ReferencesNo definition available. + Details Name: stro_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed Balance Sheets that sum to the total of the same amounts shown in the Company's condensed Statements of Cash Flows. Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Cash and cash equivalents Â $ 90,788 Â Â $ 235,095 Â Restricted cash Â Â 857 Â Â Â 872 Â Total cash, cash equivalents, and restricted cash shown in theÂ Â Â condensed Statements of Cash Flows Â $ 91,645 Â Â $ 235,967 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Assets and Liabilities Measured on Recurring Basis The following table sets forth the fair value of the Companyâ€™s financial assets and liabilities measured on a recurring basis by level within the fair value

hierarchy: Â Â Â June 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 43,592 Â Â $ 43,592 Â Â $ - Â Â $ - Â Commercial paper Â Â 37,830 Â Â - Â Â Â 37,830 Â Â Â - Â Corporate debt securities Â Â 86,275 Â Â - Â Â Â 86,275 Â Â Â - Â Equity securities Â Â 50,424 Â Â Â 50,424 Â Â Â - Â Â Â - Â Asset-backed securities Â Â 65,597 Â Â - Â Â Â 65,597 Â Â Â - Â U.S. government securities Â Â 128,306 Â Â Â 128,306 Â Â Â - Â Â Â - Â Total Â $ 412,024 Â Â $ 222,322 Â Â $ 189,702 Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 56,397 Â Â $ 56,397 Â Â $ - Â Â $ - Â Commercial paper Â Â 82,152 Â Â Â - Â Â Â 82,152 Â Â Â - Â Corporate debt securities Â Â 61,894 Â Â Â - Â Â Â 61,894 Â Â Â - Â Equity securities Â Â 41,937 Â Â Â 41,937 Â Â Â - Â Â Â - Â Asset-backed securities Â Â 10,505 Â Â Â - Â Â Â 10,505 Â Â Â - Â U.S. government securities Â Â 113,652 Â Â Â 113,652 Â Â Â - Â Â Â - Â U.S. agency securities Â Â 4,961 Â Â Â - Â Â Â 4,961 Â Â Â - Â Total Â $ 371,498 Â Â $ 211,986 Â Â $ 159,512 Â Â $ - Â Â Â Â Â Â Â Â Â Â Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash Equivalents and Marketable Securities (Tables) 6 Months Ended Jun. 30, 2024 Cash and Cash Equivalents [Abstract] Â Schedule of Cash Equivalents and Marketable Securities Cash equivalents and marketable securities consisted of the following: Â Â Â June 30, 2024 Â Â Â AmortizedCost Basis Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Â Â (in thousands) Â Money market funds Â $ 43,592 Â Â $ - Â Â $ - Â Â $ 43,592 Â Commercial paper Â Â 37,857 Â Â Â - Â Â Â (27) Â Â 37,830 Â Corporate debt securities Â Â 86,300 Â Â Â 4 Â Â Â (29) Â Â 86,275 Â Asset-backed securities Â Â 65,650 Â Â Â - Â Â Â (53) Â Â 65,597 Â U.S. government securities Â Â 128,364 Â Â Â 2 Â Â Â (60) Â Â 128,306 Â Total Â Â 361,763 Â Â 6 Â Â Â (169) Â Â 361,600 Â Less amounts classified as cash equivalents Â Â (76,827) Â Â - Â Â Â 7 Â Â Â (76,820) Total marketable securities Â $ 284,936 Â Â $ 6 Â Â $ (162) Â $ 284,780 Â Â Â Â Â December 31, 2023 Â Â Â AmortizedCost Basis Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Â Â (in thousands) Â Money market funds Â $ 56,397 Â Â $ - Â Â $ - Â Â $ 56,397 Â Commercial paper Â Â 82,179 Â Â Â 1 Â Â Â (28) Â Â 82,152 Â Corporate debt securities Â Â 61,887 Â Â Â 12 Â Â Â (5) Â Â 61,894 Â Asset-based securities Â Â 10,505 Â Â Â - Â Â Â â€“ Â Â Â 10,505 Â U.S. government securities Â Â 113,612 Â Â Â 40 Â Â Â â€“ Â Â Â 113,652 Â U.S. agency securities Â Â 4,960 Â Â Â 1 Â Â Â â€“ Â Â Â 4,961 Â Total Â Â 329,540 Â Â Â 54 Â Â Â (33) Â Â 329,561 Â Less amounts classified as cash equivalents Â Â (65,144) Â Â (4) Â Â - Â Â Â (65,148) Total marketable securities Â $ 264,396 Â Â $ 50 Â Â $ (33) Â $ 264,413 Â X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and License Agreements and Supply Agreements (Tables) 6 Months Ended Jun. 30, 2024 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Summary of Recognized Revenue In accordance with the collaboration, license and supply agreements, the Company recognized revenue as follows: Â Â Three Months Ended Â Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Merck Sharp & Dohme Corporation (â€œMerckâ€) Â $ 8 Â Â $ 140 Â Â $ 14 Â Â $ 2,693 Â Astellas Pharma Inc. (â€œAstellasâ€) Â Â 24,752 Â Â Â 7,333 Â Â Â 36,137 Â Â Â 13,605 Â Tasly Biopharmaceuticals Co., Ltd. (â€œTaslyâ€) Â Â 5 Â Â Â - Â Â Â 975 Â Â Â - Â Vaxcyte, Inc. ("Vaxcyte") Â Â 846 Â Â Â 703 Â Â Â 1,493 Â Â Â 1,378 Â Ipsen Pharma SAS (â€œIpsenâ€) Â Â 95 Â Â Â - Â Â Â 95 Â Â Â - Â Bristol Myers Squibb Company (â€œBMSâ€) Â Â - Â Â Â 2,236 Â Â Â - Â Â Â 5,402 Â Merck KGaA, Darmstadt, Germany (operating in the UnitedÂ States and Canada under the name â€œEMD Seronoâ€) Â Â - Â Â Â - Â Â Â 8 Â Total revenue Â $ 25,706 Â Â $ 10,412 Â Â $ 38,714 Â Â $ 23,086 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Summary of Deferred Revenue Balance The following table presents the changes in the Companyâ€™s deferred revenue balance from the agreements during the six months ended June 30, 2024: Â Â Six Months Ended Â Â Â June 30, 2024 Â Â Â (in thousands) Â Deferred revenueâ€“December 31, 2023 Â $ 74,045 Â Additions to deferred revenue Â Â 50,429 Â Recognition of revenue in current period Â Â (28,820) Deferred revenueâ€“June 30, 2024 Â $ 95,654 Â Vaxcyte, Inc. Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Summary of Recognized Revenue Revenues under the Vaxcyte agreements were as follows:Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 650 Â Â $ 567 Â Â $ 1,297 Â Â $ 1,071 Â Materials supply Â Â 196 Â Â Â 136 Â Â Â 196 Â Â Â 307 Â Total revenue Â $ 846 Â Â $ 703 Â Â $ 1,493 Â Â $ 1,378 Â 2020 Merck Master Services Agreement Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Summary of Recognized Revenue Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:Â Â Â Â Three Months Ended Â Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ - Â Â $ 79 Â Â $ 6 Â Â $ 204 Â Materials supply Â Â 8 Â Â Â 61 Â Â Â 8 Â Â Â 2,489 Â Total revenue Â $ 8 Â Â $ 140 Â Â $ 14 Â Â $ 2,693 Â Â Astellas License and Collaboration Agreement Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Summary of Recognized Revenue Revenues under the Astellas Agreement were as follows:Â Â Â Â Three Months Ended Â Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Ongoing performance related to Â Â Â unsatisfied performance obligations Â $ 21,590 Â Â $ 3,239 Â Â $ 28,820 Â Â $ 5,811 Â Research and development services Â Â 1,381 Â Â Â 1,562 Â Â Â 3,004 Â Â Â 2,719 Â Financing component on unearned revenue Â Â 1,758 Â Â Â 2,532 Â Â Â 3,918 Â Â Â 5,075 Â Materials supply Â Â 23 Â Â Â - Â Â Â 395 Â Â Â - Â Total revenue Â $ 24,752 Â Â $ 7,333 Â Â $ 36,137 Â Â $ 13,605 Â Tasly License Agreement Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Summary of Recognized Revenue Revenues under the Tasly agreements were as follows: Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 5 Â Â $ â€“ Â Â $ 38 Â Â $ â€“ Â Materials supply Â Â - Â Â Â â€“ Â Â Â 937 Â Â Â â€“ Â Total revenue Â $ 5 Â Â $ â€“ Â Â $ 975 Â Â $ â€“ Â Ipsen Agreement Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Summary of Recognized Revenue Revenues under the Ipsen License Agreement were as follows: Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development services Â $ 18 Â Â $ â€“ Â Â $ 18 Â Â $ â€“ Â Materials supply Â Â 77 Â Â Â â€“ Â Â Â 77 Â Â Â â€“ Â Total revenue Â $ 95 Â Â $ â€“ Â Â $ 95 Â Â $ â€“ Â X - DefinitionMilestone method revenue recognition. + ReferencesNo definition available. + Details Name: stro_MilestoneMethodRevenueRecognitionTableTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandTwentyMerckMasterServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_AstellasLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TaslyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_IpsenAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Components of Lease Costs The components of lease costs, which the Company includes in operating expenses in the Company's condensed Statements of Operations, were as follows (in thousands): Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 1,984 Â Â $ 1,538 Â Â $ 3,968 Â Â $ 3,076 Â Short-term lease cost Â Â 38 Â Â Â 19 Â Â Â 91 Â Â Â 43 Â Variable lease cost Â Â 853 Â Â Â 441 Â Â Â 1,447 Â Â Â 851 Â Total lease costs Â $ 2,875 Â Â $ 1,998 Â Â $ 5,506 Â Â $ 3,970 Â Schedule of Maturities of Operating Lease Liabilities As of June 30, 2024, the maturities of the Companyâ€™s operating lease liabilities were as follows (in thousands):Â Year Ending December 31, Â Amount Â Â Â (in thousands) Â Remaining in 2024 Â $ 4,684 Â 2025 Â Â 9,533 Â 2026 Â Â 8,994 Â 2027 Â Â 8,289 Â Total lease payments Â Â 31,500 Â Less: imputed interest Â Â (4,974) Operating lease liabilities Â Â 26,526 Â Less: current portion Â Â (6,933) Total lease liabilities, non-current Â $ 19,593 Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Vaxcyte-related accrual under Vaxcyte Supply Agreement Â $ 8,342 Â Â $ 6,933 Â CMO-related accrual Â Â 12,260 Â Â Â 8,195 Â Clinical trials-related accrual Â Â 8,868 Â Â Â 4,283 Â Tax and related expenses Â Â 11 Â Â Â 15,165 Â Other Â Â 3,581 Â Â Â 3,897 Â Total accrued expenses and other current liabilities Â $ 33,062 Â Â $ 38,473 Â X - DefinitionSchedule of accrued liabilities and other liabilities disclosure, current. + ReferencesNo definition available. + Details Name: stro_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Deferred Royalty Obligation related to the Sale of Future Royalties (Tables) 6 Months Ended Jun. 30, 2024 Deferred Royalty Obligation [Abstract] Â Schedule of Royalty Obligation transaction The following table shows the activity of the deferred royalty obligation for the six months ended June 30, 2024:Â Â Â June 30, 2024 Â Â Â (in thousands) Â Liability related to sale of future Vaxcyte royalties - beginning balance Â $ 149,114 Â Non-cash interest expense associated with the sale of future Vaxcyte royalties Â Â 14,470 Â Amortization of issuance costs Â Â 321 Â Liability related to the sale of future Vaxcyte royalties - ending balance Â $ 163,905 Â Â X - DefinitionDeferred royalty obligation. + ReferencesNo definition available. + Details Name: stro_DeferredRoyaltyObligationAbstract Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRoyalty obligation. + ReferencesNo definition available. + Details Name: stro_RoyaltyObligationTableTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Tables) 6 Months Ended Jun. 30, 2024 Stockholders' Equity Note [Abstract] Â Schedule of Common Stock Reserved for Future Issuance The Company has reserved common stock, on an if-converted basis, for issuance as follows: Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Common stock options issued and outstanding Â Â 8,779,966 Â Â Â 7,905,032 Â Â Common stock awards issued and outstanding Â Â 6,050,784 Â Â Â 5,244,873 Â Â Remaining shares reserved for issuance under 2018 Equity Â Â Â Incentive Plan and 2021 Equity Inducement Plan Â Â 1,844,438 Â Â Â 1,777,919 Â Â Shares reserved for issuance under 2018 Employee Â Â Â Stock Purchase Plan Â Â 1,495,303 Â Â Â 914,911 Â Â Warrants to purchase common stock Â Â 127,616 Â Â Â 127,616 Â Total Â Â 18,298,107 Â Â Â 15,970,351 Â X - DefinitionSchedule of common stock reserved for future issuance. + ReferencesNo definition available. + Details Name: stro_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock Namespace Prefix: stro_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Option Activity The following table summarizes option activity under the Companyâ€™s 2004 Plan, 2018 Plan and 2021 Plan: Â Â Â Shares Â Â Weighted-AverageExercise Price Â Stock options outstanding at December 31, 2023 Â Â 7,905,032 Â Â $ 11.24 Â Granted Â Â 1,284,250 Â Â Â 4.36 Â Exercised Â Â (23,748) Â Â 4.91 Â Canceled and forfeited Â Â (385,568) Â Â 10.45 Â Stock options outstanding at June 30, 2024 Â Â 8,779,966 Â Â Â 10.28 Â Stock options exercisable at June 30, 2024 Â Â 6,078,851 Â Â $ 12.09 Â Summary of Status and Activity of Non-vested RSUs A summary of the status and activity of non-vested RSUs during the six months ended June 30, 2024 is as follows:Â Â Â Number ofshares Â Â WeightedAverage Grant-DateFair Value Â Non-vested December 31, 2023 Â Â 5,244,873 Â Â $ 8.31 Â Granted Â Â 2,437,530 Â Â Â 4.49 Â Vested and released Â Â (1,323,104) Â Â 9.76 Â Canceled and forfeited Â Â (308,515) Â Â 8.53 Â Non-vested June 30, 2024 Â Â 6,050,784 Â Â $ 6.44 Â Schedule of Stock-Based Compensation Expense Recognized Total stock-based compensation expense recognized was as follows: Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Â (in thousands) Â Research and development expense: Â $ 3,072 Â Â $ 3,127 Â Â $ 6,246 Â Â $ 5,948 Â General and administrative expense: Â Â Â 3,087 Â Â Â 3,534 Â Â Â 5,981 Â Â Â 6,734 Â Total Â $ 6,159 Â Â $ 6,661 Â Â $ 12,227 Â Â $ 12,682 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for

restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Summary of Computation of Company's Basic and Diluted Net Loss Per Share The following table sets forth the computation of the Companyâ€™s basic and diluted net loss per share. Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share amounts) Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (48,018) Â $ (38,524) Â $ (106,231) Â $ (88,574) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Shares used in computing net loss per share Â Â 81,224,628 Â Â Â 60,339,475 Â Â Â 71,341,211 Â Â Â 59,535,918 Â Net loss per share, basic and diluted Â $ (0.59) Â $ (0.64) Â $ (1.49) Â $ (1.49) Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended June 30, 2024, and 2023, because including them would have been antidilutive:Â Â Â As of June 30, Â Â Â 2024 Â Â 2023 Â Common stock options issued and outstanding Â Â 8,779,966 Â Â Â 8,351,659 Â Restricted stock units issued and outstanding Â Â 6,050,784 Â Â Â 5,212,174 Â Warrants to purchase common stock Â Â 127,616 Â Â Â 127,616 Â Shares to be issued under employee stock purchase plan Â Â 300,818 Â Â Â 203,206 Â Total Â Â 15,259,184 Â Â Â 13,894,655 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Principal Activities - Additional Information (Details) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Segment Dec. 31, 2023 USD ($) Organization Consolidation And Presentation Of Financial Statements [Line Items] Â Â Date of incorporation Apr. 21, 2003 Â Headquartered in South San Francisco Â Headquartered in state CA Â Number of operating segments | Segment 1 Â Accumulated deficit $ 665,639 $ 559,408 Unrestricted cash, cash equivalents and marketable securities $ 375,600 Â Substantial doubt about going concern, within one year false Â Vaxcyte Â Â Organization Consolidation And Presentation Of Financial Statements [Line Items] Â Â Unrestricted cash, cash equivalents and equity securities at carrying value $ 50,400 Â Minimum Â Â Organization Consolidation And Presentation Of Financial Statements [Line Items] Â Â Period from issuance date of unaudited interim condensed financial statements 12 months Â X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionDate when an entity was incorporated + ReferencesNo definition available. + Details Name: dei_EntityIncorporationDateOfIncorporation Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionOrganization consolidation and presentation of financial statements line items. + ReferencesNo definition available. + Details Name: stro_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod from issuance of unaudited interim condensed financial statements + ReferencesNo definition available. + Details Name: stro_PeriodFromIssuanceOfUnauditedInterimCondensedFinancialStatements Namespace Prefix: stro_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definitionunrestricted cash cash equivalents and equity securities at carrying value. + ReferencesNo definition available. + Details Name: stro_UnrestrictedCashCashEquivalentsAndEquitySecuritiesAtCarryingValue Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUnrestricted cash, cash equivalents and marketable securities at carrying value. + ReferencesNo definition available. + Details Name: stro_UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -SubTopic 40 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479710/205-40-50-13 + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Accounting Policies [Abstract] Â Â Â Cash and cash equivalents $ 90,788 $ 69,268 $ 235,095 Restricted cash 857 $ 872 872 Total cash, cash equivalents, and restricted cash shown in the condensed Statements of Cash Flows $ 91,645 Â $ 235,967 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 41 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Assets: Â Â Total $ 412,024 $ 371,498 Level 1 Â Â Assets: Â Â Total 222,322 211,986 Level 2 Â Â Assets: Â Â Total 189,702 159,512 Money Market Funds Â Â Assets: Â Â Total 43,592 56,397 Money Market Funds | Level 1 Â Â Assets: Â Â Total 43,592 56,397 Commercial Paper Â Â Assets: Â Â Total 37,830 82,152 Commercial Paper | Level 2 Â Â Assets: Â Â Total 37,830 82,152 Corporate Debt Securities Â Â Assets: Â Â Total 86,275 61,894 Corporate Debt Securities | Level 2 Â Â Assets: Â Â Total 86,275 61,894 Equity Securities Â Â Assets: Â Â Total 50,424 41,937 Equity Securities | Level 1 Â Â Assets: Â Â Total 50,424 41,937 Asset-backed Securities Â Â Assets: Â Â Total 65,597 10,505 Asset-backed Securities | Level 2 Â Â Assets: Â Â Total 65,597 10,505 U.S. Government Securities Â Â Assets: Â Â Total 128,306 113,652 U.S. Government Securities | Level 1 Â Â Assets: Â Â Total $ 128,306 113,652 U.S. Agency Securities Â Â Assets: Â Â Total Â 4,961 U.S. Agency Securities | Level 2 Â Â Assets: Â Â Total Â $ 4,961 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Â Â Â Â Estimated fair value of equity

securities Â $ 50,424 Â $ 50,424 Â $ 41,937 Unrealized gain on equity securities Â $ 4,808 $ 8,321 $ 8,487 $ 1,329 Â Vaxcyte, Inc. | Vaxcyte Common Stock Â Â Â Â Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Â Â Â Â Number of shares held Â 667,780 Â 667,780 Â 667,780 Estimated fair value of equity securities Â $ 50,400 Â $ 50,400 Â $ 41,900 Unrealized gain on equity securities Â $ 4,800 $ 8,300 $ 8,500 $ 1,300 Â Blackstone Life Sciences | Royalty | 2015 License Agreement Â Â Â Â Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Â Â Â Â Revenue interest percentage 4.00% Â Â 4.00% Â Â X - DefinitionRevenue interest percentage. + ReferencesNo definition available. + Details Name: stro_RevenueInterestPercentage Namespace Prefix: stro_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalanceShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=stro_VaxcyteCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_BlackstoneLifeSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandFifteenLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis $ 361,763,000 $ 329,540,000 Â Unrealized Gains 6,000 54,000 Â Unrealized Losses (169,000) (33,000) Â Fair Value 361,600,000 329,561,000 Â Less amounts classified as cash equivalents, Amortized Cost Basis (90,788,000) (69,268,000) $ (235,095,000) Marketable Securities Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis 284,936,000 264,396,000 Â Unrealized Gains 6,000 50,000 Â Unrealized Losses (162,000) (33,000) Â Fair Value 284,780,000 264,413,000 Â Cash Equivalents Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Less amounts classified as cash equivalents, Amortized Cost Basis (76,827,000) (65,144,000) Â Less amounts classified as cash equivalents, Unrealized Gains Â (4,000) Â Less amounts classified as cash equivalents, Unrealized Losses 7,000 Â Â Less amounts classified as cash equivalents, Fair Value (76,820,000) (65,148,000) Â Money Market Funds Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis 43,592,000 56,397,000 Â Fair Value 43,592,000 56,397,000 Â Commercial Paper Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis 37,857,000 82,179,000 Â Unrealized Gains Â 1,000 Â Unrealized Losses (27,000) (28,000) Â Fair Value 37,830,000 82,152,000 Â Corporate Debt Securities Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis 86,300,000 61,887,000 Â Unrealized Gains 4,000 12,000 Â Unrealized Losses (29,000) (5,000) Â Fair Value 86,275,000 61,894,000 Â Asset-backed Securities Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis 65,650,000 10,505,000 Â Unrealized Losses (53,000) Â Â Fair Value 65,597,000 10,505,000 Â U.S. Government Securities Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis 128,364,000 113,612,000 Â Unrealized Gains 2,000 40,000 Â Unrealized Losses (60,000) Â Â Fair Value $ 128,306,000 113,652,000 Â U.S. Agency Securities Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Amortized Cost Basis Â 4,960,000 Â Unrealized Gains Â 1,000 Â Fair Value Â $ 4,961,000 Â X - DefinitionCash equivalents unrealized gains. + ReferencesNo definition available. + Details Name: stro_CashEquivalentsUnrealizedGains Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash equivalents unrealized losses. + ReferencesNo definition available. + Details Name: stro_CashEquivalentsUnrealizedLosses Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=stro_MarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash Equivalents and Marketable Securities - Additional Information (Details) - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Cash And Cash Equivalents [Line Items] Â Â Â Â Â Long-term marketable securities $ 0 Â $ 0 Â $ 0 Investments in an unrealized loss position 287,600,000 Â 287,600,000 Â 110,900,000 Unrealized losses 169,000 Â 169,000 Â $ 33,000 Recognition of other-than-temporary impairment $ 0 $ 0 $ 0 $ 0 Â Maximum Â Â Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Â Â Marketable securities maturity period Â Â 1 year Â 1 year X - DefinitionMarketable securities maturity period. + ReferencesNo definition available. + Details Name: stro_MarketableSecuritiesMaturityPeriod Namespace Prefix: stro_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionOther than temporary impairment losses debt securities available for sale recognized in earnings. + ReferencesNo definition available. + Details Name: stro_OtherThanTemporaryImpairmentLossesDebtSecuritiesAvailableForSaleRecognizedInEarnings Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and License Agreements and Supply Agreements - Additional Information (Details) 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) $ / shares shares May 31, 2024 USD ($) Apr. 30, 2024 USD ($) Mar. 31, 2024 USD ($) $ / shares shares Nov. 30, 2023 USD ($) Installment Jun. 30, 2023 USD ($) Jun. 30, 2022 USD ($) Program PerformanceObligation Apr. 30, 2022 USD ($) Jul. 31, 2018 Program Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) GoodsAndServices $ / shares shares Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) $ / shares shares Dec. 31, 2021 USD ($) Dec. 31, 2022 USD ($) Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accounts receivable, reserve for credit losses $ 0 Â Â Â Â Â Â Â Â Â $ 0 Â $ 0 Â $ 0 Â Â Common stock, shares issued | shares 81,861,584 Â Â Â Â Â Â Â Â Â 81,861,584 Â 81,861,584 Â 61,009,829 Â Â Common stock value issued $ 82,000 Â Â Â Â Â Â Â Â Â $ 82,000 Â $ 82,000 Â $ 61,000 Â Â Common stock value per share | $ / shares $ 0.001 Â Â Â Â Â Â Â Â Â $ 0.001 Â $ 0.001 Â $ 0.001 Â Â Total transaction price Â Â Â Â Â Â Â Â Â Â Â Â $ 50,400,000 Â Â Â Â Nonrefundable, non-creditable upfront payment Â Â Â Â Â Â Â Â Â Â Â Â 50,000,000 Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â $ 25,706,000 $ 10,412,000 $ 38,714,000 $ 23,086,000 Â Â Â Vaxcyte, Inc. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â First installment milestone payment received Â Â Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Â Â Number of installments | Installment Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Additional milestone payment received Â $ 25,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Additional milestone payment Â Â Â Â Â Â Â Â Â Â Â Â Â $ 60,000,000 Â Â Blackstone Life Sciences Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Upfront payment received Â Â Â Â Â $ 140,000,000 Â Â Â Â Â Â Â Â Â 2015 License Agreement | Blackstone Life Sciences | Royalty Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Upfront payment received Â Â Â Â Â $ 140,000,000 Â Â Â Â Â Â Â Â Â Â Revenue interest percentage Â Â Â Â Â 4.00% Â Â Â Â Â 4.00% Â Â Â Â 2018 Merck Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue $ 0 Â Â Â Â Â Â Â Â Â 0 Â $ 0 Â 0 Â Â 2018 Merck Agreement | Merck Sharp & Dohme Corp Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of target programs | Program Â Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Revenue recognition aggregate contingent payments eligible to receive Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500,000,000 Â Milestone method revenue recognition description Â Â Â Â Â Â Â Â Â Â Â If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low-teen digit percentages on the worldwide sales of any commercial products that may result from the collaboration. Â Â Â Â 2020 Merck Master Services Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue 0 Â Â Â Â Â Â Â Â Â 0 Â $ 0 Â 0 Â Â Revenue Â Â Â Â Â Â Â Â Â 8,000 140,000 14,000 2,693,000 Â Â Â Supply Agreement | Vaxcyte, Inc. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Reimbursements expenses accruals 8,300,000 Â Â Â Â Â Â Â Â Â 8,300,000 Â 8,300,000 Â 6,900,000 Â Â Reimbursements expenses Â Â Â Â Â Â Â Â Â 2,600,000 900,000 4,200,000 2,800,000 Â Â Â Astellas License and Collaboration Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue 40,200,000 Â Â Â Â Â Â Â Â Â 40,200,000 Â 40,200,000 Â 69,000,000 Â Â Number of target programs | Program Â Â Â Â Â Â 3 Â Â Â Â Â Â Â Â Â Â Upfront payment received Â Â Â Â Â Â Â Â Â Â Â Â Â 90,000,000 Â Â Â Â Transaction price Â Â Â Â Â Â $ 90,000,000 Â Â Â Â Â Â Â Â Â Â Estimated service period Â Â Â Â Â Â 4 years Â Â Â Â Â Â Â Â Â Â Recognition of up front payment Â Â Â Â Â Â $ 89,100,000 Â Â Â Â Â Â Â Â Â Â Upfront payment revenue not recognized Â Â Â Â Â Â Â Â Â Â Â Â Â 24,800,000 Â Â Â Â Nonrefundable, non-creditable upfront payment receivable Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 90,000,000 Number of performance obligations | PerformanceObligation Â Â Â Â Â Â 4 Â Â Â Â Â Â Â Â Â Â Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate 422,500,000 Â Â Â Â Â Â Â Â 422,500,000 Â 422,500,000 Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â 24,752,000 7,333,000 36,137,000 13,605,000 Â Â Â Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue 17,800,000 Â Â Â Â Â Â Â Â Â 21,590,000 3,239,000 28,820,000 5,811,000 Â Â Â Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC") Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Recognition of up front payment Â Â Â Â Â Â $ 900,000 Â Â Â Â Â Â Â Â Â Â Tasly License Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â 5,000 Â 975,000 Â Â Â Â Maximum potential payments related to development regulatory commercialization contingent payments and milestones Â Â Â Â Â Â Â $ 350,000,000 Â Â Â Â Â Â Â Â Reduction of research and development expenses recognized Â Â Â Â Â Â Â Â Â 0 $ 0 0 $ 0 Â Â Â Initial licensing payment due Â Â Â Â Â Â Â 25,000,000 Â Â Â Â Â Â Â Â Initial licensing payment in escrow Â Â Â Â Â Â Â $ 15,000,000 Â Â Â Â Â Â Â Â Revenue recognized from contingent payment Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5,000,000 Â Â Income tax charge related to contingent payment Â Â Â Â Â Â Â Â Â Â Â Â Â Â 500,000 Â Â Contingent payment recognized as deferred revenue Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5,000,000 Â Â Withholding tax on deferred revenue Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500,000 Â Â Ipsen Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue 50,400,000 Â Â Â Â Â Â Â Â Â 50,400,000 Â 50,400,000 Â Â Â Â Milestone payment received Â Â Â $ 7,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Upfront license fee Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares issued | shares Â Â Â 4,827,373 Â Â Â Â Â Â Â Â Â Â Â Â Common stock value issued $ 400,000 Â Â $ 25,000,000 Â Â Â Â Â 400,000 Â $ 400,000 Â Â Â Â Fair market value of common stock issued Â Â 24,600,000 Â Â Â Â Â Â Â Â Â Â Â Â Common stock premium Â Â $ 400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock value per share | $ / shares Â Â Â $ 5.18 Â Â Â Â Â Â Â Â Â Â Â Â Additional purchase of Common Stock Â Â Â $ 10,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Percentage of VWAP premium Â Â Â 0.17 Â Â Â Â Â Â Â Â Â Â Â Â Payment related to development and regulatory milestone Â Â Â $ 447,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Payments related to sales milestone Â Â Â $ 360,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Number of goods and services | GoodsAndServices Â Â Â Â Â Â Â Â Â Â Â Â 3 Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â $ 95,000 Â $ 95,000 Â Â Â Â X - DefinitionAdditional milestone payment. + ReferencesNo definition available. + Details Name: stro_AdditionalMilestonePayment Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAdditional milestone payment received. + ReferencesNo definition available. + Details Name: stro_AdditionalMilestonePaymentReceived Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdditional payment related to development and regulatory milestone. + ReferencesNo definition available. + Details Name: stro_AdditionalPaymentRelatedToDevelopmentAndRegulatoryMilestone Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAdditional payment related to sales milestone. + ReferencesNo definition available. + Details Name: stro_AdditionalPaymentRelatedToSalesMilestone Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAdditional purchase of common stock. + ReferencesNo definition available. + Details Name: stro_AdditionalPurchaseOfCommonStock Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate transaction price. + ReferencesNo definition available. + Details Name: stro_AggregateTransactionPrice Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon stock premium value. + ReferencesNo definition available. + Details Name: stro_CommonStockPremiumValue Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContingent payment recognized as deferred revenue. + ReferencesNo definition available. + Details Name: stro_ContingentPaymentRecognizedAsDeferredRevenue Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEstimated service period. + ReferencesNo definition available. + Details Name: stro_EstimatedServicePeriod Namespace Prefix: stro_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair market value of common stock issued. + ReferencesNo definition available. + Details Name: stro_FairMarketValueOfCommonStockIssued Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFirst installment milestone payment received. + ReferencesNo definition available. + Details Name: stro_FirstInstallmentMilestonePaymentReceived Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncome tax charge related to contingent payment. + ReferencesNo definition available. + Details Name: stro_IncomeTaxChargeRelatedToContingentPayment Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInitial licensing payment due. + ReferencesNo definition available. + Details Name: stro_InitialLicensingPaymentDue Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInitial licensing payment in escrow. + ReferencesNo definition available. + Details Name: stro_InitialLicensingPaymentInEscrow Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate. + ReferencesNo definition available. + Details Name: stro_MaximumAmountEligibleToReceiveForDevelopmentRegulatoryAndCommercialMilestonesForEachProductCandidate Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum potential payments related to development regulatory commercialization contingent payments and milestones. + ReferencesNo definition available. + Details Name: stro_MaximumPotentialPaymentsRelatedToDevelopmentRegulatoryCommercializationContingentPaymentsAndMilestones Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMilestone method revenue recognition description. + ReferencesNo definition available. + Details Name: stro_MilestoneMethodRevenueRecognitionDescription Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMilestone payment received. + ReferencesNo definition available. + Details Name: stro_MilestonePaymentReceived Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNonrefundable, non-creditable upfront fee payment. + ReferencesNo definition available. + Details Name: stro_NonrefundableNonCreditableUpfrontFeePayment Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNonrefundable non-creditable upfront payment receivable. + ReferencesNo definition available. + Details Name: stro_NonrefundableNoncreditableUpfrontPaymentReceivable Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of goods and services. + ReferencesNo definition available. + Details Name: stro_NumberOfGoodsAndServices Namespace Prefix: stro_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of installments. + ReferencesNo definition available. + Details Name: stro_NumberOfInstallments Namespace Prefix: stro_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of performance obligations. + ReferencesNo definition available. + Details Name: stro_NumberOfPerformanceObligations Namespace Prefix: stro_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of target programs. + ReferencesNo definition available. + Details Name: stro_NumberOfTargetPrograms Namespace Prefix: stro_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of volume weighted average price premium. + ReferencesNo definition available. + Details Name: stro_PercentageOfVwapPremium Namespace Prefix: stro_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionReduction of research and development expenses recognized. + ReferencesNo definition available. + Details Name: stro_ReductionOfResearchAndDevelopmentExpensesRecognized Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReimbursements expenses. + ReferencesNo definition available. + Details Name: stro_ReimbursementsExpenses Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReimbursements expenses accruals. + ReferencesNo definition available. + Details Name: stro_ReimbursementsExpensesAccruals Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRevenue interest percentage. + ReferencesNo definition available. + Details Name: stro_RevenueInterestPercentage Namespace Prefix: stro_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRevenue recognition aggregate contingent payments eligible to receive. + ReferencesNo definition available. + Details Name: stro_RevenueRecognitionAggregateContingentPaymentsEligibleToReceive Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRevenue recognition of up-front payment amount. + ReferencesNo definition available. + Details Name: stro_RevenueRecognitionOfUpFrontPaymentAmount Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRevenue recognized from contingent payment , net of withholding tax. + ReferencesNo definition available. + Details Name: stro_RevenueRecognizedFromContingentPaymentNetOfWithholdingTax Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTransaction price. + ReferencesNo definition available. + Details Name: stro_TransactionPrice Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront license fee. + ReferencesNo definition available. + Details Name: stro_UpfrontLicenseFee Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUpfront payment received. + ReferencesNo definition available. + Details Name: stro_UpfrontPaymentReceived Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront payment revenue not yet recognized. + ReferencesNo definition available. + Details Name: stro_UpfrontPaymentRevenueNotYetRecognized Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWithholding tax on deferred revenue. + ReferencesNo definition available. + Details Name: stro_WithholdingTaxOnDeferredRevenue Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_BlackstoneLifeSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandFifteenLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandEighteenMerckAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_MerckSharpAndDohmeCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandTwentyMerckMasterServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_SupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_AstellasLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=stro_OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=stro_FutureServicesOnCollaborationJointSteeringCommitteeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TaslyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_IpsenAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â $ 25,706 $ 10,412 $ 38,714 $ 23,086 Vaxcyte Agreements Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 846 703 1,493 1,378 Vaxcyte Agreements | Research and Development Services Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 650 567 1,297 1,071 Vaxcyte Agreements | Materials Supply Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 196 136 196 307 Collaboration and License Agreements and Supply Agreements Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 25,706 10,412 38,714 23,086 Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS") Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â Â 2,236 Â 5,402 Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck") Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 8 140 14 2,693 Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas") Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 24,752 7,333 36,137 13,605 Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly") Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 5 Â 975 Â Collaboration and License Agreements and Supply Agreements | Vaxcyte Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 846 703 1,493 1,378 Collaboration and License Agreements and Supply Agreements | Ipsen Pharma SAS ("Ipsen") Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 95 Â 95 Â Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'') Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â Â Â Â 8 2020 Merck Master Services Agreement Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 8 140 14 2,693 2020 Merck Master Services Agreement | Research and Development Services Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â Â 79 6 204 2020 Merck Master Services Agreement | Materials Supply Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 8 61 8 2,489 Astellas License and Collaboration Agreement Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 24,752 7,333 36,137 13,605 Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue $ 17,800 21,590 3,239 28,820 5,811 Astellas License and Collaboration Agreement | Research and Development Services Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 1,381 1,562 3,004 2,719 Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 1,758 $ 2,532 3,918 $ 5,075 Astellas License and Collaboration Agreement | Materials Supply Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 23 Â 395 Â Tasly License Agreement Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 5 Â 975 Â Tasly License Agreement | Research and Development Services Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 5 Â 38 Â Tasly License Agreement | Materials Supply Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â Â Â 937 Â Ipsen Agreement Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 95 Â 95 Â Ipsen Agreement | Research and Development Services Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â 18 Â 18 Â Ipsen Agreement | Materials Supply Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Total revenue Â $ 77 Â $ 77 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=stro_VaxcyteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=stro_ResearchAndDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=stro_MaterialsSupplyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=stro_BristolMyersSquibbCompanyBMSMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_MerckSharpAndDohmeCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_AstellasPharmaIncAstellasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_TaslyBiopharmaceuticalsCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_IpsenPharmaSASMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_MerckKGaADarmstadtGermanyMember Namespace Prefix: Data Type: na

Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandTwentyMerckMasterServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_AstellasLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=stro_OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=stro_FinancingComponentOnUnearnedRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TaslyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_IpsenAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-07-01 $ in Millions Jun. 30, 2024 USD ($) Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Â Revenue, remaining performance obligation, amount $ 74.0 Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-07-01 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details) - Collaboration and License Agreements and Supply Agreements $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Deferred revenue $ 74,045 Additions to deferred revenue 50,429 Recognition of revenue in current period (28,820) Deferred revenue $ 95,654 X - DefinitionContract with customer liability additions. + ReferencesNo definition available. + Details Name: stro_ContractWithCustomerLiabilityAdditions Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Loss Contingencies [Line Items] Â Â Â Â Operating lease expense $ 2.0 $ 1.5 $ 4.0 $ 3.1 Â Operating lease payments Â Â $ 4.5 $ 3.5 Â Operating lease, weighted average remaining lease term 3 years 3 months 18 days Â 3 years 3 months 18 days Â 3 years 9 months 18 days Operating lease, weighted average discount rate, percent 10.80% Â 10.80% Â 10.80% San Carlos Lease | California Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Lease extension period Â Â 5 years Â Â Lease renewal term 5 years Â 5 years Â Â X - DefinitionLessee operating lease option to extend period. + ReferencesNo definition available. + Details Name: stro_LesseeOperatingLeaseOptionToExtendPeriod Namespace Prefix: stro_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=stro_SanCarlosLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_CA Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Schedule of Components of Lease Costs (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Operating lease cost $ 1,984 $ 1,538 $ 3,968 $ 3,076 Short-term lease cost 38 19 91 43 Variable lease cost 853 441 1,447 851 Total lease costs $ 2,875 $ 1,998 $ 5,506 $ 3,970 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 51 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Remaining in 2024 $ 4,684 Â 2025 9,533 Â 2026 8,994 Â 2027 8,289 Â Total lease payments 31,500 Â Less: imputed interest (4,974) Â Operating lease liabilities 26,526 Â Less: current portion (6,933) $ (6,420) Total lease liabilities, non-current $ 19,593 $ 23,154 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 52 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Tax and related expenses $ 11 $ 15,165 Other 3,581 3,897 Total accrued expenses and other current liabilities 33,062 38,473 Supply Agreement | Vaxcyte Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Collaboration and license agreements and supply agreement accruals 8,342 6,933 CMO Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Collaboration and license agreements and supply agreement accruals 12,260 8,195 Clinical Trials Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Collaboration and license agreements and supply agreement accruals $ 8,868 $ 4,283 X - DefinitionAccrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: stro_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCollaboration and license agreements and supply agreement accruals current. + ReferencesNo definition available. + Details Name: stro_CollaborationAndLicenseAgreementsAndSupplyAgreementAccrualsCurrent Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=stro_SupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_CmoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_ClinicalTrialsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Deferred Royalty Obligation [Line Items] Â Â Â Â Â Non-cash interest expense on deferred royalty obligation Â $ 7,300 $ 400 $ 14,470 $ 442 Percentage of interest rate amortize liability Â 18.40% Â 18.40% Â Blackstone Life Sciences Â Â Â Â Â Deferred Royalty Obligation [Line Items] Â Â Â Â Â Upfront payment received $ 140,000 Â Â Â Â Â Blackstone Life Sciences | Maximum Â Â Â Â Â Deferred Royalty Obligation [Line Items] Â Â Â Â Â Milestone payment receivable 250,000 Â Â Â Â 2015 License Agreement | Blackstone Life Sciences Â Â Â Â Â Deferred Royalty Obligation [Line Items] Â Â Â Â Â Transaction costs incurred 3,800 Â Â Â Â 2015 License Agreement | Royalty Â Â Â Â Â Deferred Royalty Obligation [Line Items] Â Â Â Â Â Upfront payment received $ 140,000 Â Â Â Â Revenue interest percentage 4.00% Â Â 4.00% Â Amendment 3 2015 License Agreement | Vaxcyte | Royalty Â Â Â Â Â Deferred Royalty Obligation [Line Items] Â Â Â Â Â Revenue interest percentage Â Â Â 4.00% Â X - DefinitionDeferred royalty obligation. + ReferencesNo definition available. + Details Name: stro_DeferredRoyaltyObligationLineItems Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMilestone payment receivable. + ReferencesNo definition available. + Details Name: stro_MilestonePaymentReceivable Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon cash interest expense on deferred royalty obligation. + ReferencesNo definition available. + Details Name: stro_NonCashInterestExpenseOnDeferredRoyaltyObligation Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of interest rate amortize liability + ReferencesNo definition available. + Details Name: stro_PercentageOfInterestRateAmortizeLiability Namespace Prefix: stro_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRevenue interest percentage. + ReferencesNo definition available. + Details Name: stro_RevenueInterestPercentage Namespace Prefix: stro_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionTransaction costs incurred. + ReferencesNo definition available. + Details Name: stro_TransactionCostsIncurred Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUpfront payment received. + ReferencesNo definition available. + Details Name: stro_UpfrontPaymentReceived Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=stro_BlackstoneLifeSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_TwoThousandFifteenLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=stro_AmendmentNumberThreeTwoThousandFifteenLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details) - Vaxcyte, Inc. $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Deferred Royalty Obligation [Line Items] Â Liability related to sale of future Vaxcyte royalties - beginning balance $ 149,114 Non-cash interest expense associated with the sale of future Vaxcyte royalties 14,470 Amortization of issuance costs 321 Liability related to the sale of future Vaxcyte royalties - ending balance $ 163,905 X - DefinitionAmortization of issuance costs. + ReferencesNo definition available. + Details Name: stro_AmortizationOfIssuanceCosts Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDeferred royalty obligation. + ReferencesNo definition available. + Details Name: stro_DeferredRoyaltyObligationLineItems Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLiability Related Sale Of Future Vaxcyte Royalties + ReferencesNo definition available. + Details Name: stro_LiabilityRelatedSaleOfFutureVaxcyteRoyalties Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNon cash interest expense associated with the sale of future royalties + ReferencesNo definition available. + Details Name: stro_NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties Namespace Prefix: stro_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=stro_VaxcyteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Additional Information (Details) - $ / shares 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Stockholders Equity [Line Items] Â Â Voting rights per share one vote per share Â Preferred stock shares authorized 10,000,000 10,000,000 Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, outstanding 0 0 X - DefinitionStockholders equity. + ReferencesNo definition available. + Details Name: stro_StockholdersEquityLineItems Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 56 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details) - shares Jun. 30, 2024 Dec. 31, 2023 Stockholders Equity [Line Items] Â Â Reserved common stock 18,298,107 15,970,351 Common Stock Options Issued and Outstanding Â Â Stockholders Equity [Line Items] Â Â Reserved common stock 8,779,966 7,905,032 Common Stock Awards Issued and Outstanding Â Â Stockholders Equity [Line Items] Â Â Reserved common stock 6,050,784 5,244,873 Remaining Shares Reserved for Issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan Â Â Stockholders Equity [Line Items] Â Â Reserved common stock 1,844,438 1,777,919 Shares Reserved for Issuance Under 2018 Employee Stock Purchase Plan Â Â Stockholders Equity [Line Items] Â Â Reserved common stock 1,495,303 914,911 Warrants to Purchase Common Stock Â Â Stockholders Equity [Line Items] Â Â Reserved common stock 127,616 127,616 X - DefinitionStockholders equity. + ReferencesNo definition available. + Details Name: stro_StockholdersEquityLineItems Namespace Prefix: stro_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=stro_CommonStockAwardsIssuedAndOutstandingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=stro_TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=stro_TwoThousandEighteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Millions 6 Months Ended Sep. 26, 2018 Sep. 25, 2018 Jun. 30, 2024 Jun. 30, 2023 Jan. 01, 2024 Dec. 31, 2023 Feb. 28, 2023 Jan. 01, 2023 Aug. 31, 2022 Aug. 04, 2021 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Reserved common stock Â Â 18,298,107 Â Â 15,970,351 Â Â Â Â Restricted Stock Units Â Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Shares vesting period Â Â 4 years Â Â Â Â Â Â Â 2018 Equity Incentive Plan Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Reserved common stock Â 2,300,000 Â Â Â Â Â Â Â Â Annual increase period of common stock reserved for issuance Â 10 years Â Â Â Â Â Â Â Maximum number of shares issuable Â Â Â Â 3,050,491 Â Â Â Â Â 2018 Equity Incentive Plan | Restricted Stock Units Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Total unrecognized compensation cost related to unvested granted Â Â $ 31.9 $ 38.1 Â Â Â Â Â Â Remaining unrecognized compensation cost expected to be recognized over weighted-average period Â Â 2 years 6 months 2 years 7 months 6 days Â Â Â Â Â Â 2018 Equity Incentive Plan | Employee Stock Options Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Total unrecognized compensation cost related to unvested granted Â Â $ 10.9 $ 15.3 Â Â Â Â Â Â Remaining unrecognized compensation cost expected to be recognized over weighted-average period Â Â 2 years 1 month 6 days 2 years 2 months 12 days Â Â Â Â Â Â 2018 Equity Incentive Plan | Employee Stock Purchase Plan Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Unrecognized stock-based compensation expense Â Â $ 0.3 $ 0.2 Â Â Â Â Â Â 2018 Equity Incentive Plan | Maximum Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Increase in stock reserved for issuance as percentage of capital stock

outstanding on last day of preceding year Â 5.00% Â Â Â Â Â Â Â Â Â 2021 Equity Inducement Plan Â Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Reserved common stock Â Â Â Â Â Â Â Â Â 750,000 Amended and Restated 2021 Equity Inducement Plan Â Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Reserved common stock Â Â 2,000,000 Â Â Â 500,000 Â 750,000 Â 2018 Equity Incentive Plan and 2021 Equity Inducement Plan Â Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Shares available for grant Â Â 1,844,438 Â Â Â Â Â Â Â 2018 Employee Stock Purchase Plan Â Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Reserved common stock 230,000 Â Â Â Â Â Â Â Â Â Annual increase period of common stock reserved for issuance 10 years Â Â Â Â Â Â Â Â Â Maximum number of shares issuable 2,300,000 Â 30,500,000 Â Â Â Â Â Â Â Â Number of shares issued Â Â 1,554,697 Â Â Â Â Â Â Â Shares available for grant Â Â 1,495,303 Â Â Â Â Â Â Â Shares available for grant, increase Â Â Â Â Â Â Â Â 114,754 Â 2018 Employee Stock Purchase Plan | Maximum Â Â Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year 1.00% Â Â Â Â Â Â Â Â Â Â X - DefinitionAnnual increase period of common stock reserved for issuance. + ReferencesNo definition available. + Details Name: stro_AnnualIncrementPeriodOfCommonStockReservedForIssuance Namespace Prefix: stro_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIncrease in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year. + ReferencesNo definition available. + Details Name: stro_IncreaseInStockReservedForIssuanceAsPercentageOfCapitalStockOutstandingOnLastDayOfPrecedingYear Namespace Prefix: stro_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award number of shares available for grant , increase. + ReferencesNo definition available. + Details Name: stro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease Namespace Prefix: stro_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=stro_TwoThousandEighteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=stro_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=stro_TwoThousandTwentyOneEquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=stro_AmendedAndRestatedTwoThousandTwentyOneEquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=stro_TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=stro_TwoThousandEighteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details) - 2004 Plan, 2018 Plan and 2021 Plan 6 Months Ended Jun. 30, 2024 $ / shares shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Stock options outstanding, Beginning Balance, Shares | shares 7,905,032 Granted, Shares | shares 1,284,250 Exercised, Shares | shares (23,748) Canceled and forfeited, Shares | shares (385,568) Stock options outstanding, Ending Balance, Shares | shares 8,779,966 Stock options exercisable, Shares | shares 6,078,851 Stock options outstanding, Weighted - Average Exercise Price, Beginning Balance | $ / shares $ 11.24 Weighted - Average Exercise Price, Granted | $ / shares 4.36 Weighted - Average Exercise Price, Exercised | $ / shares 4.91 Weighted - Average Exercise Price, Canceled and forfeited | $ / shares 10.45 Stock options outstanding, Weighted - Average Exercise Price, Ending Balance | $ / shares 10.28 Stock options exercisable, Weighted - Average Exercise Price, Exercisable | $ / shares $ 12.09 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -

Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=stro_TwoThousandFourPlanTwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details) - Restricted Stock Units 6 Months Ended Jun. 30, 2024 $ / shares shares Number of shares Â Non-vested, Beginning Balance | shares 5,244,873 Granted | shares 2,437,530 Vested and released | shares (1,323,104) Canceled and forfeited | shares (308,515) Non-vested, Ending balance | shares 6,050,784 Weighted Average Grant-Date Fair Value Â Non-vested, Beginning Balance | $ / shares $ 8.31 Granted | $ / shares 4.49 Vested and released | $ / shares 9.76 Canceled and forfeited | $ / shares 8.53 Non-vested, Ending balance | $ / shares $ 6.44 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense $ 6,159 $ 6,661 $ 12,227 $ 12,682 Research and Development Expense Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense 3,072 3,127 6,246 5,948 General and Administrative Expense Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense $ 3,087 $ 3,534 $ 5,981 $ 6,734 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Numerator: Â Â Â Â Â Â Â Net loss $ (48,018) $ (58,213) $ (38,524) $ (50,050) $ (106,231) $ (88,574) Denominator: Â Â Â Â Â Â Â Weighted-average shares used in computing basic net loss per share 81,224,628 Â 60,339,475 Â 71,341,211 59,535,918 Weighted-average shares used in computing diluted net loss per share 81,224,628 Â 60,339,475 Â 71,341,211 59,535,918 Net loss per share, basic $ (0.59) Â $ (0.64) Â $ (1.49) $ (1.49) Net loss per share, diluted $ (0.59) Â $ (0.64) Â $ (1.49) $ (1.49) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferenceNo definition available. + Details Name: us-gaap_NetIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferenceNsReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferenceNsNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferenceNsReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 62 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share - Summary of Common Stock Equivalents or Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of net loss per share 15,259,184 13,894,655 Common Stock Options Issued and Outstanding Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of net loss per share 8,779,966 8,351,659 Restricted Stock Units Issued and Outstanding Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of net loss per share 6,050,784 5,212,174 Warrants to Purchase Common Stock Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of net loss per share 127,616 127,616 Shares to be Issued Under Employee Stock Purchase Plan Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computation of net loss per share 300,818 203,206 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferenceNsReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in the calculation of basic and diluted earnings per share. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferenceNsNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=stro_CommonStockOptionIssuedAndOutstandingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=stro_RestrictedStockUnitsIssuedAndOutstandingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=stro_WarrantsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=stro_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ÿ.Z61V)[TW);^PM/X7*ES87. <+!F2S[C^N-Z*N&L4[H$83X*;EF!+QB/O:6##XM^%C'D7&"_?[#!Y@YDSQL8C^'@.]NFGU6R3@*Y9&^DELW_("Z-+X^2)2V5^R MS>_M=EO$3Y46<2&&$L1ADO]G+\6+.!!X;HV %@+ZE<"M>X)7"+P,-"]9AG7' M-!L.I-@2:>X&-W.0O9M,#31A8JIQIB7\&H).#^^$GT*M:,*2@+Q)=*AW9)+D MS<.\YC91*R:Y&G0T/,UH.G[A?)L[TQKG'GDO$KU2X!KPX$M]!TI9%I7NBWI+ M4,XK0AW:M91GC,M'Z?*"\'V; (OB>.6;\S(_K\9O+#9B"BLL-;PU_^L'M.;_:\+Z3V1>PW1*VB[E7 MS>1YM^8V4ESN.NT/-B14U1#LD2Z1,LT IX@8[]/V-+&A.L7+%*V5S%&90VA M>B54[[1ZFG(9"M.C P+C@K7*<*>RM]5V-U3?D/,JŸ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ŸK43YI7LBSS=I>][G^9K$$S- BRH#Q.CH3ZD%BHZ=T+V!W3T>.8]L M?C[0?O(= =/$JS9OM%K*8B5JUI!:?;PX:W =57CK_X9.J5XJVGWM'Y/30 MGO6Y2R@S"F/T!IJB3$"#UFC%B[9!$SS&N/U#:L%K0Y&-7L@Z_Q? UQ8UM!UR(3Y1TLU.=3Q'-8LL_^N5*&;!.,3& 8@)]VI3-FJXWLA3V7[58F%<*X&.]G4 M,P{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{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ÏU]B:(V<]!%$811. CE-A #7/5 M_67$TC#)+L[O]PESS;AEV%@H_+!6_='?%K'Q[IOI(5[;WY=GE7__"1/AW:! \ M@O']-DV3Z90GS&I92J\Ÿ)9@D C/(3'9D)BB9^;>RG55=.MA7G1(7*OM1!ODJ[ME\[TLMY/HQW4[M6ZCM7_!13:80K*A@H73U!IR:(U\A]P8CSF£1TD$9M"5[NA*GXLN;#BB3GV' M8^HP$L53=SQ2^LPIP201F$%PMB,X0PG^H^SZJKX=^%7@?5O-AMWB#XZK'IU5 M46A?&C.'QBQDJ9A:-%+ZS"G!)!&80>-T1^,4I?%Q_/5M47?%-O+NNF96;?;^ M#U6_"/KBF]J%#A\7Y7(>;,) [B&^(YZE#C=HO6]O(*[2"OK/L&(\YI4=)!&:P MQT(=3(E@; M2EO7N&* DF(/-!C)H0E]<&^:B-!,FK3BPG#)Y5EHPK8\>'V\YU!7I&$B87&: MV-R2BC2D:) (*S>P"G]=AN%#S;T7ANF[+8EG]3\VCMX6B_M5R4$R'1;*X+ZIE M\6593FZ;=C*0'G3E;-U6?76 8%=3XACRT.:#41*Y)T?)2-'F\14P:M!;#<#%F7\I7T^).G(Y!7@#E M(^-JLK)Y$:Y2;\?B); (,A9Q>ZUR[28L3.W.#%CQ,!+B@G]{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Ÿ(<(T'FM.I]G2 '?'6_;O5CMJN:<*)B+_RQ*=C9P+AR20TC+7MV+S VH] M? <,7BUS97[*I8SV'Q*72HJC!F$'!>/6D3[4/.P#D:0?X-N4QI7*?EOI!20&X&;*<'J7[>!?E M-1KJK<:QWTGXJ^1G)/!.B> Y84L^0 ?#@Q;XM!M^0R7>VWP/35!4[' \HO5O M\%W=W;1YV@DRA\>E6M$81@Z>#@KD&ISH\Z?>P/O69L@AR:8'(MLS*VS,"CO- MFHBBP--%F:_YE#*E2LIC(+%0NO7+[&3[J(L5V<"2F>-W'?7ZO:&[WC7G=4S@

M730Q>YK[C>9^I^8%_FWD1C*M@9/?:0J2\66;V$Z:CXH])-GT0&1[]@T:^P8' M_60&KRL8GH?[99YT;OE1=PY$5KGC[O2. N32]F"%U0]T)CO[/##*\P(ŞT MOD^%T-N)V:"Y%$7_ %!+ P04 "
#O@PU9M!8M:< ("J)P & 'AL M+W=OL7O_&'G3)?K#;G M>_K ;IFZV]]4^FK5>\EXP4K)10DJMKU87,*S*Q*; 8W%'YP]R8//P(1R+\0/ M/XLW.ZZ.]!!AY^?O7^K0E>!W-/);L2
M^;]YIG87BV0!,K:E=:Y^$T\_LRZ@T/A+12Z;O^"IM8VC!4AKJ431#=8("EZV M_^ES-Q$' [0?^P#4#4#3 <0Q '<#B2=0&6OMS7QHYJ89 MK:/AI4GCK:KTKUR/4YLK468Z*2P#MXHJIA.D)!!;
<$7E#GS33;@PUU)ZXPK MEGT$2W!W^Q5\^.DCC^ GP$OR^$[52Ş/5TJ#,2Y7:7?C+^V-D>/&$?@N2K63 MX)\:0#8>O)]!)&@UTB^(*_#?]7E9X"#3P %B%CP7!T ''O@X'YB<>,/._S]
MNF<55;Q\:%S"8^DWN:LHN%WJ6258]LL?G[WV 4_,,6XHF< MC0(F?<#$YWWSBZXYN9#6(-N143/2%);'S1(&$<++P?/5XB-]BER1A3'JS$;*P M1Q9Z4W&9_4=OI'9I*Z&+3RK*E.
<,E!UD\ZWYG)I%7YO-H->VL"3PS!9<>,H, MGLC9:)ZB?IXB;P: ,NTTY;2MKV4&:"$JQ?]JOK!%WKH+#]*%PW":4XL1)I$] MHW&/-/8BO4S3BC4P=:G*N$Q%72]@+S45_6"*WNOD2I;6E7/;Q3-4RY
D>(+= M8H4CE-C!)SWXQ O^5HGTQ])P3P9246A"ELX93F8 ($(HGL"T644)LL-<]S#7 M_OTLRF6S(7*FH0+V;(#:)W,]NS\B![=O0%'>E5]\Y/PO
M/9WLA_YW:4VH0DTYFUF4&,U@[8!ZP+CYM<7BJF=]ZG5\3 M@%8AK*IT1)5XH;D.1=SG _&Y1KIC6:6D#B8AC(W(\2Q1B : D'>0'Y5.U99 M4:'Y[? ,T]Q(\X(#T\"\T$^]5SM:/C
Y*>)2,EW_35G+.;WGN;N@PY-R\JF\ MC2=C8&7HIV5=*DUQE(;V&'\TI=$:,YGOX34*'5=,'.S)4KBV)&R@:&AE]@V M-Q7;4Y[U5:;)DS!KJTN<%7-H 1,D9(K98K8.'(@'KH1^LNSG=4]?G),ZY[ZE
M+A[3RF@SBT)7C1DX$KY-DO41' ,M+$?B XKN4%K)$&,'S($-H9\.7V%:4G^P M4:W Y[RW#/&,Q"UF$(:N!3#0(,3SX]>^2K-'5M;V!6!A1@B361F5' /5RZGL)YE3>Q0@$;(N\!+:Y
MJ:MT1\W&U5K\:/W=.1W7[C7">%H<;8:00!Q!1[8&9D1^9OQ.50?P?<@M3!F% M&$[+CM4N(9&C*"!*Y&?*V]I_E[(M>*O$3#':B5QO\V)?BN M*'T$!B_/],7]B[X^@10+V>_ MNT*=R-
LXZ(&ID9^I;RJ,I9)L*U$ >3K]M&ZJ/#=EC3M^*?F_$=_R:6L)0P0 M :MTK,0Y69T@+V29+!O"VUHS#NK9>[[QWK#K_ M/8^:\"YJ2\N-US%QG+'B@_/N-W3 *&SVS*J42S9;FV)O^A!
[C'.JAW"ZKRQ& M&+K #UH ^[7 [_29F5:.&SF?4Z7+>GE@-_JJD&&L@[SO:!GL;-XY!<2$,T MIO::&+:Y]LC+]J&_KK[64T_R/U"Z6_*=RMMX1@:50/PJH7E\W91S'71_R&X- M>ZX"HJE2L-
C$R"%T3@:=0/PZ00LQ43"@Z'.#U K.0M:A7EE3?/^_:C',) ^ M\1^U>U9>.3SBZ)LCO9&&(O[F@CSI,?RIO(TGZN#AN%]@.)I@31-YG;7'7'1R MHMP^@AV?CEKG:2X>)HM88N1BQO((#"(7V ,
[:0Y9!9ET]=+*4:Q6!V\]%:QZ:%X&DZ#91.UK0_VW_0MGE\UK5I/OO\"SJ_:U ML<%-^Q;;=UIL.2-!SK;:9? YUBFHVA?#V@LE]LV[5?="*5$T'W>,9JPR!OKW MK1#]]<+&PO M=V]R:W-
H965T&ULG5?;;ALW$/V5@5($+2#KYDN"^ +(=H*F M:! C3M*'H@\4=[3+FDMN2*YE]^MAKN2Y=0R@CXD6N[.#,^^3=8XO@H4V[I6X?Z=U]'4,%+U=KT MR:]^Y3Z?0XFO8WY?
UIUMOLPUFU,ONZ=@: VKOM5=ST/6PZO)SL<9KW#+./N M-LHH+U529R?!KRB(-:+)0TXU>P.<<5*4ZQ3PU< OG7T,I7+F']51Y JZ"L9I MTRA+^;I2[SZOI\2]#,I$4:< S6MF]F" (Y!VZVY?
WI#MK3-LM5*0QKJ1H M$N_%AK59&IT1.H^/>YU,X44R"U_);0E -W?;:D2QR'Y0//+BSBBST#3PZ"5 MBH3\?&A\@%F!K6G>]&-I-I66F^S3,&\"F!6D[UNK0N(0^/H#EI7T5R)"XH
MD!2UA_6%L@9@G%'T>"_HJ>PA&V(;IL6:M<@eU"X-27CJ4Y470NUBS:7F-@E% MU 1?M!J"3!]SP$Q*%P%4HJV%-,27)0('1XY(*G(!&"TJHRNX-(H@4+XP0\ M(AO7D2A5E;+<*F/5PO*:
+Y5MLTL!2Y;JX*]I\5]1GU1&5[2VSO6K8@M?5RB M.ARZE+9J/GUU'$EG8[]'7Z"86>MK=2,^X$=>%?*MPK0D3\IB3 4M>M6W08-% M :5B!(%BAV 9O-.\@W6QQW?T%RH ;C;THP6D'/Y[-A_%V8#?
D2F WHR%1R"N.=E?N M6:#LF.K[0T[LA']=$XO?%V>DJM=)B!K1[^9;"_;3_2,BJVY4VB#='TWI9 Q M;MA%JI#1BHV3#(49K6)%2QS^2#3X>DVP=]ABGG.%MO-&VW.O)Z,I'"E=5NC
MR008#ENC39Z'G^CHZ'!TA!/16H0:T8=2.+=5&1W?SL,5Z0:W##BD8+5P(J\..6T:9T!XRZ<.^O<,-IXP^HC]#}]:9 MM?U76ZQUG05OE/A[P\)Z&!M-
Q0>T:C=5'C+&'@806!J!,$5!20#/7N4CP<7O)I*Y"X[4*U8&L0!"U5J<[RAVKQ=!VRBCI$2YU6H^?^ M6P/U5$-D5T\W9S MM9]W-]H'\^[O@@\]E :I6%["=3)Z=3B@T-VUNT7R3;[?+GS";3D_RAG-
00SP M?>E)6B]D@\U?}&?_ E!+ P04 " #O@PU9&%6Q;T84 ;/@ &0 'AL M+W=O#7B:#8<#C^ 52)5C@%*JZQ?EZG\P$4*@BV:WQH]2DRP B;R< M/)E O;ISS5>_J95W]95[5?
K=IV\^+LS!K;6MC]ZXN\^-F]+>N:ZM;&T^-LIWZ[5NMF]-Y>Y>'UT< MQ2\^V>6JI2 .WKS:Z*69F?;SYF.#3V=IEM*N3>VMJU5C%J^/;BY>O'U,S _,# MOUISY[._%>UD[MQ7^O!C^?KHG
0RE2E:FD'COUOSSE05300Q?@MS'J4E:6#^ M=YS] ^\=>YEK;]ZYZA^V;%>OCZZ/5&D6NJO:3^[NKR;LYPG-5[C*\[_J3IY] M?'6DBLZW;AT&0X*UK>5__2WH(1MP?
7Y@P&48<,ERRT(LY0^ZU6]>->Y.-?0T M9J, _>*L\&L+9FHPR:QO\:C&N>C?3,38RBW4#.[K.W"%KINU4U1N*YN;;U4'UUE M"VO\][,6Z]&HLR+, ,5;FOCPP]U/UDZO;E5?OZ]*4P_%GD#,)>QF%?
7MY[X3_MUM53=74^49?GEX_OF>\j;?Z*Y[LZ,-^>7:K_NIG[MH&S_/>^#Z1]G*1]?-_L_Z2I[I_[T/?O_>M1<3@T5]6!I%7N/5&UU:N:Q-:M:>Q:%0Y.47M3
MJH6M=5U872F/F0PBON7)6PQ])P.5;HSJ:MV5MC7EE&;%0M\YU4K?&C4WIE8P MR@8SE1C)0C4EGC:(N':EEJ8VC:ZJ+?UB-EB&'PE;WS06\VXJ[AC2;+/-8FB M9BUO$^+>K"%,H=7QG_]T?
7EY_O+S=#95?[FY^L()HJ-YLH$@]KXQJ M.IJ2?FC,LJM8D6GS,U-TC1C>W>.+]MV*EZR4K96T]PV)<;/;^75H&2)U4TRO$ MUH+@EHS8E-E9M)[345I5.U:[%4T75E1"QJEB$;!3+L'"NQ7.0]#&_=99T
M.=^JM%5>FXQ=F=;LM0;;3OU@"K.>FT9=77 P7V4VG.N*K2(YZ4Y[@&P#Y,;B MC5N+ L4/]IM;!_ W15I7X4LT[_.$@\7A_04>%*V#NZ"L^JF M(91ACYC .USQ]92,7K+78\?R6-C]1-
WJJDMN+L9F2_F$?A-EH67;\-)XJ'+U M\K3BD!8S3:+Z6OV-'@>K,@T%7N.VND)HN'EEE[((O$;+7EFO7E><<19=VY&G M\ ";,%6>K5U]6FB_EBHGOIZ;'"-*V6E-!T9N P!)5M!Z?&*/ \DL$E2-
%9$Y2$^"9<@!39F1=4 M%$Y[X/MR*P+E!:>0TR M7=0:GK9,$+^,T\>'VU5C!*>_:;6PE<-\54%MFD2VTRQ%G=HL2=;ET *BMB MF,?I&<;6&G!IV->*B GTT!9!26N0"L>9V&$/(B>)+ 5H
R^K>N:/#'+[K+# MN,$^C84L%U .WO%SIX%*9(9/#%#D0%34J(OSTY^1:=FIYPRT9>+ MYU?0&T(\4"FF^RH&H+L<(XII"G,B.(VKL;?1=C%?\#@_PD6]!18#SB21\ MXAV9-*^'=RP 6RB+NC?
0G^0QVW M0 4,(,1PF!^X&O-$P7-S\)K1W$T_-_^>4BHYHCV\$H5Y"Y@@$#L=$T;I6)\[' MP!E3.=S_KE;WS#P;E"6\X0^$.--'$(2>,420-1X=\T2N\]B+/WG$3R>@RO?Z
M+^KY^>39]37^N+QZ,CE__N31I]'6KY\\4]?/+A_]PK+OU]EDK](&>\)*%Y.G MCY^$E9X_?:9^K,&MVL1"R;Y(LUF(_:J_%=N6L'T-4!0:H%:F8JJ25V9 ES7H M64?H#XT3VC,E,/2)&9
8D".$\4H)FPC^6 #+0X55,(R&E3-*EDD0!E4:.1Q5 M.D-HJ;EHW;O61."+! 6V5?9W6KA!#DZ?ELC\@2RCBT"_^GK+5 M5'T@+?S*6OA)E"./?>BU8ZFN0> Q">*%3$0U404[%V/S(61(HA3@Q GV@J(
ME9 AL#9/I$0G_K+E7*#)JX%\ZPI_X>"5O+)VD&=NB0R#B8 WPT\+N"/;OOE MTMQ<0R.6H2I.[[2\%O">F_:.Z$J8!)2EM;06*TJ67_=:D2J-# "/!')8%'X$ M&IDGK2Q4"QZ[%6%2941;
_:V6RF,OH$&_RV8VTD?PLVI'<-P9.M-US*7)O36 MM]I6]+V$# _'E\=BNWAE-@^L@._E8+^*P1HMJ%$ZCH?1P)$* M@*M%8^?&!P)3$;EG-PR2Y@2$BP;2D"@]FY:3I@"W?Z'^1I.H" _;TRY<_=X[@
MA-W&2\>$F8Y851@4\!WZ+P[NY668\S+,^:,()[0&(M9QS>!E$*Y7^D09RP^6 M,';1PLF8^L1/$V'>V,!O TE)+@]K5KJ)4F5^R^7(;^.MQ3TE*8CIR7XG?<&:
MJW8H*CV#7$O*!G@TCHLI*>NRAT(\P-^U2-G-J7QM+;>=V. =]5W@.S%1[=W M2U3:S:.XJ:/;S'F]-@OIN$W(H!,(Q7\'?#XI3^F%%N K
M^>0&5.0;EV>Y_&5G4A&Y@G9.6>^AI)'48\1"#>SF#__Q>U:M_4N#R_>*+^ M!K>$&M3-$J'-$,E)+*;D;#_2B,ES+BMY4+D(PB'=I+3K.G@K2CB:.2M<]PB6 M2A?
L@"H9W1"FN=L@;1Q,5EGT-5!0!.LSZR9,P2\,46JCKJ?@L4%OG\+C?^_U M]FFHMUG0VP<1[U,2CW-AP,)-I)8T(L1&#(0(@%'> ZZ<FQB^H$!R" M@.?^!X%_3GVHC],0?F#J40\E6HY:&Y(]F5L@?
P3H,X,^"X2IJIS@^@+%+W>5 M9^_4]?DU>'B_ $#X)A]\?!2>.CKIC7QP*5O?N@I3?'&6VC'"6BA(!0-B7,7Q M4QOJOD?'?Z88+=1>(4,0-3L*A M\:2D*'^ I@;G!OLT#TP1542B,Aa!P<*-GMR@M-
F:2O%#=I(,D56#\"/?+!QV MJGYWQZ_EP=_^(VME!/SY^>3%(\K;>!8EE%?4N[-&GXP^R/<;%(Y"I^LR(&KZ> M9$2QD8#^G8F^+,&DCDT>Y@6$MUP5L*8<5XV W+4E+UXZ:IQ2]D:V)?XP"4Q8
MDEQDJ-Q&\\&LN9V25P>!!&(]F3EP?)HOU0*]IG<6YGA)5#-MI\D@BP$R#W[) M[4D;:;;3TV0^%%>LPDQF80-^:#;CDL3T)['"QC5I@&Q[[DU"3 M)7V_Q-/CQ\,27-
'W&36=OL79>"C&]FK@6C\K1ICDT6.W)]35=$?$_YV'8J1] M]](4-L>8-OG4T*6.N15\,H@@XB=^P1A[8)VI^]N[PS2(8#L\ QWAQV&0LG+6 MU2M8SJQ2EWN \T!{AVJ$^7"(Y1X[\G'%(%%
]CDP#&A7G*WP I2'PG:K"&! MU#L'8"4 FI=E$Z)H:1V571%3^T' "L21HB.2BKLZ#B?94Y- SQ)-F:_ M+%P)UESHQ-5D@+:@!Y@GJ3)//&F$[S',9]<>;$07.NBID<$P0(Y< M-U!PG0C+*.+#O077:,?
ACA(5CNW34?5RQ^,K9LVG#727:&0GK@#G1X: MYKB,:8U+FATB$D]T4D3>:C@AA>* 2DZ&C71QDGC&+CU>-X_=6FZ]K.A*17PB M%/NC*-T3GUGT;ASE PKN@21#=]A#L:5C8.FT>IOU3P-
20F.>L)6KP*#W<+]& M^)).#$#L&^Z-['?BT#\E1KX1&*;0XDX M_*ZEOY:P /&1Q&#WD_TEI[Y!\, MP#E&E<[H][#F)>,5IW@+---=9!/CDJK0$W]_=PT<&1+.'@@A =;\EQV53 O]E-5
M_4'+\=%L]O$(A5;TVP>@ 44LA4FX;A.($Z:(9+/OT6;]V_8/@\0N1G #:/:Q MOU!SP.J99D9$/5X7_&JV@\4I.T1C4>/UE!VT/UJ#CC[\IYTA"6]JVM3T5FJ M:Q#:?>>K<)XR M3'4*F:=
(6G#S\K*2QEC4%.[^_^40X%!:;[!:A@0];]&*/P M!?O;89HS]+X'D[A=#&!W$6Y!/ R>H#%D\)WL Z:$MF]+K_KW'(6)NU $2(@ M")^-#4%DE5VH".>)5)YG"X;X9\N$FTL2_1+SKG++40+K*+
<.@6M?!% M1I_2T*TEN2-[N%+D4(DT8*)WSAID1#YVQRU)ET.C=R7:N6-$V>*3=8F^A M+]+"\1$>)Y!$8/?-^9&-=Z]Y]O>Z$"5BJTYG5;1=?45D2N*#M;2S!MJNH*S0_EV
M%/Y3I%.\B7<]F\IP?!]WW-L\W[E 48;F%2J114LBW]OKMHG*)X^FFF8@X3Z^ MEPX\I'V'SU8+*?C74*I .JVHU8(2OFB_^[V9GQK[6%7D1L&?';#@!@=+GE\5WRE!
MA^<_(6*Z37FP41R1@C8O;C?<4.8^Q/1I^P\J_K[B M04X.4F] 6H9[*XI[^73()ND,^N"=8S%L%:60%TSJ;6@B9Y>(Y2I_X!.4' _*(MQLAB==IMPMSQFE)B>/U$N?
I[EA2SEQ"IT!BD0I]\PW6^ZIOOAVLG&VA1?K%V M]_Y79 ^NR?MG,,WW%-,92G#G:1#]^QWH4\|)?\@X^2QR)N$UD6GNY-WQ%@Z2 M_)$N]&&J]!!UR$K^[^'CD_Y<,V:..=*$-
>MDY^^+#@>P@H\D98Z*(@YLTT9&1 MHU-7;\9MNV%W.36J'VS^I0FM"%K';L,PJT_4;GNGQ1B-)+G-[F M7I=8-TK5G3JUO_F56O0%4#D4H#83?C*]" L(&PNL+O_ODX#3P M@YH4J^7,?
N4J88?TE@FI,9. X6C9..\# *5K[[LC\YI(9S43W[Z+[[&D$Z-] M;WZ>92_L@GHN^;5D?KFD;N7=W?1M>O/Y1E[X[1^7UZ9_TLV2SJHKL\#0\^FS M)T>]D5>1Y4/K-OSZ[]RUX+G\Y\IH^!<]@-_I?;?
X@19([X._^1]02P,$% M @ [X,-61]$A*@$!P @1$!D !X;"]W;W)K&ULK5A=;]PV%GV?7T%,NL4N(,^,I/FR:QNPDQ;MHED82>HNL-@'CL09,99(MA:0\F?[ZGDM*LNS8$Z3H@RV*NCR\]]POELA?
CPKGZ;#JU M62$];B>Z%@I?MMI4W.'5[*:V-H+G?E%53I/9;#FMN%3CRW, _=V,NSW7C2JG$ MC66&VJ2IN#M>BU/N+<3SN)M[)7>%H8GIY7O.=>"_<;_6-P=NT1\EE)9256C$C MMA?
CJ_CL>D[R7N!6BKT=C!E9LM'ZCEY^R2_&,U(E")SA,#QN!>O15D2$-3X MU&*.^RUIX7#/+/+0^#!>O9"PN2=D'B]0X;>2W?<, M,T/20*.!-]6OAG)2D5/>.X.O$NOOXN7LAR,*SWN%Y\?
0O\4UQX'2"7L!BWTHI-OJ$JDIU8XYOBD%LP(?D.ZN M8(X^T])[OU1O_L7LYK4P+%U%ZW2&K]T (J;6ACN!4K!QX ZV!:/7RRA9+2#;#48 _M?FJD.PQE%K-
HGLR[QPEDO)XG&Y[=@:Z!Y'(!S580Z0:CWR;O)VRG[X51Y,NA M<)RLHW2V[)\$'-B"B7$2@3V,DB2)TH2LC=>GT6KF[1Z]$9FH-F1K['E._T:> M%\LHA>Z#P0L\KY,H7B3$73LXPO,RCM:G1%XW>
(;G>1R=IJON<8SG>!8M9N2U M;G"4YSB-EE"O>YYTXFAG*GNL072ZC"'0/GMWI*LXFI^NR1TQM%LOR1V+TV@1 M!W?\7@@C&*_K4F:4G=$P UEC ?VIT0Y&M%S71F:8E%W#:^=]1C.9PP(
]9GJ M-/ATPJ"S#)-N@L* S"0LRM-*P,.Y+O7N$%01?F47$E+="^M\08G8OI!9P3B4 MSJ"DD9;2?LNJ+^(A8D>8I0I"AMJ"4Y$&P"W G!V<1P460V/,[E@ARISJQX"3 M"?
MEVU'R;5R0SDH[QN^Y+'NNU8NM^B966%):9#(G15-S3"8@,$KIZLPI3S M.^H-]8VPG9!>/):%=(J"#5]F1N1!GX_N3K4!D3Z,IM9!"DT2Q+>]"LIY%P='0MC*G9);Q!,"&3H^
M:6+50]/U9'W10XDZ:WT:M'8_ &:^\W+XSB!@&PJT=N]C^U \2'B#HAR,'M!W M41EWI 7M\Q_4$+9F&[I,A2JF MPL6LU\>?XX)"-UWF7.V,"/[>"+<73VH:67=](M14Q7R$0EGFS:,0S4?2EM=
M>HL?5O@HF[-_D*6,.(K(M0:FJ8;*$]H+\B:B>*RA/L(1^=F2I!!&Q-NPQ/:XZ)6EO[-B=SJR34ZJ0C$4C92.VM[0J\^H1&S?B#8DNQ1N&27QJW'26E M1Y]/UD_UY.TGZ&
(LM<@7BAEDWW.4'WN<>LA%X0F!BJ$^9?VGL]63S9.WYF M;RL__X6=)_=MZ:#:S'ZW\Y?_I&"]# NW)#[V?[WA:MPK7X0#$].O.5FAY:" M@K7%TMEDM1@S$R[\X<7IVE^R-]KARNZ'A>"HH22
[UN-T&]?:(/^5Y?+/P%0 M2P,$% @ [X,-68/*&K?5!0 7PX !D !X;"]W;W)K&ULK5=;;]LV%'[WKR#<8$@!V=;-DITF 9)>L WK4#3M C!L@99H
MBXA$NB05Q_OU^PYE.XZ3>!VVASCDT;E_YQR2YRMM;FTEA&/W3:WL1;]R;GDV M&MFB$@VW0[T4"E_FVC3<86L6([LT@I=>]*R'<1AFHX9+U;\\][1/YO)FJB_ZDSTHQYVWM/NO5CV(3SYCT
M%;JV_I>M.MXTZ;.BM4XW&V%XT$C5_>?WFSSL"4S"%P3BC4#L_>X,>2_?<<,4/=[O@%W1G[J)6K+'NO2E$^EA_!SYVS\=;9 MZ_BHPI];-61)&+ XC-,C^I)=\
(G7EQP+G@)^DH4_KF;6&93,G\/%W6E-G]=* M;71FE[P0%WWTB17F3O0O?W@59>&;(SZG.Y_38]K_(V#'=:?#IYEX47W'*@Y8
MFP=6^\!::'2Q=:)D>LY<)=A@!5[$#M737:./D7.+\]#)GZF.9S5O0V E+DV \C;$8;/XZ0N^M;AIA"LEKMN1+ M85B2!Y-Q#I93%N?LM=\G(?C,4AON!'I\YO:#F61!$H8L)8$I!+"/\W'OREKA
M!C0ARGWN;!QDX]"K'R?@QGX\S7M?AS=#MM!WPBB,N$?ZHW@2)%G*8HAD(40\ M(M!1,?\(#EVRVL;:P\C^,)BR=I,$TRK.B//(BAHJ/GD[#W3A2BF5%:(X]H\O\A M.D;>I_D>HAWA*:*3.(CR*8L(H
D!A/TX/H(H\C>9Y,@S@40883]-7T(T"H-Q M.(8'/[R:Q%'T9D,X"FF4!!G4I^&#$)'@E92"\:>*];X$L@SLHQT[[:-M!<33 M8 Q58RK!A(K*4_#]WU4 2C%*4XB?LM37PB8T^>_5OMF?4WF;Y
IHPM1M@@/22P1,C&)>XH50H41 MI71=3AM=BCI PHNZ+2EZY!W5B7+U/B&1!RAT#I(^1.!P7$C-^-S!QG5THYQYXR.M*X*H17 MO!?]QA28[4$S6&J@)H3:(-CUZF%=#=E5;77
9OM@T/V\;&MQV%#T;_('^=E MQ6W7<;6\13%VC4<^(*Y*U^7&RT7F(=S%\X?,*)HF[;F_N9# MQ8(\-+@45O2JN:,\8R_8*47Y>ELDVUQCJ;IA,'SNWCC:N_3C_%OXIPTE&@YT M] \==?
=ZNNH>#0_LW=,+]L%Y;L6&ULU3UKD]NVM=_W5V"VOJT]0\EZ M[;&B\\?_7-3J[5G:I_V;VOX-MS/TJFMZHPNBQ$!5;?GM].7[Q> MX//TP%^UVIO&L\"5+,ORWY,?OV?((_J5RE-8X@X=>]>J/R'
<",/YAQSSW M4^*+X6T=EC+4AKUILS_IK-Z\^WY];G(U$HV>?VAW/]1V?5IW:NUSS7[,A7EB40N_J,6IT7]C"I^> MZV(L?OUTXN-&P>O;G2P.8B.-@(NJ4IG015V*M#=N;L>5\;B&QPVN[G6]$?>R
MTF5CQ&XC09A3U=0ZE3FL=1EK=)-4>;E^@ 3(01:F&X4TK_G?7L]GD?4_P MB/B7ED<#35*6$O=+A2O3]>&K'2A2Q2#2"96M9V(%VD>9,1"NBEVZ)HX(D/ M:E=6M0
4#.)Z63T9P'ZF1XY*%D!YO"EMRI5VZ6JQ'Q*(C)/!#P$B%TU%3Q: M@?8R::67\.@2M7-"@\@LT[@XF$<7K/5QJ?"_DNE&E"NA ;(..?PJQR$5_>)D MFI8-+J@"D/2]7.8*=&D."U8&M!DBO:C!@@ I\AS
000VA?NRY7=75;D5S0Y^ M%;78R0/-EX!2S!6HR4(QWDM:&8ZGB[6*GH25[T'JX^]*Z>VRJ0Q!DI;&#? K MN2Q:N-BI"E$'S\)4ZR8'FE3J'HV4PQ^I=E49BR.1 J?K6E3:?*()+-ABH^'! M"M@QL=P
R_)K MQE -H*Y(2(#]J,D/RC\4?^45@\OR0A"Q'LE64M5"?\7D% M1,C<]'EI+"80R"&R 6PT&AC/LE*)'4S4^$Q9(=OADDF)$3L!;32P4#P%TLH@ M*D"#*Z_!:=T]IAV+'PN"I,J07UB:
<3D1K9*64$/4B1& H*X+_4\ "JBBBD:1 M5,!XY=Z\./NX@=R= MJM)/X@X4TD[\7FYW+\7;+2L1_!W?2#S!;)U<5,7"7S^5S,+Y[1,Y\GEY.+L MHS2 OM>ZC+6E =#&B?A+G;7#TJ-^S
LQ$C=7\/LK_)S>JB!01B(<_O]_)FX M7ER*J\E<3)/%#?Z<7UV?_;@SJG!@W]W>^>'IAA_^AL;'X5]7R-ZY>'< &1)W M_VCT[.OSH"',WFE_#[(EE,9A,Y?_Y!WB;B+4P+6C>K$_&# @AP M"'!
[D00@;%;W_E)HY.(1_7=!]K&L04,Z]@$*7"17DTNDQR193&?P87Z=7#%Q MYLGD^O(,]0/S&(C:0E"6$O=+A2O3]>&K'2A2Q2#2"96M9V(%VD>9,1"NBEVZ)HX(D/ M:E=6M0
[VZ9=]DN1$+WXNPX;^/]#@^?O>U 0>#-7O;$%M9]M4@FBXNS6VM0 M#)J^WB(N %VSF[,/+))L:E,^+LR=-O \ZG'6;4_%[#JYGDW$45!BG?($^"6Y MO%@,VB6'09BQ!Y@U2<:;'%0L
W:%M%RYS/5:\BJ)'&5312[(1H/MK!2&2?!F M56M4RV#C#+QD5EIEL?U U9S6A#&OK(3<[:KR,VE3>!?Q.YZ@^C#4J#!_X:C+P M",13?,X*Y-"H7D*#V*?BHY.FA MI,D*)(
W,L!.7NX(0,3<'F:1U1]"8$#QNI);L!@$##RREW-%X"!-#!R"I8@TA M:X0"\E&1.QJZCI8((TY@:<4\(N&RKC(W0P*,5;*R.DU.L/D"#J6@>,71_TR\!? MO'F&%T"+EI_[X8U5&"3,:CE\5-DY8J6)YNZU-
LM"D*F#9KERI =O=U5.D?! M "GEQ6@4.K+/",E*5P;H_-/;D2I 09$* 99+&=.F;C)DVLRR%#_M !JU +DU M.E46F6H"Q%N+$)9,9]8QJ94EJJ<:L-?6.[D&9*+(VIMN.BL$'<_ "5_G8920 MBA8>L1@+
(B_M41,(;9A @&PDT+L_CZ:+ZP7XFXA\8(BT'B(:"&&NTB97?E5U MI63M&(&I&L%F$B!GM%H.5@S*!Q(KD&60/NH0?4$8S4[?+RK/BXFK?;P($1" M(#A[@O'!@4F$3K1IMLZTL!@)EB-
RO&2N')+0290["6R&-8 MS5"@"P($A9P>B?5&UA20 >=TBM2_!UA+,9DF@"W9P'Q&P!R'HC*E+7)6-P20$N(VQX3#=C8@R8H!MR)EFT&+1B.B1I'W,+7#"^- M\?
O$/OA.&@RE[B!ZT1B:1J;OMEE#T$:/=XQ?9/O$^TJ-WCBK@Q/Z+]V<0,^1!P+3!\&S+)H5V"GV%H/0"7Q1 M&!)N R,1J,8*$X:AWK9:_K$O6\N&B91'XH@P^?O.%'9<
M1'*G2I!_O6UR69<5.IZU7I;98915S1K5_]\;- 0\!-O1GLP&LU_X<2 B:4!TKH]>%K..I MGJ%.=HD]MMH(L1=0;7,OHI-\07>,+4D@U1!,P:(@QE!1!$NPMFOSF*:%;21Z M, ##9] J!DU@:ZY<2H?
B1EJ]=#<*H$TG-."Y78%;-1E;]9, =IFHYL]C)I8[%^Z8R#;"(F[K/ M@+VD%'H &=M<_[1$;V=4ZZU*T\ IU K6A;D#^CKBI!I_[^1&D3H0_4Z"(#'(
M"IS(\$\ &L#Y4>+=W;\3UY)KI!Y\O)YHEGP$PAJ2D6*[@G"@_5*F]K#)$]@Y!+VKGX@ #4+3H MH^!6%GRXA0,$\K;"$-WF:3D)$,3PK<+ODPVH_4(\G3Z+7UZU:K12N0SB"O:, M8J_TI7@Z>_0 -
MKIC3!_] @<>'8'0(0\73P;%(PV;;MJP#M0[=#E0$@G_G3W MAI56#?ZJD5QQA5B3P>IP(9IG' '*E,:'&->RY%%B&,>TO?P-@.E!=<0W-2Q, MYA@D0/Q",2Q!0M6/N[OW7.8(=1[$-&7*0? 1&+PO$
#N<8L*LY\]H*'S1@,) MSX)IO!E/'082]/Z7"B$+4M&8L\ !L+;#X7\(S%(:#<,R+K[_^)W54)PYI)NX MFJV2!JC%VH64-:G&<"!.+3'\99J'$%"*"%6PI[DEMLNYP< D+:@S3(N]>,,UC M+$81-,
,1_ "8M/GV$(T]&-LWB%F>B,GXID4>"?*O0^ 7X8_=80!-K598;\.0 M+4 >FN^"LI-V:A(Z4']\>[(8]=NX+JQK ->1=JP'@%?;C&^]F\,%&\2 MIQC@HJR*P.NVY !\'5"-H5R2\?&Q):!7L9W(
C&6K9ED6>)DV"#E)5H5= \- M5[6<8]A+@AYE\>$$B.GE7\ 3+@<#= ;WGH@%F,\+CRBP=6&.)+'50.L^AJY, M6,?T$N;B*I\^8:8\G20 [P-B[P;@& DD 28.*$G020 \YJF!R./B(J>LD$UQ
MD,"TIJJB@F^JJ[3!X@N6@F-LIY@+972[\&XCY[G"K%D M.2ZY(P;H) M_R"PTZ96$%"1;H% 6I>L<3-5.7L=NM]><[9#^'G@-J6&H2*YM]4YAQJ3 MECNOJDH((S3:&TP!8A.0S0@T2&Q?
XI/M[6V9^4(%*'MFLU#YA0^<=KDYKX)U M)=:)1V+\P-M^A'OJ,QJ#KJO@#E%*_ &9*P7PR.! K6Z;ZW0S M KLBL[^#(B4RDL&O-@W]ZNE58)6M 0XQP4P5:ASBUV)=XM>@_'C<\7V.5V?=
MJ':U/EH@4H<\2ZS3I7N)|CK'IM*#RU-F#[/lH#B!(B:5L[3U%/8.9_1 EOCJ M,X&O[HJMPE85_Z0$E;GWC[C$C6V-L24%@-GLV(=!"S*0-QP((_lCB<"?+?E# M:@9* 7Rl:7)O@UF\>3*:8S:0EMR?
B(OD>CI]1"9QFLROI_#SXG(&@TPF %=R M-;TY^W[0T4/M.LS3I.K"TPR7LSQ_9OI-M9YP@<[QY4U]**FGM'O:QDDZ:K@K@/N M4T$=O7J*G09K^=S'PS][?8H#9=@3^=9>'UPX
**SP!A@&N\=H)-[=QP_ MCR:3&<7H>0./U7(KEZ#I_ZGN];*!*#Z\A44(\0.)=R7>;("IHESOD06[A_8 M@DF.T@[]!*[D#Z528X\=*ZCW,D]Z*_#:P@*(($BK_4NKG"&U9,26U(!55SI
MY72>V6)M-,4NQ:Q!*;'WZ@I'&A58:42D+F'MIO:WV\;'])K:P=% 6KE2Y(5' MGD(E$X+;#$7R.M>9F,+0L$%8P#4#@M]KTO>:O!G>"PTX.?H+$%/!2RZ(<(W;]
M;4Z!HMI(VCB%@&S/@WB6Q$<@X^+@"]T),$4 R1WU-V+QEI(U?4__7R UCI8V MQKAB"[W2-K5WH<.T'R Z8'^,Z, T9V4UF^-8<\P(!V^!$8A;-Y+.B ,
[4+G=9CDF_PRL6]&0&>;2NS&".VG.HA3]@*U?7Z!BOY./AZU+EQ-LII8,\NIKTC^)R#@UX463 MPD/FU1'S;LRRQTJOQ#*$F9Z8_MOUQA_+/3+4@\'7[
M%&EA2Q=E5&IE6P8E;WZQ>5^?;71SCL7;MAC--32JMYQL5D]<]>\@W%]'+6; M4&RS-"5L.5J,P7@8'2UBCVC;N)?V9*.*ZS,3/Y5C,1T(4WPGFN]'L2[&,4W?
MQEW))H/.D(D5%/8RHO:!7M"Y26)/1BK1;ID"G!*X;"-R+ BJ M@#J;I2V4Q/FTTGG&PT4\,QDJP*!CFPM*.OVS@JY0B SRIY%O=-#8W@83Z,X ML4DHDKQVQ-
:Z>PM.]5URL&WY9WX15M8"I_%H3#D82;;K3ES=C"KD:MZVVX1T M&5.$-H,Y%+*K 5H(RY D!-@HTHI=7XC">AJF>HU]%M;>1.=36Y@30&HAXRY M*7..^^1GEWAUBL'F-#
0\6WF$'.#+')]]B!^DA;3[U1&@?A[5WRZS7@EKL@$ MIN^G=^]O^WD 9I(.))PKG01UN3V![[*NZ)RAQD2.Q1U'\)G8A$D^ED?,G@.B0.I>]=SR_VV1S8/??CN^P_RW7>CGZ>82T '-
&2,1Z,S[L$K%]EW/8*=(B F=_#+_&CM>E4]0"H1RL,C#$C:4O% MR,W\9/BHN>O[/ >LK"DP-C")978ZB%,7TW7*MQ?J4FK M*:GC&V2>^VF1_C:?K88'E5PEQ;ZGU
@=!!,]6]86Q,ZB+]3'$H\H+D?B%+M5 M!WUIHF!380(EVH#V>.O^=00Q0QHD4AC=%!O MG9_,S=IFX[>=+-ZC^\Z/01'WR-(S;;NYTTC_\7;SP7J+340'._"^YK;K"_A'
MJGKZDC:.ME_[%8^1?_)F?N4?ZQ8_XA%Q2V[[/3BI@ AKM^;ZWT.,^$X.;ON+ M^? DGYUF+K]=V+&7 X9WVAUEKZ/.O,&)RC7]MU?
%Z/.\6'<.>R+B^"/+#R:@TK1K4'1V3=$S2VVK_XVVV)TPV M(M:.,@0FD**V

2HL^BW)YHW9DK'P8N^FH M*.QI=1Y#H$WR4M<^Z'0PW(.ZP@WEU$=C[$;(>_^3&6CMN8/ZW$D]G25K'R][@5?)HJ U,L]SJFH*]?04?(+*T77YDKI#<<;+/ MGIO1!L8[J6-CC7O1@^P(8D*:C>LJXRR'32-HB#R!9-L@B&J[I2R0#G(N$(U; M]Q7-E5M>#X@X>QAG/+L@V;;(7PU3$*CT5,Q8_,*RHQ2/5LIN[CF9'&T7YIT7 M*Q&L?P"N.*ZV@X7IS:-
)S.l@LY@=&DI-;I'8G#G;]2K/TH/<#*] M#]JP;'A['MQ@#.K0\?\E"KV\H!:_2VJ12V8W_'MR->T'H=.;2S&=7]+O^>2] MOQ%X@1N(\92G)_:_;%O"IOA[4O;H=]^^=$]]:^6/5 MSM>Y3#^14'3Q81[S A]I7Z8_Z MZKV2L38WS&+\]?:_1];EQX_S*4@2G7X5A.6DL9!:K8L=+O&1IV6ISID\WWDC MV"\JA9:#AS_:0< 5KUO 7=II,0&RJT-MGO9(NOIW.G$<6?
2BQX'6P;Y?+A8 MQGWW=:M@+%3&^V0=_]X!ZS*&1W"0D /'-X+S2]E^#K)O[GPI<=$Z M.3Q)_PPV=Z+:+W>WSV+""[@4>$O F>#;C,H]:L/;U4KGVNXPL&1QD7$F%LGU M[K$<\
[;6+S3UH]:MENL2M>E/:2I5QBL:0N>[?GOG3@SGEYC_9IG28;::2AV MH;WE1I%O!-?HU!!G-'1QKVPS?.LH+UDNCJD$CQW!;?Q6MFYL]-WG_1_;2;KL M3VXHNIAK114V# 51CNF-
WCL3])DJ2FULLW5O'\<: M1*3!I+:\A+U-D7OEI),:JGC2TX[\O%4A9(E)>;:M?:-]_LEB.)2_'\ M[?;]H\68I&X)QXUH49'Z;>3!8WT^VPHQ#^1[8OW7R++#S',QX ^#^^X[*)Z ML;B*
<1VS"K?P#CK0_F2KX<9M?--7^;L>,5O^>#1_V&RT7?/0>]^/W[4Y<+03 M;M2DPX CQ\,9Q7@;IO?UW3XB$TC&:8/'Y.B ?N2HA"-#8 BK*\5[I"G%5AU& MR\/(?K0;I
L@LJQR36,!43&N=/O-_9F9/AH,&M3=D6-NZ=[>@J,*U.,(@&9R MCA;&&''Y]!CD=*P>;CHMZ)A_TV&-Y'C%*+EAGYN#8T.)3U>S]I,#1[X/M^L,^E-
WMI1Q69=E9L^9=N%9W*>*@WJ&M^1)PD,Q7=6![59TH&.;1GX(;G,: M)#FXBS/L#I7NL+]<'CB162MPP,'DE]1>VVPC8PB("=S;MK:33[=&KZ\VHG/ M4>O_^S[.WP8K=M=(6 S
B!^/$^&CIX;;F1F9QRCM)..XX:-IN=EEM%=M>^.0 MQ^LSYJ=<&'=8C,^]'SG;Q#;KAIUWY.Z5NJ#-!D2T_:83TM#9'-PQI%B^6#QR M\(HJQ GF&\9JG/P&PD AG0WR$1A>-><8J2RPMQO]"Z4RTZLG="4:$=(*ID#. M["C+?,V)LVG0L-'YVD^=7?FFC>!C+X%VTVG@B/HWADY?"6O%H60-GFW=*0=W
MP]+QT)\=>1[\D1GPO=;TIW0,^U;\]V;\5>'^6L\M_Y&:]G'^4S\0?Z_1ZN5J M!:].QE<7YYRK<5_JOP&BW:79&UA3D>^W2OK;6Y3+@\U>W&OG1*9CPI-^/99+(#"3FDC$H#69#X
M>U!WRA@R!#=^]VT.VB5I8O>YL?Z68T;UY/A0:Z+^"_U3AT)JPF7Y@PJR?,V.^X M$'OY1@9Y<^7LU3@:#6OTP*'R;#BG"TK*?7#HU9@7;NYLGNL E(,7LLC$G2V" M+G:J2+7R5^.
)6C@.*W-O8[F9E\PMQ0_P\#>BS\5FO:L MP;I4Q4@DDZ&836;S9^PE;;P)VTN^)5[Q1OO46%\Y)?YYN_'!@33_>@J%N,C\ MZ45H(UWZ4J;]>H"=XI5[4(.;%]|-EV-7SX0P;T.8/V?]?
T_9\^:6(_$*#\I ML-Z+CWM% TM9'(6)3:ER ?M>V.U6IVHHC-Q8X62P[LAV-)& M!S*).?=0B+VXEX5XZR06\]D=BCMI-(2FT)+G4^^=,A(MVM$KGC5..'4;Y5&
MPG(BGJE!$Z4\QGC"7@8X79_!MJ((%^:*2!HZD+IH)>V>KW1Y>X;$V M+H)R.>!IPZ2NT\K2>$L63)4IN%&H RS:DM0&G=%.*S!Q+6]?%"BL %1]D*D:-*9YWN>Z'6N6<^GU:O/?,-
)O7H/WK*2T9=8'8 F'FSS+LX%S%C%:2-(-U:@P/3 MBY=LQ58>F?$_7)Y[W#NE>BHK[O6G7L,91%.Q:#8/9Z2>)*&):)_.WO7QXC#% M]V(Z7*_F_+](5OA/ANME_)[<+,_N]]:%
<\IN=Q8&3M=B/17SY.P7Z< S$_ MM0QAQ)>*2PIS'(E;SF-O\?Z:I=31Q*(UB@F/'6A5RRG#NPTR<>)I9T?^'AL+ ME',I]'M1^2@"IY6X#FIE^.L(>D>FWA(?1]^0AV^"?]I!*L*?C*9?
#W_R)/S) M_S_\3S"-\7FC4I5OH&O)M O @JGF'DK'R XR2BI#QDR MEXQ6\:T/]9 [GS209D1J(]! [(V).!)CP%O(#VR!L)%OT#*_K&XI2) MNOQTS#$Z5.5@(X/9/U]??+>:32]>^2^N2%-
^3VK_@?A)46EV#]L;G (]ZX_ M^] BBW:,"_;[<+F:D_HNQ!IZFM#C4JP@<-P*+1S.5NN>&K8DQ$J+R>3L)^7] MI=!Y607F$O!4D-27L+V^F(L?/M/Q;HBSY7
Q6]8VTLKQT5E"PFD'O!3+X3I) M8**[?H_FA2W.FVG8DXAAG8@?P=*\T*CY8CGQ0N;E*_$.\#OTQ40[H(9+'BA= MN;BE-Y4'#;SO;TRJS$IG'U"N(+:>7<[I
XQ0:.!6&:6&^.2)6@]0&DL$-;#* M#\T2P-"%0G&3E0Z%*.<.K[%2I2#ZK2& M(1.;8QB8)[VHTO"(^T/QH*TY06CDX3.3L+-U-F6[*5[!B:4R4#%9F;3V
M<78[2$3D,Q3Q*:X.47_Z5XNZ4>6EL4>EZJJ>2\>F_.^%)W$6[>KTPN%B1ZP[MNA?@ M?,VQU[T*U()DZKM&$ WGM4-S9-?A-V^F@0<8KNG"J9[C+O/61MAV:UN=U05^#
MS)/*UBI$I#0"XT\(I"HX2T@&W$[B$E-O3CKI4MQ+D%0C D$=08N3^K?G)V:V M^M0=UXA*Y$*MD3R^!$[-8C[3>4[*MB*$36[=20L<=[I""TK5UI_*G^(.= E
M=!NZU!&JADM_9O()S,NMJ23,#QZZLO'N//A*E=NQY_GB%$X7N,WK+:U_0)X M&S]\G8;'SX<_2[=#;G$8;#%U,KI8#.(%MWD)MN3/8"@M@LWY<:^P[1P-0/_6 MVM"\T
+M=!&;_P)02P,$% @ [X,-6>Q=(D'A @ F08 !D !X;"]W M;W)K&ULK57;CMLV$'W75PR4H&@ =76UK=W:!K0. MBJ3H(HMLFCX4?:*EL4Y$(E62BKU_GR$E*RZR:R! 7\3;F3-
G9LC1_*#T9[-' MM'!LA#2+<&]M>Q/'IMICP\R5:E'2R5;IAEE:ZEUL6HVL]D:-B+,DF<8-XS)< MSOW>O5[.56<%EWBOP71-P_3C+0IU6(1I>-KXP'=[ZS;BY;QE.WQ ^V=[KVD5
MCRPU;U :KB1HW"[*57IS6SB\!WSB>#!GST_LO_G8*98-,[A6XB]>V_TB+$.H<9U]XZ\RM?, MLN5FL2QZ4KRH/5=,K)SBY75:4[K.'-D]2P M[K1&:>$/SC9<<,O1S&-+/IUE7
W\MSU_]@S_%_Z4M'L#;V2-]7_M8I(Z"LY. M@F^SBX2_=_(*\B2"+,F*"WSYF(#<\^7/\-VS1[8TO^ ^&TP8^'NU,5;3E?GG MJ9!
[QN)I1O>,;DS+*ER$]$X,ZB\8+G]ZD4Z37R_H+4:]Q27V_Z%@%_F?5C^[M@A_S.\+O'*X\O!K0X@Q>*7KFQH+: F%@]P1U"RYW-P'5&WV]7V.%S8;L\S0*
M7/'=#!9_8L7JT^(M&P2SY9WU%H:/KIV$XA8>N;<4CK'8: ML7%:7D(9Y45&XS2ZSO-@???^.XHTB()I0L#T>A*L*6^\HEVK.5V8[\!E5$Y+ M***LS(./[.C#/V'&G*0II),HG4Z"/I%Y-
"E3^I;7L^"CLD3#?BR-+R'/HV3] MXLC+])CE\-2-B_:18-ZYYNBJT$G;=\YQMVQ[Z]Z=O,-WC?M.Z9W7!H0N"73 MY&HV'4'WC;!?6-7ZYK-1EEJ9G^[IWX': >A\]Y0]+9R#\6^T_
I02P,$% M @ [X,-62L1,=&'" X1@ !D !X;"]W;W)K&ULM5EM<]LV$O[N7X%1<^W=C*)W.VYJ>\9.VVD[;;R\7S+TT+QXIU?K0"_&5Q>E7*DI%7XI;QV>QJV65!?*>&V-
M<"J['%Q/7]\L:#]O>*_5QG=^"_)D:>T'>O@^O1Q,R"'"5JR20!HE_[M4;E>>D M"&;\5NL28/=WH_U;]AV^+*57;VS^JTI[#^G)P/A"IRF25AW=V\YVJ_3DE M?8G-/?\M-
G'O&38GE0^VJ(5A0:%-_%<^U"H")O/GA"8U0(SMCL>Q%9^+8.\ MNG!V(QSMAC;ZP:ZR-(S3AI)R%QQ6->3"U=./1,_&1-6'0Q MC4E5VI62-:I37*^<4F"-
M@$(*:W&3R^0#JLBHH2@KYRN)%F4G0R+/!AB%^LI[0!IV]9BRSZ84"I'JYV]NV]?$BV ;N<3:LD>!)+\BK5 M9M6S/X734;&H4!R.%V>3Z:GX42?@PHZ#(W'M04
^<7K)H1!O88(X'<&E/)=+ MZV*TI4D?"WM^?5>59;[MO!VVAK;OAB*#.KLA2V4_N,U>&R- -$EYUT83U792
M06=5);:I+%/,PT9YC@O)2>Q)>=!;BS)N8''8ZXB#_2PT2>ADBZSZ8SD1%BHH MXM(T:J;EC;OOK*B]LW[W?[Z'37_7 -H9'XN8,GIP)ZHH_F4F^@W:GVB84P
M1R2%FMR6XEXF":K*(] QWP'M-7! \ *GENMM+A\T&TVJH441UF$I//?"V" 2 M61%ZEEOL0#0XS+;RHI1A;5?*= &72),H-]JKKP[P"YDJTE.5F0-30\DVFI.)
M%V*ZF(PFZ$5Y3NCJAX#]VF!)R-Q;DH,.V@-E,DTU 1+9>"%FIUTEC V&0K+6 MB$ISV+UT[1B63G:@5RO4:= KQ<>N43$@,,Z^8\Y8"1^:8OH\>]0K85P8HVI MIP3&-
=6]KTGI<'VV0AKL308$0@M95Y0HHVD4F.E$"MQ2!,P]:!<@CS2&?0> M0\0_6_3=-!Y26Y04XK9%'A<9//9>KR(GP!,,%"#BHQSS\V%R1<@BO&/-Q$D%
M4QUKC>2"+3'A/:)SBML$I'DI D8ZAT"!\H>[]#?9255A=*:32&:V[2*>,I?) M>Y0(0]B '.#-A4=5F%B74F+P1JED:7KUMEEK"5@\E&\>JEFJG+15,D%PC/NB" YSKK*W&1CLA
M33!R5A&3E6^Z:=MF=N<5"CR8\@2?-OEH?&PW.:H&Q!"2:43#S@194+0B8/&. M8Y\][C"-=36F/"4SNJ=V6NONPAV<0-NX1@#]PF%4S'Z9(GL/+ MZ-@OQ'QT MWN*8^]A\#)R6&
(]E4\<<21L6BINW@7(\N\,,+OT"/]DA)+.I/E/W:H[H)'F M95T/M2W'JJ^!SB<[QI0!$\E,*4Q5+!63"E69=3[V610+!D12ZI!NY$!R#%AQ M)K5#L\JKC[%[A+$+B6F41V]$]\LJL 74S7,
+!++L!Z1"Q_$GMUY$FXA6$O M\OVD/,\B: 9F14;X *72I3R9)+-5.00FXJC$C(T5@%D%$MB-OWLLYN&DH)1 MM]PP@'.ZNE=PCT8@--4M11_A[]:0(M,PB@@FU
D""G$5IV)8$0X,V0KAM4), M4 <5X.DTE*#[+9$ H=;I)%)GS0B5;S-83V4=DRF TW>(E.%"GUP=Z",*<1[N 2#(\BFWV+)#1AI@.1XAS M/#]"X$G.CEA;=UC]$75_2K6U!(?$:INBO7-
)>;_HSY[6X[@^_N78MYJ!BZHE MIJA34M3ZVHKR%4\1]2F8K#OEGFK4NZM5((X5((OI2M,\YCJ^^0-Z/!PAHHC MY]+_84KR1SI/$_)FK*B)339U]"RQ7',A\DS?? T9/L77?&)S9^A:S<-
B9%1^ MGVNYU#E7CA?3)UZ^N6#2FN*87T%0>;??Z013QRXZB+SN'+.D.9G6_W\]MKT;S MMK616AK;1]?-]V$S\G)4AST0/X:H>2YH;:E%.'!/:0N$\5!W)/@\L_K#3\X]V M>H*X-
DY_HDM/X*!3)'1A(5YIVP$;UZ^R0Y6TFP"?Z\W-"4NUJDQ=KVV?C@RP M^ZP0Y!*#,VYV&U_? I%< MQ'# '-['H<>Z]/>H\G_V0VQ=42?OE_G?S80KPS MT>]-\TTD=E/-2_),&T,N-&,+8?
7+X72Z.'EZY 7+V43S,7R%.W!U>'S8=#%< MO)J<7.]1@O;T20L'\] GYK/I86<^ZHR7%+HJ;\[FPR\GI^+0Y\EQY[-SH=R* M/ZY37T(AQ2_0[=OV^_UU_&R]VQX_ O\DW8IND[G*
(#H9O3H=Q*MK\Q!LR1^O MES;@HLD_T=@QI- &K&<6PU#]0 >T_ZMQ]7]02P,$% @ [X,-65Z/>2N2 M P %0@ !D !X;"]W;W)K&ULE59+;^,V$+[[
M5PRTQ2";"6M3#EIRV239+;8%M@B2;?=0]$!+8TN(1&O?&Q*"MY? 5/_9Q M.#'(^2L&\=X@]KR'BSS+C**Y5RK'6BG36ANX5WUUD2NEBXI#U;3:4UV=OE@ M5?
%8J:9$;7Z&3]_[VC[-0TO([CPL]B@W TK\"LH4OBAI*P.?9(GEN7U(C(ZT MX@.MF_@BX.^]'$/"&<0\3B_@)4+G0""AM;1LLP2I0$F'K8M'JR>P%0YXU?,U3D84.B&?
QO#U>0.5,+"/:'E&AOFK)-3K M7PHEMZC=%=26M6% (PIJ8WHA"P0"6*N&9HZY&E$UH:^FCUA@NR+62<1&KK1< M?26CVU-O5>?&A2%
(A"UD"33,C*5%+3>0LRR;L=ET"AF;\0GC27QN+W9"EZ^: M3QF?<);E*4Q8G*8LSY+]:KIZ4Y],$\\/_.HI|[21#C*#]F+6$X0:9+3*LN(M3S0:/;P5HNT:]81(INELPA*>P"Q*"2(:?1-
:"VE|&KM>%Y0,/*^(*,[8-)H> MOJ.ORHH&HIS%LYQ%/(-HPF899\DD@CL:LZ@U41FJ[-IG_I@2GP47I=/<^+2P MT_*@BB@AXHQS_W>(%"%U1_QJ_'M;*5W_2X)=;2L0T D-6]'TZ-1_
C[F/']N MW3'-@0MP.W3E?9)!\5;^XY=F0'@RJEO4&_\@&8IN+^TPM8_2XYMW/8SZ9_7A MP?PB|*:F0FUP3:9\G$T"T,_C-&RLZOS@7RE+SXA?5O1NHW8*=+Y6U*#[C;O@
M^$M@^1]02P,$% @ [X,-6<"($[]A"@ G"(!D !X;"]W;W)K&UL[5I;<]NX%7[7K\!HMSOV#"/SJDL2>\;.9F_3S7CB M9/>ATP>(A"0T%,D H!WGU_<[$E1LB3;VW;:3OMB$2!P[N<[!S!?
WY7JDUX) M8=B7=5[H\'*'F.KEV9E,5V+-]:BL1($WBU*MN<%0+<]TI03/[*9U?A;Z_OAL MS64QO'AMYZ[5Q>NR-KDLQ+5BNEZON:]_$GEY=SX,ANW$>[E<&9HXNWA=\:6X
M$>9C=:TP.NNH9'(M"BW+@BFQ.!]>!B^O8EIO%_PFQ9WN/3/29%Z6GVCPP_M]1_L+I#ESG7XDV9_RXSLSH? M3HY^9]>?>3(/1)B%Y;YMK^97?
-6G_(TEJ;&7[Q6Y1U3M!K4Z,&J:G=#.%F04VZ,PEN)?>;B[>=:FGOV M:([U\UF="CC!=" 655[>"\%N3)E^8M>U2E>PBGW->)&Y^1=7 MF,O8FW*-Z-&<'/#ZS$!>XGJ6-K)=.=G" [*-
V:]E85::O2TRD6WO/X.>G;)A M]^Q5>)3@+W4Q8I'OL= /XR/THLYXD:47':!WL^)*-*I>\WMKIDNE>+%T)OO+ MY5P;&<4
[ZS[E'>UX/VU*QI>ZXJDX'R+;M%"W8GCQW3?!V'IU1/*XDSP^1OW? M[/;CL@7^B.V7C_TK!$0P^/%^AA0HP?3PNS X((JG.5YBC,"US^^%-MQ@<&07
MQNQ&5$:LYT)9UAXS*V&EY<4]XUE9$0F:VPC&=B5C)!]],PU#_Y5=0S-V'+PZ M]=C=2J8K-A(76K&@;P:"+*UG#>4MNQ*VH; M#*#T%/6/$7?>X#5*&1(NM:++(D4+H6WDT>*%5-
I V7MB\PLO:C0(EC!GE5"R MS&B^KJS)1,'N!5>$!B20*%)R0)BU^P(;OS,/7!@%RIJL$:3B2UCO]^W'4:)'SC1(T!G"GPBX@@=F)*NNBY_A" M$#>$Q*K,FRA#BEJE298(R H"9L?
G]7B'G)>4"=F02W$VI]$X>_U$G M2]<-5QC!],C M]O$/IM8D>7IB5;6B)T/^+20BT+AH.G$K[H[L!?(VV:Q JCR1K@GP7,8 8X(5+ M]!X+O,(TM)<%7AQC0/H0?
5W/M+,L>1RY8YH$+! ;(0 M:0.G%*(]2S04.BFV\<5Q?Q)OX U: D"^P>E-[VDY]^2@ MNUC(5!*7!^C'F\H.\RH*,.6PE/HXO7#B-O.N#$6L]D+34',;SH-U./ -#&= <0_+@$9#Y8LS7'CL_Q
M,A7*X&C?"V-.Q:1+LU[JN:HF%>$2FDDKQR/9+!^"6(-6?VI0:@?3$%N=:?)[M6^%_$'-ERBPZ4BI[HK$>,XM^D7R"00#A(1^9W3;
MSU";6!>B.\UO.W[%0;"1"RL#;QK'7AQ-.R#9:RB0&ANINH]:="[P=AAVSEX,;)^[O]FY)9"\&-UN-Q!:P&?8] MN0W&)CU7Q&;>#,_\?PH9-
^R(!B%\>#')K0"+YS&7ICX+!Y%X\';+T*EDC][M$X8LFL13=HHWLV#PAKR6-PZ"M19"&KLLFB9>,J9U.+#'R'1MGS%IMYD,O-F MXS%M#:
<[6X63O=6#W:UCSY],O6D2D$;AR)_9H&DZ*4?GH^VDR$_41;%;K%Y M@<;4(@:IL12%4&[8U!,D,=Q:4^MZT&++#HS0MU;-80-1U]YGY:)^6SEIT]E%EWXY>-=E5!L
@W<;V@^]G7@A MPGPZB6";Z2@*.F>'B/V)ET3D['@V^,T1<"B7NX;^!!$1P?,!@O*4S4:3\1'/ M^U,O"1*LFXZ2]"_3 U^A>$VF,>09C^*XN;0X=E'SO!L0]@BUMIM^>W-]_/7UHGO?K
M"ZGJR/+E4HDEX/019-Y#X#_MQ!]_3^Y!.[\]_N83T(8F^2Q_>/ZM&C,4.L M6E@TS=94#F3VHT/A%?N5-M4 8RC5*,DYJM]2Z M>_8L10$D2>^/9I"5%C9<]S[9HZ*I'X,6S!+)$
M[3IW"[K5A1V^0768=O#^_NT7>A;L0]FE^HNY79;VEXEF&:*O7!9HUC*;)OV" M^V&E4$GZ_W1B-ZC8_8E!9X'V86!KG2W W=/@1))W<;Z']OJ4;0\':%G@)Q0A
MLDV&B, +RG;DC8PO43+AIDEH?X-P0@44Q7V,W\2;Q=/!CZZ#<;U'!GB1(\F M6\!O$L6T:QJ QB2*!Y.1#%(9O9W/';ME!=:5G@83\/]'J^+QG[L M:WMU==S8N3MT.?
RLBZ91>'@A9ENE]N!#COF6FL,9 RKDMJ/&&E@CV$P1D.C* M5>_\W@$83OXX'E$B=X)^W94M+8'@SQ1,;JM2VFR9;X61Q42.F&ZZ=$YYONQ? MM82CH*F ML$?)6ZT]\&A IK_3?
Z.-SR\?BI/HYV?1S^UW$03YZ+O&ULC59M;]LV$/ZN7W%0AZ(%"%OO MEE/;0))VV(8U"))L_3#L RV=+:*2])4G/S['2E;M1$GV!>+//*>>^Z-Y\5. MJN^Z0C3PU-
2M7OJ5,=W%=*]+"ANN]!+#EDXV4C7*M]TW#U?,5UG*W\$/_(+@3V\I8P72UZ/@6[]'\ MU=TJVDU'E%(TV&HA6U"X6?]7X<558N^["W\+W.FC-5A/UE)^MYO?RZ4?6$)8 M8V$L
J?/(UYC75L@HO%CC^F/)JWB\?]_JOSG7Q9\ MK\V=W/V&>W]2BU?(6KM?V UWX\"'HM=&-GME8M"(=OCRIWT ^&',O/W/#50LD=*'N;T.S"N>]TB9QH;5+NC:)307IF=4-Y_U-
J#;>HX+[B M"A=30[CV=%KL,:X&C.@5C R^RM94&KZT)9:G^E/B,Y**#]2NHC(%+ MGQI!HWI$?_7^79@%G]X@FXQDD[?0_V=&WL0XSS ,)_ 2'!XJA(VLJ3LI1&#X MND;0:#0)E:G
T'$AFZXWW+61W#C1-8EX^_S^71Z%LT_:=H8H@+'9*K"E$,.X\CZ(EGC(7I-) MS0"?"NS,8,:Q&(T";V3?&OW1N^D;5-Q(=>'=+C] A@R5D0Y0#1;>*D&TBO=VN$LTEO^(5W]2V'
MEP7B71[I)3O+5H/0NB<*UB:)6UH8>WD;#:,LWF6T2L0Y:E<^\.Z540A?5L MP.A;85Y%R%B0!FR6)Y!2^B(6SA+0&U>*VS@:5VOBHI&QFFPPVC&6LC [? \5 M1/?7>+#44] 48-
/5\IDZ9E 'T?V5]ZV@0->X M(=5@,DM]4,,X'#9&=FX$K:6A@>:6%?V#0&4OT/E&2G/86 /C?Y+5?U!+ P04 M " #O@PU9+(0.GZ84 #V0 &0 'AL+W=OO0"FIK%1%43?
+EJ]5L59.9C>S\8CC2:52^P!V@R3L M9J,'0(OF /H]%P"-;C8I3S)Y&8MDX^ M-R_/SERQ4FOIIJ91-?RR,'8M/7RTRS/76"5+6K2NSB[/SY^=K:6NC]Z^IN\^
MVK>O3>LK7:N/5KAVO99V^TY59O/FZ.(H?G&ORN/7YR]?=W(I9HI_ZGY:.'3 M6:)2ZK6JG3:UL&KQYNCVXN6[%_@\/?"S5AN7_2U0DKDQ7_##]^6;HW-D2%6J
M\$A!PC\/ZDY5%1("-GX)-(_2EK@P_SM2_T"R@RQSZ=2=J?ZN2[IZ.XU\GK\\;(T$SHJPS3O>YG+/-L_$ M#Z;V*R?>UZ4J^^O/@,7$IV7D^]WE08+_W=93<74^$9?
GET\/T+M*>K@B>E=[MZ(T)_.;N?,6_:_Q@1F>D_'Z6$LO72-+-2:(P@6I^R#.GK[IS]HOWTGG79HLX](N_;2/:PNQ2>G\OWSEMP6>7&./^!:(N?5@K"JC#K
M1M9;5)VNO;)Z+0H#9JZ=*L5"U[(NM*R$ TH*PMD3<0]+[WBAD%:)MI9MJ;TJ MIT@5-OI&4BQVH,1B08 MO+$:Z#852 1KD;-/-;(B9I[$!'9OU\!,
(<7QG_YPD95DTI=FT)@E7;"6ZU%:41M?'P5%&U);!85<1" MMHIX6!CCX3G@R*I?6HVZG&]%$I7V1F-7RJM1:Y#MQ'>]4.NYLN+]@L+S*K/A M7%9D%2XX&^D@@UI(R["Y-
6M6(/O!N+EET)_THH0OQ;R%/POP/)0O:/D_)"+[M&I.%G499!5<"N7%[[;?LAMT^87<'J;R&VH6)T8BUC?@')]NF 15QKJ$/I_M)=37!@RFT(9($&K%^5/7:,*+!T"U&>
PLL5>H!*\D_ JI#O%9:/:" $/D M)9RI*6!:- H]16- WT%1!HDK+N:XXCH9]^A[%P\?^4R M-WP7V"'"&;NBZV.VV0#EK%VP CF76JJ./7])DL8I>ABHQI1,-9T

M@DT/E'I*A6+H&T;E!]DGC/D!5/3N<+B$9@IW]WAK'AQOI-#0 OI#1 M(I_5=CAU(]'<[C66,# 4G]NRN[_3U>H[:0Z-!{X58]J6M0X">!K' M)Y&2\1Y7.TUO!]W+;XRM6Q].VO&F7"A/-)-/#_5K7(:TABW-#A")9X4I(A\D M."&&8@I*3OI'"^PD\88)CYK-/ Z-:0*TP@M%\8DP7"A\:[&-AOCADP)&G.86ZD+#'H/M\L8+\F$ -B^X=;4N!.',2XB M\H;3,(86#21HHMAZ_&L-GC<\G.F-H**W=,@_>&9,'%,\ 1Y!U_&"W;J%=-94 M>_'DH+4*T-0=QJ8!(VO,@WM"N">2HI:K O."/%75'3T='\UF'X^@T8I^^TAJ M@"86PR1<-@O "4A$L-F-BK,QLO_-26(W1]
<:O:QNTZVO^]99@9 /5Z6_:*V MOG?S%6LH0&"\70,=:*BZ'V.4OB1_VPIS^M[W:!'7BUI: M780]0(\G3X O=*Z@ 8-!6R@RZ_Z]Q\),=3268B9! ZHNLGD55VG2BV>,7 ?9WBA0J
M$09,T@R>!NU8:/"XCP]_DT[GBB\KUERTAR3/Y'E6<+71-6CC%@L'XD\^'I=NY.QAL1=;)BM$@\W9; M,,:!J]]=-DUSX*0+GG@'U:J=$_B1&7C*U)DYXL6P.-+ ,\)\][UMCB)L#NOKW
MK^"3?@:,)=.-XA[>:A30A-J[=RS1OV?6& Q_H.,AV-O$\Z6X19^ W;H=9I.] M3#(9NMD W6<=1ZQIR=A1UDVEXHD%=['+MDY7C?,^.^#XDBYF=I1\'CX-
Z'E%7UQ&9HFC!6I)P0XV7NW8@WX["?XAPBH2XZ]!4EL?' ML./H\'SG2DD9AE?0B2P\LGQPUJT3E<S:U-C\,OO)?.77G(!]R-]#H<;L) MO3M)IQL.E?ZB<03
$U).PW$JKETHE%6X>=&_%H>>:!U?L"K:-;T@\I -VD@\ MK$=D+/!-\@-GJC;7+-[WHRE6C,DLH7;Z2/=#AB&U(V#"_ZHN$X+"4V5 #XJX M'E[,Z0?:]>(IXP'N'0;J1+QO-
:92!0!2XX1+L]-084_A,0E7F/NO*T2M8"JE MUUQVQ9O1?&G&]+:IW#A4L$$\;R M-+SQ//?K9@PT!I#54*./^"9BOSU8T("#.,]?E-AI0?OG/R%BVJ;<.RB.F0*% M9[>;*V Z/JV72T7M#?
HHI(2=^]<<^&K2(7_'I5O0U#Y.P*/;_($O $UH<\HF%EL3IMFT [WI9*"*\C ME*N_0TFQ>C&0"H-!;/31-TSKJF[XOK]WT@$6Y=?*=V_$1?1@;#X_]-\2S.= M90F://5"?=R![G-
,_EV&R6<1,S&NB4ASI^X,1=@+\@>ZD/NATF/0(6OYOP6/ M3[ISS5@%TKTZT.O.V1<==#F0'&39'C DB]B[IT>$>&&IVF>C,:V_6GRVE0_>2P+M+STPZ4W14>OQT 30A?
FASSPR1N2RKX(Q87@-X.N8)K.BR&\/M.;?P:ZK_E=]F[Q_G_"/"#M$L\]ZJ[4 I:>3YI?'PG+;IGS!V\:>K-] M;CS@7/ISI23X%SX O^/;GO$#;I#^5P=O_Q]02P,$% @ [X,-6207/BK\ M @
K@8 !D !X;"]W;W)K&UL?57;;MLP#'W/ M5Q#>L+5 4+O.M5T2H.E:; ,*%$VW/0Q[4&PF%BI+KD0G[=^/DM/TLC0OLB[D MX3D418_6QMZY I'@H53:C:."J#J-8Y<56 IW9"K4?+
(PMA3$2[N,7651Y,&I M5'&:)/VX%%)'DU'8N[:3D:E)28W7%EQ=EL(^3E&9]3@ZCIXV;N2R(+\13T:5 M6.(,Z6=U;7D5;U%R6:)VTFBPN!A'9)>GTZZW#P: _)*[=BSEX)7-C[OSB>SZ.
M$D\(%6;D$01_5GB.2GD@IG&_P8RV(;WCR_D3^F70SEKFPN&Y4;]E3L4X&D:0 MXT+4BF[,^AMN]/0\7F:4"R.L&]M!-X*L=F3*C3,S**5NON)ADX<7#L/D'8=T MXY
&WDV@P/*K(#$96;,&ZZT9S4^"U.#-Y*3VES(CRZ>2_6@R:RX#S)F/LTV0:1,D?2=('ZZ,IL+! MA)#,<1/Q6'=H71Y-.'XW[R90 ;[I9M=Q_Z9,8O,Z\5 M^DN[PB:>)(Q^U^M[>) M=-(?
P*X:C%_TD!+M.G1*GP?.4M-.MKO;9GS6I*\G\Z:37PF[E-J!P@6[)D>#_M7@2VZ8|-@DP5.M+<$/>W,"WXAX+6&_#YPAAZ6O@_VU_4Y!]02P,$% @ M[X,-61FT<#6F P >0@ !D
!X;"]W;W)K&UL MK59-;]LX$+W[5Q#JHF@!)9(H2Y93VT"2-N@N&B!(TNYAL0=*'EM$%(EJ;C^ M]SND/JHN$N]E+\D,R9G'IX:DQJN#5$^Z!##D1UT)O?9*8YJ+(-!%"373Y[(!
M@2L[J6IF<*CV@6X4L*U+]JN AF$:U(P+;[-RU%WG#Q#W?E\9.!)M5P _;P .9KZ$E!!44QB(P-,]P#55E@9#&]Q[3&[>TB5- 0+]Q MVE%+SC136+Q"5MK])XWD6/YD1FV62EY(,I&
(YIUG%27C>2XL(?R M8!2N//;*\ OU^%1C:!G9ZYEW3!Q?/LFH!'B M \:.E-E/RM6$%1BO MRNO1&MSRBTN->DM[&_>.239:B2CW\^Z8E[,\/+"$5^8>L(OXJ[%-?(;F<=^
MLJ13Y\S^S5!H#5.F?4CQ)J:]<{)^]<1GZVM,4;G!?J/(_\9;P8S*DZ1Z&?A/;4 M!N=DG:/83Y'>8,^&<.QWHOB5@;],(PSH[7@<\2+RY\O,'D>$[++4'D>R])/(
M'<=+GY=@T@ZP;'O7]#0I9"M,UQG&V;&O7G;MY&=XUY1OF=ISH?'I[3 U/+=M M3'6-KAL8V;CFDDN#K++ /LCFCN9SA&7(TV0EYKS8 FORHJT9-W8W6VRO?5\4&:J9&8@L-
MOED)63.-HESI:BN!E=:IKOR0TM2O&6_ V5 MV$W=P-TKOO+U1AN%YMLV1H6H.^VMQ(E?XA2\AH:Q45#)*RF[CRXNHZ-O37X M@\-.':R)I02P,$% @ M[X,-61FT<#6F P >0@ !D
!X;"]W;W)K&UL MK59-;]LX$+W[5Q#JHF@!)9(H2Y93VT"2-N@N&B!(TNYAL0=*'EM$%(EJ;C^ M]SND/JHN$N]E+\D,R9G'IX:DQJN#5$^Z!##D1UT)O?9*8YJ+(-!%"373Y[(!
M@2L[J6IF<*CV@6X4L*U+]JN AF$:U(P+;[-RU%WG#Q#W?E\9.!)M5P _;P .9KZ$E!!44QB(P-,]P#55E@9#&]Q[3&[>TB5- 0+]Q MVE%+SC136+Q"5MK])XWD6/YD1FV62EY(,I&
(YIUG%27C>2XL(?R M8!2N//;*\ OU^%1C:!G9ZYEW3!Q?/LFH!'B M \:.E-E/RM6$%1BO MRNO1&MSRBTN->DM[&_>.239:B2CW\^Z8E[,\/+"$5^8>L(OXJ[%-?(;F<=^
MLJ13Y\S^S5!H#5.F?4CQ)J:]<{)^]<1GZVM,4;G!?J/(_\9;P8S*DZ1Z&?A/;4 M!N=DG:/83Y'>8,^&<.QWHOB5@;],(PSH[7@<\2+RY\O,'D>$[++4'D>R])/(
M'<=+GY=@T@ZP;'O7]#0I9"M,UQG&V;&O7G;MY&=XUY1OF=ISH?'I[3 U/+=M M3'6-KAL8V;CFDDN#K++ /LCFCN9SA&7(TV0EYKS8 FORHJT9-W8W6VRO?5\4&:J9&8@L-
MOED)63.-HESI:BN!E=:IKOR0TM2O&6_ V5 MV$W=P-TKOO+U1AN%YMLV1H6H.^VMQ(E?XA2\AH:Q45#)*RF[CRXNHZ-O37X M@\-.':R)I60]P,$% @ M[X,-61FT<#6F P >0@ !D
H()"FP@,_Q[@!JK*!$(8W_N8[I#2.!ZN]]$_ MVMJQEB53<".J/WFI-U,W=TD)*]96^JO8?8*^GL3$*T2E["_9=;9)XI*B55K4 MO3,B]'G3_;,?_3X<..3T%8>P=@M[BZ11?
F>;3::2+$CTEAC-+.PI5IO!,<; M0\I"2WS+T4_/;IC:D _?6_[*FBT(JPIR1:@R/DWHU$7 M$U]C8N/N%WV2ZRY)^$]2E'P1C=XH\]$IH?S5WT? ^IPC_HZ//!GP<]N,2$0]
M$M(P/A$O&G8ALO&B4[M@*G^Q'7 -ETI+[)V_CY7=18V/1S7GZ4IM60%3%P^, M OD [NSMFR"E[TY@C@?,\:GHLP6>S[)%BL3])>Q763Q6Q%9POHI
MH7!JFT+@"58:2@-4;X"L1(57 6_65P[R" ./SKP64O-_T/*NP0NF>K[\R+AT MSGF#442K,*.Z<+"QX+'/3%8MZL@9B2,O&8>XN.R?3N'+,E0)]:6Z' M\M
Z3;PTH39\$]$URLDX<^Y&BQ%9BP>0#5YOO\0/PMR+TIB$Z))2=+$*FCK? MA$;441IX61J1%%\']0%@-"FESN^@D(1:M(:,HF)*\15'- REYUR=DRSU>R-HQ17YC$(0@S1Z;.
<.N^A@'IIMC6PC$;_'Z,)[OLX M.V"T4[QD- ^](!N3P!"4&X)03L(3C.+^Y7F&^VQ(,ARA/(Y?8S2@7D(31/#V M31X&P;M><9+2(/)2#!_3)R>C0E36"T=?4SP>>N N(_?!8&[D8-
\!X=A+,%1B M6c R364U^/Z_=0"V8A#'Z'Y.8ML'O2K_I9Y(8]QZTP'8VF=[%)T^#B)R[&KS M#P84\K6V8]A<#0BVFU6#=ICT\V[/9EWGPEXJZUYHT@%*W2EHPP']^Q&;R=H
ML;7C;BDT#D^[W.#7"DAC@.]70NB]8!(,WS^SGU!+ P04 " #O@PU9\=A9 MUJ8& "A&P &0 'AL+W=OCDP7CW\6,4HGNLS07IYV9E,51KR>B&*T@SO+#S?)=";5A][@!"!3.J+R:W'-
H=>KN<1)1G.1L!QQ.CGM#/'1F6TI M CWC6T(78J6-E"ICQKZKSD5\VK&41#2ED50L"+SNZ">:IHH3R/&C8MJIUU2$ MJ^TE]\]:>5!F3 3]Q-
(_DEC.3CM!!\5T0N:IO&&+GVFED*OX12P5^HD6U5RK M@2*YD"RKB$&"+,G+-[FO-N(E!'9%8&NYRX6TE,=DL)9PO$U6S@IAI:54T- MPB6YLLI(%.G#ZM>]
M6S).J=@_Z4D01+'K1=6B9^6B]A.+>NB*Y7(FT$]Y3.-U^AXH4&MA+[4XLUL9 M_C+/#Y%CF%4?S_,:RZ*D9Z!::@FB? M$^C/2^",+B3-Q%_:]JD4H[]=#(7((U&0B)YV
'*"\CO:&7S\@#WKN$7)?]UD MOXWI8%0"$;$)NJ$1F^;)WS2&YAW-YW2;L.WL+A3$(L9CDD<4O%C.D)Q1%*TZ MF(G2RKN42XG2I4CM4]:F^,2R@N0/@/E:*%X*A8A $^#'%N+
(N)T!V9HCH5%R MO_:[+ ^@VB^6#4,YB/(2!]4M8R,)86$V%R"4V$?K7>.*\N@!<{+]!'DA7' MZ)S-.B4F+Y:XV?OX(;!MZUC/U6U\O(^Z*(]_W+;T%$QZVZ86.,102#B%0Y1IX M9@1=Y-
%AS6$Y6#.Q^Z;OVL@W'<=!CF=BQT?8,3W+-6Z)@.T[2UBA&45T+I.(MI)$.S3I8P;MGIJS=-%!RCTX6E\(_?1@Z1F)42GZG?V4=#WD&\Y")O]4#T= M/S
N"D'SI=BCX:AFKP=]JJ'FK]B?\01.L!1=/5 NT.C'/!F/;_LNB<^N1C7I M >R1[7CP=LV^95>;_^L7,C31.2PK)(FEB;Y0D$"Q@.BD3)!/D38:15_S1((G M'.B_P+AEDJ2U^X
%7-.W/&4/R^QC&QI.8/JE<1S3"KP67+DUKMR7XU4G<3BCG M#:K0&4D5/+:AJY7IJ@%A0N\:!V0*KC&.E1=5!I\,W4L226FU/MO-IM[!\+ M%;U*%98;-"
[%0Q/..DW18!/%#7.%*B.C*=QJ,8?X;)6*[R.^;5M\UAG&K9)M*N&!:.S2J,TWC$TRQ M'(6UHSG,AY,:?"=A,=I#=F &MH6>%&5-?! C=$W/I:,67_%]7_%:?64-?]N\
MHI7\E0'"KX7S=R,*^N^@9% K&;QM%&QEMUW8BIM K\Y.TP[+M^5CXXI(P)$*.U4\ MQZ$'$-+&Z#"VIQAJSE!70N54>.*0"SE:+14
MHDY=MUFUE>LK71!;31)N[0;2*CG>6,^58@._+=C:^;T8;;:%@\HK:B_0WEX. M/N\RNPW. X6G4*%4Y3%6?Q.3 ?(P/&RS'X2;@-R2I;9A$=N-O>U6>]>I[N5* MVK]>T>.X"SW_,I4_DM
M)(7ZMRZ5!G.:$E5-0)8)L,"F&RJ0.%"A*+!562-$13/ ^ 5 A2 78'BZG@U, M+ OD@MHC-#XG.2RG%H\@06>Y(@)D@"Z$YRN)+89*4&'8=11["$>.:'Q'8W40[MJ'V '%V!:11 93G9K0K*
[K*D[%9%92ONFPH(MY= 966Z\4O25E=Z1=WSO.LW M^3?V=@3B[Y)XR:5QZU)I"L@_HJD? O$2T_XOV2Y+OSKF@\?ZY\&FNXFR [J MF2'@9SGM,=[6.;H?
79I^FV&;\@6WUR_E;S+M$'M%R?*\ZS49.0YW!&+OD<3; M31)OMR;/_QYB[?Q>#+'2 S8.V]U&&@[6@(%;H>;7^%II;D M?(2UYZ#66[DU MR2B?ZKLA 3%XGLOR J7^6M_#7EU1?
@T 0]-Z01(K4,?@AHO[X/* MCF2%OH,9,RE9IIS2L"':@*,3QB3RXY:H+Z5& P#4$L#!!0 (.^##5EM MX04NPP, ,T(9 >&PO=V]R:W-
H965TZYY\B'.L^V4GW1!:*!YZH4>NX5QM27PZ'."]R8OI U"MI92U4Q M0TNU&>I:(MWO#(-X6QAN%B5K,-+M'\7C\H6@T[E)Q7*#27 A2NY][5Z/(ZL?[.X3/'K>[- MP5:RDO*+7?
R6SIW $L(2,V,1& W?\ ;+T@(1C:\[3*]+:0/[\SWZ+ZYVJF7% M--[(\@^>FV+N33S(<G4,O8!+\("#!+[HBYUS3*<>_1D-*IOZ"W>O1FEP8<3)<1= M"?$I],627FC>E AR3?
2K6@I7#:WND(1*-FWT.=(G88^3?BH0LH,%6 *=$28> $NLK+)Z2BY /]$*&9/%_"9OB:ZM?:\?]((1*AK1R6AAFL M]FD^M;%2V"Q(]\$TK&5)'Q.2IT.1C:8+U.>7@Z="(1X(#Y;\^<
P(!VAT]%^ M,K"'LJ[*H)L-/G6,7\N$MS#RIY/8C4DTH3'RIVD[\N-TL"RD,N\-JJH?18ZC M*4Q'$$>#STQQ^Z+Z^Y,D@C@>$68G$E/QG,=TSTRAN[$-XO0$ZBU96=U0"+]WV,7&=3'-
<7%3,+1^(/N2:L]K_*5W+_*Y4]DRJK"1M]BAM4*%40C'ZX] MV0@S./0?/*)MVT=\SM>%"$YTUA0878U*,:IMGNS"R=@UK)0VU/S9>L" !\!@ &0 'AL M+W=O>[.O@Q74CWI)8 A
MZY(+/?*7QE2#,-3Y$DJJSV0%_D_F4I74X%(M0ETIH(5S*GF81%$O+"D3_GCH M]F[5>"AKPYF 6T5T7994;2Z R]7(C_W=QAU;+(W="_?#BB[@'LR/ZE;A*FQ1 M"E:"T$P*HF ^\B?
QX*)C[9W!(X.5WIL3&\E,RB>[^%],_@* @ZYL0@4AV>8 M N<6"&7\V6+Z+:5UW)_OT#^[V#&6&=4PE?PG*\QRY&<^*6!.:V[NY.H+;./I M6KQ<AGQI,\5S44Y&J-
9=:@"14%N3%+4&1: M*P7"D.^,SAAGAN'IAP86H1ZZE,$M-KD0!Q?_^ M(8INE2<[Y1?)4;RX!+"^6;_)K, MM%%X=WX?"KE![!Q&M.]IH"N:P\C'!Z-!/8, ?O\N[D6?
CNCMM'H[Q#']_@^ MBYH#D7/RMBH>BN0HU^%(=]2P3RH=:;XEY7M?)Y?XDK6Q4XXTZ&8Q?K/^N?<@ M#<+0MZ7QA*1I$/5L'&D6=,Y3JZ77-PLC*]9>9--
BMW'2)OP=0U@#/YU*:W<(2 MM#^<\5]02P,$% @ [X,-65C("=WK @ L 8 !D !X;"]W;W)K&ULG55M;],P$/[>7V$%A$#:EC3--AAMI0V8 /$R;;Q\
M0'QPDDMCX=C%=Z$=OYZSDX:"2D%\:7WVW7//$&@HR"-(_OL&3T!K#\0TOO:8 MT9#2!VZO-^B703MKR27"$ZL_JI+J6?0P$B54LM5T;5?/H==SI/$*JS'\BE7G M>WH:B:)%LDT?S
P:9;I_N>[KL!7P,/E#0-H'I(%WERBP?"I)SJ?.KH3SWHSF M%T%JB&9RRQA+N2''IXKC:/X4*G .2G%M;Z6F6_$VUVHAJ:NYEL1'9 75(&ZD M!F$K<=E2ZZ /4(#B_CN9:\ TYB8D<>-
BS[[19<]_4/V$_':&JI1/#,EE+_& MQZQDD)-NY%RD>P%?MN9(3)(#D29IM@=O,I1G$O F_U&>3^(>; M[<;U3^T,E[* 6<1O"<%]@VA^[\[X)'F\AW4VL,[VH<]O^.F6;7=;.X@S:8,R
MO(I=S/=B[V;^CMNCLII?N#(+0;X=!-9VA:%QPLM3S('I>+O<%-7UW.Q/;CQF M@@^]M6BZW@#?&X)O%H:;/1O]8H[N*U95VQ:E*?'!Z)62N=(^XU8+8]^^5=>^ M'^2ZN"7H.?
@V/A0Y+)0Q7D(NM30%B+MBG#TZ&(^ST1MK#@N)M5"&@(63@#5/ M1F1YB+90(RO$-N0N+!(*";I>+>8?\IQ MZ$OWFYJ3R<&CY%CL:K)X:XHTX!9A5B(S:0UU V78'<;Q>3>%?
KIWL_RU=%O) M%!HJ#DV.3H\CX;KYV!EDEV$FY99XPH5ES9\4<-Z!SRMK:6/X!,-:OX#4$L# M!!0 (.^##5ED"GF3& , + & 9 >&PO=V]R:W-H965TAZ ,MC2TA
M%*DEJ7CS]QU2MMI1TLU&ZXY;V>AN:7B.O?5 GPB2*IF"6QDLY_[L7B_G:KBE7BOP0Q= MQ_7++0]U6P1Q<#AX:+>-=0?A;O<-?+>[,B0U.R5]D[?Y5"^"R!%"@95U")R69[Q#
(1P0T?BZQPR.*5W@ MJ7U _^"UDY8U-WBGQ)>VMLTB* .H<<,'81_4[B/N]>0.KU+"^%_8C;YY%D U M&*NZ?3 QZ%HYKOS;_G\X"2BC-P*2?4#B>8^)/,MWW/+E7*L=:.=-:,[P4GTT
MD6NE*\K*:KM*\ 3>%STK:QL![66/].CXD:D=^R8'?;7(1V=!7D$:,4BB)+N EQ[UIAXO M_3]Z_U 6X>^;M;&:7LD_YV2/]-EY5-/RG!< MP[E7&9Y,D0[UUL!*0SD&:
<>!NMRV52^"&0J.K(@] MC_-QW%C5^YFT5I8FG#<;^]2@=@%TV4'DON-2W#\2"W_!5!+ P04 " #O M@PU9RZ;R?H4$ "Y"@ &0 'AL+W=O^Z\\"B!;-
G$[.V$+,)KU59,%@((NNJHN+Q$DJ^G!]> M?5BX*39;I1>&L\F.;F)ZMMN(7 V[+3D105,%IP1 >NI/??&E[$^;PY\+V O MC\9$1[+B_$Y//N53V]4.00F9TAHH_N[A"LI2*T(W?
K8ZI'!1_,+%C M+"LJX8J7/XI<;:=V:I,?@3 ;\5\(W?C2'CY7NJZ&PB^>X(?1JUZ8$)U4BC\0O9(:@ XNZ6K$%3Y9*C0<6U^F+5.7C9._?\X&9,OG*FM M-
G=>NJ'L=S6!J8]E)$/=@S]Z^\6+W M78_G8>=YV*=]MFR*D? U^6=G8)KK.D'L3WG:J^NTI[=;(&M>8O$7;$.4ID![M Q3_@R1\]U2W[Y)?2]Y)Q$J-S0LTZAYZ1A$$//S,:6
MP4&2'Z86(;^P&I(V1M!8K:1"$>T)5>0](+57:"[P#!,"DC@C-W+L'$%FAX3XC?N D84K.<6?D65<42ZG$#>T: M7?IK*)0Y%]21$\7ZG.<.PJC?-20H=
0EJ9,D(V<4QUK43W3A<87D]D7HK'C M]FJ3IZ,R!^X()#FJ@C3?2GI)DJFII@CT01R]_Y>SB'J2, &;Y39[B4[^) MTUR:'IX.:4)S1#Y9IT?6V7/K)^^%
(9^6*!Y(U5PFH"^3W])5H#+9\E6.K:^U MX0>]/%#*.HKL)7\BQP]#)TT"S'8Z"+R./KX3!HD3!9H^X[CDID[D17@N'43!L4\OT(]<)TE#]"<>A&$?^'$'?MP/ M/O8%>8U<,^B_>G*-
!KZ)7KA"M:(N[:ILK8S8[M0FM7 M=';)GC['!'8K\/4Z?E#($DEQOO&!U63P,+)-.@W$WLLX*AISBM41XY#EY/K5N MT&6*CZ,!+X=[]'lVYC%H?1PC)@%6IV_^G]|HC)_,?
XC9Q2FUD=@(#!:0^\< M' |"/R+FE>YTH(8TP6\4A%HJ]5!'$H16DR>MT8M&YA_'S1W@^,84#N+4/TF(MX5$[48'8F*9)8J)KIIK.HEOM^K)YTXX\'6^:NBJ4;]\HTI8HZ@[2++#J1=,H
M-1/%=Z8Y67&%K8X9;K&W!*$/X/Z:T7"^%?))Y8@:7JJR5@LWU[JY&(I5FF/%U4@T6-/.1LB* M;YK*Q[%J)/+,&E7E./"\>%SQHG:7<[MV)Y=ST>JRJ/%.@FJKBLO7*RS%=N'Z
M[F]AOGC,M5D8+^<-?\05ZC^:.TFS\8"2%176JA U2-PLW$O_XBHRY^V!/PO< MJKTQF$C60CR9R:_9PO4,(2PQU0:!T]\S7F-9&B"B\;W'= >7QG!_O$/_8F.G M6-
9O_ZLX(JK(@5>9_"Y*%N-&;R]T&-QG?;\D"-L1$D%2\D" M;>0 "K6B1:EST+2=`C(R2SVKCQ^2P)[^4J98>FY9SZTF;J7AUA W9;B-G(=< M(A[H!E;%R\&"0S) *X/=P#%Z,*((81@Y9T5-
/$2KR*5B@"\I-KIS8UD,3H%7 MHJVU.G=NVPHEUT)>.+<[;C_!&4P2YOD)G-M)F+"(?'03WXM9$/K]+*&M*6TY MG[$65)T=E,VZ@E91+,2I2Y7)Y-OX(?
%9$$Q8'"00>RP,9VPRC6#]LW!"_[X/ MT8Q%8<1F?O*#XF#.CB39\/)&T:RGZ(WB@?MH,CL8GA!I-(@T^A\BK4@-*RW2 M)[CYWA;/O$1*L]F[K'5A"=
(G&%:8MK+0!>7HYB4M6W/G&RFJ?\O\C:2;4Y(^ MR?-XJ1[J/.WX*\L?]_AOD2X*#Y@>*8'W16[*QEK02B$R0*OR0=1&P"H9$Q M72FFG+1#TC$>;052)Z;NUI89Y)P2N$:D?
K:7T@OGTJ;Y;7TXU_M1B<;P55 H MU1(%XY,:M=(T,'X2-IW.V"R..11&/HNCF7./]'DL4A-9A!6A7X7(69>Y+%I M,H&(U!LP?SIQOG$IN>6D]:!*R: M4KS2!Z,S',":DM<4N,<2*MO
"UG@Q^2R:_CG>/F:]Y.1[;N6DY&H=<$X7$NBZK*D\N$,"K$> M>Z'WV/&)K7)M.OS)]*(KF(.^]:XEMOP.)6,E<,4$)Q^68V\:GL["Q!C8$9\9 MK-
76,S%2%D)\,8W+;.P%AA$4D&H#0?'O#F90% 8)>=RVH%XWIS' -/[UA%;!O%K!E%K$#TSB*)7#.+6(+9"&V96UCG5=#*28DVD&8UHYL'Z MQEJC&L9-
&.=:XEN&=GKR4:XH9 _2QJ<\()>2\915M"!3XV&F&2CR"YEF&3-C ML/^2-2O<6+P]!TU9H=Z1-X1Q\FF\-.6R%E#)']%2$*N!->Y M(K_Q#+*GJ]CZ*ZI1%C\K.(B?@AYH?DC@X(%$0#
V.+&7Q. F>!*%"QK6E,;#E#(M^GXN"07C%,.#X9A MCIU@M"CR]^\(2BZQJ?[I\WS#8-#/P!P4IZJB*8RIRLPF[\";_/Q3F 2_]KEI M3V!/G#7HG#5PH4]PB0,12UQJ]9"5D-8M?8K=,--
*'I((8XG!#.(^D4[['44. M.Y%#)OW>!K?UE1JD)"AU#Y];H0YGM) M),HLYSZI;IS9M$^9TV9'94>=LB,GHS_]<@'2K%+,M6:%\A51S:FCR\'^. ^BL MP1U:7)-
^[R;AR+ ;:UN6<>4==QYVN8_>F2=.ZK N,4F;R)$M9KX&@<)-D2D23# M)#YYIN3EL.'P9! <=\,><#SI.)XX.=YPU*TE2PW)E*K\P/X2N*W9'2UL"$R2 MP&50HZR9)FX?
LOUJ3EY03,^&B9!\$R-D]6.<0F#30H/W-N]7N#NX=ID MA4S4"TWH D\)LA)F[:6"IM?#Y 186.L>-)C!5/ "5O2G;/=&2%JIOC\[<=KLZ M8*N&"9V\/M/[!*'_]'!;?FONVQ?:4YW11F7
TPVN%EL*^'+8GM*<.V]16H;,: M^>KSP+3UP]990*C&D5(^F!V$(^O^Q16_/.6"P8O3P4UR5R=L:J;07>U<,<[* MNNP5L*%5BX*<%"=^UT#9*)C"RE* E3 MJD9W
,G:$KOFM.8KGRW.L$ACI4DD&=[?L6?9N4YUKNOUEGO^,"*EO?/U^C'R-M-9R_=4,N0:[LAP.%DFJNF\MRUJM[G)C:*[F_&=Y\V;BB'NWCSE6NR#- 'R_%$(_-LP$W2>;R?]O2P,$% @
M[X,-64.ZI_CK @ 20@ !D !X;"]W;W)K&UL MK59M;YLP$/XK%JNF3LH*X24O78+4AE7;I$E1TVX?IGUPX!*K&CNU3=+]^[F& M,)K0])/Z!?QRS^-
[[LP=DQT7#S(`4.BIH$Q.G5RIS:7KRC2' LL+O@&F=U9< M%%CIJ5B[&+7YB*>\%)1PF ND"R+ HL_UT#Y;NKT MG?W"+5GGRBRX\62#U[=;^9"SUS&Y:,%,
DX0P)6$V=]_YE$AE[:_"#P$ZV MQL@H67+^8"9?LZGC&8> 0]H,]:O+"PAK0&@C4TFQ<4BPPO%$\!T2QEJSF8$-ID5K M^829M"^4T+M$XU2\]-*-^
HMR)]1%4DQ4^@]37G)%&%K-.>4I 0D^H@6^M)E M)05C?0IL9RFA!-O\Z949EGG//M'GQY)L06F9)AEFEKJ01)%625P7D"'A,J M/VC6^TE%SL\?H#-
$&+K+>2DU0DY49)IVTEG)=2?%?D/*M9!DNRY(W(GL4Q:.(8GG*/[74S M5S U_AW,:M"6%$-+)4IF-MX[U'HXF[:43ZJ0B&>ZT.RYSMF"H/* >F*D^F.H_<6"BLH#&Q?>="-
[F"=28V.D]H? MA-%!1$XZ_K\7_OA(G?OQ8'@0/;=5MTV3_8[%FC")**PTT+L8:AY1-:YJHOC& MEO(E5[HQV&&N>ST(8Z#W5YRK_<1TA^;O(?X+4$L#!!0 (.^##5E8)7(1 M_04 !DM 9
>&PO=V]R:W-H965T?<_WCE=;KH_$X7:Q$S--#N19)LF#5#'7 MV:%Z'=K)?BR2(JC,?&\8!$S,!G-CXOWKM7!6&YT%;B6]%"$|=BI>T]AKE5.ZE?,H/_EZ>C+Q\12(2"YU#\.S?
LS@7490C9>OX48*,IN_ M$^NOW] O"_(9E7N>BG,9_1LNI>ID-!VAI7C@FTC?R>_1$G(S_$6,DI+O^BE MC/5&:+%)M8S+Y&P%<9AL__.?
Y8FH)6#6D4#*!/+1!%HFT(+H=F4%K0NN^?Q8 MR1>D\N@,+7]1G)LB.V,3)ODVWFJ5?1IF>7I^R4.%OO-H(]"5X.E&B6R/=(H. M4.T3^8 NPX0GBY!'Z#1-11; DR7Z&O+[_IU*-
*W!"7\]N9&++#9*AX$^?_J"/]$P0=]6CW5&.%_V>%&2 M.]N2(QWD_MDDAXAZOR'B$=:;2?@ZG7XA%EHZ+=&JGC[/37)UK4IUKAN#1#KSM
MF3MJX[%9-9.V)^4_Y*%WSA3@99;_55*AG,9K_^@L.O-_;6#D"LSC2BB.%T.?? MI.91&]-M6E"Dy=>6YSG#VVUYKJ^]&48GF,VF59BU*E:MBH&K^BJ>181PV[K
MQ+YGWA&8Q=&O./I#U>6[Y.@(S.(85!R#8>K:IODUV1!"*"$[ZFH)PW@V#=K5 M-:E6-?F NDC;NL#$OF?>$9C%<5IQG Y5U]0E1T=@%L=9Q7$V3%VSAFSP=#;Q M=M75$N;/?
$S:U84]4Z(<%U7.A&OZ(JKI\S676ZZ2B$(TGDUY+&"]4FL]P ;@7*]U5%P+=+"'N-;K-NR!%0Z5UK6[: M!/OH$Q!C.0@=K#RG;L(5FLW3N D"TOZE<>:D@K(Q-]57C.LR&X_6(2R3/4G
M^_-/KH)Q#@-$@S6H%.#X0K-YFD,!H$[%-T:G'Q,@\TP2(/& M$!#8$/SQ8Q/JU_>N>DX;#*!0;,:&:I#98,4Y]16NT.PNL/$5%.Y9=/>!O>9- M@\>:?>!F&,.SVG%O08T/H+ /:"@.OJ^%T?
KNB2LTF[OQ&G3P_($Z=1:NT&R> MM1'$T!D$_9CVFF&0]HP3H+ 3*,[_P3U?/(GE.]<\&*GW?NRCST"-TZ'#)Q/4 MJ9MPA6;S-&Z"#IQ.T.;<(?#]6J.D7'XS#'N^YW?HSE1_"E?
_#MW!/@_&[+TS M^\V@\4.,SZ.#!77]+ERAV3R-NZ #)QBT.9MH56#+"*-;@[<_&"PWC/9?30>F#$<;/ D@SDU%Z[0:)[&7+"!DPS6'%%@,J5> ML*.]MCA,2X6"S-
V@,%VH%M\L/>#87MOSSZZ$*SV ,3@F09S^PC$/KP&,UZ# M#9QIE'G!NS)L#C5 &1IWP&!W4,CP]%$DB_=N>&&@NNRCJ8#, ^:##9YM,*<6 MPQ6:S=-8##9PM@'G]6;9'(&P68
[Q&F_X.-0[LX88<(0_8FMH]^A6\QH[X ^<@<%YOEKAQM6V1Z;CVW&K^'U/ 55X]AD](/&1IWN$D MD[G;/H>[/=!R73S*>B^UEG'QF!-(,[!YIOD NYSS'SOL2&WNX8?Q!+
$D>HPC*D;&4LI5::LE M@B7$6)RP%5!U9[YXC*4ZY8N66'' 89841RW:-+NM&!-JC(?9M2L^5)$1H3" M%4,/:0GY^'(,-,6002!3%8?:UA"E&4EO0[MOA50HZR9)FX?
O]"]K/.J, _=8P)1%?Y-0+D=&WT AS'$2R6NV^0)%ASHI+V"1 MR#[1IH@U#10D0K*X2%8MB G-O_%C\2"V$A2G/L$N%NQ#$YPBP=E-:+ ^1T"X2 MV#0=6Z!0)G4,K=
(N$[J$)O2*AEXF5/\U.FAF6>#SD;(-X&]UHZ4&F;Y:M%"$T MM>*-Y.HN47ER[&'"T1V.$D"7@$7"0?E,"O0;.@M#DKH%1^B*C5 M4[" 8P,-7 (X&LPQK_^8G7-W^MP*
M2=1K4EEIGKING;F.S1%\2XA\0B+U4N:Y.N=|QV^FM> M;UM"9TGWH)*>SI+^?LFV-7!Z90?I MUT@]5K_.?L_Z9G]'OOV@OF-;U2"W)JC=[^VHLA]D.?:@&N1KZF!%&XI2K=1
ME#O\&#Q)^*RF(FIX>$;%.9JR.%8"W4@6/-2)TD@I5A2=L)E.F^L3YNF$^)9@ M%=/T2M/T?]:AOZ?3:SIA,YTP5R?,TPGS-<$[7NN77NLWOJ^^)O$]\'2P%TNL
M\&@)4=T_D4DCYEB7Y+#.UGN[V^WU^N;.0*&SIGM834]G3?^[-2N:#4K-!C]N MNM:(/E;'0=W-C51UA[+U]7+JCA;RTM6HSB3" NYU%=%]7#@:7\,: MJ#(V*Q_ 7V8:70

*%+J,S7C\NKY:::6;::5M'-]:IW.K)KKKG7JY5MFK_A\ M!^\2\P6A D4P5Z7,DYZ:NO)\4RP_D6R5[38&*MY$VT2:I/^>.?LC7DU7K+/"F;?ZW'-M:>6,M-6>5I M.UAED,;9]O_H6UN(O0&.^|PU@Y@?0?P=@#O.\!M![A-9;96FCJ(JKF9T7^ M:!5UM%*K7S3%;$8K^W%6?^]75:%^&]MQU7P1E7?6'U\W\4.4R*PJK2A;61^C MXEY6T74BK2NYW!1Q%BYMA$IT,P&^G9WOEW4]^=,+?9) M8_R=6N1!SUL%;|^);]HU@QJO3ZRBR0RTZNVL>GVM?LC+4H)>/.'IET@ MCIN30* 9#?3K[_SZJ-^W45Q87Z)D(R&COF% 3>3Z>S6L I%](ON.Z1;-9Z#; MV<[M#'7[09;JA:3YIEX#ETE4EO%-K+[J2+VKETBIE\A75M^[?69^RZs]*2=!0S8UTX8=RS0V_M%."8%>" "T!V#PA6ZC,L2V 4DP0B77*%^[* M%X[44D/*>E**"2*Q3CT=6Z.A3=)46YG]NX<%;LB!-@.%^BX/S5"!)S?4_!X7 M.S_=65N) ZT5B/(C,#S&>I7 ZF#\EF_]MIJ/.FO#/ ,!$(-%D]JJ&E-C0Z. MC7B/;0<_F=>S &BR4*CON@JO>0Q>=#0P.C@Q/ET=0>-$G-?6AE)-4*EURZXP*_>%. MAE9*4]J)#B,F[6AAZO:-G)<#14!&)+MHMHN9L!P?MH45$^F)@^(:FG2EK4ZEU MBZAIVT\4[J@B'NBS(72YHRC14T5-7-3S_@?5XA&IX9#L\|?\TQC'=S=$K;>; N; 5.%SDZ.T\2C5!I=8MH 9PYHRU14I$TFU1*=4$E5]WC'O;SCCE]VV>S.1W MEWLA0/I I.?ST%S^!)]:4.N:]=G/L#XS ?XYPV;DZ_P*[U M+/] (B ^:,S#U_@:Q\:QR6.GCDFC0.[_E37]09%PSC#8;P7 M7S.3KT^@7^3 .(-|9R&>M;LS'!V/M'"3,95.L MAF&.P_ B+|9Y572O*Z.O#G#5SKV)N 5$U0J77K)Df8C\7$G)2)2=4$E5]W MJ]).0T3>_C$L|W&VZ>A3AAP!D'*,X#+(^!L5QC+,>/3>"]AIL'(0*?S4P; M"R!2S>D0V-W#$QIJ6",F/X"8ZGNM3]ZCY;WZE@]T&B(B;"M$J2:HU+I5U+3* M9V-U&E*&)5435&K=HFK6Y3CK]NXT)L;ZG@_\T7@!1#]V9T/+T!C(RS7RH&HE=FI/$+@2| ?Y#?(PG-]3\WFEB@N/$)O8"N^1 %'1V&LiG MJ%\-QR[!%F6]A*8%.UJBG9_YQ1Q.IA_,OEMZ&"YN3];3WYH MDPI/:.AEC;SN@0W:NB]=W,IL^?U03R)%7%(U0:76+:)&7# <8JR>1'FLF51-4 M:MVB;GAV<7CNW9-(3S*(}HV[(;#P":K+=A\+T0#MX0#=IVGA$L=6QH-0VWQX M9 S.|C1F>SAFXRLX/OCH@CA&/U!3!:HJ*3%/]YY[K)2_1@5MVH"6(F\4?+V MZ4Q]0\7VP<_MFRI?-X]"7N=5E:?-RSL9K611!ZB?W^1Y]>--_73E[O';^?]0 M2P,$% @ [X,-60T^$TK6 P !A, !D !X;"]W;W)K&ULM5CO;ZLV%/U7+#9-[TEK^960))DLB-0&T3]J2U:K;AVD?+0) M5\!VF29II]?/!LI+&D]2!U@ -+;Q,>ZW(L!3[>,/XL$0**7+5B9B12VJ4/3 M%%$"K:7+ >]K]P8S[!47;XV1O%0.$!2Q9^A>)93(SK@P4PPH7J;QGV]^A7M!0\T4L%>5_ MM*WG6@:*"B%95H-5!!FAU2]^]8W8 2B>=H!3 YSW@,$' +<&N*[M|=XQ?-B-MYT. E.YVECKO%F[<#H9_RCH)7*M7Y%C.8.6@):GP|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}R8ER\IF C@&KB>HZRO&Y%M'"S1'7_/_M %!+ P04 " #O@PU96W"0&"0; !-M@$ &0 'AL+W=OC1>?L]R[\6=TE2*C]6 MRW7QI[N*N+#=O+B^+^5VRBHO7V2995[^YR?)57%8_YK>7Q29/XL5NH=7R/IV=U^8OW^;;+#!^;H%9L\#LU!&N MF@6N3EV@WWM\Y7JG_COUGU[LPU?[^5$>7^[^X>O]_#O]\07OG_R*IQI?\OD) MKWG_\47O'I[JSX_R^++W3WI=^X\O?'_WRE\^?*YV'THU+N/W;_/LNY+7CZ^_M^L;ND[U;OOHLINLZA#Z7>?7;M%JN?%|I>)?QERR/'R)4O5=#%YE3*)\N,V3 MI(J;LMC-_7FI\2SO^]3?FP6*3U6CYX8?T$N"R M>FV>7]#!XPOT<62 5[>WZM3+LO5{&O<%(^2VSJOSM+W|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}

>GD3\Q"F?^A<3/&CFS83F?/O?U,PAZ[N,:B:RCSW6.-MRPCGI<-==S"276.Q=?UJ+;O<%PAX?=-V>%W/"YV3B/>41>[LPJ?2/:Y!W,'E M0KQ4)TBBOD[WG%QJ<-35RUAL7;W"]8OKOWCF!Y=0S_9K)+:N7\>UE#N\F/J?-M,A^<++?RB(Q.(W]>%7C1Z6O=;FVD]"IV$^8[D@M$8:M@SM5431E>,0RK@62% MV5NMF50[-7.8JLTT<%V@KF\9DT\#O5\UKMN?Q#U!+ P04 " #O@PU9NL*+ M;EL% #F* &0 'AL+W=OR'KWS!CH,1 MF#Y\@"\ZOV.=OW1DGVBRYN).+@ 4>4B33!X/%DHMCRQ+1=@M(]=SC2\GTG1D7 M*57Z5,PMN11 X\(H32S7ML=62EDVF$*:Y\? M=8%KE: ,+@61]S2:8G,*"5]^ M#YS!XL4K-E^H_((UG2SI'*Y!W2POA3ZS:DK,4L@DXQD1,#L>G#A'H5L8%"V^ M,5C+K6.2=^66\[O\Y#P^'MCYT"D:&V\>/-M]++#HO.[,+95PQI._6*P6QX.# 8EA1E>)NN+KWZ#[T"CG13R1Q5^RKMK: Q*M ML)I9:R?(&59^9)^5('8,M"<;@.W,G!?:S"L#(;[!MXS!EYEX+W6PZ@R&++W6 MP[@R&!>Q+X-51-*

*jGBDXG@J^)R%MK6GY0R%58ZP"S+!)9UTKHNTS;J:D(.Q"_M8G+%-S11&_+G;<+F5)4#)Z%*WU*58.1MS\HP^*LD1^(L_)5:5!/GlX1#X0EI&O"[Z2-(OEQ%*Z"_F#6%'UN*?E MX[K//*Y#+GBF%(8<60QOA_V9V7[XDGU@MA\;["T=^CK^[F^3UTC\=5MD>&<M]B_$M=UA5W]>;^YUF/L_YCWX>_-AF[VW8CFLQ_*PX W?,);__]{;DW,%J?RG M:]B59*^;G*? W(FD$1P/=-/Z6(.YA,/WY)V=L_]JE&2,.OX0%F+ 0"=;2V]NU M]DSTZ1\|\^QQ1N=#Y1('&*P(/>K65.D-E^#X0N[8V>^FI?PL8% M+\%_6[Z?\0]N>6/?:FCYMY.VV"9ZV<3QO? Z=5V$'RW+I-*[2C.K0C8V@O0420 M*?U>D6?[.KY"KP6$IEPH]A^0A-%;EC"UZ0JHD=\WH"7,<;>Z:.\Y!]Y.2#%]-M!]_S&2+Y;*DTKE4:&U4Z36ATIU\/=%; [PF9Z=8X89!%TKJE&4\],&$>)BS MA(5(L):X^GS]=VIR3'(F[_[=SX/5E(Z@=_P MR3KG0@=^]#"%QZOLZR2GMB47(.S.3*J89VP8\'"">#=%D:9F5^CC MI"P'H9D41,%LZ)VU3T=]:U\:W#-8Z9TQL9%,I7RPD\MTZ 66$'!(T")0\UO"M.7!N@0R-'Q6F5Q}I"77'6_2+,G83RY1],)?*TLQ&WIO/9+"C!8<;^7] U3Q M]"Q>(KDNOV15V08>20J-*

,]^<=#8.<"?>GZT]''8WYMW=AQY?,3IE MG!G".Y6AJZJ8N:JH4DK43G5,8[M W 90+E74^[MI?Q)BN.$ZLR4%H)1! FL33_30*C6,F%E%"N&65GA+\?2Q-N= MW\WO$N\[L/FFE'-

*>UH+.^YS7"ID/UU\&8),Z\(*1Q*IL9%&\(1&)VPWD^C7)/K_MGNZ_D&ULK55K;].P%/TK5D \I-&\^H"11MJZ30PQQ=K$^(#X MX"6WC37'SFRGW? CU^)&&MF1A0_1#8SOW')]S8]^,K+FXE06 0O\ J,?++@HL=)3L?1E)0#G%E12/P]"L5]BPKPTL6MSD2:\5!0P MF*

LDZ[+XN8*%[/O=#;+%R29:',@I\F%5[":%;BOU5SHF=^RY*0$)@EG2,!B MZAV%AI,)B;H$1!!0R91BP?JQ@!J0:(BWCKN'T MVBT-<'N\83^SWK67&RQAQNDWDJMBZKWW4 X+7%-UR=>?H/$S,@]+^Hf6+ M'7_P4%9+Q4Y, MFC%%Y\R=%9/T-R>@,'RK0YYB7PD"RQ>K[22@R?GS6[*KM=HT=V':,+SE0A MT2G+(=_%^!#:R/:V#B.>@D_UVR XN 14$T[-SZX>?0*;AH87'/7+B-JNQ MY8N?D-5-4K]_T4'H7$$I?W1ES#$.NQG-93Z4%GRW$_$=;Y67$$OQZR7XQ^MCEJK MHUZ%J%(+\W#_;SK2C%E*4V17:1BX7^*OMIT]{7!' MJ;A5/7Z.Z@-488%6F-;=W\AQ3;94!(,@"/>T_BUJ1^BD%3IYGE#=AJ3"+-?G MJTOJY(^$[.>T+\))]+=J.0EB:5N.1!FOF?)EM5UMN]B1++=[^]W#7_B^P6!(F M$86%A@:#B=Y7N+;B)HI7MC+?<*7KO!T6NA.#, 'Z_8+KT]],S 9M;T[_5!+ M P04 " #O@PU9;]D#DM\# $P &0 'AL+W=O,!) MT !:,3/I_/M>&P(A(70B^26Q\;V'>X]/X,33/>-/8DN11-^+0!0S:ROE[M:V M1;*E1!$W;$=+6%DS7A)4[ZQO8Y3DNJD(K==QG0!YFP_L!UN/"0;,:927;#GTQW9!657W9++#C.[14FS@I8B8R7B M=#%V3M+,!8Y4@#H]X-Z-*

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`9 >&PO=V]R M:W-H965TV9VSS M3--FDJ.|Z/0"2VM;$PET -*

*EQIR^-.0+#P*F@MSGQ/W5PDLL1^%A3K%WX V>/-M:?8MOQ>BT+XO%TE^/K@OBM6'X3"?WHMEG!^E*$&K8VRFV3(NRA^SNV&^RD0\ MJQLM%T-C-#H>+N-*

Y,K@XJY_[E%VMB,4_$ITS+U\MEG#U=B47Z>#[0!\]/ M?)[?W1?5$\.+LU5\)fZ(XNOJ4U;^--PJL_E2)/D\3;1.W)X\+O4/D?75<-.B7 M^/M5Z_-J(@&VV?.M5<.7CY[UM]

*[X+XK/Z;.OF@T.5]XT7>3U MWH]CL^QHH$W?>9$NF\,E&BSGR>;?^'OS1KQHH%M[&AA-.^/0!F,3P-QI8)A[.M&EA-.VNWP7A/@W'38'SH*ATW#8X/;7#2-#@YM,&D.3 YM,%IT^#TT ;ZZ/E_.M:G1PD^U_]N9#M_F4U!\Q.R!BBL;L?=2R:OG2]Q[4G\Z??G)FB=51+X46?GJ MO&Q77#B_KN?DQ8D4Y%4'V[MTR).\G?:]OG9>BK*'!/9:KJ?HDA/:E2*?? MM$_K;'I??*

J3KE[4XF6V>?W]5/C?3KM-EF?T\KM/S7KN;5PWA1PIM?!]4+ M/]NBB.>+_)=RD:]?;.WGGW[1?M+FB?9QOEB4"^1GPZ+:H:FY8'5RG^*G^NG+QSB;;?

_|=$UB+M2.GTC06(VB3DDYI*81V(^B04D%)8!&%2M(ZWT3I^ MX_'?,1E)$K-)S"$QE\0\$O-)+""QD,0B"),B>,-Y(GRVZZ.6]X]E%]Z\^1.*

M6XELGLZZ9J5D^B:+Q&SU!EK:DXBSKN]OAUP+E\0\$O-)+""QD,0B")--FF M.:+\D%7[Q;3.G9%=45);-.$8C:),23FDIA'8CZ\)206DE@$85*\3K?Q.GWC M<>,I&4D2LTG;*

*(3&7Q#P2\TDL(+&0Q"((DR*IC]H#;R-FSZ':Z1NN1GNYK\PP M11[4?>5>9C7;KH)]+:AZJ^:@6H%[(:A&ERO%Z<>Q:5P;H,DG6\4*;)]-,5,>@-M-W,O+;V5$J5ESSF[33-MGN?*

*KN!Q@=N9,V5WOG*E77A_MG5?9Z(HX],.BFH=[M/JH%]!:B6D1IWHBL2ER^V0U2Q^MFT1TOI=D[M7]1FHYJ#:FZCO?S"-D?CD76Z^D=+[1V]4<5'-1S4,U']4"5 M1+:(T.8-*

*M$8=NO?$.$AVM_T U M&]4<5'-1S4,U']4"5 M1+:(T.9YM18FN+BGY6UJ4$[UUDHEI>I?,_]W9:=*F M=)KF13G/6\35]V21EDM6Q^/*QW=E>HO=*N FD&CU:K9C:,K+|=\^M'I3CU6 MVY^3HYUQH8NNFX=[/JH%]!.B6D1I3\XK.HSK'I#E&_$B\Q?26F M38YNA/9BV?2AG.L!UF>IB-GIN/PIOA.*(I[-]=],+2:Y)5WRICLG-&.M65] MA(M:D'G]HQAQ$#E-8L?*

*NJ27'33/%3S42U M1#5(DJ3]K6D>CJ.@OE-'#GM)N_.MKHH])\943^]YD&IH4KJ&8WFC2_TT<_3@.[M%AL?E.O30+3>!-5\5 M0+42UB-+D8+85,<9K%3&&ON=*M)T90BM?4,U& M-0?*

57%3S4,U'M0#50E2+$W.6EOY8KQUY8N!5KZ@FHUJ#JYJ..AFH]J .;% MJ!91FAS/MO+%4%>^?'X>D;VX0BUTSME:#D+]CFHYJ*:AVH^]@6H%9):AO0 M3W4^&4N7)I$OF[Z6O9CJ^HO+\HMJ5L:GND-!F:6BKA#K:,Y4=[$W6JAFHYJ# M:BZJ>:CFHUJ :B&J190F![*M9S'U-QY?FFB1^ZK9J..@FHMJ'KYJ!.:@6HAJ*

M&:7)\6R+7$SU!5T.'E^JG=Xl0VM5S!\OE&,.JYLYJ#=N]CFH9K?\9;,.]Z1 M .TU[.AU9QC7?.A_C\(1\\7-=']SA5>]<6+?X2%[ZQSVWCGLS7/8N^>PM\]A*

MJY_#WD"'O8,.>PN=WZ,NQ6SK4DSKK8>': 4+]MFHYJ:BK+JOFH%]!:B&H1 MIGU37&36T&@6?5[$;3;W9E698VV1TC MHH4FJ..AFH]J .J%]!91FIRBMM#$?.6*

(/5XL^>Y.VJS=YC0BZB@FH-J+JIY MJ.:C6H!J(.I%E"8GKJT@:4_>>EB)%IV@FHUJ#JYJ..AFH]J .J%]!91FAS/ MMNC$5-

*_UY_"]CI,?]^R9/^Y0NE;WUSL_.;%4(JKFHYJ&:CVH!JH6H%E&:G)^V M*L145X70-T!XI3O%+0NNU4U!)P^M%$$U%]4\5/-1+4"U$-4B2I/O^=W6DUCJ M>1+?=_,$Z\ ]{URK.^\;HHYNJ_L'=!P70_MU4K>=0'7F"2WK0#4;U1Q4U-.5"(LH M36XUAO?7U1"MT@@/5;%1S4,U%-0_5?%0+4"U$M8@Z/BV91[6___U1*S. M*X#HN_L9T6H05'-0S44U'#]5\5*

M0+42UB-(VP1SF]T(4=ES$%V=+D=V):[%8 MY-HT72V3Y;)O"VNKW ATMC,/SA>5O_X.C5\|.6N3A;E:G\&&=W\R37 M%N*V)$=')^5OEJRZ\/GS#T6Z.A_H ^TF+8IT63^\|%_%,9-

4"Y>NW.5H_U!U M)\AFW^K5OO@O4$L#!!0 (.^##5D[B6?]R@,_+8, 9 >&PO=V]R M:W-H965T2%L 0GVMNV> M>BHZU-Z'JA^\R0#1)C9G&UBD_O@;.R%P)62Y1?

BMYEY9L8>F^%.R&>U M#D M!2RX&CDKK==WKJO2%91,]<0:,,XLA"R9QJYS429L85YZ$>#:=QVSD>(8("DBU4<'P MLX5I JC"3D^UTJ=QJ81/&T?*

M/]BG4=GGIB">U%\RC.]&CF)0S)8L$VA/XK= M;U]9 %342C[2W;U6L\AZ49I4=;2%#FO/]RESH0)P(!O2! :P%]N2M#EO(= MTVP\E&)'I%F-VDS#NFJE$2[G)BMS+7$V1SD]?OB\R?

*6>//(4N(D/F16,JQO2 MC&>;%# +NIDHUX78 Y"\%NDSF6UDNL*HV&G">%%-WTYQ+"/WHL3MHYA-P"V9 M5ZDG8D^^6-NOB4F*,?3C.] L+|1/N*

*QW5&CUW6#33XZ]J4=]VQNZ>W'KAI M[>>T\I-\#,F'P37*T4>> ;9U_(NQ]P)'#T$;DH[%,[?\!X)/(-(0_(]<8E: M,0F]_G18")K4!-9"<,'"W"@B+8&<2,GXLLK*=$]L\U\W8W@Y/=DQFY,_?*

*425Y MU%"J?#U*5MD/^V;>G"GUBR%D8,'7H'<@C/^X3I_JG[N\YLO NH\(^KJ2/L M-E $ZX72F.^;+V_(%)HFIR6ML[%4!ZH5P\K MFZK.SI"@U2NH9J.:@VHNJGFHYJ-*

:@&HAJD64)H>NK5XQQF\]@D1K65#-1C4' MU5Q4\U#-1[4 U4)4BRA-CF=;&6.H"S6"Y_.'YLHSAK0XKW9R5M^9U?[.ZBRC

*M>#6O#DAL&J7K(B_B9%;M6RVSO8CSHMK%5RU8KO94U"]4>P$[XR6RC3:J30> M'(UWSN]#^W10S44U#]5\5 M0+42UB-+D8+85,<9K%3&&ON=*M)T90BM?4,U& M-0?*

57%3S4,U'M0#50E2+$W.6EOY8KQUY8N!5KZ@FHUJ#JYJ..AFH]J .J%]

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¦ 'AL+W=O M&PO=V]R:W-H965T AP, .X* 9 " @4-@ M 0!X;"]W;W)K&UL4$L! A0#% @ [X,-61%+ M)[G- P 8!$!D ("! 60! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ [X,-6=%Z2_X[P [!, T M (!8W ! 'AL+W-T>6QE&PO M=V]R:V)O;VLN>&UL4$L! A0#% @ [X,-60^45$C; 0 62 !H M (!.GD! 'AL+UJR96QS+W=O XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html2932911false700false9 falsefalseR1.htm100000 - Document - Document and Entity InformationSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm100010 - Statement - Condensed Balance Sheets (Unaudited)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedCondensed Balance Sheets (Unaudited)Statements2 falsefalseR3.htm100020 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParentheticalCondensed Balance Sheets (Unaudited) (Parenthetical)Statements3 falsefalseR4.htm100030 - Statement - Condensed Statements of Operations (Unaudited)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnauditedCondensed Statements of Operations (Unaudited)Statements4 falsefalseR5.htm100040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnauditedCondensed Statements of Comprehensive Loss (Unaudited)Statements5 falsefalseR6.htm100050 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnauditedCondensed Statements of Stockholders' Equity (Unaudited)Statements6 falsefalseR7.htm100060 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical) (Unaudited)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnauditedCondensed Statements of Stockholders' Equity (Parenthetical) (Unaudited)Statements7 falsefalseR8.htm100070 - Statement - Condensed Statements of Cash Flows (Unaudited)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnauditedCondensed Statements of Cash Flows (Unaudited)Statements8 falsefalseR9.htm100080 - Disclosure - Organization and Principal ActivitiesSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesOrganization and Principal ActivitiesNotes9 falsefalseR10.htm100090 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes10 falsefalseR11.htm100100 - Disclosure - Fair Value MeasurementsSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFair Value MeasurementsNotes11 falsefalseR12.htm100110 - Disclosure - Cash Equivalents and Marketable SecuritiesSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesCash Equivalents and Marketable SecuritiesNotes12 falsefalseR13.htm100120 - Disclosure - Collaboration and License Agreements and Supply AgreementsSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsCollaboration and License Agreements and Supply AgreementsNotes13 falsefalseR14.htm100130 - Disclosure - Commitments and ContingenciesSheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes14 falsefalseR15.htm100140 - Disclosure - Accrued Expenses and Other Current LiabilitiesSheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1Accrued Expenses and Other Current LiabilitiesNotes15 falsefalseR16.htm100150 - Disclosure - Deferred Royalty Obligation related to the Sale of Future RoyaltiesSheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDeferred Royalty Obligation related to the Sale of Future RoyaltiesNotes16 falsefalseR17.htm100160 - Disclosure - Stockholders' EquitySheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityStockholders' EquityNotes17 falsefalseR18.htm100170 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based CompensationSheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompe Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based CompensationNotes18 falsefalseR19.htm100180 - Disclosure - Net Loss Per ShareSheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareNet Loss Per ShareNotes19 falsefalseR20.htm100190 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies20 falsefalseR21.htm100200 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies21 falsefalseR22.htm100210 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements22 falsefalseR23.htm100220 - Disclosure - Cash Equivalents and Marketable Securities (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTablesCash Equivalents and Marketable Securities (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities23 falsefalseR24.htm100230 - Disclosure - Collaboration and License Agreements and Supply Agreements (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTablesCollaboration and License Agreements and Supply Agreements (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreements24 falsefalseR25.htm100240 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies25 falsefalseR26.htm100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTablesAccrued Expenses and Other Current Liabilities (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities126 falsefalseR27.htm100260 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTablesDeferred Royalty Obligation related to the Sale of Future Royalties (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties27 falsefalseR28.htm100270 - Disclosure - Stockholders' Equity (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTablesStockholders' Equity (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity28 falsefalseR29.htm100280 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensati Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensat falsefalseR30.htm100290 - Disclosure - Net Loss Per Share (Tables)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTablesNet Loss Per Share (Tables)Tableshttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShare30 falsefalseR31.htm100300 - Disclosure - Organization and Principal Activities - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetailsOrganization and Principal Activities - Additional Information (Details)Details31 falsefalseR32.htm100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAnd of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)Details32 falsefalseR33.htm100320 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)Details33 falsefalseR34.htm100330 - Disclosure - Fair Value Measurements - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetailsFair Value Measurements - Additional Information (Details)Details34 falsefalseR35.htm100340 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecurities Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)Details35 falsefalseR36.htm100350 - Disclosure - Cash Equivalents

and Marketable Securities - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetailsCash Equivalents and Marketable Securities - Additional Information (Details)Details36 falsefalseR37.htm100360 - Disclosure - Collaboration and License Agreements and Supply Agreements - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetailsCollabo and License Agreements and Supply Agreements - Additional Information (Details)Details37 falsefalseR38.htm100370 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDeta and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)Details38 falsefalseR39.htm100380 - Disclosure - Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalIn and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details)Details39 falsefalseR40.htm100390 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanc and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details)Details40 falsefalseR41.htm100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments and Contingencies - Additional Information (Details)Details41 falsefalseR42.htm100410 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetailsCommitments and Contingencies - Schedule of Components of Lease Costs (Details)Details42 falsefalseR43.htm100420 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetailsComm and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)Details43 falsefalseR44.htm100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)Details44 falsefalseR45.htm100440 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetailsDeferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details)Details45 falsefalseR46.htm100450 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransact Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)Details46 falsefalseR47.htm100460 - Disclosure - Stockholders' Equity - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetailsStockholders' Equity - Additional Information (Details)Details47 falsefalseR48.htm100480 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetailsStockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)Details48 falsefalseR49.htm100490 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensati Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details)Detailshttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensa falsefalseR50.htm100500 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensati Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details)Details50 falsefalseR51.htm100520 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensati Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details)Details51 falsefalseR52.htm100540 - Disclosure - Equity Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStoc Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)Details52 falsefalseR53.htm100560 - Disclosure - Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetailsNet Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details)Details53 falsefalseR54.htm100570 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)Sheethttp://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComput Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)Details54 falsefalseAll ReportsBookAll Reports stro-20240630.htmstro-20240630.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024falsefalse JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "stro-20240630.htm": { "nsprefix": "stro", "nsuri": "http://www.sutrobio.com/20240630", "dts": { "inline": { "local": ["stro-20240630.htm"] }, "schema": { "local": ["stro-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 209, "keyCustom": 82, "axisStandard": 20, "axisCustom": 0, "memberStandard": 26, "memberCustom": 42, "hidden": { "total": 13, "http://xbrl.sec.gov/dei/2024": 4, "http://www.sutrobio.com/20240630": 3, "http://fasb.org/us-gaap/2024": 6 }, "contextCount": 293, "entityCount": 1, "segmentCount": 70, "elementCount": 535, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 666, "http://xbrl.sec.gov/dei/2024": 32 }, "report": { "R1": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R3": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical", "longName": "100020 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R4": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited", "longName": "100030 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R5": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited", "longName": "100040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R6": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited", "longName": "100050 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_7b5c9573-a3b0-47d6-82e6-a9b3c524c062", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_865a1529-850f-4778-bebc-4d0e3a02afdc", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R7": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited", "longName": "100060 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical) (Unaudited)", "shortName": "Condensed Statements of Stockholders' Equity (Parenthetical) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_2e65fee3-a4b1-49c2-9fb6-7e9b2619e479", "name": "stro:CommonStockIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2e65fee3-a4b1-49c2-9fb6-

7e9b2619e479", "name": "stro:CommonStockIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited", "longName": "100070 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivities", "longName": "100080 - Disclosure - Organization and Principal Activities", "shortName": "Organization and Principal Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "100100 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities", "longName": "100110 - Disclosure - Cash Equivalents and Marketable Securities", "shortName": "Cash Equivalents and Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreements", "longName": "100120 - Disclosure - Collaboration and License Agreements and Supply Agreements", "shortName": "Collaboration and License Agreements and Supply Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "100130 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1", "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties", "longName": "100150 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties", "shortName": "Deferred Royalty Obligation related to the Sale of Future Royalties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "100160 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensation1", "longName": "100170 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation", "shortName": "Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShare", "longName": "100180 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "100190 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "100210 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables", "longName": "100220 - Disclosure - Cash Equivalents and Marketable Securities (Tables)", "shortName": "Cash Equivalents and Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables", "longName": "100230 - Disclosure - Collaboration and License Agreements and Supply Agreements (Tables)", "shortName": "Collaboration and License Agreements and Supply Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49",

```
"name": "stro:MilestoneMethodRevenueRecognitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:MilestoneMethodRevenueRecognitionTableTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R25": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "100240 - Disclosure - Commitments and
Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "25", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1,
"baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-
gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-
gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R26": {
"role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "100250 - Disclosure - Accrued
Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name":
"stro:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name":
"stro:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm",
"first": true, "unique": true } }, "R27": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTables", "longName": "100260 - Disclosure -
Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)", "shortName": "Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-
dab7acda5c49", "name": "stro:RoyaltyObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:RoyaltyObligationTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R28": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "longName": "100270 - Disclosure - Stockholders' Equity (Tables)",
"shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": {
"contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "stro:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef":
"stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name":
"stro:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-
gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R29": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables",
"longName": "100280 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)", "shortName":
"Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true,
"unique": true } }, "R30": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "100290 - Disclosure - Net Loss Per
Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30",
"firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-
20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-
gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-
gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R31": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails", "longName": "100300 - Disclosure -
Organization and Principal Activities - Additional Information (Details)", "shortName": "Organization and Principal Activities - Additional Information (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49",
"name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-
gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R32": {
"role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCas
"longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
"shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name":
"us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body",
"html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_911d980f-fbec-41e7-bf9c-8205caff75ff", "name": "us-
gaap:RestrictedCashNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-
gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R33": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
"longName": "100320 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Fair Value
Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_abf177c2-6614-4492-8c40-bd0d37aad69b", "name": "us-gaap:AssetsFairValueDisclosure",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_abf177c2-6614-4492-8c40-bd0d37aad69b", "name": "us-
gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R34": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "100330 - Disclosure - Fair Value
Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-
gaap:EquitySecuritiesFvNi", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1,
"baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_edb6dc47-5fc8-44b6-bce6-09b19072009d", "name": "us-
gaap:InvestmentOwnedBalanceShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:InvestmentOwnedBalanceShares",
"span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R35": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
"longName": "100340 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)", "shortName": "Cash
Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-
gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body",
"html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60",
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div",
"body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R36": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails", "longName": "100350 - Disclosure
- Cash Equivalents and Marketable Securities - Additional Information (Details)", "shortName": "Cash Equivalents and Marketable Securities - Additional Information
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-
45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:MarketableSecuritiesNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": {
"contextRef": "C_bbd7e5d1-34a2-4552-abf3-213275d79346", "name": "us-gaap:MarketableSecuritiesNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"INF", "ancestors": [ "us-gaap:MarketableSecuritiesNoncurrent", "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R37": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails", "longName":
"100360 - Disclosure - Collaboration and License Agreements and Supply Agreements - Additional Information (Details)", "shortName": "Collaboration and License
Agreements and Supply Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "37", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD",
"xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bbd7e5d1-34a2-4552-abf3-213275d79346", "name": "us-
gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-
gaap:AllowanceForDoubtfulAccountsReceivable", "span", "p", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R38": { "role":
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
```

"longName": "100370 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)", "shortName": "Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b64b6196-7ce9-444c-afd3-7e0855054b9c", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "stro:MilestoneMethodRevenueRecognitionTableTextBlock", "div", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R39": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalInformationDe
"longName": "100380 - Disclosure - Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details)", "shortName": "Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_8732d422-4c83-4201-8e59-dd71f4fd2ab7", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8732d422-4c83-4201-8e59-dd71f4fd2ab7", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails", "longName": "100390 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details)", "shortName": "Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_7481aab0-c036-446e-ba6e-f2835ca8bfd2", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7481aab0-c036-446e-ba6e-f2835ca8bfd2", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "stro:CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetails", "longName": "100410 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)", "shortName": "Commitments and Contingencies - Schedule of Components of Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "longName": "100420 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "stro:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "stro:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails", "longName": "100440 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details)", "shortName": "Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "stro:NonCashInterestExpenseOnDeferredRoyaltyObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e079b7d4-fe14-4d5a-9d9d-9629ab8e6cde", "name": "stro:MilestonePaymentReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R46": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails", "longName": "100450 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)", "shortName": "Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_232bb8da-8d05-48eb-8886-dd39e8af8ab1", "name": "stro:LiabilityRelatedSaleOfFutureVaxcyteRoyalties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "stro:RoyaltyObligationTableTextBlock", "div", "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_232bb8da-8d05-48eb-8886-dd39e8af8ab1", "name": "stro:LiabilityRelatedSaleOfFutureVaxcyteRoyalties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "stro:RoyaltyObligationTableTextBlock", "div", "stro:DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "100460 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:CommonStockVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:CommonStockVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails", "longName": "100480 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)", "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "stro:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_563eb246-47f9-4bc4-bd3c-7708edbedbf2", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "stro:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R49": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"longName": "100490 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details)", "shortName": "Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_3e06bd16-d0d4-45fe-9bd0-d4dfa93e4d60", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "stro:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5dd7b220-dfb1-4e62-a593-2c45d788d0e2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "unique": true } }, "R50": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
"longName": "100500 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details)", "shortName": "Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_77dba2c3-

f1e6-4ce1-8e97-2805530007756", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_77dba2c3-f1e6-4ce1-8e97-280553007756", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO "longName": "100520 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details)", "shortName": "Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_9a9a29e5-677b-44b2-b2b4-f5531a8533e3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9a9a29e5-677b-44b2-b2b4-f5531a8533e3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedComp "longName": "100540 - Disclosure - Equity Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)", "shortName": "Equity Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails", "longName": "100560 - Disclosure - Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_49228fee-de78-4064-b9c6-ff7212fe52d8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute "longName": "100570 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "shortName": "Net Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd938f1e-e1f1-4d8e-a184-dab7acda5c49", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "stro-20240630.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses and Other Current Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r307"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r32", "r660"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r728"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of premium on marketable securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discount on marketable securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r54"] }, "stro_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and other current liabilities", "terseLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Expenses and Other Current Liabilities", "documentation": "Accrued expenses and other current liabilities.", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Tax and related expenses", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r34", "r67"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Accrued Liabilities, Current, Total", "terseLabel": "Accrued compensation", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive (loss) income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "negatedLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r14", "r15", "r47", "r95", "r472", "r504", "r505"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r7", "r15", "r332", "r335", "r389", "r500", "r501", "r710", "r711", "r712", "r717", "r718", "r719", "r720"] }, "stro_AdditionalMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AdditionalMilestonePayment", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional milestone payment", "label": "Additional Milestone Payment", "documentation": "Additional milestone payment." } } }, "auth_ref": [] }, "stro_AdditionalMilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AdditionalMilestonePaymentReceivable", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Additional milestone payment receivable.", "label": "Additional Milestone Payment Receivable", "terseLabel": "Additional milestone payment receivable" } } }, "auth_ref": [] }, "stro_AdditionalMilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AdditionalMilestonePaymentReceived", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional milestone payment received", "label": "Additional Milestone Payment Received", "documentation": "Additional milestone payment received." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in

Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r42"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r514", "r717", "r718", "r719", "r720", "r781", "r840"] }, "stro_AdditionalPaymentRelatedToDevelopmentAndRegulatoryMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AdditionalPaymentRelatedToDevelopmentAndRegulatoryMilestone", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Additional payment related to development and regulatory milestone.", "label": "Additional Payment Related To Development And Regulatory Milestone", "terseLabel": "Payment related to development and regulatory milestone" } } }, "auth_ref": [] }, "stro_AdditionalPaymentRelatedToSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AdditionalPaymentRelatedToSalesMilestone", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Additional payment related to sales milestone.", "label": "Additional Payment Related To Sales Milestone", "terseLabel": "Payments related to sales milestone" } } }, "auth_ref": [] }, "stro_AdditionalPurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AdditionalPurchaseOfCommonStock", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Additional purchase of common stock.", "label": "Additional purchase of Common Stock", "terseLabel": "Additional purchase of common stock" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Stock transaction associated with taxes withheld on restricted stock units", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r30", "r31", "r271"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "stro_AggregateTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AggregateTransactionPrice", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total transaction price", "label": "Aggregate Transaction Price", "documentation": "Aggregate transaction price." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedCompe], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r300", "r305"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "terseLabel": "Accounts receivable, reserve for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r96", "r167", "r201", "r204", "r205", "r807"] }, "stro_AmendedAndRestatedTwoThousandTwentyOneEquityInducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AmendedAndRestatedTwoThousandTwentyOneEquityInducementPlanMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI], "lang": { "en-us": { "role": { "documentation": "Amended and restated two thousand twenty one equity inducement plan.", "label": "Amended And Restated Two Thousand Twenty One Equity Inducement Plan [Member]", "terseLabel": "Amended and Restated 2021 Equity Inducement Plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "stro_AmendmentNumberThreeTwoThousandFifteenLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AmendmentNumberThreeTwoThousandFifteenLicenseAgreementMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amendment Number Three Two Thousand Fifteen License Agreement.", "label": "Amendment Number Three Two Thousand Fifteen License Agreement [Member]", "terseLabel": "Amendment 3 2015 License Agreement" } } }, "auth_ref": [] }, "stro_AmortizationOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AmortizationOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails"], "lang": { "en-us": { "role": { "documentation": "Amortization of issuance costs.", "label": "Amortization of issuance costs" } } }, "auth_ref": [] }, "stro_AnnualIncrementPeriodOfCommonStockReservedForIssuance": { "xbrltype": "durationItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AnnualIncrementPeriodOfCommonStockReservedForIssuance", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI], "lang": { "en-us": { "role": { "terseLabel": "Annual increase period of common stock reserved for issuance", "label": "Annual Increment Period Of Common Stock Reserved For Issuance", "documentation": "Annual increase period of common stock reserved for issuance." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of net loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r148"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r323"] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed Securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r640", "r661", "r732", "r733", "r734"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r66", "r75", "r91", "r122", "r152", "r154", "r160", "r161", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r325", "r329", "r366", "r467", "r547",

```
"r629", "r630", "r660", "r690", "r748", "r749", "r796" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsAbstract", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ],
"lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic
benefit, classified as current." } } }, "auth_ref": [ "r87", "r97", "r122", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r325", "r329", "r366",
"r660", "r748", "r749", "r796" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrentAbstract", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": {
"en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure, Total", "verboseLabel": "Securities held", "terseLabel": "Total", "label": "Assets, Fair Value Disclosure",
"documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r343", "r344", "r649" ] }, "us-
gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "stro_AstellasLicenseAndCollaborationAgreementMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "AstellasLicenseAndCollaborationAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Astellas License and Collaboration Agreement", "label": "Astellas License and Collaboration Agreement [Member]", "documentation": "Astellas license and
collaboration agreement." } } }, "auth_ref": [] }, "stro_AstellasPharmaIncAstellasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "AstellasPharmaIncAstellasMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "documentation": "Astellas pharma inc. (\"Astellas\").", "label": "Astellas Pharma Inc. (\"Astellas\") [Member]", "terseLabel": "Astellas Pharma Inc.
(\"Astellas\")" } } }, "auth_ref": [] }, "stro_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"AtTheMarketOfferingMember", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": {
"en-us": { "role": { "terseLabel": "At-The-Market Sale", "label": "At-The-Market Offering [Member]", "documentation": "At-the-market offering." } } }, "auth_ref": [] },
"stro_AttheMarketIssuanceSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"AttheMarketIssuanceSalesAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited" ], "lang": { "en-us": { "role": {
"verboseLabel": "At-the-Market (\u201cATM\")", "terseLabel": "ATM", "label": "Atthe Market Issuance Sales Agreement [Member]", "documentation": "At-the-Market issuance
sales agreement." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation":
"Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r172" ] }, "us-
gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "verboseLabel": "Unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross
Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r173" ] }, "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Amortized Cost Basis", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r169", "r209",
"r466" ] }, "stro_AvailableForSaleDebtSecuritiesInvestmentsInUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"AvailableForSaleDebtSecuritiesInvestmentsInUnrealizedLoss", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized losses", "label": "Available For Sale Debt Securities Investments In Unrealized Loss", "documentation": "Available for sale debt securities
investments in unrealized loss." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-sale, Total", "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation":
"Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [
"r170", "r209", "r343", "r460", "r649", "r652", "r730", "r785", "r786", "r787" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AwardDateAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Award Date", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment
arrangement is granted." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770",
"r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AwardDateDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Award Date", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is
granted." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772",
"r773", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AwardTypeAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } },
"auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294",
"r295", "r296", "r297", "r298", "r299" ] }, "stro_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of
Presentation and Use of Estimates", "label": "Basis Of Presentation And Use Of Estimates Policy Policy [Text Block]", "documentation": "Basis of presentation and use of
estimates." } } }, "auth_ref": [] }, "stro_BionovaPharmaceuticalsLtdBionovaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "BionovaPharmaceuticalsLtdBionovaMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "documentation": "Bionova pharmaceuticals, ltd. (bionova).", "label": "BioNova Pharmaceuticals, Ltd. (BioNova) [Member]", "terseLabel":
"BioNova Pharmaceuticals, Ltd. (\"BioNova\")" } } }, "auth_ref": [] }, "stro_BlackstoneLifeSciencesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "BlackstoneLifeSciencesMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Blackstone life sciences.", "label": "Blackstone Life Sciences [Member]", "terseLabel": "Blackstone Life Sciences" } } }, "auth_ref": [] },
"stro_BmsAgreementAndTwoThousandEighteenBmsMasterServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "BmsAgreementAndTwoThousandEighteenBmsMasterServicesAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "BMS Agreement and the 2018 BMS Master Services Agreement", "label": "BMS Agreement And Two Thousand Eighteen BMS
Master Services Agreement [Member]", "documentation": "BMS agreement and two thousand eighteen BMS master services agreement." } } }, "auth_ref": [] },
"stro_BmsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "BmsAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "BMS Agreement", "label": "BMS Agreement [Member]", "documentation": "BMS agreement." } } }, "auth_ref": [] },
"stro_BristolMyersSquibbCompanyBMSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"BristolMyersSquibbCompanyBMSMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Bristol-Myers Squibb Company (\"BMS\")", "label": "Bristol Myers Squibb Company B M S [Member]", "documentation": "Bristol-
Myers Squibb Company (\"BMS\")." } } }, "auth_ref": [] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "stro_CallOptionPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "CallOptionPlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Call Option Plan", "label": "Call Option Plan [Member]", "documentation": "Call option plan." } } }, "auth_ref": [] }, "us-
gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of
equipment included in accounts payable and accrued expense", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for
```

purchases of fixed assets that have occurred." } } }, "auth_ref": ["r20", "r21", "r22"] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCas
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "negatedLabel": "Less amounts classified as cash equivalents, Amortized Cost Basis", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r17", "r89", "r619"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r89"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "negatedLabel": "Less amounts classified as cash equivalents, Fair Value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r783", "r784"] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r18", "r65"] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents and Marketable Securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": ["r729"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCas
], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the condensed Statements of Cash Flows", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r17", "r52", "r119"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r17", "r52", "r119"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r52"] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r89"] }, "stro_CashEquivalentsUnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CashEquivalentsUnrealizedGains", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less amounts classified as cash equivalents, Unrealized Gains", "label": "Cash Equivalents Unrealized Gains", "documentation": "Cash equivalents unrealized gains." } } }, "auth_ref": [] }, "stro_CashEquivalentsUnrealizedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CashEquivalentsUnrealizedLosses", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less amounts classified as cash equivalents, Unrealized Losses", "label": "Cash Equivalents Unrealized Losses", "documentation": "Cash equivalents unrealized losses." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "stro_ClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ClinicalTrialsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Clinical Trials", "label": "Clinical Trials [Member]", "documentation": "Clinical trials." } } }, "auth_ref": [] }, "stro_CmoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CmoMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "CMO", "label": "CMO [Member]", "documentation": "CMO." } } }, "auth_ref": [] }, "stro_CollaborationAgreementsAndSupplyAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CollaborationAgreementsAndSupplyAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Collaboration Agreements And Supply Agreements [Abstract]", "documentation": "Collaboration agreements and supply agreements." } } }, "auth_ref": [] }, "stro_CollaborationAndLicenseAgreementsAndSupplyAgreementAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CollaborationAndLicenseAgreementsAndSupplyAgreementAccrualsCurrent", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and license agreements and supply agreement accruals", "label": "Collaboration and License Agreements and Supply Agreement Accruals Current", "documentation": "Collaboration and license agreements and supply agreement accruals current." } } }, "auth_ref": [] }, "stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CollaborationAndLicenseAgreementsAndSupplyAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Collaboration And License Agreements And Supply Agreements [Abstract]", "documentation": "Collaboration and license agreements and supply agreements." } } }, "auth_ref": [] }, "stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CollaborationAndLicenseAgreementsAndSupplyAgreementsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and License Agreements and Supply Agreements", "label": "Collaboration And License Agreements And Supply Agreements [Member]", "documentation": "Collaboration and license agreements and supply agreements." } } }, "auth_ref": [] }, "stro_CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "CollaborationAndLicenseAgreementsAndSupplyAgreementsTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and License Agreements and Supply Agreements", "label": "Collaboration And License Agreements And Supply Agreements [Text Block]", "documentation": "Collaboration and license agreements and supply agreements." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [

```
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than
Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r323" } }, "us-gaap_CommercialPaperMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable)
that provides institutions with short-term funds." } } }, "auth_ref": { "r59", "r226", "r681", "r682", "r683", "r684" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and
contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has
entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or,
less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains
from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r38", "r68",
"r469", "r534" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ],
"lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The
entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r58", "r218", "r219", "r603", "r741", "r743" } },
"stro_CommonStockAwardsIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"CommonStockAwardsIssuedAndOutstandingMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Common Stock Awards Issued and Outstanding", "label": "Common Stock Awards Issued And Outstanding [Member]", "documentation": "Common
stock awards issued and outstanding." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Reserved common stock", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common
shares reserved for future issuance." } } }, "auth_ref": { "r41" } }, "stro_CommonStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "CommonStockIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock, issuance costs", "label": "Common Stock Issuance Costs", "documentation": "Common stock issuance costs." } } }, "auth_ref": [] }, "us-
gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel":
"Common Stock Options Issued and Outstanding", "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other
stock of the issuer." } } }, "auth_ref": [ "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r717", "r718", "r720", "r781", "r839", "r840" ] },
"stro_CommonStockOptionIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"CommonStockOptionIssuedAndOutstandingMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute
], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Options Issued and Outstanding", "label": "Common Stock Option Issued And Outstanding [Member]",
"documentation": "Common stock option issued and outstanding." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common
stock value per share", "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per
share of common stock." } } }, "auth_ref": [ "r41" ] }, "stro_CommonStockPremiumValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "CommonStockPremiumValue", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Common stock premium", "label": "Common Stock, Premium Value", "documentation": "Common stock premium value." } } }, "auth_ref": [] },
"us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be
issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r41", "r535" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common
Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total", "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued",
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and
remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized.
Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r41" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel":
"Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares
outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership
interest in a corporation." } } }, "auth_ref": [ "r8", "r41", "r535", "r553", "r840", "r841" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001
par value - 300,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 81,861,584 and 61,009,829 shares issued and outstanding as of June 30, 2024 and
December 31, 2023, respectively", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning
Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock value issued", "documentation":
"Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock
repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders'
equity." } } }, "auth_ref": [ "r41", "r471", "r660" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockVotingRights", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Voting
rights per share", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share
owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from
transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from
investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r102", "r104", "r109", "r461", "r482", "r483" ] }, "stro_ContingentPaymentEarnedMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ContingentPaymentEarnedMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "label": "Contingent Payment Earned [Member]", "documentation": "Contingent payment earned.", "terseLabel": "Contingent Payment Earned" } }
}, "auth_ref": [] }, "stro_ContingentPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"ContingentPaymentMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Contingent Payment", "label": "Contingent Payment [Member]", "documentation": "Contingent payment." } } }, "auth_ref": [] },
"stro_ContingentPaymentRecognizedAsDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"ContingentPaymentRecognizedAsDeferredRevenue", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Contingent payment recognized as deferred revenue", "label": "Contingent Payment Recognized As Deferred Revenue", "documentation":
"Contingent payment recognized as deferred revenue." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Liability, Total", "terseLabel": "Deferred revenue", "periodStartLabel": "Deferred revenue",
"periodEndLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which
consideration has been received or is receivable." } } }, "auth_ref": [ "r255", "r256", "r259" ] }, "stro_ContractWithCustomerLiabilityAdditions": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ContractWithCustomerLiabilityAdditions", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Additions to deferred revenue", "label": "Contract With Customer Liability Additions", "documentation": "Contract with customer
liability additions." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails" ],
"lang": { "en-us": { "role": { "negatedTerseLabel": "Recognition of revenue in current period", "label": "Contract with Customer, Liability, Change in Timeframe, Performance
Obligation Satisfied, Revenue Recognized", "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance
obligation to be satisfied." } } }, "auth_ref": [ "r637" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred
revenue\u2014current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which
consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r255", "r256", "r259" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue - non-
current", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has
been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r255", "r256", "r259" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Corporate Debt Securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or
foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r640", "r642", "r649", "r661", "r675", "r836" ] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r123", "r124", "r236", "r242", "r392", "r410", "r465", "r621", "r623" ] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover
[Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-
DD." } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Debt,
Current, Total", "terseLabel": "Debt\u2014current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [
"r93" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Investments in an unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "totalLabel": "Debt
Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss, Total", "documentation": "Amount of accumulated unrealized loss on investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss.
Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r76", "r211" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredChargesPolicyTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred
Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Royalty Obligation related to the Sale of Future Royalties and Non-cash Interest Expense", "documentation":
"Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r90" ] },
"stro_DeferredOfferingCostIncludedInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"DeferredOfferingCostIncludedInAccountsPayableAndAccruedExpenses", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Deferred
offering cost included in accounts payable and accrued expenses.", "label": "Deferred Offering Cost Included In Accounts Payable And Accrued Expenses", "terseLabel":
"Deferred offering cost included in accounts payable and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Summary of Deferred Revenue Balance", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "documentation": "Tabular disclosure of
the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } },
"auth_ref": [] }, "stro_DeferredRoyaltyObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"DeferredRoyaltyObligationAbstract", "lang": { "en-us": { "role": { "documentation": "Deferred royalty obligation.", "label": "Deferred Royalty Obligation [Abstract]" } } },
"auth_ref": [] }, "stro_DeferredRoyaltyObligationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"DeferredRoyaltyObligationLineItems", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails"
], "lang": { "en-us": { "role": { "documentation": "Deferred royalty obligation.", "label": "Deferred Royalty Obligation [Line Items]" } } }, "auth_ref": [] },
"stro_DeferredRoyaltyObligationRelatedToSaleOfFutureRoyaltiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"DeferredRoyaltyObligationRelatedToSaleOfFutureRoyaltiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Deferred royalty
obligation related to the sale of future royalties, classified as noncurrent.", "label": "Deferred Royalty Obligation Related To Sale Of Future Royalties, Noncurrent",
"terseLabel": "Deferred royalty obligation related to the sale of future royalties", "totalLabel": "Deferred royalty obligation related to the sale of future Vaxcyte royalties, net" }
} }, "auth_ref": [] }, "stro_DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAndNonCashInterestExpensePolicy": { "xbrltype": "stringItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAndNonCashInterestExpensePolicy", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation":
"Deferred Royalty Obligation Related to the sale of Future Royalties and Non Cash Interest Expense Policy.", "label": "Deferred Royalty Obligation Related to the sale of Future
Royalties and Non Cash Interest Expense Policy" } } }, "auth_ref": [] }, "stro_DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" ], "lang": { "en-us": { "role": { "documentation":
"Deferred royalty obligation related to the sale of future royalties.", "label": "Deferred Royalty Obligation related to the Sale of Future Royalties [Text Block]", "terseLabel":
"Deferred Royalty Obligation related to the Sale of Future Royalties" } } }, "auth_ref": [] }, "stro_DeferredRoyaltyObligationTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "DeferredRoyaltyObligationTable", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails"
], "lang": { "en-us": { "role": { "documentation": "Deferred royalty obligation.", "label": "Deferred Royalty Obligation [Table]" } } }, "auth_ref": [] },
"stro_DeferredRoyaltyObligationsRelatedToTheSaleOfFutureRoyaltiesAndNonCashInterestExpensePolicyPolicyTextBlock": { "xbrltype": "stringItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "DeferredRoyaltyObligationsRelatedToTheSaleOfFutureRoyaltiesAndNonCashInterestExpensePolicyPolicyTextBlock",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"documentation": "Deferred royalty obligations related to the sale of future royalties and non cash interest expense policy.", "label": "Deferred Royalty Obligations Related to
the sale of Future Royalties and Non Cash Interest Expense Policy [Policy Text Block]", "terseLabel": "Deferred Royalty Obligation related to the Sale of Future Royalties and
Non-cash Interest Expense" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation,
Depletion and Amortization, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate
expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } },
"auth_ref": [ "r4", "r152", "r157", "r161", "r629", "r630" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensation1" ],
"lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation", "label": "Share-
Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r269", "r273", "r301", "r302",
"r304", "r644" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } }
}, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract",
"lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period
Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value
Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype":
"gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus",
"label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide
financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date",
"label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the
EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." }
} }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport",
```

```
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } } }, "auth_ref": [ "r694" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } } }, "auth_ref": [ "r695" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "stro_EMDSeronoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "EMDSeronoMember", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EMD Serono", "label": "E M D Serono [Member]", "documentation": "EMD Serono." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic", "label": "Net loss per share, basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net (loss) income per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r110", "r130", "r131", "r132", "r133", "r134", "r135", "r140", "r142", "r145", "r146", "r147", "r151", "r319", "r322", "r340", "r341", "r462", "r484", "r626" ] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share Basic [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r142", "r143", "r145" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "label": "Net loss per share, diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net (loss) income per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r110", "r130", "r131", "r132", "r133", "r134", "r135", "r142", "r145", "r146", "r147", "r151", "r319", "r322", "r340", "r341", "r462", "r484", "r626" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r139", "r148", "r149", "r150" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedCompe
], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali
], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Total unrecognized compensation cost related to unvested granted", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r303" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali
], "lang": { "en-us": { "role": { "terseLabel": "Remaining unrecognized compensation cost expected to be recognized over weighted-average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r303" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali
], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r780" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali
], "lang": { "en-us": { "role": { "verboseLabel": "Stock Options", "terseLabel": "Employee Stock Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "stro_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "EmployeeStockPurchasePlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali
], "lang": { "en-us": { "role": { "verboseLabel": "ESPP", "terseLabel": "Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan [Member]", "documentation": "2018 Employee Stock Purchase Plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Headquartered in", "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Headquartered in state", "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r692" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r692" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r697" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer.
```

Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r692"] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Date of incorporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r696"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r692"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r692"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r692"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN, also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r692"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r85", "r105", "r106", "r107", "r125", "r126", "r127", "r129", "r134", "r136", "r138", "r153", "r199", "r200", "r214", "r254", "r313", "r314", "r316", "r317", "r318", "r320", "r321", "r322", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r367", "r368", "r369", "r370", "r371", "r372", "r374", "r375", "r389", "r480", "r500", "r501", "r502", "r514", "r573"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Estimated fair value of equity securities", "terseLabel": "Investment in equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r92", "r365", "r620"] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Realized gain on sale of equity securities", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r486", "r739"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized gain on equity securities", "verboseLabel": "Unrealized gain on equity securities", "label": "Unrealized (loss) gain on equity securities", "terseLabel": "Unrealized loss on equity securities", "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-ND)." } } }, "auth_ref": ["r487", "r739"] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": ["r26", "r661", "r685", "r686", "r687", "r842"] }, "stro_EstimatedServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "EstimatedServicePeriod", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated service period", "label": "Estimated Service Period", "documentation": "Estimated service period." } } }, "auth_ref": [] }, "stro_ExpansionPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ExpansionPremisesMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expansion Premises", "label": "Expansion Premises [Member]", "documentation": "Expansion premises." } } }, "auth_ref": [] }, "stro_FairMarketValueOfCommonStockIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FairMarketValueOfCommonStockIssued", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair market value of common stock issued", "label": "Fair Market Value of Common Stock Issued", "documentation": "Fair market value of common stock issued." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r343", "r344", "r357", "r649"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r343", "r344", "r357", "r649"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r348", "r349", "r350", "r351", "r352", "r353", "r358", "r650"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r348", "r349", "r350", "r351", "r352", "r353", "r358", "r650"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r237", "r261", "r262", "r263", "r264", "r265", "r266", "r342", "r344", "r345", "r346", "r347", "r356", "r357", "r359", "r397", "r398", "r399", "r634", "r635", "r640", "r641", "r642", "r649", "r652"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements Recurring", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r343", "r344", "r345", "r347", "r649", "r786", "r789"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a

recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r352", "r354", "r355", "r356", "r359", "r360", "r361", "r362", "r363", "r459", "r649", "r653"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r237", "r261", "r266", "r344", "r357", "r397", "r640", "r641", "r642", "r649"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r237", "r261", "r266", "r344", "r345", "r357", "r398", "r634", "r635", "r640", "r641", "r642", "r649"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r237", "r261", "r262", "r263", "r264", "r265", "r266", "r344", "r345", "r346", "r347", "r357", "r399", "r634", "r635", "r640", "r641", "r642", "r649", "r652"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r343", "r344", "r345", "r347", "r649", "r786", "r789"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r237", "r261", "r262", "r263", "r264", "r265", "r266", "r342", "r344", "r345", "r346", "r347", "r356", "r357", "r359", "r397", "r398", "r399", "r634", "r635", "r640", "r641", "r642", "r649", "r652"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r649", "r783", "r784", "r785", "r786", "r787", "r789"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r202", "r203", "r206", "r207", "r208", "r210", "r212", "r213", "r238", "r252", "r337", "r364", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r481", "r632", "r649", "r650", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r735", "r736", "r737", "r738", "r782", "r785", "r786", "r787", "r788", "r789"] }, "stro_FinancingComponentAssociatedWithProgramFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FinancingComponentAssociatedWithProgramFees", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Financing component associated with program fees.", "label": "Financing Component Associated with Program Fees", "terseLabel": "Financing component associated with program fees" } } }, "auth_ref": [] }, "stro_FinancingComponentOnUnearnedRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FinancingComponentOnUnearnedRevenueMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails"], "lang": { "en-us": { "role": { "label": "Financing Component On Unearned Revenue [Member]", "documentation": "Financing component on unearned revenue.", "terseLabel": "Financing Component on Unearned Revenue" } } }, "auth_ref": [] }, "stro_FirstCytokineDerivativeProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FirstCytokineDerivativeProgramMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "First Cytokine-Derivative Program", "label": "First Cytokine Derivative Program [Member]", "documentation": "First cytokine-derivative program." } } }, "auth_ref": [] }, "stro_FirstInstallmentMilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FirstInstallmentMilestonePaymentReceived", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "First installment milestone payment received.", "label": "First Installment Milestone Payment Received", "terseLabel": "First installment milestone payment received" } } }, "auth_ref": [] }, "stro_FivePrimeTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FivePrimeTherapeuticsIncMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Five Prime Therapeutics, Inc. (the \"Sublessor\")", "label": "Five Prime Therapeutics Inc [Member]", "documentation": "Five Prime Therapeutics, Inc." } } }, "auth_ref": [] }, "stro_FutureServicesOnCollaborationJointSteeringCommitteeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "FutureServicesOnCollaborationJointSteeringCommitteeMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Future Services on Collaboration Joint Steering Committee (\"JSC\")", "label": "Future Services On Collaboration Joint Steering Committee [Member]", "documentation": "Future services on collaboration Joint Steering Committee." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r50", "r557"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedCompe
], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r50"] },
"stro_ImpactsOfRecentlyAdoptedAccountingPronouncementsOn2021InterimReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ImpactsOfRecentlyAdoptedAccountingPronouncementsOn2021InterimReportingPolicyPolicyTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Impacts of Recently Adopted Accounting Pronouncements on 2021 Interim Reporting", "label": "Impacts of Recently Adopted Accounting Pronouncements on 2021 Interim Reporting policy [Policy Text Block]", "documentation": "Impacts of Recently Adopted Accounting Pronouncements on 2021 Interim Reporting policy." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r48", "r70", "r74", "r463", "r477", "r628", "r629", "r722", "r724", "r725", "r726", "r727"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedCompe
], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r215", "r216", "r217", "r349", "r353", "r358", "r497", "r499", "r558", "r615", "r651", "r809"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedCompe
], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r216", "r217", "r349", "r353", "r358", "r497", "r499", "r558", "r615", "r651", "r809"] }, "stro_IncomeTaxChargeRelatedToContingentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IncomeTaxChargeRelatedToContingentPayment", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax charge related to contingent payment", "label": "Income Tax Charge Related To Contingent Payment", "documentation": "Income tax charge related to contingent payment." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "verboseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r78", "r83", "r137", "r138", "r152", "r158", "r161", "r309", "r310", "r315", "r488", "r646"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Income Taxes Paid, Net, Total", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax paid", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r19", "r118", "r311", "r312"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "stro_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IncreaseDecreaseInAccruedExpensesAndOtherLiabilities", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Expenses and Other Liabilities", "documentation": "Increase (decrease) in accrued expenses and other liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r427", "r714"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total", "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Change in operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r699", "r714"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] },
"stro_IncreaseInStockReservedForIssuanceAsPercentageOfCapitalStockOutstandingOnLastDayOfPrecedingYear": { "xbrltype": "percentItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IncreaseInStockReservedForIssuanceAsPercentageOfCapitalStockOutstandingOnLastDayOfPrecedingYear", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year", "label": "Increase In Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Last Day Of Preceding Year", "documentation": "Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year." } } }, "auth_ref": [] }, "stro_IndustrialLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IndustrialLeaseMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Industrial Lease", "label": "Industrial Lease [Member]", "documentation": "Industrial lease." } } }, "auth_ref": [] }, "stro_InitialLicensingPaymentDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "InitialLicensingPaymentDue", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial licensing payment due", "label": "Initial Licensing Payment due", "documentation": "Initial licensing payment due." } } }, "auth_ref": [] },
"stro_InitialLicensingPaymentInEscrow": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "InitialLicensingPaymentInEscrow", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial licensing payment in escrow", "label": "Initial Licensing Payment in escrow", "documentation": "Initial licensing payment in escrow." } } }, "auth_ref": [] }, "stro_InitialPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "InitialPremisesMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial Premises", "label": "Initial Premises [Member]", "documentation": "Initial premises." } } }, "auth_ref": [] },
"stro_InterestAndOtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "InterestAndOtherIncomeExpenseNet", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income (expense), net", "label": "Interest and Other Income (Expense), Net", "documentation": "Interest and other income (expense), net." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r112", "r116", "r117"] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Investment Income, Nonoperating, Total", "terseLabel": "Interest income", "label": "Investment Income, Nonoperating", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": ["r51"] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares held", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": ["r516", "r524", "r581", "r590", "r594", "r679"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Investments in Equity Securities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r485", "r507", "r508", "r509", "r510", "r583", "r584"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment Type", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r517", "r519", "r520", "r522", "r524", "r579", "r582", "r586", "r589", "r591", "r592", "r595", "r596", "r597", "r598", "r599", "r679"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r517", "r519", "r520", "r522", "r524", "r579", "r582", "r586", "r589", "r591", "r592", "r595", "r596", "r597", "r598", "r599", "r679"] }, "stro_IpsenAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IpsenAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables"], "lang": { "en-us": { "role": { "documentation": "Ipsen agreement.", "label": "Ipsen Agreement [Member]", "terseLabel": "Ipsen Agreement" } } }, "auth_ref": [] }, "stro_IpsenPharmaSASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IpsenPharmaSASMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ipsen Pharma SAS (\"Ipsen\")", "label": "Ipsen Pharma S A S [Member]", "documentation": "Ipsen Pharma S A S." } } }, "auth_ref": [] }, "stro_IssuanceCostsIncludedInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IssuanceCostsIncludedInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Issuance costs included in accounts payable.", "label": "Issuance Costs Included In Accounts Payable", "terseLabel": "Issuance costs included in accounts payable" } } }, "auth_ref": [] },
"stro_IssuanceCostsRelatedToDeferredRoyaltyObligationInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "IssuanceCostsRelatedToDeferredRoyaltyObligationInAccruedExpenses", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Issuance costs related to deferred royalty obligation in accrued expenses.", "label": "Issuance Costs Related To Deferred Royalty Obligation In Accrued Expenses", "terseLabel": "Issuance costs related to deferred royalty obligation in accrued expenses" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r388", "r698"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r388", "r698"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r379", "r659"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of

Components of Lease Costs", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r793"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r794"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname", "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "terseLabel": "Aggregate estimated base rent payments due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r386"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remaining in 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r794"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r386"] }, "stro_LesseeOperatingLeaseOptionToExtendPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "LesseeOperatingLeaseOptionToExtendPeriod", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease extension period", "label": "Lessee Operating Lease Option To Extend Period", "documentation": "Lessee operating lease option to extend period." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r792"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r13", "r33", "r34", "r35", "r36", "r37", "r38", "r39", "r122", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r326", "r329", "r330", "r366", "r533", "r627", "r690", "r748", "r796", "r797"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r46", "r69", "r474", "r660", "r716", "r740", "r790"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r35", "r88", "r122", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r326", "r329", "r330", "r366", "r660", "r748", "r796", "r797"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "stro_LiabilityRelatedSaleOfFutureVaxcyteRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "LiabilityRelatedSaleOfFutureVaxcyteRoyalties", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails"], "lang": { "en-us": { "role": { "documentation": "Liability Related Sale Of Future Vaxcyte Royalties", "label": "Liability Related Sale Of Future Vaxcyte Royalties", "periodStartLabel": "Liability related to sale of future Vaxcyte royalties - beginning balance", "periodEndLabel": "Liability related to the sale of future Vaxcyte royalties - ending balance" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Long-term Debt, Excluding Current Maturities, Total", "verboseLabel": "Debt, non-current", "terseLabel": "Debt\u2014non-current", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r94"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r220", "r221", "r222", "r225", "r306", "r633", "r744", "r745"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r220", "r221", "r222", "r225", "r306", "r633", "r744", "r745"] }, "stro_MDAAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MDAAgreementMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "MDA Agreement", "label": "M D A Agreement [Member]", "documentation": "MDA agreement." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Marketable Securities, Current, Total", "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r708"] }, "stro_MarketableSecuritiesMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MarketableSecuritiesMaturityPeriod", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities maturity period", "label": "Marketable Securities Maturity Period", "documentation": "Marketable securities maturity period." } } }, "auth_ref": [] }, "stro_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MarketableSecuritiesMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities [Member]", "documentation": "Marketable securities.", "verboseLabel": "Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Marketable Securities, Noncurrent, Total", "verboseLabel": "Marketable securities, non-current", "terseLabel": "Long-term marketable securities", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": ["r708"] }, "stro_MaterialsSupplyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MaterialsSupplyMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails"], "lang": { "en-us": { "role": { "label": "Materials Supply [Member]", "documentation": "Materials supply.", "terseLabel": "Materials Supply" } } }, "auth_ref": [] }, "stro_MaximumAmountEligibleToReceiveForDevelopmentRegulatoryAndCommercialMilestonesForEachProductCandidate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MaximumAmountEligibleToReceiveForDevelopmentRegulatoryAndCommercialMilestonesForEachProductCandidate", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate", "label": "Maximum Amount Eligible To Receive For Development Regulatory And Commercial Milestones For Each Product Candidate", "documentation": "Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",

```
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Maximum", "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r268", "r306", "r347", "r426", "r496",
"r498", "r506", "r525", "r526", "r580", "r585", "r587", "r588", "r593", "r613", "r614", "r631", "r636", "r643", "r652", "r653", "r657", "r658", "r671", "r750", "r798", "r799",
"r800", "r801", "r802", "r803" ] }, "stro_MaximumPotentialPaymentsRelatedToDevelopmentRegulatoryCommercializationContingentPaymentsAndMilestones": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"MaximumPotentialPaymentsRelatedToDevelopmentRegulatoryCommercializationContingentPaymentsAndMilestones", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Maximum potential payments related to development regulatory commercialization contingent payments and milestones", "label": "Maximum
Potential Payments Related To Development Regulatory Commercialization Contingent Payments And Milestones", "documentation": "Maximum potential payments related to
development regulatory commercialization contingent payments and milestones." } } }, "auth_ref": [] }, "stro_MaximumRefundPeriodOnTerminationOfStudy": { "xbrltype":
"durationItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MaximumRefundPeriodOnTerminationOfStudy", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Maximum refund period on termination of study", "label": "Maximum Refund Period On Termination Of Study", "documentation": "Maximum
refund period on termination of study." } } }, "auth_ref": [] }, "stro_MerckKGaADarmstadtGermanyMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "MerckKGaADarmstadtGermanyMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')", "label": "Merck K
Ga A Darmstadt Germany [Member]", "documentation": "Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name \u201cEMD
Serono\u201d)." } } }, "auth_ref": [] }, "stro_MerckSharpAndDohmeCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "MerckSharpAndDohmeCorporationMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Merck Sharp & Dohme Corporation (\"Merck\")", "terseLabel": "Merck Sharp & Dohme Corp", "label": "Merck Sharp And Dohme
Corporation [Member]", "documentation": "Merck Sharp and Dohme Corporation." } } }, "auth_ref": [] }, "stro_MilestoneMethodRevenueRecognitionDescription": {
"xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MilestoneMethodRevenueRecognitionDescription", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Milestone method revenue recognition description", "label": "Milestone Method Revenue Recognition Description", "documentation": "Milestone
method revenue recognition description." } } }, "auth_ref": [] }, "stro_MilestoneMethodRevenueRecognitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "MilestoneMethodRevenueRecognitionTableTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Summary of Recognized Revenue", "label": "Milestone Method Revenue Recognition Table [Text Block]", "documentation": "Milestone method revenue
recognition." } } }, "auth_ref": [] }, "stro_MilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"MilestonePaymentReceivable", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "documentation": "Milestone payment receivable.", "label": "Milestone Payment Receivable", "terseLabel": "Milestone payment receivable" } } }, "auth_ref": [] },
"stro_MilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "MilestonePaymentReceived", "crdr":
"debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Milestone payment received", "label": "Milestone Payment Received", "documentation": "Milestone payment received." } } }, "auth_ref": [] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Minimum", "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r268", "r306", "r347", "r426", "r496",
"r498", "r506", "r525", "r526", "r580", "r585", "r587", "r588", "r593", "r613", "r614", "r631", "r636", "r643", "r652", "r653", "r657", "r671", "r750", "r798", "r799", "r800",
"r801", "r802", "r803" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MoneyMarketFundsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market
instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly
liquid securities." } } }, "auth_ref": [ "r753" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NatureOfOperations", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivities" ], "lang": { "en-us": { "role": {
"terseLabel": "Organization and Principal Activities", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's
business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination,
including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to
the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r80", "r84" ] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash
provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities,
including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their
investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term
credit." } } }, "auth_ref": [ "r115" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing
activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used
in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities,
including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property,
plant, and equipment and other productive assets." } } }, "auth_ref": [ "r115" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investing
activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by
(Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including
discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } },
"auth_ref": [ "r52", "r53", "r54" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating
activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited",
"http://www.sutrobio.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss",
"totalLabel": "Net loss", "verboseLabel": "Net (loss) income, basic and diluted", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net
of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r49", "r54", "r71", "r86", "r101", "r103", "r107", "r122", "r128", "r130", "r131", "r132", "r133", "r134",
"r137", "r138", "r144", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r319", "r322", "r341", "r366", "r479", "r555", "r571", "r572", "r688",
"r748" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent
Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy
pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual
impact." } } }, "auth_ref": [] }, "stro_NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails"
], "lang": { "en-us": { "role": { "documentation": "Non cash interest expense associated with the sale of future royalties", "label": "Non Cash Interest Expense Associated With
The Sale of Future Royalties", "terseLabel": "Non-cash interest expense associated with the sale of future Yaxcyte royalties" } } }, "auth_ref": [] },
"stro_NonCashInterestExpenseOnDeferredRoyaltyObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"NonCashInterestExpenseOnDeferredRoyaltyObligation", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Non cash
interest expense on deferred royalty obligation.", "label": "Non Cash Interest Expense On Deferred Royalty Obligation", "terseLabel": "Non-cash interest expense on deferred
royalty obligation" } } }, "auth_ref": [] }, "stro_NonCashInterestExpenseRelatedToTheSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://www.sutrobio.com/20240630", "localname": "NonCashInterestExpenseRelatedToTheSaleOfFutureRoyalties", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Non-cash interest expense related to the sale of future royalties.", "label": "Non-cash Interest Expense Related To The Sale Of Future Royalties", "terseLabel": "Non-cash interest expense related to the sale of future royalties", "negatedLabel": "Non-cash interest expense related to the sale of future royalties" } } }, "auth_ref": [] } }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing information:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] },
"stro_NoncashLeaseExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "NoncashLeaseExpenses", "crdr": "debit",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Noncash Lease Expenses", "documentation": "Noncash lease expenses", "terseLabel": "Non-cash lease expenses" } } }, "auth_ref": [] } },
"stro_NonrefundableNonCreditableUpfrontFeePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"NonrefundableNonCreditableUpfrontFeePayment", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrefundable, non-creditable upfront payment", "label": "Nonrefundable, Non-creditable Upfront Fee Payment", "documentation":
"Nonrefundable, non-creditable upfront fee payment." } } }, "auth_ref": [] }, "stro_NonrefundableNoncreditableUpfrontPaymentReceivable": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.sutrobio.com/20240630", "localname": "NonrefundableNoncreditableUpfrontPaymentReceivable", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrefundable, non-creditable upfront payment receivable", "label": "Nonrefundable Noncreditable Upfront Payment Receivable",
"documentation": "Nonrefundable non-creditable upfront payment receivable." } } }, "auth_ref": [] }, "stro_NumberOfGoodsAndServices": { "xbrltype": "integerItemType",
"nsuri": "http://www.sutrobio.com/20240630", "localname": "NumberOfGoodsAndServices", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of goods and services", "label": "Number Of Goods And Services", "documentation": "Number of goods and services." } } }, "auth_ref": [] },
"stro_NumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "NumberOfInstallments", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of installments", "label": "Number of Installments", "documentation": "Number of installments." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [
"r630", "r723" ] }, "stro_NumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"NumberOfPerformanceObligations", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of performance obligations", "label": "Number Of Performance Obligations", "documentation": "Number of performance obligations." } } }, "auth_ref": [] }, "stro_NumberOfTargetPrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "NumberOfTargetPrograms", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Number of target programs", "label": "Number Of Target Programs", "documentation": "Number of target programs." } } },
"auth_ref": [] }, "stro_OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "OngoingPerformanceRelatedToUnsatisfiedPerformanceObligationsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "label": "Ongoing Performance Related To Unsatisfied Performance Obligations [Member]", "documentation": "Ongoing performance related to unsatisfied performance obligations.", "terseLabel": "Ongoing Performance Related to Unsatisfied Performance Obligations" } } }, "auth_ref": [] } }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [
"r74", "r628", "r722", "r724", "r725", "r726", "r727" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r380", "r659" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r791" ]
}, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
], "lang": { "en-us": { "role": { "totalLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r377" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities current", "negatedTerseLabel": "Less: current portion", "terseLabel": "Operating lease liability - current", "label": "Operating Lease, Liability, Current",
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r377" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent",
"crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating lease liability - non-current", "terseLabel": "Total lease liabilities, non-current", "verboseLabel": "Operating lease liabilities non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r377" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r378", "r383" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [
"r376" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease, weighted average discount rate, percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r385", "r659" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease, weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } },
"auth_ref": [ "r384", "r659" ] }, "stro_OptionGrantedInAugustTwoThousandAndNineteenMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "OptionGrantedInAugustTwoThousandAndNineteenMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Option Granted in August 2019", "label": "Option Granted In August Two Thousand And Nineteen [Member]", "documentation":
"Option granted in August 2019." } } }, "auth_ref": [] }, "stro_OptionGrantedInFebruaryTwoThousandAndSeventeenMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "OptionGrantedInFebruaryTwoThousandAndSeventeenMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Option Granted in February 2017", "label": "Option Granted In February Two Thousand And Seventeen [Member]",
"documentation": "Option granted in February 2017." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role":
{ "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] },
"stro_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "label": "Organization Consolidation And Presentation Of Financial
Statements [Line Items]", "documentation": "Organization consolidation and presentation of financial statements line items." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other
```

Assets, Noncurrent, Total", "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r90"] }, "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income :", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited", "http://www.sutrobio.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized (loss) income on available-for-sale securities", "verboseLabel": "Net unrealized gain (loss) on available-for-sale securities", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r98", "r99", "r100", "r480"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Other", "totalLabel": "Other Liabilities, Current, Total", "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r34", "r660"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other Liabilities, Noncurrent, Total", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r37"] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other Noncash Income (Expense), Total", "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r54"] }, "stro_OtherThanTemporaryImpairmentLossesDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "OtherThanTemporaryImpairmentLossesDebtSecuritiesAvailableForSaleRecognizedInEarnings", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Recognition of other-than-temporary impairment", "label": "Other Than Temporary Impairment Losses Debt Securities Available For Sale Recognized In Earnings", "documentation": "Other than temporary impairment losses debt securities available for sale recognized in earnings." } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Underwritten Offering", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid related to net shares settlement of restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r111"] }, "stro_PaymentsToAcquireEquipmentAndLeaseholdImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "PaymentsToAcquireEquipmentAndLeaseholdImprovements", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of equipment and leasehold improvements", "label": "Payments To Acquire Equipment And Leasehold Improvements", "documentation": "Payments to acquire equipment and leasehold improvements." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Marketable Securities, Total", "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r731"] }, "stro_PercentageOfInterestRateAmortizeLiability": { "xbrltype": "percentItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "PercentageOfInterestRateAmortizeLiability", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of interest rate amortize liability", "label": "Percentage Of Interest Rate Amortize Liability", "terseLabel": "Percentage of interest rate amortize liability" } } }, "auth_ref": [] }, "stro_PercentageOfVwapPremium": { "xbrltype": "pureItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "PercentageOfVwapPremium", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of volume weighted average price premium.", "label": "Percentage Of VWAP Premium", "terseLabel": "Percentage of VWAP premium" } } }, "auth_ref": [] }, "stro_PeriodFromIssuanceOfUnauditedInterimCondensedFinancialStatements": { "xbrltype": "durationItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "PeriodFromIssuanceOfUnauditedInterimCondensedFinancialStatements", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Period from issuance date of unaudited interim condensed financial statements", "label": "Period From Issuance Of Unaudited Interim Condensed Financial Statements", "documentation": "Period from issuance of unaudited interim condensed financial statements" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r40", "r240"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r40", "r535"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "totalLabel": "Preferred Stock, Shares Issued, Total", "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r40", "r240"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "verboseLabel": "Preferred stock, outstanding", "terseLabel": "Preferred stock shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r40", "r535", "r553", "r840", "r841"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value - 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r40", "r470", "r660"] }, "stro_PremiumOnCommonStockIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "PremiumOnCommonStockIssued", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Premium on common stock issued to Ipsen Biopharma, Inc. (USA)", "label": "Premium On Common Stock Issued", "documentation": "Premium on common stock issued," } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } },

```
"auth_ref": [ "r709" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from
sales of common stock, net of issuance costs", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount
received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from
sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA)", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Payment receivable from common
stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] },
"stro_ProceedsFromMaturitiesOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"ProceedsFromMaturitiesOfMarketableSecurities", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of
marketable securities", "label": "Proceeds From Maturities Of Marketable Securities", "documentation": "Proceeds from maturities of marketable securities." } } }, "auth_ref":
[] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceed from
sale of equity securities", "label": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security
measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r77", "r113" ] },
"stro_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds
from sale of future royalties net of issuance costs.", "label": "Proceeds From Sale of Future Royalties Net of Issuance Costs", "terseLabel": "Proceeds from the sale of future
royalties, net of issuance costs" } } }, "auth_ref": [] }, "stro_ProceedsFromSalesOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "ProceedsFromSalesOfMarketableSecurities", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of
marketable securities", "label": "Proceeds From Sales Of Marketable Securities", "documentation": "Proceeds from sales of marketable securities." } } }, "auth_ref": [] }, "us-
gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised",
"crdr": "debit", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role":
{ "terseLabel": "Proceeds from exercise of common stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise
of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r11" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from
employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the
period." } } }, "auth_ref": [ "r2" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product
and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r162", "r428", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r617", "r638", "r670", "r671",
"r672", "r674", "r676", "r746", "r747", "r751", "r808", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824",
"r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r837", "r838" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product
and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r162", "r428", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r617", "r638", "r670", "r671",
"r672", "r674", "r676", "r746", "r747", "r751", "r808", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824",
"r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r837", "r838" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss",
"totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss), Including Portion Attributable to
Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling
interest." } } }, "auth_ref": [ "r86", "r101", "r103", "r114", "r122", "r128", "r134", "r137", "r138", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235",
"r319", "r322", "r324", "r327", "r328", "r341", "r366", "r463", "r478", "r513", "r555", "r571", "r572", "r647", "r648", "r689", "r712", "r748" ] }, "us-
gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to
produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r387" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and
Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Net, Total",
"terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and
amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to,
land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r387", "r464", "r476", "r660" ] }, "us-
gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of
business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment
including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r57", "r387" ] }, "srt_RangeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r260", "r268", "r296", "r297", "r298",
"r306", "r347", "r400", "r409", "r426", "r496", "r498", "r506", "r525", "r526", "r580", "r585", "r587", "r588", "r593", "r613", "r614", "r631", "r636", "r643", "r652", "r653",
"r657", "r658", "r671", "r679", "r742", "r750", "r786", "r799", "r800", "r801", "r802", "r803" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r260", "r268", "r296", "r297", "r298",
"r306", "r347", "r400", "r409", "r426", "r496", "r498", "r506", "r525", "r526", "r580", "r585", "r587", "r588", "r593", "r613", "r614", "r631", "r636", "r643", "r652", "r653",
"r657", "r658", "r671", "r679", "r742", "r750", "r786", "r799", "r800", "r801", "r802", "r803" ] }, "stro_ReductionOfResearchAndDevelopmentExpensesRecognized": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ReductionOfResearchAndDevelopmentExpensesRecognized", "crdr": "debit",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Reduction of research and development expenses recognized", "label": "Reduction of Research and Development Expenses
Recognized", "documentation": "Reduction of research and development expenses recognized." } } }, "auth_ref": [] }, "stro_ReimbursementsExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ReimbursementsExpenses", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Reimbursements expenses", "label": "Reimbursements Expenses", "documentation": "Reimbursements expenses." } } }, "auth_ref": [] },
"stro_ReimbursementsExpensesAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ReimbursementsExpensesAccruals",
"crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Reimbursements expenses accruals", "label": "Reimbursements Expenses Accruals", "documentation": "Reimbursements expenses accruals." } }
}, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related
party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner,
management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or
ownership interest." } } }, "auth_ref": [ "r166", "r267", "r390", "r391", "r468", "r475", "r528", "r529", "r530", "r531", "r532", "r552", "r554", "r578" ] }, "us-
gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } }
}, "auth_ref": [ "r390", "r391", "r795" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } },
```

```
"auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties.
Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner,
management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or
ownership interest." } } }, "auth_ref": [ "r166", "r267", "r390", "r391", "r468", "r475", "r528", "r529", "r530", "r531", "r532", "r552", "r554", "r578", "r795" ] }, "us-
gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of
debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [
"r713" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r123", "r124", "r236", "r242", "r392", "r410", "r465", "r622", "r623" ] }, "us-
gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr":
"debit", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation":
"Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of
research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired
in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r308", "r615", "r629", "r804" ] }, "us-
gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedCompe
], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary
financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] },
"stro_ResearchAndDevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"ResearchAndDevelopmentServicesMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "label": "Research And Development Services [Member]", "documentation": "Research and development services.", "terseLabel": "Research and
Development Services" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent.
Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand
deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present
insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r89" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCas
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label":
"Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency
on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r79", "r707", "r715" ]
}, "stro_RestrictedStockUnitsIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"RestrictedStockUnitsIssuedAndOutstandingMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute
], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units Issued and Outstanding", "label": "Restricted Stock Units Issued And Outstanding [Member]",
"documentation": "Restricted stock units issued and outstanding." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or
an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings
(Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated
Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of
accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r43", "r61", "r473", "r503", "r505", "r512", "r536", "r660" ] }, "us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r85", "r125", "r126",
"r127", "r129", "r134", "r136", "r138", "r199", "r200", "r214", "r313", "r314", "r316", "r317", "r318", "r320", "r321", "r322", "r331", "r333", "r334", "r336", "r339", "r374",
"r375", "r500", "r502", "r514", "r840" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Total
revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised
good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing
transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r72", "r73", "r152", "r155", "r156", "r159", "r161", "r162", "r163", "r165",
"r257", "r258", "r428" ] }, "stro_RevenueInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"RevenueInterestPercentage", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Revenue interest percentage.", "label": "Revenue Interest Percentage", "terseLabel": "Revenue interest percentage" } } }, "auth_ref": [] },
"stro_RevenueRecognitionAggregateContingentPaymentsEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"RevenueRecognitionAggregateContingentPaymentsEligibleToReceive", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Revenue recognition aggregate contingent payments eligible to receive", "label": "Revenue Recognition Aggregate Contingent Payments Eligible
To Receive", "documentation": "Revenue recognition aggregate contingent payments eligible to receive." } } }, "auth_ref": [] },
"stro_RevenueRecognitionOfUpFrontPaymentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"RevenueRecognitionOfUpFrontPaymentAmount", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "documentation": "Revenue recognition of up-front payment amount.", "label": "Revenue Recognition Of Up Front Payment Amount", "terseLabel": "Recognition
of up front payment" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueRecognitionPolicyTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue
Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from
other sources." } } }, "auth_ref": [ "r556", "r616", "r624" ] }, "stro_RevenueRecognizedFromContingentPaymentNetOfWithholdingTax": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.sutrobio.com/20240630", "localname": "RevenueRecognizedFromContingentPaymentNetOfWithholdingTax", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Revenue recognized from contingent payment", "label": "Revenue Recognized From Contingent Payment , Net Of Withholding Tax",
"documentation": "Revenue recognized from contingent payment , net of withholding tax." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalInformationDe
], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, amount", "label": "Revenue, Remaining Performance Obligation, Amount",
"documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r81" ] }, "us-
gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalInformationDe
], "lang": { "en-us": { "role": { "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]", "label": "Revenue, Remaining
Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
```

gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalInformationDe], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r82"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalInformationDe], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": ["r82"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsPerformanceObligationsAdditionalInformationDe], "lang": { "en-us": { "role": { "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails"], "lang": { "en-us": { "role": { "totalLabel": "Revenues, Total", "label": "Revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r72", "r73", "r108", "r122", "r152", "r155", "r156", "r159", "r161", "r162", "r163", "r165", "r198", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r366", "r463", "r629", "r748"] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "terseLabel": "Royalty", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": ["r752"] }, "stro_RoyaltyObligationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "RoyaltyObligationTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesTables"], "lang": { "en-us": { "role": { "documentation": "Royalty obligation.", "label": "Royalty Obligation [Table Text Block]", "terseLabel": "Schedule of Royalty Obligation transaction" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "stro_SanCarlosLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "SanCarlosLeaseMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "San Carlos Lease", "label": "San Carlos Lease [Member]", "documentation": "San carlos lease." } } }, "auth_ref": [] }, "stro_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accrued Liabilities and Other Liabilities Disclosure, Current [Table Text Block]", "documentation": "Schedule of accrued liabilities and other liabilities disclosure, current." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]", "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Equivalents and Marketable Securities", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r323"] }, "stro_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Reserved for Future Issuance", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "documentation": "Schedule of common stock reserved for future issuance." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Computation of Company's Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r721"] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": ["r23", "r25", "r142", "r143", "r145"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureEquityIncentivePlansEmployeeStockPurchasePlanAndStockBasedCompensationScheduleOfStockBasedComp], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities Measured on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r783", "r784"] }, "stro_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630",

```
"localname": "ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]", "label": "Schedule Of Organization Consolidation And Presentation
Of Financial Statements [Table]", "documentation": "Schedule of organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Reconciliation of Cash, Cash Equivalents, and Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure
of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r12", "r65", "r806" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-
Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } },
"auth_ref": [ "r270", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292",
"r293", "r294", "r295", "r296", "r297", "r298", "r299" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Summary of Status and Activity of Non-vested RSUs", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity
[Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the
beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r62" ] }, "us-
gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Summary of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation":
"Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-
average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r62" ] }, "us-
gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of ESPP Shares Using Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Employee
Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the
fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free
rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r64" ] }, "us-
gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Stock Options Valuation", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation
Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options,
including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free
rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r64" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r691" ] }, "dei_SecurityExchangeName": { "xbrltype":
"edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name",
"label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r693" ] },
"srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r163", "r164", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439",
"r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r518", "r521", "r523",
"r582", "r586", "r591", "r595", "r602", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r618", "r639", "r662", "r663", "r664", "r665", "r666", "r667",
"r668", "r669", "r673", "r679", "r751", "r808", "r810", "r811", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826",
"r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r837", "r838" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based
Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense",
"documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Shares vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting
Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or
performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not
limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r644" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "negatedLabel": "Canceled and forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were
forfeited during the reporting period." } } }, "auth_ref": [ "r290" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Canceled and forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans
other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r290" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "verboseLabel": "Granted", "terseLabel": "Restricted common stock granted", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit)
option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r288" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "verboseLabel": "Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards
issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
} } }, "auth_ref": [ "r288" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "periodStartLabel": "Non-vested, Beginning Balance", "periodEndLabel": "Non-vested, Ending balance", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based
payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r285", "r286" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other
than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a
period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "periodStartLabel": "Non-vested, Beginning Balance", "periodEndLabel": "Non-vested, Ending balance", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or
unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r285", "r286" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant-Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "negatedLabel": "Vested and released", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the
reporting period." } } }, "auth_ref": [ "r289" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Vested and released", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-
based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance
requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r289" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": {
"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref":
[] }, "stro_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyLineItems",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items]",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items]", "documentation": "Share based
compensation arrangement by share based payment award fair value assumptions and methodology." } } }, "auth_ref": [] },
"stro_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTable",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table]",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table]", "documentation": "Share based
compensation arrangement by share based payment award fair value assumptions and methodology." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions,
Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares
over the option's term." } } }, "auth_ref": [ "r297" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions,
Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be
defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously
compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices
plus dividends, if any, over the period." } } }, "auth_ref": [ "r296" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, Maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value
Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate
during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard
deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural
logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, Minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value
Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate
during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard
deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural
logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation":
[
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value
Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r298"
] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, Maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value
Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } }
}, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, Minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value
Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } }
}, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r270", "r272", "r274", "r275", "r276", "r277", "r278",
"r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299" ] }, "us-
```

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares issuable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r645"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r28"] }, "stro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant, increase", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Increase", "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant , increase." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r279"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable, Weighted - Average Exercise Price, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r279"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "negatedLabel": "Canceled and forfeited, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "label": "Total options granted", "verboseLabel": "Share-based compensation arrangement by share-based payment award options, shares granted", "terseLabel": "Granted, Shares", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r281"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r28"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "verboseLabel": "Options vested and outstanding", "periodStartLabel": "Stock options outstanding, Beginning Balance, Shares", "periodEndLabel": "Stock options outstanding, Ending Balance, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r277", "r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "periodStartLabel": "Stock options outstanding, Weighted - Average Exercise Price, Beginning Balance", "periodEndLabel": "Stock options outstanding, Weighted - Average Exercise Price, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r277", "r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r28"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Weighted - Average Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Weighted - Average Exercise Price, Canceled and forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r283"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO], "lang": { "en-us": { "role": { "terseLabel": "Weighted - Average Exercise Price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r281"] }, "stro_ShareBasedCompensationAwardTrancheFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ShareBasedCompensationAwardTrancheFiveMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "January 1 , 2021", "label": "Share Based Compensation Award Tranche Five [Member]", "documentation": "Share-based compensation award tranche five." } } }, "auth_ref": [] }, "stro_ShareBasedCompensationAwardTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ShareBasedCompensationAwardTrancheFourMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "January 1 , 2020", "label": "Share Based Compensation Award Tranche Four [Member]", "documentation": "Share-based compensation award tranche four." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "January 1 , 2017", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "stro_ShareBasedCompensationAwardTrancheSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "ShareBasedCompensationAwardTrancheSixMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali], "lang": { "en-us": { "role": { "terseLabel": "January 1 , 2022", "label": "Share Based Compensation Award Tranche Six [Member]", "documentation": "Share-based compensation award tranche six." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionali

```
], "lang": { "en-us": { "role": { "terseLabel": "January 1 , 2019", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "January 1 , 2018", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r295" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r28" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Weighted - Average Remaining Contract Term, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r28" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "verboseLabel": "Options unvested and outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "Weighted - Average Remaining Contract Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r63" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Common Stock Balance, Shares", "periodEndLabel": "Common Stock Balance, Shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock transaction associated with taxes withheld on restricted stock units,Shares", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "stro_SharesToBeIssuedUnderEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "SharesToBeIssuedUnderEmployeeStockPurchasePlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute
], "lang": { "en-us": { "role": { "terseLabel": "Shares to be Issued Under Employee Stock Purchase Plan", "label": "Shares to be issued under employee stock purchase plan [Member]", "documentation": "Shares to be issued under employee stock purchase plan." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r381", "r659" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r55", "r120" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r41", "r44", "r45", "r85", "r105", "r106", "r107", "r125", "r126", "r127", "r129", "r134", "r136", "r138", "r153", "r199", "r200", "r214", "r254", "r313", "r314", "r316", "r317", "r318", "r320", "r321", "r322", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r367", "r368", "r369", "r370", "r371", "r372", "r374", "r375", "r389", "r480", "r500", "r501", "r502", "r514", "r573" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r163", "r164", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r518", "r521", "r523", "r582", "r586", "r591", "r595", "r602", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r618", "r639", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r673", "r679", "r751", "r808", "r810", "r811", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r837", "r838" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r127", "r153", "r375", "r428", "r507", "r515", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r554", "r556", "r557", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r680" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r125", "r126", "r127", "r153", "r166", "r375", "r428", "r507", "r515", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r554", "r556", "r557", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r680" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock under Employee Stock Purchase Plan, Shares", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r8", "r40", "r41", "r61" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement ,Shares", "terseLabel": "Shares of common stock", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r40", "r41", "r61", "r511", "r573", "r600" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units, Shares", "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "label": "Stock Issued During
```

Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r8", "r40", "r41", "r61"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Exercised, Shares", "verboseLabel": "Options vested and exercised", "terseLabel": "Exercise of common stock options, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r8", "r40", "r41", "r61", "r282"] }, "stro_StockIssuedDuringPeriodSharesThroughAtTheMarketSale": { "xbrltype": "sharesItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "StockIssuedDuringPeriodSharesThroughAtTheMarketSale", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with At-The-Market sale, net of issuance costs, Shares", "label": "Stock Issued During Period Shares Through At The Market Sale", "documentation": "Stock issued during period shares through At The Market sale." } } }, "auth_ref": [] }, "stro_StockIssuedDuringPeriodSharesThroughTheUnderwrittenOffering": { "xbrltype": "sharesItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "StockIssuedDuringPeriodSharesThroughTheUnderwrittenOffering", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with the underwritten offering, net of issuance costs , Shares", "label": "Stock Issued During Period Shares Through The Underwritten Offering", "documentation": "Stock issued during period shares through the underwritten offering." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r8", "r40", "r41", "r61"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r8", "r40", "r41", "r61", "r514", "r573", "r600", "r689"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r8", "r61"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r8", "r41", "r44", "r45", "r61"] }, "stro_StockIssuedDuringPeriodValueThroughAtTheMarketSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "StockIssuedDuringPeriodValueThroughAtTheMarketSale", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with At-The-Market sale, net of issuance costs", "label": "Stock Issued During Period Value Through At The Market Sale", "documentation": "Stock issued during period value through At The Market sale." } } }, "auth_ref": [] }, "stro_StockIssuedDuringPeriodValueThroughTheUnderwrittenOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "StockIssuedDuringPeriodValueThroughTheUnderwrittenOfferings", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with the underwritten offering, net of issuance costs", "label": "Stock Issued During Period Value Through The Underwritten Offerings", "documentation": "Stock issued during period value through the underwritten offerings." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited" "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r41", "r44", "r45", "r56", "r537", "r553", "r574", "r575", "r660", "r690", "r716", "r740", "r790", "r840"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "stro_StockholdersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "StockholdersEquityLineItems", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity [Line Items]", "label": "Stockholders Equity [Line Items]", "documentation": "Stockholders equity." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r60", "r121", "r239", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r338", "r576", "r577", "r601"] }, "stro_StockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "StockholdersEquityTable", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity [Table]", "label": "Stockholders Equity [Table]", "documentation": "Stockholders equity." } } }, "auth_ref": [] }, "stro_SubleaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "SubleaseAgreementMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sublease Agreement", "label": "Sublease Agreement [Member]", "documentation": "Sublease agreement." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r373", "r393"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r373", "r393"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r373", "r393"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Substantial doubt about going concern, within one year", "label": "Substantial Doubt about Going Concern, within One Year [true false]", "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued." } } }, "auth_ref": ["r6"] }, "stro_SummaryOfStatusOfCallOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "SummaryOfStatusOfCallOptionsTableTextBlock", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Status of Call Options", "label": "Summary Of Status Of Call Options Table [Text Block]", "documentation": "Summary of status of call options." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "stro_SupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "SupplyAgreementMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Supply Agreement", "label": "Supply Agreement [Member]", "documentation": "Supply agreement." } } }, "auth_ref": [] }, "stro_SupranationalDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "SupranationalDebtSecuritiesMember", "presentation": ["http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Supranational Debt Securities", "label": "Supranational Debt Securities [Member]", "documentation": "Supranational Debt Securities." } } }, "auth_ref": [] }, "stro_TaslyBiopharmaceuticalsCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":

```
"TaslyBiopharmaceuticalsCoLtdMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tasly Biopharmaceuticals Co., Ltd. (\"Tasly\")", "label": "Tasly Biopharmaceuticals Co. Ltd [Member]", "documentation": "Tasly Biopharmaceuticals Co. Ltd." } } }, "auth_ref": [] }, "stro_TaslyLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "TaslyLicenseAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Tasly License Agreement", "label": "Tasly License Agreement [Member]", "documentation": "Tasly license agreement." } } }, "auth_ref": [] },
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label":
"Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "stro_TransactionCostsIncurred": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "TransactionCostsIncurred", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "documentation": "Transaction costs incurred.", "label": "Transaction costs incurred" } } }, "auth_ref": [] }, "stro_TransactionPrice": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "TransactionPrice", "crdr": "credit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Transaction price", "label": "Transaction Price", "documentation": "Transaction price." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another
financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial
instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176",
"r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r238",
"r252", "r337", "r364", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r411", "r412", "r413", "r414",
"r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r481", "r649", "r650", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661",
"r700", "r701", "r702", "r703", "r704", "r705", "r706", "r735", "r736", "r737", "r738", "r782", "r785", "r786", "r787", "r788", "r789" ] },
"stro_TwoThousandEighteenBmsMasterServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"TwoThousandEighteenBmsMasterServicesAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "2018 BMS Master Services Agreement", "label": "Two Thousand Eighteen BMS Master Services Agreement [Member]", "documentation": "Two thousand
eighteen BMS master services agreement." } } }, "auth_ref": [] }, "stro_TwoThousandEighteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationScheduleO
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": {
"role": { "verboseLabel": "Shares Reserved for Issuance Under 2018 Employee Stock Purchase Plan", "terseLabel": "2018 Employee Stock Purchase Plan", "label": "Two
Thousand Eighteen Employee Stock Purchase Plan [Member]", "documentation": "Two thousand eighteen employee stock purchase plan." } } }, "auth_ref": [] },
"stro_TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "TwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": {
"role": { "label": "Remaining Shares Reserved for Issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan", "verboseLabel": "Remaining shares reserved
for issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan", "terseLabel": "2018 Equity Incentive Plan and 2021 Equity Inducement Plan",
"documentation": "Two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan." } } }, "auth_ref": [] },
"stro_TwoThousandEighteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"TwoThousandEighteenEquityIncentivePlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "2018 Equity Incentive Plan", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "documentation": "Two thousand
eighteen equity incentive plan." } } }, "auth_ref": [] }, "stro_TwoThousandEighteenMerckAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "TwoThousandEighteenMerckAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "2018 Merck Agreement", "label": "Two Thousand Eighteen Merck Agreement [Member]", "documentation": "Two thousand eighteen Merck
agreement." } } }, "auth_ref": [] }, "stro_TwoThousandFifteenLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "TwoThousandFifteenLicenseAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Two thousand fifteen license agreement.", "label": "Two Thousand Fifteen License Agreement [Member]", "terseLabel": "2015 License Agreement" } } }, "auth_ref": [] },
"stro_TwoThousandFourPlanTwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname":
"TwoThousandFourPlanTwoThousandEighteenEquityIncentivePlanAndTwoThousandTwentyOneEquityInducementPlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationSummaryO
], "lang": { "en-us": { "role": { "terseLabel": "2004 Plan, 2018 Plan and 2021 Plan", "label": "Two Thousand Four Plan Two Thousand Eighteen Equity Incentive Plan And Two
Thousand Twenty One Equity Inducement Plan [Member]", "documentation": "Two thousand four plan two thousand eighteen equity incentive plan and two thousand twenty
one equity inducement plan." } } }, "auth_ref": [] }, "stro_TwoThousandNineteenEMDSeronoSupplyAgreementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "TwoThousandNineteenEMDSeronoSupplyAgreementsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "2019 EMD Serono Supply Agreement", "label": "Two Thousand Nineteen E M D Serono Supply Agreements [Member]", "documentation": "2019 EMD Serono
supply agreements." } } }, "auth_ref": [] }, "stro_TwoThousandTwentyMerckMasterServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "TwoThousandTwentyMerckMasterServicesAgreementMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "2020 Merck Master Services Agreement", "label": "Two Thousand Twenty Merck Master Services Agreement [Member]", "documentation": "2020 Merck master
services agreement." } } }, "auth_ref": [] }, "stro_TwoThousandTwentyOneEquityInducementPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "TwoThousandTwentyOneEquityInducementPlanMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "2021 Equity Inducement Plan", "label": "Two Thousand Twenty One Equity Inducement Plan Member", "documentation": "Two
thousand twenty one equity inducement plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfDeferredRevenueBalanceDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } },
"auth_ref": [ "r323" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "U.S. Agency Securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and
other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US
treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or
Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r625", "r640", "r805" ] }, "us-
gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "U.S. Government Securities", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This
category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities
issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage
Corporation (Freddie Mac)." } } }, "auth_ref": [ "r805" ] }, "stro_UnderwrittenOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "UnderwrittenOfferingMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfStockholdersEquityParentheticalUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Underwritten offering", "label": "Underwritten Offering [Member]", "documentation": "Underwritten Offering [Member]" } } }, "auth_ref": [] },
"stro_UnrestrictedCashCashEquivalentsAndEquitySecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
```

```
"UnrestrictedCashCashEquivalentsAndEquitySecuritiesAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrestricted cash, cash equivalents and equity securities at carrying value", "label": "Unrestricted Cash Cash Equivalents And Equity Securities At Carrying
Value", "documentation": "unrestricted cash cash equivalents and equity securities at carrying value." } } }, "auth_ref": [] },
"stro_UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630",
"localname": "UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrestricted cash, cash equivalents and marketable securities", "label": "Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value",
"documentation": "Unrestricted cash, cash equivalents and marketable securities at carrying value." } } }, "auth_ref": [] }, "stro_UpfrontLicenseFee": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "UpfrontLicenseFee", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "documentation": "Upfront license fee.", "label": "Upfront License Fee", "terseLabel": "Upfront license fee" } } }, "auth_ref": [] },
"stro_UpfrontPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "UpfrontPaymentMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Upfront Payment", "label": "Upfront Payment [Member]", "documentation": "Upfront payment." } } }, "auth_ref": [] },
"stro_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "UpfrontPaymentReceived", "crdr": "credit",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Upfront payment received", "label": "Upfront Payment Received", "documentation": "Upfront payment received." } } }, "auth_ref": [] },
"stro_UpfrontPaymentRevenueNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"UpfrontPaymentRevenueNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Upfront payment revenue not recognized", "label": "Upfront Payment Revenue Not Yet Recognized", "documentation": "Upfront payment revenue
not yet recognized." } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"VariableLeaseCost", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation
for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r382", "r659" ] }, "stro_VaxcyteAgreementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sutrobio.com/20240630", "localname": "VaxcyteAgreementsMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails" ],
"lang": { "en-us": { "role": { "documentation": "Vaxcyte agreements.", "label": "Vaxcyte Agreements [Member]", "terseLabel": "Vaxcyte Agreements" } } }, "auth_ref": [] },
"stro_VaxcyteCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "VaxcyteCommonStockMember",
"presentation": [ "http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Vaxcyte Common Stock", "label": "Vaxcyte Common Stock [Member]", "documentation": "Vaxcyte common stock." } } }, "auth_ref": [] },
"stro_VaxcyteIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "VaxcyteIncMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesScheduleOfRoyaltyObligationTransactionDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsSummaryOfRecognizedRevenueDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsTables",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndPrincipalActivitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Vaxcyte", "terseLabel": "Vaxcyte, Inc.", "label": "Vaxcyte Inc [Member]", "documentation": "Vaxcyte, Inc." } } }, "auth_ref": [] }, "stro_VaxcyteMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname": "VaxcyteMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureDeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "documentation": "Vaxcyte.", "label": "Vaxcyte [Member]", "terseLabel": "Vaxcyte" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Vesting", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment
arrangement." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771",
"r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "VestingDomain", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureEquityIncentivePlansEquityInducementPlansEmployeeStockPurchasePlanAndStockbasedCompensationAdditionalI
], "lang": { "en-us": { "role": { "terseLabel": "Vesting", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." }
} }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773",
"r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Warrants to Purchase Common Stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of
stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r677", "r678", "r681", "r682", "r683", "r684" ] },
"stro_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"WarrantsToPurchaseCommonStockMember", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOfAntidilutiveSecuritiesExcludedFromComputationOfDilute
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Warrants to Purchase Common Stock", "label": "Warrants To Purchase Common Stock [Member]", "documentation": "Warrants to purchase
common stock." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "totalLabel": "Weighted-
average shares used to compute diluted EPS", "terseLabel": "Weighted-average shares used in computing diluted net (loss) income per share", "label": "Weighted Average
Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted-average shares used in computing diluted net loss per share", "documentation": "The average number of
shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in
the period." } } }, "auth_ref": [ "r141", "r147" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfCompanysBasicAndDilutedNetLossPerShareDetails",
"http://www.sutrobio.com/20240630/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted
Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted-average shares used in computing basic net (loss) income per share", "label": "Weighted
Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted-average shares used in computing basic net loss per share", "documentation": "Number of [basic]
shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within
a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r140", "r147" ] },
"stro_WithholdingTaxOnDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sutrobio.com/20240630", "localname":
"WithholdingTaxOnDeferredRevenue", "crdr": "debit", "presentation": [
"http://www.sutrobio.com/20240630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAndSupplyAgreementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Withholding tax on deferred revenue", "label": "Withholding Tax On Deferred Revenue", "documentation": "Withholding tax on deferred
revenue." } } }, "auth_ref": [] } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-
1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic":
"205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479710/205-40-50-13" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic":
"718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" },
"r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role":
```

```
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
```

```
50-13" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-
```

50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-599-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",

```
"Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r345": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r346": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-
10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r352": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r360": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-6A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r364": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-
50-28" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-
45-20" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r371": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r374": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-
45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r378": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-
50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r382": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-
20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r386": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-
50-7A" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r390": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r393": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-
20-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r398": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r399": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r400": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r401": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r402": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r403": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r404": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
```

"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r585": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r586": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r587": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r588": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r589": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r590": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r591": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r592": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D",
"Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r593": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r594": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r595": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r596": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r597": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r598": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r599": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-
50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r605":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r608": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r609": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r610": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r611": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r612": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r613": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r616": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic":
"235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-
55-13H" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r620": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r623": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r627": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r630": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r633": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" },
"r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-10" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r639": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
}, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",
"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-
80-55-8" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r648": {
```

"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",

"Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r839": { "role":

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" } } } ZIP 70-0000950170-24-096336-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-096336-xbrl.zip M4$L#!!0 (.^##5FAC[=J7X$# %T,*P 1 3+OKY]J_@<9]S.EG7L#$/SG"6XB&ONV/+KV7W<+!X%8""Q0Y% MZN7@6.?7W*F)$NR9I,B:#$K*Y'(K;VQ486GGBH4JG[^/Y_W!KU/.)[T1\-? M_D4\XO_2PV$:Y?[PXR__LK7S]L.7+? _D_Q_[$=_ZS%RI?!U[C7[VM-.U_MPF?)2\3,K,QI[8>?5C[^5PT!#BQ>?5C[^5PT!#BQ>]_M'!HDHS?9P..YQWNYTNQ_D\>_ M_OKK42[!X60TF$W169-';,3WN,?0X$!FE9MPSH=X)^42[M)\H_\ISS_Y?S)YR?^'+/1_L&X_W%WVOLA_=BK?T7/'@YQ,#CHO>@/89CZ,.CM M'#WTT(8TR>IM#0:]M_6O)KVW.,'O)\R/YO?/RY7O-@?M&3SW$\R/WC:^NOW962<_MX_N6I2Z? G7FKFETY/7MH_-8"3 M5ZO'-(U3>C4\NIXF_L]++_]]?1Y@<7_[YJ^M/O5_]!NC2_N>+!BOJ,*K$]\"/ M+A^.AJ])\.-^.O_/\G3\>'JPCX_I0C:<7WD\JDG_O#'1&XC''_GJCYVTBWO MSKYZQC.S/\'TZ,/HTV/ZXG'5AZ, +)]/!\?E7UF].73J;L(\ ^\=7%YC$;BR' M7YRZN#\9:2G<9=*:7W$\XNF8U3F87#%%]!#)N&)*'/UE@L'AO&$Y,*Y!4C^MW MLT&WA)AX)+ [(\KH/4\|ZNB]OXCO\70,PTD9C?>Z&U3IFKKZU.G[G#_SB%#]<8_F/6__3+@Z>CX930B[TC M.3SHI?EOOSR8XN?IXV!U/ZYW?7QXVY_C*[_T)M.# ?[R8_&'_O#)SV834?- MH[^W/QJ3NDY_VH=<(?5)S^]__NE!]]3<_W3T1!D_V1_ 05T^2-_^W/_\I-X- MQ_,?^SGCL/OQR_K]!?.O#UY\""Z)Y()GSEK+=,'((s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p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|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|",>SOU@KQ1Y+8'S]YNK6 MD,%X1%,Y/:B /"40KT#=D:O?#LYL&>T T>+Q8$2@`-=!NE80;4I%*8RR%HZJ M:0@0L59FX\QQY:RDY>ISY-V2GOM\KDD^UB*YX8S7W7E-7D:&4B;+GX MPK*M[$T*8F\ (D5FIH\PHLXYKOZNPDIHH-R/CBRJ+DXV67#C. M8TG%H=+4@D M"' !O(PE"M%LRMV:,;!(M< LB&Q.@5BDS]8"Y%I?V\,$/2RB(F)-?)RW:,U-Q! M%ZTU153C1,DD=HERW0@*^P#L32#7.F,F+)?NE!O3%$7E6N6';?6-%, M1^%8B"(S!=RZK*53=MTHZB:?_-R5M8)-H.QJ(:/B:U,=.F!U5+&OI6JX*8Z+ M#!;,/1S>8H|I BMOUN4.DF>F-4_D<,AZ*DDD)K0RFIN48FR6=VSZ';443LY> MIU1T)#>D'AH!&QAHLB769_K7" %KH6 A1T3+6@M5BNTP&*#:JJ 0T MNXQO?-[XMW% ,.AT- 7AW@>+)#ZRS&.M!A>/#;]YWIRQ!7X7OE"%(B7I^BB;1.#78. G!Q^"H52R2#%!0CGS?&L1%#IJH9@M. MK8%05Q1K*EGH* OS3M)*39E.HQ><95^TQH)W.AE M*597@89P\L6^+.369L@ M9'-=$U96|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|ACZ\KVY$QME\QZ1*W#E5A06\B*"]F3U@>F-01&,."954DA ME9%R)QKO|QKM/<69SK=Q?E1DRK/ZK75"^^^R&=H*DC%*0(?;U- .&Z:=4@P< M45\N@G!2"5Y2LQE/U^"8W>>_0?H3\QW%\1>))PL!-L,8Q=++VYK""!1((*Y$< M$9Y+5KK0+5BEQ^S*427>(I-?62R]HK52LF'2BIE(C&-[>'V=Z.1Y?%|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|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|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|^&6"9UF=, MJF%X]DB_=FGA,/HDX9/L,:* QK# TYEG7_HX>M9?_3S=?5+Z4I9!X+ _^Y'__ MLI#\]Y\?UV?1+.V?F'GC5SQ\ L.\I$T^]+>'LWB \Z.8'B; KGPMI9BJV M;F.XZT_]5=? PAO530(>/WW_]N6[E\]W>ENOG_6>_^?3OVV]_OUY[^GV MJU;K^^7_/Q'ULI?WOY^O=WVZ\?]HX]>OJH)[G1X;(Y.'R7NBB?:/Z_ MC@'@\,46AP&6_O08<.<3]Z@"SV0TZ.>C.\? =^]=Q7+FG&\CX2D_LC=]YQ?;,_M5[VC5SXYBBOO2*F.SP<+3O^U4^=U7_Q04IC +5A 81E.GK'0LFNGJ[S)3FI M@KH=<_2V6ZNS%')O0 AF*4AN7>F0@O&89HH.4P20='O2&4%YC/TGST9I M5EE#]9Y7.7F"L[\?]\NIR?AUY2N-?W_K3%W%A6Y&-[Y-5<*-7OF'VAFZMSW$ M'R]Z[6ZP_6$-/SQAYI&TZHMR=-IB_M==\; 3CY%73/D%(&:R\D*3GX^ZU&RQ M)&K)//>!=]IC$ZL2@0^/L,Q]2Q@X.WN#\;3Q_T.F=[^LN#/KWD!!.);C2(MY&>,IL3Q%PL75TW/Q2N@MG+YZ3S<7?"(+E?+_^<*]%K9P/[^? NOMN^=O__B0 MWMOG;[;?ONN]>]?VJ_W6ZW>]=L]XGKOB-#A.IMO^7)\7/_L;]HO?N;\[F MJVCG,07<>QJN?BV"TG>*.C<6^ZB[U_'"V1W#CQDUD//"F7R%Y3__ M41.>LTSEFEG7)3*LD63#.T0HVI"0EHQ5\40O^3?<.S^?!P%/+_4FF3]@>~M/66W_AG=Z8 =((P9#E9,,@/ZP7H""SG+$JTQBNQL#70[:1T79/6C67H#*

<;T>)4<$8TR'NWU/AS^TYN.CG^^;U-4Z['T M)W6KMO>B/\#>O'S7DZM"+^<_Y")28&4P-@0&W&A&GA>P;)1A(M3R&#)C-|<*
M>GG>;?/65YB_P2KGE'//%+$>N8G!K$,,YORW^O(H>2-ECRA<2#RRVA65Z5J0 MWP>I6/#<*9\T))"+4?:W^+&KBC6M MMZ^V'O9>OG[Z;&';MZTP]LUFYH?GGR%->U5 O5'I?
1%9#R;IG7U,-:4G]_K# M7G\ZZ3W=[?SA"V-Q&X"X_"""F$,EVG3-+,)N.CMZE#[!NK)..U,O9 Y&LRG=_M_C/FG^;/$IP_HC<]-CY,5N"B/UQV7L(EP'P=) [.@@T8
M&+KLF2:=93<B$<=<#!+70fC'!9ZZ9*/NJ.IXK.M4@(Z*+/*RKL)A4+'^_JL"UDA&*92Y[C\|_379B>`;!=*2|*RKW3>'2M?<'J4=8CS/SY)AQ\?`M=A'W^^3\'2.A"GT?_YO>H%[?
74[_5$=O>)^N;G4WB&Z0-0H?>"_#P>11K[,_MB]RD4]FKE"7+/-3V!8;&NV{URK_=ZM/(7UXO!X6^PM6TC<44H_]>]_M_G1*<(8# JGQ;%@IYN"@AT0W#WHO*U>H9?@_8>\93&%>
>(.4'^YQ\D-H;,%TMS^I&Y+[)6SSLE%[/MYC,,;) MCXN'VBQX+%T'4V6 ;@,;/?8@)8+;NJ;;_095\IX[]<]6DKLW"\F>X31I)3O$;\B)-FC M%SIX6!DRW8YH99VICIV/X\%?
T]VCKO\18<9N;!E+?IC5.^K23&M"H.0_733" M|FOOT|%E5UYP\?B.+JPL^?*B"H9:52=&5 ,.#'K.3K=[:-+Q&IGV.2W M .JU5/V/\'FJOCH_9ZT*_=?(_3#,_Y\W/U@: -@"T> #; M$(?:
!0LL&D;G.1/4C --)&N9#U P"YTD#]V"^.;7C2R^0\5-.]A]'XX-SM@6[MBSI 2(<7+7*\/5YKMTM-\K73AON)-UM{6;E6W'(WLLIV1"A1TCM-L;\^YH5L9F5C:XT,"L+-=+/S]|C^NXF;:-
*5Q.;;Y$; M9S7CW 2F,0H&3FMF,WWHZ+OD%U1){$<K?N^4[NE]S;MY"OYR7'=;EA&'N#4===2M=L,D|>H)>;MV$\IVO2:-P|;W!0 M' Y7GQY-C^T-.:9&U;?|U)|TT:YA+4|
(@IK]5^O-UXLG4QAF&.=)KQ;5Z^>+ M"@RH'^#'<_,OLDF#4]"UTC|O(+@X&1^X&4K$M%F725L%=@ZP'fP0S7CFt2:$L%/^OWE6Y(/B7,5!!0FM8E,>RD9 M8,
f,!*_!I2RL+P]ZW5T^3]_6XX-//RCD-M(W+/.LF38%68B9LZQS@:!09\L? M](:P1R\TF|"/-/M'ZLK=&N;ZO^=?ENW6|"F,QP?!X<=_A\$,'_1FP_f*>|_MO-]Y1D:6Y$1W40|Z&5-
#P;37QXP^FV>0O[+@[GZ9/A;(_E47,%LDPLV,!A;]++>P.'*X-"6'(L)G'F5%",@B\R;H)B1LHBB M9$$09^$PQNS09,&4!DEP: A"8U%,"B6=R2XH;5<)AS8\E'8#ATN-D6T8_'5K
M:'7]C>9YV%)7VMN8]WNZ&C=6ZB962C@G'"C+DC6!.1XB"|(+%L.B_SOK%;A% MD/BOB_5+4@<[5H)=54#(;8.I(K"B# O-"""R:,)QM2^.1D%\'- MEPAZ6CP.M8GX!00VT?
*5<_*ME&A2IY/>&!/V/U5G=&.2-B9I8Y*N,Y*T48)C M*LPES9D.)C*/&9G IU^[%*?8W3Q<.+[,-@-J'R#?9MI+W! MONO1\.B#YTHQC,HQ+7Q@4
,1W'IAC#7*QZ^P[S9T_ZP3]F'W&V26#:A\A9H M^9LQ]D,_]_#S?]WO.>E2TD==VZ=TZLS8QF MSF!=77]B/=?P+?7A1N4X[H/1 M,PG^?_;.M;FMXTC8?P7E3;,:<*K0R]XN
""0&]E94M@@#.7?OHVTMY"BPQ*E!R480]\=@%B**A= MCCJEV(?!?PF!GU<,>#)?RY0FV[(_>H^SH9:[C!-0S!IDI.2+6(ML998N\E! M1,,.-3Q
T;$Z&.@T>.35M'2Y]!31AR#Z<##VQUH_=,H0:@\O0[^-Y_$(78NW MTWD8DQ=!82|*>VU_B2NS4&?20;8&055-5!620R@V'") ^X@-,Y6MG!N^Q]/U'UE]LK.D1(P>M= MV-NOZNX-
\|'DW6",H8SDI>2#ZG=)] MGRC!0@@]Z<@>)\!!9,_],ZPVM7_*BZD@%+V<+!D+,_<30<4KL4:1!Y;W\O!Y MW5= 1T=(X9#"V3[LS7DT7@):TPZ/"P_>Q)\124SL]RD?
LSM3^<77TXGJ=^< MZM,;"F\3]&BU^7H;00%\L]9K!C:E:CSZRDEL#S()TLT0C!>K&R=P@],=2& MJK906'L7QO5K[.:S49KGJN\0J1>Z:$07C?9BZPS"[M:6B,@)F[EL3N ++!
M2@/!!U^<\#GHM0LSV5@ NZ:KW>%!\N.E*X7@>]RY26'WW2HC%Q40TRJT0I2A6#@!X+]*]_P%4M!@*M$\DUZ[^7MJ:K;%9?@7G
MATSMK=#+%QOFD6LQPBOAE?"ZMZ*ZWM@2!6@0C6A&9'"&<4@,N30Y2IUZ.9?3 M+UXM&U:OAO#Z*F$&]?@NN?PJ)R$WU:S$;?C? =@_744XFB\,&*PO*7Z9CY- M_W=6/P-
GW7_^AQ/<_C!8=3OXUC8l$?U6EZ.]\E_?52;HKFOO7,CF?>B MZVG\M/-IY4]E_/V&ZXY1$V\TP9=U3 ;C3PKX*8&&0$.@H9U/,_^T=SYU.WL0 ME7S=[>PB?
*169X_]'/.M7A_A=O8HDAFSY[MGOVZDM>^NYTQM-(=C'+DC6!.1XB"|(+%L.B_SOK%;A% MD/BOB_5+4@<[5H)=54#(;8.I(K"B# O-"""R:,)QNG_F>2^_#"%&I+IC"UW6Y(L/B7,5!!0FM8E,>RD9 M8,
f,!*_!I2RL+P]ZW5T^3]_6XX-//RCD-M(W+/.LF38%68B9LZQS@:!09\L? M](:P1R\TF|"/-/M'ZLK=&N;ZO^=?ENW6|"F,QP?!X<=_A\$,'_1FP_f*>|_MO-]Y1D:6Y$1W40|Z&5-
#P;37QXP^FV>0O[+@[GZ9/A;(_E47,%LDPLV,!A;]++>P.'*X-"6'(L)G'F5%",@B\R;H)B1LHBB M9$$09^$PQNS09,&4!DEP: A"8U%,"B6=R2XH;5<)AS8\E'8#ATN-D6T8_'5K
M:'7]C>9YV%)7VMN8]WNZ&C=6ZB962C@G'"C+DC6!.1XB"|(+%L.B_SOK%;A% MD/BOB_5+4@<(

JW94;TRY@ MFQU>P#[8IH3DRQ#:">V$]DNT&UO09RG I>K*&X->%-=!YBBR#F1T$YH)!03V@\=[3DK[9Q%(ZWK$-(X 4RX-+9R(W62:]9 M[=MD*O:(]G;Q7'%-;">V$]N)[:?+!ABQ<&.P&NNI9;&-A^X]>0BVBM4&K- M;-\FX[%'MCL[]&IO9SJ/%>U7N8WZWY;.,M:>OX=:[_AK'9M7O]_^[^EH7K\L MW=[-#W$04KN8'R8?1Y-W@\ET7H]_/JU"=]G5>C\]CSDZ'URW:1^4T21,4OVF MP;>&[5]VC\^C]X,T#EV5S8OP#F$RS7CUQ77(I>6K]1WC!\BC&2X%L34T7IQ/ M?LBC[F(6_AR5CU??LGPKX"17D?S0 MYJOU9;Z6S@\;BN#:+:6K@]O9YKV"8=LYO<';NYK2PP5%+[W>WRSFL^@~ QM0[TXBQ4W3H<5!W!I<3O8PJ69LDUB/U"3_UQVGZO(,Z2)OU\`)_+T;SCP\Y M8<^O8?GF^AD'TYNLN+T^5JF/\VF>_O,_G.#VA\//R^EZ-*]OEYGX_N]7"NY/ M)S;P%Y/!_&RZZ,(D=\,!?DC8CMQ4N:ZFP/ET43?]/F=D*WZW4T+W->V6=NO5 M-WY^]3D-=RG&X MZ/!IAQ=A5B7 :NQ+'W"UV=]]>2CH :@;Q=&XRN#3[??=-IG^75?2/7'& O%2 M0]_P"WS+U]P3P\0./O=KK]DGDNWB<[_^G<[L>YSN"7/[G]O]C], ^46*S]W!E M;)QY^_IJ9@F81QUL0S$_?]?Z&_Q#!GK:I)W*TDT$3<.H30.) NX$F@,2!=@--"MP*,7A]UV@WR6TN)\,:Y>>Z8=0Q-0^ ??)#NX$F@,2!=L/.)X!">K2KB#&T&V@"-M2!QH-] $D#@\2 PCYU$[1QG&M&%H DABOOC7RV1+M%=-H HY#6&@WT 20..0) M=[R=SLG0HF@@$>A!"&2^0: [E2X]6D8|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v3,L,0P0=514;1570,VD7_",,%?MLLNH=[SRU91D1%6GZ]H(RC,@R(@;0 M@A,#B '$ %IP\HXV\8ZX]|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`^0[3_6,8ATFJSQ? F@[^%63H;2#X<""84*5I2M*1H'T#M,ZE27F\Y8.Q(6*$4K0%Y4L ;UO)N%A0))=|OR3] MNN%:OWAH/%FMQ%IB+,&6PO"_CT=XV,B5!{2RE0A0"9R1"7B*0IO"-9-FS4Z6 M45: M[:NKXG\PRN* E2"6.J5KI^2]HTW_"N&07B*=-*K"?6$^MO87V*+AKC M-62A"RBK' 04 HH,ED4G7"KR2];'Z"Q73@<754FH+ /$] -HEUSAG"6OQ?Y9 M;[@=&L&)]\1{XCWQ_E'$44H(/CK/P)N80<6*4^^#@<*%Y$J:H,3Z@1=M>*!2#__;CZ:O!M, MRV!6?YR-TAS;K%4964H%U8"@2Df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fQ"M)U_P4)' P.2;"^$A\[6GQ" E!HD!M.#$ &(,8 6G/RD#?PD%KG(TG,HV@=0 MQG$(G%E@]0];O.96BOL<#C@@/TD#' MT?3B+-0]G7"QG)UN.'@Q24\&MZ3\O__[FV=_&BP3_^U@P.6GO)B\Q]6AG,&S M=S/$]A,I2E*4I"COQ]Y$#YBRZI[Y.#0@VU,01#@N$M/SP(_>2]$G1K M7;L\CH35H47+R1K)&LD:R1H9^C3D]WC(G@DG0DF@7-E5'R,\&8D8&EG-T5'L MW5JP8YO:T_LV\BTG(_^X[T_HFSH2YS7G5VG;EP?/_&TZYKC7W#^S :ASA& MJ-I9NKK3!QVF^AWS$5)_7]bFC]VJHR-_A[EB $GMN#$ -H2!S!<8@ Q@!AP M.%N"&'!B"WX8D:V3Z%H6T-I0,II),*8(^))D!TQ8#))W}?B> #8YK1T<$LP8CQ&$ M*@54"@@N&PW&*\63Y$&I^&4L[=7\#&>MP. ,SW#2C=[CBTF:GN-?!UWWI"JF MT!]7A3&^N0XH?*I^]+GK\K;\S<%M7%/,^!*U#1NRX8F[4;9X?,"\)IOM M9+8$,>#$%IQLMOU5C7I*L^($"&,KS2:+@L"8@?Y2MXI[K*-:"<9M\I]UEL" MFXVNCSY@PK1E24F)]JA$8]V$.+M^^^#;R03<=C_+@:M5.3,U^>T+(&+_7MEKA MD,E3VUC$&F(-L8980ZPUA4!KB?4'LK&(-<0:8@VQAEA!K'G4K*$R;T3)T(R M[;CTP)VSH% R<,9PX-{)XG,0QL4O$R>B1&.Y-Z!ST*',C_4]14-@4C')O=). M?!DX>8GS3YF2OK,?R@T9=[O+@!PJU^ED"P&> $^_QK@?7+<9Y8AQ810^;P@ M&-3@F1!.V2Q1JG(SF !_Z(#?]:WA;:+>AY.6_FTU"W$ZSG>8IA_#N%5)[@9A M/OB?Q00'D@T'@@#W$]^Z6W M&D<]107XD'E+]A&QD1:<[".RCX@!M.#$ &(_8 6G/RD37PD:YU3CUAA$]74K M[#KO4+-- @A(@6L]!*K)TI[3MK2C[2X\B=TJ7!?I3S/[",5PEHJ=-9_7$V2G/. MU^G3T9QNC9(fC!UV5TV6K"Y5%T4(B!:4XA&\3[*J)I>\5[^VK/?PBR_Q/FK\LMT5G T7RQ3H/?,BCK&AJ9XTFC$2%IP\OC)XR<&T((3 M X@!Q :,<&(,8 80 M.#* M00R@!2<&G/.6H!N"#Y3E6MWQF_"1+N,TX>N MFZ91:,FNWT;SL\$\?,#NEJN"[1?. <)P\I"V4)"(@'V.2[!"1,3&6;MF'LZ MW3HI.G"A,/!9YA@34!8'2A4,J14W2O

MCP//)0,X:::DF>ZNF8@R1@A7(JF809R(`A1,P9$1.2M1040IQ*[31V*ZR/M6`M7'_JQ-GN+,LQY7HG[$N+G=#O+NCG.;68*89**BSB)A"G%:C\Y_KR:> *3\H4(QOZ\NQ&S4]#'-7 M"3/DI$Y!I729A,8)C4\/C0O"6:%R"5!JP3=A&LS1G)3(>(=S9D@A\]WX)D^, MQOE!6O2>>GC\UW6-A NQ\/ZVKG.,1EW77ZR\5"-DDL%493A='#9M]CY4R1 M.X1-<""D,TAK0\&+8 M1(^W_GYU1B"^P#ROK,V=/MT*4ZWDFB"U@2M"5KW M!]U'*4>)(SY'17"#N98XDER4]"BL8YJ14?N>5;'8.K62 Y1X]A-,%U[3QL1/G M8=Z,9KDCC7] J>:DX>"2PINIPHNOT(*#]]I<(> @F,Y4B)D8]%SRG!7Y< M-\Y;NA/,:[OO#N!9 -<)) =Ii/H9^(27@PXD0OEZ3)W0STJ[&9A;(.O\"$Z'8/6!7!_S]HK M8.K1M,G4R"YG5X7? DQY\QAN&+WXC_^ Z3.946HE#',QXQ(D##\ ;C@HNC?1% MZ/E<[L)K" HL_/[/"^G].!?<\,,;D5W]8NG*#VY2U:#Q6CSXT;7_A,^'L[K M_],79D83G//=E)FM*S1%,BRH'@)Y5NFK8FCL9C>'MG#R%3TTP[&.@H M[%G4/AM'@4B]+@704@#ML.>MK22R- 8)833B6%LDO&;@BW##*F"H4)1M%\+2V MI4Z2T9X@211LO"/SFQ MX*Z nX.-80#/ZYA=ZMS(O&3@!VF,>&D+]*>B(H)*@XI:F9QR@PMZ IC-Q8#0(F%V MYC5Y%C92@Z^3[H-O34K/<):36_TT#VA+GWH6:R_[$VI,J?."U6K>;Z=*_-P MTKQPB&OX11Y6Z1%@3I@OOA+0;.I4Y7&A+"F2QY> *>0=:V&)DN?5*,L=M@4] MK4IHR*/@>=V&^RI7/7+$F"$\0GB#\0#*N*:&*$&1#VBT7 H.#PS#*#<:*%$XQ MJM8A7!)BI< >>>U"Q4%7(NVE ?<(YT9Y7^;>GP"&4Y8/9&PDRNGA>&[W2#:. MRNB;'M.S Q8_5<;CMDB7&F86V']8-Z&K1*BE&UPD/ZP_9]6H M96S@UM>W<>O+T*6P*.&7O[ZBK[X^\6,,*|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j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mMKS--ZE"?1>]DEMJKF#U3NR&QM1\L\]J7.W"&,_#UH W M E:&%K":8!.ADG/ O#S'19[Q=#6CM?=^\F%27P%ZN179#M&XU]&O\'/X0$'-M%>JWI'E@-*-*'O*P&1BG #L@L;%3BTP#7,!MXQ5X*REP.52<;9H M0EZI:C@O.@-? N"LUG$6+,N+.9T,U&5YG^CJ.-^NU%Y7SVTQ=G8)17+GOOP9)T MDW9*2_8I*;]O,A,OKN>C#PO7A)=>]C_"/<#HX:L06LLNZL\A8[*&P]$T0)2 MUI.) <6U/=4T0,!P'3PL#AZ0>]4:G8M/N!\Y^!UL81 EH,R<_F*M KJ7Q=-1< M>F\ MCN;AS63ER?[LH#QS7 8B+2-]X;UZ!P-84E;mMKS--ZE"?1>]DEMJKF#U3NR&QM1\L\]J7.W"&,_#UH W M E:&%K":8!.ADG/ O#S'19[Q=#6CM?=^\F%27P%ZN179#M&XU]&O\'/X0$'M%>JWI'E@-*-*'O*P&1BG #L@L;%3BTP#7,!MXQ5X*REP.52<;9H M0EZI:C@O.@-? N"LUG$6+,N+.9T,U&5YG^CJ. ^NU%Y7SVTQ=G8)17+GOOP9)T MDW9*2_8I*;]O,A,OKN>C#PO7A)=>]C_"/<#HX:L06LLNZL\A8[*&P]$T0)2 MUI.) <6U/=4T0,!P'3PL#AZ0>]4:G8M/N!\Y^!UL81 EH,R<_F*M KJ7Q=-1< M>F\ MCN;AS63ER?[LH#QS7 8B+2-]X;UZ!P-84E;mMKS--ZE"?1>]DEMJKF#U3NR&QM1\L\]J7.W"&,_#UH W M E:&%K":8!.ADG/ O#S'19[Q=#6CM?=^\F%27P%ZN179#M&XU]&O\'/X0$'-M%>JWI'E@-*-*'O*P&1BG #L@L;%3BTP#7,!MXQ5X*REP.52<;9H M0EZI:C@O.@-? N"LUG$6+,N+.9T,U&5YG^CJ. ^NU%Y7SVTQ=G8)17+GOOP9)T MDW9*2_8I*;]O,A,OKN>C#PO7A)=>]C_"/<#HX:L06LLNZL\A8[*&P]$T0)2 MUI.) <6U/=4T0,!P'3PL#AZ0>]4:G8M/N!\Y^!UL81 EH,R<_F*M KJ7Q=-1< M>F\ MCN;AS63ER?[LH#QS7 8B+2-]X;UZ!P-84E;mMKS--ZE"?1>]DEMJKF#U3NR&QM1\L\]J7.W"&,_#UH W M E:&%K":8!.ADG/ O#S'19[Q=#6CM?=^\F%27P%ZN179#M&XU]&O\'/X0$'

"%P#ZJ[#5%L836;$7U_G@_F,V M383PC]L6#P1>@N\42$:P9F9!C+MW?^T]0=HJX/6 (<"OU\G$_3FK@B: 90,! MB=? $R[5'R\[U\R>=P+,:"Z8%.0<^GM83F-S8F3"6_HU1C(+P#RNEJV'B[?VK MC%%FP)A5L*A&-2U& 8A-X[_?D/ !P#>48V$AN=A<8"CLNE$C6 0DPB(*L;G M> ^B'Q9QS_F#%<@B6QQ 6&=8\/+/!8)O=(C1GV9MH9_S'#"PAA@<9Q91'COK1 M&7>1@:,,8B=^RU@:S$KO)!%XQJ; 5,(Q: W7,IT[<4(49=2S7]&$4 $\#,'5S M4Z;]<:DDQ<'X[S.0Y6%$^AAF';>U^C;3&3;:2T&G,4;K'/YQT3D> #[V6 M>7, ^<;WT:C?]|-,T?Z#V#T/0C6#=C4!W@=7)]9ATHM7;E%M5-/8P47MP1,6,; M.6^EU,XS(EPP3G!;.(5]BBSC6%E>.L2DMX1AK0TWZYD116$MH90B@5#G(8<-M9G@,5M(AQS)/H\B(0 M74Z,H+>=%KPQ(^)0K/I-D))#OS2(\R"@T*0E,//V2^%!4$SC.EP6%'4GSR/0M)T'$E_V4N7(W?'C[#^=#U26UG)GA0 MKDF#A-Z^"NT%X06OJRF\VWQ%D2R, M.?N#&@;# M]%.,+;Q 9=-]M4#=(=[_^? M&;1^:9%YH3CP25H3FZZ5!4E*,\AP3D@NG:,*Y+I V,#\L-9&XI(=CRM@61PH35\88# M &_)PPI0T*8LLR=9%2Y70# 'M>6DS-Y-&[{ &,LN/(ATMB%Z^8[;=>]?3Z" MA1L@1+/1Q(%&#G^=___LO7MS&T>2+_K_^10=:N-S/1$H3KT?TNY$:&1[CV=' MML/2[(W[9SW%'H-H,#<@B?OI;U8W ($*5(4 3,)FO!0)-"/JJS,7SX]*S/[MG..1=Y9"9"=D14N(1ZL0R[GU2%0*-BW(N]:N"),V(K41>6=0ABZQ.VGL7.M48=LV2Y.VQCS#M/B-(<,<[1^QRH>@NN#);P-(L/GHT8,S5.D5N8P@LT6 N@& M$Q)#2BN7 B&6AWT+@1,F/3,({ %@(L(8LC$*)$V41&$<6>90/S&37]P!\SHA!M'"%$&Y/;Y$10#PPC;;!$TH:4L*%,QKV84:#6&>4XPE[DL_+<@@G)"!*!1!I% MU$*Z!UUL,D;$Z.K/=\"+G>C+E0D)_ZNJ_@W^O34+;3AA]9BUU$OO5,0)_&)# M$(JZ(ME[GB((CMXD:D5LD"0R9,O^O93*?-IWKVX>4XMAX?)GP2\)QZRRR=<{8BO#[M!VKL0%@$'GRJ'4GC?+!,SB+/M9=/6PTOUP_XYK#0L-K!;Q5???JQ5^^< ULUH9NN MN.%[-N&W)&[__M5=7+AV.2.YN1MZ+HCD=Q=U:Z3?G+45#S;"GA!>@*T(WC0$K!N9R%< ;.^88X; M_9MK__+7-TVWJ/YFP=LID%>$KPC?@87O(FK;2U\.W1;!*X)7!,_(@I?W2V[7 M6;!(7I&\(GG?('FY"& O>BT:^W:O%4 JV/IEFD&,IQCJ.(C5'R-A+7F",,4 B MY%K6B3)DDPK()$>PLI2DG'UWJ2ND#4K[D)#QD2-N/46:<8)BY,PY2C3>3\|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|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|=4K62T'VCLO< M!QP?NO"R)!-YQQ*7COIU2X;2(/X_XA=5]DSH::BJ_S4=EV=ZA@I"W_9[K2* M_]VL/P*GP]=s=[_-O-*[-=3N$((/&)AO2-CW$R3+<:C!)^'M: T*UCB%4M2=<:4"LBQ1I.)'\&LM>=HK#&(QW*2"0\E[HJ6,Z2I3N-Z:2=]L)@:3T+^9)?+R#E]>*-;=OS>O;AO^QT&>|)RRHYT8=N^O(%)MTHY ??#<6[*>!> MP/WAP?U^RX^,%'I* +T@SA@9X[$@SA&,O20L#41I1*WVN?2(15H8CZB(G3N M$Q%[6YE?8^QUBI9Y>"\8^"9?="DF<-AIY MSW(7*!^0S5Y@=#+*$4LB=7NQ\?MSV7^R==L[ZS_4G9\VW;*]5[?]P,=Z1HKK M]^ZVEV3W0R2[5S""/^(B[Q>54BI'5++TA&9!#Q=Y?1/!]6W5Y-G M'!KW&%GQ'ENLC$1"4P>Z+5ID/0Z@&4'/*>-QPGNI.]AQX--B"DJX4HED7$.MJL;1P2|4^T1'DA5/-9\8=N!S?5]DJ.+Q%## N8%S ^%9MP'"'3(,W8KT@,Z8 MZASW*'@]F XN>GD,,'X$V?(%FPLV%VPNV/R40E/,LH2Q$DAC;1&GW"(C(D:,M:),B@0_VR_8>$_T/DT5_X))@H\7_DFQ2%$%1\(_02->4,9K/L"H6/<77W?K MJ0.OQ,]^N@PPRU|_''+@__W%W'Z(:-;$N=[YQ?#UF@S3^!F%NHT]A[T$"5V> MS5Z%NIM/[?G+_.VKN0VAGGW8VFNJAW&M]F"&#_ZU[!9U.E^_I;\5Q5D /ON< MYPI/>+EAN<^WY"M";R+/]:MQ@7QWL4Z_;74(V6%*H/?FY_8R;?V^8=K3S197 MOW++#OI5-,)67=OK)GG>O7OQE9P77RI,Z3W/5VGS+$CQ2;.B"VE:,[(V\?=O) MKC%NM9WO'TUV#RPEW;Y:-9XG\>3&0&&GK@KD']'(,:-$J-UA5#]^%U!,,3_-WZ M:!# M@9UW\647Y]8%7V1-AU[H#\]^<=46[<>Z]UT|K1?G+!?/N&[OM7^M@+>]M[S)[7W\-.6$W77'#]^.:$;/]-5RBC>-A1'' IX$IAO9I;.SS1N@:#0P+.U=KM M:-[<_,)?@7ORM__^@O 77Y[^5R6//1R3W-8$^C1(DVNFX2LH^D/T\]L,O_FVK_|->?+5'W"3(&\ MG(MGQ%^ XL?!>;8;WTY7R((GA%\(K@'5GPAM-P1?**Y!7).[#DY2-+OGT;3N;'DYSV;W#N)B3',1(X1CMHBPS&5.D2I[CM< MW@=<'CA\G!UV<>#@X]8*DH&Z+V'C]MYD^O8),Z16E_4=1144=W44?>B(21-M<<@*"JI%*K#>F36(FN"(YIX$D2GICE(QJYDMPP%)0(B&/ID-$V(2R,"HY22IP: M21Q09DHG695?SB8)B@<"@?>PE09X%C7!2IO4_"(&>YR6D:8(Z:*!G;ZQ%Q M @\;ARYF.H%\LB/TY.?!)A8VLBMBE;FIKEHM^,(ZV91HRK&#A)GIN|MJ"-M1-V[A8W_*IX:6#X==?%!3AP70PE*EQT4=%%=XL*N^ <#D@GDA W MG"+M1$*$<\N#2UJB/5V43%21:PL6//>(*\:05=@C3 Q1E!&$%A._HZ)08K41&>(\LU4$Y2SRA>_L4]^$*'3@L5UR@DJ]YS++#G50?M&IC9[P^*:&YHH^>*K]+/L)")>Z(0BY&BCAS G[3',D8'<>\;,^OCOSGWDNK MX:(1'B8DE;CDZQAB+]!<_1GB MP1%LI$!9-(H)'-6.8J

';6\09UTA+'A#WD1@:A0YIKP9H\{1]WV',7X,!E@>'<#CRSR·MP0)8{I' 4+0D8A$#DK&W9#5!6DB+/*6,>46!U/+R0B><*#,1(Y]S3{@$P]> MX8N\"#%19;
3<6>A5\P.AFH#%E)^^Z_IG_.?MFS8UV?@/"[N"9ZT.;G^'/VQ·MX6E2U1E8.FRTP_S_!U8?Z&\S:\R;-H_.3G>0PMFN!H89@.JG]S^N?..N!XC^·MRPPU9]%VH·P'SZL/$_1.^?:#P#@%5WPE\;I95LU'\&4R,[_1J6N=&F^KVY" M?O"=.'/#8*OMC'7J/@]:>*X0.88B;@E#UC.-!,")QI)9B?TW·\F/ZF\&^;R·M6S^5?90·5V*#$D=CA&Q;H[+18^"R_L^1^,;C.I;A;B3ZJ=5L!\,J<UV1]M)&I7<>TQWL4=0?TH>"=@%%[7TCB.969"(P0)}28*2L^"Q8_#>C=HKWHHH7·*]·MSVH#^B]{^=!9BG"PV#,9!##Q0X(=/KG^Y.3QL:IW5^^&=+U\%=_D#/=/%9]9
MY'=N8UW>&9@!W+7K5_3E>M[4QS'@EL[·T[*_·,'HF>#9[PQPS=!])$ D> 4·MNP!^7\($(PY8@HP0\)O'07!K?4C\,A!)N%1K!4#DP%?DECK0I(X@FY0D1BK*·M'·X!HJNBA#$\21?P(,5M'A/;?_FU>^5TB_(O_+RY^WV#R/3$"Y2?7'UX\,B/87E7T.1,,]X%A·M/ED'B>|#VV:X6)LP*V4$VN(\A[2RA]]'F/L-BWP"*)G.\?]5UJO@Z >,2.WGRO+3"]GY^G<,] M75-%&$F=DT-!X:\VFU:}'R.1=9^<2H(3Q"AXU#QIB4#$P8@4Q&E#A.0V(&4% M:YQ4 $O36"MRJ5"##-,8N1"'E$DE&G9E_:W17)\MSP:,\L<52=XW*{@'B_Z' MBWV%W^.'.5?K,ZUEXLJG3?5M/@?Y _3NX_$=P#'YKFYPL\08XME3?8\PM6*7#AK\V%10*>M5F6P@A=U·MGP?6-N=VVF],M7;V(.-0CV+3YM.JA1H%8(U^[.1#FB1$P8·87).JOTP!·(O ML@ Z6-
ON*PEF/:S5$+IAX^S,YDW>,CE=7"#F3B!^)O?]SG]MLV&6W{ULZ& MC^W"Y@R·NO7+LQOO|?%2#@],>BWTZ^5$=&Z\6.]7EF_XC=R@69#KG*DPKHVV=8Y-?$G;2)
MP17.P^FVQK(·&NG#T6LG>F\|],^7V1:^E)=W358$/'K6;#%#/QSPA@+HFMU]·M^#SK&2B4S5I?_?]KW_3,M,]6&B:8$QL2SIK5MNPV8_2BD1FA64[S8BPR^6<-·M/'I8:'OE_E?
F]KKKP,1;'TW·.QWE2[HW\:-9·5-1!TOIEO3*&F!5#)WGRF5<;S·M·9).EYFSYSE·*6^>VXNOSYK0[Y#GL9Y4KP>9VC:NMB_X\KY]_JZ-9P <@\UM38/0K2W16VR%L9_S3;G*K30HI8*
&"6,P%WT]YR6GS_2>:-8;]Q&/4]%@98·MW5,]U&#OS?P658AD8(+=@%V=,:O9HQB0-&>]Y?3[{#'T/PP'V?P7K·M\A!6=%[.PT'+RUNDNT3?7-9C>[= U/6L_ERL8{(Y$?
V!,K)#&LPO5B9Z[;A·M!C,XC[;WX 'YET.,'L:!GX4\1F'(VY$,<_3+V·M[*9A[-'BX-$4L')AI6+N3B·MPAK9]·U2UG(IHY?>[]4:!2;#^=/(!2:DCXM'#/0IL1!4CW*693.*@U1"^SKLC
M;DS>W*·LA·U'L5C+$@ZDT&0B_2·MV]C40\1F\^6ZRWSs=MHPV!M?(1 #O<#&]7PB98%[U]<3F_(0Z8D3%V&V6Q+·60AX_·M]\/XX45/(HX>*·PYFX^···)/=?2P,%A%_^VC6Q<+·M?%FY?
W&/*·I*(J8$R83S'E$"GP>[("Q91QW!4HH]/^FK8R(;)^=MA.4(^U'Z·M]SF#[CV\X6^·E7^\·(_NAIB'](N%\WZ)&L>13{B!H/.EZ.I/6^>6"WC% MYQA>#:\C&)_@[J8W]-
!3O(LONSBWV=);S[Y/FAZ>_>*J,H\?P:1S],1>G+|<·M/^.Z^HW],YDZ,5Q_ET_N77\1^.J(+WZ._1*E<\HUH=P#WYV]Y.'3\'W/GX[*U# MWZ!ZJ!?
PIVE7_9B3W^..+*,@5Q&8(C""%)AWJ>OJW,"VVG_6Z>$,'LV.U M?UDMR?,/6YPJ* VY!K\AUX,SY'UG?]_·MIY·(RV6"#<>4V2,B(@3QY%,·B3 MX.!$B7QR?
J]"DY)6XI!K.463.WT39"QV2#!.&<;64II&U$B+3(0Y<(O91]PC·MJP#DHUKV I'!:DABL8H\>J1S141NG*[7R3%R@=0M/(M=2[U6,,C08J:U"T1.'M\!*!M >H) 9KH0P.V)#Q
"2;4'9]2;O*B@%'PL^%GP\/#Y*YX0T/*)@G4!< MQ(BTX0YAXI/5A A1]^K-8A66:8#V),...N4T6/"1ZHGFA8# ML@!D <@"D'?H.R'!PV8" &I,%.*YLK%37!H$5&4/&3(6]V"OXSI-
A'L$&Z#08·MD)029"/12'@J&=7)F(MB"P\/D&(\"%_P\5YCR#X$R)(5]9-N.:RE/K$C%%·M4ST3)?7 !LJS4$,=,O/EC(\I-H#
(8XY1RZ.C8PD"!2\\3E8')#V1B,7HY.>J6"H'!,L"DD++!98++!8 M8/&VL*B()3P1\$IU#(ASL!NU31H!"%)-DW,F[?6B54HYSQQ#$6N!>)(6&>TC M4B.YF*
(PC)GQP"*;8,P++!98++!88/&VL&BI83;9@(*Q#G%"%#(F,D1%XH); MSA1E>[8I=,46^2,3N!X$Y]CO DY*8VUS# BQ'A@D4X4*6D")5/X2%'>GZYH M,)
<;CUWZ*5745%%314UJ3;&ZF,3. B*N&<$,<(DLDX*:2AE+NRE^XK@J8@·M(X$]AWM 0^G((Q+4TD@'!22%\;@L!E'B^@*X*13X*+))9E+![XV7K7/ACNP1)W·M&B",&(ZT8!H1R8UQ.6
\09,/^,8P()82B\(FGB]OH$:6X]KA@[I&7*VV8<)T$#C=J.!Q;9Q)!B+198++!88/'VL)@LU]1+Y'ATB*?H·MD0L&HT"M-ESJY.V>M4A$DHPGA;0R#.X!X](0GQ +QBM-A;)R1
E38H+5]7VC·MG[M\E(S>>X[UOK6 %G!!FN\\GT_/BSZZ?WUTUFD4/CV-H#:TXE&PVR·MAE&PW)A$6IN·A)!4"2\(#W3O3#)57HI D&%.(OYD0F P*]0M%UQ1U9)!>WT?
!V9AIR5/I@X3T|HELC0+·TT/B32·MCZ7"SVW(;PI0/X+%[0)E.(;(7) Q6]P1&<\-_(C6>N4U%WO'Y]CWUB;#D$@J·M(:X,1DZ!E8XQC=1PBCGFX[&X*9\I<>
4LR^RU%-0@@6."QT?.#X\';·#/%2 MHL2P0)Q[AFS>|_>(@^ Q@D3DBQD2'!&L=P39!'0Q4E$VIA*93$X(4P6."QP7.'YP/(X]HBQ)-! M(=!L'#N+'·BV"%/-A:!!&<;5W2#C
Y]83AH1W*5=+T\B)R%'HK6/I-34C.@U' MV$3BHVX0/D$XW@[8P^)6)C8FI+UX]Q=?=^NI Z_$GB-AE]'^6/FI[8#7YO9# M1+,FQ/7-+X:OUV28QL\HU&WL>PER.KR;/8JU-U\;L!?
YF]?S6W(7+ZUL5,/·MXUKM? P?_·NDHD[GZ[?TMZ(X"\!GG_-A-Y+E^-;ZM<^6W·MK0[9[3D/]-[\W%ZFK=|W3'NZV5C]5V[8+;)OIO+23C_9\^[5B[_LK.!Z>58=
ML:],FVI9@6XO[NNPN_OF1#@GIHJ2QDYF4GC+'O+H_LGACS6S;6 MKB;3EU'R=5N=A6C/2?LDFU.(UMK#[9KMH8 M,'O(_*4AW'_M9^;88L@HO.Q)"(BTH(FI**W1DF6C-
_KWD(U3B]8 #Z;!?,@·M8(,_TOBY$(*4224:|CROI_3[/VKKZFF],+]6]>Z*9PT?"Q.!05@;$956(\XL1\"[2E-0^+&B^CV*O62 M2+GWP2(?)# QTOP!6TL$-S-,DDLX5WPX/A-+3[:
[]P*Z5]ST9P/")<&6HW'G_ 9OF#"9Q#L0" M-=E_\KI;Q"G84M7K#VV,^:.;3,45SI?Z@)U*J0^F/E.5U5Q6RUY/[2RLP7)!? M\+)>P.O]M6ORI@$B@771MSNN/@$+5N]MMWM6KM!JE?
F2"5/]HP83M8L72/4M M8G2@D58W+A\[X?>X>(3#Y0)H* T\NS'+P"0BDQU0Z#T*P(IZ[FAD?~EJ >UZ M ;?8/N/-A],"9\,?,;$ T`;#8WPC6K_C"U0>;,;T!L#^.#D5?OWO-A:!TZE
MF%1-6TV7<-G"GEE7+>S_O(^U6T[KV?97$QA5]1_@+< 0]S>G]Q_Y__MK2G%KZYAN?Y;\NK/)ZMA?@)@K>;+MEO&?N8>WD)#!]M];##'F?E@"]C8MS&L^·M;YN(=CK9F\$!
(#0]P'F\9TMIXMZ/HWP>X#'!]W1\\!?@90*G@3+,,ZM;I_>·M3BI0,]@#O3.M/& P/"F76UQ}MVCSD]·LY@[K0-3L*76+S===Y.$VV9[??M4VH?IHV#49Y7S7+1U2'F[W;>LSW}3-=_
M@BX&1G]W@$NZF_7)TQ*R;9'"#2""[.&/K6+GCC7\&J5>,1+V.P/OG"SC?S MGM:OW!VI--.PZET%DSP%|=XN:B'!!?&)K; \)&OXv+G@·R_JOZN%*6.·\=M?P\;IK!7NB
.'4"WLEV0MW],5S4QD^V#1V,?![[UA<·M)0O;0)@NA/<&O@32]3[L+6B4J6Q7Y(SPBNFT^929+AM__='L|\T26*]J_[S& MH5#],6L^H=/F4S_!=\M%VP"Y\F]!=&Z!%5B7(0(O_;$2@4'*
"$6O5AV ;8"%PT[Q=G5OW\RP^OAHMA2'I'C/C0?(QMKK,;]Y[6 MG0)4P.0NEG"25^ TL\#?@1TVR]U?W;/![$.3[]A&+ AX#@\ZL[!Y6'^HI_VK·M\B' IKV%F??TO!+
_*SN8)"7S,;1<$HOHS#FC+R#Z7'U0E(SH5 YN?·FD45 M:K#^9AZO Z9510O5)]3H;"DU> M^;RB;;E8 AV RR(\?;,"TT'_KEPM0.ZXNW;Y5V"4?NPK6 .;Q?D;+ ^*$0HYEP5*Y?GEZ
ME=7 5,_6HX') 8V;638!9L T7-'_;,)#F%0KM$'AP,5<$ MS;9.!?]M\79[^D">6;<*)LS;Y@_!N8U\G!S=\WZ&F/@E4^6RH/7(?=0\,"P_'^;3UE> M=[VR^\'G/-;1-/K%$L
;@817@P3[E746K=M'GN!R;#""R, 8M{[#2[%ACX]Q9^UOF!IV]YKP+[,>·)C\S#QKU,M*Z2"·M1UQ$O+;]64#Y?B%7]B>@9'M=>U.PG#,)·L9U[]PR_3_Q7>M'X^M'FN,6Q
M/G(@;0YOZR4F3\R=KW"_C2DO229RUF# 64N_AL=>/M;O/*E^6+9KYVIQ"N/O MA]?5GZLS$,;3KLH\&'9W00:C9+/S<4'Q.EP9KCY^Y%AX;+5S#@41.'#DV
MVB"M8M,)>/;WO:'8U@)@@RP>6]-PC2V-$R0@EX7/-A%M'CD'l-B]_7U/U MU1N7?MZ%GZX6-D?5T3^?;,.)]X)^%R'DG_[_IMZA%8TDR1^K!Z4S/59@Q. MW(?
45F.J·MYJK562E=0]NW^MQ2GF-_A@D(·DOD^_'I&9{$ 0(D6"($2&6;<* M!/*(\'#_^1$>[G_\OA%#1FWT.8Z<3]R!,. ^:,HQ88A<)$CY)&+;'R% ?$(V:_M*;>ED6JKP
\).GI#*,*)Y'9V)"!KG(*9.R,UL8X[<813U921(*A#*0D8MI"Y MV;:6"&:OJ),N6;'5<3M$;(+(E]+64"BKXHTYU·M,KUF!^0.7QS6=%M<6K(%>_]HG:;J'HSNE_JB1VV^7/SFU]/1J_·A]G34*_
M%C &XH1"RS^FIR-R37CVU7#%$)8=W.]=7M!EO/ET]"Y;,+LW'ZI$GO973 M>>+ B*!,82F+671U4ER>VJ{2P=GA*$/Q5+1 ANB R·G81B@GVODK&2(·MIN"B-
)Z8M+6G"KH/E$CDB'*O$-84!4W7R&\#RNJ-61W>P+MYU·MJ/EU&?>TFTK%$>VF=N:0/985EH$+4&[^]XQQ'.U;N>L0"0IPCA/H/*V;)]] MK?
#KR6^MGT_[VF9R3$M\TK*>^,>G*P<'+_H(B33S5WPV70(E)\UH Q69CHX M1[;X BOO\S+TTT7/KL#/""@%$!@RBL!\<|Y.IL)Ł,'#UC-48OXY_)ID=^]24 M796U)UZ&I5:AIT6N-
5#BX+,C CFQA'·BQ[+%U.#"%@'3&%]56$&NU9G5+·MY%6)$@'6$1B/·7&9[TD)(QLL{'P&W<8/$W]DMSOCQ_-Q"E9W$PADJ$]\-T MS5#Z<[46OUS=ON^UY*0TG M(&
(7TTFW'[/BQQ·!7QHW1 \ZZ#WW(:Y$]XN=P@B;MK?3(C#XL]LK]-WZ;2=[·M+2Q[-"K+*+"G/)%(47!:._%_U 0,+]U0&MQR)[(@5^696:$IY GB/X M2@P97\|fW$/0=ZY9W@
MU,S,1=E0\V-P^$]X$$S^/VRO0]_$4/(^WLVGV3ML1Z]"AT5=$*]DGOSQYMVK M[;233OU?&4D>W)$(:4PB)0HF)6,&I Z]A(R*·@>:@N,]<*KO+Z2O)]FL]'[MY0S@-*YT[9:
<[DDH|>GNTT(^\K/A3/SOF$?N)WD '(Y,S,G^$*1QOO,EX(\M*,FJZ89·EVPY7]+S6.3(;F6P,PPE@G(%B3(4D.9(LRIY6A+7B[5 MWJOVUS[UM}>
(3UN_#6)QTN/XH8>TG2)=MLX&U;(AS)URR;N5)9I4\JF:C9W$ M'· BZF4[^O.WW_^T;WY#;TE.Z,N9!.LIC;:])K_[>EUW1!J&\1"U5 K%Y*GB M3D5D/5;@L5&NDJ1>L?MKF$W:
[NWD883AF/1*9UBL,4R[6(:+8!UO8/_C%[WV[V9\S(;HI03\."+O"4^,*5W5ZY?.OS:[]V!RF;KR5FDJ9^ MV;ZR_F*_0YF?W\E$]_^Y:DM.\M#!)0D.6^#QFY3&;Z(DSXS);Z%+·<"]7%E:
M:VFF.>EF<39=2CS+F2U^"=M4;K\?CX;Q\Z"6Y?E M,Y"T,ILI#"9O;<_+146@R^YS'O.U#\T9-?" !>C6T|'·ONR#QAU;FU1[8=F MF"W,W'C*ULJ.Q^2,E1UV%89;SG!<*>'27?
>8'SU9ZU#R@>O+XB$X>B[N= M/*[GCA_LW/'^N>VQ797;I$9>%P38< RO0'%)\-GM'ZX0_"Z.XC,\8I,=R-XX M?U]ZUFT?,_LNR77'#?]BC[==ZRL'NM[8'&L?
_7KEZ,\OPR&HJY3XXN,^]\XF< -[VR18H%T MKP3AR<>L[0PO,N3CO-/C0\IZQ6A[IF77"OOWE#CM85]4UT7_E']6F%(=#& M@Y6$2>1\CH.3_"FEA)1-BHK$]=W>HO_F-*?
5#M2;'*9QV R.9\/B0[:F[:_M_C;>^G_]{K<@!\TRP|_)27H.Y1]ZDFPG[]S2//O,?·OVYX7:%VN<,!30*?5S MAO'V'I\M3>6&7B^E03"B/.6MIF""^'(4E·UV"1=9\B>%E-SB"\2G^<;BAL,#.
MVOBBS8<\ / 'RI5C(]VS?!BNZOZGIFVZ@^"TOAF?L*]=?7LO4]>`ZQVS{+Z(MG@.I,;KCFQM_)*>/TG/@\YFH&0TWL_83_TX(S,&]!SZC>HG /?G7$!\[?@ZXLW%[RT,W.:
[RIHNG_);C*7=GEJ,@5Q68·M*C /*3#OFRI57&(]/%%K5Y"I(/4((#5LB51PJF)2Q:2*2=7AWQG5GSLXT14X·M]<'+?N=SJU/L'CK,/E5TR^D0M^&O?11>U:6 >PO:HZ!R%=0[J.FHK"4?
&RXF4UI Z&%0^PK_>|XX!O^NX?;5_|·MH5JP3P*1]V[>MZ"@RA(5">JR5R2H)EG%@[KLWS<>'""D%:0(U!&'+%<&<L>A% Y@*4NJ@TU!(\PI6+V<"F0$44B#·6Q= M3"R(K\A]7/?
2>^!6S7>)U[!0)W;7PS?N??K<^6O7(9%BBD^Z9>B?;=6 OE_3CA7.8C_[(N760X·M[=PMYVWLNY!V34GS6K9?
8_LF/I56QI#RW0+VFR*9'M6>G[NDZ([\"Z"\&4Y7(+P@32LWEJZ·MH^=KAR|@M%4[-K(NEB6I9EW_5\OUV 0_-*<>]U-.U·A-[C,+=·'#%IVZY2IS M@DLW6G,70OP:?
3QW%08F;%*TC)%A]-;K@4Y)8:8*H% +Q'(S00C/$*+?!*. ^H91O--/\<'"%U8·M]|.F8'0XEA7F(4:K·M9#X+RP/B3DEDB%4(;T-P3@346EY=X22"IEACA+V.B$=LD69:(,J9YI1&HCP^·M_
K+4W,T*WR2K8!9[C&$/ZO\B=\M<·+V4[[:9WJ7H7ESD^DGI3=_GW;=8A>E·M%5]1(,V7?FT!H+N7&}@(]>G6]PVIK!·*B4·LI@5/53W915]9IJE M6YQ+ PDT(-A6$] , .(O"O#/X!X$
YLN/YU3UDIEDYGEG:V1R+63%*EA0](M)VU'K+$"L286224L9E$EXLA5L28X\.041XY+ &YO++*4"V1TBC@EH;2/MQ#K M/8DS/95'(\[\'-C.NN!MA
6R!B.>9$1.:!HH$,QX,&8@RZ>K**JVY$RZ 2B8. M<>TT;M(:))*S)@25 @^6UE^2H]F9;\"=5[HKBVUI]/E) -$%G[D75[$0PT M"S=F\S@O3#$6=SA]L./=I7^V]IR5-
P#€\N"BE6>=V<4*L[(E.)F"W=Q;S6 L·MKDSN3+A\+L_EA+. MK&1(ZP0K]$\M$!$D)*4EE!"GB!,,9H$F7'.%,. 4<1PC^LG(+1>=X3L931WP6KFW
M1*6G;F&;"5!E7OX;OQ3#&:91[BQ!Z&92*)EMKROQZ/_QG-'UHW@\/"T$L;N·M0_+= [OGK59I?#$8]^6R<_NO.&K.\|Y/;S/F11^>#"];@N6?1SN=3&*GAU<4·M 1=@/
7?YF+)PQ@^@>?13+*M>3Z;MDTAV@;OOIWE[P,JU:VX;6-U?06)_·I'Y>;0[V/W0\U*U5]B3:I3MO%HLL@)_G\"%,.H.# MN'9!_RQ,TTI?, ^^53+O-A<)X,}ML;GD2@JG/C 6;DGJP+KG(T6
B MI<1,$+·-U!%Q@G*Q3"]YTX"T$8\%;B!89(RVG*BD;^(9-^7LS;Q>O)RWHPW&6 MM#*.-()'(GO.F'W3] +@)A3U:FP^2X,S,@B"V/(?]$!HH4\0KQE"QRFAH4E+1:>AR"MW
PU_K',$O@VK;' ID>Q[L/Z2K_^X_>-I49M!FY\YG6·DY^^'GQ>?KX"]U< M#GX5O5GI[QY#[F IF_[Q=+3*@,AA\ %]MC BFQTA-+WJ/A+$8 J[0)-&3##P M*%GTR ;LD1+82^YB4)I?
Y1@MC($?!0I&'K,2H')+^U-&G=,@P3I@D& =':=);2Q0",U'; MI&W>G+]5+.]K[@8]7W!^.(]?"H0>L[T4L/TYS\' DSW+DN?!B3O*9CD\N MF;)SBK(MN>*C<^ Y5S8XXCA[=3&49+
(VEMN!P3;0H<2EX8>V"<6[SA \OP$/·M)8"K O/)Z<'#[[TS,Q]·LU'!;·(:N(B<'R3K\M0TQ=1@/_ZZ<<)6=813*P!·M<>H J-O·VJ9>5Q'!UBCN)HA_OS7'I'P:^,%M@;%F[F-
$DVF(PWT_=#\/XCB. M7U#G7\/,7L:HE^>3EZ%I9V-[\2+_ ^G*617WR<:V#9C,!0^IK=71?]"&_X2WE M5@0NZ4LW_9(G!T]XLI*TUQA^Z^FE98L\VXXJ]MB^·M>,Q](#IOF?
ST7WIK=AP.CY;S(\Y^B'DX+^QR,1T.S^119"B 0>?+$<#\= EP MW7R)X67W.H+!UOAQN &6F.5PS;A87 M+X9G[*K15%[+U*GA^L>,<+LOHJ>"DQNNN?%W=#CF8@Y/3>3]@//?
CA MAU&[6M=&O0>;<6W4NU09MKF0PO>DREW[+F4NU66\5F"HP.\GUOOE2Q>66S%.U M>@6IXP.IS>(#UU6-. H>>5@8&^*==V>BKY!Q5<'A*·A9A;T*6Q6VIR!LU9ZH
M$'=XB*,5XFXF:-XVK?!6!:T*VL,+&JN"5@6M"EK5:%?0J[ ]*4&K&]UZQMA·MU9|O-?MP)]_:G+>]'39VDEH_U(W ZNP5&&IPO)(^KQVU?Q*KO$-E9)KOXHG MT>_X09M-?'>-C[?
GO_=#>Q63AX%BHY'N>P5'0^,CDI% M'5)R**HD$,<<(^V81G<$)CYI$+ 7DF> MC@<=A505'2LZ5G2LZ/CMMJ·R2?! $28*;$B4&(Q-2CB.QX2.Y(2:BH\5'RL^5GR\0[F[*).)'B·I@T:<
M.HZ< =!.AJ# #J3@;=LM?,Q&HH6+HN,,<2$9U?,=V.;\GR>MDYS@>G$,.5 MUA)Q@PG2-C#$"(_$TB02W=)IF"2;<&((:PI^@A<.::D%8D%ZJ3VVB9@CTFEF M=S>AAY:PI]
[N8)O!=|*O@\"OE]J*MI^%JFP"@.'V-4\+TL7H\I=|, M\ VT+AB&M 4^L51Q(O*0PQWIFX5,XX&(^3TRAR:A&7-B*K (N3TM1A3ACJY(C MMU]^%7PK^]X-8U3PO.P=+Q7E0A*$'8F()PI
2KU$WJL0F0PNL:TT-1(4CY)3 MN!(SL)8)&+W>P2.P"[EX3SD]H]U&AA]XH_&)@V]-N=YSL/U#;B(QU."O*N^A M51X]H5DBPW29BT<_HM((EFWBVY#GV>@_SH5SH+U0,#+ER
]!UHB .#R3*NN4 M$%N]4YSD3H)-CY3/O9DY[SFUFR$5L18""^[,$:5I:WY0Y^,*/ST%#5BQN&)Q MQ>(#8#'UU.&\|?VG F^ B9K^"&\1TX)H"M-KM*+P*@6--#!*1P#TT6:2M!4^&
M4VQC$SGR<#Q8K#"K6%RQN&)QQ>)CQV(9DN J@34<'>"[=LA10U!D-EJ-I3; ,M6"PYE]H2AQ(G>1>5":0QVF <)V.*QA6·$H?:QH[0E7D MBB-M.$9,4"H$\CYPE/O# Y8GCYQ2-
DJBN5?R MF-"8*5W1>&^1>OB,6H6[:JW118K'+1V=!!4@6,CNWB79QGO+8?XP9Z·!7C"CX07<@-\|$?O'/WC:#Z]L./%Q4GDWSM?"045HN8*ZC25R,6IAMZ,0\M/B\:'+3>+^3 *]G+
<#+ M"G#;^W#N PUQ=.WR/%G=|?HR>Z,*8N5;QR=;R·\MV+LS"X T>O_]_>BG?_]? MFE+\LQQO/I.7?QD5B52&C %3N&]4K*>V^11'?V\ _C:4S$_Y'>M/V,YF]=RO
M*YMQ=U1!..5)@$>$Y=H?LHKE[O;·NTW;2*09LOG?=UP$Z&(F G(UB490(TS4B5 MI^VGYV!#»" C·MCW/@"U\[=!$P,KC)K.C-G!82>CGYJ_]#_,:.N,/H.4MS&-?PNE&*<7BB
M/9\NX1=08_]V'&8-E8$G80(R.N-'4%!.LWD5+FA8^.VG9L4G?VNFLP*$/BZ+SP7 \GKB3T<_>/]J[]L(N,(·MOAI0[6.1DP0CH-R_0]/,$./952LVXL6#_,_UN#7KC?%P)*:R$N""*VZ1XI'G
M^*8!#@*>LM90"\]D0M*6]1RQP%08)(D'4YD$FH_H8228MIH#6VH1KWKA('+G MT\G!Q=3_ZSW0-K.OVW89PP9SM>6'=;YZ_^,!%0D,R,I/=R?9'1Y973&;IAV_=!S1
MXVSW5>CMK,PQ6<).LONW)=·;)&I(V$229FB&O@#F`=E\H$3,(3HA@'FI(_MUFYM0FLOHY(8HQADS'70#'*6*&2-I-%9$R[%&TRRCKWS>-
XLS_>I<_'IXXWZ*3];%_7\XS9&_&\;!*WU'6"MZV MG.5''(FL,B&MYX$@V]4BB12<(QN0E,I$YJD4BVE55>M4REL,2·JHP53B$IGD·M%>)6.2E $20I-
V3US4#%=QT5_NS(LB\85T=D'Z_9)PTX2@X$HY@HL,*#7]PS·M (S+AM#DTO*C'0D[1(^9=&#V&F]!5V<;VAGND3 &7";B J7W\I4+.[Q:37O8·MM]M0\7OB"G)LT9AQ<)[7?
*R5>0U@.LOAWDG1]_9(@BN,&4%2-,AZF7UK·!'# M·EB%DN-<48,8NE7S!)OQXW+C\6WZYV<[ZQ7^OG8AR>Z3AH?;AAR4?*_"_OE?·MK]f=.LY2C*S/\2+T6)NBY(*]B*S3C,-
F8^F94N]78*7M*[1SAI0=IUFO+WK·M=H,)4CR?00D"(,(*3\$<18+#)"1MERZ+3B4>,@F!L,F6-0.IQ8&KPZ9#)QQVF <)V.*QA6·OH?.QH[0E7D·MBB-M.$9,4"H$\CYPE/O# Y8GCYQ2-
DJBN5?R MF-"8*5W1>&^1>OB,6H6[:JW118K'+1V=!!4@6,CNWB79QGO+8?XP9Z·!7C"CX07<@-\|$?O'/WC:#Z]L./%Q4GDWSM?"045HN8*ZC25R,6IAMZ,0\M/B\:'+3>+^3 *]G+
<#+ M"G#;^W#N PUQ=.WR/%G=|?HR>Z,*8N5;QR=;R·\MV+LS"X T>O_]_>BG?_]? MFE+\LQQO/I.7?QD5B52&C %3N&]4K*>V^11'?V\ _C:4S$_Y'>M/V,YF]=RO
M*YMQ=U1!..5)@$>$Y=H?LHKE[O;·NTW;2*09LOG?=UP$Z&(F G(UB490(TS4B5 MI^VGYV!#»" C·MCW/@"U\[=!$P,KC)K.C-G!82>CGYJ_]#_,:.N,/H.4MS&-?PNE&*<7BB
M/9\NX1=08_]V'&8-E8$G80(R.N-'4%!.LWD5+FA8^.VG9L4G?VNFLP*$/BZ+SP7 \GKB3T<_>/]J[]L(N,(·MOAI0[6.1DP0CH-R_0]/,$./952LVXL6#_,_UN#7KC?%P)*:R$N""*VZ1XI'G
M^*8!#@*>LM90"\]D0M*6]1RQP%08)(D'4YD$FH_H8228MIH#6VH1KWKA('+G MT\G!Q=3_ZSW0-K.OVW89PP9SM>6'=;YZ_^,!%0D,R,I/=R?9'1Y973&;IAV_=!S1
MXVSW5>CMK,PQ6<).LONW)=·;)&I(V$229FB&O@#F`=E\H$3,(3HA@'FI(_MUFYM0FLOHY(8HQADS'70#'*6*&2-I-%9$R[%&TRRCKWS>-
XLS_>I<_'IXXWZ*3];%_7\XS9&_&\;!*WU'6"MZV MG.5''(FL,B&MYX$@V]4BB12<(QN0E,I$YJD4BVE55>M4REL,2·JHP53B$IGD·M%>)6.2E $20I-
V3US4#%=QT5_NS(LB\85T=D'Z_9)PTX2@X$HY@HL,*#7]PS·M (S+AM#DTO*C'0D[1(^9=&#V&F]!5V<;VAGND3 &7";B J7W\I4+.[Q:37O8·MM]M0\7OB"G)LT9AQ<)[7?
*R5>0U@.LOAWDG1]_9(@BN,&4%2-,AZF7UK·!'# M·EB%DN-<48,8NE7S!)OQXW+C\6WZYV<[ZQ7^OG8AR>Z3AH?;AAR4?*_"_OE?·MK]f=.LY2C*S/\2+T6)NBY(*]B*S3C,-
F8^F94N]78*7M*[1SAI0=IUFO+WK·M=H,)4CR?00D"(,(*3\$<18+#)"1MERZ+3B4>,@F!L,F6-0.IQ8&KPZ9#)QQVF <)V.*QA6·$H?:QH[0E7D MBB-M.$9,4"H$\CYPE/O# Y8GCYQ2-
DJBN5?R MF-"8*5W1>&^1>OB,6H6[:JW118K'+1V=!!4@6,CNWB79QGO+8?XP9Z·!7C"CX07<@-\|$?O'/WC:#Z]L./%Q4GDWSM?"045HN8*ZC25R,6IAMZ,0\M/B\:'+3>+^3 *]G+
<#+ M"G#;^W#N PUQ=.WR/%G=|?HR>Z,*8N5;QR=;R·\MV+LS"X T>O_]_>BG?_]? MFE+\LQQO/I.7?QD5B52&C %3N&]4K*>V^11'?V\ _C:4S$_Y'>M/V,YF]=RO
M*YMQ=U1!..5)@$>$Y=H?LHKE[O;·NTW;2*09LOG?=UP$Z&(F G(UB490(TS4B5 MI^VGYV!#»" C·MCW/@"U\[=!$P,KC)K.C-G!82>CGYJ_]#_,:.N,/H.4MS&-?PNE&*<7BB
M/9\NX1=08_]V'&8-E8$G80(R.N-'4%!.LWD5+FA8^.VG9L4G?VNFLP*$/BZ+SP7 \GKB3T<__>/]J[]L(N,(·MOAI0[6.1DP0CH-R_0]/,$./952LVXL6#_,_UN#7KC?%P)*:R$N""*VZ1XI'G
M^*8!#@*>LM90"\]D0M*6]1RQP%08)(D'4YD$FH_H8228MIH#6VH1KWKA('+G MT\G!Q=3_ZSW0-K.OVW89PP9SM>6'=;YZ_^,!%0D,R,I/=R?9'1Y973&;IAV_=|S1
MXVSW5>CMK,PQ6<).LONW)=·;)&I(V$229FB&O@#F`=E\H$3,(3HA@'FI(_MUFYM0FLOHY(8HQADS'70#'*6*&2-I-%9$R[%&TRRCKWS>-
XLS_>I<_'IXXWZ*3];%_7\XS9&_&\;!*WU'6"MZV MG.5''(FL,B&MYX$@V]4BB12<(QN0E,I$YJD4BVE55>M4REL,2·JHP53B$IGD·M%>)6.2E $20I-
V3US4#%=QT5_NS(LB\85T=D'Z_9)PTX2@X$HY@HL,*#7]PS·M (S+AM#DTO*C'0D[1(^9=&#V&F]!5V<;VAGND3 &7";B J7W\I4+.[Q:37O8·MM]M0\7OB"G)LT9AQ<)[7?
*R5>0U@.LOAWDG1]_9(@BN,&4%2-,AZF7UK·!'# M·EB%DN-<48,8NE7S!)OQXW+C\6WZYV<[ZQ7^OG8AR>Z3AH?;AAR4?*_"_OE?·MK]f=.LY2C*S/\2+T6)NBY(*]B*S3C,-
F8^F94N]78*7M*[1SAI0=IUFO+WK·M=H,)4CR?00D"(,(*3\$<18+#)"1MERZ+3B4>,@F!L,F6-0.IQ8&KPZ9#)QQVF <)V.*QA6·$H?:QH[0E7D·MBB-M.$9,4"H$\CYPE/O# Y8GCYQ2-
DJBN5?R MF-"8*5W1>&^1>OB,6H6[:JW118K'+1V=!!4@6,CNWB79QGO+8?XP9Z·!7C"CX07<@-\|$?O'/WC:#Z]L./%Q4GDWSM?"045HN8*ZC25R,6IAMZ,0\M/B\:'+3>+^3 *]G+
<#+ M"G#;^W#N PUQ=.WR/%G=|?HR>Z,*8N5;QR=;R·\MV+LS"X T>O_]_>BG?_]? MFE+\LQQO/I.7?QD5B52&C %3N&]4K*>V^11'?V\ _C:4S$_Y'>M/V,YF]=RO
M*YMQ=U1!..5)@$>$Y=H?LHKE[O;·NTW;2*09LOG?=UP$Z&(F G(UB490(TS4B5 MI^VGYV!#»" C·MCW/@"U\[=!$P,KC)K.C-G!82>CGYJ_]#_,:.N,/H.4MS&-?PNE&*<7BB
M/9\NX1=08_]V'&8-E8$G80(R.N-'4%!.LWD5+FA8^.VG9L4G?VNFLP*$/BZ+SP7 \GKB3T<__>/]J[]L(N,(·MOAI0[6.1DP0CH-R_0]/,$./952LVXL6#_,_UN#7KC?%P)*:R$N""*VZ1XI'G
M^*8!#@*>LM90"\]D0M*6]1RQP%08)(D'4YD$FH_H8228MIH#6VH1KWKA('+G MT\G!Q=3_ZSW0-K.OVW89PP9SM>6'=;YZ_^,!%0D,R,I/=R?9'1Y973&;IAV_=|S1
MXVSW5>CMK,PQ6<).LONW)=·;)&I(V$229FB&O@#F`=E\H$3,(3HA@'FI(_MUFYM0FLOHY(8HQADS'70#'*6*&2-I-%9$R[%&TRRCKWS>-
XLS_>I<_'IXXWZ*3];%_7\XS9&_&\;!*WU'6"MZV MG.5''(FL,B&MYX$@V]4BB12<(QN0E,I$YJD4BVE55>M4REL,2·JHP53B$IGD·M%>)6.2E $20I-
V3US4#%=QT5_NS(LB\85T=D'Z_9)PTX2@X$HY@HL,*#7]PS·M (S+AM#DTO*C'0D[1(^9=&#V&F]!5V<;VAGND3 &7";B J7W\I4+.[Q:37O8·MM]M0\7OB"G)LT9AQ<)[7?
*R5>0U@.LOAWDG1]_9(@BN,&4%2-,AZF7UK·!'# M·EB%DN-<48,8NE7S!)OQXW+C\6WZYV<[ZQ7^OG8AR>Z3AH?;AAR4?*_"_OE?·MK]f=.LY2C*S/\2+T6)NBY(*]B*S3C,-
F8^F94N

*!5J]*1VF5/9DN0"K!5H'KVP:<)K"9FJZU=XA9)!)D79>=xQ@^B M:4++-K=E;6.O!SNA&?=V9L87^'JFV*$?093}(K8MEO=PX?7Y0$L1DU;AI:! M89H[@%^L2]D=QB 3$8P M:,;+1<7->XA%>+VXlN_R,'7FD/ M*SV=%(T*TM@MC8>9@6:&E_FS#9'J=6+1\Y<+WS-%.\AX?_5_M)D (?\$&G\+M0GL^O*8'89"MDZN]F$>;!0I?C'8"X#;_+ 1=_[VSM[}>MDU!_NV;_94VD;KMTQN[11-3*N_;G9B>LCVT;K[W,,BI.(9A' DUOGD8M>)U+>)[L!G7(KZU8W05 MF"HPM6/T4=.;lKE]]@E1M8EN;V%9A]%)6A;T*6[4G*L0)]L35MG^W(&CMKUD%MK0K:802M]M>L@E8%K6]T*FA5T)Z&H%-6 5DLA'5;R6@ED:D>N]P=0)Y< M!Y#M^>_]:)6Q&+$H1,2*\,23D$a+IY#WMOWLD/&>%RJY(1-Y3]%",*46G$L>3(M&2]12HH2FJ*@N>CH9B[E9D)V3JK<5_>C$Z-W'RC[7N7@H>6^PM]1+GN%OP/# M7S"<1,P#DHX"_-%(D)%4(8*YBLEB$_A6*KD2UIHD(K(}>L1#$L@F$Y!1G &8 M;DK2UF&:!X0_P6K_MPI_%?XJ_'T[_&E%*<840,^%!)8<=\A&+I%)R@G)?.36 M[,,DS8/!'SLQLL)?A;*?Q7^OAW^+-52.T$0<_E_,M466<4,HHP);'&@V*>M MCFD6'R.%0E%1@;B4)X$)T\0QOO.),%>!.R#\824K_-4FGX<)O+X_F\X7*)^U MK!'7IZ9\'MGF>#8ZAW$F18.T2BS6.D.9DD(M:0;0.V2*6[58H+P+7(:BI4 M5,.!<2CHIKM!:H;5"ZX- JP_Y[$!N.J,MSE7]M8{(N"$2LU=9(;(C;2\SWH;"5\P<.@%1HK=!:H;5"Z[=#:Y(^6H$9(@IG"S1: M9(6R*-C(F+!!B;!U9.LNL>6'@E9RPKFJX%K!M8+KD3!&!=?+Q'>>/ 9$TF MVZ N**2==XAJ+JG30MCMWB)WB6(_7$B@VJTU9_B((MT?I@L[7N\X4Y5:;8]= MVV,_8L4'%E),PB'!O +W 52628$AR4*DCC/*_5XJ/NQ;L]$3K<0A===L3[/U= M,;9B;,78 X1H= S$8(,8QQ@\J^1#2N0TYI?_C4V.!*)9;=40^6DV=:. M2XJ5)TGNOSKL:QT==F*!W, "<5/<\'0W$AR*A99PS3B3-7$2d:RMIA1@6C"D MHC2P3M8AHYQ ECNN Q;_JA1R3@!^1Z4"2P\8(#:O#8&VY@F5U B.,3;1,>UARN,_^ZB?M=_M6W:Z.U']^$P'=HWI<"3,(.&0=.I6WJH$=B3!&A<%/(Z&Y*.*6^W#M'=GQGV MK,K9.4EZ5>7'K\JOL>X+00\:?3QW<3YB9%UPN^Y;,2#['ZQ#<.,J5;/ZQ/(_SQ@\Z."IF+3C@1AK0ISH*I*FQ*'"O;.! ";]U M'(M%+%T ES_@P/.9V)B+@V.X!T#=L,A#+N/P-=\KWZNK[JI_CG,M/R8"S>0 M#6%$;?0OPG)~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h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{(3LEPR$OX_F0YK6":U49P=Z/HY7U-F!3^"N(Y#-RZ;&3]F81_%ME+),;(YN5;?RLCS[W^S89BY]?Q9C'LVNPNV]W@?^+,2Y17WWT8>U4??&P;AC MLA7)^P%UDMT3?_CNL@PQK/ARGD=Y>EVDX4&K+3\[37],A14:#M06 .!ONS_M)!MRXVOQ@[,+(K\JF7,,L:. <99,:,%?O7S= =B=I00BUP//5B]K%$#,Y*IIF!74ZJ IC-L M=_==5GV=+=>>S:7O912'+); ^_#P&5O>99<%WZZ%C=*TQ:H<[+=$9 \MA2)&NA9HV9BI5V MG5$&EMN.:L/?5-@]<"NQM0HYJPVX!E0CS;E$@FF;L"6.RJWF\G>I-OS*EXR' M]HVJR',&/^?+&/Y^B=")[&85VM?Y>+2H(27\]B'TVY1B/CX9.V;+-1=Pf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{=)$L(XE'BP M8,(KP%4*D)E;O6E*G*,'B=&ZA-B1(7(&KD_D F_>12FLO-55555=7=5Q1BF MV&@4. .UH[1'QM. YKPTQ'0#+=E2501C.F!+$'&HS;,D%DI-XY MBY$U^1YK/=*12F2=I()3K@.EQPF1_(3[&I"O ?E#E1&T7\IAX<&*'TX05QU5 M=5354;??-)91> (*)@J:.S(K"_I&*!1-B/"+%8YLE4FX2Z6__J#_ZXF?GD>0 MW;CO>#NJJZNF:=4UM07&0VFC MJZ4%QD&B20PG)CR*,.2D3DJ0XK1*:LY7B#U&QJ@0NX)8(Y)GRAFD!-;(6Y9K1A*+K/8L HXF)\,^7(*'AEAM M5(78&JP_'Z^AZ_ECOZG89I5_M0=0!0'I>,I0FV L"1Y9ROCX&Y)WK<]U2(%!4M*YSE(C[^1MF]!H-C0X7HH69RKQ#75.2^=',!P?*IC{>^^49 %8$K E<$?G@$ MQI;3I&E$'AN#N'*Q<)01">N; T,:+NXXX\#@+K$ZY]*[.#M6+,V0OD>++#X M^@+\6Z^[++;7VU.B$2RN(S/N#3 7$201)TE(C+'T(0E,*$[EW XE?8XH@:,'/ MZ84=+R[>.B!?R>3]LTMK^C#]+E?1$>^T8I^SZX74ZFAG]L^7M,.:6C1EG]XMYS[\L]R< M=Y4OVG5;^MO8^G^UB^DDGN1.1>W23DJ7O*Y7T?HC6UC>_.OE':-FT5I;C^;& M"}-U_&X4[15UN";,UN#42E*H#MP1Y[P05(*PFRBVWQM+(G+:($"L1IXHCQT)"-MB7NEM03A%F)#K[^,G^)D&5\7VK:+=W&>++17[,6XH4:!B7&E11-?5*+TIV7:G M CT41_TXFG>R5SJX5;L)EW;'><8G0S>OV31'GWO(4X>)W$Q:F'&I<'4"YM M:(BUWN)KG1?#:"\E7VIJZN0M0?2W>!L,:I8CEWJK2R^6Z/Z.G%?V65!F3ZZBH.BW ##L:?,++YQY^I>%=OGPQCW91F+MTSIO.SB[&]DM3!IT?#4\I M#>)++3TKX.K=:]7;9=IU18?3-I(C,=)E[O2I.IA_C9!T\2K,\^>ES5O)KVK?^'"%(V[[-$)$'(DS) B-E$; MCJC+'YN"118#_$OED@2""Z.W-, 1F;IV&"'[$GOB2&H."J&6/4G6MOZL 5@> .'3G1<4!3!?SO,5H#;/P(!O M7L\REDX]K.\}Y-%Q'HMV2[+_Y[V2Z: M=#&\I=R*P(JZZ.9?),O5RX[U5;.C<++0-]]$!ZN-?;^X"#$;T:,N&+0*".V6 M.>US%U#ZZ]E[O[NL6{>),1-,Y(4=?;87[6;Z)M[Y^P^*4D-'U*#.)?!?@^HU#7 MT?KIFR#_6'EGVTC1M4P&((-+)YVL=PY3#@ZT?9CF>]!ON[-\|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

*7/CGJ$KDVI)D1855-Y%V!E*1-M|7W<1"(HC(1=UGW56>+?L/#WHG=5Z2/TCA)64:2/(L)S6A(8C?WB,>_VH0; M!5Z0;U!,[M$X:L=]>2UED+)(@6-M)A@L0(8:_/#B25>L]]4OK 539O$^_]-(+O"[_P5"6G$%!D$)+)DX5XZW#XY^M/-M[1^*7EX.DK&K89*;V'6=W%2+HH%QVL!5XU7)EG"%?!^\-9+<8GTG8R*HJM3R MYTK@VSK0!NI2RVS0#22\E;*%'=H<628ZT<'TX"'18NL@TQI,5;PC*^#M7=VT M,^NLA4?"[7W9V:OHOH+2A2;%#:1F!0C-\KW"P3A>[%,'YSG)4C]7#;Y3Z]'G M-HBYB!+A9ALZ01QZ&N2D#E#@\0%(0ZC!{6!!1X+PA9S%TG3N,5QKFWMT!Y7W7Y MZ,;LBA4E:f!<=(=,#*@DI[K76t'P25N@(/K#VOPZ_FW]#(L=(=T.5?,F50.+7 M\2 2I&VU?? HO(&YD)$G',(NRZ%H;Z%DS:?$?IOLL@_91P/B!_\05>FULZQ{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

*M/FZAC#?Y!%"Q5#9Q=KVE,2R8S/#/5=)QI T0-,M 5LB%T^0BWGTF0]J$ M7.:Q(@+:0T]%RK-OM)I/>B,:FXT)8=,'Q2M"VGY#1LWLWY;,=_U<,,)2*1-2-2"02N:=HBZ-T]6;;&CB D9DD2V)30=>E+(M+UG^ MU ZZLCJS/WK=FE$]@ID=C1Q^QICQ_J9TM+4,G3$G9R6WZ[8,G8$DMV??Z--$ MU;+BP+0^Q5!H5U!\ZT%#F3DMMJ9$W9 *]0UY.TL!\JZY.V/UUB$HJQM.RV/F M;-0)_$'Y"Y?37!GNN#OH2;D^"TR&AMM.^[&E.HVV;W\IH[PX"C8Z7Z,6ME9Z M5?K;]BU"91U=1Q*$T5#E'&U!70 SE\5QAOQ,3!F95LB4$#?I&7SMQK &,^^F M=4\72/W:):S$CL>XMFVlL>/,UJ\(^LQDZ!U?D>5;1V/%"6=+]&TNMWC M#F^X0:!K~,>,JS1]UU9:D1 M=D67W9VV/3Q,OZ201&.S=+4T?^V&P\]#&3XV*!LDM$>.1DM,LEH3SL9[9$UCBTY M[_\27"5]?;D0U1"Z_:(J-?RY_U MZSN5K#B(YA4=9\4(7"IDNCSX>-GDIY7>BVM1:Y5(^$GVX)RLK%R?[!)H,II)1 MM6%=9.6'ZY32J6)^5V_!JO4\1HB' K/*5'YLEM0$NEE5EO5=_5I+'WPY"B.0 M%W@Y 7VB[D$O*+Z*[/58-'7FO!QND"KIO!6OAD#KP*/RD+AZ[@M\/PQ@%%7 M1:O[!,X: f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}3 MZ-_00[%0_N&]@WMFP4PM&^V_@07P-1:,X3Y/TH-KQO>-]L]RGROFM3 M4Q'7Y,V8/D4&EX^ $0TNC[@6 V[&^V^R39/[!#QZ3*&>XWVWV*W(^E MN(Q59MC?;/=)LK_KV+[1_4W*C&E3]"SQV10.^M;U>(X8C]56=Q=V>\:%@PS, M&)@Q,'/?T+[M^:Y!&8,R!F4,RNQ/F4GL.#:-B@S,&)@Q,+-'F"M)#&=BO;B M.S.=BG9"HJI3D1A*M,5V:5B(&9@S,&)C9I[%$[2#9727&9PPS>T] NX_/I.DZ MQ9J5&MG+U#)+)V+FA?&/8WJ=F'O)E5O=I*1X3[%?)ZNZK\X>]H?[VI7F& MN:[ZMK/#I.(;5_&I([}!'8,Z!G5V@3K4W:.V:5#'H(Y!'8,Z6O)%8CO>F\O> MP(Z!'0,[!G8VZYP[=I+L*]O^F:'.X%R#?QE,2'Z\PSQ<#_Y^!#_7%^7W2^LR M6\|+VUP-=0&^X%71P;OYM>OSLZA$PTKI$CO+X*JB[1K6%5=B6+,C&]PUV<>5 M[9JF[?DSW_=?WT'[!XTI& Y1@0_?PYM6X;HYO^\;ZWRR26QEDT;7I05WM/"U M-6\'&#\|UZIS:RZ;MJXJ4:K/WMY>5XW5MUW,9$)S!',1=L6-28,MI*Y*KB M:XN*EWU65.=6*E'KOI%7,/BY@W\XK_N]PRMOA!WI.CY%#;BL M:\XZD5DYXT59=(5H22-*^94#+Q.6\K!=*6"FL!JR1 M>G;;U?QWDO6/NH29P<+4U#R M?E8MIC,?[QB&"_"R\[*55Q87XKNPNHA-7TI9YL(\[[4@ZAQ1W`'S^]?2-_ M*F%_*%M!W^Q)H,,YO DCO S/)A5,%EY);RLKN3]O[$V8_^V?B[K%#;H5];\ M+G#5,UA\M6=%U?:-'- P7IS#E8#%:=3(Y7 8!Y*1JR^4\.SFW5ZTET*-NEA M9GV&H2 %X[2 M;OS/N*XWO4L^]{M3#KML /ZZ:3,V5 1;R8RY4^,^HOL+KZ M96G?%A6V4?A2]V6&.]0(V'3KR+(KN11XU]!O@<,8B@P>BX2% MUR"97C1U?ZZVC\L#Yl.'0-Y]>/M:/#L9\?,.!2Z@4^M=!=1O9,ZNM^T^5#GN M22'W9) LI;IH'8;K!&LA57(<0IV$.K[*FL-1QV<7O]6 3"6*C, ^ID5E?7= M+W7;?H_;\,,??=MK\"1*&4 B>H34U6YURN3CFLCE"KTXZKLZ1[+<8;<0DB Mf\=_JFZ02KX>Y3? PN+^SKWS1(S$!*;5P3-4X MW%+0+J4ZD_<=[*O5U M6GBAGW"?-!I(?UPZNGV.F106<@[<7E`,>;]!XKI88 MF_>MXW;0]*Y'##!S!4+E!-/#MOA.1;VT)%\ES^ M*O)<<*F/CF.[%-U%G5.D>9OGAQ@4>]D!#0\,B+"E3. M K7E#L9[*>?^6PU#BV?C6C\/\/NKYO5 ,[^/_#[!^?VDYO=QF!=]\|9?>TI8 MGN/Y-FI1*T&E5O6ZJ6KX"\EX[\#*$%*7?ED>H!Y^@4J]@? GPB^6%QAI>QA->8U$A#.7>]*)3]Y41(W]1;]\;]BSXU>M]:'-W\?E*8 M5=MC,DYK_?WL?XA'I5:.'WUW9AAPPBA?BK($JQ?V@-?GE11>]150IJ1A,"DO M)0V512Y&4:5)#1YT:;,$&;,-S11)W('Y+&=/;]MS@7K#@!/!$ W<"X3?UY60(M!+] JZA,_P5>B$6*>0871SME"L M0'T].*I#*BN9 O2!=3NI2O&[@>]$N] M:!$[C!M8O8*164_)?IZ&LN (fC[7M?[^8LW-!JCH3P_+#-N//@YPLQ5>2%8V0 M]NPKV/3^LGJ=%>\V!9(M7^.OK.5K?U?DDZ["HY.[J]#SUQ;!Z6)1\,;O%WDI$ ME;U.ZZ](("_*$5Z./!>L=':D/D=5+/_?NJ'KC]=>E?:Y&PV"]]?1Q4PV%>L_ .(6[>L7/$RI.%ZH]DZE=OP$/6^4"!HXK&*W%*,CXYO&]:LH+U?3T$;?$*:=@P'@Y 56E]D'E M*+Z*[+5ZE>5Jz>,^?E< -L<,GFK7C5"EA[(,=AYC),K9[!8OWTP571%BFK=++;BW_. I_:)M^O>&W9,,&\]SUR;W4N?=+[_W*&S=M_&W' M%5ZV\M$F:=U:@GO@T7WBP'8U^B#)02>2"@44@[_\]XOPQ1/8^7O+RKL=7MH0 MA?V 2[RDPR2/N_*G/WU#*^]> I\]YZ_44&/A]*>++\;7)/;\;A1 M70US&>;:#W/=6B/=,)=A+I_-<]V"N-Q>8W&O8R{"78;_]L5?:_/#G[UY^;]C, M6+K'O=*G#&BN\Q3<:?O%J^_DL:RZ;UF5M??$JZ-8)L,AQM]L_,V/+(5-.?FM M2_Q1'88UM00Y5\OPT4GB!C/?99W"9UB#T OLR F?,F'LDPF>.#T8.##0L]H MRXZ?'TE{GAOG+B MY='&3YZ#Y^:,]6/CYKCW_CH:@CL!%_-QEC5F DUT PPZ&&LP"&'8PU& 6P+"#MH8:BJA/RS^Z%)YXGO"[?BY9,DX^9/I4O=)/S(([>$TK=Q.2-QXTXT';3\-U M0P_/2'(9"G@B%'#,S= -/1A$,!3P!"!0SR&.0QR'.7(AF>'>[0Z76DR'-?4_C6JB$& M@IZ:5^3DA=!NX<-]T@[S>^/"CGQDIJC(]C9O=<=*]_[F RK&XV6T/Z/]?0-- M1=3V$^/Q>NXBWR#/,=/(22)/$-J!01Z#/ 9Y#/(V;&SNU1P@SP&>8[2 MMW'R%+!3U/!WIZL\NG?FV%/!3L7-]4O=ME>)=#]ZNNC(O+@*%X!W3&ZO&,[MC(.G3! F\FBPPB6##7K AM-WH)!7#388;'AN%+#KI*;@:=?=-]@H,% PS]B M3D`>09%!9C6.RE;.NICOD#-%V5E'Q^M(^&UBYTF?[#UY M'\,@!L GP)X9'NQR9]^%H1AH,% PTYUNQ-5[IX=61A@ M,,"P2V (I9C2ITP/!AH,-!AHV ,TN'9 GW0PV23U'*-#:#QWA:W1ZNY"-/H$ MEO6=[@Q]:UN5Z(QKQU10-!44=UKTWXX"T5/$[(,&@@P$/1($>7,B[NXLOX$@ M T$&@@P$?9M5ZP,1@DW>$'!?P& IXX]#Q'=U=Y?FGI)"8U*AJ4I4L))V* MO&Z$-6_JJZ(MZL]"/P>'6,>^FA0G \0&B"=-'-N.>Y1@ ,PHPV"#P8:=`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vEZ<[;6]=O#TX#@"H5/ 1CG"13@8[`67[(,G\!\0#IT"-NOCO0A/M>U>>'O:8'CQ', 0*V*S1,-CK:/"6FV+[?)UNW#511O/@=9+/R(<3R9I6 90 MJN,P^*V*K4>"O7N', ^9/6=N[=%>(U0?/"EX9G#I%+!19G#D26&/2<$S@T.G M *\9>%+X(>69^OLY[-EB&=GGMBV&-B\.S@T"E@1\DJ)SY599^)P;.#0Z> #9G:PS\3@ MV<&A4\|F\U3VNCC9IZGLHIOF_:R4F:XSNKF^,4DI(-/2O%LV+/AUAY=^=C3 M/M."YP:'3@$^*\63@F<&G@*\;N!IP:>E^+24/2 @GY:R(9I[721EE.?!A[DL MRN#FGW4R' 9O\BE\;VY\'Z_W<'GC/^;5F_N;>QR6T/NF9B=/A>EOSEY:I(7) M81'4;I+9SJ!3,'R73Z0?^PN40[SW@\X_&.0S.>-7;QQ4%P'@\OO)LLZ+ 8 MS&Y0P(9QQT\,,N=G4_C"/NFG&VLFKT0:%/)69O6];7R|A^NA\KE_W$?U M,)7;U/IVH2O$.EOS!#EX_RR\,'DL!;"UB|[X])J?9T2>$777DIR$I[W-(-,[M1N09D6=GA]@!&=A?T-=LWQC,@SHAWU?AP\!6RX&/9BGXGA4\"%=P"8%U43"_R^D#*8PQJ0,)&Q+'/Q7G<125A^*BJ>*LRY@OV";]=9*;JD M"'"7P@_MP/H2#@E_R#+XHLAAGDJ:X'A%$I,2&H9);&2BBB9'J2P0\3_JLIK" M=N/\<%79E;P_W\.>]R%B(4\$Q+9 9NI;,=A3LT5_I\@EE%2XHI(N##=+(># MQ><$#)04L 0@+EG!%N;C0DQA$:#4T#=,+[CK,1P$3B=4FT5;;I:=CT8E# #G M#]^B72Y!WB?:M,UFCN#C683;B<>=9[A(9S.[OTN;!N/UF^,5I2B@/G@SS$0 M9)K/Z/%2%K=)!-/'Z8P-A)T&93U;),.CX/K.$YPOW#V(7ZRD+0D@=_H+=), MD@4*0TR3?=A!<01<*ZOOW',5D:6\}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|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}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f\=_JFZ02KX>Y3? PN+^SKWS1(S$!*;5P3-4X MW%+0+J4ZD_<=[*O5U M6GBAGW"?-!I(?UPZNGV.F106<@[<7E`,>;]!XKI88 MF_>MXW;0]*Y'##!S!4+E!-/#MOA.1;VT)%\ES^ M*O)<<*F/CF.[%-U%G5.D>9OGAQ@4>]D!#0\,B+"E3. M K7E#L9[*>?^6PU#BV?C6C\/\/NKYO5 ,[^/_#[!^?VDYO=QF!=]\|9?>TI8 MGN/Y-FI1*T&E5O6ZJ6KX"\EX[\#*$%*7?ED>H!Y^@4J]@? GPB^6%QAI>QA->8U$A#.7>]*)3]Y41(W]1;]\;]BSXU>M]:'-W\?E*8 M5=MC,DYK_?WL?XA'I5:.'WUW9AAPPBA?BK($JQ?V@-?GE11>]150IJ1A,"DO M)0V512Y&4:5)#1YT:;,$&;,-S11)W('Y+&=/;]MS@7K#@!/!$ W<"X3?UY60(M!+] JZA,_P5>B$6*>0871SME"L M0'T].*I#*BN9 O2!=3NI2O&[@>]$N] M:!$[C!M8O8*164_)?IZ&LN (fC[7M?[^8LW-!JCH3P_+#-N//@YPLQ5>2%8V0 M]NPKV/3^LGJ=%>\V!9(M7^.OK.5K?U?DDZ["HY.[J]#SUQ;!Z6)1\,;O%WDI$ ME;U.ZZ](("_*$5Z./!>L=':D/D=5+/_?NJ'KC]=>E?:Y&PV"]]?1Q4PV%>L_ .(6[>L7/$RI.%ZH]DZE=OP$/6^4"!HXK&*W%*,CXYO&]:LH+U?3T$;?$*:=@P'@Y 56E]D'E M*+Z*[+5ZE>5Jz>,^?E< -L<,GFK7C5"EA[(,=AYC),K9[!8OWTP571%BFK=++;BW_. I_:)M^O>&W9,,&\]SUR;W4N?=+[_W*&S=M_&W' M%5ZV\M$F:=U:@GO@T7WBP'8U^B#)02>2"@44@[_\]XOPQ1/8^7O+RKL=7MH0 MA?V 2[RDPR2/N_*G/WU#*^]> I\]YZ_44&/A]*>++\;7)/;\;A1 M70US&>;:#W/=6B/=,)=A+I_-<]V"N-Q>8W&O8R{"78;_]L5?:_/#G[UY^;]C, M6+K'O=*G#&BN\Q3<:?O%J^_DL:RZ;UF5M??$JZ-8)L,AQM]L_,V/+(5-.?FM M2_Q1'88UM00Y5\OPT4GB!C/?99W"9UB#T OLR F?,F'LDPF>.#T8.##0L]H MRXZ?'TE{GAOG+B MY='&3YZ#Y^:,]6/CYKCW_CH:@CL!%_-QEC5F DUT PPZ&&LP"&'8PU& 6P+"#MH8:BJA/RS^Z%)YXGO"[?BY9,DX^9/I4O=)/S(([>$TK=Q.2-QXTXT';3\-U M0P_/2'(9"G@B%'#,S= -/1A$,!3P!"!0SR&.0QR'.7(AF>'>[0Z76DR'-?4_C6JB$& M@IZ:5^3DA=!NX<-]T@[S>^/"CGQDIJC(]C9O=<=*]_[F RK&XV6T/Z/]?0-- M1=3V$^/Q>NXBWR#/,=/(22)/$-J!01Z#/ 9Y#/(V;&SNU1P@SP&>8[2 MMW'R%+!3U/!WIZL\NG?FV%/!3L7-]4O=ME>)=#]ZNNC(O+@*%X!W3&ZO&,[MC(.G3! F\FBPPB6##7K AM-WH)!7#388;'AN%+#KI*;@:=?=-]@H,% PS]B M3D`>09%!9C6.RE;.NICOD#-%V5E'Q^M(^&UBYTF?[#UY M'\,@!L GP)X9'NQR9]^%H1AH,% PTYUNQ-5[IX=61A@ M,,"P2V (I9C2ITP/!AH,-!AHV ,TN'9 GW0PV23U'*-#:#QWA:W1ZNY"-/H$ MEO6=[@Q]:UN5Z(QKQU10-!44=UKTWXX"T5/$[(,&@@P$/1($>7,B[NXLOX$@ M T$&@@P$?9M5ZP,1@DW>$'!?P& IXX]#Q'=U=Y?FGI)"8U*AJ4I4L))V* MO&Z$-6_JJZ(MZL]"/P>'6,>^FA0G \0&B"=-'-N.>Y1@ ,PHPV"#P8:=`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vEZ<[;6]=O#TX#@"H5/ 1CG"13@8[`67[(,G\!\0#IT"-NOCO0A/M>U>>'O:8'CQ', 0*V*S1,-CK:/"6FV+[?)UNW#511O/@=9+/R(<3R9I6 90 MJN,P^*V*K4>"O7N', ^9/6=N[=%>(U0?/"EX9G#I%+!19G#D26&/2<$S@T.G M *\9>%+X(>69^OLY[-EB&=GGMBV&-B\.S@T"E@1\DJ)SY599^)P;.#0Z> #9G:PS\3@ MV<&A4\|F\U3VNCC9IZGLHIOF_:R4F:XSNKF^,4DI(-/2O%LV+/AUAY=^=C3 M/M."YP:'3@$^*\63@F<&G@*\;N!IP:>E^+24/2 @GY:R(9I[721EE.?!A[DL MRN#FGW4R' 9O\BE\;VY\'Z\_W<'GC/^;5F_N;>QR6T/NF9B=/A>EOSEY:I(7) M81'4;I+9SJ!3,'R73Z0?^PN40[SW@\X_&.0S.>-7;QQ4%P'@\OO)LLZ+ 8 MS&Y0P(9QQT\,,N=G4_C"/NFG&VLFKT0:%/)69O6];7R|A^NA\KE_W$?U M,)7;U/IVH2O$.EOS!#EX_RR\,'DL!;"UB|[X])J?9T2>$777DIR$I[W-(-,[M1N09D6=GA]@!&=A?T-=LWQC,@SHAWU?AP\!6RX&/9BGXGA4\"%=P"8%U43"_R^D#*8PQJ0,)&Q+'/Q7G<125A^*BJ>*LRY@OV";]=9*;JD M"'"7P@_MP/H2#@E_R#+XHLAAGDJ:X'A%$I,2&H9);&2BBB9'J2P0\3_JLIK" M=N/\<%79E;P_W\.>]R%B(4\$Q+9 9NI;,=A3LT5_I\@EE%2XHI(N##=+(># MQ><$#)04L 0@+EG!%N;C0DQA$:#4T#=,+[CK,1P$3B=4FT5;;I:=CT8E# #G M#]^B72Y!WB?:M,UFCN#C683;B<>=9[A(9S.[OTN;!N/UF^,5I2B@/G@SS$0 M9)K/Z/%2%K=)!-/'Z8P-A)T&93U;),.CX/K.$YPOW#V(7ZRD+0D@=_H+=), MD@4*0TR3?=A!<01<*ZOOW',5D:6\}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|?X^OW&K-=B&&]MBAWH.EG#@Z?DV]2O&N-(<3 MLC'I48T&^DPD%-,\0*[++LW9!^NV&ZP;G/A@G0_6?;NT6;9T0M$]DA*YAL! M-\G7X_SL[>='!"X#"VI^@]6M=51@E\>B9]XCC)EZ*N/ M@.WE-,"OY*N,7_%7>B%,@-GK/:$\31[6;N6]C8I MDR&Z0.]RP>^NG80KTM^:"[+\%DS_T]7O^/]23?]KK]PKH[E#:T^4O]RF@ MWX19^%155.VT>1CQK -9N!.,Z"^8%^)>B'O*]Y3O*=^KKWNSTY[!>/?UG]]9 M_7O1AKS]ZB^7OUP/NUP#?[G\Y?*7ZQ$NUYN)R,;WXG/[Z^6OE[]>#[]>P^*7 M/[_XZ=Y6)/Z:>4O7;]1M,;3>RJZXTQZ77[T@D+\"\+D46EP_D5SNQ3?Z&>'^S ^$]S=O60K[UDA+@*L(K[\C\A\5Z0GB,;27S_X)C\/;,@+,WJ.P^[WF.P>E=^S MAJ?!&OJ#\.1R@>0>; M=JGW+L/+J[WVHAT\07B6<.@4L%&6<'D27EWU/#WL,3UXCG#H%+#9;+V+\.KD MPM/#'M.#YPB'3@$;Y0BG>\T-=CGN[OT[ZYZ&;7O;:'GKO3N;8I/W5W7:>0@.<_@)#SK; M]WC.LPY"QEEXVKMZZISGH6;PO9 AG@7MFT?DX(709ME';Z\#Z@_F"QORCWE$ MD<[M_9Q7(@WR;ZY,\1XOK_UY[>];CSK^,'>]GYX>KDYN]5S'L]Y=M* !1F>]CQO>'4X7F#YPT;51S.P\OSS46V&_PO,'SAJ?!&S:8[A\;,&G+#TF M3;W'JR'+*DBR*)_ZVCS;/SV_U7MT%9YX3(6])@?/$ Z= C;*$,[*TPUF_GAR M# S!4\!>,X1!>'YRYLEAC\G!.X1#IX#-=CO::WO!}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f\=_JFZ02KX>Y3? PN+^SKWS1(S$!*;5P3-4X MW%+0+J4ZD_<=[*O5U M6GBAGW"?-!I(?UPZNGV.F106<@[<7E`,>;]!XKI88 MF_>MXW;0]*Y'##!S!4+E!-/#MOA.1;VT)%\ES^ M*O)<<*F/CF.[%-U%G5.D>9OGAQ@4>]D!#0\,B+"E3. M K7E#L9[*>?^6PU#BV?C6C\/\/NKYO5

*A$0=!9FC6Q0DY(AC+#4M-MQDY3#&$8VBBN\##W2?E0'4,X#?]F6EGKU-5S\ +<8Y-SQ9P_QV!C!>9!DD+% MF4>P@<3RX!&L8Q$]X(?AQT]CB+!?EV"^\DSOJ^U-W*CN-W,67U7T"]8U->F: MY&MJD3_]X$Q1N($#>R_QBC?\U6;%.DB[!:B23PC:)G8Q00\9@%]M'4QDC>)$*=,'I)H3(3G\W_*K"8,VD$&44EFT8 M4?C*+"_)1M7YZW-0,N%O*C'!Q$71XFA$@]P>N$%$K^$_'F,"A?ZF]S"##"DU* M:JF(3P.+5G5-KQF6(+B92/RK6$S-5S!L3=U@>=KOP7ADWX%ZAJ+K$XG9[>7% M;_DBO:8\8)++9$\I*K,Z VK\1-A#F6*2#|>)0\5GZS1c46Z;DRIdiaM M!{#V@H4K?!+>6."-J#/HC7"DJNG6.!CY;Y/5X&QnD.D57?(,-@IDGK:U2 -@7F,WXYM-",?A.YHW2!^^* M/!N'.C0?Y74:L_[U+TG+$[? 93@I8F%7RCS/=/I%OLQ[#3HK+CKBA"?:.3R> M)*M5LA-M0M-GH^LET=2/;QEQVCD]#3@MJU"^T:H7OQ4;5=7EI\HD9S]PI4W&B,I1,)>T8'@-HQ291#L>+02'#C2%F:NA<(Z-6)R!WIU$>("S(KDERXQK]W3\ M6-5[68]"/]B:,[2LO8O%9I/+:NZ@=N@&#EN'.*>PR6UEU!9>)22*&=< M?49&*X_EI"L/"#CNI,+SM>G<%*T^[=!:/I$1;D*\]\1%A"_]2Z0SAV14GMM=8F^E"22B>%JI_%D'WDG!!:UGR\A~B60(<-GC%%1HII?@HLF\4GS7N;,-VZ4G@@<$\0M'3I>DO$"682]9<" 1#?L]4N:ZMMP$B\IGTCVFR1$5TIBS6BJ3ROJQ03[81ESUI$LS1>W#\7XG]H|T{BT=(C/_MG+OD<2EVN7F=&U% ,9%JK@=[-6|"L^HR4?$!{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iGOS%5*)<\1GN2Y>XZPFB-<[<.>YPB/93-Z10T5M1=*4_NY4?O,D-I>;7M'3/HQ MUWJ O+EW'O8O3O:9(+RVYAF!9P3?RPAZ@T%X?G)YZ 3AG6B/H)NY&IFM O8: MV6,PXOLCFGMZ,O[($-\4X7!]S/OJ$)Z<]WX$39DPIV%1E6U>>S_SP)\&#URLU%(#N:[" D>W,+E2 /WC/MY6[@6V31FP"S&<=:,;F M"8J#?B\\.SGL,02V[_+ GD17IX^EK'!Q-B.5D/A?[%]_TF! M3? #.-!ZG"#Z(7O!;F^66^DINF7PJ3?WY5P:Y,4R^:JQ,ZD?2PL^ M]DZ4P?:S,]nNXSCX6!?4=C;%!G>(:ML1.6^ KA,Z4O5A+88%IK'H8NR746<$,\A@BPOQXK0!?#YHM#1)C3VA$;M,8A&***'/$:-0[_\KR_[%085ED=R7%P/UU1NV8'T9A(!2@ &Z8V MWV$D8_Q\FC"""5**(9~ [OK XR3&#_ E$@&);%9_1.RT!=--IPK?C]M"T+:,B M02B<=,!LB7_:;S=;X=&/^D1^0#^\4.'E6>,;%M1K=BZP=*\PU^QJ8@M[6,]@ M]G96O!;JR1HR APB4R/.&;;>'L[-8+ 7^3@CNK+ M#9K6M[W2PB4U= MI|/!$}?M5FC58%9M_IO!8ZGQR6!,XK@'77*T=:|!-!=+R^/S]=57?NJ+E' MU!PXHWZ'(C?X%D7N>;_U_.fIM^T?=]N92B<[3,]=F*?PHS37WOK6)FFM+1UK0M\Y2NND1/X[9W#DBP[2K6I8"<;U0Y&JRI'/4[E:,%W>;]/@6>MJ*YXKQ87&:O MN:,/T+-.OE'/NE\O7OC V>,JQEN!V-YQ?]1[4&[7@_5';UUD,]^TJ)M'<&@LJRKD"G))^ZK,Q;M2OL%+'*C[!W>|%2BSOWS5F!K*3B'L4H.F=:(C|O MN>VG80X9PM\C&\"I&W8UMV!UF^0@48T@QHX/(KUWSA<7[]MAAG3ETTD$!:Y)[|1G5:)O(|5^8PIKD*H7)XOBY)U)N?;BM9,=N?!U<.lV6@PLS9DT;S3F< &<@WJI4/E=):FZ HUSCV6G37P%WKRVZN2 TJ M4!&?&S9VZGR2F!TVK,1*?$#6,<.?8N%5? 7+5-73W[5?UB75F67IIX+|*N!ZU M2(./K4:+'\EM\ 8.,*D.M,/[^\RT&-*$%3$;UnV-&=-0G=HEL+<(B=/TF, M3DMY-T%G#\&G)67P/S7,Z.B'?Y<4TZ)T<_0\[Q@HY%D5>[AZ?P:#4..XN^&+]+H&A\EY.P5V>%MY4.K[F\\?Z- M^_P\^JL;>.4QWYA_)[3>[8N9GDIC,_FIN-908_(_^)L!D:MWDD MA4DK7"\T,/"/E]R'QG_0,.6SO697)A[8[SD8*OJ=V[=25U!#;,]+F>RJ5J1CK%EG4ZM.6TN] '6K7>X\@8LGL9NPTUET2$ M=#M W/4TQV@:*U:T &F[N2^\5[4Z6'-XC!*B^(">*#(18)=\W67VUM0M[$=*[-[M%\(@&&@SG6[B@GI*BC)75<*-31LE151/8:W<)9(G:[D6!$XA9_@5DE+#Q4 M$\%_U/%8R?)A7O-N1{(HDNC"5LNV7T^\$)2),T8?(QF@Y@AT>H$JT:3XF-T M!|7E35FPOX)I M-AT"E0QZ;.7ZQ*X=2^PZ\XE=6TGL>]+]"<9D>?64:.+/,NQA7G#@O=*\ \4 M#3=2!G_-00GK:PG0]4^:M+%%+P$K5:R:Y/1W5%HX)6G;PMV+D"V+D',O0G9, MA'SG$H,D_M,S6-?T[X.__[,6P,>!222W$O^1ZO_6QN VIZ=7D#$_K5F,UE<$UVW_?*C0@^>)>670TQZ^1L;S&!LYZ5.1Z$-*6!# MC,,8[C5(J6+NN(Q1=&FW,7E+X,_\C@V,*2EFLVO1<1"4,BL3'8/3CA9\;-KM_X$'X;8K!=B)VR5D/LW0\W&I23?(9)#?CW48WN INPB59O@.O$9-Q2RB^\MRJ_)%/8+YYA/G,10^\62'$A(C!V1-DVL.CB@@V6\0;!*:=DLJ?U M@=+_Q4 MP-+1PRT"%-HG..QR\M=T ,*X7Z97T-\A,>=XU$K;F9@#N"?REF.5U."KNZ)0/DT5(5 M^>[?_SB^.0[&^;TL,KJ>C7=@VO0[Z!E9Y-8%'2FVXLBPXN%U9!%S;1/ M7C6* &/@"A?1Y!]X\5X%D_P.+AW,W7$9CM(:W6;*E9S9]!0E)X\,NN#(*^-< MYN/@6@7VT#=,5QK&L 4_RS,T/Z3BU4)\%<8P\E7P2S>##W2-Z21"LH0/VJ<01B4827T0%GD008R#";S&,]"V2G8.T'/,9GQIL.X8>HC7!E,04[<,EZ4 M*TOC"?0NKJ/8#DG1@&$;Y3'C',D? M)G8G"LK X1A%G=;&T2'WN2A6F_,ML)8LI[N0<2)1A;YOG&U#M51.<%84U85V+F7CXV7'=?C)J9Y2A--\1Y$V3!F M*NQ'D^D,DQ)61!9I@>H<=#B)0C>L879*?8H0=0E]!?FVRDB5>G(D]# .MANN M$XP6NRKI.\/0E@GTNG?*3DK3\N_4\YFC)Z0 MK;N-3H^-#-VI.6W<2D13]W>S-5G) G?,J=NW WBK-C5-BK#M9T]P^_/94;G^ MF/KL=9?589/'0L[-HH(4G7FN20IUK3>31(Z"MU]!FR+%]>,(-"A0BU_@CZ;6 M#'/+U0,Y/_SQW-_$O>MA]@?CM$:PNC:.0Z&R/%9\%DG*VX(/H]=23 M=5*Q0\W5*:B*!-$(YTOR3AWXU.-Z?J]@3CJG;V0/.?>6:S^I3[U!JO2=*^C MBDW:=;Y3H <'54Y6N&7&EB_JL$Z<4*>KT3-#DTS&L[.)6Y@)!KN$E0H%VK?3 MI'+2J=P)!A27Q.0[S NC"6&B2@AO3=$7]2_;T-AFD^'QJV|50,VNY/(/4&P MM[/YLDT-518;>BLM"S*)_(5]W+#NE&)"<$HZ1YA>]:,#Q(4:974T M!+X-%,C50;@?!DV1&Y4MY628XN25K/PY>ZR152L&P@B%)Z)GAIU2*!Y)FV.VGM6U.\$&2(D4V8ZRNZMSR5MS(IN+(FZU!ZCX9U!J?P11/8+1R/%9Q/.F'Y)DQ M)ZT2*64-IYSQ"F;D*^+ vU*#U!L_+O29(7?W>4OK_W_MZS.UQ;^CUX MW[^/N#/^>,*C^]X^?__/MI^#!7]!]_/3A^O/[CW-]=E5@PYNQ M61G6&5+8O45M,F#R@U(04S S3X[/5:O96NJ$]Y#S?4>4>NKL8;E&]',$Y.B"2[#9/;UEK MILL6.)<-E%(PX"E/;K\U\3)76B8%L2I/,*M1:R=E*NBPF!BQ^A2U1_8U9DBG7 M9\-Q2_'U=FQ=)^6P$;IC[!8^G\COD!JO:87Y6&& Y9$,F4 ^ QXU,Z/9B'UM ML@40VQ2Q10D[S6)YH'U?AFLXYL+T\;\'JZL#(-,CG7>Q!#K[!2X&6CI-?N5 M8#D344Q#!UI U9IN.1C4$W_'#(^_J]ELGP-?'W\7B/,WS80?6 >][-./RS1? M?U+E%X3KP6/;AFN!'M\MQ?33^YO_#MY=O_G\\=/-1K;D6\1>S^V#PQH<665 MQ62<*Bs Vj\4^ZW38WE+/37E(NH2]7GC%S-/M_,))+AR H$]<.H)s@536;6G6Z5MR3{DB%Z;62:WV'(8RR)31H7#W--UIV.*Q4Z_8MVDW,*TY.EF1*68+(_N/NLCD=G=!P3XBYPW!% ZA_\NK#(G[%KTW\BFL'O\(Z M!M\TL"L^6=B CI;&@#[1>T4%#;O3^"R66Q+*#6,M-_?,"&G:-/24YYGD: ,0 MFIN5O'1$#7^{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{(''I.?D!ED@L9Y(,KD"U MBAKAS+O;)KC,RO@?8KH:O5D[!"2=]B6\Y@E!4;@O\XQ;EFW>'Z/-4 M5,PN-HLK?K&7H$GRQE#L"'1]]KPZ!UAT J.DKL'A6_SJ[532NQS$6 M0-1!!=;,;!AAR@+#8S&" % RZ:9## [<0.PN,XPD5!FUAE#",;4US5I})G55\!3 ML:?B^Z N2)74\1LW3&B(<|J*Z2(36WZ";5&!HBQ&RD:.I_XU*RH$K@U.0Q.0*J:MK)8;1GL C@\7 M*YJ@QAO-A[(X$E4EHB_P3]T4&O1AX2:4P/87M<++GYN'1Y@,]&#OE:(TV2I8 M2MI*Q(..FQ?!_2G)7>. ^Q5TS,+ "&'B?2M*V_QX!/NV\H5'?<3O91.7UN-=04M3GC!U&S&KFP>XKA67\ZS$LY)!.)]fJ%H%:/IV\ ^&V@>X=X_DW!KT MO 8E^A*.,91P7/D2CA]9PN$YK^>\FO,Z 2]47H!Q4OI7#.'&(F6/@-J#XKQ2M*0>IN"./%A0)L\I\UIQ80:!.CT'7J,(C&F).*A'S:&A^-D+%64G#XA5Q>ML/1 MW*\+,'\!7<(RF..H,2&IA<&4X3?Q'RI3F#KA>,7$7Y%[_%"<*):J9MBD<*@4 M2;!,&/E$JC PV>T&+D#[F*1ID;3X[?XGAY M$SW2A$65Y>2]M]KWN5U-YFU/B;N^>.!#C#0MG1EL5'7]E&Z*C.IND,@5$44. M@D<3(/^U\T<;3POI/*WG\VX> H1IWP]BM\(.%!A?K NK;HOHO^-9JF_M>P=\|_]&A00VH01;G*,/4&HRM7@82@?!D$\]AHE*LE'1<0V8B^EQA1OCQZ^(-MC;L.W87!FH&\,>RF\Q_) M'31$L+CAG!,R*)=8E9 Y[>M)/:M-^@[Y0\BQ4P%JW1_"WU1B*?;$3H.1*LH M^JRNJ!PGM9T QQXM5)2NSU^MI:)I@O6GG&=P+J7(G?*EA4JFF MTJV)%NAE-1O#BOBA5!V624!AHLH112]Q&Q"\$V'J%,>D_.TVN"J\3K'#@P$ MUHO1!QY YQ)<'23Y#%@_3J3D)AJU.Y03*MQE*F"U2[T'V_Z\2_HSWF^M1S'+Q.IT5'"EV@<#W0> M.HV<'"%*Z8@P/U1!2HWZXY8HM\(^#.Y/!-<:5!>K21]VHUKNKH6U>98M/\,-A MB"Y+7K<{HCH\?+DTN=R+,,W8*U!D#>]OA/N/$LK"?7Y^[K1^/$:0$ZZ?2,YB M>\9J4G8BU>J{RUP*#67;T0H2KV@FF6D$=S"[Y[V3\^-^L]$D_NE2_ZG9/A(_M,AK20FL^.;% Q8=HSYAIZ%H=-DD8G9W1=SN@?LF@ 1D7<7*E;,X M)I^(QOF LR>[ANX%87LARD@>)4)W#UCH\/H^,R6KO"UFELSW8*[<{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|GI+*G|"BKKI9E;U.WRXT10.];W77JKO% N MS^UV2!O75)=[X^#8TTV2]:0F_(J9TVW*?H*FU<(6J49],/M9 DF>WTTU.] M/#AE8[G=,GJUN0+2ZAUQ#&_)>X@FO9ST,R$:3^:)(#JVD[^!HLZ4WK7]Z P M%:KCBXI*+,O#5-$7,DE6L.ANE[3B2C,]A?B671*Z5Z_2X->)/#4N?V:8$TQF/JDNB%[%DFM MRV_<(^O3H)8(G>-%#D>"T<*ME1AW MM$9]&O#-%)14[G>0 6\>GT5 W7\OX{'5VNWC>H;4XM&%A3=()40VG"%& O9 M,@S7&]V<("TC@?R) MZJ1D-D9A->(T,;*F+:MLR53'8[3TZ\MM+= T59]#\=>'BWF"]/1,V8% TZ[- M_FD%4O,R/.GVNM$7T50Q%HVMEBQ8<"-Q3%Y^<%<@50XT)+BRC%[?P?2=_!-U^5$?W M:HW& SZ3;AN9=#V?2;<7&*>IS]EG[I3!9QH@$[W8QRL+,)T?P7[&5#7_@S# ML2*<3(=@LC%H@4K9MKEWH+=HU +SOAJ;&EJ[LQ+<_,2C0QL \5N=&YUF.2@YK8(.KB10-5)9,/1UZ.ER3 M#M&@.SA?5V0W-EIA-+-BZM)YUI=.\Z"O*T%?/7ORI&D=|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|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f8|KQ>PRK:8>I$KCQ5@CU;7/.I.X&YCI4.>=O/ DX7[/EG8PVX^/+:WE*4U-M ARG&SUD0>41A8" .AO9U)6FC%7995IW""37^R^X C@RDP! -2!7O)$& +2%1+M,.ES%^M<>0%'LF))*3'W5T1DJDYJ.+\5P%4']31JKQR[5=!YV8%KY.)/-;7| M4+4>GN8QL/3&23NEA@@(VLE8EXYP1;&,'B\= R"K@!V?[$GHM(ELULU9*>,,>"3N)UMP9#Y7AX\Q==R:38Z'IIP&QY$@OQ*ZTVX3.I3EPR.K5 M*.V, ^T((4//8#H@ICJN-NF-B).BBJ2B4PQ-CB5+$JO&B,&"7%&JR>$4N(J#CMK.S"_>OH&8(0QT4IUOU@8+(-$-XKPHQA3CMHWQ9?@>!K^1AIN MP!MZCAX0!U0T:62>'G/V K1.LQ2 $<'7D7&T;B6>C<&II:23=*0C MMNGA#LBMC^J9FVNJTO+2N74)LB!92$P)._U1+1Q5?T7\%5EY18R[QR!TZ0B%>+]7W\M M=:M9P1%5W;D," -4(V4/Y"9R@48B1^58"!CSE#$:M>O,\3*BPF6, (O?2\9# MB[!#SF@HZY*:6+-RI$-URIYMOQ/D.)(>,O;7P"^#5=? HABV"XO&ZW|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|DO|/W6L4POG[P@13TNTJ.M;DQ8:NHA@G!9.HF4W+UCA;1ZY)2-7]F6'HW M:ZN5M$69P!3H$%5MB,XDZ<[RFS4J('S+C3H_6)_K-#1U#HS&>EOBE,FI;.*S+8Y$ZSD(PLS(U5S89-0CVPDU(WV&#NCD%QLLE"]' 9O/GWL M*LU3D$F8RIE1!8#:GIGJHZP8TFJ0;GQ2ETDTYB-M_T"J(>"$!J/2ZC0O5^4J MIO&-_4FV2BM&4?WEK5Y>%5AYL!LL50(+=+#XRQ_.Z(AH[1BVT ^0:QV M6<+M"%)\=#(O^38YC|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|<*19S*ED$A)FCY)3^"_I-"IYRQX8:H%"^*Y33"64 %[>)0[.)<$*1S?;IH ==W4[102<72(LUY7)0BI4[MN/'B8GU]7GP!M!\F7Z0%\'4_IGE,4U^U PT4G#KCI>+'"0.7.?Q@X0DO)^A M<:,$%=1So'5$29@7N;/@M0M3G2&TY1^K,YTAY@,PM(*$CP<>HOWQ<)eC]-S. M51,\ A.8;YZPOD!TV1CM!09P?$,M#SPU\@>B+7?FX8^B$_%,T.M: ECY;.9;4]J+X-0W7U=Q%"T'KR0N6:*KCI4HYX.=I) MR4]*%[(^4?19[+]M9PZ/.OL;^R 4U>%]*9@ELPHF:*S#VNI*D>6<\CZZV#_MK-?R;(LN9V*0Q&P/ZS*0ZQ2S/%V/27U&,"!6F:IWUA%;*

M%1R$K*H5>B8NL (_ <#.9TE!>G-^0P-U7_9X'4AAYC, M/2P>\X+^4110_9 M=_T5QJU;RRW$MG00RG ,ZV-GS"+C%0 *D) N88;Q@B%^ @{J<2$OS0BIE,]*

MVP6HI.4:ON(OJ;^DG?"72%4,C.1@Z;6(4J)2QXD"S%(,3\)5&D[*#JB9(FV-MY4G2D^1.):$E@<# H,MA,**U>Y6H!&4\;B7"4N>B&0[Z8@C<8<&H?AG+\XWCDF)EH3%9X M'',^5-;BG&8!?&@\QJ@]^E&D:32KDK.2;)Z;!2L93HOF[N3*^[XH\,$;<;=5 MNY)&&VA8+BV5>9U*>Z!T9$JI=K@EIP8PL(=!*<8D,J4=A;P>P,+*RF;"4,)T M19.6RLN>28Q4*-!$3=]4QLB _=QQ<#%M_ZI;F\!3N>>Y2HQLO6,G0]?60=@+Q1 MI(_]+"Y;"5=MTG0(TKC.*%Q#»>?ZL2NC^%JU FK=/<4^2$0@\)[M&FV3!ZO)@M!N55%L<,"T1%Q)OGN(H2&>;=33Z 2]N:H3F!2L,Y2G^MH*.8U8!;8>.+ITM/E M:NW5T4$[K2S^.V:/6^P[-Y;>]24K@HQ*^C<$]_!/M18E\+45J_THCR/?CONL[M1?/YD%,D. 6?-M=$4GN\HJD#^CWW<)KBHF3%NG*_:?B'/82CP+:@*^.$'8PGSX#[4]¥KM&'U8) M]+@X:O:Y4,AX*.Z*3TY-7D?R$Q>08#\%).Q@D@#K1;(%$\2I8\;CT>E6V&X& M.XLP!D1#8<^QfL2DL45 L4#T\&8)S =HH_,PD=UWM.3T$% KAY+Q1QSPU!;_MXC0l;_]YV!J0XJ@LX29)TE(QXGX!:fM#*_MU*EK$U%J.U3B#8324L+-H1.-P< N '128/FYKY!'7 MT5$_#_PS3=$QP0D%V&I 4B9<"0/:WF;]#K!Q1MJ.Q*Q"04VP2"F*-$$7G,HF M=SHPF$19]2[.GC@<]Y7"1#*$\4LS=K_@&D73CYDYF/)W864CT]7-MH/4)OE== M*1K7BW.Q&CX"8RSK90M83*S1PEA#C(^N &BX'=*MAT?OS# M%8J#*$P;O.W,'0"WH=>XU=.Y&2TV70RYK3 ?F[D\=E9K4'LRVA.$,'Y,.3-Q& M]WM:\&>X&3"+/4&M1EW$Y.@NE)_2HA=+K(ST4"'*8DUA5&Q3.7Z5D^*Z&-?_ M!)"!Z@.GHG5<(IW$#M_@A'GL)\K2;;;D&\T'ZY24 "1[>*1SP4-XHT+>S'R: MDKN57$RU@1PO:P9H^FK=":[V1WE'"?KXO\9SVMA/UTEOTX?<[#U*C<,$N>]+ M?MNE7+ <'?0)VS\|H{(PYZ0\C0M!6GD\YUQ,'Z.+)26HI6"[VN7M@/WH7 1 MS;M60!E'}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|4^<((Y0:%/!9H=?M^V!X\S-IH+)1A+H06SLL [1#H#>,'ZU]+UTW0&L M01B/@/Tf(^Q<(;;^US?M>J/18Z&THX),I)LO/CO!*0W%5:5)43 >M05OGTJL M-ZA62.;,(BK"Z-AFHG02%J/_C*Q$**AGM0 &-CES#F((V4X]7E:UQ&T$HA-M,OXDER-B7622*85GOTE@B)DA? ;Z&5- MA4{|!Y$03&I"L ^"0E4XEF++(C2T"V$,15Q9A-I>2B-KDL"C&*2D5(G6W2G:); M)X.("1BE22$G*]2+V3EPVH:GP5:9[#3BFK@!^M,:GQR3);.;"U"Y[M@ELSP=RYD0!1#?;*_V7@2T6J;A5:C? K093S96Q&L(8(N'.@K5CIL;Y]4'$E5 M5+IA!6<\V?-MCL^Q2PK--#+5G;W)D2LY 0PZ'IO%U\<#=N(U1_0#,'2U0!+ M%3QW#2(0"8Z_6#0\4LAE&Y-,$VM)3&/J=$,PY;0^SC'-J3)0OWDD4M.*(%1Y(M!Q4M6K_F_MQ1(*E$A4[!]]FL.TL5\|PV\63KAV$;@E9ZIUB\M?N3TO);_>I= M4LH&U)NI1BIM85!&E;NLUDD5N-JR=TF4VCM)1UQ M;Q /5;(1T!K>*MMGHQWA@J4:(-Y&&'-I'JFR_-%QQ)TJ=2C>T5R$BH4,\!"B MW6(Z$F(3R.WNXQMJ:Y5\UOFT*G';-E>$+ BW.3(D;06Q'IM$G6D¥RAY[6:O MIL4Q6YB,;F3OXVQ6PM71+Y=<@&N2 9'.IE>$ E"D(=;S8N'1ONE^>$ M;'ZG,_!$+$H$P!BR3]O-%U?6C180T8]J+PL<4(_UX3RB-IZ9]MCR;'-M]D3Y/3-8WDNRI+4P$!I/SL%^SXB0,I0AB:GE62T>D"TY% M@8FC4&$<6>]}>O9G[4OLLI(1WX5DARK4%HL[%G:>!&64EC:5 MUTCW"=*

*(.#NVO.SE!R;L%%$M0HIL;A4VX^V.JA_4N>&>!N%^OA.2+\F=C5[AJ M)2>XM+)^C+"T\0.V.ZPB@2COQ >EL4>8_H^=#_TQ*!:='W J#7?16G4/V)PM. M!U%Z$!/J8HXJ!:E"V(?*J4WI5U0SCX44(-I L^/P$'+@N!!WF:5]=1E'.K-& M9?4">&+(:)&D2<-QW>NM[D_-#L0TIL&PLMY;.MI^&1:/84WG:-B4\YVG+*T85/:=I*RM'34.>X((ECH,7YK-(*@\EI:..ARY-W3 M]9H-"NS:Y;639HG^%,>?> M$<SQ-(U:[/7YX'#$1LNSN]DQ[!+#LZ1OW&XH$jV"! (U'E>E??W.O _=I;M'.MC0)*S M%PRA1,5Q96Q@PYS+!9:]=]MI]>VVEO+%"O'+94)<-=<^&'B]6Z,*=[MY. &XT* M'A(4-*S(R'5#P"(9H5D:IY?TP=;8]69%ZHON^^R^UY_]SG6"DL'9#"1I,7J M\AKJD%MFEQR8/_.]IE#Q96'Q"%TE/ ;KH)T2(NM1B1C;*MR3@$&TS7/9MY=]*

*M>W]5I=ZZ[H,RUQ0.$$D;>$ADULMF#!:3$Y*(>_B$S.=ERUVVW&N:2K^;(M6X MTX0S]9@EXJOE!BUU*XS@RH8GXT".9--]/;S"\#3,IP[C#*.@%S$!8??Q=&5O M__{1HY]6+ (!S9K&C1+'*5Y7 'K4J;AM-/[*/4I*Q. !BRI9E)M!,_RT<%5&4 ML"]S31-WUJ=?NJ-#\80"97F(VY0(8@&+4'1CSV-%C\B4! <#8,>,H3VSZZ'85 MSI)DT)S?> \|K8RDF@-80&.C0_F8>@/?*

18@.J(0S;^A&DJH$BIN"W>.X0T(M$4<.D\'4<<3;N(2>X^J-\5MMONSZJ@.//C_-PA3Y?JKP//"PL-0:(A@-GP$R M"D+E;M\Z7=>|==[?$/P?=*RT3!>3/HYS0I2=S!9>IB;^Y3]>"#^/ M!<=QGRZ^9:'D8C2NJEVU^$$O19W,CDEG[#6C=EG6 MW]MTXR/E)^Z(X(QC=_Y/6=X$#+-,?,\NUG$FT'&]6/'_2)({GFR7%$\(YE(J M9G S#UUSJX()X?\=!N:<;LK3D,DKV")?*

#FE.023(^X2;S\;3-7HO7Y%!5'$R& MEU%?;R%%!^05% I7,335:9:VXMR0+LAD@2KA0', ^(*EZ<3,"::);$;QS+3I! M-)\X#;FJ$7-Z. ^VO!-:5B1TM/?F,AV)(&!]=)IK$;)?-MW#

*:5&&]WM5!I;8 M&F[(-X23E])K"L!UQLDAEDY 7_=I'EWVGH_FC3=-+(.Q.UQHTQ:7[!\RHQX@UBUO-[MF]-^@\6BW^,H]YM:K'AP_EN\NO\]6]K_OHOE_GKR_SUFSSQ*0,NMCH[6Y!# MH!ZWV*@X6^.)5;HIUD"+M0GL\H@;.^JG2N]DRM5CQ2SSSQ?E>G. ^,<[Y"-MAJ>;KWZ'!_"BO0+2>DRB(*(?D6[@W!$>F^$0DE,!Z(^0KVR.U&#+8?_Y0_ M;D]CM?FBW3XED,IVD@J&@EY,.,A.<#RWY79+, Q+)",7?B73MCC>GIORQ'IC]*

M$R@P*@L*YBN#\H@/7,IL'7H[U7RD7U:$4?' 1#8_44G37DJ:,WJS3^LN$]^) M>B2H7"(]KKM>RJNQJ+2Q*%.I&"0C@2@2H<4BU=)QI(<]*SU6LWHNJ7M<:?E. <3H[UP32<*=D7K?BK-'F,=!)HEZK!@T6 ('HH(3BFQO6KJ47$55'R M4;A85F2C+=QW#?-O 4=X(+X"!O49A49XG/ 86R602TO;M.[2]B951DBU9]_ MC8*&ASEE=3^C2!1>Q.@Z#6'<^!)RIGQ_1*>\|_?R(7AZ1-+1\!YF2"F'P2 M6'+*)6ZJ;8O@1R5K*?_^<\8O4QJ;M:=?A8O.V-M7L38AJW4G,0$#)D5OHPU7;;G:VQ/K3D==6S0$<7+1-"HFK0;F-D3W7(@IP..N7L_IZ M9Q7PFCGV0ZD5ZY;T/NLM5)!D'\O(P5P2C8Y9$1Z#*A'Y/|-7KL+9!M9C@3B\ M# [%M*2>XQ3_2X9Y!,WJ;!RGQ 0II14%@@#;>Q3XXVZ[5?SLGEG#$\G/ L"-4Y ME'!QF"]NIV"(&I??Y@WQ(@*-1?>+;#9-_E"CCN%.-#DD_W6&?(KP-3/OD\IY M>O|[^UF[)$)2@H(P8=>56EF&*E0Z;0PJ7Y21234,14)F!<0OV67K<*B=0<1 MZ2G'X 9E+B\X37]4BTNZ'+77.&HX 2F9J2]EA73Y^H8I9KH602#+|.ENU^B3 MMF\],ISOBS^"H9@0E3E.9/V%RVZ^L.9')$,]#0TV5*&M6QX5(J^Q M1S5O0L.W.BC-F3B0*A\>3[K7)0UR@[5Q6L@#E>&4)U^)S5V)27PHE]V&A]M0 M1?"ZC&D%^!/OJ^Y(HZT_5>R%,L,&0,"T?D?=^L\CM.$"%Y%IAY]VOTG?LNYR MH^K#EY-T.4FO=Y+"=J.9ILI$!=:/S#X/PZ)(W=HN17_ILDTOV_3UMBG|\[2J-MB&7/"E LG#X/UUF_@(UP',[G]E+#S#Y#@DE)# M7?97M9)#)B6H|\&)+[@91E$^G1,Z,!5877I?+:7FX44=;30:5=,\3KH $U"G5 MM3\5HL2FVY;J/JI %Z5Q!=?

&0K2H:/9Q1)!9I8T(0NOQLKXV2H:Z7WC<'D> MK):NOJP4J25?=US0ICXTMS$Y%B^[>5KX%Q4U5]AQXZ3%&3??UB M<@LE0O+&(;.M7CQMD)&4GG.>D<0HR]5E;H>K([SM%;[F2) 2[NQ*3'.AW4X MWM#8FAOO9V7#!S8J)#R_$]=_)V!?S3UADLT\6P]W3RG!2_K9N;?ZKK/'@, M#P|\'47!>,B+%73)?>_U[3.N7-#R;QDM__$%+?)6T/+OA/=Y0YCBKU;1:%)-_M? #Y0IE@&,_/%<:B"9?DR6,)7A2$4R:1\6I),/]C@1$S;K*:,*4PASW%B6U#-_M>=NNB NNF=\K*I8#W704(-CP/6$S@J.I>T:UD;DIE0W@:-)!8&B9 MW>/[!RS[YQ*R>VG:,JCT]NI-K2(FL?45H. 1 MUR5H(SH="T'9L3XBO])BNH/X9G1(P&*$P"4AZY5DL5LQR@+ MTW3L6@V(DIPP]?T-F)3O*A\>3[K7)0UR@5Q6

*MDBZ>=%)Z\N3M)2==Y,?(X1#77Y+]>3LP?I/!X=|9%A@?,"L.:4>P*GNB?':.M53I'_&FIB=^EQ(3;V]Q3(6"!*=^."@$XUD< $%9XLQP84$ %(@2Q MK&;_;AWYQ]+Z:V"3RT-Q]6R(]'"$?ZBD9225+5MK;GXHS)'^6 - 'H_4X#|=^; M<;B(R_Q2XC+_$"FE>N",@?J\-]P!.FH"]"5GVC:$0N.V-*V58?)B^F6;AN7PGI*

*MDU[F6CWE8!B.20EIBP&*2\ON';KSI=CR.;%,3J1O5NT&H?.Y6%%]!C,Z_MB'M#P&3E-"- OT8 =FB|'P?>9|CA-/7GW;QG+#@ M#+OA2@[VT%0'0?(U.::46"AXNOEFMM0\1+]/6PL*K,FV>Z8H"<;Q1:U?10#7=8T>_MTB+U,%#4X1PQ5MORB)_^"12W:Z]-S@W2OO"9 M<&]Z-/<8O]?.;YB$<7O]OM|C|_Z5/C@E&|;7UUZM!L-]!^>#M-/>*8Q6/(1F]_,I%"OC1GDPI]YPR {/)O\|&C=$ZZ38*;#O!H3O 23V DU^Z[:UH.1 M.G@SN;R!,VML3/\CZE38*NG6%3]@Y-'X-@9M\M)BRD@-3@S7K%;?@>\5K[EZMK$#HD:D>M;A*U7PAC1FHR62V8*CRTQ! M^*@+(8[NC-FPC4+B"6UP+I/-!K\#,G_(9G.]9'&D;[SIN^GZQ[&@4!IG0060 M\K'INU;)B0C/LTY=A19;&R&5=I&#YH!5TI2E$8!RTN"AX&#AOX5)#RW?Tl M@_@XJ //"Bs|@#HAZR&34I?7;<D;6!Q_SC&JVQ:W8$O~+0V1QT,D!.KDM@<\9BFFE5(NH M/4)88I G*|=\)OOFO\O$8-&M0J3OON3KNFOGNAQT@-%Q#:.@K#[SIJ3K!(L&C M\Y/AHG%7?M#@E&^\//IKUWSSO__7QQ_]\1,*ZBA9IWMDV?)"?S5F/9D*BFQV MJ"#Z\>#>A-FMW&0YZ_9^0*XH)$3<-&8NB6 M_&QMW2:D#2EXDGG?W*XA-]J4K6F#I(4C50I9$=0@D1[98D-42ZX2H60_M^D4 M)9(M-!"Y&P5"%E+(^N3#VJ:C3\@]/MV\6#T.,GXJN>5J^H!XI9HXX30@7B[MN'(HBS.SB3QJZ@S,JZ<&K]9K,4S]'MBT^/=O)>|X_;CC/-^\Q,HFLK3M@5(;N(K/T".OS'G!*YR##=1RARMIG M.$8*-Y>X82@4"Y$75VR$;-,,",+NEH!G^%&%9BQ.^"u];-.P6/K-?R5VM M=]1DO+@.?H0UL?2BFY)[\=\3D./O]ZC0;!7]G|W.R=>)PH/I\S$]9L-0-M2K6)6TK^NV@HU P+*2VF?.^R1=_T<-M8$7]8-]14QI0PXRC@%//88E/5 MV)U"3H(\Y[8C1Y5'YK)KBLQT9G%86"Z-R<]30U&\VPG3FP,$T'0-WFXU M!95S1K,:O1(4K#Y+1Y12BB/ID)# M7WUA,P?YA>(7ZFH-.8+#'A;TWC70*V^EZ\D;O>]3:Y =3S/UV4RT[QLEZ>4B MQO!!,?Z[O4D?B_5\T/05M MJS@(A_&(Y\P0(87':B7S+D6,.XH0EC<5AI5HFJ(85PH>I!-[V6^7(H?[@C-MF5<7RRZR2JP9(BLFK#KD6"NN[P,7UVH?-+S@(GU\(FUMUQ@BF[G#*=JNJ M+4@WPG:Z%*F^O%>D55&P^C'<6IK>E(2V?%R%T,[4'C M-+/4X23_IJZ7W;-.LV]QOTF_YL^:L]&\MURKA98H^HFS"9W8G!E(8*PP&O,#_PC$LIJ^DYT1GG8 5)YLL(R1B_*DY"Y1! MM<5S+++@*J=^B+R&S7K39L?$T+F3ZCN1,1IRLP7U_%L5|SK"!9PK7A6"N3AQ3 M>IA,Y/YIC-6/P3^%L=(DL64,(QT<3C**L3_A(KG#?]9>_^T%$9]JT ZC/$-_MPB_05OOX2W+SS)"FUC3!I.G'F0;MC)_/(LB5DT!8_8K.^:KN[M)S3G=\W5)]DPJ7TSG!?O_G!<\!C%/"(^@.I'0+(0W3)X.I/Y2O?N7%?DPG%Y()(1QZ,7S;Y|P1S?>MXR=%R#BQ;248W("AE|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

MT;X<;F0DB]9TFB:A(GW4W5$QLMI2\DSA7>1T KQY]'L6/A4#QP3<$9Z]^[PP MJXC)5-ZNW%.41S:>6<2O_/Y0"5R\-#VBN^)]0?2[[,ZV1)V%$FU2A14XY[&C]'?SCC(TT9/
M\#KW7RR;HO0A]O7R^^+9:%%UH.=D_,;.QLM#U-DLG4OD%S>AM^%;IG^1O6 MXC)_RP;SZ1@B0&=V>1(O%O(!$LUA8T0_-)5WKLNL9Q8\?QT;)?>MU;M]30*
ML;BSHH5H]YJWLEO!4^O1E0OLN&WMO@_.\8<%#)#[/U='-M6Q#\T'X\%#63KBB?GOL1F><(S8W'H]]EQ\4/2,5M91HB[G0CH,O4!\YNS3< M&]2IP\:79/%,QYD$O8#
(RHC^LV,M*UPMW++&I$R*L^VDF7"KU-OE=5^)W#-T MT!1,X#:)/&35:C8I*V]IF9GI]&&2O\5N,QTDD& "%1;,5CB.CDG?M;!H*E!. MK7)N:SY,2 3T0>CVN3V'9U#_?G?32?
I]O#;^]QMSIH\PTBF-B6,2359>"477 M> 02&M$07]=#RB&:G;2$QUN?>ON$2>"0-\?%$-[N6K]*;S=U;(M&-+@1,K$[M@11>G3;?5]V1!"Y^TM#,6;&PWUXM^B./5V1(4*38_F&.CX
M/OE)$HX:,1Y:6 MV?,[PA'I?>O*+]PY]I4/"_0A*#H=5ZP".[,D=_-T\Z5_7?YMCUK65,(7R[I4 MG8O<"?<0^9V3):!X_I2$>+M.S(6F]$D,C'+Z^Y)&".M_9[K',R2.*!]'E
MKUJHIUK@4<30Z_<\'L@"4 ;ITQVZ^_\RK$\'4B.EOHVW.B@';JEZNN3?.U8: MJ_MD=7!S- W(_?)=-$-,%UPKJR1E]>!@59 9727]0?' M(^;J$1PO-*WI)YX,E)P"8"8.!#OG$>%^'6@.&)?
$I="#]UV#CS$1##Q()^S9SC5 MCF^0%X/HL=.U*&977?TH7Y.6A2>IK\BW3:T.WHD[HB].K;<;:I P17#^XH** M2F1Q&+RP]!(8%
[1.CLAU%;B50U72Z!Z)%WD/!0DG9/)V#/TIC8=XXQU"*:9 M7'SX2^93(UV^\F@'3TZ$FHI&-K(K]E*PP],V1ZGVC+Z7 GIDF.3?RAM]U2 MND JWC*DX],+I.
("]7CT<H+E>CSQN9AH./\^!LTM] M*2@UA);S@YEB\("S90MK?*=N&,-1Z:6#<>9*C"Z#8M+WKQ5(5*V;X'@DH&81 M$>->QM]]"GT8]4@451<(=CMAE)>S30A8DHK=KMM"UK
D*<)]5:FFBRMFN,%M MF?OT_I\5&34T0U!2!\^ON*!5Q*;_";XEL-E6MRZ-E/I+7]0NA7*81 MCRTI\&E!?9@(0EHJU$]R"MWZ6@WJ2UQ_:Y7AW*),>T"CBWDY<I3702,.=R-
15EV(G;)]24F MJP./#P@%3WB,4X8*'5V(+5\ADA@=%C/)8F)>F5^,U)DGT1(;54&G&U(8&81K-;]L!P2%>P4(W=C7E, %-M?)U.>4MQ]!$-3N/,7,+C=-
WMBVN]5[+/,K!8WDU(^QT4(=S,?_&*?L"%0Y5 M?0^]>46DMD)?1Q7$$49O:N.K?\?A_(^"69#YD12KL/7CT9(#&BW'JN5^O+]C M@KLZ^W L..P9[H$.BZ@I%\SB@$L2ZK"N[HK-
FPK['XX8PBW#*%;#KYZ$Z#*T M4], VJ=$]23(=AM[M.S]43M#(8^;!YF%<]SA. /5#EP,S&A\75.]2!B-N73. MJD5Z27@M14970"R9[T3/Y9DJ%[/PJZ"2,.(=<4--
P%7:A]XON!3UW6D*P:@'UWL:Q MW+ZJ=@*..&T0QYW_8MF,W34HVN8\WF=(XOY]/0D-V^SPF*G#@:D85(JM%I,A M7W1CBKD@NZ"6)TE"$NSF&L&9]]/G\"\/*?
&_Z=:#\)";MDB^(FEE]H\9I M/<7YP].//OKSQQ]^_.%'?_SP@S_]X>_Q^>N6[KY)WC\,T],B=%?GCW]DV5& M+FWDW_CP@P_RJ_Z:ME=]@E8MDXV8(7X.D)
1XN"!0%EH.TP$B+.Z%W9_><@ MH#,04I]>\,),+B7?IE]T29-K'"0%Z@A2"(>1\11HA,?4,\WG+_O\LL_I]NXJ M)8MT(KYBU7A(WOB'%%Q?R\V;E[5;%MH8(E(W&HI_+*[+
[O[;>_N^_&*U#4 M>!HN&_;R85\G[$@@F=[M! "2BA@.02,+9^ V$V\1RO?&4P^M #@5IZ;M0K M90=?=O"Y'5PF.&6-F;MFG9_=I!#*L9%"HOAIB&R99D0C3$*G>M.2.\N6.]O3E
MM4"XS(Q?56Z/SWKVEZUZV:KW1+%D1]7[.P$QWQ1(*N5#V++X[+++KOL;/_> MU9)L4B^:L%P>@6+/-Z0Q]PG]YV6W7G;KN40I!?QI[^*\4I>;M:L=P#F2HTFG MEHF\9Z"49
KVIFI1^!6PK,W6D70G="%M+-/]ZMB9%?=A@_5S]>E":G0*=C^4 MWS-&0(8&E6;MZI\4]H07,9X8N&I[YYG>]P;GIHW_@.(6=1_^? %%O^>@Z#]>0-$74/2CC_,N(O5XIV'V&S,&
N3FP:))VP5,: MT_-WE""N6"A=':ZZW+:4_T#I6RGMT4Q7>^D=2K.!!KQ*8]Y]M]_'SXR=E=# (3&R M>?'$RX!_&)XF,2"]I*FUT5M"3C^Y"5$?27GUHZA7?PMS*@TUGZ]4_^=-
D0D3";_Q=GYX"]HI]MJAW)P*U2;*A<:D:V MH:/,CDWBS=%Q1+W<*K*5S!Z^=21"?D)B($)-+LUDZY,\K*ZHWI9T!)EC%/G) M(%R_:N*$'(Z^8!F;YLF>E&"O(/$X MG%KR6Z3]
F$>MHZEZ*1CHI;JDRY,V-=5LX-'Y\DS-7(8M>!C1I)5FW]]H6P M=?N/EBE)7HH& C/()8@PWV"V$$.-_61<#EWG_\O49@,+_[ZR(K<+8E9A$Q: MWBPHV=V+^M/3/[_6F_K?
_^O#/W_TR:]>':0%UX7X?]]KE3B&C0("8*[NOB:< M?#6\"/_PJCHGRV<&"9'N:EXKG0%AR[QU:$4Q>(.(EMZ50D!$%XF@B4>M(RS[CH9F&\D1P_DM2U#DC:-$CJEI#K@ M^E7
9+A,V&A=(2R5=S=56_#_Z Z2/E \>$>;E:>%9D-QOGT"#SX&%W$4:2& M*Y4IX1P:.&090H+EBGDZMF2B;Q!?20V):335X:8]=[KW]ZKR5=6*-L+]O_P5 MM./VW,22^4'P.@F M
MUQU;QW+UW]MA1*K*@1\6N&R!K;>0I+IG-7;E0D%>^VI7A#D?0_%_-R/U=_ M=AN--STQLW73Z&S!.[W.CYIL-U: S;UIW">;,
(C,]@8[6%4@[FZ5&*0,L7HB7YQ5=_3C21@+O[]$S_,POU?P=-6QC$/%$="4&A,_M_+%@R3ET7YG3RE;]1:2MM!MD;)]KTT P:$K[5?7]Z_*@M'7]/8*;XQN/VLBK MITU&C?
L'$'>;WW=R+]ZVY0@]4QP>%U>3A^>8G@GT-'DE5A938#6B5/CVK>@+ MZ[\G(/WV40RGUN/R*_.)P\ D]WK&]"""+/-=/E0;52HA['XEN=I<^Y)\OP_Q" MD,I!P?R6]9LQ9& MZ%
(=E3]R=_VUH\IPKR1._+@N\7+9-]<6\R+M$+S@PCQEOASXB,%_\ &1AH ' M)E\00>\I(NA/%T30!1'T^+DSRP:9N!:N).NDQPR/#1NI%3S*;)E7(Q,ZO +O
M;27"-9+Y[A+1P_";=GWW9UP'_Z,7\W*)?$,,-<< H[8 L S]MUM]RHG.QH[M;2THS8\D^@_Q@:ADW^\IU;^3NR3\E8!IF_(NW*.?"[SW2DR\1"QHVOG: M!HP!E#5LR[LR'.1=5$-
W664L[A'KI;$>OW]Y8GA_,8_4(9&1[+);$>86OX M5_I<'1("UDH*Z_=O&Z'3!TTAX:UXUUO!SE^$15?IT\+O_Z*S6LKF6]\K"R_L MZQ??%JC?#9/='Q?>**B]]YH0KR="&4R-
E]S5T\VG]$&*:%]XI,EIO!MK*;2Y M7GMB0\KQ[R]+B7_^7;'YSS*\M6+SG*!XX766N/"+LBUW)1<6N0.,V*^5H#$8 MX7I'82WQ/Q8,]% A D"QT09B
C>Z9K'YM"]_]IMB\R*L0OC/OY/:Q'[U]$!? MA*N%OWPQ]&45/O!E2(RW78&]]_]598-;>!FRXIO-\SVID>M__5<(^.F!%GSO05FK]>74RF4 GZ/;#5(^5 MZ@O),^V*Z=L8:64A!:<](2U60
MR-O[6V@S#1%Q\G6[I=&^AF:(]3UJ@W@-H!CMT2PQ\EXOTM;GD+_%8$.\K_MH MD4IUQ])[W!.,;OPC'-Z8UL7U\+^9AJ&NC21/ JZ!LF;OWO54V&-#QY(
M$IGH%@F[N@#_Y*:%>O[1P+SKS[=_&U^,VCT0!Y1?BF[8M9%=1?Z9YR)=]>
M8T7VPDM+@DN/9T76^_IBGU(@&\:IVVXG#&VM]5?.]E8RHUZ2/8^DV0KA/O[$@.HSSYX]]S@B25Z2/UHQ.'P>5$OR^6/'X]-QWH2BE$D?LU= MU ZJ=)H S[0-
]_A3V,HW]9&63AT!Q1BD)DI%.;:\8&&C/RFW!2'Q.M;2@U)- M?0"Y<%/R9C#8--OUO5%DLJU:,L0/AU@JY0)!R,0/#UP8R'&U R M(@(0RD9"
;H=2L;PO]!_^&$"1,VAZ6;MF%656QFGB#!^?B9 [DVU7HC-40"$ MC#!.RF!0^XQ.;>F5^*7:^0^QYG;;@8&:[GL50"<>*?Q:6?>@PI'$ZQ=H^%W$ MJSW&"KD=F'#G 8Q4V[6A=
[Z9U\6@0;162L8:X >60WVY(P9?FQGMKNY5 ^D>FW[UV M@_\>IQ9GUC7"_%4HRVS1XH/Q)6_+9]HB6CL5$-V1:"BK&#IT]9Y,G>-3L7.9 ME&?D37;S+L67_!
[5QK$]#M>8@H_M3]+"]&ZP'SBKE(#Z?NYDCO5-L'PN&9NX MJ$-Z*Y%XV;]JM8[)6%5(:BD^B%%!FH%N8%9&15 4>4+;=FXWLHB&;00*!VP M_;?PD4[$.ZD-?
4/INW3Z@F[[.H3SF5U,FU,$<6TY(SYQ-EN,UEPPID<=#'>: MVY;$"# QFN15<3&9:R78R428W!5*.[(R\PY.MYISA1 MCX(+IUL*E@BR0!:=0B4I#O&&5CDO-[!
(5TY>NPP89M]_02,/,*????U"^G\F M#I,X@NU-2?#!LL+7R1U,1/BA/X#>^?H'<&1A?IM3C3]I3S2"G<%6H=!T&2T#4HL0K/I=?\$_WB]]8CD4(Z'N3.#AKU=K>X M)ZXAN;6N#SZC%-
WD82QR@XJ.L4F6NZ9O>:#:%\?!>S:>!=/]\S:DQ8P1G M_FK=Q39_OZBNZM) M6&B@!Q=2/4__5:[,K,K"I4G)DF69B-BQQR+9:*"0E967E6L-^XL?EUMX;RBO
MVY2(,SV'!,B!RI;/LS8X3RJGC07'IX_WW(1D@22";I8$.-9,]+U-WV!*KHK+ MK\EY&O")V4AD9>O*_&BK#"Q%8]B1YF#%LVPX3>A,C27>)[T@.Z?^?0DP%2
M*DJO3KWJR=!8@Q\M;VBK24 R5FTD8&&3V8LL%\$TE5N*#>\UR"K#%4+Z! MPP@6)XF"&3 TN(VBG54411PI?V:VQ'3.E'QI^#KH,[E+T\]$@)M\D?CH1DO' MJ&ZEY^,"-(%-
KZ/=3DY8(+N>>X MD"\67,B""WGK[=QZ5]=W5#6P]"8<,(9FA'=>]'PQS;UH.OU-76ZM$P+AB^P M9>R1,"=NKIKPB\]6D-\=^3LCCRZ*Z=H)KJL*^:00&=CNC%6DP:^O'/H$D@+;
MG #EE="/%Z6G+4KT14NM2)2TR/_S)3(8IFO8Y"HSI;O:]VRB^ZR/H -(./ M9WZ'P4+HUO+<;@,\5W2$H2![N-@]& 93##U]@ MOL;)IZ28+K2VY$Y9W(VJ2HZ)4F[
.#>Q5C07;LY1C2,4]$(=IN'*#19NXF U M57A0'O@"\]^N[80H@Z?PFJO\@*Z&QB(Z<;B_R*7WD0L,DC-\%!C5G"H3]'X1&,-C$;NO\D6^DH5B#4TI
M">%38*)*82C\BK5Y,2R!#>+3B3(*@#1]M2.=21:*E_V8#D;UG#^C]]N'4D)H ME28,!U1ZB\-H6]Z+)?>BB\Y#S)?W+L+DGVRU>#/@)"AVDY];6O7\KP#S6]2
MW<8Z(8DL2^&\"Y9I@6BY:O;^I]=H;B$N8=:&!"9|%: MJG<\'4&;)%)\R:ZRH.=\3W$R_28,E,]IX%EQ=N+@;9C7_(Q^T!2-<@;RP7NA M?Q)X=V9('$UFNO>7]NZ=
[=4PY@2I7AH'/W(IQ1:5>%:2+X3^M;_;H5_[A5V1 M6Z625. G8\,*&_+*Y0V+'.[K2%86,ZVFV"?]#YL]),7<,R$ORE@5_W5Y>6QY
M.]#&;?']_)M7'&M]#'Z]4RU4>$PO79OU(R639K0&A'RQ7_?YM6Y5 YMOGUZ M.H/6+%!YVV$U.T&U2\QOZT"8(X.KXHX[/OG-I[1K]V0R RF9NV6W,M/Y45<& MWO_
(6^OW=&T(^B$.&,GEDQQT(O8U(T,X 9\KVU)$"A&"I<4]AR*)@Z23UPX MJ(0"_34IBF[F28-8 ;]=4)N&N2V#Z&Y"-EH)$NDUY!2P8]FBP"SWLAB=PV48
M^&"%4[6F\#*6DYP@4@P"DL.Q(!.=*<'+;MAV_/FDH"I/!,4HB/OI]1R*%'FX M!OB)(& MFUA6A_I_"8G%99\#RN@T9PL=TN0IA$,9IYA+"/C0E1\M;%BR\!2=%?,=C0FB
MXYSXDO$51K'K*X'/U(AK,V\<#0SKQHT2I1N!^>HM^E;(P%<,#B.^E; !2P-B M\=VS]*7<1]BYL'P4@]9O8P+]V"*;]G<;1V?WHF"G;8/]_KG!?_5^S0B?"W)8
M"Z>*WU+F*EF.@4<+T'R)]#E!G]KIT&\[3_N%^3]I"4(KB)DX-PEC(&V/_\N M:1P DQVMOYN-?!Q_B(*&#%O[)\2;RV6MD)7*(MH5#MU+:EK'%\V1WT4048K
ME%201T<].2I!5G&\/OH.AN4*H-6Q_B8YVI"_./*UC'@ M'\[]?QP,=S-0@IC2#<4-$B_A:&\K+IPN6B^3.:]Y"SI M',=B N R_"! YSRIQ7$_\D[_]F3P7%!FX:KT]^>K)^(O>5N-U7.-&AE/2"04
M!/0A:,NCHYZF@ M@%AFP!:%GPP]3B?A4U4/_@XRKFNW'>3OMA'8\>MG;N,)6OHCF:"F!;1[' -MH(O$7,S>@9V;?#]705KR6,#=H-6FV%:HTDU$1RY$C&/IYB%RV.25-UQ0$-
M=HX@V@C]$L8GR'EM *O55;)*4+'V&$N,"@B?&T^]59N_83]7-C)NZ=T?QSS:8RY-P#B&Q%@V9"+2*B63"1%_F-QP7WGAO MY*]@2SNP>A..Q0PCS$78%L)50145]>--?
UM(7]6*Q@^ KNY4X*>X.\V-!\,> M @NU];.MF^;C)#:07AB9\ZGL>2HKE]8"S9GQ%+#]7%R=B<:AA<*@SKE _M\P6!T5PJ9R5A)N]<;QBGP_=OC\<<4>5+P9*F67NKC:AQ)4DB-
HZV;?5G'6#% MVP W09&R;K!\!!:$$C*=-UT&;S]W+9Y/LVFX06,9^(="*HL"I" <&:_]M5&.S!7Q;KH]#;MY6,Q@]39<'AEPT] OZX MY"^/+Q?PQP+^>.OM; C!Q,?X[Q5] VV/HY+'$-
*#/Q&;^IB7.CG[E]:> 25N MX&Z2T;E1;IP-0.;&^/QQ'Y#O2XSF5=M6"+71N4M+1);.W0ST8I]0;PC-#)F M& 8C"A$B&]NX!@!C()9]]^
.$&5.M%A*)N65O<.'43,*X49H7D<$M8O%KS@E M)<@ ^S:H3-B SR.&B8'I;"Y*9 R)68>ZB5\RY(*MF78BSCC-F^/T?0PS2ZPB(D4$P6^A?&=\P0?%), M?%V7U[;N=+
<^OJ1EZZ(V"7C40B?[B47:X0FYG5D<93G*8O&$<@+_,@XI9?G[MBG#O[H.998;>M6M_]WB;2],)4D2JDP;#&%+:]E"'@]9I;"@;^*#]8-#WPWD@
MRR9A7WG_FF1H&=E%GUO$$8PD@(P=^!TF5=?*6+/EOA%&]+#HTC#X"6\)_NC;MY_):B?C!VT!$YCGZ'5W]T8-'!#$U,O_#NHU3*AXKJ-9/'2 M0"3/PG]&V+_*HH,R CUW(%VBB
S%2FEOL,FX*;_9=D.3(DTP',TI8:BHM1< MPE(,Q='M%Q?] RKB0IZC?C)'U;DZ:K5WW,73=CQ.=:XRWBHB)UB(;6A+1T8V M.V#%?:ZH&S(ZT.,] @UE;S2Y,;DMU@A@CMFZ,8VG^//-
L:M?$= P\TM2[L[* M8B<\/S(=7G<0U&M+*I7+*WF/!'5KXL$A7:3-U:8R]H;<%(@W4*RV]-E'\00WOJBX#UV]$6(:*/[>,G-5U 2".A^'3 MZS'M4YRT3D"4*FLWP)94H\@HU&!I9I\FUF)?
<!#S<?&;Q0@3,H/V?R@R,4%" M"$+:VX83$SMAC,]C?;#"5A!4H_>EPC<;84Y0-M,R>2]RH%H)(68/2K2(>S> MNGVE)5>\<8H6P"U^RP]+@9]2&.9- 4 */-%TE))$%L HNW&!?
>K)R,!];$0E MQ>WJ0N_^MIL/G_C-MVF(B)BY0G7!M<%A-8WT:V4D[QW$M4Q4 'V0,J*AYMH(MM\>)/""@28I-G:AR("M%?]USBF(P.*#&T0X+?U4$'=9PBPS$D?
O.8O[-55V+$_'9)#XT>"[^^2GQ]I:&) &&IU48B"7O,T,2,P')&[.GKJU&KV5]27VT/=372GLYG#&U2R(MWK1LPH2@T+]T;Z5G M/I"@ETTT578R7T[#
<2PEEZ%'TPNEO/6MSZ!R@1A%5SW-]NA=_9:.WV3BXM W MU*"+594XLQNH96\9 +\C;!]#4. YQXM>@0)_%[O[\L5,&70<5#5"]JM1L>6G MOSU)SL"[1IN# % :'@
MB&$2)'XO0N\GVE/#"L7IUZ75*!GOMRVV8?1C2.RGMY:*7PUM_MY5]]Z)+_ND M6AB1UK8;_T*O+V?]-&RD\J.AN.)VH3_!O'I\Y5$POKQ5?.2SK2%BS,ONPER%
MG;>HDH@@+5(!AZ# RD@M%C%.IY!,]NQH,](1K6):52\FEQ, MTT7@EUIAFYQ+$Z?"59ZJ1/:7+A,K(&^D0 -(A>..P&W^< M)8= E%VI?NTO+[QV]69K8TZ+;[:2(RH
MM+EVX^UUSW!=!"OVP:WP<9K&T>-'C2D*_8ZND^?=BG0>['^']TU(. .@A * M*L>$4]/5+WN:O,ZAO!=Y?+)A-0):2$GZ.QAO3>XQ8RA]P-K-Q:AWG$/T1ASQ M-
OH\RGT,S\I2&-3RNY,N?7_QT]N#! MXT#LIB=(.9."-X?QRUMPP?$QK3,]1?M/(9)M6$ * ?13K,ER],2K9<4I+=VT*9)M]6VBK^ZUBN6O^?E]&>;8N>^K!Y
MVHH^R8"90\G]3W36N*MVM/,\,]-;T\8?LX3YN9$!;&TQ\<7$?Q<3-S(32?>(MF\7ME1]D$O30==;VQ+-]S6%#QD*+8MLEPG9,-I8V9U8B+U[[^\8Y-=VI ^Q MDWE[_]7)'2N@,
(A&!7YLU2F:Z<(+E&_48XDS(WQ0^L7Z5VVG"Z2N0>T-Y1,+ MEP@LQW<^6&U;YMZ5)8T<4MKEU^%X:NWPV[PS54A*YO0;1F8_HD%9'%@[GO^< M>.!$8CP)?
4=D8Q'M&^=$>;8V]%B%2BY=C0HF.K>7Q^,=9 >HCOI'FD.=?,QL MM!J#853I%?!+=XK5Q6%$5:)<&R,K9H0X'ND_GD"_N#&>),2"3.[1N]XK73H[M*MTK-
K.);];NJ0S!GKBLMDFE[U=)>]XH02=O][GD)*(% M--;E_&,UX3X48QI[ZQ:2%M"\NW.V:?=^^=2&ZE75<2"V]N:]R$'?V/B\6Q2U M3'NQR6FC&;F5'S5B(\Q@B&$E05;G\]3?
0=6HG"KG%_(M0;690-+$G4R\A763-P6/!?A;\IZ6R^4Z8ZB;T)98M#4_CX(,]":H$"0)#T"C M.BR! $FC@RRPY<4;]_,;S&X37]+6P8%6]:]LO0N,8/HW]<. %]+T&.!]#%9 MF*> NV?
C6Q91)8$,&"Z6XL>(^SH__*4"G:H&/5'<0O +WB)>B2=19V'T7.+[YQ (1ZSW+G'/QI1;K4.C'P3"K'Z: M.IHWLIS[RMZ:!".=H7+]#2RN;T3B*OW]]\;CFKR[-Z5R_=%; [WBC../-((<
MX[S2@#<(ZAK$%B4!=:O<@MYD^HW3]50/&.HMNW2I+#!^_,WEN623%32\38JU M-2&3]4_X_%VDX6B4K"4C2&_@$BS71B<]YMWYC"WH1I]OL;$[95^\ M/;VCTW0K/F-
ZR.)]WH\H28<8&IS8E,>*1'@#S50?L1Y(_AN(9$8Q1LC-G>5? M#90..F^CP5"!.4/^U2;V*@NCQ\IP/=WA7W>+5]*I\X/Q+LIAL'[F55Q%]#' M'PKH\<6#!>CQ08
>'\4Q];Y2K61$!&6Z8V33BY0DJF;+=2$9&TFGT.*P71A' M.]4%LSVM3904.2W K$61E)E7SAG-#(QB\GQS*TQ,X5NUDAYG(GFHL46X"A:(M^Q?E_&08O@(7!FDUT[M'422&B^'W-
RY!X>!7F]7I9ZI]<$^P=1.(9F.(.89Z M(=#@_F8I8]_\9YD^AV($?!21>K'+XEMB"XEO4P M@<8$ LP"Z.O,8X]IB,[B,B+O]629VQVR.9D]Z^!3-.].- E"OLS';(U#Y,]]%T
ME0]G8E2+K3<61IFX@,VDTJE#6@W"'*4L_I:G+F7G>M]EWFQYT%9C9]EVV)D$.^A:^'71:TU%?-RPSR4QIOI0-J5WQI& M;RK25T;<-]9:0HD]!L*;*+'W4#2=,#S*7BD?
L\/WCDWZ"M1B^2OB:+%Q)VE\XO8NOY!]O\UF/?YS]65FTW9F ^O%(_AO^CRZ +!FMC:Y^DO4D:S^9W/@4 MO>F^QA*7T?>U?
Z.QL)OV*GW$1+ONVIOJ#YF/JS\\>/O_CJX5C1YR$4-WD*?\?!P^&5_T]2\A%I8P4/A. M#&G!&%.<.CE%]N(SQ9L!TMC&%"3-ZQ;S6\Q/S0]4,ETD9)FC")Q".-*9!.X[
M59]N9EQEPG!1"R*HX! H(5IS4XYT,>/%C&_UHB8;_7-Z"C%N]\7Y:)VJ"-< MIQKUW&7T >%5<5A\Z&\\M[+]AJK 1.U]_@"_0=X:6V%$H]ONCC)//GG-Q1@7 M8]S-$[+2;MV0]V+_=T,
<1_2O5(>7?D=0X,.K^F:J@_1K71 PE=IO4FF5OMST M&2_C,+$B @UL40\57FFZD:_I)XL=+W9\BQU/JD?'HSTMR\W8TY^_@C&$O5A; M/CZ
PAQCI8#T1]W@NH[2BJ^%CE8:&9#^:'6>@V>9XNV$$F9+&/5" M&1;)[?A+#3)9X9L"8+ZW^& 45W-HNB6Z/=Y8X_$:AORXDL-EYRIO&N_I;J0R MM_8;GU('60U?
R0Z]XZR/S@E1946O."?KA1<328W#=75$,[U\&-RL&V_4^M>-#EGYC;W+T\EH@0H$%' MI'^>KP)DIOI-O+;]C[55=S?%1/\V?8B1/TH^;G.RQ[;\V1COC:@ZGO8NS"C M'-&F,/!@9-[E-
S3!2ZJ6Y(4"\#)E^.XODNQ!$A*\'AQ)/=SI6HB&':P^ZC(-Q3H-M-$4_M:4"*H;LZW$+G*X->5PY62]*I6R8RU87]-1P1BI2:3,@D3=[!G)@#?02!7'VRB
ML'9ONXE6%T#UTJ.^CHQ80Z,%;W-3-JW@,RJ%'LN4G%6@RQH*F+*F#&:5L MM@9M3]B6]+@)XD$&FYRFD4E76M_1,Z4K/4^LO'$1X0K6 @V@UUE!#^/8'Y^ M01&]OP >_V"
OX<+X'$!/[LX:$P'O",=E O551^PM !1S\X3YK!LNL!XVI1 M-W[=[E]@]%QX)R0'T\]#QWCFX!6*8IN:0=>.1;[H*TK\@.0%ID"\@"E'R M8LM5EHKF#8P!8 1NK31P8>AK5X\>B-
(XSP<0;YD23$ /G>C:0^4$ Z>!=>>)! MJ;^"6D2;M@W2UY,:)/G7R=]AETB49Q%,61!U*"MJ,TUKNA-N-Q-BQ//#0# M!><$046BF->)$9G]2%Y+YGS!8L'- N0D'J@WK? !2Q2D!-F\-
!*+A1ZA7"#RQ MI])2[F-5X>#U!_[WPOLR-/Z8=JC"28+^)(_1*7ZW<9H6(UI M%(CH&AG0K_!GAN5A^1EA]!,5)Z*WN:];#FI!%<<=?D@]:S%>VD)Q/2(!@8^^
M]43W@E91!"]HRUA9D7%>/M6^4W"S% L<$$KP/^14(E,SHT'8)L2'U/!!]-) ME";P6/.11"L_=8'WQB=B7=NIQ=/]-'7V"$ MD1_K8H-M0"K+\'D/*+#^2'O-E=GO^2O_5M;71 MC*#S
>85*R+9QY:I[3HL M%-2AO'^FP!LV#@.S+O@YG]O#46G^)K)P59:Z4]7!0$+MGRO?EJO'E?XI^C6! MY3ND8KD9!YVK+KNK]#*O"Q,F?@&'UK%"NI)? M@?/53\3<1-
M(_;5KQ]I=],188LO)>6^^@B'/_&M>W;JCO-K8P]H=_7Y?/7QL M#_ZPQ=$0K4IM]$ME(Y@B3C&[J:W?ER0YPS)],$$AET?)//E%!,S+'ZA#D">9 M)A<2@9:9#=2(_5"*O8O\)
<84V\FUYE4C\A]_LE?)H=;[:VCF3AS5;U%W^3@SHQ:*X]":\,< M/@)+3*W7&V+8SR;OLLM?$6D-;13B91+WSC/C<"$H7 P\"IU,+?7=X7W]I@_% M.;]! Y$,?
OKO_W:Y1PYY'VUN9)2CBXOAZ4-OTN.7Q\N$\SXYC]',Y>I9.^ MH"\0NW90I-#C%_;CCC'>4WJY$XQ<0UEMF87@/0PD:0[,P[,;//6C'0'$;*. M2>% H!BF]*%,O>EA=FV_WA=MRW-
2COSH<8!'MEY;1]\PD'-)]VB'T=?2<(4 MFT+UIZ?O=+BOF/V^X!$CIGN4/PV?0]D5S!'R4=O-6^7!\+[%9I32TA;TF0VE MFHY7O^]I6,OIKG\5;@/\2I-7A[^IHW2L3+
(E5(+]G"D>X78W)<[:2H>,;?(U MIVPC"!S+69\21%)-ED(F_[FV0QL)#6C-A9$"R@=/W#!KK9A2X=@2# B3/#2M MSE16^X*13-*Z8MO2I0//*;
<"*$C3VIT5S5Z_"V5]I=_H[TGZM'7E^)]Z:F35 M)KP/"(\!7@1P]^?7$UENOKNEYQD?=8,*C:^?ESG-OO&LH;\(<)/<=4DS'> M_24L7.,/??IR_P&:]>:;Z A)==R=01OXBB9>!2 M4L
46_8[@O$Y&E28#I^M70<*SX_Z1;W-<6O>@H"S;#F4%KX>CFL-MC7^:)(M&9\4EZ2OU&Y3?;D!=4:72-DXN0I%/2I18:[F#0U^:GIYEX$BTWN]$+FK[>Y'X)P$=)A;*,ILX!').""B*4
MO.U"^,*% A&4,Y/;WT3#T@6*53,)!\@@7O8'BG573_P]\X0YK1,FF?5;M.R5 M\]B6O@9\>1:HV]3-CC\24Q;L9(*2' ?KD?&+^.-4T,WX?,%]^&2WB]P!]DAB MK+K]>#P_)Y9ZZS8(.73D?
Y(=_"4NVK;>%+&(V/M7V9/,WN?'4/Y M5>V=ZPX?&A^X !X^..#AT0)X6*2\WGH[!]Q>K (18QI^*%)2^3^K,AB1ICFZ: MOHH".M)PU.Y=]X=ZZY1&D-
MC<N&_U6U(]X*OE]CY^WJFNZ?KOVEBXSV5$'IW5QT&)C:4=(R!WI8- M=3356C?I4*OUGRDURBAMNW]UB5M'4U(XNVLMQ:+ ^XV4<9@"Y$2;&3\: K,5 MHP#AQ'L P5D57BN7*
<_TGYS5[]+ = 5A=RY6'%P3S8'.D'R]RIP656T'@$H5 M8E:-H]O1&.B,P.6Y).]B;Q/D4 *2]G9EP?@O0E&TAC,*S5*:513]ZI:9UG?H MU-(I^7BQV/94T:;'@QQ[>"H!': $ROQG=>-
(3@.G#\MAZ8_XL*;K,,T;*@A; M?6C;-(XD\#"#?=YU7/&/]Y,ESY0P$^X&[]]^DPGSYLDO#:4=70TX 5PZ+IHW M@61CQ[$2'D:/T^NWSERHU!)W5]J7F/ OL[X%
RS^8,^9ISICN1VK]"4A@S/D MDW'@E?=94^R.L^.E.B8[!:MF9T,"$..]SX<(83R G)NRAS;"2458DT#^V#/1 MY]GK4GV&VPEUW\'YO\W$Y!O/>"2K]8Y'(QU!2=Z_\X92]Q:-RE%]\)<\)(;
M2NF$8#"]_-A)R+J9.(]47(:#Z1'&PT)1&R"RB]OT@WX*22EQ-ZL10MD:.7# M]O$-F?69 F^Q0V^X2TRA"-_LSIX-WWYEN @=YTQOG>;*8)NM4"Y6,KFL43D8G1TX/VW$;8=#
MLN(_&GL.TOIC(E49>^DFDYCK9G)U3IWE <'Z^U)0?-1.X?TQZZ.929/-Y.K% MK6/0F=*,>.H921@I<0G6N9K1/%GW!4A4,%6S]2^K0E'][(U\KK2Z8Y 0ZBD4 MU.[T. OU3^73^+C?

Y=M&2^8MU4WRDI1T09(4>C-!=SZ3CJI(K6+W4YKAMCH? MQ3^3#3Z6<<0>9'03?3>K,DYIW,3F>$*&0_"">?L28OC$B[7^[0ANG3^/|\UB MV;5RBN4AM$(2J!1B"!!|[?]6]-(MG+'.:]>Y_D4/<>.+;\I8CT],,,$X6 M2&5OC+;1+;0P'T+D\8^W@=Y)M?I%T?HW]4((D/W;^#[D /ZG6JO_]'W- ^R.O M44&?*

IAYC=B2N*;>F?T;-6<,*6O%H6>MF$%&K/"4W8M"&>|%DM\M%;>//0)"5_2).K/PHU M&Z6H/YDKSM$RHX>5M&/TJ 1}YN6BPL5+3-Q).2O(R|A!#C,B;&:QX5 M1N1WVB@%*<&\YJ5,U@<%NB0$RABX(U@"GI08N?QV({7MX'N3^$* ML2:>1E@X%RRZ6DB+M[UD$ZCBK&!TK&DB(%B5X@'N#1-$+>BY^:+.1[H:IN0>/6XYRE"*A+*L M;V(3VP?BE8+^=X+&*+A#ECYF)H.E*1_&\0#51O %$[*);K'R<6D9A4`&_]X*.M\A)(.6.B".@<9ZYB;!L5@7F!J(.WS9MM+(6&M2EXPARQ%"!@KJ&J0@MN\QNJ M?FF43,\0!^9^[;>7H==*P11#N52]WV,-BPX=_F)#$426":8U9\<247,\=6W M"N>KBXK6A=3"",@1;V<$RT ,2S/;8L,NF>R. X@B D6;P#Q(<%WY"U6_S,R? M8'8\6B'+

G)5V98M$+%E3"9B"2PF+!C5I-E.TMSL(@;EDX0+3K A+H<%%KF-M9U7T7E([>2QYRF8R9.70N $NEW4=#+!X+>/6:>,M\R 76IW+,9M""S$7: M+':8D?D,>$9RR/*13>8*DY0?$OOR?'1;A(*:6,N5PP:V8$;I-1VME7$2W+O^ M/7W5,.'F%;KL"QY>',T@Q6OR=VQ#ZR*.$7#SG&\A2M6-I<%^JC8\3/&$\1#^ MD]^^WE#;0,MK&4>Y0F]0:1*MMM%2?.>Z%&HV!_S).5 M^ IB3ZBCDB7=FMQ @_]M=03I-=V.8VTCH?EP(2WF45-\O9)V<>;,#]\N?>HF MSBXG1U"6THAMKXI=%[49^#$"ILL1^>;BIQCMOR+.4Q_5_U>O@#[#<[=>U(]

M7.L==BL!20L)Q AUX2.'4.]&5G['%!=T+I:1"2I"\\(ZAP76$R/TKL MX$KYAIZ;/#]6V]_KX#U25NF/JN;2$<_5H=?QIY]P!Z=-+UI0JS2QF.F)AO==

MXP.1%SUKH:8V)_/1ES6S,UG97_\^\KT#$^HN\&'M+V1)QG7((/#IX;EI+5"V-MAG)^PA*W1N@YGD7!M5\K- 8H4@F/KF>P3ZX+A"5>U@BS0#MW&D3LV&5#WR+'K MXS5A

L;HZBKWJ2E!T<(V3OVENBJ&8QSY53N%*7@# MN?2+%KL..!+6AEK=GTDTXOARK@+AG9FPO0FB0IQM(*I&5$;=D+)>TV;X.L!2 M>*:*'&1+N]MTI'S[!S,JE|/DP@%TIV

M@%>OWE,'%U+ ^)/CCX\"O3(H'F9WBRLE@^@PC1):3XYUK+=N!Z=P+,L'D=1'1\OF1J5TZ MVGU\4^1R;-U/_U;8WF-!3T ZMI;&S-.N[I9CKN!S+#.$C&9@C:/E1HKN"9V

MKIHV\I9&'M?=W63SG;X?? *5*8I)FC @5<'IK6)H#;\'QPG7%NW]I\<23= M?8.\=1<]W6+%*C1!;Y*>.1-ZGWGI4.:&/6Q"A=5>U@BS0#MW&D3LV&5+WR+'K MXS5A L;HZBKWJ2E!T<(V3OVENBJ&8QSY53N%*7@# MN?2+%KL..!+6AEK=GTDTXOARK@+AG9FPO0FB0IQM(*I&5$;=D+)>TV;X.L!2 M>*:*'&1+N]MTI'S[!S,JE|/DP@%TIV

M@%>OWE,'%U+ ^)/CCX\"O3(H'F9WBRLE@^@PC1):3XYUK+=N!Z=P+,L'D=1'1\OF1J5TZ MVGU\4^1R;-U/_U;8WF-!3T ZMI;&S-.N[I9CKN!S+#.$C&9@C:/E1HKN"9V MKIHV\I9&'M?=W63SG;X?? *5*8I)FC @5<'IK6)H#;\'QPG7%NW]I\<23= M?8.\=1<]W6+%*C1!;Y*>.1-ZGWGI4.:&/6Q"A=5>U@BS0#MW&D3LV&5+WR+'K MXS5A

[G*SG5'D+!#HT%@7G"*T*!/'2/R U3VN!A2$XIR@V]WXR&I.D9W4X-! MH_(X&KY2N#Y1I<|"(!WR.K_IX;41ZT3XL*ZT-B-(+RK'R\4NE&$#+|'U"?PQ M<>;G_O_

IV8M*SBID"X*QM\V16%N(-80WI5^;J3..2CNG)&]M"6,)P\2CV.,2 M0+)YT>`RF]<61@9F3%YMJAL3&=]B?#]>B$!RJUCWRA@LC;Q-^A*YJ-WBC%/E M,3'N;!G,IR.;VXS'.:*;OA({JR;B"

<8O7S5%~VKE *\,VZ=Q"&P^:5!#'2DM-=XC_DP8[_N M_;#,Z$\&('4A_Q8WTYKMQY7,< M/9K6-._G_^9)\UID<*;2UZKC$*=0$_H,4H,8)1OX:,/C6*L*ZBM'W)SL; &

M4)E<:#&$E81#V>'%M[Q#Z2Q8U]=<'Z>R!/VO7*9C#Z# #:YII,WELMX,| =% M-=W2'D:O<{7N<*/(O#!6I<=*WLT6O^//89]UGTOM$=FH-XPA??!\FB@<9MN

MVE\3CS*=BCE7=D>G;;RMN\!DA+)X=$!^>$59TCW_P-WSQTOW?!$S^9WA@D^Y M53/(&,9N2]+\]J4R]5*9Q+O#W?L0SLZF;_]!TS@$!OX:!U, M!2J<)85-U SN

LU\R5@&:,2NYB$[%E5V?A.D6%$USBL?&^E+=R-&"#@"Z. M.H,3+YJL1.Y\+&>!*A;1\^:1.0ZEM$,/ASID=1^IK$HCA)4O<*EI/FYDLAWGO M.3RA-11:=$-MJVWW[W]\+I-

#TE./V,V\WQ8<\%S[")%XB O'"K'&DNW/37L M(?'W;&<7Y9,/@@Q(/DIOCQF,5 .8DXD!&R_?I\Z61!)),)*+Q)10.GV7/"I(M.TJ=*<.'GQV_(+O_9I>FB4IU<@NB%L;?E'*3J19P!#,I9=5H"-

FVY^ M*K-;_:?/86&R_V*Z.^6ON9,KY,//9D_73UK80&8AQ MO49WDS9AAA'YHU94;^8+%"N7H)BPRRL!+^,/A\||R9-HKS9GI_)"\S$KVFLR MP?68-SV9^Y>Q$M'BD!>9|L-

NE$LWK6@%;(%U19M8.8KS*RRC(LO3(KNKCG$R MV+8)6&S]<9^+|RDP,I0$))YH)HM=VPJ|_OZT&P91DZ|&PK*F9B'8%. M;?A!T8HE'3[Y%,]7HM/|0 @1V]C&_`^4A!?3%?

4QY+6MV%< MY<#?R=|/A!$S;_E459XH=#9,29?6YT=E?IUZ$#8Q+>490:X0B8!ZHI)HU)@,_M73T,(I9'U/YMFE#T=C*G'),26/MNY"KY?H4%AS):ZOV+G5FF;L7#A_.;!1]#?3IL MN-

?:\'N;ARO439P)I7O4\I7MVIEOB\?/<+N%5(_O)2X5'-W=9D0A2@-E-GM*B02,RLX9TUPX9P+?D6<3N/7N#.*5 M|"5P N\;1'0.+*=*.O(3X;99E;G;L8.4,T(/TY.>EJ06(*;(:K Q:B;/V1GV

MJ+B"TYW-':LYWN3,8%LZH@7T/(CRZ1%+A(VG/%"XW25EJL;M^C:95L'*"3/O MQ#DLC+PL($FN;J6S(PFCM-9/(JE>\&SV!PA>0+!E)6!.-\DDJ$LMT9^H/;3 M*#I\K_DMEA6PX+$"

(ZBIH9(3EU]=F7Z?M2#(,)<-^H&8 1/R/=-=A&= 6TPW M*ZD#;(4K,V QR&NWS$J |*ZUBQ_V+_%Y&9NW$J]_ZUZKC$*=0$_H,4H,8)1OX:,/C6*L*ZBM'W)SL; &

\3_H^],WC*\3C68I#V;F.MD%[;M_!I\#:LXH^]K_T.:'H%7ITPHOE_Y MMO=]4_/-O_.'S_^XJN'7SU_->'#S[_[*LOXG,7%=W\&1[_Q!-3R_#+1X\^

M#SU#TU#E[WCXX,'PJK_GEIF*.&+2.K+2-*C([AYOT*6NZ[*"7IQ<=\N6//"U ML;V:]JP7BUTLEFYO$)-08N.=2QY9B\R7@@.O=@$OK[EM%_L\Y1]HF[S^/J33Y(

MM0/W=&4:U&-5):B =:N.*CI*B5ETPLS>MW'Q-59C%ZA.K.V%UL8;7&AX-M8<,'U@N%/>IAA&J>OG.9VSK5U_3TT9.P.*A1QA4O<*EI/FYDLAWGO M.3RA-11:=$-MJVWW[W]\+I-

MA$,1LAI#7\VEZQ.0YXK0I[M$-2)&OY-'8G-H'PS1B\EN_<$Y?0 #0:VS2IT=LUO,;@S 37Q8(5"FHU=/3X MSLT51!@1%+8\H]?4.T(*2G-*>A-8\"&J]\Y(P(UM;#N=9S)45B84-

]U1CB9=WO5D.UFR M'V2^.])YA!G5P.=B!GROBD;)86 ;K]R1CM2VKBHG\T@;4IF0D=^CD@##T+0UM M07',*.A<1[H!LC_\(8DM\2;3MR((GR;FD08[)%>3<[;FK71!.E5Q\7\3KO/ M?

#/TEX$5E_&IAM-@EH(+SVOFY=$_"Q"177E1-5V5 ;%5DA*#%W;^>]0!L. M^,R$ZTW0-_"HX*3" %U*3AAG[AF%5-;'V_XO2BMTS686/SFQ,&A>$[S\4T>N?

MW]\/.U>HI5,FG8M:A[TVJ3CB7X24=2%_4.&>E5<7H%9BNH%V,$RZ0Y70M!X ML:T"C5_OD-ML)B,^^(Q8509[\3]AVNCAVZ((5): Z9D:^;.M\&U@DZ$YG@+;$H8AW88IGI?

M](@<*Z59/2+;.8+OKWWEO)HP>/"G-DYLV?R7@B7Y3_(Z--IYH]$X H&^"R,`;B MR\R&UQ/OZ*6(%U]MZ;BBAQGSHFD(UY-0)R^H3#0TA41^,3#OD\GK$64&;0X M.V72&=VOG-

93TMGY?EC<|K3300S"R*GW0T?O/"IVG((3NY\'V>^\"KC>(47-\14 M0#0QL0HGRI(@-M9F++'P'/+)2.6&SB0T+.:?"]ZK3 M&*WR16S 692"Q2+WCC&,}3'XD)-& K2=>"4?#0!DF?

YRX_<:8_M$\%KT3R/+ M:01]A1LU:NMQF(4PL)SK&,52H3/2O6%ACM<43L@R14747WW;/HFI+?,U"M3?;06PFF?M3F^/Z$;VBS^PC3T#0&2S*!G*7B M%0+:O7<&F#_\]!?

V;?;YM[&R%;ST?13N)(N<8\N10D)[8]HHW3 F%I(4"=) M40;L)W3L?/C0]0VCU:5P.5^XO'^;]]F$M43"1Y DNBH99)94B44Y,6FNF5K;N MT'(K, ^,\EMDX3]"X#^C" 5 \B#K:HP(W'!-

/R09-T?NMBT ,T^.-#!\)P5HMJ@*O7V$X^,(/GU?4.F!-MJK#XGW ^&<]>=%H"BJIR05!5=NHRL!AAP_=8:%(K)997@&?N*&#*WHL8@5!-M\.'S^_"5;K=-0*!H\GPG+,'&;UFJ$$(

MYQ3/9/O4 /VQ@^-)!]B2*BH?CHA@3D?^GB*:CH(QCA0I4(0M0&%QYX2$-40Z.M-223'5."A<.E%'KU]B0TEK,1< MGYTC$%..XD$ UO$D M;IM),72[>O0_?!-

AOO!'$.TV+F96W!R2B<<#-6N+EMP(T82O ,BA&[SPG]E< M/S+-]U^3>!_9,7 ;-L\H%K%V]>?Z_7K5E> MNCZ];9OG(-\P7Y'26R=$4]3+^DE\F8'4'-_F_R7SD>VG]!819P$+

MLN<%RV;^F.?$Y?P-$\C0DOKG6#W\DE@CNBM+H<(&*;<"'14)RV5N@HD* MO(5^PG-RH,&CEAUS%,U^3GY#(^%R"7[":3XVE^-NH>1"]T@7;P'8#$@,I^R^R[3N)ZLZ5(

M%/=*P@9\QC;.?6-O\(4OA.EU!:.FSfW^[ZW)+5WW"7#Z^W-ZC7GTD/R <:2Aj6.S35D'M+#W44UND-T$L T'.AVT(O(,\ TXXRB/G-?SQI++4CFF\BO5L:(=(@W9,3SZ

ME=P2[.#0"UI3Y^:&.RO2G6E'=L$\[^8C>=$I&N2B9%K6&S^K=69N7 M*0%Q/KJ:.L-=\9JX^1R5'QKRX.QNUJZ[@0^?>U15\K-#ZS\SAH\/[8!+[JXD M:BOY42G^4R5LR4F]JRDUC-

3ET@CRV8N+##--Y>KQ_NO(6<.#?O8(6)6G;F.- M[\F/+_U"MSULR\QSI$DM8LHZ$1D"76&A'PIG&ED%WRA[&.YVGM!=?N#4=5L]9

MJL>>1;9PQSN6?,/N:Q0Q$B43O1H!47"/$$/_9^$)&+F;t1]LJ-|SC2A^D-9"OL-8 M-]YG^_M+'\O0?*@9$!V(\ [$NZ+97'$#Q]K$N3T=1DN]OZ0)*S5"]=N_!'V MG#;2!1-^^Q?

Q,#/*&LE;>_0X,^<8*EKY@4KPIQ;6W _:&T,[@787^R,8!RBB MAG"1L ;>]%P)^"BTG+^5_[:F23=@Y;UN=1[D:%"S$H2Y1L8H!)3/3# ?M!,M M,GI!]_R.,$+_ #M3X'G'0E:76^W/:^VK]-

;l.OO)&X7.3@AX_@ILA1($0 +]M- M""4GR2$"%PW%]]OI(!%#\E27/1Y87"Q$C=9Y^ /\0 T9Q* BU>I8TT%$-3?. MZIK)+S,AC=$^^(G6N^@S*B>2J;NSO@^X3.C_34>X M\@3

==P2M[>(8B#&KH& M\ZV.2Y'[3Q9U7;%,08K0E'1!"WS^Y+-&>]CDDIR+GWfI(:'E_+7>]/_4A_7>QA*L M-"@N2,=&<+8+*NL8?_2P$E>$\]?I-'GNZ.*BQV#H Y?

1K6@>FI1N!",)CDLK5 M\'EHY;H"\B0$_//1(?YV\R1 GJ9D1?I39K ZA\P<1$/EFL"?N275>UM=R/_M%BG7CVE(3?5A Q=:,"&9/L0YXB66K[KL*[\3JZTJ:TX,!LW!A:@(I C\6N8L

M)H4,U(_R$-($VG'A:F(T4?!QO.RK?ZH*CLB,0:B-F7;_]XC^\G!'5)>.H)W MEMC,W$WXFL"=E]^X*PZ]1D4,DI]"(Q9PN_?LDQ+< YP#^C[C=|[']%-'<'-M)U#X6G1-_;N'5F;-

@45ON9R0ZPG-9#I05+D=+*$FUL96A$ZEUC++Q4LU?\=O# MR[D<*K4PSY_W^ Q#@O[P/7XUDZO_=&D^]2#VQU(XG&XONM+0C/(_D++)R1EU M5^3?

00Z+N8DYQ%LGIROS04H#3$&_]AJF'40(D'_WLV3-<^]G_BHD, M68/EK4?X9+@EQ&4'R!\R=2IKL/.@"+M//"$7+.(R/&YNC/GO!A3?^QGMW /^< M:C1R*|)5"=Z.PM5-

0[,P1^,O8ZH>4CF.A')I)MBZ3H\.",.+)E85#"25IPU#E/_X,146U006(O,]K&\K]B@]4IZC 2V3C*:.M.8:[-6B-D-WZ&+;RKZ_],K;+.B*",E)D(%8]$:D.I2,#1T]K+&*OFJ1G&]$

M+692D4/(_]V(6Q(]8>E1%@T)=N -!7@9(4!;'*!"%Z&+-2-);S)IMKO.]ZR M'0Q(ROY,A94(4L M3*]ZX-'C^!= -J8,,Z:XL; X3SXIU6 S-IB\EEP]2X+0)M-Z,NN*+"_K=17I)

M:A]^71^%=H5/XF[:Z4WPPP\OH8?G+NNN8.%:Z*N73$Q'M32PXFH-JR"Y649X MLXRX@'^B6FML9CB24:9<^4/7@1;@S0<&WGQ &\6X,U;;VF!

MDQ_AGM;YZB=2QJ;QQ#/30Q]T8J.OBO]Q#"74#";MJC|DTM_JDR_D/W:Q_RF7 M;/>$^=C7!0]O!%LB!-KMIYC8AE#,3F=NV>T*CE^D7*(WEH2=NM5QD&;5W=3R

M]4P:+BY;.H3TFW[,+N.5|57!4CV=-2L6\T+=X='C.]\#__WG?.Q7I[_LF^DO M^_P-O^S+S#/9&H:H?+9_,Q"]I&<&=M_)'F_P0 8.$,Y=:VL>W>N"(>B\)\NCH$@U.SCA$7:\/[<%,24;5T-

CH>^$6.*Y2&)K9I# M-5?RUP_Y]'K"Z5WDC5N:&%%$5Z4*027KC3__MY)W-7(D/G@((5&\G,G[RQE ME"7I>):RZ[-U8 6*78T^7*%GF:X.7[C'$;3S9^\146 %T H;NL,I4!_N:" M!5AE*

P_XLT6OI^&_>:_2QK47"R/F!"[LL" ^U_[*\C&M)CR%H4A93H-S/28 MGB>'I,H"7(C':X-'")MQL,G1Q8T1VF<;8#@'T8V;!!FP5KOW9**9$^ M@SP9V^ C^AKUUI-

_%TL6#1FGM(Q@.$S#Q>_EI=LTW#VCKA:G+@'M0]{C$.F M2'5; 27P"FG."[A(?>"*0AQ-AD5HFY"SKU)[?3^.375&B TW/6Y=*'%!V MJ1^&2:.9V/8(3R63#AT>-

{)!1N*;V>$,;,PH+8A50+R*Z?<]+G3V:0#C)2 M"U RB^N?E\W@/S(Q+6G9Y.9=D1ZC+,0]*2#^_J #>1= MXAT1W0.[WW4T]$XQF:@?S(fH"\M\'4'0Q?HBL(EJ5XAN"0ZGG&Z,$,--(2/?

MTXB@OR=R)B2&B/?4=Z;1('AW;KTXQ M23\YQ31SU8=.R?_\-9Z++H 2!.*;A?HDH7FQ7>+\,#EN*NE@E-P;D8[3Z+"_M;7$S:+(,K, :K@DW0TG3M&*YS-.8-

J8M0OKKTY1A@=A0SQ!,2Z?!\=]-TV\B M>]?6 E#AU^ALHXOX +-7,A1;?=4)VHP[HU0^)C<)%H0L>6[_Y]ZXX;5,C1(A M+]>X<*.AA+SNRU?&"=Z_HN- LY&ZL><_?

+/Z!AXV7[V@,@R]H9^]M#XHPHR^F8$9\G@%O-%6>%'(@.]7JTV@^)9"C0VA9P:%C1_"H;GOZJ)A,6#+R M,A!=#,1,1=^(=ARZYZ+1]W! (R^98\

E^YMBZ;3D:W!OMF6IK4Z]*1!8#[G^ MZ)_3QY^74&A+ST&E 1;T"= GBC\(&YCC-#E(AWIGF'65/XQ*[+8HSS?(D2PW M;&G*(S<+3I9-L2OZ;AB9H\T

-7IW41!5Z'>MZ]WA)B&V15YN8V:3M<(:EBF M\2,O"18EK^;N^>3@-VNZ>0=)28@5!&2]*A*O'W@.%9N6(SNHQ-$#90RX]+P] M1E3K.D<+4E'Z@A[@KE;'%Y

!O7\>Z!>>9]&B1YB2TV HDFWQ4GP.3&,<7M$ M#XHX,K]VP\D;'G$;=1L<),6MU00!YB7Y_1@#1#D(5)Q."^J6[H!GQ'+.H< M%-I0K9+)\]!@E^F&4-\6O+3]'$;; &3)Z?

H;0*1E*+!VXM4/Y M0H.J!? "+C]7]93W=%,\G0S!VKN&IMQH9_QY\&[?$T?(3WZ!1+!+=8IM7UAP M$^:E&>RK^6G=7.:.5>&22BO=ANP]V!/HZH+6@J8T)'4\SU$(XT[-U4ZP=,7?B

M7Z_>;[.-Z\R.C9[F4Y;>R>415%7W'D65Z=A:#*/;,DSB V;YF ;V29[0A^E M/#N!Y+C- W/>@(8K"]!2&AO:YOL1N%5-T\9 M;>N/ A@>R*-**.$_D#-*4W8HR?M!=LX,C$E)&D-H

;!M*#VKB(UW.?BG"B_& MOTS%)(4O:\ +^.)E?!+?Q'@NR-3^C(<=1[TFQ.IZ885/01NP'Z?_U\Z?U\(C=ADCDYD-/DQR99RRIXA MO[^LZZT1 N?FIH!PY.O_$T=T^W#I0$1H'2FF1PH&99L

F,O>)BYK7]=U"5.^BB8\#KH M%6DIBHKYQM?DT6W:TE5KMKK!;2?V9RIKQ_YV,O1X92[%OSXW'_&WG#D A'-M+_P=KO*$KV+X6D0H13EN-

*"C[_!_TG:E6P.A0=OA/WVQZOP.E')%X-*V8:+N M.E0J;@DO8P!)U4-NYG'-+>?A-*92E%\ZCOGL8\4D+=,EXAD==C&A&<&+2*DM MYK|FN=$9 ?)]0"U/Y;>I,^2Y9 MS3P-H?D>P]?B-

>E2UW5!+$%.$$",Y=H5&{]V&H -4UZ"RAWGUV[0:&MC@;8B M#U1=8E"6:$X5+PW1?\V?#L!+*ZQ<1'6'Q'ZIOAS MYCOA]"3!EWE,+E;3+[& QM&J_SZ^'#*90P;

3]PBMJ.^.0#M-[CR<#. L MYM_)Y:S[IH\R?A+$V@N,5*-G6V_6U8IB,\]BT:\?/ 5YZ\B0Q(FV_7@F5V-!/ MSM1+\B6L7'S.Q^=S4N:G'Y[]_,V3'U)/9.*'!*QTJL-AZ0\LOJI[M8)("6QX\@=N:R-

"PDO';,&A >-.M-T4D>E*1NL 8&DDKNOR6B/=MJN15YTQ M$*&Q2"J@G#5")=973-KN"M3F_^*3OD2JD#$ \6:S5%V1EC#$#&N

M&5[<,B!4NBEO>',+3UI\TEU373N03@<8R6\]CKOGK<8MS#LP<*"=9(_F+V@[*76Y$%#KE+Q7H]4QHFA4I.>D> M%;ARU?;4^ L *MLTEG70;G,MQ#;"+EHB&P0K8MRM4P2

@>0G-I3AK7:R%" (9 Y"'>37MZA/E M"675)W0IM[4(K,)AM!2!0U?]<-_^M0;[V/QS]$!:IHZ@-59;2?9O'Z@0R1 M/A48>Y4X+2=*G@U0#)RRKBI,08[C)9F$?>8OIC39:WKJ^#

<*$_QHH]V0%GPK0CO%G0>)V=8;2O *6%0^]/X T% MUH%!/ Y[]7CWS=NW?I=N#C8Q<'>YF"!=.A.4 O/ZH:4<+W+D(].HHX??O7% M%S8ZO&-#&!

<75IT(FO!V[_/,LCXZ^1EQTW72)59P+1)$*AT5[. S;/O!\RW@ MC3P*_7C/&JS173&L$'>YCT#%NR&7)U8T,.HT"">A1[QP#U*[> M+3YA\0FG?$+N3;B^5+U0EUC8--1(&VP&JJ1H2?

;TL,;1509H9Z8BC0032:7B(F+ @VJT5ZR6IW"L+!Z+$Z.O.X.(R!UQ M(NG,T8'!PZ=EO10_X.J-=L*E8DP9Q@.1V1OSF?\X\)?LLU:CS(6Y\!H<*2V MP!FN>!!9 NR).?8%D?F!$9E?

+8C,A7'LK>SG7^C1(&$3+D/S*3WK+3=[$666V>2^'AV^39J M>?%XZH%E3]B+:Z\LT0O[+B74F/"$6G!,JA7MNQZ+>-/WK\\+,O

M_OK@T5=?/'[XZ(L_8<@>&;E8^2EP,$D0%L/@,Y+;WJ/M8;%ICX^F^+L#KP6'*XKLU:.27!OYRV?1O59AWJ>9SNU]/#NQ%9,IKB1";5G$C,@/Z.*R%&TY&

(PWGPOC]-319E*GR[HAFX$4,%.T MM0#.A:6ERXMR+XL.X]=>-)4T]U/GA%Y*/L,=O?IV Z&D.N&>AOWMZD:WN M'M4$=X%66D*.88FKPML;\^CPBB555O08,HR7I@Q

M.X&M>TDE8TN7(V(W4].(T^@,_28-+B7'B_*"IJH55/HN&%?@<&]':H:\^VXQ M39:02%046B!GA: HV*.BOVNEL.ATRU=JE1"7>&7]AF_HQJVTUP41G8B0F$Q* M]"KP2LPYH([AE

=!HXE;@->$)I#4$X_U;Z)K%WY@!$D;1UK4G M@2-Y=5C M:4AZP;'43*C@*C*"@7E2351M5MV-M[UK!WI;^NG6[>BKR)O%U&\P34"("W>M

MB@_^T91HR;RAH8>==*NRU\F'I9WUNPM]1;6+((6/&?>XLLO-'Y*P5]Y(G&2M+M2$Y%Z>+7U@0[_(C;1Y(2GPF Z1[N:I/V/NIW M]8.3R30S7Z>]J,X90PZT9=46<&

(S(%1_D5U0AXG13!6IM68Z#@/DXYT Q(D3]]M_XH(C,_|-_8.O]WR="::?SO?PB5\:>K[Y\^M?Q$D0=3-YRV'"*,:OS%]-NLLC'*H4@ES@"1ABZCX@8>R5/XBOR[D/&O&U/%<-M

9J"YO4+1%OB0")D9?(OV7I((M;1MU8MQA_(H5OL+Y//:42,FIC?)\LJH4F M]W[@EI7,CPBG+%U;HAO,,5"3XMR=9ZM7CG*]K=M^"H-2P'F0,E)L8GK;

<_<0CKMO>X(/^7W_K5'>X>E]L M5A?^\?_R]W_\Y;?2*/U39E70B"[;'=TSF^)W-L_>FS]EUHL,:UG7O!5TUL MTT=@Q\H53D3^=YXJSYCG76ZB^>R M!;\+5)\]WD^??Q?LVU!*,VH?

J_R7(;3A@;BDX;<+10,$Q666/PL$#0N,AX\K M^^_5)RFTWS_Y/\[QWLS:?JJ84Q,+B9US82/" _V@#(OT$W_[M'S"^TN@+N^6 MARS(JH#^Q'LZH-

S^3O6"31C!">_]W]*LZG'V,@/<'X%@.CTHV" M)\|!:"!T$(K'G]B_8OA$.@L$1Z9X/9>40CKE7\4)TC<*/(& M#[<8(H9P?^:2;$9D\G2)N$ G1YSK()*4J4?P1H8$>R+AB,O$D<

M"UP3/^V3B.8 MJEOTU2[T]6 (48':L)<.UB#9_-)0S)<.K;%>DV7-@,;MLU! M^E&#DS2Q3'C.NI/8 $DKJOUX,S,WLJ,1//_*O0?X(//'7S|ZX/.BLH1?1L[Y

MNJ!HS3_,.9GEP)\IH7=N*BPD0C0659KI(%P)\81F3-%W=:.97# MC#8S[6&1(KA_(> 5<6X3BTX6%H@C(@?./?H6PP4^B%X988/)P'63MP6["_>Z

M8+',@;A(8MLLUD,BUF<0/SXA!93:/W\>P1?LCS7?R4&3RF B7&5X?R%*I57O MJZX) 3,O.!2+ M,YSK'PI20!R9_1$YYPW)\818XG3YY?Z_$_'/L;7$LO 39J

MH8/HZOJ5$14R(H2?"4_YL/)F2&"MG5@,VE!_8X.7N4T;N5R))!U6D7F9N-/G MT?U=\-]K6//D>7QL_\JF,UQHDL31!]- MN_B$BS:E+!A1XZXH0;^.6$I=K+5_4X-$C3@E%&K,C-

U4SXZ*1[&NF,4H/$BX M%E60>OW]92A6'U+KCX74^O+!@M3Z(&BM/\T _HO3EH4J$N2M#4I4B6OND^'2B

MAVA'=9&O"M@XX5<71G6A_M!2YURXB,/TD\)_'<_X1U%UIGZV0HMAE.7FZU!$D0JYD4LNS#2^D)!QK038V_,:MI/XOBSH^\M&?

{V1OX=5PT@08&2&6EQQI+9RV^?!"V$S9%&BVNE'.0[S\V)+9AMBOY7WWZ<.M PK?ES864;'D,6##O5*:$<.>L06""X% YS#S0ZD]7'<:BE,H]EA+]J3I/@^(

MV\EA>%VX&ZZ3#97WZ'+^+ZZH!]952]&_2O#*8%%;77L? =2?5M-9CF<<^#!TC MGE*DQ_3T /5 0"9F*<[HR.P4HP4^B+!+7G]!* 1>1V2)+B)E:..&1%LM"E)P#J - MNQ,W/:,5:Z0\>?QH;:

{\KU_#3I^LQPPF5)5*")CPVKL,>R0")54 M4E5I0?2A?3\G237S@7:JGILX%?PQX6LQ1293 O?_>U5A+)$^_!$+A&H)\X&K M+N6(HM)9*0PBTM2E]#:TDH*R+FT<<5))(6 $1I-"$I]H-

#,_9UUO2+@=,1BKV MVJ0PG@7E>F+'%W 9W)H-#\!V60>]J&'_K#N!,-Q8H0U/2X'+LDH>@[-:\NFB3XJ7-K.BQ_M[;;9%,_=W@2?2LX&6U&T^@B]9K$Z[8U#3Q0U/K]/?\:[^]

MA&GSRU3"4J_NK,&WI"T?'L/:#<(QVZ<2"VJK%ELK:+_L-^KM.EXO#E/!4?S M\^+BMFBU,7RDT'(?!(G#:E!D?61Z=(Y64&);P0E&4&#*$^**:*F0^-K4'C6 MD08R8*@J&P<*TN3:

{V4W\B[2G?RKX>EM*SURTB54$T04S.@QVR#Y_-:4%-MH= M2EG)P902F&035IONB&W-'9\ FI]8&%52G%C=L-VVCI+@U"'D4XPL, 5^AO#0 ML7[*+N#8KH3JTB6IAN^U%EWP

>8:/4Q0- ^\YP8R>O\&8 P[<9 M=QP%I*Y^+/?3&3)BM\| MOTU0%EZH1/ST-A!0B'Q(L$,X4P:?5_\?^/\,4B-,^82"(K)* C<^_=H>4"!S M>HYG84RA@*IEE !)>;WK

MN:#&+"SD:MM$P"A1U=V7XR$Y"LS/9(&Z32+QL'*9/&;.QOC*]M>QEH/G B)\)5>0NC\/ W+U\!'C2*6F@_IET;2=,.VX,?;12G*Y#'" MI54F\IM_7GRD'<'/W\C!?^B-

^91Y#'RXWQJW>$9O<=HN*1SA IJ2Y5!@R%!F MY1_4$-%?$*0!4;!M_,:YY@L;DIL0!*<;97D6IC>WX^E9XEG7NP'].8WJKIMV=WG%[,P)

'"%,K!'&_)>KHF1MJM,:LB%15G\@N"":'D0, M0K]-O)O,$ A=G&"PX@-D,;.-UI-]IVJBWV2Z(3%UC7YD(6F.R7K>33KR<6WH

MGXDRGEYBSK@T+MU/5^!#+1DUQECE#]Z89DPF4@+KI:6L2$>$WU0E-!M+!4O1LYS$4#:JJJ-O2E8M5BORKXE@%EU#NJN

M:X&!GY',TF'O@.5."VHF,Z.D0C#]H&M7UOM*S'=TKP1O>-9W^%$[CRDP_;'V M46N&R8<,=/9#Q MK)LP"]V4*5N^Q0S1ZZYJ03@,#+6,)^W-HU5L%-0H,W0N#9126SR4&130TV>

M529/SZ:*# 7CYHZN8YFX+'9XMHYHOKDZ7?4DE_ 3XH;?%Z^47Z7D 5L6"(_(MD%=T?!UL3[^W/NY2T_N##YRN/DOAN;5-HU#JX^^K^E/B.$ \77#! P;C]O[^%=]=9?NJPDIJT3%QP

M.U;NZ5], 4VD*35J6'8D,.K-*]NWO>$(ZM! [3SVJID.5&&U9.[)K;UC0J(O1Q M2HGDG5G3%YV"*L%<($Z&8LU*,KHP>.381"=YW'!5F=U/3#E2+L0:A5Z=16TL

MC(Z0I1N&X^C\D27'JE:(JX!,//>.-_ P_#-\?>PT_*X5/^ .#%N!'^]2=HO6 EH/G B)\)5>0QC*]W+U\!'C2*6F@_IET;2=,.VX,?;12G*Y#'" MI54F\IM_7GRD'<'/W\C!?^B-

^91Y#'RXWQJW>$9O<=HN*1SA IJ2Y5!@R%!F MY1_4$-%?$*0!4;!M_,:YY@L;DIL0!*<;97D6IC>WX^E9XEG7NP'].8WJKIMV=WG%[,P)

'"%,K!'&_)>KHF1MJM,:LB%15G\@N"":'D0, M0K]-O)O,$ A=G&"PX@-D,;.-UI-]IVJBWV2Z(3%UC7YD(6F.R7K>33KR<6WH

MGXDRGEYBSK@T+MU/5^!#+1DUQECE#]Z89DPF4@+KI:6L2$>$WU0E-!M+!4O1LYS$4#:JJJ-O2E8M5BORKXE@%EU#NJN

M:X&!GY',TF'O@.5."VHF,Z.D0C#]H&M7UOM*S'=TKP1O>-9W^%$[CRDP_;'V M46N&R8<,=/9#Q MK)LP"]V4*5N^Q0S1ZZYJ03@,#+6,)^W-HU5L%-0H,W0N#9126SR4&130TV>

M529/SZ:*# 7CYHZN8YFX+'9XMHYHOKDZ7?4DE_ 3XH;?%Z^47Z7D 5L6"(_(MD%=T?!UL3[^W/NY2T_N##YRN/DOAN;5-HU#JX^^K^E/B.$ \77#! P;C]O[^%=]=9?NJPDIJT3%QP

M.U;NZ5], 4VD*35J6'8D,.K-*]NWO>$(ZM! [3SVJID.5&&U9.[)K;UC0J(O1Q M2HGDG5G3%YV"*L%<($Z&8LU*,KHP>.381"=YW'!5F=U/3#E2+L0:A5Z=16TL

MC(Z0I1N&X^C\D27'JE:(JX!,//>.-_ P_#-\?>PT_*X5/^ .#%N!'^]2=HO6 EH/G B)\)5>0QC*]W+U\!'C2*6F@_IET;2=,.VX,?;12G*Y#'" MI54F\IM_7GRD'<'/W\C!?^B-

^91Y#'RXWQJW>$9O<=HN*1SA IJ2Y5!@R%!F MY1_4$-%?$*0!4;!M_,:YY@L;DIL0!*<;97D6IC>WX^E9XEG7NP'].8WJKIMV=WG%[,P)

'"%,K!'&_)>KHF1MJM,:LB%15G\@N"":'D0, M0K]-O)O,$ A=G&"PX@-D,;.-UI-]IVJBWV2Z(3%UC7YD(6F.R7K>33KR<6WH

MGXDRGEYBSK@T+MU/5^!#+1DUQECE#]Z89DPF4@+KI:6L2$>$WU0E-!M+!4O1LYS$4#:JJJ-O2E8M5BORKXE@%EU#NJN

M:X&!GY',TF'O@.5."VHF,Z.D0C#]H&M7UOM*S'=TKP1O>-9W^%$[CRDP_;'V M46N&R8<,=/9#Q MK)LP"]V4*5N^Q0S1ZZYJ03@,#+6,)^W-HU5L%-0H,W0N#9126SR4&130TV>

M529/SZ:*# 7CY

"\U+JZ.X=<`M?#"|@#;P.-;M&I<7X/%LL<+'`D]*7E]\(\DY#+:BV;H8{EU=I^G(R5R7&>)2VD(1#WT2D6K0H=|\M2Y)-7A=O_;G.K,'-M*

F3"$_VQN+,8YF*8;QY+,G",!E*=&A)KYOHTNBLC#(0)3I2"/$G =QBX-G,# M;O9>+G#3#P$W?;3 37]/N.GBA\T+9LU&T:DDI0K AC]VKU/

*<7%E/XXC,2U(P,RJ2F!21ES8_[A;TE>S^*\^VU%B MJB@80VY+;FL@]^KW9WZO%% *7;D###5,7@#R1[D/N=[*,-'<,_C]77;!FZ/*A M^?,$R4^(Z;ZN' A*"(Q/C!*B223MZ2W;R>CR-P[""J)=!KUBG@T?CBPVJT?GA-MB,D!*G8/U?]6/-=P>0R#[8*[XQ&K4RKX[[RG-T2\M6UZ%(/"4'%AI@/Z2]H&UC0.TP),-O\;,K0#M <+&A[^?-57>]=)2:$$ M$8*

6]C&F$9R=#5ED!(37"/R4] G:F]/KQ+A?^CU8X$G_ ORFC6.6Y2O':]A@ M'Q.M$9DAWX*92R,VDZ#0>$,66Q8.OGRB=Q'> *TT"Y!*S#Z^[$U@B@9#M%L= MZWZ G6>ER<*

*TPS=8=.>K;^/|;.L F)A>!V%;8^--W)AA5C",!I.>3!Q5-N7$ M&-LFY;*ZNF;:&/\+>@9|<.L?KXWO(VF*SQBY?[BBT\5NX{K8B4'@G5=E71$4 M1UAT&.D19XT2]-[@B4C"-$N(-

GW\.BGK]\GJU'-Z[^:,8N/VIG__N?SC\U M'QK++>$}>YO;#>>=JM/2?65DA1?2+DF^_^\OT_G[W\=`7OXS\SW41AC\'QSGTE M71O<1LJ0 ELXP1L#

0)EA_Q#WM;9$*4&RDNYZ[2]W*:R,PL#.W-)ZL#4)59*O\ M(3Al, ^'S<5O@.PLWWJUAJ5V16,W!;?^KO9VV,T/8,K UPDU/=I(E8=L>$!\ MF=I1{]"%;V&UN4R&M/@>^?QO-

1KPKPBT7"P&T_ Y^7!+UM]P1,&<,.^H>QC MK-4?%O_&B!O=BUT=%E(RYTB\E1CN3-T*6F55LB/XB,&DWLE/VGE+O'P;[F 1* L') M%=0!*M+'"9%*

MSF8FEYJZ+^#P)QYX;J.0S^M\NKWV^XHO7S)GKUITQ)0'*%= MTRY_3>FW=P2L*T7S C[R]:^!T%'$#MP."(J+'72'> L*7U<[>T,TL^7^TSN MADN<7TN=)IQ\"'"9=7;1IG:A"H M% ZQ.+E&.]"Q$?$0?',S!/Q/@^WID^&'X8DX>=,*%73%]0T6VZ0\?)8XSK M3N1$;+.]O6*$+H$P-*SSH1\E+4H%8=>;&FP5B3$|K_!F_$%HKQ@=);PG I<MQ"K-L2.NKA+3]^]*

-0Ef($!#>=H9-A3DS/A=K;MS.0+1H%QCV?AS-@;HY019_JS.)=?N'$D9AS?@(M20>5?X\E 'Y?33'0UNRDE MQ;/IT.N&%Q?86*?.@$6?*

*8#H2&9LOQS91|)O)9^EX7>L;CC]'D@@81N0W[# M*4D9CQ&9J;&@+8GCYK9UCB%P22>)I.'(.>L4?3_CI B00%*\0!(8V[K)6SOF MXX]9T7$F,L/=&V|KVCJL5HZ(3{G,N*CA?A:D9-

*|HY<{.; M7#%N=[OFOAOU|R-U5OKH*H-_ ;WUH M2 +#C%,6,$ 1-2-K_=>]PB4C*_^BI=Q08_'STB'3O'G[A;=2V3E`>HXR7;Z32?RMN*7D3U'E<6F.!F C|+3K[VA+A:X*

*M6.!I"_1?WCKFD*7Q%,XH]T5+95ZA0=K7@JY7X$.JSL[MU-)1J>T4^>1|&\|+ M>LRZ=#DC4M/I1GH_D^EKWK@@@"!#W5JK@XHS>CM23EJ74/|S*

M#$^)|3(BI6[J>MN7_ENU#7/JAL|?3W"|+<,"PZ,:79B3S\OXHT/#S)VUMI & M9.(J0#M3H; ,%H!-S&.VBM?#>G_B%VP MDlV>R1+|%-/A;-OMINF|A^`D64 ;

*M])>4J$#|\$5V0=.3]T;=F$H%_-CVJ-M"C8O/-NJ16TW;|%I [WB\DNT*M5P]2 M^LXLR.[PP^2=T.[(Y^6B=}?BH%#=F?ODF27:BEV[^JG:2"Q*>KK%]OKHJ5[M>U+O44MQ1O?*

*LQ}H<:D<16.!Z6W]YB/>)D7F ;WF?P#0TK2GR 21.KDL&&%@ M5*2K3#$\X%BUI.2=O6JN8!U"(V3==Z,N.(&B% UN!F=R7,U5/8P,L/)4N)4$*

*M@75=EWWE#JB//"I>3IX=%5Os%Z1@S2C3- 3WH,';,!*O/) F)EO7_LE8^+V M*^#YYJPFMO5\Z8&A=L3?F #P@=2$35^R@_0CJ$CU$G)+*\;FET3Z.BZ|\CH*

*MY43E9'S;H7./3F[0$*CK(#9E-]24]9[-W=3-*Q0P:^[0%JW?",T.:ND=1/8$+,(9;NL><3255=4LY7B;)D+RWV^"9U>U 44NVD*P,O: M%GI-1;@>0!VE*,S4)&2CO&'V\&J$N7]$=(,^6*

MJ#TCZ"'(\"GDD))^EZ0^VH<;+QC.A:DQ#(O_!.)"U5d:..H6?MMX_-N"H_/5 M<^KYYMPTDFM]%!'#@_;_5?)F+D+G0|"'2H'Z60A2"+PJY1MOEG\|=9 M.)2G4Z9Q-

{]MTW^S5RQD\HKY>\.MA$]8X45^(@?T?O(LVL'WQ_-?MV$Q1)&F M4|0V%?;ZQMG:SKA"`V"^:);)R2+AKGN8H:XGWA;%B]#4ZE;+/S[|%XHT?S\?87C[_^W5-9VK2Z$/_O*

M7J\$,7E1'"\2EA/(\SI,+$P5E9>F[^*[;D/B^%'^6?DPOP|(^RL?KRG' (>B M',,X?_]Q_GIS[!8PP6)7MX@\!&RGOUCH>T&R-55-S(ORYM9@M--&W81.YJZO M8*+">D:A6_7XPl.3]'$T->

*(!D9)H\b;YTU#W6C1+PE0<1+0N60^A>,>FPQ.!%Q? MR5@ZPI*Y%3EAW_;"NIV2+40#*-NDYT&WCY;A+9=;IL6R+TI*GU5\'(.5I;.D-M'-*

*@)_^Hf^NF.NMQ.IB!NVI[AM_5!A:0RUOh&J<;&9T>HL5;*W#&;? Y>QJCB MW(IA;B\j3-IL%R-=C/0N>RZ.OHT >CB7>$KQS8CELB/"T70UH,Z90A"1< M:)XWTCA#Y+D2BA4SXF=*

(VS;_Z8M6R;VVQ!/C_X0,T/_-P7]5O=OY__P5]D$ M-9-?A2_C$G0XWC<":O->-<<12L%CP8L&G+#B=2)T7'V^GU,>S$%G&J;T$IB,\ MB-

*0)H"Z4\SNGOX'K(=F3L9\ZV*UB]7>43/25#E;Z=P@>YFMCG97=1LJ6\8 _M+S;WV-QMI5&E!0)D$B-&'P(NKOQ!0S FD3I38*/; &FH!H8?;@!|EC_4L_O MQ0 7*

*SQE@.Y0;$E"Q5N6_T;^3R%8Z/)+L-((f<)B2HLIG3OEDS$(*7L(U8B1 MP?]AO4\XB!<.O.6H;C6]XXV4VP"(HG(?47OYH.S^3MAQB'E'8-IO1ITQ.T*Q*

ML;%M;-4J=3809AA4(1DPT$0'+F8B5\N0#MZ*KR+/,8W5VN= AJZZOJDR ;Z= MOK4$!C>XLU^BOA2FFB9OC/66BE.6"J2-0>M [XM&J&@$]'(TI\%C.9:+C49Z MK@)-

*$+09RB)PK[4#AF_]<FZ0^$4@4 8N LS[A|LI.*OR|C>,Q.^.1+!S_ M.NOR5R!L0D,5XC5]^-5@\]W>]%*XJ)13Z:GS*2$Y*V2&<$CH^^:5K1LSAX?5 M:EOK9.=&I*

*4#VIC0.X[JSR#/)-9Z$NGK M>MSC/GG8^F#ATJV,,/\^"&]T0; MZ4#OB243SP)=5R)@K7)N[MT_/)/4/]M.U9V(*A6NN.#^Y-W1P$',#P8_O7 MZR/5"CB^RIK*S(-S,>V/P)8CE-*

>E<[=LS1?U]2EK6CY(US9(\T%^5]8@8%% M%9TQ!A1C!R_<40]WQ4<2. JQZGB,UDP2)!TL &00(=#>%T+&V\!-7?@&*0 M$7Y>&?2'S*4G-*

Q(5;GLE6Z+++&TD8/N6"RE|QDLG;BfW/M7_X52&^/<.@.TMA" MVYIW'O2??$@^:=.T"L:JN8^%;OIQ+Y66QPE-6>"_5L=,EAA'YL?N=U@

*MJU#7Z4&LG_P1NF!;B&ALKBIS[JKHMD&MVE#B\4\%_,\W=SE 7&,Z)Q! MZ(D*BM>U4GKE>Z<$+,/+NWLH>56L?4YC/9:0 MC:Q]=-@00QQJ5*W_@-8K*

*V<*3'#T21WXITI1M8+6E|CG$DXN)OK6)KKH]|"# MOW822RZ@AL5ZWJ!P2&I=&U2_J9,M/HS;-Y0?2T4<_@N:%R5W!K^D MJ;@:\X!{:KLT6NX7@6 4%M%Y7A_3@YN*

*{7>]K=_4XWNA,\88V9WSP$P9.$A+ MAP2U_0. +@&%.NEN^.0PBU)003SKB?\6H#F?@%^R.2J%,)3#Z1^AE5>T@NE0 M[7%O OV>_O_? +?PK[*X9L\D9R>;B(Z[K9NZ]TD %?*

*E@2>X]+W=?\|@[_[UW M5/28M.*B-C83>,V*;>_#.T:))|UQ|@,BGGF9%Y5?@IZP$@4/0QM:-WJ \$#?^M*YCLB4FL_TG+),.F3I[_\L\W>@TR+C>,8>Y B7FU;-N4MJNAIU(,P4TDAN*

MOB-F@Y.ZKFU#/$LI[@4LSE19$#[J88L.C,.D=&:%Z1'?8"Z1@#F1>KP-,@!#@ MMOXJN)LN6 $#=W9NBP7UCL[?VP;-OZ8+LNND\GU[Q5BA.,,2SO.V+I/9J/#C

*MYC13E*PC4U/MPAK+NX_*$2\CVDAY T'<)K?\';[VN19B2%BJ8-FLUNW!KB8E/7H;_8Y1M6M+_VWF6J4YZ)9I@XT$K4|(7XU5|5%QAM M3KH!66!P/C%C(.*

|.4%TD%C|XE";+$6/,+,BBBM:!TH^D)SGX!HH6%Y]XT_/MKZF6&AJ$T:EK$G2U0O4CGF;U&3/>_EF=C<|ZPZ6A:.(@XA8ABV3OG&ZE8=?_M??

99!A@4[Y!@!4/C4&5"O1W_H+KT6'&F?""BXN&?F==R_Q $(O5X50M(CO>R MV054G&>V^:0Z%"5.(_\NK$>$1V:[!E7 A?EUUE1RBY+2$/K[T?)F)C\AT4 M:O4L8=M=R22CF1 +

{0)O 80= + D=4QK[;Y+ 1 M2,3DE<,%&>]WB6B+,! TQN.MAV$Q.CQN-> ^\)1,8#JKS--@3Y\RFJ#N$H W; MB:6#"P^4E>(SN&RW(RR,87SPRU]<\MYE&6N"<]

!BDLJO0%S+3PH^M"@)8I M2ND)W"& Z[^QH[+,.T92,%(6C)%#15-05>Q$ KU<7";.551Q!?XYM3Y"Y"H MK#>Y\|C'+[+@IV$!KKE>NFRBYP"\ $+IZR,GI6L#A:!1-*

*SE^HEV>9P"R=KR[B M>4G4]@5K7Y(C4<5,,F*ZC13L(N;*P0",@0BV\F$Z.UJ^ =AO7XF'Q]%@P*_MA+ML*#Z<&D5W//#DN!8ODMBM#5K'_K50A&$I0LA*ALIA.+>OF*

MP^*.)1EQLBX8UP^,JRGS[6D[66)YY/%F>L7[XOGJF P6XG\R?A3>,Y"]%R$ ^Z9,,BS'!Y= ^O-[+-CC;!7ICWS\3A>1 M?M/Y>VL1ZM0!_ .:%AU-

*E.YGKX=WQ=EZ.L1!)S6*J7E*8;^IX"">\F!UAF8_M^ZABPEY7F)@&^N73.K&F:9M\"CXSUQ^V9%AK"7Z#N=ZI AY.? MRP@$[@;GW>Q82\GK1%%-\.0LT|NXA?,7[UWW>&6-1?C:WKJL4S9KZ)*

<0(\ M\;=Y47=DV4VF8=9SK[83;BBCO^!Y+18;GV/5N"WY&.XP8D=$#'9AV#6ZDI(MMD00D$!DT:ZYZTV-#64E-GQ@6432*N?4H_>H/Cl;69^R&3U&FL@2J-&N)1 MLAXIH-*

*8V+P[X?:WQ.H,EKT%?DT^O M1[''%3O+2N.TQ36[B*2P54* ?G4[6I1FB0UL)9$P4*2T2#;IVCX.>Y|O]9.1Y*

*M)C^NOMK>E6PC^2;A$;1#+EW=/X[Y9!'"1=9&2]RGAMEQI#F%B3H99H-XE5LF M L&U+E OM6BC7\OPP+9X_S*6<0:\^2QT7N*H7L"-^@)\1 R&8+A.1?:L.1*

*F]0A@"Q%#B9%IJ+L*C-_S^:%"\! M_7@S+ZG_"&A;Y',ZV:18X7_MU#;2UXQ+S^#OK,WMXYHT]A_M#VH4)TCY7VB\ M(&L1]*.SC=ET;]94Z^O&9FJ.AYOO!L!9E(7X*

*MQ9(7Z#11WJ56X09 M3OR2@E-X6.=93XH08$C.EK,,E-:BLA6F-!?,'0"'2; M5S^\S,0#G^;@6-V"-]P%;)C1?(4?$X^DS(9 ,X*V:0&/Q^_7|S33$]YCFO3 M);VCEM U9:I*RUPV3]2 WXB]*

*]G@(?V5;QVYRJ6PS<;S9LV>Y2(%@:T!9X?= MFX.5;8\'O=IFT,1W3SRO9;-7$;6FKC;&F2N15*6$=#!#*KB^>J8&V>E7:P+& M1(>{B;N$9]0#'9ZEC-V^.1H5UQ_A\@IJK96;-*

M<,HN\>GGV6Q M;V+]JOKTWI ?!S%SVX6G:3[RT7P!X@-.KXYH,1C#BBC[G<,+KU_ MHO3MM6GE[(+V!G";@\EQK -]-79T9<2:]XM,A@3S6Q99YZ5C!&4JV3IPX7DW*

*M>4<&2EJH) -.OW-\C"9Z9=[]<@JM%>-01Z,Q#*RH#J)T3>0H'Z?]VR!'83RL-MP' W+B&%T9_=6RT?U8TM9=*BF)!"R1(V379AOLA+5LEN[D)9G<^=S?BC79%/ M=_H&AD.|*

*{4G#H0SKELNPGH4RK&]9AK7#EMM7]^Q@1\U@W,WRDA2+V.]ST)!8 M/8S"#[6A66DD#SBK*U^KLO(.2P14;Z2K)>:,*Y]V M=']/ M'U2R5%D_^A5\@YPB- KL[G/-*

*;,+@7.8Y]O08F4@HZ\&SR7HRX;WC9XM\Y@Z#%0%TWJ1C<&I&T^EZF^.;A5G*3W)\,HK1B5R1"BU,4Y M.G <6Y!<.(I/Y$I?DYLNY@T:<]S#1+Q^]P; R/)1*@4%8X6HY/N+I/\]>3@D!*

M@!I7-JRV&=,F^N /%|UK|_B&?)732P7F=8+ M0A-7!H[QN>RIX+-KF%<=,X8&V7_%#!4F9.B7A4N#Y/&LA-ABH!CMMU-6JM/JR M&A'[_=]E+YTH@>C7R7JK<#-[*

*B92Z335'//%>BE=2"6)8VY7 MAV2.#FNAJPV:]++P+)PLC-1@ <9C+^'P\:!X3'N"TR!CQ&P$XP.D[\O)\@+@'DF%EQ3H"KG,\;S MQYV!I2] *E& ^P3V>+OT+SEHR25#*

*(Y7"BX0Q@%+CD(C_0 8VOPZ@KR#OZIE3"_M>7ABPEY7F)@&

*#",5U>*9URQ3$.L_7G.LJ?/W[+RD.D^">X"-X#,=L^25'G|\K$9(X M9VOE)??L9?IC@?TDW<3U@L)?"H]FR=&#YVV]_4?"@\O/,+D3R8EWG_Z_'_+ M"&/XZ-/[?/(K$RJF_].?*

_O2G#^RO/_S[_T"(K?)@O8GB%/"%_C5:,FHMNH7_M.I(/H*?CCY]IBOO/27V PIK/Y.&V?DPC FY+O=B0BWJ?9F0:O)&_T/3N+6+ MN-><(2>,J8O\Z@G^UCEI=?;N-*

6UGH'S!)$_BOUK&KW\=^XLK=_?]17UBUI^PI MJ_X!N7%]*%'G 94WCTFN/A^QVQ_MWF>VT;O"&&^SO]?LJU^2O6]OD49XOT^[Z]V.6?^I>=9SRBA:H9SVVI?>>>[[; MI^LD6E.5/;*

(%[_E~Q_-]=L>< [IOG!>&0##&VIR;_-9OTFCYZV-$?!PG M9__(]'6T^S?>?1]-C':?RA|SK0Q_@=XJ,\K02[*$?%PKH8%@=T$ MX&W-

F%PS)U[R>$ZBYST,A9I7.],:!O_0^,RAIQ&B_S?:.]W452EC$#UX8 ,8$ MH=?PJS@(E\'&(RSD0/G$B7YOW^6UCEG^(]N_YR&-(Z339+=X117E9-]F=Y?9 MOTCTZ>

B#%=T9PW2^7$99F ;APU5$@F73#/=\M6.6_U2994&7[>,Y M992311I+VVU3O,M7G7A# _I)$,?\,> _#?;)6MGMOI)]HG\]+$RD4 &,3IQ_0V M:]O,&AQA8, |>0241[?

2;U[*TZI>X)O\#*+FI?@GJ]V5,NGRKRR4U4CS+:,B MG#3*:,_IdL'4J3'1'BW4>O/#,_:fJB#'4L0P^_M5Y>]/@I;_Y(\@IF5!IZ'Q21;#C?1KX-T'A&V8G_B.

M|O5FQ|S^OC*W@C:2Q-D$,_)(T$?: &^3W7.R3_$*4^WYU'6(^EV<4^"!R;0 M-:,"8?\VNGW$-_3H7*S.LY2^P!]4GI,12AV+X0^5Q2#'0F(PE(^&8CX<2B-$ M5P>"$<$ZYV,B-

*>C;"MGIYE5OBM7?LJJ/=R^9?*LA%^4\4.8D//AM\E2^H/@BN^X)#DB_V96X+P^]$Q\(9TYMX6 M0_%>(E3B'Q=X?CFT8MQ>?V4_]PQY54/&R7 0VN4!&(TWJ;&O#O-@%NMIWOM

MTQ#W&GHG__7F,K>P"F[!63)D#0@"[2O@<]4OM\L*X&.|S?]P3VO+=+<]WS&[M5>]<@]?U;2HMNE];YG8G AV37>..#Z^V*?9M_9S[9MM6P/[F.M5'GNMO7/_NV M5DP[.EN71-

=;'3-?=>RU.FW?)M>:]U:;?Y?U?]YCNJNMN-S_NV_R[<^C+6C+Kol M\]#I62-4!,,"Y^]9#'EYYZY]30|W3'C5=5>? /DV@Y-Q_=;O#/8'[%)58^@ M,R?PV_I"]^K;C-5Y&=%9(P$3G>?95

*M;10U3M(X6%/(+$/[6MLISQU\VD=(\@A/%[F410.SBF=MQA9ZSBU_MX&TIHWIFU?IZU8_TQB,A@N9)@MD*T>ZNXAW*]C4X-NFN\T#MB" I+%M'8W4L*

*MT:JOMLDQ7_@+W+P42!)G2[CN\@N\Y S1],IX0XRYMP5I,&*S|SF\.Y6.151U-MZC8OHK?#UGW<)S_L^CW?MGCLCMBQT&I\R/TC2\4#=9>0U-O:M+F-|*

MPF&&32^[H$Z[5"S]H[6DWVIPC)%AZ6X+NEN 5CW9TRYQ'C9SLOY2N,73' M(]TZ^ (0#4K.V?[<-UK,]X,'4)IK'P,46 M*H'DWI:DZ6RG/?;&_6BU+Z,?5R,7[9E1;

[N6LR6B^3&B]28,8,"^HJ]A+Z5 MI.V>DN%D.O9.#>9!0\(I>$##T/!2;'#$1G];1Q;7T3EI^2'E=V]C+TR\ MI96UN-NP'8O3"GI&.2^E2BC-

&7U:LJ;2L7>^]^Y(HE,I!0/K>+N93OU&\=G- ME>)SUWJJ"T)8O5.@SV\K;]@.5/!9K.0/2&;X)U',3\H+I(DZW+;FJ++=L<;J M,82&/:OD%*CBZ(*

R0&B&YD\"'43;UO:E.I4=KDIC.5&OW*MAA0Y._MBI5E%@4*1A1+4553.E>*BH.N:N3;_!0^'4C M;^529\EFPRI_DILD"!]&.2!:V.GX(*K1K=&.AV*]U!G-

*U16OJ$X0DT1:3U=Q ML(3__!;YF+0[' OY6VI79=<"/&Y>@/5_%S':/%&WS4TS,DL=WTDU\M;XG1CZ M'!H?$R+H^<]O7\&43@EIJ$#4C9WR4)9&B+!WV52-83>UL=.Q^]NAO;',)A8K

MY*83]ZHC1-TCWCZ"@4@I;J6 ^C.N$OX?7KA-H))Z25?9;4 R;IZ6WFUP"ED8 MH6.I5D.'-1@MA26E\]2+_DW+SNX35CB_9VA0>7CV?1)+U^%/+..,[U M E+).UI1YLO?0F7=;

*[ZW=0_'XY47MFY(<&METBCX"6I>XQ42_]2_CI?IF+R/ MH4K&(7'&**GY-ZZ3-=!8R$GQ[!O]^_)/X_6^F ME-V__3 $|&C%/WPPQ!GJ-W03C\(CJCLO(^F>?#;2L&9# M'*WQ^A[^S)

*<1\,*MX^4.+S,[O&14M*>/+=0&L(Y#(R3M?<>9W&T@?]A(W^@ M.\Y*2?$<^#@^"KTXCI[*)W$L7H7B!^)_Z#2?/KCT:=/1Y_,9GJZ>XM3J+/ M!#U1?

*U),)++#=PWYV%*1X714@]4X!?5O;/H\^O>"NHR+/1<$22OE(DF3,[T5(@5S5AMZBF.[F$>-4[P'>0[9=B4U(-MOD)'>:,"UE(>17*l5;O("*-

WT%3W).I78D[^M)3"S'&C[!M/%Q*7O+(/)3N MZ/-<320S.=\]]+U0 X4OTJXZVH<:73< VG-.HF>CFT S41?G]`Y0]OJW.ZST-M.I6S'YCGCK+N1M2IO/4M[7<3KY6&4VGZ-H7?

*2;$=B+]5=Z _Z+M)/V (Q[IH M:0>`^H\B=E.Q*MD?UZZS:K=1 M<-]Y=\&%*XU6NMWV54++#BQ.TL*Q:6]-:7+LU0;4@?9'T^-,F7]+VH#1!RW,O M4?S="<;"%6D@+Q/4KL%%9V[

*R=\]36K-TO"3UV&/ M_A/6%=F;A\EKE MG!T'G)Z>=H,E-Z^V?<;?G%\U" RV<5_L<&:F!\=LO.Y&G_Z6MP1Z]B^6O=B M:&2?NL%#>#_B(\N_)SSH0.4,&O451"S,,(

*C,_@*Yj$+F7$",]&/Q=R:K&:Q[MIS@-MC0,_.N-Q_1G3@C#_Q"0CQ [@O MOGKWN =D#.!5Z*\!ZL:?CCY]/OKTSTQ1==1LL'M+|%S8+,]5DH?MU_X\ME/[MX08Q>KXXF&-

@4E]X:GQ;@ METBF1:E]Gj%P>__%WS^0+6<%%F/]<\8YF% C"#TZ7T1\GDNPA33&TH]K&^6 MR[BM$\;>8,MH|G_WUS"]\[<"_.EKT'Z' Y=NB>>1_SHKEPB&M<;%(I&U)#@ MY?

N'Z.F#CP.N ?]/7'#Z'W_8|A\'<]^G$Y%<14GJD?\;,;$XBO]R$.QX>;=: M*7K5G+2;QRA.]1FPOF .D;S"YY:>(L>4IU^;MN|AA"?S@3?):HSL:.,OLE^N M,>SJD'U=EX+4,,/]WAU-

*.4[ZIGES#?6N)#T?-MRJ)NC[W2OHK9(%&]$TA2S MKT[$HFWK9M6^ULCVF3\"+SR K@?-II?Q;=&8U>Y='#\% #26MW1I5S/\VE7N@4%UQVU_5^>VN3$5*T/[*9[O,T?

*$=PRQ8LOX^P%Q\L@@7/A MKSAX>(3OIHDNO0F<(?2W\ M53'2_A>=&8YEM^?3L6+*;$GRWXII[P'KS\^:,D,=;|<__'CG$"\?MU^]4OF M+T'3P'=']SY?

*&%NP@W=+TPCCZWGAIM;QS>?MOI>AQ.V/#16>_VZ8VBI^D^Y(R M[?9[HD-%64+WJO.HB\"]/UTQ@X@'-9$3.E.K3UX^TS_LJ4F2UTT&-PV^7 M-|>+ON2&B0@1>?

*DO6N@L:37Q=J4RGAM'7A3 -<6=JP+5(GQ@QM?\GDX;9;,) MK=/[_7$WQ4(IQ&64XOZ;?__W#7]D(BZ@O*XX!MO)>ZC|KIH?-LQ5M_K)GAI M-

*IMV>7V\30#8.:4V?),N]M/C,>*Q;4SFED%:P6.EE7V?)\"#U>'#&;IF,0@O5N/R4?:/-06ANGXZLW6F-5SM)M3=4^,?A"K^)HB;&?0,4 N=%42[&5] M;K2F3U#?5T=4N,PIV\]D-^Q(6J2-

6FIY98QZ K8%C'5]5,05G^.A^?@!G1 MY;WJ7T30G(DHVB-Q=Q[A"Z;.8V\O8'MS:MW(=`<4:ISALK'>!7%6'5P0KDO MW=.BV]"+]ZRD O$9.B;<40(1&&$|=&Z1=H9T?

V6\E.S>W7>5"(;W;.W=Z M?]RL#3H5U0XY31D9]0^,-EB\A&R@VA#+=^UM\09:V.,]_Z.^BVV1_=,X]XR MJ@A<%3/_OCN_EZYVN]\DP9+M*9 ,!A5V!G1THIY$3I1^K[>WJG\?

*SR7BQ5!#_M]> -&!Q%DP^D#EGCB?I\-Y17H$),.K76IM\[XUV@GKR P"]$BE%J,9SB^U0# MV5\NLW7&DA^_Q'1KN@MCS:7$#0QZA#1=NXS0'B]16][X"CVV_7+2_/R(;K>0

*M<0"5P2=9DM)%%ZL$/P&"V^B#Z_&JZ3BJ0DR4UEL!*Z4VEMKQRG@?%O?+Z25? M-?!035],OY=-9X+4MSFKS?IH>-2XA:AFDI^;W/*';30OY6BV69'YW:(+0<=! MV<>/T/F^8=[O-

JLXTHWJQ@!>PY,CYIFD].S OC0$M#.&W@>"9="TV_5X<708 MDL,D5,_NIY2) .;/]NNEXYO&"$L-JU;8/7OUK-*B.,]XY MQCS\XL#OL(#JGYU"T%'$VGDTL1$DNSLQ?[R]2R"U

*M7]US$;23%9 C(XU'W9:WQS?)RTV*M0+#A1+.&SF1..9GL)o4SN?A=1++-NH_F2WD]BK"!9X"0 QP? MCEY0V5-ZPG5!LGVL%+!,1DV=[_ -

*BJD^RY='2&]TW/3G=B_O>F>X_LRA. MPRUZ FA9N_(WXA6:^?"OH,2\;^/@IG?&N\I5:X$KO4Z*/VA/-MWU!M$T76]5 MC*5(-ZC85S5.F-]RJ]XON'T:I:X

*_R/]FN5W38L7A./E%&*K[P2_1V99Y'S+6 MDL;%_&H3*;=8^RGO62_FO;OU!>$1)A(W@WQN>-HVO0)?%,;WMZ M>A+61V^38VP[HVL#&;YO&&"1KD'<4-

*4GN@/TNU'O0VE49SX$T^"C'!+<42-8 M]^S4]M/N?@VOTWOH,.N&:9O/EW#V2NN&;&E?.K3]Z<0%, HX_*=.J)^_*W_A MBFVMM55Z*1, ^N8UX<:OZ.QP*EU'Z-YR6&V_3[T?

*!;\U]9!SS(3A;UD4DX8/ MJK)I$=Z%V(M#U72Q^4/N__*8^_)ZK^&O, A\)FW8_HBJG:\;9FAEA*;K_]@CX%YHS9MO?67DBU7K M+>H

*"OOJ<@=4{C>.U8;A'@/;*_)&C]C|FZRUOFZ;0^J1*+A9BQS+V@FXGFP M @NQG#[0 GTZA)[IX&)-H[>6N&+STZ_0#"Z&8T..!HV)-<9A"73ZO8V1'EZ;N->/?':WGN% M&

*[1<1QCZYR8/Q\9F445U$*CB=P._*,$ZV*3D&H?,,'^)BC>)N[*3/-|;9- MK)]HLL14B:19^R4Y&MFPOA[SDQL1KCK>F :T6'=.[GYIG1V-=]O3D$RE.(1 M6?

*H8Q>#1M!SWR,>99B\7^NE1@2[*VV"-5[&WQK4EZ;P$/5 >U-PAW!@TLSFF MX8WAKU[,H@NWD:QYUCP/S3?C/]]-)(NE%"^!KQ]N95"T*5"?> ^6X]"!C>&K. MDC18PXXD(AFU-

*E_;D^,7W>1,;=>1WQI*Z1U/:/VV6.GW(V]DW270]T)HLM=5 M?R"QD6'YLM60ZWI@:I 5; M^Y?XF?UE1P"+TKN3%.T ZFP+G?%RB/*D3I"*V:'M;Q@"% ^IC,3>D-WKI M(V\Y"VX?

XRA[@ R.MNK3=YC3Q/-?C5) MNHDYX_ OK9B1_M:?3^:,5K9;_>GB.]=H$[2!QL_?$QDB60D5?HLAG:"/?Q%>@<]T$AAQSV-V%T7U"F85#\]2+<9"S-FQJU& 3MU#MNJH.'-

*KXO)T+:Y\ ?&4M/&L_5?P(00GKI?,2QM\%9 M&BR3UBX6'6I, "GBFT+Y(/]K|(5IY)NS?NS(!!3 ?"\A.>GO<:[AN/P-4& MP3I>L5;&KL7:P"2+GS"4I? " EE)OTO1^A[fT3%?

I;E9QI')F6NISZYZST0KF MBB[1M?)P0>ZY M[=54H6"_,@60. '7KSEA4F\"*&]4WO]\V.FDX%,Z2].G@(?^\?:NP1R%GF% M#]6X0#(+.I./2>Q":0,D3?'TGI.IZ

*.DW;,&U^G9[O#A>K+H,W$?-Z>77AI3H MGB^-)DQ=/4D[IGO;&V/OH!QDL9KKQ$$8X>.@EQKZ__QFM.-]*$W!<\EC3>"|_MKI80]/=A]])BS?\M;"CEY8+-.U%N[G9O>,>[4T%&

*[L!AD)'M6N/8|HBFI;IX M#IKW@&%=Y7I)YFMH&O=;8I_V'5|>,PQ@#U0+B*GXG'&/5YRD)lLT^I4;4Z=T MI"?

6%U8TBFKS>_5X;YIW!86FD1OYN]T2Z@B,FYQ76,F74=IMK+I2^9!K'(=) M9448%SPX59ORW/CLH6*@TI,V:IP&F*%MQR']JUZ@\5E+P:M:KTMK"*OAC?&6 MD__?&;^4

*]RV9GD'=&,E M9-,VJW?S\X;7;+'&AW=[>(@Q78&X6DUZ1I=F)[X"'I(T^V@;DT/I#A^KJ=(M*3G&(5X%G0F?I:<=&6;T! +7Q,UV?1^1&H.L^/<)G?N]SWKCOH?T]A%SCU8W

*M$FOSPX=W8>NLJU=P=-<1(>=1#"^9OKOMQ\2(?^B#8[3+4!/0GL)>4SM=XU1?LIX=YIF]>-XT(.0%ZZ2<6QJZ=4Z,>7KBO?&6KMFZ^^SCY3(SK=S&\>,2%=M0N%ATRWK(CQ.LC6BI

*7[$_+TTI5 M1K_R"Yl.=K *>$>5CIMDT_-N__L\Q3^_]T?'T09=G [M%$9&4EI*PY1?,BP MTH_I=$9/WA7=">;>$FC?T=T!(@++/[C*XE1YE+5)E(V!($-$

*M1UOZ5=>47!]0FW"2)2DU3U4A7%,@8U[&G]\?9K! >>1/@V03)1[Y0BW6#?3; 'P?.)^H7=O9 M7M I"Y.JM;] 2(!'KC)Z]"T;HI.[OV\;$I8=OZ+;90+702W5[3^C(${OO4LQ&

*MAHLB1$9;LA/V)^8*[QR..AI?!+YM0!G^I]'B&CO?25L)3,%6.IVQY]!4($F ME,/P(2K"YR@[](Z=]4F^8_EA]BD\ W<)^VIAH>-)W1)HY]!L-"L*G["4.$L=_F0D2]B]*] M;XR*

*(!*DLNRD@)N3\|L%B; 3C!2&=9,9/GRA"-MZG; [O#EBV7/JT7W5 MEYMM.RI-_+!NA8_=.71:<)_EWMY M/D>-"8J[43%]B6>SSM!:(SMHGCW0CU*

*[JD+9*5WB<%MMN;/O3,2P%'5*Y$S= M1F2UQ^8 *0\N M4L[?:7W:9,O33L/BWX*PO>MQX>]3)%LKX>H/#>>CU:Z3;CSN&%Q$S0XVZGS M=C|\\3($F'XGA>E1+"7:R&

*>C.9#G,P2X47^"5W\<"H!@A3/AQ:04:WM:[YC)!)42*G7>=$Z^2=;&<[HHYD9 MUY"($!172K:^8!H^[*!6U44LASFI"">T_JH<62C:D[_-R^%?VV:;?D>;[DN M?#$%R3(-

C7%1[N_/^(:"ECA7"6OP'(5+#_&:5Y!=!O5=5)5UZ]\DVI7/K2- MH<;,>Z1,J_C65W%*MI8LMK|S>7?')7ZA=W],GO"W*$P?&Q'][R4W+BX=3]?O M!&RI?]8X[D&"H;4U)&_EUU:92]"\A?

*=ZSYUB?QF0O3FLV?,EX\<1]F_9@U% M^4ER""&O/0B%V7N39GXY:WFG5TW7XY4.0+-SA2=0YA9Z';_]7C1?8TSM-8\;M/,5@4FN]

*<<=+=IVEY_@^SKOX6_1TWH#&=O*7]I,SA:MQFXE?>6O$&A=@=C*;= MBHT.,,&J#'G;%_Y0+8FP=TE&"XF)>6J#FV&>H&_)N.]W_@2"!/7,]H0?;7EW M&HYO5N&RT PYGSY=-

*VPLXYE8)RZR/M?X),>2:(!I?&:\5" ^VK9% 7-C)7[3 MHU/+[=@MJ6,"W4J.MZ+I-2NTBO$_,APNVWJY!GG3\#J!4XWN"DQW;=[3VN>F MF-FU>Q[7!,#X]VU9VV7/&:IS

*_"57%#*QC>0Z[_% Y_/D-M3*M@13=F9 MC&F_GDDL-H#Z8E&RB$0/V!H+K9LQW8)@K3U"CK.$VE<5X+ ^FIT:T4S?BXZ&G M-KYO6I65Q\8VK#O,8N-&[4VV7GOQ%ES_D?

*A=\"%CTPWG9]VUH:IHI;]SB! M/(/:\RU;WANWBT%3 7CI]L V"M;LZ3R*5YA#5#09>H/IFD8#6_>I*:EY:E2X

*M2\RV;UY2)"F#*LBXU=TX8K2N^@UVXO[$#/]#5&]/KM[PA)@6<=YM.?VF0ZY M7818YCWYV9)-1'L%Y6":HTTP6.PUR1RB-'B'O)$]"!U>HEYGYT\C6="&1A_] M*BE3-'E^IA:(

*K/)&AH/^4A"\&!+K%&QYD"DYHEJHR0KPDZ>=Z+CUO+S A M2QM9*G%'9*+XI/AJK?//MZ9_)7ES?+&T=ND_[=Q@_;>Q3YWBS;\)PI+!L0U& MJ#X[W@1 2/<-!3I5W

M&F7WZ2HCU8! TP?3{^4ZX8 0>ED3^J_PX2_X/#H[N:'@KSTXAYE<;/YK1[M9R(?CB&"N':J;(TN.TN0KID MJ,DD#&_>>W:@&B1?2#"&B^ 2P7]]>F]'>ZKM5>$8:8!\U*A5/M&

MO22)E@'3W#,=']70IHO]\Q$3'1$G\@Y8&<O9^#$]AI45#('@=@1HX;$C0MI M%[(9DO8'6D4QHKP@C1EM)=K23!YPG_I-?2:YHG<@C_S?8 /XUD-.24X5";(S M9

DC2AD!Z<.0B(PJ2WTU0f5=G+K%:D&^8MA\T(5.C X,'IO?M.'9QI?7J/<-M%?;Z="+6 @PUJU>$-A3ZA0V&8#3$AK-KW^Y_J.ZMCR:C)\;'>)0?HW']..KB

*MQV@L69FJW3%TR,19&"75W#19&+ ^\X16D[S8&=&5[Z^E56C!$\V* &158#($V M^1C:AS5#WAH<%@4#KOM!8+PQ 50+G/AU0 R,\314 ^%K$CA> M **A7!\SI#

*()4)ZG9EO07LA^*3)(1;41YU\.\0< R.$A.B;]4#H\.61/0 M#5R.PWTA1ZQ>*5]J.7EAO&MS1O;)X16QE5CK)<]09A%PPY>B'I]9!.SF0A/00_4 ^P M?Y@"2TN0^:K11VH M3?)

*{0Y2S@*6Y@ZSZKZGC4I#%3AZ)@)K)X|P\+ C),?_ M\G*+G^06O_7@F3V)Q5!NZ.63)R&+81Q<5RK=IHM5%W*/ID]\\O(Z82*[JMR=_M>LC4'W^[T4XA5C7QB'F9$/R)CRO3NA)'!{)E9

Z;52>M3IW:H;-V>Y>QV5 M#C_0@5=<.,4'/SRWYKP*I*X!(;E M:N!%42.HUH/&.E{]"_7GF$GG3Y?!->8PN%^\((1&L<."O0)2|\SQ4];"B M\BUQ!E1E0U+IR>*RY+3I#?CGH\L+2 T7XL

*(Z!V,81W.QEPR6W-'-M'!60_'I.+7J9OW;M?A;$;K;#W(I]%DCU:4;#[!"1J_H>(8$[>]51^8"'<6V M.9)5;F!09A%PPY="7KO4?-4)>=;15C:(0AVSV)SXA>?%4J1.#SFS&IQ"8E@% M3 1?

+4^VYT,Z.LXMZZ,V7B=%%W@W!,8,=FY;_#-A>[E%>R:?V?9?<.SXD9(M21R4_Z8G)3H^3T-7?!SIEE'H#]Q A>)G:M5@W@I{U85E# Z#N6OK@8D4S%,] M"M'WH-'B73-

*#",5U>*9URQ3$.L_7G.LJ?/W[+RD.D^">X"-X#,=L^25'G|\K$9(X M9VOE)??L9?IC@?TDW<3U@L)?"H]FR=&#YVV]_4?"@\O/,+D3R8EWG_Z_'_+ M"&/XZ-/[?/(K$RJF_].?*

_O2G#^RO/_S[_T"(K?)@O8GB%/"%_C5:,FHMNH7_M.I(/H*?CCY]IBOO/27V PIK/Y.&V?DPC FY+O=B0BWJ?9F0:O)&_T/3N+6+ MN-><(2>,J8O\Z@G^UCEI=?;N-*

6UGH'S!)$_BOUK&KW\=^XLK=_?]17UBUI^PI MJ_X!N7%]*%'G 94WCTFN/A^QVQ_MWF>VT;O"&&^SO]?LJU^2O6]OD49XOT^[Z]V.6?^I>=9SRBA:H9SVVI?>>>[[; MI^LD6E.5/;*

(%[_E~Q_-]=L>< [IOG!>&0##&VIR;_-9OTFCYZV-$?!PG M9__(]'6T^S?>?1]-C':?RA|SK0Q_@=XJ,\K02[*$?%PKH8%@=T$ MX&W-

F%PS)U[R>$ZBYST,A9I7.],:!O_0^,RAIQ&B_S?:.]W452EC$#UX8 ,8$ MH=?PJS@(E\'&(RSD0/G$B7YOW^6UCEG^(]N_YR&-(Z339+=X117E9-]F=Y?9 MOTCTZ>

B#%=T9PW2^7$99F ;APU5$@F73#/=\M6.6_U2994&7[>,Y M992311I+VVU3O,M7G7A# _I)$,?\,> _#?;)6MGMOI)]HG\]+$RD4 &,3IQ_0V M:]O,&AQA8, |>0241[?

2;U[*TZI>X)O\#*+FI?@GJ]V5,NGRKRR4U4CS+:,B MG#3*:,_IdL'4J3'1'BW4>O/#,_:fJB#'4L0P^_M5Y>]/@I;_Y(\@IF5!IZ'Q21;#C?1KX-T'A&V8G_B.

M|O5FQ|S^OC*W@C:2Q-D$,_)(T$?: &^3W7.R3_$*4^WYU'6(^EV<4^"!R;0 M-:,"8?\VNGW$-_3H7*S.LY2^P!]4GI,12AV+X0^5Q2#'0F(PE(^&8CX<2B-$ M5P>"$<$ZYV,B-

*>C;"MGIYE5OBM7?LJJ/=R^9?*LA%^4\4.8D//AM\E2^H/@BN^X)#DB_V96X+P^]$Q\(9TYMX6 M0_%>(E3B'Q=X?CFT8MQ>?V4_]PQY54/&R7 0VN4!&(TWJ;&O#O-@%NMIWOM

MTQ#W&GHG__7F,K>P"F[!63)D#0@"[2O@<]4OM\L*X&.|S?]P3VO+=+<]WS&[M5>]<@]?U;2HMNE];YG8G AV37>..#Z^V*?9M_9S[9MM6P/[F.M5'GNMO7/_NV M5DP[.EN71-

=;'3-?=>RU.FW?)M>:]U:;?Y?U?]YCNJNMN-S_NV_R[<^C+6C+Kol M\]#I62-4!,,"Y^]9#'EYYZY]30|W3'C5=5>? /DV@Y-Q_=;O#/8'[%)58^@ M,R?PV_I"]^K;C-5Y&=%9(P$3G>?95

*M;10U3M(X6%/(+$/[6MLISQU\VD=(\@A/%[F410.SBF=MQA9ZSBU_MX&TIHWIFU?IZU8_TQB,A@N9)@MD*T>ZNXAW*]C4X-NFN\T#MB" I+%M'8W4L

*MT:JOMLDQ7_@+W+P42!)G2[CN\@N\Y S1],IX0XRYMP5I,&*S|SF\.Y6.151U-MZC8OHK?#UGW<)S_L^CW?MGCLCMBQT&I\R/TC2\4#=9>0U-O:M+F-|

*MPF&&32^[H$Z[5"S]H[6DWVIPC)%AZ6X+NEN 5CW9TRYQ'C9SLOY2N,73' M(]TZ^ (0#4K.V?[<-UK,]X,'4)IK'P,46 M*H'DWI:DZ6RG/?;&_6BU+Z,?5R,7[9E1;

[N6LR6B^3&B]28,8,"^HJ]A+Z5 MI.V>DN%D.O9.#>9!0\(I>$##T/!2;'#$1G];1Q;7T3EI^2'E=V]C+TR\ MI96UN-NP'8O3"GI&.2^E2BC-

&7U:LJ;2L7>^]^Y(HE,I!0/K>+N93OU&\=G- ME>)SUWJJ"T)8O5.@SV\K;]@.5/!9K.0/2&;X)U',3\H+I(DZW+;FJ++=L<;J M,82&/:OD%*CBZ(

*R0&B&YD\"'43;UO:E.I4=KDIC.5&OW*MAA0Y._MBI5E%@4*1A1+4553.E>*BH.N:N3;_!0^'4C M;^529\EFPRI_DILD"!]&.2!:V.GX(*K1K=&.AV*]U!G-

*U16OJ$X0DT1:3U=Q ML(3__!;YF+0[' OY6VI79=<"/&Y>@/5_%S':/%&WS4TS,DL=WTDU\M;XG1CZ M'!H?$R+H^<]O7\&43@EIJ$#4C9WR4)9&B+!WV52-83>UL=.Q^]NAO;',)A8K

MY*83]ZHC1-TCWCZ"@4@I;J6 ^C.N$OX?7KA-H))Z25?9;4 R;IZ6WFUP"ED8 MH6.I5D.'-1@MA26E\]2+_DW+SNX35CB_9VA0>7CV?1)+U^%/+..,[U M E+).UI1YLO?0F7=;

*[ZW=0_'XY47MFY(<&METBCX"6I>XQ42_]2_CI?IF+R/ MH4K&(7'&**GY-ZZ3-=!8R$GQ[!O]^_)/X_6^F ME-V__3 $|&C%/WPPQ!GJ-W03C\(CJCLO(^F>?#;2L&9# M'*WQ^A[^S)

*<1\,*MX^4.+S,[O&14M*>/+=0&L(Y#(R3M?<>9W&T@?]A(W^@ M.\Y*2?$<^#@^"KTXCI[*)W$L7H7B!^)_Z#2?/KCT:=/1Y_,9GJZ>XM3J+/ M!#U1?

*U),)++#=PWYV%*1X714@]4X!?5O;/H\^O>"NHR+/1<$22OE(DF3,[T5(@5S5AMZBF.[F$>-4[P'>0[9=B4U(-MOD)'>:,"UE(>17*l5;O("*-

WT%3W).I78D[^M)3"S'&C[!M/%Q*7O+(/)3N MZ/-<320S.=\]]+U0 X4OTJXZVH<:73< VG-.HF>CFT S41?G]`Y0]OJW.ZST-M.I6S'YCGCK+N1M2IO/4M[7<3KY6&4VGZ-H7?

*2;$=B+]5=Z _Z+M)/V (Q[IH M:0>`^H\B=E.Q*MD?UZZS:K=1 M<-]Y=\&%*XU6NMWV54++#BQ.TL*Q:6]-:7+LU0;4@?9'T^-,F7]+VH#1!RW,O M4?S="<;"%6D@+Q/4KL%%9V[

*R=\]36K-TO"3UV&/ M_A/6%=F;A\EKE MG!T'G)Z>=H,E-Z^V?<;?G%\U" RV<5_L<&:F!\=LO.Y&G_Z6MP1Z]B^6O=B M:&2?NL%#>#_B(\N_)SSH0.4,&O451"S,,(

*C,_@*Yj$+F7$",]&/Q=R:K&:Q[MIS@-MC0,_.N-Q_1G3@C#_Q"0CQ [@O MOGKWN =D#.!5Z*\!ZL:?CCY]/OKTSTQ1==1LL'M+|%S8+,]5DH?MU_X\ME/[MX08Q>KXXF&-

@4E]X:GQ;@ METBF1:E]Gj%P>__%WS^0+6<%%F/]<\8YF% C"#TZ7T1\GDNPA33&TH]K&^6 MR[BM$\;>8,MH|G_WUS"]\[<"_.EKT'Z' Y=NB>>1_SHKEPB&M<;%(I&U)#@ MY?

N'Z.F#CP.N ?]/7'#Z'W_8|A\'<]^G$Y%<14GJD?\;,;$XBO]R$.QX>;=: M*7K5G+2;QRA.]1FPOF .D;S"YY:>(L>4IU^;MN|AA"?S@3?):HSL:.,OLE^N M,>SJD'U=EX+4,,/]WAU-

*.4[ZIGES#?6N)#T?-MRJ)NC[W2OHK9(%&]$TA2S MKT[$HFWK9M6^ULCVF3\"+SR K@?-II?Q;=&8U>Y='#\% #26MW1I5S/\VE7N@4%UQVU_5^>VN3$5*T/[*9[O,T?

*$=PRQ8LOX^P%Q\L@@7/A MKSAX>(3OIHDNO0F<(?2W\ M53'2_A>=&8YEM^?3L6+*;$GRWXII[P'KS\^:,D,=;|<__'CG$"\?MU^]4OF M+T'3P'=']SY?

*&%NP@W=+TPCCZWGAIM;QS>?MOI>AQ.V/#16>_VZ8VBI^D^Y(R M[?9[HD-%64+WJO.HB\"]/UTQ@X@'-9$3.E.K3UX^TS_LJ4F2UTT&-PV^7 M-|>+ON2&B0@1>?

*DO6N@L:37Q=J4RGAM'7A3 -<6=JP+5(GQ@QM?\GDX;9;,) MK=/[_7$WQ4(IQ&64XOZ;?__W#7]D(BZ@O*XX!MO)>ZC|KIH?-LQ5M_K)GAI M-

*IMV>7V\30#8.:4V?),N]M/C,>*Q;4SFED%:P6.EE7V?)\"#U>'#&;IF,0@O5N/R4?:/-06ANGXZLW6F-5SM)M3=4^,?A"K^)HB;&?0,4 N=%42[&5] M;K2F3U#?5T=4N,PIV\]D-^Q(6J2-

6FIY98QZ K8%C'5]5,05G^.A^?@!G1 MY;WJ7T30G(DHVB-Q=Q[A"Z;.8V\O8'MS:MW(=`<4:ISALK'>!7%6'5P0KDO MW=.BV]"+]ZRD O$9.B;<40(1&&$|=&Z1=H9T?

V6\E.S>W7>5"(;W;.W=Z M?]RL#3H5U0XY31D9]0^,-EB\A&R@VA#+=^UM\09:V.,]_Z.^BVV1_=,X]XR MJ@A<%3/_OCN_EZYVN]\DP9+M*9 ,!A5V!G1THIY$3I1^K[>WJG\?

*SR7BQ5!#_M]> -&!Q%DP^D#EGCB?I\-Y17H$),.K76IM\[XUV@GKR P"]$BE%J,9SB^U0# MV5\NLW7&DA^_Q'1KN@MCS:7$#0QZA#1=NXS0'B]16][X"CVV_7+2_/R(;K>0

*M<0"5P2=9DM)%%ZL$/P&"V^B#Z_&JZ3BJ0DR4UEL!*Z4VEMKQRG@?%O?+Z25? M-?!035],OY=-9X+4MSFKS?IH>-2XA:AFDI^;W/*';30OY6BV69'YW:(+0<=! MV<>/T/F^8=[O-

JLXTHWJQ@!>PY,CYIFD].S OC0$M#.&W@>"9="TV_5X<708 MDL,D5,_NIY2) .;/]NNEXYO&"$L-JU;8/7OUK-*B.,]XY MQCS\XL#OL(#JGYU"T%'$VGDTL1$DNSLQ?[R]2R"U

*M7]US$;23%9 C(XU'W9:WQS?)RTV*M0+#A1+.&SF1..9GL)o4SN?A=1++-NH_F2WD]BK"!9X"0 QP? MCEY0V5-ZPG5!LGVL%+!,1DV=[_ -

*BJD^RY='2&]TW/3G=B_O>F>X_LRA. MPRUZ FA9N_(WXA6:^?"OH,2\;^/@IG?&N\I5:X$KO4Z*/VA/-MWU!M$T76]5 MC*5(-ZC85S5.F-]RJ]XON'T:I:X

*_R/]FN5W38L7A./E%&*K[P2_1V99Y'S+6 MDL;%_&H3*;=8^RGO62_FO;OU!>$1)A(W@WQN>-HVO0)?%,;WMZ M>A+61V^38VP[HVL#&;YO&&"1KD'<4-

*4GN@/TNU'O0VE49SX$T^"C'!+<42-8 M]^S4]M/N?@VOTWOH,.N&:9O/EW#V2NN&;&E?.K3]Z<0%, HX_*=.J)^_*W_A MBFVMM55Z*1, ^N8UX<:OZ.QP*EU'Z-YR6&V_3[T?

*!;\U]9!SS(3A;UD4DX8/ MJK)I$=Z%V(M#U72Q^4/N__*8^_)ZK^&O, A\)FW8_HBJG:\;9FAEA*;K_]@CX%YHS9MO?67DBU7K M+>H

*"OOJ<@=4{C>.U8;A'@/;*_)&C]C|FZRUOFZ;0^J1*+A9BQS+V@FXGFP M @NQG#[0 GTZA)[IX&)-H[>6N&+STZ_0#"Z&8T..!HV)-<9A"73ZO8V1'EZ;N->/?':WGN% M&

*[1<1QCZYR8/Q\9F445U$*CB=P._*,$ZV*3D&H?,,'^)BC>)N[*3/-|;9- MK)]HLL14B:19^R4Y&MFPOA[SDQL1KCK>F :T6'=.[GYIG1V-=]O3D$RE.(1 M6?

*H8Q>#1M!SWR,>99B\7^NE1@2[*VV"-5[&WQK4EZ;P$/5 >U-PAW!@TLSFF MX8WAKU[,H@NWD:QYUCP/S3?C/]]-)(NE%"^!KQ]N95"T*5"?> ^6X]"!C>&K. MDC18PXXD(AFU-

*E_;D^,7W>1,;=>1WQI*Z1U/:/VV6.GW(V]DW270]T)HLM=5 M?R"QD6'YLM60ZWI@:I 5; M^Y?XF?UE1P"+TKN3%.T ZFP+G?%RB/*D3I"*V:'M;Q

*7K+C"Q+IB@S?%#@C:OVEJ2(1\|A6VL$*N0-RD=58=?'VR:S3_A'3;^(CJIAUMA_8,__1^;% M,#D,UB!)+5Y03,M2DR4N"&N]1R7Q0Q&*C"Q/U:W,5:)C/E2,EU&X#$B@:C_:M>N)HL%3PP"O0BIJ#*FE,=.V(^J3,'F#<>I+J33N1NF;4Q5\),1 N)@$7+4Q8SR*++[Z$(^QO2> MCU4#0)RC%6P:=.?@:]$TJ-G'$#F$Y#+&M@"%TST9&&]@_$]A7 M>%-GV2'0?F;&A)13O/OQ# 9N7>=LH9POJ;N\AR2$;(NLJ%"%U0M'I4-D'P*<.M)(Q+9 7AD7;R\TAD=;WV4N0+\;B/(/!#E9J4A%8RRB7 L\3)(=!UP0[7$0;1Z]>.TM<98&M2X]0L;ZF_G#/+;..]N2IH.lGB }G'KW]@3WT@[64.DMBDFX)04!'Q5?&QO2M!`ME3Os=--=`+Xl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{?,!@X3U!T!)G4 Q2E, HJ$9"4J+K6DNK#M"K^DR#D+LRSB$YH8[Q;M@ M&>SL==BP|,*S4!8FRQ&0"K6\TWU|8I0?J0W-C\1CCW@.\15M"7Z3>G&ZJ^C'-M^"$(PX.67@^]J9,;28C-H*RUE?>Z:#XG>$ BU7EF7H- 9*>E:%L^2*;&?C.# MVTY#C2D0FC++#\,2KY2Y%W%&9I)@0+[EBR507X5+^8.1>(XDAGJL%04M(LY,_M__"C9=^R6>&D;UD*QL2$02*)T*\17'I,2N!-68>>-|*_.@LY/)@4P65:@W+."GQ!_A%) *'S M*#[/H&6,K&@$Q\. 7+9->|"<,,>H(M8PY*MPS;?0A!=TX,),>8#@H6Q*$=+X=EZI@ZW%43\|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`)(/>YGEP%[ZPX>FF:NT",K@+; O3@I$>,EG/1N6 E*S6\38ZQASA[PYZ M73:VE!R^.8G:RC1"]U@B'-Z-UE_3F0I(C?0"Y9!W%\52>NXK5O#&&V=ID^:1;K1-">N+%\38('P87=>B#LR*9&2^5P5HG M7IGG1&V7'$@0>5!4P[FPZX@?1TFD1C_;?]XT*IZ+C*E":A&;0T] 4(_=A4Q) R\G8@WD!I*$M(@A6.2]7JO/B? MKT$XK$7?6:G7O/@'`L+@_3P(@':,,,$MZ..KGU]&\'IUM%^2*7*20DO9Q>RU3G# MUA6?W22^4(/IXO?BVG?&ER62#++6Q^4C,2*0;AQ;Q"_I>,,:6W$O'58-3(?69,L7;*'|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|L_] MAI(_"NBQR@@A+IZEL6U<[R$97'WU\I=27*)8!X&20[!)9KVP0H,LZ:TMH3L,%!4>GEC"7EPY>U4&XBB%3Z%4;2Z_Y:.M9MA4#.&GS") M6 N&LQ>0 P!WR4KRO#PL'P")$0Y0/-)/.CM[MX|/$Z=^OX:0P@##H#M2RA)&52]U!9@HIR35]:===:G\)@D,<>X2>$'_`80!(-1'R8K8QX=X7 5I=D04 MB/@/DM9C6P:.ML5YN_"D<$0*/R7(==~TO]Q2!*5(Z0&;[P@K\;>8,TWV4OV9=496V+05WH[-Y M-"9:H8FI%9$WTTW']?38G$^DS4W9W\_7&&Z,)8@7%IF%*MG,_V]38GR^7^@/H,_M(1C(B,M"WF0@6830;()&,'Z&F_@0Z+/1-#++TV0#5,X6!!8D8TAPAG+64)$W MZ#?&6F$(]I#B[WM1(;&B;;2)7+=LG9IBRP:C%07;M3N/B;?\E15_?PU6^&89 M8,J8&4=C3AH12ALE@OCA""0^`$T0H(DD43>6M4F!],VT22]W]2,B5C7({"Z7-MC @4@P.1A)2%8-1E,IHG7H]FR_1$XY#&$S6[`BEXNAY20\#>&9[K"%9ED0M&Q0829]-U:?F=RD MEL7G(L."=QF">B'G[R(2Y9QI&PBUX5(V@I>*P@19N0/2312E$]155-ZD%(UM),>TS)GU?!D[$7B>F5VZ7.;91X8VS),4N?4I.#IHEY>GR;'^B=<8,BX_O8J MBM=PC"SN2?# E_A;P#LO@W6]!&Z-4'>QHJR1_\VN%9(<(4"TCC >5,(.D% MXFQU8O.B.UJEW$U1@K*FG5J:U915^1677Q'2)(,&#N)DC2YQ@2*46XCV;SS M.MIZ)-WF3%^$[O OLBWVY/GT*V\98GAZQZ'CHY@S `$C7_4/Y3R@*%]G=#OQM.!OTGL3YL!Q@=]PE>5Q(;!QD1@8W49(=5<58^M?X46Q/ R*];R%>.!8.04S MP=3ZL:HA;3#>>O$#3ND5^""VUL,"Y(ZMQ3X=S3<>=!*9?!%(*0Q8$OO&>3?B6+NOPH]CG'7Y=1NBN81^R2B5==(0$:14! M1(PX_;;!S"0B5++#BK$V@%'YD)>ZPC).^(02-Y,QJ?H,4'-7/D-W/%*0#-5* M=HR^H1M'N52&!2SGR/680NLW\M"FVTS2,4Y3=8U^U!$(!7N3UC_^)RB;4G@M8K58:?O?T/Z5)Q&A0T2BR%"W#U@T2/MO#5>_\-)!B$Q,26NY+V8.Q[S>Q/@1 MHHQ/F)>D7.(4O'HO0\H["F2=%"_9%(34R5 JUX$*G@@<&&ER!`ME7+/V")/ !F:/U6$G96.-VTUYE/YH75TY=ZB.L\\^QV.*!.Q04?U5SP$_Q4#)\68Q;] !PBQ0]E+-H):IR*=N= MLLN P$R9/+5ZJ2O=*!B$`+TYF53H,.6O0.E/3.F>IG2XL*QS?]V[93*>)@DMXR6\V@+3AK%^2;$F&VD3:X:NQJF1U2ZT#!F;9\OBO#I*_:W<,L7(\!8&9BM8 M#*UWBX&?*SUD7H\^JIX(:=>HIXIYG2K0+Z]RG93VS>I2(4(_7G&IN&^{4X1RMN/+B1""O0#6#_:A)!0, MRDPVBSCS8O Q)7+|'V_K"0QUQNM4'98^3T@;!%41CISO>3^1^@M&'O]A^]A= M&-#OA&74+2G#0;IE90U&+*;;;+WVXBVKG*#ZSV21#A\'?LI;2Z/KFSOID9:C MZD;_RI8#_OF%"FI35(B.IZ."(!-<<;SRO)G%_0W'RU__ZXLW/_7N=?E9>9Z?OH% M0!W;=GB8GY&O*0'N&%/49$O31NIQS<1"B!$S33"UT$.7+Z<3+_1\3R0WPR.AMM\;H=[_+FQO^[G=V4P4,ZX<45(.^>&B>ZT:IQDF.@&')2L>]M*F7>@;21SE=I!%&0-EV1J5I MDM!^!^""'G'CQ'Q+],;.'K"NP'>U/:+DE4$ M##8+R[`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`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`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|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`0GC/%]3OSB-L>/)!;-C_4!5P J7A%)=&>$Y=PWGY, M:GF3_ O1Y/Z%"V@!F^M+/%/F0^RFJL0T!#T 56;1BGKLPQ"6%.18 MK! CR"IR;PY)CD;0M.J\N*N0YPCBW[\]>S^(KR&F!W$2YGK_BZ,IH$G< !=MA)LL!>2:\&@5B2,%F+$OA?Q245R] NG9_ 'EE'1 M_I'!3?E)9"(-G*<*&)4G20&G&9.$M AA?5[TW$V5XFNF@VU,/U4IOI8QD@U) M(:9#0FD MD4Y;EG%"$LX/++,\2:+X!VL-B2Q(25H%!/GPZY. CG,"?-LMFIH+X"ZN?D#TDT4I4*7-N+\$.7 XHLH39"5"E^POYY%'-$=ID;;2T7(<>LE&-#UR.)!R^:?S6:*,|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|'FS*@X MI$T2(]237ZF;E1)R7[VX@#,:M6Q=%CR B>&" N*0';/Y/DG)=:U9JLN.)M2 M>N@$'CF-LOMT?A]EZ9>(V[\G= ?`<0BUXD&X"/"?L#?HJ]%&0CX,A3P8"SW M8. 0A=%FK&8^"!%T -[2$0];?E(5_503G8V#3D]BT[$0#(9^H5891BN/)-AV M*J](NU3-BJF)$"T#*!4&^45.[SD>W.,F3_!ML,6^-,;E M%C.?RZN&0/.2O#)K&&X8Y5'%K4"H$[%U"7!Y"B]/67.W'85>CA%FO^M]A M+[Z,TK,A5(23?ML]^52W8#N=1A#]K+&0ON4!;HMJA# ,)WGXUF&CJS>Z2A3 M=Z8S%V\6QHI:.8\$C =^B"3JG74P&XR2JMQ'1A9?%:WK9.(T/^.8NZ$"?YO M5(5AHO7A@0*U;+,A6_43RU*@YZ:!(W"Z*Q6C?#QM>Y)O%4.8R'_%7F"B5>F M'-*D%S&TWI>)U3!RO:A?D1S?2=J(>_V4+)[AZP>)N[/#1CR]-JPY(=%2Y-_G M6P)/@6-%&L;I5_.[$P1]7IPP%YVQ\-[KJNZ4+%?!ELK8FD1GT+=]B?1U6;03]G MJL%:L?#$\L7\8,7"MQ3)N15'% S=$,M W?%9,-%$O)"'<&BSTFY:442ISFX MVE4,9OKF.5AZ9*AS7:=U$,R3*M^6G>827%5N"E#A)%N]++%9WH9?XQ00UF%2E M0#Y^>QK5LCX2N!!)VBQ0FIH),9&:G"4=R^X>9VZJ<(R51?1A-:/2HW6T+P@#^(4 MWZ=YM1^U K-UQJZ,K&/X';U=\A/S*_VO8[R*8KP+5.:?N*Y"EO\ILV%RH@BH MVC^?W.IK\QBOX"Q"D#'BIDC2O@(V)DAC07$>$"E=3%#]XP/EW"Q M.3AYX . DFE]\Y[3=X='T/!3"S,OWJ);(@^?_S\\6'"%]TWO6JQ$ALXGAD$P MCIM4)9LRUX$7UE5O<63"5,B^HN-9Q@AXCFX?HRRAMQ!9\"88ARJNQE<`"_H MBX^434BRV$_RXD8F.I"N!19YRB;XHR=;-3-?VIS^6.\E*-A#P<> *F_;IURZK M^-2A:X<]E*-A#P<> *F_;IURZK M^-2A:X<]E*-A#P<> *F_;IURZK M^-2A:X<]

^5NG&CTE%-T$Y+>0TI%'23F=5G+,R%)I73+HJ95P-GMF0Y4QF.($] MJBUL<$<&_>CX\8NLC*V>+MS8W]_BUS<^'\O,6R+#.FSF3%UW(QSB72 MI(SNE4X.RY3.VQLMRNO3B)3YT\+.!V-TS#8X]A"[".(DKRF97|W6-OV]$(S8) M!@:^(_2*6<=:R0T)_BQ?'D*^Y>[_4GIVWZ-DOEZX'|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{!0X1$\/MH2@G$<+L-3$5RVE4%]),._29+4N-KAGT6 M_R]RQ \[_,N(I&2%D(EXU'}K*AP+=E0R)!(F&24.VG8>(IJ_.5_;R[AEK< M/#OAH!)\)3GP<.RH6.4ZW7TIF'9W7/*QXV29;09)$"VXS[W#OE$;M@;M,K@-MH)OJZI:G.ZV4H_M/("KK__*Z_=.9@\HO8216L))=G[B1/]:A-[DA!-D-H>2/FS)S[4L-(>(-15 M6+W2!OXLOAK8=]\9B9Y/9P_A4.^RA35:A#<8P]#6-P7HY5SB2PI1*(JGKI-M\)%3)430KB9T28V-T4($2]=>=PV@?"X=!0.^G/;1;GMB-2^EA7<'HZ8.@+%3 MMOOCQ=>Q.1IN=6;FG*!S;)BLLEO'5*S,@=KX&1GP#'=]H+.J9*?:U^QE0CO2U-MGWI?3O@XWK>.."C;K4KQO(-=BOEK&'+.4V-605SK#C@ M\;'$;WQJR@,=>9P'F_&X#%+,=PA^!!4](;.PJU^0E\/8%Y#.G.83!\A9KN.M++!YR49RZ%.L<=$X#EYWS/">X=0G<!%^0XP/GSY"T'.4HA5=\@O P>Z6:L?& MXWN(C#A>?D%? S!3!&SZ8.8HB?S&@NF&]@("+(MJFRB"VP4IH66.)R&85,VS(FII(=V M6D2.F^#63%XDGX/_!_73T]/"G_7-.L/AIL@5 R.) WH4K-'C4MD5B\ZL2TUS&G# ;(N-P MTAR@[MN%>G]\PLGI^1"AK9=NYX& MB$]#4=8\D>Q$(TRJA0_&J'?0,[]^D=5Y4"AKP,*.C#27TG6FG[ZS MX7<25D505I@>;"TM"4V114Z DEL<>K0XBIZ8\LWRHXM4(JSK2M#&JGNQ",.L4X.08U,+D-F&8\D M@.81C!2A(9$*.A;(X-HVB;(Y.,>Z$G@T3IQ1YYQP.LA8SAVL2.3AF_M0K*)T MFZS8#[UX&]A83]56DY^LL. IR0G_^[.!AH<-PRB8-CW$/'#Z4.,PE'+*??SV. MPV@83L7M5,/NK[COOQI,)T2[, +;/#A-TTYIZDQ!8 ,[V<@.'?I8 M6/*-0.OZH9X^=_&*31PY@BD?4IQB*H# M565!U@;&&L^#8/L8?X M++J}^EB4C9G)@HXZSGW1*TL5A+,.-9X#@CUPn[>OV)4+//:KF"HS17&RFCC2 M@CB'(RPTK^K4M*C3F:.$BN3XM8W>2:G#:#.%8;G2@3Q DV+D%9F MF%?+ XT!8V%&/M(Z2H>OJO.33@&G[E#A_.)^+/=)8?,%:'#?>C49@E_,4 KZ-M(IHV3<(NB6\]H(<$+_:R;88/W1V*-'1F2U RPU&5J)[':3\8_AMQ;_W&!;(&K^_M_H0V< _\0.$FO\,SK'GDLCG84Q/M5N@NW/QXQ6Y)WH13ZD'W'P1\.+:,^B'"*O1.2*]!!-RYOSOK[_Y^O4;?OAPM.,O MSK>O9U^_DO]?11$!M1A?XG|) ^3_!5F_ON_D^@??!T0@3@_?R-__? G/6'WF M_9GI'MJ%>9F^YE,=@9"I/^{]6%4$59!+>&EOZF9UKJ@(SET?W%9'P^!3XD9)-M0Q;/T<8+@N/B4E1NZ_@:!4RR\Y[\)NP,G^2V\I"X2,W&E0=/(@/B&OD!6YVER M'R9_0\F#ZW6+3&&A3S&';-\QP'/(;9\8T75I6C&,5AZ2 @4G#*0TV%X%2-<(K2*KZ-PR\.Q M;@"(P/4?TA??6_.:!,<<_0E/KP!@8ET. ^1@[F&IQ]7\9Y%N_&/N'0;XP#0D=M MP$\H>O.6* (;84]&VSU|"+TB>$D3(@*A3P(#K 8B8N0WX5R'PM%A3B'S8X5]V MLD\[/_WJ+T\7PP5HC"L27RZ->6-IC.)G'4T<)>|=$TLL+))E({$,FA5^ >CB M$7(OPE4GJPN,X\! #HOD*\7^F.0V!6T/=;8&CS5P8..2SBJ=D0=]RF"\@%3 M#<0=<|^:=WAZL/#Z)<|/ASF$'3\?VWXVV+H5!AH\4YNLQWFP">DJ7(?1%LZ# MS.'^3)P3,821"#_GGOEN$$_LPXXPM!BM(7R\T$3X_#BJQ/@^%NU?+JB=(_4A M*"$5!"4VR4,8AJM@:4A A>+PFF64-%I&@PIG\1XN7L,TQN_B*Q)5B8+S;7SG MQI@'KI[VB/<$'DSG_. I)H5_(I?-Q$*\&X);=!N"[Y)IR^+?TG(IS7(P@@M+Y M *)(N"B0*(IIM%47Y&AD>@TI5*+7IRJI42ST.%GP%I6-5_^)1 5$0)?$2P%-#] M.HSX&Y(&V)E+6$P;*.U-? 2ZT*F/NX9Y'MW@E7;K[^?HA0DL$?X- D&YUG7*@ M8OIZB1AU#CZD\\>)&\.MQB@D+QIF%Z*=1#\\?O?XF$YGY1+@V1TGU=EC6J\,T)TD$ AF'B#1P31"PXQ*$A8DC)#4"7;]VW#1^@^O8=!#W00RED,&&R']?OROE_MA$ZPHT"1N\ M|X &5D3R2/F$VZJDGCK414#*>#8=!=6:[6("V$D H'+U'QEB#\FG'RYS?>(4. MJGTH4,,.>Q44UR(AQT3|85GF0:UZYAX\NO9&>?)UC-?)3V5V(=T3 X/-\(D MWLKST1!{$Z .KSYH;",$+T!.O(BD/?23ZB@#DX9HT0$BZP M99BA68+T$L]$3EI"H5OT$*_XE<<00+CL3U[2'! D?_1 M$.-):9$LS?) 'V11KW^B[5H0]QJA<(R!F"LHC(N[8V2!ZVXP.H_JR:S^Y -C M>T<'8K3TRBFNQ,SX3J.UAW>"9K X2M2"V6KE'9;](RY*@<C55&$O.Q&@FD8D+=,_M_V08#'\5,1CR$|)/Q%'$%H@FW^\B27G-;_V7/ZAP=_ECRAQ]=-LQ=]L/1R:.M2\|QK2B-Q+M'.6WJ#7'!H],,$6+D/B&OD!6YVER M'R9_0\F#ZW6+3&&A3S&';-\QP'/(;9\8T75I6C&,5AZ2 @4G#*0TV%X%2-<(K2*KZ-PR\.Q M;@"(P/4?TA??6_.:!,<<_0E/KP!@8ET. ^1@[F&IQ]7\9Y%N_&/N'0;XP#0D=M MP$\H>O.6* (;84]&VSU|"+TB>$D3(@*A3P(#K 8B8N0WX5R'PM%A3B'S8X5]V MLD\[/_WJ+T\7PP5HC"L27RZ->6-IC.)G'4T<)>|=$TLL+))E({$,FA5^ >CB M$7(OPE4GJPN,X\! #HOD*\7^F.0V!6T/=;8&CS5P8..2SBJ=D0=]RF"\@%3 M#<0=<|^:=WAZL/#Z)<|/ASF$'3\?VWXVV+H5!AH\4YNLQWFP">DJ7(?1%LZ# MS.'^3)P3,821"#_GGOEN$$_LPXXPM!BM(7R\T$3X_#BJQ/@^%NU?+JB=(

4RA{Q-MN56Z65]+&.W@&,I<0)=>O MCU_^!M?8=5",#1#;X'[%NKZ]\/>;WK1"X+,.7S M!GQ*KO^0XCMU*?.TM^YL7@&A;@ KY1[#UXUAQ8¥LANQB&;@+!<0--F$1 M#,*

{6UABN;L;R *AZA;-H\YS5.?! M+9ZL2W<_7V,E/\BVQ0_5N/0ARI -#T$4QL# M;S2&+7/49\Y[K:FSEX&-W].W(7XN/KR&@2)&KOR[%7.JBS$5UF/l:ZO2O?S> M5WK65(#_^O96S-.,OT-64"G/>Q/#J MI4NZY1A6,*Z IMRBUHK0;POPQ05<102>#V,%9NL&;7C . -0 WCI@'U!9 M5-J.8)YIV2Q1-A;AU4>"@E6U$G&KCE8LYSS,KZ,.W0"JHH\OF%\7_'[#CV%>*

M>9+9!H62Q.1APZL29WDT547A\+&L6#VB*K8^/ &S4UD2]K]*B8ZPS9R9$9S MP)&M*#" A9BWCF*R@*&<=4G+/.I8#]++GORD[=5Y:.;3;@2"@=8U(/7_"-!

fCD6K<&0[TT5 !HH!1 M%)H8;R>X50'>D6:&,%S'ZINOXWA6K.#4X*HFRC'KHVS*ISL +X/"3 D*A^\ M1..%O+(LJ>B@\W\$NJR8(%$?\O"R8FXF3=*[KH/Y38A7/SQAPX D9,0R3Z2N MG7D&9,E1=VX" ,]HKGC_U72Q@]RZS_1+%R\C;E1-'6W>V9%=QS,IX$0*=P1*0 M+E"2)XHN0H@]PTKZFX?_ /JO;&99A<==!F WS'"@%2^C.?[2U3 M2Y M[-H.5K#4U*

9UCSZ2Q3ORW]!=:&"20\OH!:XYEA2#(C4F3E?28]#&YH\R"-7 M;2%$5+ 9\.@0#)/U[M7A9/2;K:2Z[51OW,,_B\6PL 4.QVI '?^9NIPEZC7N;9>TIW6'-VJMO=//+-D!M0)2??<^

*E,4VAPQ,K/-[5QHP6W,64! M>Y1XD$,_W.PK!HI1/FB)D^=IZ_K<>1!CG316X-45FEBQ!1[1CFU*K(N@%^D2 M+[>QA'#R=M"]*RQX%3REVZT;[<&O!#O,]

*5ZP(>29+0+H9XT32$K/TH5C!_L)K&+B5!V>T] M=Z2?3ULAYG*4.0TQ%[RN8/"#,"WA3[F?DKWAM<:7?K(@A= $SP6)7KOPW3AN MX.8H-C9_J):@[,'237(N=$ZT0D.

[9D/F15('E#;H9A=[-\$.'RRW$%SXLS[\M7]/<"G:*QA@5BC?Y40DCWG8,.QB';PXNE B]0N+=&\ICN-7%N?,_<*)Q+]P/ MJ4!Z&MO\D?2(O.U+&L4T+$KI<94WLV*>2_==-[-XL:453-

B0/O48^C>LS\[MKUK,."1;,FWXV0=!JO\%OKYU5:64$\I(^@YJ!)7H9A8D,)O6KGD/1!FK4 ML\SD__?;G;=_,"A%_+#3L 9A-,9ARL,QRD=%O4Y6'PHC)Y?)MZG*IV$VY

*M9+Y_2J9BJ.6R^7FJLBG9A;D_GV]\I";I+E8?C=ML53,X%PNOY^J7-26=RZ: M/TQ5-%)+/Y?*Z12Z> MB;O"<@\F%\YD->*BOY2)XP^358&KOEHNDJFKOEH?,1?

*29!5@N2>:BV6R*G#5 M^\U%,ED56.EUYY*9K/*K=O-ST4Q<]ZT)*^!2FK@>K(I=X.(910]F^5[EE*K! MT[ZRFD478;""/-75N>N3 O:O"""7Q<^"F*R\1"GB,GO[U=N,7(D*64$?C4)"?

MQ/PO>4!:QR:PE50DA>G:JA(ZTX%(/$2*\WZ&F-- MP-!H-C6:#L:8T$=0E!>6O+$-,P#564 Y?PU!?,S%-.^X^7SHNQMCL#5+-C+Q MP.^3:I&:$O6RE@9ESZZ2>9KA-

-^&7<4@5L]I9;-#5W)8G-T2C:\0\L;)RG/I# M2M?#Y#%,0F*J/6D5[3U(HV3<)O#2.VKM0?+=WG#W@;9DI?1 MJO!1.F;P6 UW*$KV *1'X WP<;lC #/*\U73Q1@CNC))0:D3>W<$?

K]W:BK M,<84(-ZUF[R^G[D#6%Y16]C.J1.XOJ.E_0(#KS]7,,R.7=:(I*?0R_0W1E M#A2O$6D72^:DX7%0T\G< RL,-@!>]-C?M;M?T=CDDDJW*2DSH\-L*V.!55=9

*MJU',+3Q=)>CR>I.V-?E"W,'#E4'+<8S2@B5+ 6*$M]#F4)3]! MV-!3G{JU^+4 M1-7(-5FHI*<1\R2$UTY<4O_B1.34W$59V)DE#^ DA"5W>U;%,LTMU_@^U#ID

*MF:B^G,2H6M^""L_OU*35^B)L[*>A"3;RJ[LSYZ(D Z[$!LOTTF(L?ZRU(X >80#D]\WDY91N\NR643%U 37^MYL$+\OA QJB\373F!-HD.FL>K[MS_V.F),)2.F"%"4P>U<)D!?-)RZK=!5

7/3,UD;6W"2HB=B8AN):'?MOXH$G(ML,$-(\TFI!T&AQDC4:..,R28NLW050B)F:FGP:G_9]17A-0L#M;H4F<6*3 M$%O]1:".'/IN0@]\ J2G_N]Z%4Z(GZLV":.?9J=|V!&\

(T;VAZ"6T:V5UlUOH-M OX&67FV;4>(MW:S>]W&@2ITLP$QO M(!3/T#PB!]((P#B@B"IX^UAITM88YBD<[2Y!7OPG_EN&9.!8I=K&+F)H[3 M5HRP#E8QH:X@VK27#4

*H+;=.DYXVL-5PT^AZV,.&=KNH6MM#?OU&:5MH]XB" M#IM>5).(0.]'B-6]/8E0Q#Z%QT^4283R]"DX&23\;,O#*Y5>(QUC$DZD'B2H M//).W<[?

*D^1*YUV_)LF3E9JT_L64@,6SO\3S-0M;#(-C11BGX6X92S7F'U5K M@S@X;RA(T35>ZK(4@JN/I9_"2@67%OY_*S7:RWSG^GE3MS>)8(3P MZ040"Y=8]'Y(N6E=#2/-E\C3?

=""9O@G>4$Q1)VI*A^7GIXG2MZ[;8S\OR)(1D2K1O>]!M6P'*^KCQ7 M=3/2;@<$:9Z3t-2STG84.RP8-4_58H#Z <_"23A;:E^.I3A_W1MM$@)KL>HT MLIV$+Z7,5&H^_W

*M(ORU=+.S)\.25E.RLT*G[OVH1,]6*_PHB-G_X$+<+-W MH(Y4H:4)0@F^P#PBSK)@]59(%_U-D/R W^^N__^\G5@-1D5PL7%8*HJD7(VH MEH@_CT22"IE?(*O29-Q[]$&.?

*O4VTG4:B7QF7L87^:?(5+'$*O5[:,&02OWU_M68"914->UF3D=^7_3=TH09&_+|+Y2EZ5Y99CFUT4P,,R$TRYZ:@;"APB61(C M.;$'YUNR:\@H5S:7$*R:&/LQ=:[<^%37Y:O

MG#\I^D+Q.ID5L8\33:OY8;1"T?_YU;__Z3=??^7I\&, MN3_^=7W75EIC D) M=S1@#WY<4'JW5 O*$@E]6# Q(BUM%T7)DLCD\,NO

*MK()622_(&F%9H\I>YREB% BK?M1V# O&#%ZG Z 1>G. ^ N\P>]G P28H,/ % M!;ZQBJR1VNG3^R.NML'.#E@O**TE0\G-?)/PY>]LA1PWM=@-A0U>M,W!D@0] M@0%0"7"^6YV4-555,@&Y;5EJ^ORS"IP^0/P6F4'VU(M_FNI/F7 65*H26A.T8^VYU?9YW6@_/=/V4GZL3:OZ_0'6'\9E-N5_V;9-)*Y3](/BL\ M/23/IRIPW-^3- K!9_\ GET?*

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fVKWFU+NSU4@U4_/R;BNV4] A9;*_F\H^#L!N5 T+T4]1JPIEN_<9HJ" MU5QCSMS3*0KQU+AY*&\?_D_]^;L/e0ZWUI9GN8?HE2H<*B YTTI?ZNZ0N>(:/ M1T@4DUV6'B$Y^J,7R\'9R9#%/#KQ/H8\,Z3$7YT@ X\@QE/E6A2ULR&+RT'? M9VF2.J$';X7 5C5[&?#2#A#9.J4KB_0M7W#EH/SM#$44(KMHH,1H-.-H*11) MC0%KS+$:>B^6+T5-HS^)BW?JTG"26N[=RK$)UIR+Q.%IV:FNXK6A\$)O![_MNXOB7/ L9?9-JI+$_.;BU3L^6P@\N;NFQ-[*4(->"C]8OT(-M,NJI"'17E_GM%LD< (0Y7/T[%HLD 4IAY%.%L!H9G6Y4A0KIO"?4\H81JZ&]O M\-\>PAF$2;[!IKB]3#=*PV52PYXHC;2H&Z;J$'0+U)B]O>H=I#1_RM6E;E+$ M5.)WF*;/E#CPIKF<;\D8^AL4PDZW-[3;Z)\]DSAT6TFF#GO\('U"[Q>J)W8'

MWN+,B2^-2X_37GI 4PTO/U^UC'I[GZ]007Y9AZ351-M$OX($^,0FFMELH?N- MS(/<;K.5^[O@'HK|$5?8G/7S)@UGRPZMU>Y=@RR9PF-/R/Y5,@?WS2&&\;\

M3AXN9>]9TG;9G_,0,E/B%OF&&3>Q!$/ MV8ICZW>#21R$=""}T=0450'Z__AH<4.K|/O^>00);\17U6((CWU=NZ29@JZ M4KF &C>L(OOPLY.D-\YE?

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

FZ%HA%;MQSM61J1_GNW3EVF5=%"W=`],fKI%[8"9I)=H\UI%GB-;G%7 MQ@MJ;14(DZ;4S"C_S.$.P3NBKBL 7(4Y56HT_I8CTRVH2B)6 04,N&&L+7K*J*"#)5E->V43'/U%E&D;Y\${=U;F)&^K1*VEF^!1J;_5,C6 MK2:R:,/QY-OLRXW:]_,C-VENRW^Y8Q]N^2 Z1'7^@[QX_Q'=LE27;*CP(\00\@/49>%$3O

ME]Z5;X9&S_)=^URR2*N[_7X&*,6U$I_!X0_,>A=Z)3B[%U1$[*^Z4SL0_3K'.ME^TA+;3XZ7F^.>_,+T"[!VW\96K\QXU:4Q.=K%,!A LB_/#FI=&]>@2\O&=:" MM=":;CF!18.B-

I=+J0SD@:6YQ<, M\'QD@?7Y90!<$KX;,\/W0.C-S3.TOFMAZ5J!=C6#2M2?.KN.0HM;DT (LVCF=_MJ EH%0Q>PJ/4:!VEYTCF%MX7O76S*B@H9;07"N[_"]26FBR\.+O^%TZUYF?1

M$2?S$XKYSLNV<1;?NTK^7W1MYL7O8JED6'0-TN7L(EFYN>B2?,O>O^X9769(MU,+WL$-$EUEP.3E[2%8&SQ=!M5@_P+(VR3.<=(:VMRQ/LC]4!64,<

.QNK@(_^WM1",AH/4,"$K%>1E!RX5FN>KM,GB/EK@Q M[20/LX/?^?SB 3;O^(O,;X%,!\5?2'VUWH]-Y6AGWS M\#*5Q%VR])>M(FF[_-]TB*

[I%V\3"^.W6+[\XZ]IK;ODFE2@NT2:M,#/Y$_R7 MWP8!^[\U M.9,!G@=]K_VA7GGN?XU%>SZG!9G7[I9]APIBV# MZ3"[K.YE)C@4B+GCO7>K0XZLK^B+SMY/D?

@D9=04'L*"IR==69.!)#).<+' M{@9\@" ZHT-;3&LH?^)@3VW+ ^@1"$#L!*A+BG:"P@*X<>O%Y%L;7UQ"N4^4C MW61$F4_:*I3G'(\Z!V"KL]"IM/A(/> ^KV

U%SWXKEQGG4ID*O+G8YTYD\O!; MO KH9GO6I-^)55C(A$\IV)SLV'WB+C=,KB^2]'$%>)P^^O$X0%*&36!%EEQIJ MDJR,.CFTZ?

=)D@'O)HO]\#TG0GD0)OYQ7ZIZ0>SZ25T0L:MP$Q_(/E_68@G[M+$U2)_3@*M5D_;9^Q[Z00G)L?>&/P@R^5/ U:T]<.TW:ISA*I,>M,KYD!H^@ M0/8;0?Q4<,L&YH)3

+9\HKN27(^]D(%-5?A);>`)9'}0*AP!PN,$GR -"@K M@E<-4:G$E80B%E:2-CH'TYX22!VOHM4(7

MJ.:VS*@N5HZBDJTQS,?^^6DSB0JQN0DMV"=*L.!,R,#9V=C3 ;,#*HP1JDY M,!G@8%|M|5*UGI$1.5UKW24+WNBNV%)7\C7-LJ>^^E ML&[:TA""-=Q+(@A)*

*fVRU[KZ:8LGQSZ*7ELZM VA]ND_,9[T;RFOCA^^;/2QAX M\^?<#&O<;-0MYYSB%6XYY^03OBWGW.;H)@BZD>6%N>5$ MRQ%1:#%7)'X:#?*

A6+WBK%VSPE52M(UBK554W\K8G2[-_RS/AF;1!BP]W9GE MN-N>S\QV^"U/6&81_-9G)'N"__/;@!?#D,-"#\P&4T_\';$6)N)N-%/ZA! MX0.IXP>)-B>&;HD@_O!=0#DB ?

XX_*_)9YZ]HYT'25!HCMV'0V7[\8X-X@~M9TE\K@XROZ4-.GBUHA- F?DPK?E<3)9A2V;U.&3?&<.=I_E+.4W2+.=+$@U MYI7*+'P'PR'>D(+.^4M7%VUIEB#4 FX@A?GOOP*

*8+HC+:@F-90HK7!GMJ6]0F$ M('8"E*W3.\$G/TEC!SW!/ OCZVNM^4/1ZTRVA4A]T1:FHE7PVCB;#-E#RQ'DHNOQZZ3 &.8L++"]P3>A2IR.;D.6%O<+_<,)+PF\)|Z+CH8?9"C9*

*M1KNO=@V&$X=^^%[-!\]V4"'|[F2"?H$TPZL+W)-3%%X'3L*K.^ (7C *4T3AL&2KG,RB(B??+S40YEM-O(B+(/%NNR%3] MD/&S\Y8#*4[4Q0^KY1 IO)UT*QG7U)^" =HP#.MZA-*

*05K> MCY0P 5O;3K^FASV+/*S[IRA!$SH 2S(M=*TJ4.K,K"PI]%RM^M"M5"_Z=A'=JEU_"!N< \UN:3RUCVSG41XOV%0?A?0%?85\5*?!H3/[@4K'$-*

*ET7K]%/OFH'L;028I? >AVZ2Z MS:4;OF[R$D-LL__%3X_?69)&)Q"772Y?HM#MW%,3ESM(A!^<^>0(D)4\[E= MDF37<6;3WA@RYXQWU8*ET[GO'M)>!|W)SP *&D|H&?*

O#:P)PCZ9L:?H2^*6QI$&P;L#|=WVKUDRA25AW?5.H"Y^BBQ.DE_U;X+_C M\9X 7NY+!.S@XK49*@"_<2V[7K MC$?7@+

*<>1;9@<70*55OPD&Z1<$[_9O[fV%N'[VTAS1:'-2E/:]&O@ZZN//%(LDF0Z26ZLD?:P3(X4(L3HHN^]:R)Y+/4;:9UPE1S M('7NM!X.E\%I\],LB:^WMN4Q#7S$);%ZZ*11--*

*,=C4Q\1VM;PH!XE=-A> B-ORW\'?=G7b.8FXC^(3,*36LTV%/:LEKF$^+TFRT,R+/>-8I0K@NEN>1+(F#$Z%&_L[Z M=%*T4FP59WT5%>=H-*

*@CZ(%N4,_H*D3LF1*1%/UEV1_*\[P*#0KM*EF6O/8 M3]1'R>"C5D_W"ARBN&!N(4^+@D$AGQ_%GA\Z\06'[:*]0=Q_%_OO)?UAYE>-M+UP24XIAG5Y@R:8C03S1I/5^@#_#Y:GH*

M"LIY@#7] XG!0&$QFW:4DQP08'"MJ*&+G/FVDU2DKV$,G_"5.OP$9?$6 M'V&!8_M,_&+)!C9#W"@*AG_Y0B(8CI)P!A,$C,GF.4/I7R8CUE@VHQ_M%?1?G4<(FP$I8G5T-5_4K\-=K'-*

&:KD59A-.N,LUT["MVNE4BK$+&IHFC-%'MXU)&R-JB"]4!8|)&ZLH0*"GEC=-%,Y,4H33?"IZE'C"M:,,JV:,]$UPGR\]D]^'X 7)KN(MB=(T:.^1:|_Y?

*E#U;OI%EB114!KM!SM V@DM9<\Z[#Z]Y+Q>7O$0[%S)C,2#Y-)(@,%9[-MB\#HQ(^T730@P|/^0Z/E(XC|"*+GQL@/]0;D_Q?^.Q?DH$1W%7WGN!%N#T<_M +44*O.)1F3E&*

<^G_@O]MD'"&@<>>>'3NCR M4!H7]K#5$;7)08ME4$S)]T:>.H#Q9 FB \,&E!,_8')@6RX&@82X'(FV(/ MKM.($/* RXE.@^*@BGE)!D2-2J3&X.1GIZ16>Q&M;L.^?)+N(F)8AZZA!49(*

*M8ZA\8#V!]=IUY!W.1=L?F+G[_FKG\]$P&$K5O|N[XH"/GIN(/MZ?F1OK%_1%+;CT! BH&2+R.DM1Z6+A>H*X@6L6:OSJ-#PE*'7%_.LQ0?MM M_@|WV9.JDFB$4\T!ZG&_F>*

*]1(E|VND?E/IS@,7L+?'C*G;7@\ M@7-Q=2 W"|Z(69ZL.@>LGR%C0Q\(R*'B(1E^+I+IBLH351"1, R M $8?B"+^NF1#B"8-4 6*Q4G7YDB*UH-AKV[G|%8E&4/"Z)+?'8LR"\L&Q9F*

MJIT:&0NRV,I&A|(FI<;$U^2WXD#T?8IX:|]"98+'R'R$NHM' M)U@],CX=H(T M@+Z=X/-]{6|25U^MV57G-VL1TK3,. F-&6MXO%:($%U-8T,!A_/BI &D G*

*M/1[RJ&4Z8%^DMWWOJQA6G,6[Z\U,>D8#PSB'HT<3.'&,=TEV'O&ZJHOOSY% MWT/<#DIC(ZX^R\P^>/A9G>5')1'LX?V#0VRG^%QSV:B'SSC/,+)7,L*L3%B(M^^A&!>3U;*

<7$@_5U8@[/6#XY7[6R?TUAB9W:,G$E?2:S1(@R,2N$NF4X"!&

*M71E38ECEA$&1+:.#$]=#;&W'S*0,.X8>Q1#%HNUK[V!M'V;@H4I*=]I$*)K39(@$M2*.GYY)A=]AAU79I/,4[WU%2ZY(DW M*7G&C?6VTXD:4E/U4;/*

*B5,%,:TU1QM0]3N3%,6D6!T[:NBPBYBZ8%X8,08% MSK&M>T#*0/U@U$]*4'&IEL)+Q_G2& M1'*<41[^ .^F%YTA#!Q(/H)@2S,5?7)/OSY+S_ A 5F__0$5B@=:.)&@GO;'' M*.V$L3Q*

P8Y2[P3|=R,O I5906DIP3!/4S8SA< />SD$?NB[3Q"'"U<,=YH7X MFY'|]N(DP86M%F0V,7)1#Y N_HX,+V?(4MQ$OQ.\1O&YX#PZ"GZ>ID8NLF'P MWA|>SW<-LTL9YT7RNF"U-

*^4.\C!9XF$TO?=GXB#&OC"BZG_+5?VEG_E]_EH^ M@03$'\"|B^+2D7*7--4FU\[93YT@+_]7RY3[\+.3I#?.!>L<7(#^EN=*]GQ9 MU7ZF"'ZXA3K}?(OA6'[+00_V1701?*

3O2/PM9|!T#'[5>HBS&2S,!S03/[=$C?$U/SO.N$^])_LU(4O**I9]B_TT!2$Y M+)?5PL@EP0<,BMA.;K]KIZ+OA48--31R@13'!?OP-G'CZ-N ?U/=5!XZ] 3

*MTUL6)SE'4KDS%"JSFNUCM[*V:-J43[[(=.!5&OF.3E'YZ+8XC.B('UA#!K1 MTYAC/KSOE;6Y3;AZ?S:2+.W"$-XSS#1BUU8\/.W5+|_]RN-B7&<3_0_**UD^*

MEBBH"2XLR#QD3^^4DH7'MN.DU;W9HX5AY1Z<[_XI.SUA]4#QKH6H0(N?BQ{O3GS+K4;-F=S$Y^^;K1O M@G+]J0.<,;'U:,VG&|"Q/_5*7EP$GB9(0_W 86Q9%@IR=_52$YP'[

*|H?\' M'NAQ^0G\'7CIYVl\.K=W_|.*9P!,/2#E9XEQ1+M!:XW?|\,^6'Z#&E_+O*AI+7?'YW4,.',/+4< 2!OQP!20|=G9M)0QA#%X7< M2W,_?*

*2'WTN$N1IX/E!8E<=S|_4_0W<<%2:K'D/ZJ,3L[.(%COL[#C3Z[!_ ML^L#V*_S%K#;&+EU#3FNC)\J LHPOU|%5Q'DOH'V]FQMGBSN),H"^.+.U#M.>$'>S:7K*QI)S<:%WK).X8Q M6*

V_7F2GX)[P& S8YT">K%DM?BU2RKJ7>Z=1HT_8_:Q.+?IM+PAI^)\N^\H M_7@47P2> XXAC(%JF(@4:47OD03R'K"/.O!DKDV2A_P.N4_)&=58VHF=IBBJ4?)O M1K(Y]7Y-TENV<^]

('7.$'G2N$)P[/T[2ZTL:_>Z'X 8,_N'@)+EY=LAN@F>_MMF:>D0QVR=2?C5S,4"X-"S)H##[0@PGLR+1:N)NQQ+FA8GF,_=IMI_]W M8S:5@T%-TY*G*#V*L):!EC.*

*(M[F1UU1A_K:>Q6Z>;QEGSRN3-'B%:KZ=5(?\ MJXEV_#0\)D/HG)GNV#ECDQI2JW9?8'8K(^\!*24_GRYN3$\C(6AE6V](U!3W*

*M(NQL2/)0G#Z,,8|%MX@:,^TABD^H5[VRGK!.:R57;)=RU0$9-2F*_2 M9"=L M&5+?/&=M;87=I==.'%\@O6TE.Y$[S)NQ/*X/-'LWAO\AGA0(?N/9|> M-*

*"_#_-.N7M((5F@;.P>;&;/)@]=Z'[Y^<4TL6?V*6K]BC4=R\(%'E@0Z&5,:\|!-_*^AFGA]J9N3B<*Z@*S|ZM|V.KZ//J4?(M*C30TL@E(FX42G$XKK8K_)-_L^?Z=C-VN-V,'5299TQ/4WCY,?*

$KA{5PXHQ M>A\C3SHYB*)TL>X51^9H;.^0RAVL/HLJEHO4*FWV,7#9O5D+|2RXR63W&;>MQOD_,+L59) 5)!8TV282GI8GFD4[0>,_H*?UW>]Y'CFL/'.%9)4$-XRS)

*[RQVR2FQNY6'Q"D3@&&XB1_L?NF7%83XRRP_=FV_:AH/X|8R%PN M470-^[_WAR^=-C9QA\H4CTY>(E,D(X\/ MGW*KO>1Q1:+E#F\DF$6EAYXG8?_O1DZ_L,85$19$T9_9Q!*

*f"4'+;+Tf\#M(B MIJ+'BW=_-9 3KPRGA>*MJ7,K3ETO'E>LCRG,'4?RB%,GKVCC#T;>MZ+4'\IP M0LD'R6IASVWKE-S<9>]9DK8+,I;U2)FU.GDZ&KG1Z E#*

*(JX3$*GK47XT<80SM@".P,)=N_P1,.|]3D9,V8#>ZAS M+T'#0/U@uL|>\$ OZ]T@318IV2[9D9VWEY%+/TE0V%(CFI]3OZN1(.1F5:2K M*K9<#.+(.B(. A<;A"?:0]OL$6+*

(&PZ+$|SX\>H55YELIU LYM>LTXU=!^BLO?-E(]QC.F M:'|.^^*\K]EJD:G_^NLL+]_2?"^*ZZKX/^EL7I15G%?[M\SA)TOQ]+WH[_IS_5[IMDEZ;+\FG6U4QWWNQ_3K-

*]V=IOC55Z=6TVMN!7T:% MYRV=_AOO,"K*1)5;\|>XST|S3&O|GD8?,-]^FP2S)\LL7>9 MSI2.3M1-=%[XMQ<.'']JJC!M97Z7&W%67J5[Y7X>'P(?M\|YV:.5FI+S^.Q MVIN7.NNFC.?*

fWL-WX>&W/@\|=1,FU71ODE9,8[A2Y?B0__S;SIL7^S|!C|_]M^T_?S'_88)HHH|\>E>UW&9PLKMZ5F<95OC>[WQT56E'M_>T'_M/|\)YPX MX49%EOA3L_/*

*J3G^/$U':17Q|K,3]+6G9@O/5^4SGYN+CY?GH]'/P|.S7P_.M/OP,HN')X78_2?TD??$D'?PX/CDZ/HIV7^R\C8X_G+T__=?O<71Q>7KX/|'9 MQ_/#7P\NCJ.S|P@i8+-*37.8JW_ZZ_PU-*

E6EN]2V5]IG) MX,ES5?|5C(R&GN8)?+;W9OO-FQ^^|;U(IR2WVI=I9.%>?[>)%-PQE5Q635F MA(X4-V:YK5=+TVT',$Z53^-\K")=CZ=NC/_YM\^@P'_BGCWFU+$Q_"6

M(A]4|QF"ZH*7JUS&KYTE,=H#-0HY(*O8+UJR)R+5FEUN5X"HL878#ZYDON MIUU3^/XMVA7N]VM\%O$0JO'M<%RH7?-$>VH>+OZ|!H&=+/"@#^PSASOFZ'M-*

!,C3VI4L%USOB;9CVH0J=]JU>[+|VX06-N@+[,ZH05/-P?=DV",X?>&11H MJ>!F8\5_@B^2\I:.,0D1#$#U5/I":(1C*=.S;NK$C0OO-X\'@Z@9DG+JL^P MIEIG"U^;NGN,;J>*

*(48/+P4*5V.JC5%.1[F$<9M M\(\#/NE*=167=(04. PIHFJEAV*\WL==',$'Z-#[_YGW-=5,; -?H-)Q84Q MD[OS"L0& ,@#V\TI[%+)?C^VENH1;%7>$?'5%@+&$%ZI"$-@=E!^<* M-*

:lL0SC\9FE5P5$VB_$(I-4XWR"]06;@R2G1^]68\@X6%'$;_8-?I*=_M3N ZDWV\C?Y8IQSFH"^\+$F\)V_%R6L+$/Z19AA^_2R>1*^4$VS<_2_+>B1CFEI*8%@*?*

*MQBUFG*MS^&O.0M@(/#Y^V!_$3ZP;K]= -88'<5)02(PREJ0!R9GP[\9ARM*B MC,)P_GA:8!$%)G=F5$ZQ@1D%25Q3!ER'>463'-V\$|_X.+'=9P5>O"2OL 1? M$(^7/,R:#KC8PAQ?*

*DG61L*7U5--)A XH'"*X7)V5':,;2)?0&:4$P.5FAY1XC MW*M<\+I.X,#ZK2Y3G:2<%B+LU32=R7,(V\]Y4ARX31IAHK0CN&GN?5/460)V M6ZU5 /&]3HL,W>REZ%A$;<%[DD>M$8ZF*

WP5/"#+!#PY@M6.TYR"!5>E4]P/ M\;620G$5BC$!"/R\,:Q:"[UQM+01,+61;#@$X09A.'1?E.0BPTQ! M\YI>RA4*#0:)LP!RH8%\KY&(&\8G&) +\CTB-!*

UP59O//B!G$+971M8 ,"_M1]&2VY6QM&)M8CQ3A4S9P.K3#&=|>(RZXQ IB.%CR-8#=K*N;Q5"\I-05Z M+K)/T]@(S UIDS%A!',S5FDV53;.WI^7.RHD^-*

*[3>N.'7ZY@;.GWWIOA\>/)+ M='1P>7SQZ%NP/TG7/T5S'+?U=0@NDAP(_*V>4W"&PLQ;FK+H&|L_V&!@4GO8 M/M:5&&!1B#HC?Q@A?^RC5#0Z"S7J1/-VCHQ<&C@Q8(NY(*

*|&_Y],/8R'G&&"_M$+0KM*E2U /'4H0H"|K&;(*ZV4$@>Q?CTAFBGP|B"BG37H%A9.*5!V+8L-', MFP=&K< #)-2K+"N89|YX_3 4HLL?'OA2U72%@334%!=2F5G%6C\|X>P8%!*F*

*M6*2@UZ&2FLI2%"4!4%E7ZO3S%FGKIK9$Y2Q 56_R7>3W]R:(K3|S/C/'A@/ M$#RU;&%Q%\CP@EIX3:J5+<,FX$/N1Z-T/9HS-KO$_<< ,+>B1CFEI*8%@*?*

*MJA,X7$J8;8OH!M\V25$\T*NSAHI]< (M/]IQL|:IE#9%)5[V % 1M1S-P 8 ME^V AV)T_[+UT(S4(SO\=W6/CK9\7/)SX]E*(Q|">*ZA[(_%RA['X9:61C]*

*MS3J&HW%%]^BL@V59FD24:*82)^! K-6[!$T92E;"F9I>,RY0R#2YX2V ZI MUSLXP-7)5B49%'3(\LB3\?(;(7$&[D4I*.)K8K)H(FXDC++ZS1F;BE3)DEU*

*MO9HY$C&Z@7^*D;TG|A_J>)R:E8@#=$@G*0IXB@IVIW%^A3|^7)';6%2CMA/ MT/R?@=U=NA)ECJ$8IK>J'7Z)-G G39O$Q_@4+ZJIML MJF#F6M/FVM*55 5|Q|U[+?=-1@X?6*

*I'_.=^F-% MIAN:K+,^@ZJ-Q;_W+Z8"O9 &JU'K(2&N14ZZJ 7\B\)HIY>HI[& NCP?6/%T9O ML&)IWDH2%$2H%RBC3%VK+*ISPCL'E2OT"M4T*0EL@WQ&(/H@Q 0K,)|(0;F- M"1=,+(?*

*%_8@YK428UEYA0< Z""/EG5G1XKY#;T!A5WRHD*XJPZ3 MW*C!2?U:PE?O;0P_K>Z:@!$R6V3"CFOHUA ,U7U6W>< G! M,PB/BAP9;!MSAX=XN&[3 I=+.';)-1"L0,A>J3R.-*

'P+BN9OD]MX"\0Q"1Z/ MUAVY09@SY,XY2G$W4,;@L.R]73@H6]9S[%[CM1NP3<% IR[!\%WWA MP$3 MN;VYLL'RI293+AKO3N$<<*3AOF"C$-9Z-QN%&+1$Q1%-

*$]@_,Q<#?/K M$8\TAHK,@:'V(CSUG_6$?OIY?S@Y/+Z/1==*I&_B_\[_CD_/3]^P_')YHX@TCQ$ E46M7"V<043!N.UMU^:"?DS-QO.@.6*^^4\F MZ&L7I$KH*FTD?N]HX @HW"UFP- S*

*G<)2T&(&%3H-14[*Y."(-4 ^RZ(/ TC; M)HM36BU8 >FHFI,,=$[05QO)-I- !A)4D G0,9*,X6L3.F!H1RZV0B3. M_K.342CFV3"S%ZQ'M(&TP_!N>4%\"%4DADW,%\/\YXX!S3(%,-*

*) D4]+A\RAC M"E;&+G6%MBDE>K3+%9@'1KL_O0:I3N6'X,2+&3@=s=L#KV.R3FP%W *3RRYQO M1K=2,2G)VBIX|D+-[FP =TPLTZ9F:<=#+)-2]-]KBCF&PR A$R:B+9 E5H<, MI#*

<:UMMH>+N.1H/KYG0^/#Q>/0VG/<#% , E:%8%&UN'!&-H&ZA)&[:#!8] M?>?!8=50SXCP3:8'_CCDKL.TZ+!Q]B-7$MKOH&\|I|/H5=U!_]G|#9_^/:KGV-M'_P+0P,8,@C-@/T(/L+*

*(071T?/3QD*0)\/)'+|<7^]'%KP?GQ|'PXN+CP95+,.M2!$6#OE047ZG?PUO:/[@K:"]&5^*C]]C3H+C6S*9;@I7Y[G8=F"\Q;&_8S2B M-M,XPVI.Q FDA*

*&&^PJ_V>,&>]SPPV9U37'#3VPZ/E\[C%+BN=1E=:37_&X1<26M-M#V]NL3*HJII%QT.0L/%_/PAW]nL:./,6S>8CIA8D"\[NO)TYP5E);3#^(MD5D2NW& !,%#1T5>:_S!-2$,'T$-#*

f3F0[6@\]>9&L#XP!)",,4LK6?8I#&K M=<6(FACI8G3E?'_/G-4=_0_;]+92G]U6(",D",9"\|)II)R[AA)=6;1Z6TM,Y-\Y.@IZ2.=G9?XW=>O=C9^:]?PB|S_O66=G/&[Z2S[BBQ00 @ZE+<,W

*M2E*F7I_%GTRC:GE3F+FSMO7?*&:EOBF=-->0<3N%NB^!%(/*J Y 5IG3]RG$! MPHCQA,7C=[*T&\=#%V'+8QL4;A7E8ZUH&FPMFH^KZ6B34_ET4 ,/3B,<308U-M0W8?*

*LVC!C]5XZG5=-)+!%2=6%0:X?]QI;O19=L=YC[T.5;0:M0%8952R='W%# M27N6+B]=`)2.T\5!^-K NRB'(1D$#MRN2[.IO;/.7Z&!.%/RI[LKU38Y9&;O(*ZC5/2LDM0XJ(&-1*

M2B%1B'D;8?@#<\2$%;23+2C)6^:;,#V$4J!GM K1280-'8"3\N9.2P7.9Z4O, ML/+;2U\/J'-Z#W&)UQU-,8.E$^1,S'QW9+):,-TGC MNDK(4/_Q?&^H3>]PFF=+"6UA"X(?V M?>@

*R*XT$\7U5#)3S:W.6\=/K#R3=5">U-FK.T%%YD.@7*FS@2?8GH8UHMS5 M@1R_EJAYH>E[=E]>J9P(OR?P',^9)521=ZL'O62*SL!RL.3O;&L*EB]=K[^>6&&I-5!8IU++V$ Z.Y0Q--*

*ZTIWO8A0U*_M*F7+$A:XL'-Q7<<@3CO(@9>1XND?22)D=9=C1RJ@OJ7]JHN\TX+;]"A9%QC<],W5,EZ6^.FD6%9\f'+25+%CF4636X,-ZR/(Z M:"/>P.]W%,DQQJ-GIS=EOY]MA=*

J3.8AZDF>[P3_=8)_L5F4H0OPX[MXON]7DG]VX!)5"@43"D.,^B7BJBG0,N.V[2;H>D[< \LBYHZNB=(>T7?#*$ M@aF=8]AZ'4211|\%16H$0>$3 "RJE_,/W5FBL64%*

(D^9U\N)26\1R3;7^,++T M@]D|'5T1F-"V2"BLUY&;!P>8W70QMY& . PZ+LN4&SO=Q&4RL*%[:T!L//R0 M[,$./=C!>_BK'NS0@QUZL,,?$>QP/W=1R_DG>K)EMH22Y*=*

M@7>7G/<_;^;O@MD\H! 5,R:0;GZB0f|(O BH[|!K[<1&4Y,07-KI=HMW'1 ML .;?YZO},.!U_W$7O=D#;SN T)\S.:87B7T1U<:HK$_VRY@JG5MI=]D%SJM M]Y'*%8S*

*T=V8@+=\#R#?T8I+LL /,^HDW]-4;,@CR?5U;|L_MG2A&V;5V4]=!AB1,[.W0@<@+Z,%UV,.! 2.Y%T4N\F]R#/2!W(7)F;UP9@-M/XV:IW/4MSTZ\+(A2V /,"$G2H&?6B*F;R*

*1E|UV'!*_,+2@]&@=(*4E MZG@V+XK2XBNS^&;02!H)D)!;D7%9(EB(+1!,E.L)]1=>-.DT5>%@KY&L#7Z& MMA^V/J.C(?YLTA;!YXN5R"7S;I)&&T2^]ADBX).IH=3#"WRI0[MVIN"*

9G)9@P#YN)?1#,%!FG""$:MB=_4A2.]".3YZ8PVF5?V1G7?3$<'D<8]3 M]QQ_DKP)\@'+S;GTN==XM:[C-.[M1M*WW=H%.V&1?*;!I7F>-->V@:#_%!UG MA')"\M%%A**!B4/9 *

(#B9'(VV3;?8(&62W_M=@ H<7NZC 7;$]O5U',CW9B M#N]3O O.'[&!4012D) MYYH2F^,=UV7)13V90@IRZ7!%M2-<)&N/_M Z "\:P5)K*

M'6W\S!\BG6QTGE/>F=6&&;I.BUIG"'\U;AM=M-$)(8)12OMV$TR3+K>V @0N M;,(C&DW!VS;&URZN4J&J$9C!EX6B!{QL87!)I9V-,1?*AJO7WQ5T5C1{K]= M)'$,]Y_$YRA)WZ",-*

*&LR6WB/>'.P?',V,QIA$PZ"6)'@.6AR4-?1!9=)<{\! MA#P ?2>[N[>CXUOW+!ILKHC(@\&\!VGT95'6Z8.<;88IE@CC(SE0+%BWI=2XM-!;S+(@2\0LJP)<6*AIX&8(F MG88-JM=*

*!H%;8ZEW(.2F,E7]*1);P\6WO;/"55EEJ%.W E*1*NU*5/)H4T!3Z@M&[.$ MG*MFI9'(K, 9D;AR\AG5&;IV,0Z@& <EY*5Z2O)<H\I9JJ&&Z1YZQT/&!H*

MK,$]'S7+X?/D3MUD!/SW.J64,V-=F(;()5>N@_0Y7Z34KG;%?8=TH&X?)8P3L M[D4+[@3M]"?>R!-_=%7]WE$D)<$;="MA.')F88[G3 M%L'LV1O,A&JB\L%JYN,?&X5HRW'>/A5&-*

*^2TFI.L$15[4KCX7>G-;]#JJ$O M7SR+JT._[*PC^N6?P\M?C\X/_GGPOH>X}!"7=G?!IL%D0]NB+XC2=Q,M/H= MSV(#Z'1%V1/C&4O.K<&Z8:B=/%H B1P3&;A*EK:,RR'6U>*

*fYH41O93TV9&F ME*R<"PXZ9*/R?;C ..RP*9<;;>;V^,K*]-CB])*RH!%!?1V_@*VP.!8ZAC&U-MZR)CKPX,Y+B$J691{J3HL+/HL]J&+ERNO$;W=("0,DD,0YZUUJQ#R+L.1H^*

MH]'IO2L)U51U"/,R83.!C*IAT<5;9*MWI;Q6I?2GOQ2LM,K*I.IX[W]6 _4T4 MC\!AX& #K&^*+:F73E:OY/H(V>U5+'XE0KJTI:Y/LXW\>^)0&BC44IA+[/8F M8TU4CGL?_6T-XGXU-*

3UK[O_6^$0_MU6*=\)#OG00M"^^!CEB[!<^K5^[NXY^_M[>7Q^8?AR0$WM7\7'?\X>W_ZKY4WM;\4||C4W"7+/P/$,5F" @\ME#*

M84'D=AV>SK!6H+Z?;=9.%MQA+7\1!:Y1AKYE{C&K4)WF=J0D=/8 MSU)!3Q3"'3\R)L/BT]A M__#5LEO,3!6$LROJLUN_>,-=5F'T@IPOV=FUY_0)3C'9J VB(>|)E'V^FBC9'J.0:G"_>B U;:Y,1VQB@MS71)YUT&$0.D,ZG)PO%/M-,91D1@CJ7;,"RSVZCB'Y\0,/\= :G0$$A$O] 9:W!VB{M,%'KR/#G\]*

M,/GE>,4*K@F516$Q72FU@$U=|SHB%,*;5)AP$*H\0<=I',^14_N_)7[$5\#4 MI^17@>K1*ORCKD=X YU:MXY$'=+=4/!+226HPL&#-I?!:V."4AN&B#?14N'$) M>D0B8Y[R&/4 ":\Y<-PP1LG.#N\V>$&FAG@>);4NXEF#6CU79YX*:&| M<5E;<&(/"$CX5LM7%O PL5]K>C L5-6@KAOX#P#OE10C0A'Y-4P[V%VZ;->% M1!A:%O.BI+I>"O[QA.

-8<%^LPW\%D[YQK97K3V!3+R2%AQILV#YFR$E*94G M4O?4M:!J(\2U&M=E6F%?"'''L]7ZCQM;0W\OYP5/KQ\>(R*]GHEIW+?]Z';7\

MR>G)P<7%\)>3@Y^'[X>7_U]IFC]1,;6DEYUOW=V1P\Q- @,GRO;SP*'8,\T< MPRSV^9P,#4Y!9VK5U^0+,$;>*%14_=A&!A1H&>=ZHLH2?YEG*KGB-D]>,B)X%T@'1?S(O8]

N(^JX:OBY1)#\P! MQ[-7I&MN2)HLXZ*L./%,7OFYY?#P^'9P7Z[6 MAO53#*A%:KYTOU-7N[BT:H77]-9SK MK%@\>'X<)& ;IR***%VLCLFA-

JZ]2[MQB359%%=_5ZFO0;8O;BC3^W%GO<[++F M\>4535'2-(;0?IN=G9^A=^/CR9>NSX\|"1^_N>7D5.26,55#99U),.>#|%#54YU=T2%7

M6,G2$K2!U[<;'F@@15[H5,K];4P3 M'0"M,IND<55VX<;C{\UR!VQ'_@O"HZBT#^V-$ND" M,&M^('*>V*U!*P1?''?[M&0\[_)/_\+<]_JG'/SUL5M<4_]2;S*LSF=>2$^O@

ML.S]\/#@9S"#WQ_|<^5T F$2^PIA95ZL%%.@%5BGZ+ 2IP@6\0N5.Z=1\TF6 MLE5(GY,1N&D55"9H< 1>[PW8+,V7NN8BMY8$10P.7:3GK5\\|BPPC"]POI<=%+"U@S;AA:O

M3;79*\A8&GRC%EAA-1KEJ#UVO48F7T=2J.$?;*-?Q(!9AM,#SLBJ/'4Y6 IIN)F+[=DB-KOO$G3'+PW^TOME\3& MS4@LSTVXQF.PI +ZMY17$70J.8\AZQS3T1&2HPL@L/-

JDY:NHXMAR)=J4T3X MW5AC2G9@1J#%*;=/I\/&LF>VE$8;.&6//ENUM*,1P)AHD]NB M',|&N^:,,^!+M?(^CH8]7K'\>)8BUY2)E\|.SP\NCZ/+\X.3BX/GUAZ$ $V'

MMCCE$@FS6!$-.HL.K$WK!P68|:.M Uj'2C2L.BA3;#/=+NZ@+WE<6:VKA+^K M_6V_((6)D8/>L:@UCW^6^NSJ06[*O^S[WB574&!A"M1U92;WH===0\=M9;G1\?

1Q3&IHNC5BQ\/]J/+@_^-D/!G^&YXR/"5>]"C M/"H, ^ JLSF\$![P,&/W3.5MRAFZI05QT!3J_I#@MQ@+49V*9MW$-"589M6BI M$V '^OP^OD]?-)X'FCV@4-5>Z %-

R0>0.0'EM/>UT8.\LT6'8!;>#*@>Z5* MF!0);AJ4&4&*9Z/TJF;$D@U8X.E1E;5*!(,-X$5K+PX1>{(§^01E'1R6T# MT1=8 ,G#!^2^/A-

I$%+R0CTZJ$<'>0__L4<']>B@A\WJFJ*#GMI.>;Z'_GW(M$4=MM@:.D%*JI<@YPBLA6_+X),ODH:\|_8+Q+2WLSDV \3U.U@9YP;*CVH_D M-

9[DHLH&9.ZG=PU0/.BJYA$L=@UO[D)B2_G1F_Z,.B&%47'*F#3HN&$+W_/ M,!B]_7#Z;Z@&9('DQ[@')&;!*$WGRG3!M2^HX 6,(5]OV%AU'X>-A02VV3@

MMXB;QVEB'IJX)YIDHK!PN%WE@^_OL_B7F"ZIRT4 ?"Y-6M^(8H^3#4VO21W MXF/BPT!Y"-AWI.#^0RRSD;UM1WK&<8*T>$Q..]C(L8" ,B%==622QH>)Q:.T M2ZM%]YF6@:%

(Y1)\L#]!V2MNDA4&P8SY9P9]-ZD^&S:RRFW!M2%N4'P72Z(M8$.9;X!9XKR-] A3$UR+\|=15K%]T+/1UK*LZR@XR%ZKL,]4LB?PWI@6Q V- M&3{FW%UX*A'WHLL<@M\45:

[&&G@'# 3O:U59X+;^>Z3'?2+$E9=C4GSKC+ M6L+=2<.G;GS]]#)?>]^C&%VK[:H51[L$=YWU8C0HKCG"3O'#]*APQ.VHXIGYA

M&,5GO$)CR6^J835NM'3=NE:Y(+N06)Z8@MSV0+U%*^=GFX/5&[1Z28Z]PO_$PA=)X3%C8MH/P%T][\PW%=]>RU871\?OAB?#,/'6DUGT0>RP M*=(S;R!U,)F D0X:>O7-

HZAK@&;@=Y$Q.3L@@[*0<0!7@:.|PI:1WP;4CKV@ M4MV,$JH#)N9-JDY*)#WCI#C7-6+)U!X4A-6)0V?G/I%P^9"T*B(T2}> $

MY@I=>KJ:4<;D8PMZG=5LSIROE^JJF2JZ."lNI(.C8G=.,?4ZI7U6O7'H/8SV5 M"R$;GHUB\. 6D^B(5$C10GSUPO;$PC;NA>UQA W]SVIE[8IE+>1E[+)D3,^Y9"5Z X/;Z44V\

{Y#B3U)%HR,JV=9< MT88) X_7;*80J*W#;SM^MH IO)?CIY5CU[V\5NTHO=8XE=!UK]V0@AY:/'4L>L;&_@ MB:3 LZRXP?

0(%3$H/1NW,C//C)SVGAM816[P^A29TIPGD5R2CG9>@F%&D:B= M5_B38=SWJ/4VI?\(#\X\R1+'9E%QOZLR>":5W?&3SNM,P5.2K9>=|UX>9<,B M4D=ZURB1"GJQ3[))M3

%9=‘&ZQ??;5I+0KY7%; IHNN":Z*+&Z*?DUNT6A1Y M_=F1;,"O#I$[N(!MVVSFLNH('7/;# 6TT%R+.&IW>,\RH_/O6&U+L(_Z0TQY CZ@8DRH:H'CR 7CW5[VI)/ MKO7|)+ZO?

_@3U3_LO.@+(/H"B(?-ZIH60/21A_N;*|/>7'D<<^5=G);1A[C\ MI*KH'W%6/QN+A?)B$FI(B N&7!,(2[-!$L0B]]|C>P^[7@D'N/CH. M\DN7X/7V"SN

/R"/.LV@CVFCF29M,\JI38*R;!@GL4[BWZ-?LF($1N\%L M_P@-PZ+A#1D?H=^>PPGJ/8F0\WQHC*&C-1XB"(6#UKW2!OPV^Q>X7A4V1<\^2+M1+4T:L-,_M9INH5;)V6N06>1]@#]\OK-$&6X.GI-

\]LC[.[(9ST=AR&([E4?K?3=GO#AC]0 MY%BV9_BM\0Y)X;6]H):S'F>QV<9=QK?]Y(U9_O3]J.C5T2.I(Y"Z9Z-Y2]T MEO-'<-G;Z-C8'Q<8\/8Z21]OON?(68TXSGMQ?"1Q]'OI/2.Y%

(!K9R2\T9*] M%[XG%KI?>^%[9.%[KI%PZ>W+ 7#B9TU'-5NO8N%29_6JN&'6*N4"XZX2 M\]A?O^?*=A)"-(T#)W9=%4#M]^NKJ1S=!^63XK[QS)M)S(-AD(.A@XWCG"CKR>!E?

\E'7UM M(F$"W(&FTZQ2$NO4D8AH->J9:Q>&%"K;_EG,$ZFFK9Y,A6$78LRN=<+32K"O MG=,)9)V8N(K.A4;A@R@3]A!U4^!E3:M-W7_KST>2B<"F_%0M#(C@K'A6=!=

MN#"_KU747K"M =N^; YL&_BP\5YIW=Q=%;O^ M]%N7-9H\:!SM\CUV=/:?E('4F[;%Z%DJFX-WWS M$37WF\WFWU|K/LO>JZ'*E*P-_(B_,,2=1^-;+L4VALE&O+RM\)72P(1\)

M9L1(AD1 "$M^SW' (114W8M*&)C.F4?M$E8HQ\SG3,;G)G-'LG=3;D)N$U M=I&&^^TYI2@&F4#IE>>L,+F K=QX8!#/.$EP9R16++>8A;AND$,;_3A=P|@52$PEIN MIB22\%N!?

A=T6MR+8 RZ5.1,] \2"*4)\P1B*9K#$J03#/,3#IG-Z<>|_5@8 M42JA 232*B0]R$+86+HA!F@S$7H#22]P+76$88[0+&+]Z>(T;.GRTG1I;C)= M!(ME"D 2MN< K(K,=CL_!P-

)*DN$82N8(2*,!0=^=]?;$W Y9K/385HPR8@##4&]3Z MC-/-PFY865L@V&AJ!,N6?MEALOS8VC#>|&[PZ0?GPS,.PW3MJVA'\9PM+>]^-8

MXM)C{)OQ(SR:@4[95X)0QP3&W0=8AB1.8@G\#OD>NL980Z5MCG;4N=&J@'5F M=@BW+9L%RB.!&A10+4[*8<\'0C6P69_G2M(^!K#\;J8\TU]D8&NBDM)>5Q:

MT(GT,_((\RPK4$^VK-U1?*>C&!W1.)>Y!PF*[UK/P]>2 P3O9=S]M2EV=/33 M2>.D<73TT!*I%X/Y:=S'[7HYXQ0W#.FC+7F]*^5/I >2O@KV&*UDA%W MWM"^E9'D1M(

9!$1>L^;DJ;<4I3F-QCK0SKOE[05,,C:!#U*C#$LJPUQQAX/MV7DDQG9WSA&KNU$A%S??>S-C_! MZ9&,B';5]Z/8]HEG8)3R'/CH+@=T07 M4C#OSB?E@++

<9&"G]>%L&&H3>0-\,C80*:)4!9+BBX>-F$=G\UGTH(RR?CQ0@7K5SEJWTS*J8 l;5*^>C*KDB?:./*4L+P/-M;ZK[E?F-?

[*:1%_AO2A:U&&8&T+Q0fBV2FVBK<,#>1<&93:$IC^*NC?;?:A-.M#$+"LRR)E[:'P)NO6E)\,\UGENT5=@VYG46RY),\@47DG;6?DM*13IF2MT*5

M)\>^+9I2NS;T#..M%4LT=!;'B*Z+7 M>QG=W#:.M,Y18V<1H[\'G4DBG1/B2\ZXKQ&4DD D8:'7L@ON =*6?"M^4W99 M,1GBCU0B.'YWR-

/0%SOWMG64;1WE45Y169WR)PG64!&.RGFA%(!Y&>[-ZAEC MP6\!?BOR%Q_:^&=S9]-&G].8\N:S:IU4"P8&VSG!&'A71!8 MX%^REG2I%7&43$=:C00%4RD?E.^*3>FU1)

(J/15X.A[]PE7Q.V0$>9XGV-Q_M"-5_V8-$[[$.+=;)!X ::S1K[+!^>/0GGH9;-?*?&NN/;QIOZ^VEP3E'YE]O M'|'AYG9Y#)ELH5/),)W$_ *.3O43T34GG%N'ZPK&V#O%,^1:-FB}C7;BOQI

MXT*W/R$- TS5.U7BB@VZ5;4OA2 5W:7X6_2%;3MP7D."1W<%\(=9[]\\> ^WG M94[&9712EB"Z$MA-.%T.[XDT?@O=[.-K[$\#PER*XEXAK M?

0+PC:%M_3E#VX54/$-2%.0Z$E6;G3MHIT\LBPH:\GN*/O,DO9N*5Y_OS2.= MY2_X#G%C9<8JTNAU/NU[R@H\FL6MNP++*>1PMH'YO2BV*QXC,VUQ->93ZW>H

MTP/ZT/+LA],#_XGF_P!02P,$% @ [X,-6>V2]G2[" &#H \ !S M=')O+65X,S%?,BYH=&WM6VU3XS@2_KZ_0L?4;4%5###$!YG!8JC),Y1;J+9B% M3-7<1]FZ8QVRY97DA-

ROOV!)S@%=(=1=\OR2695>?H+ M.[^R9Z_!(&]6N(D5FQ"C)U(_MM63O50%!&AE55_M$YMV1M*6%[9:4,5$,(_^&|>[[Y=0R,6H:U4\#]!HO7LHBFXNBB#C8IA9N\&^ MASNQN@V,^

\JB95F7 =P!U2=E(V65!4617@4MDO;]99XG5WW+*6YD)-H(')N MR 4?DRN5TZ(1C)6U*@=9RV]M0*48%!%&"[3;_ TDRBI=/2N[?YUQYFP/# E M37A4:AZ,-2U]=V-O?ZPDZ\

[9%H)MWS0';!D+9K,H%39(0)(7:$(_-A.QL,3/ M FHX/=DKX3\,!!O0%08BW'^L\X?'(@$SN'XC@W'6OQJD__7L]!%/_ND=S: &2+A<>>@M9FGUW>|=TUZ'R_ M#_H?%P@&4^=

{UVGOXW2YV>Q=?>A=[*^#RZ]_I/_53.1^N!V_WO/X(\NEY.F3 M(\>/.7K>(GTVIIJ1LUW2D[$H1(LD7%N13HC-J(WNC 1&XD128W!; HOR0 IC M

RYYSG$6P*]2ZZW&\!R9,*>DD2B6_G1^K({#VWY7!3AI;G$Q@+-6VZP8E0/4F MGA4A3\WO#-/.KL=C[=O[_6>-:]-ZZ*]T-G,??<'K--QM1G8NN?$]PW;[

MKL)70@?)Z(@3S4>"CSD#0 A#]S :[EA%QO3-F(*L@GI7,2MH, B4K)=66U M(A^$*C.]<]HBYT6RVYU1"G.062:R -=0S 6I _#0#U 0:?(6#R":DIU%AR-N0M

MCROMT<04,"J4)=B*BH+08D*JPNJ*@ZW4.F @S"C)X4H+*DE*$[BEB'0[YQ. _<8& -=2@PFV <*)$(G50YB!30'2Z"<(# _M249,A3]F[<=<\UH).I +(Z']@2]$C(7-

P$%3\L09B'H:U!T(Q<',$S1B)) ,#_L1?.EL\YTX205!0 2L3T#8 NX N+P6,\|%T4*JS.U O2((1$5 YT \CFT MM8 @ E=T,.X@O9!V4L[X4T/7W.D.+&4 "%;=0HI(@ *11 $'7G7'V)-1D))5J

M;!&;3X$U&HH0G%F[YNL+(U1PS3&'//\@TW7IH;!VO C<$"D'Y[=|O?#H^[MHH9_G<+EBYJO25,"EP|@YH9HF-,Z12PYHHYP\#L&L&0HCF(YO!V,/7@-OB92 MF0K:8>=:20_K4JN$,

[AMR#:@F'&@A8=[_S,):.#'DI >+_54E0<+M,1QN\QW7 MU&TRX)6_%%C'%9Y.}}(@1)ACF4<|VK)R1^E'1RETA'[>Y1Y(8'X7/0N?:@X@ MO,_B[O^;8@<'[X_#X_#@,&P?=8[?/X%N=

WHQKB!H07?;JE*@P) VD@8%VE BA=.#]:GLQ@U'^S)A=Y"]14&O M40E3*I)*4@RGX)858I;M00N?\ZGO/!75%$0@S:< 8\$6[#R"0%9]2A->(OM1 M! I-

3T18)40)$;6[8>*K,C%9 R;R$965"R (4YZF4'J)$0#,+"EY9IGJ"A'1 M7RXO@QSSH'"%$,^,+K5A5]F$35HG9=*K-L9),'|^H(%3H|K%!!X*L*>+RC?D

M>57RL#4@3PW+,^_#&?;^ZOG%/EI/H.Z(79HLJ22]-*)Y+59;IS96Q\ #?L8$R MDX'FQ_R^-

!E^]$T*A(3{\MCT!O+E=2]$0+*J!93O>KHR::2:+,PKPCW_KQ47HVUOX<%'W:]LKA&M#RB=LK[GW1E-*M673 M8#5/]EF@0%9\1_9ZKZ*;V4:AK+-*FVG&Z&Z SCP7UG+^K6

<*WP)"@),@(5. MRS9P#R!M,+;",ZPNFR6#_U4)<,"M#E61N,W.GX;8ZUD|\"6(,; M<+B=EP@.,*_3O>E^QIC3&|S??/WB,CA7>;D772Q^\]^#W0)1&%,FAI M^#2@/,RTNF*#-L

6**Q:/HTTD$.;*@>0P2 Y=^!@OO1UA LV&))LMCH>)0VD M@JF&U1P1S%T$ A*X=ZPU6UH^C1+%2,D1QURJH,/Z5,&N@Q,/2ZDF')Z,.^4C M%5W@(G#G>7+-W8= O<(YHJ-

U/$;T$-B(AKU[*$@C8:=%|MOI[__#LW#+/"\I M7W1]%OZUNW>;N_4A9+0%SR2#Z2@> *V%@8@?UMYQUIV3;!=+5 M#6#R)"T-CXS?^9N1.AN_L--#MDY1UZP#M0 /12FN7^/E]>20695E&

[_,&S!< K#T\F;V?ATC|+|28/-L_)3%[^[-48IL.+ M%\/S\328O/IS_#<,15,WT<0#WKV#]*4I]*XHW-A#OW=XNPZ(KV7 _POUK 5_ M<2$XR>%UV\D5(5HPRCA+8;QB26GY)8-)FO*$;5

I3$NK%;S@JLB(SDD+SF32 MAD.;,7CT<-4+NTD\4GE!Y+JZI/%1"ZB"C&DV7P-JL3Q=MZ HM2GQ2 >KX$IN MLL1R)>O<) 8/585E=$N\$7(D18^B"1=<6VA44B2#&/#] S/-

<&,#)EC.7+XA|@73:\[YAZ\+M0=91*MC]*A7\?U/:5RP#=Q>*#"6:!0=WQ(CS;$QQ35W#H- MXU62$;E@#?N[S_]/JQS*O?,Q$$DW7'=%X;?2<, Y,\7YWD_'>2Z1R#GQU'(C

M!+VA>:>$JDZ#E'"7%&C:.#:VW# 1 G :TQS)CP,%TM.TZHR01"N/BJDW*M&MRCFI4E1D5L@C;]<2ZOV+<3\L4_=NS9I<.W(L60NV';K&SCO(M?^QG6CZMQP M?

2O&X,0#9)$JD7U\A;F!85@,.59/P%@$*0R+#"L(PKY)-M^L5;I]#XT.Z,;Z M)3?8/ ENUU$SOQ9"*;I-Z"=H"_'K6'}+P.-M ?Q'7[=7=^>>>RSOA7F(PP5PS M\B'RWX&

[L<.E2U=9X(Y<+VZUU+=U]MWH=!MO#C%1,(1#,L%;C&XXU?GR0&8S MOP/KW9%O'F]47K? . "0124XA<:WGPN0A+LQZN<*>(A+^NOKN+8 MDY1UZP#M0 /12FN7^/E]>20695E&

[_,&SI< K#T\F;V?ATC|+|28/-L_)3%[^[-48IL.+ M%\/S\328O/IS_#<,15,WT<0#WKV#]*4I]*XHW-A#OW=XNPZ(KV7 _POUK 5_ M<2$XR>%UV\D5(5HPRCA+8;QB26GY)8-)FO*$;5

I3$NK%;S@JLB(SDD+SF32 MAD.;,7CT<-4+NTD\4GE!Y+JZI/%1"ZB"C&DV7P-JL3Q=MZ HM2GQ2 >KX$IN MLL1R)>O<) 8/585E=$N\$7(D18^B"1=<6VA44B2#&/#] S/-

<&,#)EC.7+XA|@73:\[YAZ\+M0=91*MC]*A7\?U/:5RP#=Q>*#"6:!0=WQ(CS;$QQ35W#H- MXU62$;E@#?N[S_]/JQS*O?,Q$$DW7'=%X;?2<, Y,\7YWD_'>2Z1R#GQU'(C

M!+VA>:>$JDZ#E'"7%&C:.#:VW# 1 G :TQS)CP,%TM.TZHR01"N/BJDW*M&MRCFI4E1D5L@C;]<2ZOV+<3\L4_=NS9I<.W(L60NV';K&SCO(M?^QG6CZMQP M?

2O&X,0#9)$JD7U\A;F!85@,.59/P%@$*0R+#"L(PKY)-M^L5;I]#XT.Z,;Z M)3?8/ ENUU$SOQ9"*;I-Z"=H"_'K6'}+P.-M ?Q'7[=7=^>>>RSOA7F(PP5PS M\B'RWX&

[L<.E2U=9X(Y<+VZUU+=U]MWH=!MO#C%1,(1#,L%;C&XXU?GR0&8S MOP/KW9%O'F]47K? . "0124XA<:WGPN0A+LQZN<*>(A+^NOKN+8 MDY1UZP#M0 /12FN7^/E]>20695E&

[_,&S!< K#T\F;V?ATC|+|28/-L_)3%[^[-48IL.+ M%\/S\328O/IS_#<,15,WT<0#WKV#]*4I]*XHW-A#OW=XNPZ(KV7 _POUK 5_ M<2$XR>%UV\D5(5HPRCA+8;QB26GY)8-)FO*$;5

I3$NK%;S@JLB(SDD+SF32 MAD.;,7CT<-4+NTD\4GE!Y+JZI/%1"ZB"C&DV7P-JL3Q=MZ HM2GQ2 >KX$IN MLL1R)>O<) 8/585E=$N\$7(D18^B"1=<6VA44B2#&/#] S/-

<&,#)EC.7+XA|@73:\[YAZ\+M0=91*MC]*A7\?U/:5RP#=Q>*#"6:!0=WQ(CS;$QQ35W#H- MXU62$;E@#?N[S_]/JQS*O?,Q$$DW7'=%X;?2<, Y,\7YWD_'>2Z1R#GQU'(C

M!+VA>:>$JDZ#E'"7%&C:.#:VW# 1 G :TQS)CP,%TM.TZHR01"N/BJDW*M&MRCFI4E1D5L@C;]<2ZOV+<3\L4_=NS9I<.W(L60NV';K&SCO(M?^QG6CZMQP M?

2O&X,0#9)$JD7U\A;F!85@,.59/P%@$*0R+#"L(PKY)-M^L5;I]#XT.Z,;Z M)3?8/ ENUU$SOQ9"*;I-Z"=H"_'K6'}+P.-M ?Q'7[=7=^>>>RSOA7F(PP5PS M\B'RWX&

[L<.E2U=9X(Y<+VZUU+=U]MWH=!MO#C%1,(1#,L%;C&XXU?GR0&8S MOP/KW9%O'F]47K? . "0124XA<:WGPN0A+LQZN<*>(A+^NOKN+8 MDY1UZP#M0 /12FN7^/E]>20695E&

[_,&SI< K#T\F;V?ATC|+|28/-L_)3%[^[-48IL.+ M%\/S\328O/IS_#<,15,WT<0#WKV#]*4I]*XHW-A#OW=XNPZ(KV7 _POUK 5_ M<2$XR>%UV\D5(5HPRCA+8;QB26GY)8-)FO*$;5

I3$NK%;S@JLB(SDD+SF32 MAD.;,7CT<-4+NTD\4GE!Y+JZI/%1"ZB"C&DV7P-JL3Q=MZ HM2GQ2 >KX$IN MLL1R)>O<) 8/585E=$N\$7(D18^B"1=<6VA44B2#&/#] S/-

<&,#)EC.7+XA|@73:\[YAZ\+M0=91*MC]*A7\?U/:5RP#=Q>*#"6:!0=WQ(CS;$QQ35W#H- MXU62$;E@#?N[S_]/JQS*O?,Q$$DW7'=%X;?2<, Y,\7YWD_'>2Z1R#GQU'(C

M!+VA>:>$JDZ#E'"7%&C:.#:VW# 1 G :TQS)CP,%TM.TZHR01"N/BJDW*M&MRCFI4E1D5L@C;]<2ZOV+<3\L4_=NS9I<.W(L60NV';K&SCO(M?^QG6CZMQP M?

2O&X,0#9)$JD7U\A;F!85@,.59/P%@$*0R+#"L(PKY)-M^L5;I]#XT.Z,;Z M)3?8/ ENUU$SOQ9"*;I-Z"=H"_'K6'}+P.-M ?Q'7[=7=^>>>RSOA7F(PP5PS M\B'RWX&

[L<.E2U=9X(Y<+VZUU+=U]MWH=!MO#C%1,(1#,L%;C&XXU?GR0&8S MOP/KW9%O'F]47K? . "0124XA<:WGPN0A+LQZN<*>(A+^NOKN+8 MDY1UZP#M0 /12FN7^/E]>20695E&

[_,&S!

*of America ("U.S. GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The December 31, 2023 condensed balance sheet was derived from the audited financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company's condensed Balance Sheets and the amounts of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining research and development periods under collaboration arrangements, stock-based compensation expense, valuation of marketable securities, impairment of long-lived assets, income taxes, deferred royalty obligation related to the sale of future royalties and related non-cash interest expense, and certain accrued liabilities. Actual results could differ from such estimates or assumptions. The accompanying unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to state fairly the Company's financial position, results of operations, comprehensive loss, and cash flows for the interim periods. The interim results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, or for any other future annual or interim period. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company's audited financial statements included in the Annual Report on Form 10-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, for the year ended December 31, 2023. Recent Accounting Pronouncements Not Yet Adopted There were no new accounting pronouncements issued since the Company's filing of the Annual Report on Form 10-K for the year ended December 31, 2023, which could have a significant effect on the Company's condensed financial statements. Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed Balance Sheets that sum to the total of the same amounts shown in the Company's condensed Statements of Cash Flows.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.66%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:12.98%;"></td> <td style="width:1%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:13%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,788</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235,095 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 857 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 872 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents, and restricted cash shown in the
  condensed Statements of Cash Flows </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">91,645</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 235,967 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed Balance Sheets that sum to the total of the same amounts shown in the Company's condensed Statements of Cash Flows. <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-*

align:left;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.66%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:12.98%;"></td> <td style="width:1%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:13%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,788</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235,095 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 857 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 872 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents, and restricted cash shown in the
  condensed Statements of Cash Flows </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">91,645</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 235,967 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>907880002350950008570008720009164500023596700 Investments in Equity Securities Vaxcyte common stock held by the Company is measured at fair value at each reporting period based on the closing price of Vaxcyte's common stock on the last trading day of each reporting period, with any realized or unrealized gains and losses recorded in the Company's condensed Statements of Operations. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date and establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs that may be used to measure fair value, as follows: Level 1—Quoted prices in active markets for identical assets and liabilities; Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of accounts receivable, prepaid expenses, accounts payable, accrued liabilities and accrued compensation and benefits approximate fair value due to the short-term nature of these items. The carrying value of the deferred royalty obligation related to the sale of future royalties under the 2015 License Agreement with Vaxcyte approximates its fair value as of June 30, 2024, and is based on our current estimates of future royalties expected to be earned over the estimated life of the royalty term arrangement. See Note 8, Deferred Royalty Obligation Related to the Sale of Future Royalties for a description of the Level 3 inputs used to estimate the fair value of the liability. Revenue Recognition When the Company enters into collaboration agreements, it assesses whether the arrangements fall within the scope of ASC 808, Collaborative Arrangements ("ASC 808") based on

*whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If it concludes that payments from the collaboration partner to the Company represent consideration from a customer, such as license fees and contract research and development activities, the Company accounts for those payments within the scope of Accounting Standards Update (ASU) No. 2014-09 (Topic 606), Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense. The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The total revenue to date has been generated principally from collaboration and license agreements and to a lesser extent, from manufacturing, supply and services, and materials the Company provides to its collaboration partners. Collaboration Revenue: The Company derives revenue from collaboration arrangements, under which the Company may grant licenses to its collaboration partners to further develop and commercialize its proprietary product candidates. The Company may also perform research and development activities under the collaboration agreements. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial milestones and other contingent payments, and royalties based on net sales of approved products. Additionally, the collaborations may provide options for the customer to acquire from the Company materials and reagents, clinical product supply or additional research and development services under separate agreements. The Company assesses which activities in the collaboration agreements are considered distinct performance obligations that should be accounted for separately. The Company develops assumptions that require judgement to determine whether the license to the Company's intellectual property is distinct from the research and development services or participation in activities under the collaboration agreements. At the inception of each agreement, the Company determines the arrangement transaction price, which includes variable consideration, based on the assessment of the probability of achievement of future milestones and contingent payments and other potential consideration. The Company recognizes revenue over time by measuring its progress towards the complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price ("SSP"), of each distinct performance obligation. In instances where SSP is not directly observable, the Company develops assumptions that require judgment to determine the SSP for each performance obligation identified in the contract. These key assumptions may include full-time equivalent ("FTE"), personnel effort, estimated costs, discount rates and probabilities of clinical development and regulatory success. Upfront Payments: For collaboration arrangements that include a nonrefundable upfront payment, if the license fee and research and development services cannot be accounted for as separate performance obligations, the transaction price is deferred and recognized as revenue over the expected period of performance using a cost-based input methodology. The Company uses judgement to assess the pattern of delivery of the performance obligation. In addition, amounts paid in advance of services being rendered may result in an associated financing component to the upfront payment. Accordingly, the interest on such borrowing cost component will be recorded as interest expense and revenue, based on an appropriate borrowing rate applied to the value of services to be performed by the Company over the estimated service performance period. License Grants: For collaboration arrangements that include a grant of a license to the Company's intellectual property, the Company considers whether the license grant is distinct from the other performance obligations included in the arrangement. For licenses that are distinct, the Company recognizes revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and the Company has provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement. Milestone and Contingent Payments: At the inception of the arrangement and at each reporting date thereafter, the Company assesses whether it should include any milestone and contingent payments or other forms of variable consideration in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty, the associated milestone value is included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Since milestone and contingent payments may become payable to the Company upon the initiation of a clinical study or filing for or receipt of regulatory approval, the Company reviews the relevant facts and circumstances to determine when the Company should update the transaction price, which may occur before the triggering event. When the Company updates the transaction price for milestone and contingent payments, the Company allocates the changes in the total transaction price to each performance obligation in the agreement on the same basis as the initial allocation. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment, which may result in recognizing revenue for previously satisfied performance obligations in such period. The Company's collaborators generally pay milestones and contingent payments subsequent to achievement of the triggering event. Research and Development Services: For amounts allocated to the Company's research and development obligations in a collaboration arrangement, the Company recognizes revenue over time using a cost-based input methodology, representing the transfer of goods or services as activities are performed over the term of the agreement. Materials Supply: The Company provides materials and reagents, clinical materials, and services to certain of its collaborators under separate agreements. The consideration for such services is generally based on FTE personnel effort used to manufacture those materials, reimbursed at an agreed upon rate in addition to agreed-upon pricing for the provided materials. The amounts billed are recognized as revenue as the performance obligations are met by the Company. Revenue subject to governmental withholding taxes is recognized on a gross basis with the withholding taxes recorded as a component of income tax expense. 3. Fair Value Measurements The following table sets forth the fair value of the Company's financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 *

</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,592</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,592 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Equity securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-

family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,424 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,424 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Asset-backed securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,597 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,306 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,306 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">412,024</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 222,322 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">189,702</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr></table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,397</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,397 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,152 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">- </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,152 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,894 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,894 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Equity securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41,937 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41,937 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,652 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">- </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">371,498</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 211,986 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">159,512</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:14pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> Where applicable, the Company uses quoted market prices in active markets for identical assets to determine fair value. This pricing methodology applies to Level 1 investments, which are comprised of money market funds, U.S. government securities and the shares of Vaxcyte common stock held by the Company. If quoted prices in active markets for identical assets are not available, then the Company uses quoted prices for similar assets or inputs other than quoted prices that are observable, either directly or indirectly. These investments are included in Level 2 and consist of commercial paper, corporate debt securities, asset-backed securities, and U.S. agency securities. These assets are valued using market prices when available, adjusting for accretion of the purchase price to face value at maturity. A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. As of June 30, 2024 and December 31, 2023, the deferred royalty obligation related to the sale of future Vaxcyte royalties was classified as Level 3 within the valuation hierarchy. Refer to Note 8 below for information relating to the Purchase Agreement between the Company and Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in potential future net sales of Vaxcyte's pneumococcal conjugate vaccine, or PCV, products, including VAX-24 and VAX-31. Investments in Equity Securities As of June 30, 2024 and December 31, 2023, the Company held 667,780<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of Vaxcyte common stock with an estimated fair value of $50.4 million and $41.9 million, respectively. The Company recognized an unrealized gain of $4.8 million and $8.3 million for the three months ended June 30, 2024, and 2023, respectively, and an unrealized gain of $8.5 million and $1.3 million for the six months ended June 30, 2024, and 2023, respectively.</p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table sets forth the fair value of the Company's financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 1</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 2</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 3</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets:</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,592 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,830 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-

wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Equity securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,424 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,424 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Asset-backed securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,597 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,597 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,306 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,306 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>

<td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">412,024</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 222,322 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">189,702</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> Assets: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,397</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,397 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Commercial paper</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">82,152</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Corporate debt securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">61,894</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Equity securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,937</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,937</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mortgage-backed securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,937</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Asset-backed securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">61,894</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Municipal securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,894</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> $ </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>

family:Times New Roman;margin-bottom:0;text-align:right;">- </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Asset-backed securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,652 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">371,498</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 211,986 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">159,512</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:14pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr>
</table>435920004359200037830000378300008627500086275000504240005042400065597000615830600012830600041202400022232200018970200056397000563
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">4. Cash Equivalents and Marketable Securities
Cash equivalents and marketable securities consisted of the following:<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,592</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,592 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,857 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (27 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (29 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Asset-based securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,650 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (53 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,597 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (60 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,306 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361,763 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (169 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361,600 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less amounts classified as cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (76,827 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (76,820 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">284,936</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(162</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 284,780 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,397</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,397 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (28 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,152 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,887 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,894 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Asset-based securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,612 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,652 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 329,540 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (33 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 329,561 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less amounts classified as cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (65,144 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 264,396

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 264,413 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> No marketable securities had maturities of more than one year as of June 30, 2024 and December 31, 2023. There were $287.6 million and $110.9 million of investments in an unrealized loss position of $0.2 million and $33,000 as of June 30, 2024 and December 31, 2023, respectively. During the three and six months ended June 30, 2024, and 2023, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Company's procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio after June 30, 2024, and 2023, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of June 30, 2024. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Company's cost basis. </p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recognized no material gains or losses on its cash equivalents and current and non-current marketable securities as of June 30, 2024 and December 31, 2023 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income (loss) for the period then ended.</p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash equivalents and marketable securities consisted of the following: </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized
Cost Basis</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized
Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized
Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair
Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,592 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,592 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,857 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (29 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,650 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,597 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (60 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,306 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-

width:fit-content;">Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361,763 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (169 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361,600 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less amounts classified as cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (76,827 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (76,820 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">284,936</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(162</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 284,780 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains

</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,397</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,397 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,152 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,887 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,894 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Asset-based securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="font-family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,505 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,612 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,652 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,961 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 329,540 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (33 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 329,561 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less amounts classified as cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (65,144 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (65,148 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">264,396</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2,25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(33</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2,25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 264,413 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>4359200043592000378570002700037830000863000004000290008627500065650000530006559700012836400020006000012830600036176300060001690003616000
4000651480002643960005000033000264413000001P1YP1Y2876000001109000002000003300000000 5. Collaboration and License Agreements and Supply Agreements The Company has entered into collaboration and license agreements and supply agreements with various pharmaceutical and biotechnology companies. See “Note 5. Collaboration and License Agreements and Supply Agreements” to the Company’s financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2023, or as further described below, for additional information on each of its collaboration agreements. The Company’s accounts receivable balances may contain billed and unbilled amounts from upfront payments, milestones and other contingent payments, as well as reimbursable costs from collaboration and license agreements and supply agreements. The Company performs a regular review of its customers’ credit risk and payment histories, including payments made after the period end. Historically, the Company has not experienced credit loss from its accounts receivable and, therefore, has not recorded a reserve for estimated credit losses as of June 30, 2024 and December 31, 2023. In accordance with the collaboration, license and supply agreements, the Company recognized revenue as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> <span style="white-

space:pre-wrap;font-family:Arial;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ccecff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Merck Sharp & Dohme Corporation (“Merck”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 140 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,693 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Astellas Pharma Inc. (“Astellas”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,752 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,137 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,605 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ccecff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tasly Biopharmaceuticals Co., Ltd. (“Tasly”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 975 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vaxcyte, Inc. (“Vaxcyte”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 846 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 703 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,378 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cceeff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Ipsen Pharma SAS (“Ipsen”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Bristol Myers Squibb Company (“BMS”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,236 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,402 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cceeff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Merck KGaA, Darmstadt, Germany (operating in the United
  States and Canada under the name “EMD Serono”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,706</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,412 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,714</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23,086 </td> <td style="white-space:nowrap;vertical-align:bottom;border-

bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table> The following table presents the changes in the Company's deferred revenue balance from the agreements during the six months ended June 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:69.846%;"></td> <td style="width:2%;"></td> <td style="width:1%;"></td> <td style="width:26.155%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred revenue—December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">74,045</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Additions to deferred revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,429</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recognition of revenue in current period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(28,820</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred revenue—June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 95,654 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company's balance of deferred revenue contains upfront and contingent payments for obligations from our agreements which remain partially unsatisfied. The Company expects to recognize approximately $74.0 million of the deferred revenue over the next twelve months. Collaboration with Merck 2018 Merck Agreement In July 2018, the Company entered into an agreement (the "2018 Merck Agreement") with Merck for access to the Company's technology and the identification and preclinical research and development of two target programs, with an option for Merck to engage the Company to continue these activities for a third program, upon the payment of an additional amount, focusing on cytokine derivatives for cancer and autoimmune disorders. In April 2021, Merck initiated the first IND-enabling toxicology study under the first cytokine-derivative program in the collaboration. In December 2021, Merck did not extend the research term for the second research program of the collaboration, which research program reverted to the Company. The first research program of the collaboration is focused on MK-1484, a distinct cytokine derivative molecule for the treatment of cancer. The Company is eligible to receive aggregate contingent payments of up to approximately $500 million for the target program selected by Merck, assuming the development and sale of the therapeutic candidate and all possible indications identified under the collaboration. If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low-teen digit percentages on the worldwide sales of any commercial products that may result from the collaboration. <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-

family:Times New Roman;margin-bottom:0;text-align:left;">In July 2022, the first patient was dosed with MK-1484 in a Phase 1 study. As of both June 30, 2024 and December 31, 2023, there was no deferred revenue under the 2018 Merck Agreement and 2021 Amendment. 2020 Merck Master Services Agreement In August 2020, the Company entered into a Pre-Clinical and Clinical Supply Agreement (the "2020 Merck Master Services Agreement") with Merck, wherein Merck requested the Company to provide development, manufacturing and supply chain management services, including clinical product supply, upon completion of the research programs under the 2018 Merck Agreement. As of both June 30, 2024 and December 31, 2023, there was no deferred revenue under the 2020 Merck Master Services Agreement. Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:37.948%;"></td><td style="width:2.541%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:2.541%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:1.2%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:2.4%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 79 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 204 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 61 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,489 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 140 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Astellas License and Collaboration Agreement In June 2022, the Company entered into a License and Collaboration Agreement (the “Astellas Agreement”) with Astellas for the development of immunostimulatory antibody-drug conjugates for up to three biological targets, to be identified by Astellas. The Company will conduct research and pre-clinical development of any compound (as designated by Astellas) in each of the three programs in accordance with the terms of a research plan between the Company and Astellas. Astellas will have an exclusive worldwide license to develop and commercialize any such designated compound, subject to the Company’s rights to participate in cost and profit sharing in the United States, as described below. Pursuant to the Astellas Agreement, the Company received from Astellas a one-time, nonrefundable, non-creditable, upfront payment of $90.0 million during the year ended December 31, 2022. Under ASC 808 and ASC 606, the Company determined that both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the development program, and identified four performance obligations under the Astellas Agreement as: (1) performance of services related to the first target program; (2) performance of services related to the second target program; (3) performance of services related to the third target program; and (4) the Company’s estimated future services on the collaboration JSC. The transaction price of $90.0 million was allocated among the performance obligations using the Company’s best estimate of the standalone selling price, or SSP, for each of the associated performance obligations. Revenue allocated to the three target programs, which totaled $89.1 million, is being recognized on a proportional performance basis, using FTE cost as the basis of measurement, with such performance expected to occur over an estimated service period of four years for each target program. For the JSC performance obligation, revenue allocated to such performance obligation was $0.9 million, and is being recognized on a proportional performance basis using FTE cost as the basis of measurement, and such effort is expected to be incurred on a relatively consistent basis throughout the term of the Astellas Agreement. Additionally, under ASC 606, the Company determined a financing component associated with the $90.0 million upfront payment and has calculated $24.8 million as of June 30, 2024, on the unearned revenue portion beyond one year from the effective date of the agreement, which amount is being recognized as interest expense and revenue over the estimated service period for the target programs. The Company is also eligible to receive up to $422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teen percentages on worldwide sales of any commercial products that may result from the collaboration, subject to customary deductions under certain circumstances. The Company can also elect to convert any product candidate into a cost and profit-sharing arrangement, for the United States only. In the event the Company makes such election, it will share commercialization costs and profits relating to such product candidate equally with Astellas in the United States, and no royalties will be due from Astellas for net sales of such product candidates in the United States. In June 2024, Astellas notified the Company that it would not be nominating a third target program. This decision was based on Astellas' strategic portfolio considerations. Pursuant to ASC 606, Astellas' decision to not elect a third target program is a change in the scope of the original contract and thus represents a contract modification. At the date of the modification, the Company determined that the remaining research and development activities related to the first target program and the second target program to be undertaken by the Company after the notice of termination were not distinct from the related activities performed on each target prior to the modification. Accordingly, after re-allocation of the updated transaction price, the Company updated the cost-based input measure of progress for the remaining performance obligations and recorded a cumulative catch-up adjustment to revenue of $17.8 million on the modification date relating to the ongoing unsatisfied performance obligations. For the JSC performance obligation, as the remaining services were determined to be distinct from those already provided, the Company determined that the contract modification should be treated as a termination of the existing contract and the creation of a new contract, to be accounted for prospectively. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

family:Arial;min-width:fit-content;">Revenues under the Astellas Agreement were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.948%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.4%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Ongoing performance related to
  unsatisfied performance obligations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,590</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,820</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,381 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,562 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,004 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,719 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Financing component on unearned revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,758 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,532 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,918 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,075 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 395 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,752</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,333 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,137</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,605 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of June 30, 2024 and December 31, 2023, there was $40.2 million and $69.0 million of deferred revenue, respectively, related to the upfront payment received by the Company under the Astellas Agreement. Collaboration with Tasly Tasly License Agreement In December 2021, the Company entered into a license agreement with Tasly to grant Tasly an exclusive license to develop and commercialize STRO-002, or luveltamab tazevibulin, or luvelta, in Greater China (the “Tasly License Agreement”). Tasly will pursue the clinical development, regulatory approval, and commercialization of luvelta in multiple indications, including ovarian cancer, non-small cell lung cancer, triple-negative breast cancer, and other indications in Greater China. The Company will retain development and commercial rights of luvelta globally outside of Greater China, including the United States. The Company determined that the Tasly License Agreement falls within the scope of ASC 808, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of indications for luvelta in Greater China. The Company concluded that the Tasly License Agreement contained the following units of account: i) licensed know-how and Sutro patents, license to trademark rights, and initial regulatory data and information necessary to prepare an IND; and ii) collaboration governance and

information sharing activities, such as JSC participation and ongoing regulatory and pharmacovigilance support. The promises related to the licensed know-how and Sutro patents, license to trademark rights, and initial regulatory data and information necessary to prepare an IND are considered to be interdependent and not distinct from each other, representing a combined output. The Company determined that these promises are capable of being distinct from the collaboration governance and information sharing activities discussed below and further determined that this unit of account is a vendor-customer relationship and accounted for it in accordance with ASC 606. All potential future milestones and other payments were considered constrained at the inception of the Tasly License Agreement since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur. Since there is only one performance obligation accounted for under ASC 606, no allocation of the transaction price was necessary. The Company determined that the unit of account consisting of collaboration governance and information sharing activities, such as JSC participation and ongoing regulatory and pharmacovigilance support, do not represent a customer-vendor relationship between the Company and Tasly. These promises are considered to be interdependent and not distinct from each other, representing a combined output. However, the Company determined that these promises are capable of being distinct from the intellectual property and data license promises discussed above. As such, based on the nature of the agreement and collaborative activities, the Company determined that the costs associated with these governance and information sharing activities performed under the agreement will be included in research and development expenses in the Statements of Operations, with any reimbursement of costs by Tasly reflected as a reduction of such expenses. During the three and six months ended June 30, 2024, and 2023, the Company did not recognize any material reduction of research and development expenses under the Tasly License Agreement. In April 2022, the Company entered into amendment No. 1 (the “Tasly Amendment”) to the Tasly License Agreement with Tasly. Pursuant to the Tasly Amendment, the initial nonrefundable upfront payment due by Tasly was amended to $25.0 million, and a $15.0 million payment will become payable to the Company upon the achievement of certain regulatory milestones. The Tasly Amendment also added an additional regulatory milestone payment to the Tasly License Agreement, providing additional potential payments totaling up to $350.0 million related to development, regulatory and commercialization milestones, beyond the payments described above, and made certain other ministerial edits. During 2023, the Company recognized a $5.0 million contingent payment as revenue, net of withholding tax, after Tasly received its first IND clearance by National Medical Products Administration, or NMPA, in Greater China. The withholding tax of $0.5 million was recorded as an income tax charge related to the contingent payment. During 2023, the Company also recorded a $5.0 million contingent payment, received by the Company from Tasly related to the first patient dosed in the Company’s REFRaME-O1 trial for luvelta, as deferred revenue, net of withholding tax of $0.5 million. The REFRaME-O1 study consists of two parts, Part I being the dose-finding portion and Part II being the portion of the study that will focus on the selected dose from Part I, and is intended to generate data to enable the potential registration of luvelta. Although it currently intends to conduct the REFRaME-O1 study to completion, the Company has the sole discretion to terminate the REFRaME-O1 study at any time. Given the above, the contingent payment received by the Company was considered constrained for accounting purposes during the three and six months ended June 30, 2024, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur. The withholding tax was recorded by the Company as a tax charge related to the received contingent payment. 2023 Tasly Supply Agreement In June 2023, the Company entered into a Master Development and Clinical Supply Agreement (the “2023 Tasly Supply Agreement”) with Tasly, wherein Tasly requested the Company to provide development, manufacturing and supply chain management services, including clinical product supply. Revenues under the Tasly agreements were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:37.948%;"></td><td style="width:2.541%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:2.541%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:1.2%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:2.4%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-

family:Arial;min-width:fit-content;">(in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 937 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 975 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Agreements with Vaxcyte Vaxcyte Supply Agreement In May 2018, the Company entered into a Supply Agreement (the “Supply Agreement”) with Vaxcyte, wherein Vaxcyte engaged the Company to provide research and development services and to supply extracts and custom reagents, as requested by Vaxcyte. The pricing is based on an agreed upon cost-plus arrangement. During 2020, upon Vaxcyte’s request and their agreement to reimburse the related costs, the Company entered into agreements with third-party contract manufacturing organizations, or CMOs, to conduct process transfers to allow for such CMOs to manufacture and supply extract and custom reagents for Vaxcyte. As part of the agreement with Vaxcyte, should the Company decide to purchase extract from the extract CMO, the Company would be required to reimburse Vaxcyte for a portion of all incurred process transfer costs. As of June 30, 2024 and December 31, 2023, there was $8.3 million and $6.9 million, respectively, in such accruals related to the Vaxcyte Supply Agreement. For the three and six months ended June 30, 2024, the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $2.6 million and $4.2<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-

width:fit-content;"> million, respectively, and were accounted for by the Company as a reduction to research and development expense based on the Company's conclusion that Vaxcyte was not a customer for such activities and associated payments. For the three and six months ended June 30, 2023, the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $0.9 million and $2.8 million, respectively. Vaxcyte Agreement In December 2022, the Company entered into a letter agreement (the "Vaxcyte Agreement") with Vaxcyte under which the Company granted to Vaxcyte (i) authorization to enter into an agreement with an independent alternate CMO to source cell-free extract solely for the products it licensed from the Company, allowing Vaxcyte to have direct oversight over financial and operational aspects of the relationship with the CMO ("CMO Relationship Rights"), and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract for use in connection with the exploitation of certain vaccine compositions (the "Option"). In November 2023 (the "Exercise Date"), Vaxcyte exercised the Option by submitting written notice thereof to the Company and concurrently paid the Company $50.0 million in cash as the first of two installment payments for the Option exercise price. In May 2024, Vaxcyte paid the Company an additional $25.0 million in cash as the second of two installment payments for the Option exercise price under the Vaxcyte Agreement. Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay the Company certain additional payments totaling up to $60.0 million in cash. In the event that Vaxcyte undergoes a change of control, certain rights and payments may be accelerated. These contingent payments were considered constrained variable consideration or otherwise not eligible for revenue recognition at inception and as of June 30, 2024. </p><div style="font-size:12pt;font-family:Arial,"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenues under the Vaxcyte agreements were as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:37.948%;"></td><td style="width:2.541%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:2.541%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:1.2%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td><td style="width:2.4%;"></td><td style="width:1%;"></td><td style="width:11.342%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development services</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 650 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 567 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;font-family:Arial;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,297</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,071 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 136 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 307 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">846</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,493</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Refer to Note 8 below for information relating to the Purchase Agreement between the Company and Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in potential future net sales of Vaxcyte products, including VAX-24 and VAX-31. Ipsen Agreements In March 2024, the Company and Ipsen Pharma SAS (“Ipsen”) entered into an Exclusive License Agreement (the “Ipsen License Agreement”) pursuant to which the Company licensed to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. In consideration for the rights and licenses granted by the Company to Ipsen in the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $50.0 million in April 2024 and (ii) Ipsen Biopharmaceuticals, Inc. (USA) (“Ipsen USA”), a fully-owned Affiliate of Ipsen, purchased 4,827,373 shares of the Company’s common stock for $25.0 million, at a price of approximately $5.18 per share, in accordance with the terms set forth in a certain investment agreement by and between the Company and Ipsen USA dated March 29, 2024 (the “Ipsen Investment Agreement”, and, together with the Ipsen License Agreement, the “Ipsen Agreements”). The fair market value of the common stock issued to Ipsen USA in April 2024 was $24.6 million, based on the stock price on the date of issuance, resulting in a $0.4 million premium on the Ipsen Investment Agreement. Further, pursuant to the Ipsen License Agreement, upon the occurrence of a specified developmental milestone according to a specified timetable, the Company will receive a payment of up to $7.0 million and Ipsen is obligated to purchase up to an additional $10.0 million in shares of the Company’s common stock at a price per share representing a 17% premium to the VWAP of the Company’s common stock for the twenty trading day period prior to such milestone achievement, in accordance with the terms set forth in the Ipsen Investment Agreement. The Company is also eligible to receive up to an additional $447.0 million in developmental and regulatory milestones, assuming multiple indications, and up to $360.0 million in sales milestones, as well as tiered royalty payments ranging from low double-digit to mid-teen digit percentages of annual net sales of STRO-003, subject to certain adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement

expire on a country-by-country basis no earlier than ten years following the first commercial sale of STRO-003 in the applicable country. Ipsen may terminate the Ipsen License Agreement for convenience with sixty calendar days prior written notice or for certain other specified reasons. The Company may terminate the Ipsen License Agreement if Ipsen or any of its Affiliates challenge the validity of any patents controlled by the Company that are licensed under the agreement. Both Ipsen and the Company may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other party's bankruptcy event.

The Company concluded that the Ipsen License Agreement contains three promised goods and services consisting of the STRO-003 license, technology transfer, and IND-enabling activities. The Company concluded that these promised goods and services are not distinct from each other, and all play an integral role in allowing Ipsen to file an IND and begin its development of STRO-003. As such, the STRO-003 license, technology transfer, and IND-enabling activities are accounted for as one single performance obligation.

The Ipsen License Agreement and the Ipsen Investment Agreement are being accounted for as one arrangement because they were entered into at or near the same time and negotiated in contemplation of one another. The Company determined that the total transaction price of the Ipsen License Agreement was $50.4 million, comprised of the one-time, nonrefundable, non-creditable upfront payment of $50.0 million paid by Ipsen under the Ipsen License Agreement, and a $0.4 million premium from the Ipsen Investment Agreement.

Revenue for the performance obligation will be recognized at a point in time when the Company has completed all its deliverables, i.e., STRO-003 license, technology transfer, and IND-enabling activities, at which time Ipsen would have what it needs from the Company to file an IND for STRO-003.

Revenues under the Ipsen License Agreement were as follows:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2024	2023	2024	2023
	(in thousands)			
Research and development services	$	$	$	$
	18	-	18	-

width:fit-content;">- </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 77 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 77 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">95</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of June 30, 2024, there was $50.4 million of deferred revenue related to the Ipsen Agreements. 00 In accordance with the collaboration, license and supply agreements, the Company recognized revenue as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-

align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ccecff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Merck Sharp & Dohme Corporation (“Merck”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 140 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,693 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Astellas Pharma Inc. (“Astellas”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,752 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,137 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,605 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ccecff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tasly Biopharmaceuticals Co., Ltd. (“Tasly”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vaxcyte, Inc. (“Vaxcyte”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 846 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 703 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-

content;">1,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,378 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cceeff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Ipsen Pharma SAS (“Ipsen”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Bristol Myers Squibb Company (“BMS”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,236 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,402 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cceeff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Merck KGaA, Darmstadt, Germany (operating in the United
 States and Canada under the name “EMD Serono”) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,706</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,412 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,714 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,086</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p>800014000014000269300024752000733300036137000136050005000975000846000703000149300013780009500095000223600054020008000257060001041200038714<p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents the changes in the Company's deferred revenue balance from the agreements during the six months ended June 30, 2024:</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:69.846%;"></td> <td style="width:2%;"></td> <td style="width:1%;"></td> <td style="width:26.155%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred revenue—December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">74,045</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Additions to deferred revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,429</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recognition of revenue in current period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(28,820</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred revenue—June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">95,654</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr>
</table>740450005042900028820000956540007400000P12M2500000000If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low-teen digit percentages on the worldwide sales of any commercial products that may result from the collaboration.0000<p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:</p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.948%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.4%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-

align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 79 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 204 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 61 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,489 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 140 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
79006600020400080006100080002489000800014000014000269300033900000004900000003891000000P4Y900000900000002480000042250000017800000 Revenues under the Astellas Agreement were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.948%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.4%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Ongoing performance related to <br/> unsatisfied performance obligations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,590</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,820</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,381 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,562 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,004 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,719 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Financing component on unearned revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,758 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,532 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,918 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,075 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 395 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,719 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,333 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,137</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,605 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
21590000323900028820000581100013810001562000300400027190001758000253200039180005075000230003950002475200073330003613700013605000402000006960
style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenues under the Tasly agreements were as follows: <table style="margin-left:auto;border-

spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.948%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.4%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 937 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 975 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>5000380009370005000975000830000690000026000004200009000002800000500000002250000006000000 Revenues under the Vaxcyte agreements were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.948%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.4%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">650</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-

width:fit-content;">567 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,297</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,071 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 136 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 307 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">846</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,493</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>650000567000129700010710001960001360001960003070008460007030001493000137800000.045000000048273732500000005.18246000004000007000000100000000 style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenues under the Ipsen License Agreement were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.948%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.541%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> <td style="width:2.4%;"></td> <td style="width:1%;"></td> <td style="width:11.342%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;font-family:Arial;min-width:fit-

content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Materials supply </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 77 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 77 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">95</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>18000180007700077000950009500050400000 6. Commitments and Contingencies <span

*style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases The Company leases certain office, laboratory and manufacturing facilities in South San Francisco, California and San Carlos, California. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional 5 years. These renewal options have not been considered in the determination of the right-of-use assets and lease liabilities associated with these leases as the Company has determined it is not reasonably certain it will exercise such options. The Company recognizes rent expense for these operating leases on a straight-line basis over the lease period. The components of lease costs, which the Company includes in operating expenses in the Company's condensed Statements of Operations, were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.48%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:12.32%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:11.52%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:12.32%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,984</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,538 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,968</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,076 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short-term lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> *

 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 853 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,447 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total lease costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,875</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,506</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> During the three and six months ended June 30, 2024 and 2023, the Company recorded operating lease expense of $2.0 million and $4.0 million, respectively. As of June 30, 2024, the Company paid $4.5 million of operating lease payments related to the lease liabilities, which the Company includes in net cash used in operating activities in the Company's condensed Statements of Cash Flows. During the three and six months ended June 30, 2023, the Company recorded operating lease expense of $1.5 million and $3.1 million, respectively. As of June 30, 2023, the Company paid $3.5 million of operating lease payments related to the lease liabilities, which the Company includes in net cash used in operating activities in the Company's condensed Statements of Cash Flows.</p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of June 30, 2024 and December 31, 2023, the weighted-average remaining lease term was 3.3 years and 3.8 years, respectively, and the weighted-average discount rate used to determine the operating lease liability was 10.8% for both periods.</p><div style="font-size:12pt;font-family:Arial;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of June 30, 2024, the maturities of the Company's operating lease liabilities were as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:73.96%;"></td> <td style="width:2.7%;"></td> <td style="width:1%;"></td> <td style="width:21.34%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year Ending December 31,</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amount</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Remaining in 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,684 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,974 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,526 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,933 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total lease liabilities, non-current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 19,593 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Indemnification & Other In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company's condensed Balance Sheets, condensed Statements of Operations, or condensed Statements of Cash Flows. The Company currently has directors' and officers' liability insurance. In addition, the Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. P5YP5YThe components of lease costs, which the Company includes in operating expenses in the Company's condensed Statements of Operations, were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.48%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:12.32%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:11.52%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:12.32%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:12.32%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td

style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,984</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,538 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,968</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,076 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short-term lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 853 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,447 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total lease costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">2,875 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,998</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,506 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>19840001538000396800030760003800019000910004300085300044100014470008510002875000199800055060003970000200000040000004500000150000031000006
style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of June 30, 2024, the maturities of the Company's operating lease liabilities were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:73.96%;"></td> <td style="width:2.7%;"></td> <td style="width:1%;"></td> <td style="width:21.34%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Year Ending December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amount </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remaining in 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,684 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,974 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,526 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,933 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr

style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total lease liabilities, non-current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">19,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>46840009533000899400082890003150000049740002652600069330001959300<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">7. Accrued Expenses and Other Current Liabilities</p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued expenses and other current liabilities consist of the following: </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.793%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vaxcyte-related accrual under Vaxcyte Supply Agreement</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,342 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,933 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> CMO-related accrual </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,195 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Clinical trials-related accrual </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,868 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tax and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,581 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt

solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,897 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,062</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,473 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued expenses and other current liabilities consist of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.793%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> <td style="width:1.72%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vaxcyte-related accrual under Vaxcyte Supply Agreement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,342</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,933 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> CMO-related accrual </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,195 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Clinical trials-related accrual </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,868 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tax and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,581 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,897 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,062</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,473 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>834200069330001226000081950008868000428300011000151650003581000389700033062000384730000 8. Deferred Royalty Obligation related to the Sale of Future Royalties In June 2023, the Company entered into the Purchase Agreement with Blackstone, pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte products, including the Purchased Interest under the 2015 License Agreement. As described in Note 5, Collaboration and License Agreements and Supply Agreements, Vaxcyte Agreement, following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of the amendment No. 3 to the 2015 License Agreement, the revenue interest in the 4% royalty on potential future net sales of Vaxcyte products other than Vaxcyte's PCV products reverted to the Company. The Company retains the right to discover and develop vaccines for the treatment or prophylaxis of any disease that is not caused by an infectious pathogen, including cancer. In June 2023, Blackstone made an upfront payment of $140.0 million to the Company and will also pay up to an additional $250.0 million upon the achievement of various return thresholds as set forth in the Purchase Agreement. Under the Purchase Agreement, and in connection with its sale of the Purchased Interest, the Company has agreed to certain covenants with respect to the exercise of its rights under the 2015 License Agreement, including with respect to the Company's right to amend, assign and terminate the 2015 License Agreement. The Purchase Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The Company recorded the $140.0 million upfront payment from Blackstone as a deferred royalty obligation related to the sale of future royalties on the Company's condensed Balance Sheets. Due to the Company's then ongoing manufacturing obligations under the 2015 License Agreement, the Company accounted for the proceeds as imputed debt and, therefore, will recognize future non-cash royalty revenues. Non-cash interest expense will be recognized over the estimated life of the royalty term arrangement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of potential future royalty payments to be received from Vaxcyte. As part of the sale, the Company incurred approximately $3.8 million in transaction costs, which are being amortized over the estimated life of the royalty term arrangement using the effective interest method. As future royalties are earned from Vaxcyte by Blackstone, the balance of the deferred royalty obligation will be amortized over the estimated life of the royalty term arrangement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the vaccine products, and other events or circumstances that could result in reduced royalty payments from Vaxcyte to Blackstone, which are not within the Company's control, and all of which would result in a reduction or increase of non-cash royalty revenues and the non-cash interest expense over the estimated life of the royalty term arrangement. The Company periodically assesses the estimated royalty payments to be earned by Blackstone from Vaxcyte and, to the extent that the amount or timing of such payments is materially different than our original estimates, the Company prospectively adjusts the imputed interest rate and the related amortization of the deferred royalty obligation. As of June 30, 2024, the effective interest rate used by the Company to amortize the liability is 18.4%. During the three and six months ended June 30, 2024, the Company recognized approximately $7.3 million and $14.5 million, respectively, of non-cash interest expense on the deferred royalty obligation, which amount will increase such balance. During the three and six months ended June 30, 2023, the Company recognized approximately $0.4 million of non-cash interest expense on the deferred royalty obligation. As of June 30, 2024, Blackstone has not received any royalty payment from Vaxcyte and, therefore, the deferred royalty obligation has not begun to be amortized. The following table shows the activity of the deferred royalty obligation for the six months ended June 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.855%;"></td> <td style="width:2.621%;"></td> <td style="width:1%;"></td> <td style="width:18.524%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability related to sale of future Vaxcyte royalties - beginning balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;font-family:Arial;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">149,114</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-cash interest expense associated with the sale of future Vaxcyte royalties</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,470</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Amortization of issuance costs</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">321</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability related to the sale of future Vaxcyte royalties - ending balance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 163,905 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 0.040.04140000000250000000140000000380000000.184730000014500000400000400000 The following table shows the activity of the deferred royalty obligation for the six months ended June 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.855%;"></td> <td style="width:2.621%;"></td> <td style="width:1%;"></td> <td style="width:18.524%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability related to sale of future Vaxcyte royalties - beginning balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">149,114</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-cash interest expense associated with the sale of future Vaxcyte royalties</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,470</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Amortization of issuance costs</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">321</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability related to the sale of future Vaxcyte royalties - ending balance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 163,905 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1491140001447000032100016390500 9. Stockholders' Equity Common Stock Holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. The Company has reserved common stock, on an if-converted basis, for issuance as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.74%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:19.42%;"></td> <td style="width:1%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:16.8%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td

*style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,779,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,905,032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock awards issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,050,784 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,244,873 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Remaining shares reserved for issuance under 2018 Equity
  Incentive Plan and 2021 Equity Inducement Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,844,438 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,777,919 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Shares reserved for issuance under 2018 Employee
  Stock Purchase Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,495,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 914,911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,298,107 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,970,351 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Preferred Stock <span style="color:#000000;white-*

space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of June 30, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock authorized with a par value of $0.001 per share. No shares of preferred stock were outstanding as of June 30, 2024 and December 31, 2023. one vote per share The Company has reserved common stock, on an if-converted basis, for issuance as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.74%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:19.42%;"></td> <td style="width:1%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:16.8%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,779,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,905,032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock awards issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,050,784 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,244,873 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Remaining shares reserved for issuance under 2018 Equity
  Incentive Plan and 2021 Equity Inducement Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,844,438 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,777,919 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Shares reserved for issuance under 2018 Employee
  Stock Purchase Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,495,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 914,911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,298,107 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,970,351 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>877996679050326050784524487318444381777919149530391491112761612761618298107159703511000000010000000.0010.00100 10. Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation 2004 Equity Incentive Plan, 2018 Equity Incentive Plan, 2021 Equity Inducement Plan, and Amended and Restated 2021 Equity Inducement Plan In September 2018, the Company adopted the 2018 Equity Incentive Plan (“2018 Plan”), which became effective on September 25, 2018. As a result, the Company will not grant any additional awards under the 2004 Equity Incentive Plan (“2004 Plan”). The terms of the 2004 Plan and applicable award agreements will continue to govern any outstanding awards thereunder. In addition to the shares of common stock reserved for future issuance under the 2004 Plan that were added to the 2018 Plan upon its effective date, the Company initially reserved 2,300,000 shares of common stock for issuance under the 2018 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2019, in an amount equal to 5% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year (rounded to the nearest whole share), or a lesser number of shares determined by the Company’s board of directors. As a result, common stock reserved for issuance under the 2018 Plan was increased by 3,050,491 shares on January 1, 2024. In August 2021, the Company adopted the 2021 Equity Inducement Plan (“2021 Plan”), which became effective on August 4, 2021. Upon its effective date, the Company initially reserved 750,000 shares of common stock for issuance pursuant to non-qualified stock options and restricted stock units (“RSUs”) under the 2021 Plan. In accordance with Rule 5635(c)(4) of the Nasdaq listing rules, equity awards under the 2021 Plan may only be made to an employee if he or she is granted such equity awards in connection with his or her commencement of employment with the Company and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. In addition, awards under the 2021 Plan may only be made to employees who have not previously been an employee or member of the Board (or any parent or subsidiary of the Company) or following a bona fide period of non-employment of the employee by the Company (or a parent or subsidiary of the Company). At all times, the Company will reserve and keep available a sufficient number of shares as will be required to satisfy the requirements of all outstanding awards granted under the 2021 Plan. In August 2022, the Company amended and restated the 2021 Plan (the “Amended and Restated 2021 Plan”) and reserved an additional 750,000 shares of common stock available for issuance under the Amended and Restated 2021 Plan to be granted by the Company to certain employees as a material inducement to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Additionally, in February 2023, the Company amended and restated the Amended and Restated 2021 Plan and reserved an additional 500,000 shares of common stock available for issuance under the Amended and Restated 2021 Plan to be granted by the Company to certain employees as a material inducement to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The total number of shares reserved for issuance pursuant to the Amended and Restated 2021 Plan is 2,000,000 shares. As of June 30, 2024, the Company had a total of 1,844,438 shares available for grant under the 2018 Plan and the 2021 Plan. The following table summarizes option activity under the Company’s 2004 Plan, 2018 Plan and 2021 Plan:
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.14%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:16.38%;"></td> <td style="width:1%;"></td> <td style="width:1.96%;"></td> <td style="width:1%;"></td> <td style="width:15.98%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options outstanding at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,905,032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,284,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-

indent:14pt;white-space:pre-wrap;vertical-align:bottom;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (23,748 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"> Canceled and forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (385,568 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options outstanding at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,779,966 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options exercisable at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,078,851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12.09</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted Stock Units</p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The RSUs vest annually, and generally, will become fully vested over four years. A summary of the status and activity of non-vested RSUs during the six months ended June 30, 2024 is as follows:</p><div style="font-size:12pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.271%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:17.584%;"></td> <td style="width:1%;"></td> <td style="width:1.7%;"></td> <td style="width:1%;"></td> <td style="width:17.764%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of
shares</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted
Average
Grant-Date
Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-vested December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,244,873</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,437,530 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.49

</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Vested and released </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;text-align:center;"> (1,323,104 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.76 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Canceled and forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (308,515 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.53 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,050,784 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.44 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table> 2018 Employee Stock Purchase Plan In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (“ESPP”), which became effective on September 26, 2018, in order to enable eligible employees to purchase shares of the Company’s common stock. The Company initially reserved 230,000 shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2019, in an amount equal to 1% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year (rounded to the nearest whole share), or a lesser number of shares determined by the Company’s board of directors. As a result, common stock reserved for issuance under the ESPP was increased by 114,754 shares on January 1, 2023. The aggregate number of shares issued over the term of the Company’s ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed 2,300,000 shares of the Company’s common stock. At the Company’s annual stockholder meeting in June 2024, the Company amended the ESPP (the “Amended ESPP”) to increase the overall limit on the number of shares that may be issued under the Amended ESPP throughout its ten-year term from 2,300,000 shares to 3,050,0000 shares of the Company’s common stock. As of June 30, 2024, 1,554,697 shares had been purchased and 1,495,303 shares were available for future issuance under the ESPP. Stock-Based Compensation Expense Total stock-based compensation expense recognized was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Six Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="white-space:pre-wrap;font-family:Arial;min-width:fit-

content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development expense: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,072</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,246</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,948 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative expense: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,087 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,534 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,981 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,734 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,159</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,661 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,682 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of June 30, 2024, unrecognized stock-based compensation expense related to the unvested stock options and RSUs granted was $10.9 million and $31.9 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options and RSUs is expected to be recognized over a weighted-average period of 2.1 years and 2.5 years, respectively. As of June 30, 2024, there was $0.3 million of unrecognized stock-based compensation expense related to the ESPP. As of June 30, 2023, unrecognized stock-based compensation expense related to the unvested stock options and RSUs granted was $15.3 million and $38.1 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options and RSUs is expected to be recognized over a weighted-average period of 2.2 years and 2.6 years, respectively. As of June 30, 2023, there was $0.2 million of unrecognized stock-based compensation expense related to the ESPP.
2300000P10Y0.053050491750000750000500000200000001844438 The following table summarizes option activity under the Company's 2004 Plan, 2018 Plan and 2021 Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.14%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:16.38%;"></td> <td style="width:1%;"></td> <td style="width:1.96%;"></td> <td style="width:1%;"></td> <td style="width:15.98%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options outstanding at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,905,032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,284,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (23,748 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"> Canceled and forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (385,568 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-

width:fit-content;">Stock options outstanding at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,779,966 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options exercisable at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,078,851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12.09 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>790503211.2412842504.36237484.9138556810.45877996610.28607885112.09P4YA summary of the status and activity of non-vested RSUs during the six months ended June 30, 2024 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.271%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:17.584%;"></td> <td style="width:1%;"></td> <td style="width:1.7%;"></td> <td style="width:1%;"></td> <td style="width:17.764%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant-Date
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,244,873 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,437,530 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.49 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Vested and released </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,323,104 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.76 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Canceled and forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (308,515 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.53 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <span style="font-family:Arial;min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,050,784 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.44</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table>52448738.3124375304.4913231049.763085158.5360507846.44230000P10Y0.011147542300000230000030500000155469714953O3<p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense recognized was as follows: </p><p style="text-indent:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.07%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td><td style="width:1.3%;"></td><td style="width:1%;"></td><td style="width:9.182%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development expense:</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,072 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,127</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,246 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,948 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> General and administrative expense: </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,087 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-

align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,534 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,981 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,734 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,159</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,661 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,227</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,682 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>3072000312700062460005948000308700035340005981000673400061590006661000122270001268200010900000319000002P2Y1M6DP2Y6M3000001530000038100000
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">11. Net Loss Per Share The following table sets forth the computation of the Company's basic and diluted net loss per share.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.408%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Six Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;"> (in thousands, except share and per share amounts) </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td

```
style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-family:Arial;min-width:fit-content;">Numerator:</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2"
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-
indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p>
</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-
family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">48,018</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt
solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-
width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid
#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">38,524</span>
</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p>
</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-
family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">106,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt
solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-
width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid
#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">88,574</span>
</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-
color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Denominator:</span></p></td> <td style="vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr
style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-
indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-
width:fit-content;">Shares used in computing net loss per share</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-
bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-
family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">81,224,628</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-
bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-
width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-
width:fit-content;">60,339,475</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,341,211</span></p></td> <td
style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span>
</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
<span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,535,918</span></p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-
space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td> <td style="white-
space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p>
</td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-
family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.59</span></p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt
double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-
width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-
align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
```

style="color:#000000;font-family:Arial;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.64</p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"> (1.49 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;">) </td> </tr> </table> The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended June 30, 2024, and 2023, because including them would have been antidilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.448%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:16.897%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:16.477%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,779,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 8,351,659 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,050,784 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,212,174 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares to be issued under employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 300,818 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 203,206 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,259,184 </td> <td style="white-space:nowrap;vertical-align:bottom;border-

bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,894,655 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table sets forth the computation of the Company's basic and diluted net loss per share.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.408%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> <td style="width:1.221%;"></td> <td style="width:1%;"></td> <td style="width:9.928%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Three Months Ended </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Six Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom,"> (in thousands, except share and per share amounts) </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(48,018</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (38,524 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (106,231 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="color:#000000;font-family:Arial;min-

width:fit-content;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(88,574</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Denominator:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Shares used in computing net loss per share</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">81,224,628</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,339,475</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">71,341,211</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">59,535,918</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss per share, basic and diluted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"> (0.59 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.64</p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"> (1.49 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"> (1.49 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;">) </td> </tr></table>-48018000-38524000-106231000-8857400081224628812246286033947560339475713412117134121159535918590535918-0.59-0.59-0.64-0.64-1.49-1.49-1.49-1.49 The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended June 30, 2024, and 2023, because including them would have been antidilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.448%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:16.897%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:16.477%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,779,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 8,351,659 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,050,784 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,212,174 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 127,616 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares to be issued under employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 300,818 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 203,206 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,259,184 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,894,655 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>8779966835165960507845212174127616127616300818203206152591841389465 5